Number O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
lymphocytes B-cell_type B-cell_type
and O O
their O O
sensitivity O O
to O O
hormone O O
action O O
. O O

The O O
study O O
demonstrated O O
a O O
decreased O O
level O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
( O O
GR B-protein B-protein
) O O
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
from O O
hypercholesterolemic O O
subjects O O
, O O
and O O
an O O
elevated O O
level O O
in O O
patients O O
with O O
acute O O
myocardial O O
infarction O O
. O O

In O O
the O O
lymphocytes B-cell_type B-cell_type
with O O
a O O
high O O
GR B-protein O
number O O
, O O
dexamethasone O O
inhibited O O
[ O O
3H O O
] O O
-thymidine O O
and O O
[ O O
3H O O
] O O
-acetate O O
incorporation O O
into O O
DNA O O
and O O
cholesterol O O
, O O
respectively O O
, O O
in O O
the O O
same O O
manner O O
as O O
in O O
the O O
control B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

On O O
the O O
other O O
hand O O
, O O
a O O
decreased O O
GR B-protein B-protein
number O O
resulted O O
in O O
a O O
less O O
efficient O O
dexamethasone O O
inhibition O O
of O O
the O O
incorporation O O
of O O
labeled O O
compounds O O
. O O

These O O
data O O
showed O O
that O O
the O O
sensitivity O O
of O O
lymphocytes B-cell_type B-cell_type
to O O
glucocorticoids O O
changed O O
only O O
with O O
a O O
decrease O O
of O O
GR B-protein B-protein
level O O
. O O

[ O B-protein
1 B-protein I-protein
, I-protein I-protein
25-Dihydroxyvitamin I-protein I-protein
D3 I-protein I-protein
receptors I-protein I-protein
in O O
lymphocytes B-cell_type B-cell_type
and O O
T- B-cell_type B-cell_type
and I-cell_type O
B-lymphocyte I-cell_type B-cell_type
count O O
in O O
patients O O
with O O
glomerulonephritis O O
] O O

Content O O
of O O
receptors O O
to O O
hormonal O O
form O O
of O O
vitamin O O
D3 O O
, O O
1.25 O O
( O O
OH O O
) O O
2D3 O O
, O O
constituted O O
27.3 O O
fmole/mg O O
of O O
protein O O
in O O
lymphocytes B-cell_type B-cell_type
of O O
peripheric O O
blood O O
of O O
children O O
with O O
glomerulonephritis O O
. O O

In O O
the O O
patients O O
concentration O O
of O O
total O O
and O O
ionized O O
form O O
of O O
Ca2+ O O
was O O
decreased O O
down O O
to O O
2.04 O O
mmole/L O O
and O O
1.09 O O
mmole/L O O
, O O
respectively O O
, O O
while O O
an O O
increase O O
in O O
parathormone O O
( O O
PTH O O
) O O
by O O
36 O O
% O O
and O O
a O O
distinct O O
decrease O O
in O O
25 O O
( O O
OH O O
) O O
D O O
concentration O O
( O O
lower O O
than O O
1.25 O O
ng/ml O O
) O O
was O O
found O O
in O O
blood O O
; O O
content O O
of O O
cAMP O O
was O O
also O O
decreased O O
in O O
lymphocytes O B-cell_type
by O O
33 O O
% O O
. O O

At O O
the O O
same O O
time O O
, O O
total O O
content O O
of O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
was O O
decreased O O
1.5-fold O O
in O O
peripheric O O
blood O O
. O O

Treatment O O
with O O
I-hydroxyvitamin O O
D3 O O
( O O
1-1.5 O O
mg O O
daily O O
, O O
within O O
4 O O
weeks O O
) O O
led O O
to O O
normalization O O
of O O
total O O
and O O
ionized O O
form O O
of O O
Ca2+ O O
and O O
of O O
25 O O
( O O
OH O O
) O O
D O O
, O O
but O O
did O O
not O O
affect O O
the O O
PTH O O
content O O
in O O
blood O O
. O O

Concentration O O
of O O
the O O
receptors B-protein O
to O O
1.25 O O
( O O
OH O O
) O O
2D3 O O
was O O
elevated O O
up O O
to O O
39.7 O O
fmole/mg O O
after O O
I O O
week O O
of O O
the O O
treatment O O
, O O
whereas O O
it O O
was O O
decreased O O
to O O
the O O
initial O O
level O O
24.8 O O
fmole/mg O O
within O O
4 O O
weeks O O
; O O
simultaneous O O
alteration O O
in O O
the O O
cAMP O O
content O O
was O O
observed O O
in O O
lymphocytes B-cell_type B-cell_type
. O O

Treatment O O
with O O
1- O O
( O O
OH O O
) O O
D3 O O
normalized O O
also O O
the O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
content O O
in O O
peripheric O O
blood O O
. O O

The O O
data O O
obtained O O
suggest O O
that O O
under O O
conditions O O
of O O
glomerulonephritis O O
only O O
high O O
content O O
of O O
receptors B-protein O
to O O
1.25 O O
( O O
OH O O
) O O
2D3 O O
in O O
lymphocytes B-cell_type B-cell_type
enabled O O
to O O
perform O O
the O O
cell O O
response O O
to O O
the O O
hormone O O
effect O O
. O O

Tumor O O
and O O
serum O O
beta-2-microglobulin O B-protein
expression O O
in O O
women O O
with O O
breast O O
cancer O O
. O O

To O O
investigate O O
whether O O
the O O
tumor B-cell_type O
expression O O
of O O
beta-2-microglobulin B-protein B-protein
( O O
beta B-protein B-protein
2-M I-protein I-protein
) O O
could O O
serve O O
as O O
a O O
marker O O
of O O
tumor O O
biologic O O
behavior O O
, O O
the O O
authors O O
studied O O
specimens O O
of O O
breast B-cell_type O
carcinomas I-cell_type O
from O O
60 O O
consecutive O O
female O O
patients O O
. O O

Presence O O
of O O
beta B-protein B-protein
2-M I-protein I-protein
was O O
analyzed O O
by O O
immunohistochemistry O O
. O O

No O O
significant O O
correlations O O
were O O
found O O
between O O
tumor B-protein B-protein
beta I-protein I-protein
2-M I-protein I-protein
expression O O
and O O
several O O
histologic O O
attributes O O
such O O
as O O
type O O
, O O
histologic O O
and O O
nuclear O O
grades O O
, O O
mitotic O O
index O O
, O O
necrosis O O
, O O
vascular O O
invasion O O
, O O
and O O
lymphocytic O O
infiltration O O
. O O

Likewise O O
, O O
beta B-protein B-protein
2-M I-protein I-protein
was O O
not O O
associated O O
with O O
markers O O
of O O
disease O O
extension O O
such O O
as O O
TNM O O
, O O
( O O
UICC O O
, O O
classification O O
of O O
malignant B-cell_type O
tumors I-cell_type O
) O O
staging O O
and O O
axillary O O
lymph O O
node O O
involvement O O
or O O
with O O
estrogen O O
, O O
progesterone O O
, O O
and O O
glucocorticoid O B-protein
receptor O I-protein
levels O O
. O O

However O O
, O O
there O O
was O O
a O O
significantly O O
positive O O
association O O
between O O
tumor B-protein B-protein
beta I-protein I-protein
2-M I-protein I-protein
expression O O
and O O
the O O
degree O O
of O O
lymphocytic O O
infiltration O O
in O O
the O O
tumor O O
tissue O O
. O O

Beta B-protein B-protein
2-M I-protein I-protein
serum O O
levels O O
were O O
determined O O
by O O
an O O
enzyme-linked O O
immunosorbent O O
assay O O
in O O
samples O O
from O O
22 O O
of O O
the O O
above O O
women O O
. O O

Although O O
some O O
of O O
the O O
highest O O
values O O
had O O
been O O
obtained O O
in O O
women O O
with O O
larger O O
( O O
T4 O O
) O O
primary O O
tumors O O
, O O
the O O
authors O O
failed O O
to O O
detect O O
any O O
statistical O O
relationship O O
between O O
beta B-protein B-protein
2-M I-protein I-protein
expression O O
in O O
the O O
tumor O O
with O O
serum O O
levels O O
or O O
between O O
serum B-protein B-protein
beta I-protein I-protein
2-M I-protein I-protein
and O O
the O O
above O O
histologic O O
, O O
laboratory O O
, O O
and O O
clinical O O
factors O O
. O O

[ O O
Preliminary O O
observation O O
of O O
level O O
free-form B-protein O
E I-protein O
receptor I-protein O
levels O O
in O O
serum O O
of O O
normal O O
childbearing-aged O O
and O O
pregnant O O
women O O
] O O

In O O
137 O O
cases O O
of O O
childbearing-aged O O
and O O
pregnant O O
women O O
, O O
free B-protein O
form I-protein O
E I-protein O
receptor I-protein O
levels O O
( O O
sE B-protein O
) O O
in O O
serum O O
were O O
measured O O
by O O
ELISA O O
. O O

The O O
level O O
of O O
sE B-protein B-protein
was O O
significantly O O
decreased O O
during O O
the O O
first O O
trimester O O
, O O
slightly O O
higher O O
in O O
the O O
second O O
trimester O O
, O O
and O O
recovered O O
to O O
normal O O
in O O
the O O
third O O
trimester O O
. O O

The O O
level O O
remained O O
lower O O
in O O
29 O O
PIH O O
women O O
but O O
appeared O O
higher O O
in O O
overdue O O
pregnancies O O
as O O
compared O O
with O O
the O O
normal O O
3rd O O
trimester O O
range O O
. O O

The O O
results O O
indicate O O
that O O
there O O
is O O
a O O
relationship O O
between O O
a O O
change O O
in O O
T B-cell_type O
cell I-cell_type O
function O O
and O O
pregnancy O O
. O O

Kappa B-protein B-protein
B-specific I-protein I-protein
DNA I-protein I-protein
binding I-protein I-protein
proteins I-protein I-protein
: O O
role O O
in O O
the O O
regulation O O
of O O
human B-DNA B-DNA
interleukin-2 I-DNA I-DNA
gene I-DNA I-DNA
expression O O
. O O

Transcriptional O O
activation O O
of O O
the O O
human B-DNA B-DNA
interleukin-2 I-DNA I-DNA
( I-DNA I-DNA
IL-2 I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
, O O
like O O
induction O O
of O O
the O O
IL-2 B-DNA B-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
( I-DNA I-DNA
IL-2R I-DNA I-DNA
alpha I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
and O O
the O O
type O O
1 O O
human O O
immunodeficiency O O
virus O O
( O O
HIV-1 O O
) O O
, O O
is O O
shown O O
to O O
be O O
modulated O O
by O O
a O O
kappa B-protein B-DNA
B-like I-protein I-DNA
enhancer I-protein I-DNA
element I-protein I-DNA
. O O

Mutation O O
of O O
a O O
kappa B-DNA B-DNA
B I-DNA I-DNA
core I-DNA I-DNA
sequence I-DNA I-DNA
identified O O
in O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
( O O
-206 O B-DNA
to O I-DNA
-195 O I-DNA
) O O
partially O O
inhibits O O
both O O
mitogen- O O
and O O
HTLV-I O O
Tax-mediated O O
activation O O
of O O
this O O
transcription B-protein B-protein
unit I-protein I-protein
and O O
blocks O O
the O O
specific O O
binding O O
of O O
two O O
inducible B-protein O
cellular I-protein B-protein
factors I-protein I-protein
. O O

These O O
kappa B-protein B-protein
B-specific I-protein I-protein
proteins I-protein I-protein
( O O
80 O O
to O O
90 O O
and O O
50 O B-protein
to O I-protein
55 O I-protein
kilodaltons O I-protein
) O O
similarly O O
interact O O
with O O
the O O
functional O O
kappa B-protein B-DNA
B I-protein I-DNA
enhancer I-protein I-DNA
present O O
in O O
the O O
IL-2R B-DNA B-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
. O O

These O O
data O O
suggest O O
that O O
these O O
kappa B-protein B-protein
B-specific I-protein I-protein
proteins I-protein I-protein
have O O
a O O
role O O
in O O
the O O
coordinate O O
regulation O O
of O O
this O O
growth O B-protein
factor-growth O I-protein
factor O I-protein
receptor O I-protein
gene O O
system O O
that O O
controls O B-cell_type
T B-cell_type I-cell_type
cell I-cell_type I-cell_type
proliferation O O
. O O

Novel O O
region O O
within O O
the O O
V B-DNA B-DNA
kappa I-DNA I-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
is O O
responsible O O
for O O
tissue O O
and O O
stage-specific O O
expression O O
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
in O O
human B-cell_type B-cell_type
lymphoid I-cell_type I-cell_type
neoplasms I-cell_type I-cell_type
. O O

Immunoglobulin B-protein B-protein
gene-specific I-protein I-protein
transacting I-protein I-protein
factors I-protein I-protein
have O O
been O O
shown O O
to O O
play O O
a O O
role O O
in O O
lymphoid O O
tissue-specific O O
expression O O
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
. O O

The O O
role O O
of O O
these O O
factors O O
in O O
B-cell B-cell_type B-cell_type
differentiation O O
and O O
stage-specific O O
expression O O
of O O
these O O
genes O O
is O O
, O O
however O O
, O O
not O O
fully O O
understood O O
. O O

We O O
have O O
used O O
a O O
model O O
of O O
human O O
lymphoid O O
neoplasia O O
to O O
address O O
this O O
question O O
. O O

Different O O
fragments O O
of O O
unrearranged B-DNA O
human I-DNA B-DNA
variable I-DNA I-DNA
region I-DNA I-DNA
of O O
immunoglobulin B-DNA B-DNA
kappa I-DNA I-DNA
gene I-DNA I-DNA
( O O
V B-DNA B-DNA
kappa I-DNA I-DNA
) O O
were O O
used O O
for O O
cell-free O O
in O O
vitro O O
transcription O O
and O O
DNA O O
mobility O O
shift O O
assays O O
. O O

Previously O O
described O O
enhancement O O
of O O
in O O
vitro O O
transcription O O
that O O
was O O
only O O
seen O O
with O O
nuclear O O
extracts O O
derived O O
from O O
B-cell B-cell_type B-cell_type
neoplasms I-cell_type I-cell_type
corresponding O O
to O O
the O O
late O O
stages O O
of O O
B-cell B-cell_type O
differentiation O O
was O O
shown O O
to O O
be O O
dependent O O
on O O
the O O
actions O O
of O O
these O O
factor O O
( O O
s O O
) O O
on O O
the O O
DNA O B-DNA
region O I-DNA
within O O
the O O
V B-DNA B-DNA
kappa I-DNA I-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
. O O

This O O
region O O
is O O
located O O
within O O
the O O
920 O B-DNA
bp O I-DNA
fragment O I-DNA
located O O
210 O O
bp O O
upstream O O
from O O
the O O
coding O B-DNA
region O I-DNA
and O O
this O O
fragment O O
represents O O
a O O
possible O O
novel O B-DNA
DNA O I-DNA
region O I-DNA
, O O
which O O
plays O O
a O O
role O O
in O O
the O O
stage- O O
and O O
tissue-specific O O
expression O O
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
. O O

[ O O
Determination O O
of O O
the O O
sensitivity O O
to O O
glucocorticoids B-protein O
in O O
vitro O O
] O O

A O O
modified O O
method O O
for O O
the O O
determination O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
human B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
is O O
suggested O O
. O O

The O O
principal O O
distinction O O
of O O
the O O
method O O
is O O
standardization O O
by O O
the O O
lymphocyte B-cell_type O
count O O
in O O
a O O
sample O O
( O O
1 O O
mln O O
) O O
and O O
the O O
labeled O O
hormone B-protein O
concentration O O
. O O

The O O
modification O O
saves O O
time O O
and O O
money O O
, O O
limits O O
the O O
range O O
of O O
the O O
data O O
variations O O
, O O
and O O
makes O O
use O O
of O O
a O O
lesser O O
volume O O
of O O
blood O O
. O O

Examinations O O
of O O
70 O O
children O O
aged O O
4 O O
to O O
15 O O
suffering O O
from O O
the O O
nephrotic O O
form O O
of O O
glomerulonephritis O O
have O O
made O O
it O O
possible O O
to O O
distinguish O O
two O O
groups O O
of O O
patients O O
: O O
with O O
relatively O O
high O O
values O O
of O O
specific O O
binding O O
X O O
= O O
6820.1 O O
+/- O O
530.0 O O
( O O
n O O
= O O
30 O O
, O O
p O O
= O O
0.95 O O
, O O
t O O
= O O
2.04 O O
) O O
, O O
this O O
corresponding O O
to O O
a O O
clinical O O
form O O
of O O
hormone B-protein O
-sensitive O O
glomerulonephritis O O
, O O
and O O
with O O
relatively O O
low O O
values O O
of O O
specific O O
binding O O
X O O
= O O
1815.2 O O
+/- O O
302.8 O O
( O O
n O O
= O O
40 O O
, O O
p O O
= O O
0.95 O O
, O O
t O O
= O O
1.96 O O
) O O
, O O
that O O
corresponds O O
to O O
hormone B-protein O
-resistant O O
glomerulonephritis O O
. O O

Dynamic O O
studies O O
have O O
not O O
shown O O
any O O
statistically O O
significant O O
changes O O
in O O
the O O
specific O O
binding O O
values O O
. O O

These O O
results O O
permit O O
regarding O O
the O O
specific O O
binding O O
value O O
as O O
a O O
prognostic O O
criterion O O
in O O
the O O
assessment O O
of O O
corticosteroid B-protein O
therapy O O
; O O
this O O
allows O O
a O O
wide O O
employment O O
of O O
the O O
described O O
method O O
in O O
practical O O
nephrology O O
. O O

Octamer-binding B-protein B-protein
proteins I-protein I-protein
from O O
B B-cell_line B-cell_line
or I-cell_line I-cell_line
HeLa I-cell_line I-cell_line
cells I-cell_line I-cell_line
stimulate O O
transcription O O
of O O
the O O
immunoglobulin B-DNA B-DNA
heavy-chain I-DNA I-DNA
promoter I-DNA I-DNA
in O O
vitro O O
. O O

The O O
B-cell B-cell_type O
-type O O
specificity O O
of O O
the O O
immunoglobulin B-protein B-DNA
( O I-DNA
Ig B-protein I-DNA
) O I-DNA
heavy-chain O I-DNA
and O I-DNA
light-chain O I-DNA
promoters O I-DNA
is O O
mediated O O
by O O
an O O
octanucleotide B-DNA B-DNA
( I-DNA I-DNA
OCTA I-DNA I-DNA
) I-DNA I-DNA
element I-DNA I-DNA
, O O
ATGCAAAT O B-DNA
, O O
that O O
is O O
also O O
a O O
functional O O
component O O
of O O
other O O
RNA B-DNA B-DNA
polymerase I-DNA I-DNA
II I-DNA I-DNA
promoters I-DNA I-DNA
, O O
such O O
as O O
snRNA O B-DNA
and O O
histone O B-DNA
H2B O I-DNA
promoters O I-DNA
. O O

Two O O
nuclear B-protein B-protein
proteins I-protein I-protein
that O O
bind O O
specifically O O
and O O
with O O
high O O
affinity O O
to O O
the O O
OCTA B-DNA B-DNA
element I-DNA I-DNA
have O O
been O O
identified O O
. O O

NF-A1 B-protein B-protein
is O O
present O O
in O O
a O O
variety O O
of O O
cell O O
types O O
, O O
whereas O O
the O O
presence O O
of O O
NF-A2 B-protein B-protein
is O O
essentially O O
confined O O
to O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
leading O O
to O O
the O O
hypothesis O O
that O O
NF-A2 B-protein B-protein
activates O O
cell-type-specific O O
transcription O O
of O O
the O O
Ig B-DNA B-DNA
promoter I-DNA I-DNA
and O O
NF-A1 B-protein B-protein
mediates O O
the O O
other O O
responses O O
of O O
the O O
OCTA B-DNA B-DNA
element I-DNA I-DNA
. O O

Extracts O O
of O O
the O O
B-cell B-cell_line B-cell_line
line I-cell_line I-cell_line
, O O
BJA-B B-cell_line B-cell_line
, O O
contain O O
high O O
levels O O
of O O
NF-A2 B-protein B-protein
and O O
specifically O O
transcribe O B-DNA
Ig B-DNA I-DNA
promoters I-DNA I-DNA
. O O

In O O
contrast O O
, O O
extracts O O
from O O
HeLa B-cell_line B-cell_line
cells I-cell_line I-cell_line
transcribed O O
the O O
Ig B-DNA B-DNA
promoter I-DNA I-DNA
poorly O O
. O O

Surprisingly O O
, O O
addition O O
of O O
either O O
affinity-enriched O O
NF-A2 O B-protein
or O O
NF-A1 O B-protein
to O O
either O O
a O O
HeLa O O
extract O O
or O O
a O O
partially O O
purified O O
reaction O O
system O O
specifically O O
stimulates O O
the O O
Ig B-DNA B-DNA
promoter I-DNA I-DNA
. O O

This O O
suggests O O
that O O
the O O
constitutive O B-protein
OCTA-binding B-protein I-protein
factor I-protein I-protein
NF-A1 I-protein B-protein
can O O
activate O O
transcription O O
of O O
the O O
Ig B-DNA B-DNA
promoter I-DNA I-DNA
and O O
that O O
B-cell B-cell_type B-protein
-specific O O
transcription O O
of O O
this O O
promoter O B-DNA
, O O
at O O
least O O
in O O
vitro O O
, O O
is O O
partially O O
due O O
to O O
a O O
quantitative O O
difference O O
in O O
the O O
amount O O
of O O
OCTA-binding B-protein B-protein
protein I-protein I-protein
. O O

Because O O
NF-A1 B-protein B-protein
can O O
stimulate O O
Ig B-protein B-protein
transcription O O
, O O
the O O
inability O O
of O O
this O O
factor O O
to O O
activate O O
in O O
vivo O O
the O O
Ig B-DNA B-DNA
promoter I-DNA I-DNA
to O O
the O O
same O O
degree O O
as O O
the O O
snRNA B-DNA B-DNA
promoters I-DNA I-DNA
probably O O
reflects O O
a O O
difference O O
in O O
the O O
context O O
of O O
the O O
OCTA B-DNA B-DNA
element I-DNA I-DNA
in O O
these O O
two O O
types O O
of O O
promoters B-DNA B-DNA
. O O

Identification O O
of O O
a O O
putative O B-protein
regulator O I-protein
of O O
early B-DNA B-DNA
T I-DNA I-DNA
cell I-DNA I-DNA
activation I-DNA I-DNA
genes I-DNA I-DNA
. O O

Molecules O O
involved O O
in O O
the O O
antigen O O
receptor-dependent O O
regulation O O
of O O
early B-DNA B-DNA
T I-DNA I-DNA
cell I-DNA I-DNA
activation I-DNA I-DNA
genes I-DNA I-DNA
were O O
investigated O O
with O O
the O O
use O O
of O O
functional O B-DNA
sequences O I-DNA
of O O
the O O
T B-protein B-DNA
cell I-protein I-DNA
activation-specific I-protein I-DNA
enhancer I-protein I-DNA
of O O
interleukin-2 B-protein B-protein
( O O
IL-2 B-protein B-protein
) O O
. O O

One O O
of O O
these O O
sequences O O
forms O O
a O O
protein O B-protein
complex O I-protein
, O O
NFAT-1 B-protein B-protein
, O O
specifically O O
with O O
nuclear O O
extracts O O
of O O
activated O B-cell_type
T B-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

This O O
complex O O
appeared O O
10 O O
to O O
25 O O
minutes O O
before O O
the O O
activation O O
of O O
the O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
. O O

Studies O O
with O O
inhibitors O O
of O O
protein O O
synthesis O O
indicated O O
that O O
the O O
time O O
of O O
synthesis O O
of O O
the O O
activator O O
of O O
the O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
in O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
corresponds O O
to O O
the O O
time O O
of O O
appearance O O
of O O
NFAT-1 B-protein B-protein
. O O

NFAT-1 B-protein B-protein
, O O
or O O
a O O
very O O
similar O O
protein O O
, O O
bound O O
functional O O
sequences O O
of O O
the O O
long B-DNA B-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
; O O
the O O
LTR B-DNA B-DNA
of O O
this O O
virus O O
is O O
known O O
to O O
be O O
stimulated O O
during O O
early O O
T B-cell_type O
cell I-cell_type O
activation O O
. O O

The O O
binding B-DNA B-DNA
site I-DNA I-DNA
for O O
this O O
complex O O
activated O O
a O O
linked O O
promoter O O
after O O
transfection O O
into O O
antigen B-cell_type B-cell_type
receptor-activated I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
but O O
not O O
other O O
cell O O
types O O
. O O

These O O
characteristics O O
suggest O O
that O O
NFAT-1 B-protein B-protein
transmits O O
signals O O
initiated O O
at O O
the O O
T B-protein B-protein
cell I-protein I-protein
antigen I-protein I-protein
receptor I-protein I-protein
. O O

Characterization O O
of O O
thyroid B-protein B-protein
hormone I-protein I-protein
receptors I-protein I-protein
in O O
human B-cell_line B-cell_line
IM-9 I-cell_line I-cell_line
lymphocytes I-cell_line I-cell_line
. O O

Although O O
putatively O O
identified O O
more O O
than O O
10 O O
years O O
ago O O
, O O
thyroid B-protein B-protein
hormone I-protein I-protein
receptors I-protein I-protein
in O O
human O O
tissues O O
remain O O
poorly O O
characterized O O
. O O

As O O
a O O
first O O
step O O
towards O O
understanding O O
the O O
mechanism O O
of O O
thyroid O O
hormone O O
action O O
in O O
man O O
we O O
have O O
characterized O O
T3 B-protein B-DNA
binding I-protein I-DNA
sites I-protein I-DNA
in O O
nuclei O O
of O O
the O O
human B-cell_line B-cell_line
lymphoblastoid I-cell_line I-cell_line
line I-cell_line I-cell_line
, O O
IM-9 B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

In O O
whole O O
cell O O
experiments O O
at O O
37 O O
degrees O O
C O O
, O O
nuclear O O
binding O O
of O O
[ B-protein O
125I I-protein O
] I-protein O
T3 I-protein O
was O O
saturable O O
( O O
Kd O O
34 O O
+/- O O
6 O O
pmol/l O O
) O O
and O O
of O O
finite O O
capacity O O
( O O
approximately O O
equal O O
to O O
350 O O
sites/cell O O
) O O
. O O

The O O
binding B-protein B-DNA
sites I-protein I-DNA
were O O
extracted O O
from O O
a O O
nuclear O O
pellet O O
by O O
treatment O O
with O O
0.4 O O
mol/l O O
KCl O O
and O O
sonication O O
. O O

Separation O O
of O O
bound O O
from O O
free O O
[ B-protein O
125I I-protein O
] I-protein O
T3 I-protein O
in O O
the O O
extracts O O
was O O
achieved O O
using O O
the O O
calcium O O
phosphate O O
matrix O O
, O O
hydroxyapatite O O
at O O
a O O
concentration O O
of O O
0.3 O O
ml O O
of O O
a O O
150 O O
g/l O O
slurry O O
. O O

Rectilinear O O
Scatchard O O
plots O O
were O O
obtained O O
only O O
when O O
the O O
hydroxyapatite O O
was O O
washed O O
with O O
a O O
buffer O O
containing O O
0.5 O O
% O O
Triton O O
X-100 O O
. O O

Under O O
these O O
conditions O O
T3 B-protein B-DNA
binding I-protein I-DNA
sites I-protein I-DNA
in O O
the O O
nuclear O O
extracts O O
were O O
present O O
at O O
a O O
concentration O O
of O O
22.4 O O
+/- O O
8.6 O O
fmol/mg O O
protein O O
and O O
showed O O
an O O
affinity O O
of O O
( O O
Kd O O
, O O
room O O
temperature O O
) O O
140 O O
+/- O O
10 O O
pmol/l O O
. O O

The O O
same O O
assay O O
system O O
was O O
used O O
to O O
determine O O
the O O
hierarchy O O
of O O
affinities O O
for O O
a O O
range O O
of O O
natural O O
and O O
synthetic O O
analogues O O
. O O

Calling O O
T3 O O
100 O O
, O O
the O O
order O O
of O O
potencies O O
observed O O
was O O
: O O
Triac O O
, O O
500 O O
; O O
3 O O
, O O
5-diiodo-3'-isopropylthyronine O O
, O O
89 O O
; O O
T4 O O
, O O
32 O O
; O O
3 O O
, O O
5-dimethyl-3'isopropylthyronine O O
2 O O
; O O
3 O O
, O O
5-T2 O O
, O O
0.7 O O
, O O
rT3 O O
, O O
0.4 O O
; O O
3'5'-T2 O O
, O O
less O O
than O O
0.01 O O
. O O

These O O
results O O
suggest O O
that O O
the O O
T3 B-protein B-DNA
binding I-protein I-DNA
sites I-protein I-DNA
present O O
in O O
human B-cell_line O
IM-9 I-cell_line O
lymphocyte I-cell_line O
nuclei O O
and O O
extracts O O
thereof O O
are O O
thyroid B-protein B-protein
hormone I-protein I-protein
receptors I-protein I-protein
. O O

These O O
cells O O
may O O
be O O
a O O
useful O O
tool O O
to O O
increase O O
our O O
understanding O O
of O O
human B-protein B-protein
T3 I-protein I-protein
receptors I-protein I-protein

Definition O O
of O O
T-cell B-protein B-protein
specific I-protein I-protein
DNA-binding I-protein I-protein
factors I-protein I-protein
that O O
interact O O
with O O
a O O
3'-silencer B-DNA O
in O O
the O O
CD4+ B-DNA B-DNA
T-cell I-DNA I-DNA
gene I-DNA I-DNA
Rpt-1 I-DNA I-DNA
. O O

Analysis O O
of O O
the O O
region O O
3 O O
' O O
to O O
the O O
CD4+ B-DNA B-DNA
T-cell I-DNA I-DNA
gene I-DNA I-DNA
Rpt-1 I-DNA B-protein
( O O
encoding O O
regulatory O B-protein
protein O I-protein
T-lymphocyte B-protein I-protein
1 I-protein I-protein
) O O
led O O
to O O
the O O
definition O O
of O O
a O O
silencer B-DNA B-DNA
element I-DNA I-DNA
that O O
inhibits O O
heterologous B-DNA O
gene I-DNA O
expression O O
in O O
certain O O
CD4+ B-cell_type B-cell_line
T-cell I-cell_type I-cell_line
lines I-cell_type I-cell_line
but O O
not O O
in O O
B-cell B-cell_type B-cell_line
or O I-cell_line
non-lymphoid B-cell_type I-cell_line
cell I-cell_type I-cell_line
lines I-cell_type I-cell_line
. O O

Functional O O
silencer B-DNA B-DNA
activity O O
in O O
vivo O O
was O O
associated O O
with O O
the O O
presence O O
of O O
a O O
specific O O
silencer-DNA-protein B-protein B-protein
complex I-protein I-protein
in O O
electrophoretic O O
mobility O O
shift O O
assays O O
with O O
T-cell B-cell_type O
extracts O O
. O O

Formation O O
of O O
this O O
complex O O
was O O
selectively O O
inhibited O O
by O O
the O O
region O O
in O O
HIV-1 B-DNA O
containing O O
a O O
silencer B-DNA B-DNA
element I-DNA I-DNA
. O O

We O O
discuss O O
the O O
possibility O O
that O O
DNA-binding B-protein B-protein
factors I-protein I-protein
may O O
coregulate O O
HIV-1 O O
and O O
Rpt-1 O B-DNA
gene O I-DNA
expression O O
through O O
a O O
common O O
transcriptional B-DNA B-DNA
silencer I-DNA I-DNA
element I-DNA I-DNA
. O O

Congenital O O
immunodeficiencies O O
associated O O
with O O
absence O O
of O O
HLA B-protein B-protein
class I-protein I-protein
II I-protein I-protein
antigens I-protein I-protein
on O O
lymphocytes B-cell_type B-cell_type
result O O
from O O
distinct O O
mutations O O
in O O
trans-acting B-protein B-protein
factors I-protein I-protein
. O O

Coordinate O O
regulation O O
of O O
HLA B-DNA B-DNA
class I-DNA I-DNA
II I-DNA I-DNA
gene I-DNA I-DNA
expression O O
during O O
development O O
and O O
coinduction O O
of O O
class B-DNA B-DNA
II I-DNA I-DNA
genes I-DNA I-DNA
by O O
soluble B-protein B-protein
factors I-protein I-protein
suggests O O
that O O
common O O
trans-acting B-protein B-protein
factor I-protein I-protein
( O O
s O O
) O O
control O O
expression O O
of O O
these O O
genes O O
. O O

In O O
B-lymphoblastoid B-cell_type B-cell_line
cell I-cell_type I-cell_line
lines I-cell_type I-cell_line
derived O O
from O O
two O O
independent O O
class O O
II-deficient O O
bare O O
lymphocyte O O
syndrome O O
patients O O
, O O
we O O
observed O O
a O O
drastic O O
decrease O O
in O O
transcription O O
rates O O
of O O
the O O
class B-DNA B-DNA
II I-DNA I-DNA
genes I-DNA I-DNA
. O O

When O O
these O O
cell O B-cell_line
lines O I-cell_line
are O O
fused O O
, O O
class B-DNA B-DNA
II I-DNA I-DNA
genes I-DNA I-DNA
are O O
reexpressed O O
, O O
indicating O O
that O O
immunodeficiencies O O
in O O
bare O O
lymphocyte O O
syndrome O O
patients O O
are O O
the O O
result O O
of O O
two O O
distinct O O
mutations O O
. O O

Further O O
studies O O
show O O
that O O
genes O O
governing O O
the O O
expression O O
of O O
class B-protein B-protein
II I-protein I-protein
antigens I-protein I-protein
fall O O
into O O
at O O
least O O
three O O
complementation O O
groups O O
; O O
two O O
of O O
these O O
were O O
previously O O
unidentified O O
in O O
mutant B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
generated O O
in O O
vitro O O
. O O

In O O
addition O O
, O O
we O O
report O O
the O O
identification O O
of O O
two O O
discrete O O
complexes O O
, O O
NFX1.1 B-protein B-protein
and O O
NFX1.2 B-protein B-protein
, O O
that O O
bind O O
to O O
the O O
DRA B-DNA B-DNA
X I-DNA I-DNA
consensus I-DNA I-DNA
element I-DNA I-DNA
. O O

Though O O
the O O
mutation O O
in O O
at O O
least O O
one O O
mutant B-cell_line B-cell_line
line I-cell_line I-cell_line
generated O O
in O O
vitro O O
( O O
RJ2.2.5 B-cell_line B-cell_line
) O O
affects O O
products O O
functioning O O
via O O
interaction O O
with O O
the O O
X B-DNA B-DNA
box I-DNA I-DNA
, O O
clear O O
alterations O O
in O O
either O O
NFX1.1 B-protein B-protein
or O O
NFX1.2 B-protein B-protein
are O O
not O O
found O O
in O O
any O O
of O O
the O O
mutant B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

In O O
vivo O O
responsiveness O O
to O O
glucocorticoid O O
correlated O O
with O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
content O O
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
in O O
normal O O
humans O O
. O O

Dexamethasone O O
loading O O
tests O O
( O O
0.1 O O
mg O O
dexamethasone/kg O O
, O O
iv O O
) O O
were O O
performed O O
in O O
18 O O
normal O O
males O O
to O O
evaluate O O
the O O
individual O O
responsiveness O O
to O O
glucocorticoid O O
. O O

There O O
were O O
inter-individual O O
differences O O
in O O
increase O O
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
polymorphonuclear I-cell_type I-cell_type
leukocyte I-cell_type I-cell_type
count O O
, O O
decrease O O
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
lymphocyte I-cell_type I-cell_type
count O O
, O O
and O O
increase O O
in O O
plasma O O
free O O
fatty O O
acids O O
levels O O
after O O
dexamethasone O O
injection O O
. O O

In O O
addition O O
, O O
there O O
was O O
a O O
significant O O
correlation O O
between O O
the O O
maximum O O
increase O O
in O O
polymorphonuclear B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
and O O
the O O
maximum O O
decrease O O
in O O
lymphocytes B-cell_type B-cell_type
( O O
r O O
= O O
0.7514 O O
, O O
p O O
less O O
than O O
0.0003 O O
) O O
. O O

Simultaneous O O
measurements O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
content O O
by O O
whole-cell O O
assay O O
revealed O O
that O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
content O O
in O O
polymorphonuclear B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
linearly O O
correlated O O
with O O
that O O
in O O
the O O
corresponding O O
lymphocytes B-cell_type B-cell_type
( O O
r O O
= O O
0.9482 O O
, O O
p O O
less O O
than O O
0.0001 O O
) O O
. O O

There O O
were O O
also O O
significant O O
correlations O O
between O O
the O O
maximum O O
increase O O
in O O
polymorphonuclear B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
and O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
content O O
in O O
polymorphonuclear B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
( O O
r O O
= O O
0.7239 O O
, O O
p O O
less O O
than O O
0.0007 O O
) O O
, O O
and O O
between O O
the O O
maximum O O
decrease O O
in O O
lymphocytes B-cell_type B-cell_type
and O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
content O O
in O O
lymphocytes B-cell_type B-cell_type
( O O
r O O
= O O
0.7703 O O
, O O
p O O
less O O
than O O
0.0002 O O
) O O
. O O

These O O
results O O
suggest O O
that O O
individual O O
differences O O
are O O
preserved O O
both O O
in O O
glucocorticoid O O
responsiveness O O
and O O
in O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
content O O
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
in O O
normal O O
humans O O
. O O

Estradiol O B-protein
receptors O I-protein
in O O
the O O
cytosol O O
of O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
hepatitis O O
B O O
virus O O
carriers O O
treated O O
with O O
interferon-alpha B-protein B-protein
. O O

Estradiol B-protein B-protein
receptors I-protein I-protein
in O O
the O O
cytosol O O
of O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
the O O
effects O O
of O O
interferon-alpha B-protein B-protein
( O O
IFN-alpha B-protein B-protein
) O O
on O O
estradiol B-protein B-protein
receptors I-protein I-protein
were O O
studied O O
in O O
asymptomatic O O
hepatitis O O
B O O
virus O O
( O O
HBV O O
) O O
carriers O O
, O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
and O O
normal O O
controls O O
. O O

The O O
level O O
of O O
estradiol B-protein B-protein
receptors I-protein I-protein
in O O
the O O
cytosol O O
of O O
mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
was O O
significantly O O
lower O O
in O O
asymptomatic O O
HBV O O
carriers O O
and O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
, O O
compared O O
to O O
normal O O
controls O O
. O O

This O O
low O O
level O O
of O O
cytosol O B-protein
estradiol B-protein I-protein
receptors I-protein I-protein
in O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
was O O
increased O O
by O O
the O O
administration O O
of O O
IFN-alpha B-protein B-protein
. O O

In O O
addition O O
, O O
when O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
were O O
incubated O O
with O O
IFN-alpha B-protein B-protein
in O O
vitro O O
, O O
the O O
level O O
of O O
cytosol O B-protein
estradiol B-protein I-protein
receptors I-protein I-protein
also O O
increased O O
by O O
increasing O O
the O O
concentration O O
of O O
IFN-alpha B-protein B-protein
. O O

We O O
previously O O
reported O O
that O O
the O O
response O O
of O O
mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
to O O
estrogen O O
is O O
impaired O O
in O O
HBV O O
carriers O O
, O O
and O O
our O O
present O O
results O O
suggested O O
that O O
this O O
may O O
be O O
due O O
to O O
the O O
low O O
level O O
of O O
estradiol B-protein B-protein
receptors I-protein I-protein
in O O
the O O
cytosol O O
of O O
mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Association O O
of O O
increased O O
lytic O O
effector O O
cell O O
function O O
with O O
high O B-protein
estrogen B-protein I-protein
receptor I-protein I-protein
levels O O
in O O
tumor-bearing O O
patients O O
with O O
breast O O
cancer O O
. O O

Tumor-bearing O O
patients O O
with O O
breast O O
cancer O O
were O O
assayed O O
for O O
their O O
natural B-cell_type B-cell_type
killer I-cell_type I-cell_type
( I-cell_type I-cell_type
NK I-cell_type I-cell_type
) I-cell_type I-cell_type
cell I-cell_type I-cell_type
activity O O
and O O
for O O
the O O
function O O
of O O
activated O B-cell_type
cytotoxic B-cell_type I-cell_type
T-cells I-cell_type I-cell_type
, O O
as O O
assessed O O
by O O
lectin-dependent O O
cellular O O
cytotoxicity O O
( O O
LDCC O O
) O O
. O O

Tumor-bearing O O
patients O O
with O O
breast O O
cancer O O
had O O
a O O
significant O O
increase O O
in O O
NK B-cell_type O
activity O O
and O O
in O O
LDCC O B-cell_type
, O O
as O O
compared O O
with O O
healthy O O
control O O
individuals O O
. O O

Although O O
the O O
enhanced O O
NK B-cell_type O
cell I-cell_type O
activity O O
and O O
LDCC O B-cell_type
were O O
closely O O
associated O O
with O O
high O O
levels O O
( O O
greater O O
than O O
31 O O
fmol/mg O O
) O O
of O O
estrogen B-protein B-protein
receptor I-protein I-protein
( O O
ER B-protein B-protein
) O O
content O O
in O O
the O O
primary O O
tumor O O
, O O
no O O
other O O
clinical O O
or O O
histologic O O
correlation O O
between O O
the O O
increase O O
in O O
either O O
parameter O O
of O O
cytotoxic B-cell_type O
effector I-cell_type O
cell I-cell_type O
function O O
could O O
be O O
found O O
. O O

Thus O O
, O O
ER B-protein B-protein
levels O O
greater O O
than O O
31 O O
fmol/mg O O
might O O
be O O
associated O O
with O O
increased O O
cytotoxic B-cell_type O
effector I-cell_type O
cell I-cell_type O
function O O
in O O
tumor-bearing O O
patients O O
with O O
breast O O
cancer O O
. O O

Properties O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
Epstein-Barr B-cell_line B-cell_type
virus-transformed I-cell_line I-cell_type
lymphocytes I-cell_line I-cell_type
from O O
patients O O
with O O
familial O O
cortisol O O
resistance O O
. O O

In O O
a O O
previous O O
report O O
of O O
two O O
patients O O
with O O
familial O O
glucocorticoid O O
resistance O O
due O O
to O O
reduced O O
numbers O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
( O O
GR B-protein B-protein
) O O
, O O
we O O
have O O
shown O O
decreased O O
numbers O O
of O O
GR B-protein B-protein
in O O
peripheral B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
cultured B-cell_line B-cell_type
fibroblasts I-cell_line I-cell_type
but O O
normal O O
affinity O O
of O O
GR B-protein B-protein
in O O
both O O
patients O O
. O O

In O O
this O O
study O O
, O O
peripheral B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
from O O
these O O
patients O O
, O O
one O O
patient O O
's O O
son O O
and O O
daughter O O
, O O
and O O
normal O O
subjects O O
were O O
transformed O O
with O O
Epstein-Barr O O
virus O O
. O O

Reduced O O
numbers O O
and O O
normal O O
affinity O O
of O O
GR B-protein B-protein
were O O
found O O
in O O
the O O
Epstein-Barr B-cell_line B-cell_type
virus-transformed I-cell_line I-cell_type
lymphocytes I-cell_line I-cell_type
from O O
both O O
patients O O
while O O
the O O
son O O
and O O
daughter O O
had O O
normal O O
numbers O O
and O O
affinity O O
of O O
GR B-protein B-protein
. O O

The O O
thermal O O
stability O O
of O O
GR B-protein B-protein
and O O
thermal O O
activation O O
of O O
cytosolic B-protein B-protein
receptors I-protein I-protein
in O O
both O O
patients O O
were O O
found O O
to O O
be O O
normal O O
. O O

Although O O
the O O
percentages O O
of O O
nuclear O O
bound O O
GR B-protein B-protein
were O O
similar O O
in O O
both O O
patients O O
and O O
normal O O
controls O O
, O O
the O O
absolute O O
amounts O O
of O O
nuclear O O
bound O O
GR B-protein B-protein
of O O
the O O
patients O O
were O O
about O O
one-half O O
that O O
of O O
normal O O
controls O O
. O O

These O O
abnormal O O
properties O O
of O O
GR B-protein B-protein
( O O
reduced O O
numbers O O
of O O
GR B-protein B-protein
) O O
were O O
preserved O O
in O O
the O O
transformed B-cell_line B-cell_line
cells I-cell_line I-cell_line
from O O
the O O
patients O O
. O O

Octamer O B-protein
transcription O I-protein
factors O I-protein
1 O I-protein
and O I-protein
2 O I-protein
each O O
bind O O
to O O
two O O
different O O
functional B-DNA B-DNA
elements I-DNA I-DNA
in O O
the O O
immunoglobulin B-DNA B-DNA
heavy-chain I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Immunoglobulin B-DNA B-protein
heavy-chain I-DNA B-DNA
genes I-DNA I-DNA
contain O O
two O O
conserved B-DNA B-DNA
sequence I-DNA I-DNA
elements I-DNA I-DNA
5 O B-DNA
' O O
to O O
the O O
site O O
of O O
transcription O O
initiation O O
: O O
the O O
octamer O B-DNA
ATGCAAAT O I-DNA
and O O
the O O
heptamer O B-protein
CTCATGA O I-protein
. O O

Both O O
of O O
these O O
elements O O
are O O
required O O
for O O
normal B-DNA O
cell-specific I-DNA O
promoter I-DNA O
function O O
. O O

The O O
present O O
study O O
demonstrates O O
that O O
both O O
the O O
ubiquitous B-protein B-protein
and I-protein I-protein
lymphoid-cell-specific I-protein I-protein
octamer I-protein I-protein
transcription I-protein I-protein
factors I-protein I-protein
( O O
OTF-1 B-protein B-protein
and O O
OTF-2 B-protein B-protein
, O O
respectively O O
) O O
interact O O
specifically O O
with O O
each O O
of O O
the O O
two O O
conserved B-DNA B-DNA
sequence I-DNA I-DNA
elements I-DNA I-DNA
, O O
forming O O
either O O
homo- B-protein B-protein
or I-protein I-protein
heterodimeric I-protein I-protein
complexes I-protein I-protein
. O O

This O O
was O O
surprising O O
, O O
since O O
the O O
heptamer O O
and O O
octamer O B-DNA
sequence O I-DNA
motifs O I-DNA
bear O O
no O O
obvious O O
similarity O O
to O O
each O O
other O O
. O O

Binding O O
of O O
either O O
factor O O
to O O
the O O
octamer B-DNA B-DNA
element I-DNA I-DNA
occurred O O
independently O O
. O O

However O O
, O O
OTF B-protein O
interaction O O
with O O
the O O
heptamer B-DNA B-DNA
sequence I-DNA I-DNA
appeared O O
to O O
require O O
the O O
presence O O
of O O
an O O
intact O O
octamer O B-DNA
motif O I-DNA
and O O
occurred O O
with O O
a O O
spacing O O
of O O
either O O
2 B-DNA B-DNA
or I-DNA I-DNA
14 I-DNA I-DNA
base I-DNA I-DNA
pairs I-DNA I-DNA
between O O
the O O
two O O
elements O O
, O O
suggesting O O
coordinate O O
binding O O
resulting O O
from O O
protein-protein O O
interactions O O
. O O

The O O
degeneracy O O
in O O
sequences O O
recognized O O
by O O
the O O
OTFs B-protein O
may O O
be O O
important O O
in O O
widening O O
the O O
range O O
over O O
which O O
gene O O
expression O O
can O O
be O O
modulated O O
and O O
in O O
establishing O O
cell O O
type O O
specificity O O
. O O

Identification O O
of O O
a O O
novel O O
lymphoid B-protein B-protein
specific I-protein I-protein
octamer I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
( O O
OTF-2B B-protein B-protein
) O O
by O O
proteolytic O O
clipping O O
bandshift O O
assay O O
( O O
PCBA O O
) O O
. O O

The O O
octamer O B-DNA
sequence O I-DNA
ATGCAAAT O I-DNA
is O O
found O O
in O O
the O O
promoters O B-DNA
of O O
immunoglobulin B-DNA B-DNA
( I-DNA I-DNA
Ig I-DNA I-DNA
) I-DNA I-DNA
heavy I-DNA I-DNA
and I-DNA I-DNA
light I-DNA I-DNA
chain I-DNA I-DNA
genes I-DNA I-DNA
and O O
in O O
the O O
heavy B-DNA B-DNA
chain I-DNA I-DNA
enhancer I-DNA I-DNA
and O O
is O O
a O O
major O O
determinant O O
of O O
the O O
cell O O
type O O
specific O O
expression O O
of O O
Ig B-DNA B-DNA
genes I-DNA I-DNA
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

An O O
apparent O O
paradox O O
is O O
that O O
the O O
same O O
sequence O O
serves O O
as O O
an O O
upstream B-DNA B-DNA
promoter I-DNA I-DNA
or I-DNA O
enhancer I-DNA B-DNA
element I-DNA I-DNA
in O O
a O O
variety O O
of O O
housekeeping B-DNA B-DNA
genes I-DNA I-DNA
such O O
as O O
the O O
histone B-DNA B-protein
H2B I-DNA I-protein
and I-DNA O
U I-DNA B-DNA
snRNA I-DNA I-DNA
genes I-DNA I-DNA
. O O

The O O
differential O O
usage O O
of O O
this O O
regulatory O B-DNA
sequence O I-DNA
motif O I-DNA
is O O
thought O O
to O O
be O O
mediated O O
by O O
different O O
species O O
of O O
octamer B-protein B-protein
binding I-protein I-protein
proteins I-protein I-protein
. O O

One O O
species O O
of O O
100 O O
kd O O
, O O
designated O O
OTF-1 B-protein B-protein
, O O
is O O
present O O
in O O
all O O
cell O O
types O O
and O O
may O O
exert O O
its O O
activating O O
function O O
only O O
when O O
it O O
can O O
interact O O
with O O
additional O O
adjacent O O
transcription B-protein B-protein
factors I-protein I-protein
. O O

The O O
lymphoid B-protein B-protein
cell I-protein I-protein
specific I-protein I-protein
octamer I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
of O O
60 O B-protein
kd O I-protein
( O O
OTF-2A B-protein B-protein
) O O
specifically O O
stimulates O O
Ig B-DNA B-DNA
promoters I-DNA I-DNA
which O O
consist O O
essentially O O
of O O
a O O
TATA-box B-DNA B-DNA
and O O
an O O
octamer B-DNA B-DNA
sequence I-DNA I-DNA
upstream O O
of O O
it O O
. O O

Here O O
we O O
present O O
evidence O O
for O O
yet O O
another O O
B B-protein B-protein
cell I-protein I-protein
specific I-protein I-protein
octamer I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
of O O
75 O B-protein
kd O I-protein
( O O
OTF-2B B-protein B-protein
) O O
. O O

From O O
several O O
findings O O
, O O
including O O
the O O
absence O O
of O O
OTF-2B B-protein B-protein
( O O
but O O
not O O
OTF-2A B-protein O
) O O
from O O
a O O
lymphocyte B-cell_line B-cell_line
line I-cell_line I-cell_line
that O O
can O O
not O O
respond O O
to O O
the O O
IgH B-DNA B-DNA
enhancer I-DNA I-DNA
, O O
we O O
propose O O
a O O
role O O
of O O
the O O
novel B-protein O
octamer I-protein B-protein
factor I-protein I-protein
in O O
the O O
long O O
range O O
activation O O
by O O
the O O
IgH B-DNA B-DNA
enhancer I-DNA I-DNA
. O O

We O O
have O O
used O O
the O O
proteolytic O O
clipping O O
bandshift O O
assay O O
( O O
PCBA O O
) O O
technique O O
to O O
distinguish O O
the O O
three O O
different O O
forms O O
found O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

This O O
analysis O O
indicates O O
that O O
the O O
75 O B-protein
kd-species O I-protein
OTF-2B B-protein I-protein
is O O
closely O O
related O O
to O O
the O O
60 B-protein B-protein
kd I-protein I-protein
species I-protein I-protein
OTF-2A I-protein B-protein
. O O

Inhibition O O
of O O
interleukin B-protein B-protein
2 I-protein I-protein
-induced O O
proliferation O O
of O O
cloned B-cell_line B-cell_type
murine I-cell_line I-cell_type
T I-cell_line I-cell_type
cells I-cell_line I-cell_type
by O O
glucocorticoids O O
. O O

Possible O O
involvement O O
of O O
an O O
inhibitory B-protein B-protein
protein I-protein I-protein
. O O

The O O
ability O O
of O O
glucocorticoids O O
to O O
inhibit O O
interleukin B-protein B-protein
2 I-protein I-protein
( O O
IL B-protein O
2 I-protein O
) O O
-induced O O
T B-cell_type O
cell I-cell_type O
proliferation O O
in O O
two O O
cytotoxic B-cell_line B-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
( I-cell_line I-cell_line
CTL I-cell_line I-cell_line
) I-cell_line I-cell_line
clones I-cell_line I-cell_line
has O O
been O O
studied O O
. O O

A O O
complete O O
inhibition O O
of O O
DNA O O
synthesis O O
by O O
dexamethasone O O
( O O
Dx O O
) O O
could O O
be O O
observed O O
when O O
IL B-cell_line B-cell_line
2-depleted I-cell_line I-cell_line
cultures I-cell_line I-cell_line
of O O
CTL B-cell_line B-cell_type
were O O
either O O
incubated O O
for O O
6 O O
h O O
with O O
the O O
hormone B-protein O
prior O O
to O O
the O O
addition O O
of O O
IL B-protein O
2 I-protein O
or O O
treated O O
simultaneously O O
with O O
Dx O O
and O O
a O O
low O O
concentration O O
of O O
IL B-protein B-protein
2 I-protein I-protein
. O O

No O O
significant O O
reduction O O
in O O
the O O
number O O
and O O
affinity O O
of O O
IL B-protein B-protein
2 I-protein I-protein
receptors I-protein I-protein
was O O
seen O O
after O O
6 O O
h O O
incubation O O
with O O
Dx O O
. O O

The O O
order O O
of O O
potency O O
observed O O
with O O
the O O
different O O
steroids O O
indicated O O
that O O
this O O
inhibitory O O
effect O O
was O O
mediated O O
through O O
binding O O
to O O
a O O
specific O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
. O O

The O O
action O O
of O O
these O O
hormones B-protein O
possibly O O
involves O O
the O O
synthesis O O
of O O
an O O
inhibitory B-protein B-protein
protein I-protein I-protein
( O O
s O O
) O O
, O O
since O O
the O O
presence O O
of O O
cycloheximide O O
during O O
the O O
incubation O O
with O O
Dx O O
prevented O O
the O O
inhibition O O
of O O
DNA O O
synthesis O O
. O O

Furthermore O O
, O O
supernatant O O
from O O
Dx-treated O B-cell_type
CTL B-cell_line I-cell_type
contained O O
a O O
nondialyzable O B-protein
factor O I-protein
which O O
inhibited O O
DNA O O
synthesis O O
and O O
cell O O
growth O O
of O O
CTL B-cell_line B-cell_line
clones I-cell_line I-cell_line
induced O O
by O O
IL B-protein O
2 I-protein O
. O O

Blocking O O
of O O
IL B-protein B-protein
2 I-protein I-protein
synthesis O O
and O O
IL B-protein B-protein
2 I-protein I-protein
receptor I-protein I-protein
formation O O
have O O
been O O
proposed O O
as O O
one O O
of O O
the O O
major O O
mechanisms O O
of O O
glucocorticoid-induced O O
immunosuppression O O
. O O

Our O O
results O O
indicate O O
that O O
these O O
hormones B-protein O
may O O
also O O
affect O O
T B-cell_type O
cell I-cell_type O
proliferation O O
by O O
inhibiting O O
IL B-protein B-protein
2 I-protein I-protein
activity O O
. O O

Identification O O
and O O
purification O O
of O O
a O O
human B-protein B-protein
immunoglobulin-enhancer-binding I-protein I-protein
protein I-protein I-protein
( O O
NF-kappa B-protein B-protein
B I-protein I-protein
) O O
that O O
activates O O
transcription O O
from O O
a O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
1 I-DNA I-DNA
promoter I-DNA I-DNA
in O O
vitro O O
. O O

The O O
enhancer-binding B-protein B-protein
factor I-protein I-protein
NF-kappa I-protein B-protein
B I-protein I-protein
, O O
which O O
is O O
found O O
only O O
in O O
cells O O
that O O
transcribe O B-DNA
immunoglobulin B-DNA I-DNA
light I-DNA I-DNA
chain I-DNA I-DNA
genes I-DNA I-DNA
, O O
has O O
been O O
purified O O
from O O
nuclear O O
extracts O O
of O O
Namalwa B-cell_line B-cell_line
cells I-cell_line I-cell_line
( O O
human B-cell_line B-cell_line
Burkitt I-cell_line I-cell_line
lymphoma I-cell_line I-cell_line
cells I-cell_line I-cell_line
) O O
by O O
sequence-specific O O
DNA O O
affinity O O
chromatography O O
. O O

The O O
purified O O
NF-kappa B-protein B-protein
B I-protein I-protein
has O O
been O O
identified O O
as O O
a O O
51-kDa B-protein O
polypeptide I-protein O
by O O
UV-crosslinking O O
analysis O O
. O O

`` O O
Footprint O O
'' O O
and O O
methylation-interference O O
analyses O O
have O O
shown O O
that O O
purified O O
NF-kappa B-protein B-protein
B I-protein I-protein
has O O
a O O
binding O O
activity O O
specific O O
for O O
the O O
kappa B-DNA B-DNA
light I-DNA I-DNA
chain I-DNA I-DNA
enhancer I-DNA I-DNA
sequence I-DNA I-DNA
. O O

The O O
purified O O
factor O O
activated O O
in O O
vitro O O
transcription O O
of O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
I I-DNA I-DNA
promoter I-DNA I-DNA
by O O
binding O O
to O O
an O O
upstream B-DNA O
NF-kappa I-DNA B-DNA
B-binding I-DNA I-DNA
site I-DNA I-DNA

Lymphocyte B-cell_type B-protein
glucocorticoid B-protein I-protein
receptor I-protein I-protein
binding O O
in O O
depression O O
: O O
normal O O
values O O
following O O
recovery O O
. O O

The O O
number O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
sites O I-protein
in O O
lymphocytes B-cell_type B-cell_type
and O O
plasma O O
cortisol O O
concentrations O O
were O O
measured O O
in O O
20 O O
patients O O
who O O
had O O
recovered O O
from O O
major O O
depressive O O
disorder O O
and O O
20 O O
healthy O O
control O O
subjects O O
. O O

The O O
number O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
sites O I-protein
in O O
lymphocytes B-cell_type B-cell_type
from O O
the O O
recovered O O
depressed O O
group O O
was O O
not O O
significantly O O
different O O
from O O
that O O
of O O
the O O
control O O
group O O
. O O

Although O O
the O O
mean O O
plasma O O
cortisol O O
concentration O O
in O O
recovered O O
depressives O O
was O O
higher O O
than O O
in O O
control O O
subjects O O
, O O
the O O
difference O O
only O O
just O O
reached O O
significance O O
. O O

This O O
study O O
shows O O
that O O
the O O
reduction O O
in O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
numbers O O
which O O
occurs O O
during O O
acute O O
depressive O O
illness O O
does O O
not O O
persist O O
on O O
recovery O O
and O O
is O O
, O O
therefore O O
, O O
state-dependent O O
. O O

Identification O O
and O O
purification O O
of O O
a O O
human B-protein B-protein
lymphoid-specific I-protein I-protein
octamer-binding I-protein I-protein
protein I-protein I-protein
( O O
OTF-2 B-protein B-protein
) O O
that O O
activates O O
transcription O O
of O O
an O O
immunoglobulin B-DNA B-DNA
promoter I-DNA I-DNA
in O O
vitro O O
. O O

The O O
octamer O B-DNA
sequence O I-DNA
5'-ATGCAAAT O I-DNA
, O O
in O O
either O O
orientation O O
, O O
serves O O
as O O
an O O
upstream B-DNA B-DNA
element I-DNA I-DNA
in O O
a O O
variety O O
of O O
promoters B-DNA B-DNA
and O O
also O O
occurs O O
as O O
a O O
modular B-DNA B-DNA
enhancer I-DNA I-DNA
element I-DNA I-DNA
. O O

It O O
is O O
of O O
particular O O
interest O O
in O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
since O O
it O O
is O O
found O O
in O O
the O O
upstream B-DNA B-DNA
regions I-DNA I-DNA
of O O
all O O
heavy B-DNA B-DNA
and I-DNA I-DNA
light I-DNA I-DNA
chain I-DNA I-DNA
promoters I-DNA I-DNA
and O O
in O O
the O O
heavy B-DNA B-DNA
chain I-DNA I-DNA
enhancer I-DNA I-DNA
, O O
both O O
of O O
which O O
are O O
known O O
to O O
be O O
necessary O O
for O O
cell-specific O O
expression O O
. O O

We O O
report O O
here O O
the O O
chromatographic O O
separation O O
of O O
ubiquitous B-protein O
and I-protein O
B I-protein B-protein
cell-specific I-protein I-protein
octamer-binding I-protein I-protein
proteins I-protein I-protein
. O O

The O O
B B-protein B-protein
cell I-protein I-protein
factor I-protein I-protein
was O O
purified O O
to O O
homogeneity O O
using O O
affinity O O
chromatography O O
and O O
consists O O
of O O
three O O
peptides O O
of O O
62 O O
, O O
61 O O
, O O
and O O
58.5 O O
+/- O O
1.5 O O
kd O O
. O O

Each O O
of O O
the O O
polypeptides O O
was O O
renatured O O
after O O
SDS-PAGE O O
and O O
shown O O
to O O
bind O O
to O O
the O O
octamer O B-DNA
sequence O I-DNA
. O O

The O O
specific O O
DNA O O
binding O O
activity O O
of O O
the O O
pure O B-protein
B B-protein I-protein
cell-specific I-protein I-protein
factor I-protein I-protein
was O O
indistinguishable O O
from O O
that O O
of O O
the O O
affinity-purified B-protein B-protein
ubiquitous I-protein I-protein
factor I-protein I-protein
. O O

This O O
B B-protein B-protein
cell-specific I-protein I-protein
octamer-binding I-protein I-protein
factor I-protein I-protein
, O O
in O O
pure O O
form O O
, O O
activated O O
transcription O O
from O O
a O O
kappa B-DNA B-DNA
light I-DNA I-DNA
chain I-DNA I-DNA
promoter I-DNA I-DNA
in O O
vitro O O
, O O
thus O O
demonstrating O O
that O O
it O O
is O O
indeed O O
a O O
B B-protein B-protein
cell-specific I-protein I-protein
transcription I-protein I-protein
factor I-protein I-protein
for O O
this O O
gene O O
. O O

In O O
addition O O
to O O
the O O
ubiquitous B-protein B-protein
and I-protein I-protein
B I-protein I-protein
cell-specific I-protein I-protein
octamer-binding I-protein I-protein
factors I-protein I-protein
, O O
we O O
identified O O
several O O
additional O O
proteins O O
, O O
one O O
of O O
which O O
is O O
B B-cell_type O
cell I-cell_type O
-specific O O
, O O
that O O
interact O O
with O O
the O O
kappa B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Decreased O O
deoxyribonucleic O O
acid O O
binding O O
of O O
glucocorticoid-receptor B-protein B-protein
complex I-protein I-protein
in O O
cultured O B-cell_line
skin B-cell_line I-cell_line
fibroblasts I-cell_line I-cell_line
from O O
a O O
patient O O
with O O
the O O
glucocorticoid O O
resistance O O
syndrome O O
. O O

A O O
patient O O
with O O
the O O
syndrome O O
of O O
glucocorticoid O O
resistance O O
was O O
studied O O
. O O

A O O
27-yr-old O O
woman O O
initially O O
was O O
diagnosed O O
as O O
having O O
Cushing O O
's O O
disease O O
, O O
based O O
on O O
the O O
findings O O
of O O
high O O
plasma O O
ACTH O O
and O O
serum O O
cortisol O O
levels O O
, O O
increased O O
urinary O O
cortisol O O
secretion O O
, O O
resistance O O
to O O
adrenal O O
suppression O O
with O O
dexamethasone O O
, O O
and O O
bilateral O O
adrenal O O
hyperplasia O O
by O O
computed O O
tomography O O
and O O
scintigraphy O O
of O O
the O O
adrenal O O
glands O O
. O O

However O O
, O O
she O O
had O O
no O O
signs O O
or O O
symptoms O O
of O O
Cushing O O
's O O
syndrome O O
. O O

During O O
a O O
5-yr O O
follow-up O O
, O O
no O O
clinical O O
abnormalities O O
developed O O
, O O
although O O
hypercortisolism O O
persisted O O
. O O

End-organ O O
resistance O O
to O O
cortisol O O
was O O
suspected O O
. O O

To O O
explain O O
the O O
end-organ O O
resistance O O
to O O
cortisol O O
, O O
the O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
( O O
GR B-protein B-protein
) O O
in O O
peripheral B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
and O O
cultured B-cell_line B-cell_type
skin I-cell_line I-cell_type
fibroblasts I-cell_line I-cell_type
from O O
a O O
forearm O O
skin O O
biopsy O O
were O O
characterized O O
and O O
compared O O
with O O
the O O
results O O
of O O
similar O O
studies O O
in O O
normal O O
subjects O O
. O O

The O O
patient O O
's O O
GR B-protein B-protein
in O O
whole O O
cell O O
assays O O
had O O
an O O
increased O O
dissociation O O
constant O O
( O O
Kd O O
) O O
. O O

In O O
the O O
cytosol O O
of O O
cultured B-cell_line B-cell_type
skin I-cell_line I-cell_type
fibroblasts I-cell_line I-cell_type
from O O
the O O
patient O O
, O O
there O O
was O O
also O O
decreased O O
binding O O
capacity O O
. O O

The O O
thermal O O
stability O O
and O O
the O O
sedimentation O O
coefficient O O
in O O
a O O
sucrose O O
density O O
gradient O O
of O O
the O O
receptors O O
in O O
the O O
cytosol O O
of O O
cultured B-cell_line B-cell_type
skin I-cell_line I-cell_type
fibroblasts I-cell_line I-cell_type
from O O
the O O
patient O O
and O O
normal O O
subjects O O
were O O
similar O O
. O O

GR B-cell_line B-protein
complex I-cell_line I-protein
activation I-cell_line O
, O O
analyzed O O
by O O
DEAE-cellulose B-cell_line O
chromatography I-cell_line O
, O O
was O O
decreased O O
in O O
the O O
patient O O
. O O

DNA B-DNA O
binding O O
of O O
the O O
GR B-protein B-protein
complex I-protein I-protein
after O O
temperature-induced O O
activation O O
was O O
lower O O
in O O
the O O
patient O O
than O O
in O O
normal O O
subjects O O
. O O

Nuclear O O
translocation O O
of O O
GR B-protein B-protein
complexes I-protein I-protein
from O O
the O O
patient O O
was O O
also O O
slightly O O
decreased O O
. O O

These O O
results O O
suggest O O
that O O
the O O
patient O O
's O O
glucocorticoid O O
resistance O O
was O O
due O O
to O O
a O O
decrease O O
in O O
the O O
affinity O O
of O O
the O O
receptor O O
for O O
glucocorticoids O O
and O O
a O O
decrease O O
in O O
the O O
binding O O
of O O
the O O
GR B-protein B-protein
complex I-protein I-protein
to O O
DNA B-DNA O
. O O

Granulocyte-macrophage B-protein B-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
. O O

Sensitive O O
and O O
receptor-mediated O O
regulation O O
by O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
in O O
normal O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

We O O
show O O
that O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
( O O
1 O O
, O O
25 O O
[ O O
OH O O
] O O
2D3 O O
) O O
, O O
the O O
most O O
hormonally O O
active O O
metabolite O O
of O O
vitamin O O
D3 O O
, O O
modulates O O
sensitively O O
and O O
specifically O O
both O O
the O O
protein O O
and O O
messenger B-RNA O
RNA I-RNA O
accumulation O O
of O O
the O O
multilineage B-protein B-protein
growth I-protein I-protein
factor I-protein I-protein
granulocyte-macrophage B-protein I-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
( O O
GM-CSF B-protein B-protein
) O O
. O O

The O O
regulation O O
of O O
GM-CSF B-protein B-protein
expression O O
is O O
seen O O
in O O
both O O
normal B-cell_type O
human I-cell_type O
mitogen-activated I-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
T B-cell_line B-cell_type
lymphocytes I-cell_line I-cell_type
from I-cell_line O
a I-cell_line O
line I-cell_line O
( I-cell_line O
S-LB1 I-cell_line B-cell_line
) I-cell_line O
transformed I-cell_line O
with I-cell_line O
human I-cell_line O
T I-cell_line O
cell I-cell_line O
lymphotropic I-cell_line O
virus I-cell_line O
1 I-cell_line O
( O O
HTLV-1 O O
) O O
. O O

In O O
contrast O O
, O O
cells O O
from O O
a O O
HTLV-1 B-cell_line B-cell_line
transformed I-cell_line I-cell_line
T I-cell_line I-cell_line
lymphocyte I-cell_line I-cell_line
line I-cell_line I-cell_line
( O O
Ab-VDR B-cell_line O
) O O
established O O
from O O
a O O
patient O O
with O O
vitamin O O
D-resistant O O
rickets O O
type O O
II O O
with O O
undetectable O B-protein
1 B-protein I-protein
, I-protein I-protein
25 I-protein I-protein
( I-protein I-protein
OH I-protein I-protein
) I-protein I-protein
2D3 I-protein I-protein
cellular I-protein I-protein
receptors I-protein I-protein
are O O
resistant O O
to O O
the O O
action O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
. O O

Inhibition O O
of O O
GM-CSF B-protein B-protein
expression O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
can O O
occur O O
independently O O
of O O
interleukin B-protein B-protein
2 I-protein I-protein
regulation O O
and O O
is O O
probably O O
mediated O O
through O O
cellular B-protein O
1 I-protein O
, I-protein O
25 I-protein O
( I-protein O
OH I-protein O
) I-protein O
2D3 I-protein B-protein
receptors I-protein I-protein
. O O

We O O
conclude O O
that O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
may O O
be O O
important O O
in O O
the O O
physiology O O
of O O
hematopoiesis O O
. O O

Altered O O
interaction O O
between O O
triiodothyronine O O
and O O
its O O
nuclear B-protein B-protein
receptors I-protein I-protein
in O O
absence O O
of O O
cortisol O O
: O O
a O O
proposed O O
mechanism O O
for O O
increased O O
thyrotropin O O
secretion O O
in O O
corticosteroid O O
deficiency O O
states O O
. O O

Thyroid O O
hormones O O
occasionally O O
appear O O
less O O
effective O O
when O O
administered O O
alone O O
to O O
patients O O
with O O
panhypopituitarism O O
, O O
and O O
manifestations O O
suggestive O O
of O O
hypothyroidism O O
have O O
been O O
reported O O
in O O
patients O O
suffering O O
from O O
untreated O O
Addison O O
's O O
disease O O
. O O

In O O
the O O
latter O O
condition O O
, O O
thyrotropin O O
secretion O O
is O O
increased O O
: O O
this O O
occurs O O
already O O
after O O
as O O
little O O
as O O
2 O O
days O O
of O O
temporary O O
withdrawal O O
of O O
therapy O O
with O O
substitution O O
doses O O
of O O
corticosteroids O O
while O O
circulating O O
levels O O
of O O
thyroid O O
hormones O O
remain O O
within O O
normal O O
limits O O
. O O

Therefore O O
, O O
a O O
possible O O
role O O
of O O
cortisol O O
in O O
interaction O O
between O O
triiodothyronine O O
and O O
its O O
nuclear B-protein B-protein
receptors I-protein I-protein
was O O
examined O O
at O O
the O O
level O O
of O O
circulating O B-cell_type
lymphocytes O I-cell_type
obtained O O
from O O
patients O O
with O O
primary O O
or O O
secondary O O
adrenocortical O O
failure O O
. O O

The O O
affinity O O
of O O
these O O
receptors O O
was O O
found O O
to O O
be O O
decreased O O
, O O
by O O
more O O
than O O
50 O O
% O O
on O O
average O O
, O O
in O O
the O O
absence O O
of O O
cortisol O O
treatments O O
. O O

This O O
change O O
was O O
promptly O O
corrected O O
upon O O
resumption O O
of O O
therapy O O
. O O

The O O
number O O
of O O
binding O B-DNA
sites O I-DNA
was O O
not O O
significantly O O
modified O O
. O O

The O O
influence O O
of O O
cortisol O O
on O O
thyroid B-protein B-protein
hormone I-protein I-protein
receptors I-protein I-protein
discussed O O
here O O
might O O
account O O
for O O
the O O
clinical O O
observations O O
mentioned O O
above O O
. O O

Inhibition O O
by O O
cortisol O O
of O O
human B-cell_type B-cell_type
natural I-cell_type I-cell_type
killer I-cell_type I-cell_type
( I-cell_type I-cell_type
NK I-cell_type I-cell_type
) I-cell_type I-cell_type
cell I-cell_type I-cell_type
activity O O
. O O

The O O
effects O O
of O O
cortisol O O
on O O
the O O
natural B-cell_type B-cell_type
killer I-cell_type I-cell_type
( O O
NK O O
) O O
activity O O
of O O
human B-cell_type B-cell_line
peripheral I-cell_type I-cell_line
blood I-cell_type I-cell_line
mononuclear I-cell_type I-cell_line
( I-cell_type I-cell_line
PBM I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
were O O
studied O O
in O O
vitro O O
using O O
a O O
direct O O
4-h O O
51Cr-release O O
assay O O
and O O
K B-cell_line B-cell_line
562 I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
as O O
a O O
target O O
. O O

Preincubation O O
for O O
20 O O
h O O
of O O
PBM B-cell_type B-cell_type
cells I-cell_type I-cell_type
drawn O O
from O O
healthy O O
donors O O
with O O
1 O O
X O O
10 O O
( O O
-8 O O
) O O
to O O
1 O O
X O O
10 O O
( O O
-5 O O
) O O
M O O
cortisol O O
resulted O O
in O O
a O O
significant O O
decrease O O
of O O
NK B-cell_type O
cell I-cell_type O
activity O O
. O O

The O O
magnitude O O
of O O
the O O
suppression O O
was O O
directly O O
related O O
to O O
the O O
steroid O O
concentration O O
and O O
inversely O O
related O O
to O O
the O O
number O O
of O O
effector B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Cortisol O O
was O O
able O O
to O O
minimize O O
the O O
enhancement O O
of O O
NK O O
cytotoxicity O O
obtainable O O
in O O
the O O
presence O O
of O O
immune O B-protein
interferon O I-protein
( O O
IFN-gamma O B-protein
) O O
. O O

A O O
significantly O O
higher O O
suppression O O
was O O
achieved O O
after O O
sequential O O
exposure O O
of O O
PBM B-cell_type B-cell_line
cells I-cell_type I-cell_line
to O O
cortisol O O
and O O
equimolar O O
levels O O
of O O
prostaglandin O O
E2 O O
( O O
PgE2 O O
) O O
. O O

The O O
concomitant O O
incubation O O
with O O
theophylline O O
and O O
isobutyl-methylxanthine O O
failed O O
to O O
enhance O O
the O O
cortisol-induced O O
suppression O O
, O O
whereas O O
PgE2-dependent O O
inhibition O O
significantly O O
increased O O
after O O
exposure O O
of O O
PBM B-cell_type B-cell_type
cells I-cell_type I-cell_type
to O O
methyl-xanthines O O
. O O

The O O
inhibitory O O
effect O O
of O O
cortisol O O
was O O
partially O O
or O O
totally O O
prevented O O
by O O
the O O
concomitant O O
incubation O O
with O O
equimolar O O
amounts O O
of O O
11-deoxycortisol O O
and O O
RU O O
486 O O
but O O
not O O
of O O
progesterone O O
. O O

Treatment O O
of O O
NK B-cell_type B-protein
effectors I-cell_type I-protein
with O O
a O O
monoclonal B-protein B-protein
anti-human I-protein I-protein
corticosteroid-binding I-protein I-protein
globulin I-protein I-protein
( I-protein I-protein
CBG I-protein I-protein
) I-protein I-protein
antibody I-protein I-protein
produced O O
an O O
enhancement O O
of O O
the O O
spontaneous O O
NK B-cell_type O
activity O O
and O O
a O O
partial O O
suppression O O
of O O
cortisol-mediated O O
effects O O
. O O

Our O O
results O O
suggest O O
that O O
endogenous O O
glucocorticoids O O
play O O
a O O
role O O
in O O
the O O
regulation O O
of O O
NK O O
cell-mediated O O
cytotoxicity O O
. O O

Since O O
the O O
effect O O
of O O
cortisol O O
was O O
additive O O
to O O
that O O
of O O
PgE2 O O
and O O
was O O
not O O
changed O O
by O O
phosphodiesterase B-protein O
inhibitors O O
, O O
it O O
is O O
conceivable O O
that O O
the O O
hormone O O
acts O O
at O O
a O O
level O O
different O O
from O O
the O O
adenylate B-protein B-protein
cyclase I-protein I-protein
- O O
phosphodiesterase B-protein O
system O O
. O O

Data O O
obtained O O
with O O
the O O
use O O
of O O
antiglucocorticoids O O
and O O
the O O
anti-CBG B-protein B-protein
antibody I-protein I-protein
are O O
compatible O O
with O O
a O O
role O O
both O O
of O O
high-affinity O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
and O O
of O O
CBG B-protein B-protein
in O O
mediating O O
cortisol O O
action O O
on O O
the O O
human B-cell_type O
NK I-cell_type O
cell I-cell_type O
activity O O
. O O

Interaction O O
of O O
cell-type-specific B-protein B-protein
nuclear I-protein I-protein
proteins I-protein I-protein
with O O
immunoglobulin B-DNA B-DNA
VH I-DNA I-DNA
promoter I-DNA I-DNA
region I-DNA I-DNA
sequences I-DNA I-DNA
. O O

All O O
human B-DNA O
and I-DNA O
murine I-DNA B-DNA
immunoglobulin I-DNA I-DNA
heavy I-DNA I-DNA
chain I-DNA I-DNA
variable I-DNA I-DNA
region I-DNA I-DNA
( I-DNA I-DNA
VH I-DNA I-DNA
) I-DNA I-DNA
genes I-DNA I-DNA
contain O O
the O O
sequence O O
ATGCAAAT O O
approximately O O
70 O B-DNA
nucleotides O I-DNA
5 O I-DNA
' O O
from O O
the O O
site O O
of O O
transcription O O
initiation O O
. O O

This O O
octanucleotide O O
, O O
in O O
reverse O O
orientation O O
, O O
is O O
also O O
found O O
in O O
all O O
light B-DNA B-DNA
chain I-DNA I-DNA
variable I-DNA I-DNA
region I-DNA I-DNA
( I-DNA I-DNA
VL I-DNA I-DNA
) I-DNA I-DNA
genes I-DNA I-DNA
, O O
and O O
in O O
the O O
immunoglobulin B-DNA B-DNA
heavy I-DNA I-DNA
chain I-DNA I-DNA
transcriptional I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

Transfection O O
studies O O
have O O
established O O
that O O
this O O
octamer O B-DNA
is O O
involved O O
in O O
the O O
lymphoid-specific O B-DNA
transcription O O
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
. O O

Octamer-containing B-DNA B-protein
fragments I-DNA I-protein
have O O
been O O
reported O O
to O O
bind O O
a O O
factor O O
present O O
in O O
nuclear O O
extracts O O
of O O
human B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
; O O
however O O
, O O
identical O O
binding O O
activity O O
was O O
detected O O
in O O
both O O
B B-cell_line B-cell_type
lymphoid I-cell_line I-cell_type
and I-cell_line I-cell_type
non-lymphoid I-cell_line I-cell_type
cells I-cell_line I-cell_type
. O O

Here O O
we O O
establish O O
that O O
nuclear O O
extracts O O
from O O
distinct O O
cell O O
types O O
differ O O
in O O
their O O
ability O O
to O O
interact O O
with O O
octamer-containing B-DNA B-DNA
fragments I-DNA I-DNA
. O O

We O O
have O O
also O O
detected O O
a O O
DNA-protein O O
interaction O O
that O O
may O O
be O O
involved O O
in O O
the O O
cell-type O O
specificity O O
of O O
immunoglobulin B-protein B-protein
expression O O
, O O
and O O
we O O
have O O
determined O O
that O O
a O O
sequence O O
upstream O O
of O O
the O O
octamer O O
participates O O
in O O
an O O
interaction O O
with O O
a O O
nuclear B-protein B-protein
protein I-protein I-protein
( O O
s O O
) O O
. O O

Preferential O O
transcription O O
of O O
HTLV-I B-DNA B-DNA
LTR I-DNA I-DNA
in O O
cell-free O O
extracts O O
of O O
human B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
producing O O
HTLV-I B-protein B-protein
viral I-protein I-protein
proteins I-protein I-protein
. O O

The O O
promoters B-DNA B-DNA
of O O
the O O
adenovirus B-DNA B-DNA
2 I-DNA I-DNA
major I-DNA I-DNA
late I-DNA I-DNA
gene I-DNA I-DNA
, O O
the O O
mouse B-DNA B-DNA
beta-globin I-DNA I-DNA
gene I-DNA I-DNA
, O O
the O O
mouse B-DNA B-DNA
immunoglobulin I-DNA I-DNA
VH I-DNA I-DNA
gene I-DNA I-DNA
and O O
the O O
LTR B-DNA B-DNA
of O O
the O O
human O B-DNA
T-lymphotropic O I-DNA
retrovirus O I-DNA
type O I-DNA
I O I-DNA
were O O
tested O O
for O O
their O O
transcription O O
activities O O
in O O
cell-free O O
extracts O O
of O O
four O O
cell O B-cell_line
lines O I-cell_line
; O O
HeLa B-cell_line B-cell_line
, O O
CESS B-cell_line B-cell_line
( O O
Epstein-Barr B-cell_line B-cell_line
virus-transformed I-cell_line I-cell_line
human I-cell_line I-cell_line
B I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
) O O
, O O
MT-1 B-cell_line B-cell_line
( O I-cell_line
HTLV-I-infected B-cell_line I-cell_line
human I-cell_line I-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
without O O
viral O O
protein O O
synthesis O O
) O O
, O O
and O O
MT-2 B-cell_line B-cell_line
( O I-cell_line
HTLV-I-infected B-cell_line I-cell_line
human I-cell_line I-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
producing O O
viral B-protein B-protein
proteins I-protein I-protein
) O O
. O O

LTR B-DNA B-DNA
was O O
preferentially O O
transcribed O O
in O O
the O O
extracts O O
of O O
MT-2 B-cell_line B-cell_line
although O O
the O O
other O O
three O O
genes O O
were O O
transcribed O O
with O O
relatively O O
constant O O
efficiencies O O
in O O
different O O
extracts O O
. O O

The O O
results O O
agree O O
well O O
with O O
the O O
previous O O
in O O
vivo O O
studies O O
on O O
the O O
promoter O O
activity O O
of O O
HTLV-I B-DNA O
LTR I-DNA B-DNA
. O O

Mixing O O
of O O
HeLa O B-cell_line
and O O
MT-2 O B-cell_line
extracts O O
revealed O O
the O O
presence O O
of O O
a O O
LTR-specific O O
stimulating O O
activity O O
in O O
MT-2 O O
extracts O O
. O O

A O O
nuclear B-protein B-protein
factor I-protein I-protein
that O O
binds O O
to O O
a O O
conserved O B-DNA
sequence O I-DNA
motif O I-DNA
in O O
transcriptional B-DNA B-DNA
control I-DNA I-DNA
elements I-DNA I-DNA
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
. O O

Trans-acting B-protein B-protein
factors I-protein I-protein
that O O
mediate O O
B-cell O O
specific O O
transcription O O
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
have O O
been O O
postulated O O
based O O
on O O
an O O
analysis O O
of O O
the O O
expression O O
of O O
exogenously O O
introduced O O
immunoglobulin B-DNA B-DNA
gene I-DNA I-DNA
recombinants I-DNA I-DNA
in O O
lymphoid B-cell_type B-cell_type
and I-cell_type I-cell_type
non-lymphoid I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Two O O
B-cell-specific O B-DNA
, O O
cis-acting B-DNA B-DNA
transcriptional I-DNA I-DNA
regulatory I-DNA I-DNA
elements I-DNA I-DNA
have O O
been O O
identified O O
. O O

One O O
element O O
is O O
located O O
in O O
the O O
intron O B-DNA
between O O
the O O
variable O O
( O O
V O O
) O O
and O O
constant O B-DNA
( O I-DNA
C O I-DNA
) O I-DNA
regions O I-DNA
of O O
both O O
heavy B-DNA B-DNA
and I-DNA I-DNA
kappa I-DNA I-DNA
light-chain I-DNA I-DNA
genes I-DNA I-DNA
and O O
acts O O
as O O
a O O
transcriptional O B-DNA
enhancer O I-DNA
. O O

The O O
second O B-DNA
element B-DNA I-DNA
is O O
found O O
upstream O O
of O O
both O O
heavy B-DNA B-DNA
and I-DNA I-DNA
kappa I-DNA I-DNA
light-chain I-DNA I-DNA
gene I-DNA I-DNA
promoters I-DNA I-DNA
. O O

This O O
element O O
directs O O
lymphoid-specific O B-protein
transcription O O
even O O
in O O
the O O
presence O O
of O O
viral B-DNA B-DNA
enhancers I-DNA I-DNA
. O O

We O O
have O O
sought O O
nuclear O B-protein
factors O I-protein
that O O
might O O
bind O O
specifically O O
to O O
these O O
two O O
regulatory B-DNA B-DNA
elements I-DNA I-DNA
by O O
application O O
of O O
a O O
modified O O
gel O O
electrophoresis O O
DNA O O
binding O O
assay O O
. O O

We O O
report O O
here O O
the O O
identification O O
of O O
a O O
human B-protein B-protein
B-cell I-protein I-protein
nuclear I-protein I-protein
factor I-protein I-protein
( O O
IgNF-A B-protein B-protein
) O O
that O O
binds O O
to O O
DNA B-DNA B-DNA
sequences I-DNA I-DNA
in O O
the O O
upstream B-DNA B-DNA
regions I-DNA I-DNA
of O O
both O O
the O O
mouse B-DNA B-DNA
heavy I-DNA I-DNA
and I-DNA I-DNA
kappa I-DNA I-DNA
light-chain I-DNA I-DNA
gene I-DNA I-DNA
promoters I-DNA I-DNA
and O O
also O O
to O O
the O O
mouse B-DNA B-DNA
heavy-chain I-DNA I-DNA
gene I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

This O O
sequence-specific O O
binding O O
is O O
probably O O
mediated O O
by O O
a O O
highly O O
conserved O B-DNA
sequence O I-DNA
motif O I-DNA
, O O
ATTTGCAT O B-DNA
, O O
present O O
in O O
all O O
three O O
transcriptional B-DNA B-DNA
elements I-DNA I-DNA
. O O

Interestingly O O
, O O
a O O
factor O O
showing O O
similar O O
binding O O
specificity O O
to O O
IgNF-A B-DNA B-protein
is O O
also O O
present O O
in O O
human B-cell_line B-cell_line
HeLa I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

The O O
new O O
world O O
primates O O
as O O
animal O O
models O O
of O O
glucocorticoid O O
resistance O O
. O O

Many O O
New O O
World O O
primate O O
species O O
have O O
greatly O O
increased O O
plasma O O
cortisol O O
concentrations O O
, O O
decreased O O
plasma O B-protein
cortisol O I-protein
binding O I-protein
globulin O I-protein
capacity O O
and O O
affinity O O
, O O
marked O O
resistance O O
of O O
the O O
hypothalamic-pituitary-adrenal O O
axis O O
to O O
suppression O O
by O O
dexamethasone O O
, O O
and O O
no O O
biological O O
evidence O O
of O O
glucocorticoid O O
excess O O
. O O

These O O
primates O O
also O O
have O O
high O O
levels O O
of O O
circulating O O
progesterone O O
, O O
estrogen O O
, O O
mineralocorticoid O O
, O O
androgen O O
and O O
vitamin O O
D O O
. O O

The O O
glucocorticoid O O
target O O
tissues O O
that O O
have O O
been O O
examined O O
( O O
circulating B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
cultured B-cell_line B-cell_line
skin I-cell_line I-cell_line
fibroblasts I-cell_line I-cell_line
) O O
have O O
normal O O
concentrations O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
with O O
decreased O O
affinity O O
for O O
dexamethasone O O
. O O

Transformation O O
of O O
B-lymphocytes B-cell_type B-cell_type
with O O
the O O
Epstein-Barr O O
virus O O
leads O O
to O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
induction O O
that O O
is O O
less O O
than O O
that O O
observed O O
with O O
cells O O
from O O
Old O O
World O O
primates O O
. O O

The O O
receptor O O
in O O
these O O
cells O O
has O O
a O O
low O O
affinity O O
for O O
dexamethasone O O
. O O

The O O
low O O
affinity O O
leads O O
to O O
an O O
increased O O
loss O O
of O O
specific O O
bound O O
ligand O O
during O O
thermal O O
activation O O
. O O

Meroreceptor O O
generation O O
is O O
normal O O
. O O

The O O
molecular O O
weight O O
of O O
the O O
receptor O O
, O O
determined O O
by O O
SDS-PAGE O O
, O O
is O O
similar O O
to O O
that O O
of O O
Old O O
World O O
primates O O
( O O
approximately O O
92 O O
, O O
000 O O
) O O
and O O
the O O
activation O O
pattern O O
per O O
se O O
, O O
examined O O
in O O
vitro O O
by O O
heating O O
cytosol O O
and O O
performing O O
phosphocellulose O O
chromatography O O
, O O
appears O O
similar O O
to O O
that O O
of O O
human O O
controls O O
. O O

The O O
ratios O O
of O O
nuclear O O
to O O
cytosolic B-protein B-protein
hormone-receptor-complexes I-protein I-protein
and O O
of O O
cytosolic O O
activated O O
to O O
unactivated B-protein O
receptor I-protein B-protein
complexes I-protein I-protein
in O O
intact O B-cell_type
cells O I-cell_type
are O O
similar O O
to O O
Old O O
World O O
primates O O
. O O

Results O O
from O O
mixing O O
studies O O
do O O
not O O
support O O
the O O
hypothesis O O
that O O
a O O
binding O O
inhibitor O O
( O O
s O O
) O O
or O O
a O O
deficient O O
cytosolic O O
positive O O
modifier O O
( O O
s O O
) O O
of O O
binding O O
underlies O O
the O O
findings O O
in O O
these O O
primates O O
. O O

The O O
New O O
World O O
primates O O
, O O
unlike O O
men O O
with O O
the O O
syndrome O O
of O O
primary O O
cortisol O O
resistance O O
, O O
have O O
compensated O O
for O O
their O O
condition O O
with O O
intra-adrenal O O
and O O
mineralocorticoid O O
receptor O O
adaptations O O
. O O

Thus O O
, O O
unlike O O
Old O O
World O O
primates O O
, O O
cortisol O O
in O O
New O O
World O O
primates O O
has O O
only O O
weak O O
sodium-retaining O O
potency O O
because O O
the O O
aldosterone B-protein B-protein
receptor I-protein I-protein
has O O
a O O
low O O
affinity O O
for O O
cortisol O O
. O O

The O O
common O O
element O O
that O O
would O O
explain O O
the O O
apparent O O
resistance O O
to O O
six O O
steroid O O
hormones O O
in O O
New O O
World O O
primates O O

Acetylation O O
and O O
modulation O O
of O O
erythroid B-protein B-protein
Kruppel-like I-protein I-protein
factor I-protein I-protein
( O O
EKLF B-protein B-protein
) O O
activity O O
by O O
interaction O O
with O O
histone B-protein B-protein
acetyltransferases I-protein I-protein
. O O

Erythroid B-protein B-protein
Kruppel-like I-protein I-protein
factor I-protein I-protein
( O O
EKLF B-protein B-protein
) O O
is O O
a O O
red B-protein B-protein
cell-specific I-protein I-protein
transcriptional I-protein I-protein
activator I-protein I-protein
that O O
is O O
crucial O O
for O O
consolidating O O
the O O
switch O O
to O O
high O O
levels O O
of O O
adult O O
beta-globin O B-protein
expression O O
during O O
erythroid O O
ontogeny O O
. O O

EKLF B-protein B-protein
is O O
required O O
for O O
integrity O O
of O O
the O O
chromatin O O
structure O O
at O O
the O O
beta-like B-DNA B-DNA
globin I-DNA I-DNA
locus I-DNA I-DNA
, O O
and O O
it O O
interacts O O
with O O
a O O
positive-acting B-protein B-protein
factor I-protein I-protein
in O O
vivo O O
. O O

We O O
find O O
that O O
EKLF B-protein B-protein
is O O
an O O
acetylated B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
, O O
and O O
that O O
it O O
interacts O O
in O O
vivo O O
with O O
CBP B-protein B-protein
, O O
p300 B-protein B-protein
, O O
and O O
P/CAF B-protein B-protein
. O O

However O O
, O O
its O O
interactions O O
with O O
these O O
histone B-protein B-protein
acetyltransferases I-protein I-protein
are O O
not O O
equivalent O O
, O O
as O O
CBP B-protein B-protein
and O O
p300 B-protein B-protein
, O O
but O O
not O O
P/CAF B-protein B-protein
, O O
utilize O O
EKLF B-protein B-protein
as O O
a O O
substrate O O
for O O
in O O
vitro O O
acetylation O O
within O O
its O O
trans-activation O B-protein
region O I-protein
. O O

The O O
functional O O
effects O O
of O O
these O O
interactions O O
are O O
that O O
CBP B-protein B-protein
and O O
p300 B-protein B-protein
, O O
but O O
not O O
P/CAF B-protein B-protein
, O O
enhance O O
EKLF B-protein B-protein
's O O
transcriptional O O
activation O O
of O O
the O O
beta-globin B-DNA B-DNA
promoter I-DNA I-DNA
in O O
erythroid B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

These O O
results O O
establish O O
EKLF B-protein B-protein
as O O
a O O
tissue-specific B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
that O O
undergoes O O
post-translational O O
acetylation O O
and O O
suggest O O
a O O
mechanism O O
by O O
which O O
EKLF B-protein B-protein
is O O
able O O
to O O
alter O O
chromatin O O
structure O O
and O O
induce O O
beta-globin O B-protein
expression O O
within O O
the O O
beta-like B-DNA B-DNA
globin I-DNA I-DNA
cluster I-DNA I-DNA
. O O

Recognition O O
of O O
herpes B-protein B-protein
simplex I-protein I-protein
virus I-protein I-protein
type I-protein I-protein
2 I-protein I-protein
tegument I-protein I-protein
proteins I-protein I-protein
by O O
CD4 B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
infiltrating O O
human O O
genital O O
herpes O O
lesions O O
. O O

The O O
local O O
cellular O O
immune O O
response O O
to O O
herpes O O
simplex O O
virus O O
( O O
HSV O O
) O O
is O O
important O O
in O O
the O O
control O O
of O O
recurrent O O
HSV O O
infection O O
. O O

The O O
antiviral O O
functions O O
of O O
infiltrating B-cell_type B-cell_type
CD4-bearing I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
may O O
include O O
cytotoxicity O O
, O O
inhibition O O
of O O
viral O O
growth O O
, O O
lymphokine O B-protein
secretion O O
, O O
and O O
support O O
of O O
humoral O O
and O O
CD8 O O
responses O O
. O O

The O O
antigens O O
recognized O O
by O O
many O O
HSV-specific B-cell_type B-cell_type
CD4 I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
localizing O O
to O O
genital O O
HSV-2 O O
lesions O O
are O O
unknown O O
. O O

T B-cell_type B-cell_type
cells I-cell_type I-cell_type
recognizing O O
antigens O B-protein
encoded O O
within O O
map O O
units O O
0.67 O O
to O O
0.73 O O
of O O
HSV B-DNA B-DNA
DNA I-DNA I-DNA
are O O
frequently O O
recovered O O
from O O
herpetic O O
lesions O O
. O O

Expression O O
cloning O O
with O O
this O O
region O O
of O O
DNA O O
now O O
shows O O
that O O
tegument B-protein B-protein
protein I-protein I-protein
VP22 B-protein B-protein
and O O
the O O
viral B-protein B-protein
dUTPase I-protein I-protein
, O O
encoded O O
by O O
genes B-DNA B-DNA
UL49 I-DNA I-DNA
and I-DNA O
UL50 I-DNA B-DNA
, O O
respectively O O
, O O
are O O
T-cell B-protein B-protein
antigens I-protein I-protein
. O O

Separate O O
epitopes B-protein O
in O O
VP22 B-protein B-protein
were O O
defined O O
for O O
T-cell B-cell_line B-cell_line
clones I-cell_line I-cell_line
from O O
each O O
of O O
three O O
patients O O
. O O

Reactivity O O
with O O
the O O
tegument B-protein B-protein
protein I-protein I-protein
encoded O O
by O O
UL21 B-DNA B-DNA
was O O
identified O O
for O O
an O O
additional O O
patient O O
. O O

Three O O
new O O
epitopes O B-protein
were O O
identified O O
in O O
VP16 B-protein B-protein
, O O
a O O
tegument B-protein B-protein
protein I-protein I-protein
associated O O
with O O
VP22 B-protein B-protein
. O O

Some O O
tegument-specific B-cell_line B-cell_line
CD4 I-cell_line I-cell_line
T-cell I-cell_line I-cell_line
clones I-cell_line I-cell_line
exhibited O O
cytotoxic O O
activity O O
against O O
HSV-infected B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

These O O
results O O
suggest O O
that O O
herpes B-protein B-protein
simplex I-protein I-protein
tegument I-protein I-protein
proteins I-protein I-protein
are O O
processed O O
for O O
antigen O O
presentation O O
in O O
vivo O O
and O O
are O O
possible O O
candidate O O
compounds O O
for O O
herpes O O
simplex O O
vaccines O O
. O O

Fibrinogen B-protein B-protein
activates O O
NF-kappa B-protein B-protein
B I-protein I-protein
transcription I-protein I-protein
factors I-protein I-protein
in O O
mononuclear B-cell_type B-cell_type
phagocytes I-cell_type I-cell_type
. O O

Adhesion O O
to O O
extracellular O O
matrices O O
is O O
known O O
to O O
modulate O O
leukocyte O O
activation O O
, O O
although O O
the O O
mechanisms O O
are O O
not O O
fully O O
understood O O
. O O

Mononuclear B-cell_type B-cell_type
phagocytes I-cell_type I-cell_type
are O O
exposed O O
to O O
fibrinous O O
provisional O O
matrix O O
throughout O O
migration O O
into O O
inflammatory O O
foci O O
, O O
so O O
this O O
study O O
was O O
undertaken O O
to O O
determine O O
whether O O
fibrinogen O B-protein
triggers O O
activation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
transcription I-protein I-protein
factors I-protein I-protein
. O O

U937 B-cell_line B-cell_line
cells I-cell_line I-cell_line
differentiated O O
with O O
PMA O O
in O O
nonadherent B-cell_line B-cell_line
culture I-cell_line I-cell_line
were O O
shown O O
to O O
express O O
two O O
fibrinogen-binding B-protein B-protein
integrins I-protein I-protein
, O O
predominately O O
CD11b/CD18 B-protein B-protein
, O O
and O O
to O O
a O O
lesser O O
extent O O
, O O
CD11c/CD18 B-protein B-protein
. O O

Cells O O
stimulated O O
with O O
fibrinogen B-protein B-protein
( O O
10-100 O O
microg/ml O O
) O O
/Mn2+ O O
( O O
50 O O
microM O O
) O O
for O O
2 O O
h O O
were O O
examined O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
, O O
minimal O O
in O O
unstimulated B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
was O O
substantially O O
up-regulated O O
by O O
fibrinogen B-protein B-protein
. O O

Fibrinogen B-protein B-protein
also O O
caused O O
activation O O
of O O
AP-1 B-protein B-protein
, O O
but O O
not O O
SP1 B-protein B-protein
or O O
cAMP B-protein B-protein
response I-protein I-protein
element-binding I-protein I-protein
protein I-protein I-protein
( I-protein I-protein
CREB I-protein I-protein
) I-protein I-protein
factors I-protein I-protein
. O O

Blocking O O
mAbs B-protein B-protein
against O O
CD18 B-protein B-protein
and O O
CD11b B-protein B-protein
abrogated O O
fibrinogen B-protein B-protein
-induced O O
NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
. O O

To O O
determine O O
the O O
effects O O
on O O
transcriptional O O
regulation O O
, O O
U937 B-cell_line B-cell_line
cells I-cell_line I-cell_line
were O O
transfected O O
with O O
a O O
plasmid O O
containing O O
the O O
HIV-1 B-DNA B-DNA
enhancer I-DNA I-DNA
( O O
bearing O O
two O O
NF-kappa B-DNA B-DNA
B I-DNA I-DNA
sites I-DNA I-DNA
) O O
coupled O O
to O O
a O O
chloramphenicol B-DNA B-DNA
acetyltransferase I-DNA I-DNA
( I-DNA I-DNA
CAT I-DNA I-DNA
) I-DNA I-DNA
reporter I-DNA I-DNA
. O O

Cells O O
were O O
subsequently O O
stimulated O O
with O O
1 O O
) O O
PMA O O
for O O
24 O O
h O O
, O O
inducing O O
CAT O B-protein
activity O O
by O O
2.6-fold O O
, O O
2 O O
) O O
fibrinogen B-protein B-protein
/Mn2+ O O
for O O
2 O O
h O O
, O O
inducing O O
CAT O B-protein
activity O O
by O O
3.2-fold O O
, O O
or O O
3 O O
) O O
costimulation O O
with O O
fibrinogen B-protein B-protein
and O O
PMA O O
, O O
inducing O O
5.7-fold O O
the O O
CAT O B-protein
activity O O
induced O O
by O O
PMA O O
alone O O
. O O

We O O
conclude O O
that O O
contact O O
with O O
fibrinogen-derived B-protein B-protein
proteins I-protein I-protein
may O O
contribute O O
to O O
mononuclear O O
phagocyte O O
activation O O
by O O
signaling O O
through O O
CD11b/CD18 B-protein B-protein
, O O
resulting O O
in O O
selective O O
activation O O
of O O
transcriptional B-protein B-protein
regulatory I-protein I-protein
factors I-protein I-protein
, O O
including O O
NF-kappa B-protein B-protein
B I-protein I-protein
. O O

Peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
and I-cell_type O
monocytes I-cell_type B-cell_type
and O O
B B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
derived O O
from O O
patients O O
with O O
lupus O O
express O O
estrogen O O
receptor O O
transcripts O O
similar O O
to O O
those O O
of O O
normal B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

OBJECTIVE O O
: O O
To O O
identify O O
and O O
characterize O O
estrogen B-RNA B-RNA
receptor I-RNA I-RNA
( I-RNA I-RNA
ER I-RNA I-RNA
) I-RNA I-RNA
transcripts I-RNA I-RNA
expressed O O
in O O
immune B-cell_type B-cell_type
cells I-cell_type I-cell_type
of O O
patients O O
with O O
systemic O O
lupus O O
erythematosus O O
( O O
SLE O O
) O O
and O O
healthy O O
donors O O
. O O

METHODS O O
: O O
Peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
and I-cell_type O
T I-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
prepared O O
from O O
patients O O
with O O
SLE O O
( O O
n O O
= O O
6 O O
) O O
and O O
healthy O O
donors O O
( O O
n O O
= O O
8 O O
) O O
. O O

T B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
separated O O
into O O
CD4 B-cell_type B-cell_type
and O O
CD8 B-cell_type B-protein
. O O

Some O O
monocytes B-cell_type B-cell_type
and O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
stimulated O O
with O O
estradiol O O
, O O
PMA O O
, O O
and O O
ionomycin O O
. O O

Epstein-Barr O O
virus-transformed O O
B B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
( O O
n O O
= O O
7 O O
) O O
and O O
B B-cell_line B-cell_line
cell I-cell_line I-cell_line
hybridomas I-cell_line I-cell_line
( O O
n O O
= O O
2 O O
) O O
established O O
from O O
patients O O
with O O
SLE O O
and O O
a O O
healthy O O
individual O O
were O O
used O O
as O O
a O O
B O O
cell O O
source O O
. O O

These O O
cells O O
were O O
examined O O
for O O
ER B-RNA B-RNA
mRNA I-RNA I-RNA
by O O
reverse O O
transcription O O
nested O O
polymerase O O
chain O O
reaction O O
. O O

Amplified O O
cDNA B-DNA B-DNA
were O O
sequenced O O
by O O
standard O O
methods O O
. O O

RESULTS O O
: O O
In O O
all O O
cells O O
tested O O
, O O
ER B-RNA B-RNA
mRNA I-RNA I-RNA
was O O
expressed O O
without O O
prior O O
in O O
vitro O O
stimulation O O
. O O

Partial O O
sequences O O
from O O
exons B-DNA B-DNA
1-8 I-DNA I-DNA
were O O
nearly O O
identical O O
to O O
the O O
published O O
sequence O O
of O O
the O O
human B-RNA B-RNA
ER I-RNA I-RNA
mRNA I-RNA I-RNA
. O O

There O O
were O O
no O O
notable O O
differences O O
in O O
the O O
ER B-RNA B-RNA
transcripts I-RNA I-RNA
between O O
patients O O
and O O
healthy O O
controls O O
. O O

Variant O I-RNA
receptor O I-RNA
transcripts O I-RNA
lacking O I-RNA
exon B-DNA I-RNA
5 I-DNA I-RNA
or O O
exon B-DNA B-DNA
7 I-DNA I-DNA
, O O
which O O
encodes O O
the O O
hormone B-protein B-protein
binding I-protein I-protein
domain I-protein I-protein
, O O
were O O
identified O O
in O O
the O O
majority O O
of O O
the O O
cells O O
. O O

Precise O O
deletion O O
of O O
the O O
exons O B-DNA
suggests O O
that O O
they O O
are O O
alternatively O O
spliced O O
transcripts O O
. O O

Whether O O
the O O
detected O O
transcripts O O
are O O
translated O O
into O O
functional B-protein O
receptor I-protein B-protein
proteins I-protein I-protein
remains O O
to O O
be O O
determined O O
. O O

In O O
vitro O O
stimulation O O
did O O
not O O
affect O O
ER B-RNA B-RNA
mRNA I-RNA I-RNA
expression O O
. O O

The O O
presence O O
of O O
variants O O
did O O
not O O
correlate O O
with O O
disease O O
activity O O
or O O
medication O O
. O O

CONCLUSION O O
: O O
Monocytes B-cell_type B-cell_type
, O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
and O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
patients O O
express O O
transcripts O O
of O O
the O O
normal O O
wild B-protein B-protein
type I-protein I-protein
ER I-protein I-protein
and O O
the O O
hormone B-protein B-protein
binding I-protein I-protein
domain I-protein I-protein
variants I-protein I-protein
in O O
vivo O O
. O O

DNA O O
damaging O O
agents O O
induce O O
expression O O
of O O
Fas B-protein B-protein
ligand I-protein I-protein
and O O
subsequent O O
apoptosis O O
in O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
via O O
the O O
activation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
and O O
AP-1 B-protein B-protein
. O O

Apoptosis O O
induced O O
by O O
DNA O O
damage O O
and O O
other O O
stresses O O
can O O
proceed O O
via O O
expression O O
of O O
Fas B-protein B-protein
ligand I-protein I-protein
( O O
FasL B-protein B-protein
) O O
and O O
ligation O O
of O O
its O O
receptor O O
, O O
Fas O B-protein
( O O
CD95 O O
) O O
. O O

We O O
report O O
that O O
activation O O
of O O
the O O
two O O
transcription B-protein B-protein
factors I-protein I-protein
NF-kappa I-protein B-protein
B I-protein I-protein
and I-protein O
AP-1 I-protein B-protein
is O O
crucially O O
involved O O
in O O
FasL B-protein B-protein
expression O O
induced O O
by O O
etoposide O O
, O O
teniposide O O
, O O
and O O
UV O O
irradiation O O
. O O

A O O
nondegradable B-protein O
mutant I-protein O
of O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
blocked O O
both O O
FasL B-protein B-protein
expression O O
and O O
apoptosis O O
induced O O
by O O
DNA O O
damage O O
but O O
not O O
Fas O B-protein
ligation O O
. O O

These O O
stimuli O O
also O O
induced O O
the O O
stress-activated O B-protein
kinase O I-protein
pathway O O
( O O
SAPK/JNK O B-protein
) O O
, O O
which O O
was O O
required O O
for O O
the O O
maximal O O
induction O O
of O O
apoptosis O O
. O O

A O O
1.2 O O
kb O O
FasL B-DNA B-DNA
promoter I-DNA I-DNA
responded O O
to O O
DNA O O
damage O O
, O O
as O O
well O O
as O O
coexpression O O
with O O
p65 B-protein B-protein
Rel I-protein I-protein
or O O
Fos/Jun B-protein B-protein
. O O

Mutations O O
in O O
the O O
relevant O O
NF-kappa B-DNA B-DNA
B I-DNA I-DNA
and I-DNA I-DNA
AP-1 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
eliminated O O
these O O
responses O O
. O O

Thus O O
, O O
activation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
and O O
AP-1 B-protein B-protein
contributes O O
to O O
stress-induced O O
apoptosis O O
via O O
the O O
expression O O
of O O
FasL B-protein B-protein
. O O

A O O
small O O
, O O
nonpeptidyl O O
mimic O O
of O O
granulocyte-colony-stimulating B-protein B-protein
factor I-protein I-protein
[ O O
see O O
commetns O O
] O O

A O O
nonpeptidyl O O
small O O
molecule O O
SB O O
247464 O O
, O O
capable O O
of O O
activating O O
granulocyte-colony-stimulating B-protein B-protein
factor I-protein I-protein
( O O
G-CSF B-protein B-protein
) O O
signal O O
transduction O O
pathways O O
, O O
was O O
identified O O
in O O
a O O
high-throughput O O
assay O O
in O O
cultured B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Like O O
G-CSF B-protein B-protein
, O O
SB O O
247464 O O
induced O O
tyrosine O O
phosphorylation O O
of O O
multiple B-protein B-protein
signaling I-protein I-protein
proteins I-protein I-protein
and O O
stimulated O O
primary B-cell_type B-cell_type
murine I-cell_type I-cell_type
bone I-cell_type I-cell_type
marrow I-cell_type I-cell_type
cells I-cell_type I-cell_type
to O O
form O O
granulocytic B-cell_type B-cell_type
colonies I-cell_type I-cell_type
in O O
vitro O O
. O O

It O O
also O O
elevated O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
neutrophil I-cell_type I-cell_type
counts O O
in O O
mice O O
. O O

The O O
extracellular O B-protein
domain O I-protein
of O O
the O O
murine B-protein O
G-CSF I-protein B-protein
receptor I-protein I-protein
was O O
required O O
for O O
the O O
activity O O
of O O
SB O O
247464 O O
, O O
suggesting O O
that O O
the O O
compound O O
acts O O
by O O
oligomerizing B-protein B-protein
receptor I-protein I-protein
chains I-protein I-protein
. O O

The O O
results O O
indicate O O
that O O
a O O
small O B-protein
molecule O I-protein
can O O
activate O O
a O O
receptor O O
that O O
normally O O
binds O O
a O O
relatively O O
large O O
protein O O
ligand O O
. O O

Minimal O O
residual O O
disease O O
in O O
acute O O
myelogenous O O
leukemia O O
with O O
PML/RAR B-protein B-RNA
alpha I-protein I-RNA
or O I-RNA
AML1/ETO B-RNA I-RNA
mRNA I-RNA I-RNA
and O O
phenotypic O O
analysis O O
of O O
possible O O
T B-cell_type B-cell_type
and I-cell_type I-cell_type
natural I-cell_type I-cell_type
killer I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
bone O O
marrow O O
. O O

Here O O
we O O
studied O O
minimal O O
residual O O
disease O O
( O O
MRD O O
) O O
of O O
patients O O
with O O
acute O O
myeloid O O
leukemia O O
( O O
AML O O
) O O
who O O
have O O
PML/RAR B-protein B-protein
alpha I-protein I-protein
or O O
AML1/ETO B-protein B-protein
as O O
well O O
as O O
the O O
phenotypic O O
analysis O O
of O O
lymphocyte B-cell_type B-cell_type
subsets I-cell_type I-cell_type
involved O O
in O O
antitumor O O
immunity O O
. O O

Eight O O
patients O O
in O O
long-term O O
( O O
LT O O
; O O
3 O O
to O O
15 O O
years O O
) O O
and O O
15 O O
patients O O
in O O
short-term O O
( O O
ST O O
; O O
up O O
to O O
3 O O
years O O
) O O
remission O O
were O O
studied O O
. O O

Using O O
the O O
reverse O O
transcription-polymerase O O
chain O O
reaction O O
( O O
RT O O
) O O
assay O O
, O O
the O O
limit O O
of O O
detection O O
was O O
10 O O
( O O
-5 O O
) O O
to O O
10 O O
( O O
-6 O O
) O O
for O O
PML/RAR B-RNA B-RNA
alpha I-RNA I-RNA
transcript I-RNA I-RNA
and O O
10 O O
( O O
-4 O O
) O O
to O O
10 O O
( O O
-5 O O
) O O
for O O
the O O
AML1/ETO B-RNA B-RNA
transcript I-RNA I-RNA
. O O

Simultaneously O O
, O O
T B-cell_type B-cell_type
lymphocyte I-cell_type I-cell_type
subsets I-cell_type I-cell_type
and O O
NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
the O O
peripheral O O
blood O O
( O O
PB O O
) O O
and O O
bone O O
marrow O O
( O O
BM O O
) O O
were O O
investigated O O
by O O
flow O O
cytometric O O
analysis O O
. O O

Four O O
of O O
the O O
eight O O
patients O O
in O O
LT O O
and O O
7 O O
of O O
the O O
15 O O
patients O O
in O O
ST O O
remission O O
were O O
MRD-positive O O
. O O

Although O O
all O O
MRD-positive O O
patients O O
in O O
LT O O
remission O O
are O O
still O O
until O O
now O O
event-free O O
, O O
3 O O
of O O
the O O
7 O O
MRD-positive O O
( O O
MRD+ O O
) O O
patients O O
in O O
ST O O
remission O O
soon O O
relapsed O O
. O O

The O O
total O O
populations O O
of O O
CD4 B-protein B-cell_type
+ O O
, O O
CD8 B-protein B-protein
+ O O
and O O
CD56 B-protein B-cell_type
+ O O
[ O O
possible O B-cell_line
T-cell B-cell_type I-cell_line
and I-cell_type I-cell_line
natural I-cell_type I-cell_line
killer I-cell_type I-cell_line
( I-cell_type I-cell_line
T/NK I-cell_type I-cell_line
) I-cell_type I-cell_line
populations I-cell_type I-cell_line
] O O
in O O
the O O
BM O O
of O O
ST O O
patients O O
and O O
MRD+/LT O O
patients O O
were O O
significantly O O
( O O
p O O
< O O
.01 O O
) O O
low O O
. O O

The O O
CD8+ B-cell_type B-cell_type
CD28+ I-cell_type I-cell_type
population I-cell_type I-cell_type
showed O O
the O O
same O O
tendency O O
( O O
p O O
< O O
.01-.02 O O
) O O
. O O

The O O
T/NK B-cell_type B-cell_type
subsets I-cell_type I-cell_type
in O O
the O O
BM O O
of O O
MRD-negative O O
( O O
MRD- O O
) O O
LT O O
( O O
MRD-/LT O O
) O O
patients O O
showed O O
similar O O
numbers O O
of O O
cells O O
as O O
normal O O
volunteers O O
. O O

Basically O O
, O O
the O O
total O O
percentage O O
of O O
the O O
CD4+ B-cell_type B-cell_type
, I-cell_type I-cell_type
CD8+ I-cell_type I-cell_type
and I-cell_type I-cell_type
CD56+ I-cell_type I-cell_type
cell I-cell_type I-cell_type
populations I-cell_type I-cell_type
in O O
the O O
BM O B-cell_type
was O O
increased O O
and O O
in O O
the O O
following O O
order O O
: O O
MRD-/LT O O
patients O O
, O O
normal O O
volunteers O O
, O O
MRD+/LT O O
patients O O
and O O
MRD+ O O
or O O
-/ST O O
patients O O
. O O

The O O
percentages O O
of O O
the O O
T/NK-cell B-cell_type B-cell_type
subsets I-cell_type I-cell_type
in O O
the O O
PB O O
were O O
not O O
significantly O O
different O O
among O O
these O O
groups O O
. O O

Thus O O
, O O
the O O
difference O O
of O O
the O O
possible O O
T/NK-cell B-cell_type B-cell_type
phenotype O O
in O O
the O O
BM O O
may O O
strongly O O
influence O O
clinical O O
and O O
molecular O O
remission O O
. O O

These O O
results O O
still O O
remain O O
to O O
be O O
confirmed O O
by O O
further O O
studies O O
of O O
the O O
functional O O
anti-tumor O O
immunity O O
of O O
T/NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
of O O
AML B-cell_type O
in O O
remission O O
. O O

Mycobacterium O O
tuberculosis O O
mannose-capped O O
lipoarabinomannan O O
can O O
induce O O
NF-kappaB B-protein B-protein
-dependent O O
activation O O
of O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
1 I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Tuberculosis O O
has O O
emerged O O
as O O
an O O
epidemic O O
, O O
extended O O
by O O
the O O
large O O
number O O
of O O
individuals O O
infected O O
with O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
. O O

The O O
major O O
goal O O
of O O
this O O
study O O
was O O
to O O
determine O O
whether O O
the O O
mycobacterial O O
cell O O
wall O O
component O O
mannose-capped O O
lipoarabinomannan O O
( O O
ManLAM O O
) O O
of O O
Mycobacterium O O
tuberculosis O O
( O O
M. O O
tuberculosis O O
) O O
could O O
activate O O
transcription O O
of O O
HIV-1 O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
with O O
the O O
use O O
of O O
an O O
in O O
vitro O O
cell O O
culture O O
system O O
. O O

These O O
experiments O O
are O O
of O O
prime O O
importance O O
considering O O
that O O
CD4 B-protein B-protein
-expressing O B-cell_type
T B-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
represent O O
the O O
major O O
virus O O
reservoir O O
in O O
the O O
peripheral O O
blood O O
of O O
infected O O
individuals O O
. O O

Using O O
the O O
1G5 B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
harbouring O O
the O O
luciferase O B-DNA
reporter O I-DNA
gene O I-DNA
under O O
the O O
control O O
of O O
the O O
HIV-1 B-DNA B-DNA
LTR I-DNA I-DNA
, O O
it O O
was O O
first O O
found O O
that O O
culture O O
protein O O
filtrates O O
( O O
CFP O O
) O O
from O O
M. O O
tuberculosis O O
or O O
purified O O
ManLAM O O
could O O
activate O O
HIV-1 B-DNA B-DNA
LTR-dependent I-DNA I-DNA
gene I-DNA I-DNA
expression O O
unlike O O
similarly O O
prepared O O
CFP O O
extracts O O
devoid O O
of O O
ManLAM O O
. O O

The O O
implication O O
of O O
protein B-protein B-protein
tyrosine I-protein I-protein
kinase I-protein I-protein
( I-protein O
s I-protein O
) I-protein O
, O O
protein B-protein B-protein
kinase I-protein I-protein
A I-protein I-protein
and/or O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
was O O
highlighted O O
by O O
the O O
abrogation O O
of O O
the O O
ManLAM-mediated O O
activation O O
of O O
HIV-1 O B-DNA
LTR-driven O I-DNA
gene O I-DNA
expression O O
using O O
herbimycin O O
A O O
and O O
H7 O O
. O O

It O O
was O O
also O O
determined O O
, O O
using O O
electrophoresis O O
mobility O O
shift O O
assays O O
, O O
that O O
M. O O
tuberculosis O O
ManLAM O O
led O O
to O O
the O O
nuclear O O
translocation O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
NF-kappaB I-protein B-protein
. O O

M. O O
tuberculosis O O
ManLAM O O
resulted O O
in O O
clear O O
induction O O
of O O
the O O
luciferase B-DNA B-DNA
gene I-DNA I-DNA
placed O O
under O O
the O O
control O O
of O O
the O O
wild-type B-DNA B-DNA
, I-DNA I-DNA
but I-DNA I-DNA
not I-DNA I-DNA
the I-DNA I-DNA
kappaB-mutated I-DNA I-DNA
, I-DNA I-DNA
HIV-1 I-DNA I-DNA
LTR I-DNA I-DNA
region I-DNA I-DNA
. O O

Finally O O
, O O
the O O
ManLAM-mediated O O
activation O O
of O O
HIV-1 O B-DNA
LTR O I-DNA
transcription O O
was O O
found O O
to O O
be O O
independent O O
of O O
the O O
autocrine O O
or O O
paracrine O O
action O O
of O O
endogenous B-protein B-protein
TNF-alpha I-protein I-protein
. O O

The O O
results O O
suggest O O
that O O
M. O O
tuberculosis O O
can O O
upregulate O O
HIV-1 O O
expression O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
could O O
thus O O
have O O
the O O
potential O O
to O O
influence O O
the O O
pathogenesis O O
of O O
HIV-1 O O
infection O O
. O O

Human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
1 I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
quasispecies O I-DNA
differ O O
in O O
basal O O
transcription O O
and O O
nuclear O B-protein
factor O I-protein
recruitment O O
in O O
human B-cell_type B-cell_type
glial I-cell_type I-cell_type
cells I-cell_type I-cell_type
and I-cell_type O
lymphocytes I-cell_type B-cell_type
. O O

The O O
generation O O
of O O
genomic O O
diversity O O
during O O
the O O
course O O
of O O
infection O O
has O O
the O O
potential O O
to O O
affect O O
all O O
aspects O O
of O O
HIV-1 O O
replication O O
, O O
including O O
expression O O
of O O
the O O
proviral O B-DNA
genome O I-DNA
. O O

To O O
gain O O
a O O
better O O
understanding O O
of O O
the O O
impact O O
of O O
long B-DNA B-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O I-DNA
LTR B-DNA I-DNA
) O I-DNA
sequence O I-DNA
diversity O O
on O O
LTR-directed B-DNA B-DNA
gene I-DNA I-DNA
expression O O
in O O
cells O O
of O O
the O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
and O O
immune O O
system O O
, O O
we O O
amplified O O
and O O
cloned O O
LTRs B-DNA B-DNA
from O O
proviral O B-DNA
DNA O I-DNA
in O O
HIV-1-infected O O
peripheral O O
blood O O
. O O

Sequence O O
analysis O O
of O O
nineteen O O
LTRs B-DNA B-DNA
cloned O O
from O O
2 O O
adult O O
and O O
3 O O
pediatric O O
patients O O
revealed O O
an O O
average O O
of O O
33 O O
nucleotide O O
changes O O
( O O
with O O
respect O O
to O O
the O O
sequence O O
of O O
the O O
LAI B-DNA B-DNA
LTR I-DNA I-DNA
) O O
within O O
the O O
455-bp B-DNA B-DNA
U3 I-DNA I-DNA
region I-DNA I-DNA
. O O

Transient O O
expression O O
analyses O O
in O O
cells O O
of O O
neuroglial O O
and O O
lymphocytic O O
origin O O
demonstrated O O
that O O
some O O
of O O
these O O
LTRs B-DNA B-DNA
had O O
activities O O
which O O
varied O O
significantly O O
from O O
the O O
LAI B-DNA B-DNA
LTR I-DNA I-DNA
in O O
U-373 B-cell_line B-cell_line
MG I-cell_line I-cell_line
cells I-cell_line I-cell_line
( O O
an O O
astrocytoma B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
) O O
as O O
well O O
as O O
in O O
Jurkat B-cell_line B-cell_line
cells I-cell_line I-cell_line
( O O
a O O
CD4-positive B-cell_line B-cell_line
lymphocyte I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
) O O
. O O

While O O
LTRs B-DNA B-DNA
which O O
demonstrated O O
the O O
highest O O
activities O O
in O O
U-373 B-cell_line B-cell_line
MG I-cell_line I-cell_line
cells I-cell_line I-cell_line
also O O
yielded O O
high O O
activities O O
in O O
Jurkat B-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
the O O
LTRs B-DNA B-DNA
were O O
generally O O
more O O
active O O
in O O
Jurkat B-cell_line B-cell_line
cells I-cell_line I-cell_line
when O O
compared O O
to O O
the O O
LAI B-DNA B-DNA
LTR I-DNA I-DNA
. O O

Differences O O
in O O
LTR B-DNA B-DNA
sequence I-DNA I-DNA
also O O
resulted O O
in O O
differences O O
in O O
transcription O O
factor O O
recruitment O O
to O O
cis-acting B-DNA B-DNA
sites I-DNA I-DNA
within O O
the O O
U3 B-DNA B-DNA
region I-DNA I-DNA
of O O
the O O
LTR B-DNA B-DNA
, O O
as O O
demonstrated O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
. O O

In O O
particular O O
, O O
naturally O O
occurring O O
sequence O O
variation O O
impacted O O
transcription B-protein B-protein
factor I-protein I-protein
binding O O
to O O
an O O
activating B-protein O
transcription I-protein B-protein
factor I-protein I-protein
/ O O
cAMP B-protein B-DNA
response I-protein I-DNA
element I-protein I-DNA
binding I-protein I-DNA
( O I-DNA
ATF B-protein I-DNA
/ O I-DNA
CREB B-protein I-DNA
) O I-DNA
binding O I-DNA
site O I-DNA
( O O
located O O
between O O
the O O
LEF-1 B-DNA B-DNA
and I-DNA I-DNA
distal I-DNA I-DNA
NF-kappaB I-DNA I-DNA
transcription I-DNA I-DNA
factor I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
) O O
that O O
we O O
identified O O
in O O
previous O O
studies O O
of O O
the O O
HIV-1 B-DNA B-DNA
LTR I-DNA I-DNA
. O O

These O O
findings O O
suggest O O
that O O
LTR B-DNA B-DNA
sequence I-DNA I-DNA
changes O O
can O O
significantly O O
affect O O
basal O O
LTR O B-DNA
function O O
and O O
transcription O B-protein
factor O I-protein
recruitment O O
, O O
which O O
may O O
, O O
in O O
turn O O
, O O
alter O O
the O O
course O O
of O O
viral O O
replication O O
in O O
cells O O
of O O
CNS O O
and O O
immune O O
system O O
origin O O
. O O

HMG B-protein B-protein
box I-protein I-protein
containing I-protein I-protein
transcription I-protein I-protein
factors I-protein I-protein
in O O
lymphocyte B-cell_type O
differentiation O O
. O O

The O O
identification O O
of O O
the O O
mammalian B-DNA B-DNA
sex-determining I-DNA I-DNA
gene I-DNA I-DNA
Sry I-DNA B-DNA
has O O
led O O
to O O
the O O
discovery O O
of O O
a O O
large O O
family O O
of O O
related O O
( O O
' O O
HMG B-protein B-protein
box I-protein I-protein
' O I-protein
) O I-protein
transcription B-protein I-protein
factors I-protein I-protein
that O O
control O O
developmental O O
events O O
in O O
yeast O O
, O O
C. O O
elegans O O
, O O
Drosophila O O
and O O
vertebrates O O
. O O

In O O
lymphocyte B-cell_type B-cell_type
differentiation O O
, O O
several O O
HMG B-protein B-protein
box I-protein I-protein
proteins I-protein I-protein
play O O
a O O
decisive O O
role O O
. O O

Sox-4 B-protein B-protein
is O O
important O O
for O O
very O O
early O O
B-cell O O
differentiation O O
, O O
while O O
TCF-1 B-protein B-protein
/ O O
LEF-1 B-protein B-protein
play O O
a O O
crucial O O
role O O
in O O
early O O
thymocyte O O
development O O
. O O

TCF/LEF B-protein B-protein
proteins I-protein I-protein
have O O
recently O O
been O O
found O O
to O O
constitute O O
a O O
downstream O O
component O O
of O O
the O O
Wingless/Wnt O O
signal O O
transduction O O
pathway O O
. O O

In O O
flies O O
, O O
this O O
pathway O O
controls O O
segment O O
polarity O O
; O O
in O O
Xenopus O O
it O O
controls O O
the O O
definition O O
of O O
the O O
body O O
axis O O
. O O

Deregulation O O
of O O
the O O
pathway O O
occurs O O
in O O
several O O
human B-cell_type O
tumors I-cell_type O
. O O

These O O
insights O O
in O O
the O O
molecular O O
events O O
that O O
are O O
involved O O
in O O
TCF/LEF B-protein B-protein
function O O
in O O
these O O
organisms O O
may O O
eventually O O
lead O O
to O O
the O O
understanding O O
of O O
the O O
function O O
of O O
these O O
HMG B-protein B-protein
box I-protein I-protein
proteins I-protein I-protein
in O O
lymphoid O O
development O O

Transcriptional O O
regulation O O
by O O
C/EBP B-protein B-protein
alpha I-protein I-protein
and I-protein O
-beta I-protein B-protein
in O O
the O O
expression O O
of O O
the O O
gene O O
for O O
the O O
MRP14 B-protein B-protein
myeloid I-protein I-protein
calcium I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
. O O

Transcriptional O O
regulation O O
of O O
the O O
gene O O
for O O
the O O
myeloid B-protein B-protein
calcium I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
, O O
MRP14 B-protein B-protein
, O O
was O O
investigated O O
in O O
human B-cell_line B-cell_line
monocytic I-cell_line I-cell_line
leukemia I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

The O O
MRP14 B-DNA B-DNA
gene I-DNA I-DNA
was O O
not O O
expressed O O
in O O
monoblastic B-cell_line B-cell_line
ML-1 I-cell_line I-cell_line
cells I-cell_line I-cell_line
, O O
promonocytic B-cell_line B-cell_line
U-937 I-cell_line I-cell_line
cells I-cell_line I-cell_line
, O O
or O O
promyelocytic B-cell_line B-cell_line
HL-60 I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
gene O O
was O O
expressed O O
in O O
monocytic B-cell_line B-cell_line
THP-1 I-cell_line I-cell_line
cells I-cell_line I-cell_line
and O O
in O O
the O O
HL-60 B-cell_line B-cell_type
cells I-cell_line I-cell_type
treated O O
with O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
( O O
VD3 O O
) O O
. O O

The O O
level O O
of O O
MRP14 B-protein B-protein
in O O
VD3-treated O B-cell_line
HL-60 B-cell_line I-cell_line
cells I-cell_line I-cell_line
was O O
two-fold O O
higher O O
than O O
that O O
in O O
THP-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

Among O O
several O O
known O O
transcription B-DNA B-protein
factor I-DNA I-protein
binding I-DNA I-protein
motifs I-DNA I-protein
, O O
nuclear B-protein B-protein
protein I-protein I-protein
( I-protein O
s I-protein O
) I-protein O
of O O
VD3-treated B-cell_line B-cell_line
HL-60 I-cell_line I-cell_line
cells I-cell_line I-cell_line
and I-cell_line O
THP-1 I-cell_line B-cell_line
cells I-cell_line I-cell_line
bound O O
to O O
the O O
CCAAT/enhancer B-DNA B-protein
binding I-DNA I-protein
protein I-DNA I-protein
( I-DNA O
C/EBP I-DNA B-DNA
) I-DNA I-DNA
-binding I-DNA I-DNA
motif I-DNA I-DNA
that O O
was O O
located O O
in O O
the O O
upstream B-DNA B-DNA
region I-DNA I-DNA
of O O
the O O
MRP14 B-DNA B-DNA
gene I-DNA I-DNA
( O O
-81 O O
) O O
, O O
as O O
evidenced O O
by O O
the O O
competitive O O
gel O O
mobility-shift O O
assay O O
. O O

An O O
antibody O O
for O O
C/EBP B-protein B-protein
alpha I-protein I-protein
super-shifted O O
the O O
nucleoprotein B-protein B-protein
complex I-protein I-protein
in O O
THP-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
but O O
not O O
in O O
the O O
VD3-treated B-cell_line B-cell_line
HL-60 I-cell_line I-cell_line
cells I-cell_line I-cell_line
, O O
whereas O O
an O O
antibody O O
for O O
C/EBP B-protein B-protein
beta I-protein I-protein
blocked O O
the O O
formation O O
of O O
the O O
complex O O
with O O
the O O
nuclear B-protein B-protein
factor I-protein I-protein
of O O
the O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
but O O
not O O
with O O
that O O
of O O
THP-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

An O O
anti-C/EBP B-protein B-protein
delta I-protein I-protein
antibody I-protein I-protein
had O O
no O O
effect O O
on O O
the O O
complex O O
in O O
either O O
cell O O
. O O

Thus O O
, O O
it O O
was O O
concluded O O
that O O
C/EBP B-protein B-protein
alpha I-protein I-protein
and I-protein O
-beta I-protein B-protein
were O O
able O O
to O O
bind O O
to O O
the O O
C/EBP B-protein B-DNA
motif I-protein I-DNA
, O O
and O O
that O O
C/EBP B-protein B-protein
alpha I-protein I-protein
bound O O
to O O
the O O
motif O O
in O O
THP-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
and O O
C/EBP B-protein B-protein
beta I-protein I-protein
bound O O
to O O
that O O
in O O
the O O
VD3-treated B-cell_line B-cell_line
HL-60 I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Furthermore O O
, O O
to O O
examine O O
the O O
transcriptional O O
activity O O
of O O
the O O
C/EBP B-protein B-DNA
motif I-protein I-DNA
, O O
we O O
transfected O O
several O O
constructed O O
luciferase B-DNA B-DNA
reporter I-DNA I-DNA
DNAs I-DNA I-DNA
into O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
and O O
THP-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

The O O
luciferase O B-protein
activity O O
of O O
the O O
C/EBP B-protein B-DNA
motif I-protein I-DNA
in O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
was O O
increased O O
by O O
VD3 O O
treatment O O
. O O

The O O
C/EBP B-protein B-DNA
motif I-protein I-DNA
in O O
the O O
MRP14 B-DNA B-DNA
gene I-DNA I-DNA
was O O
confirmed O O
to O O
function O O
as O O
a O O
regulatory O B-DNA
region O I-DNA
in O O
VD3-treated B-cell_line B-cell_line
HL-60 I-cell_line I-cell_line
cells I-cell_line I-cell_line
and I-cell_line O
THP-1 I-cell_line B-cell_line
cells I-cell_line I-cell_line
by O O
the O O
assay O O
. O O

Since O O
C/EBP B-protein B-protein
beta I-protein I-protein
was O O
also O O
detected O O
in O O
VD3-untreated B-cell_line B-cell_line
HL-60 I-cell_line I-cell_line
cells I-cell_line I-cell_line
by O O
immunoblotting O O
, O O
VD3 O O
activated O O
C/EBP B-protein B-protein
beta I-protein I-protein
to O O
bind O O
to O O
the O O
motif O O
, O O
probably O O
through O O
post-translational O O
modification O O
. O O

Patients O O
with O O
high-risk O O
myelodysplastic O O
syndrome O O
can O O
have O O
polyclonal O O
or O O
clonal O O
haemopoiesis O O
in O O
complete O O
haematological O O
remission O O
. O O

The O O
clonality O O
of O O
mature B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood-derived I-cell_type I-cell_type
myeloid I-cell_type I-cell_type
and I-cell_type I-cell_type
lymphoid I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
bone B-cell_type B-cell_type
marrow I-cell_type I-cell_type
haemopoietic I-cell_type I-cell_type
progenitors I-cell_type I-cell_type
from O O
18 O O
females O O
with O O
myelodysplasia O O
( O O
MDS O O
) O O
( O O
five O O
refractory O O
anaemia O O
, O O
RA O O
; O O
one O O
RA O O
with O O
ringed B-cell_type B-cell_type
sideroblasts I-cell_type I-cell_type
, O O
RARS O B-cell_type
; O O
three O O
chronic O O
myelomonocytic O O
leukaemia O O
, O O
CMML O O
; O O
four O O
RA O O
with O O
excess O O
of O O
blasts O B-cell_type
, O O
RAEB O O
; O O
five O O
RAEB O O
in O O
transformation O O
, O O
RAEB-t O O
) O O
was O O
studied O O
by O O
X-chromosome B-DNA B-DNA
inactivation O O
analysis O O
. O O

Using O O
the O O
human O O
androgen-receptor O O
( O O
HUMARA O O
) O O
assay O O
, O O
we O O
analysed O O
the O O
clonal O O
patterns O O
of O O
highly B-cell_type B-cell_line
purified I-cell_type I-cell_line
immature I-cell_type I-cell_line
CD34+ I-cell_type I-cell_line
38- I-cell_type I-cell_line
and I-cell_type I-cell_line
committed I-cell_type I-cell_line
CD34+ I-cell_type I-cell_line
38+ I-cell_type I-cell_line
marrow-derived I-cell_type I-cell_line
progenitors I-cell_type I-cell_line
, O O
and O O
CD16+ B-cell_type B-cell_type
14- I-cell_type I-cell_type
granulocytes I-cell_type I-cell_type
, O O
CD14+ B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
, O O
CD3+ B-cell_type B-cell_type
T I-cell_type I-cell_type
and I-cell_type I-cell_type
CD19+ I-cell_type I-cell_type
B I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
from O O
peripheral O O
blood O O
. O O

In O O
high-risk O O
patients O O
( O O
RAEB O O
, O O
RAEB-t O O
) O O
, O O
clonality O O
analysis O O
was O O
performed O O
before O O
and O O
after O O
intensive O O
remission-induction O O
treatment O O
. O O

All O O
patients O O
, O O
except O O
one O O
with O O
RA O O
, O O
had O O
predominance O O
of O O
a O O
single O O
clone O O
in O O
their O O
granulocytes B-cell_type B-cell_type
and O O
monocytes B-cell_type B-cell_type
. O O

The O O
same O O
clonal O O
pattern O O
was O O
found O O
in O O
CD34+ B-cell_type B-cell_type
progenitor I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

In O O
contrast O O
, O O
CD3+ B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
were O O
polyclonal O O
or O O
oligoclonal O O
in O O
14/18 O O
patients O O
. O O

X-chromosome B-DNA O
inactivation O O
patterns O O
of O O
CD19+ B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
highly O O
concordant O O
with O O
CD3+ B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
except O O
for O O
two O O
patients O O
( O O
one O O
RA O O
, O O
one O O
CMML O O
) O O
with O O
monoclonal B-cell_type B-cell_type
B I-cell_type I-cell_type
and I-cell_type I-cell_type
polyclonal I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
, O O
therefore O O
suggesting O O
a O O
clonal O O
mutation O O
in O O
a O O
progenitor B-cell_type O
common O O
to O O
the O O
myeloid B-cell_type B-cell_type
and I-cell_type I-cell_type
B-lymphoid I-cell_type I-cell_type
lineages I-cell_type I-cell_type
or O O
the O O
coexistence O O
of O O
MDS O O
and O O
a O O
B-cell O O
disorder O O
in O O
these O O
particular O O
patients O O
. O O

After O O
high-dose O O
non-myeloablative O O
chemotherapy O O
, O O
polyclonal O O
haemopoiesis O O
was O O
reinstalled O O
in O O
the O O
mature B-cell_type B-cell_type
myeloid I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
immature O B-cell_type
and O I-cell_type
committed B-cell_type I-cell_type
marrow I-cell_type I-cell_type
progenitors I-cell_type I-cell_type
in O O
three O O
of O O
four O O
patients O O
achieving O O
complete O O
haematological O O
remission O O
. O O

Therefore O O
we O O
conclude O O
that O O
most O O
haematological O O
remissions O O
in O O
MDS O O
are O O
associated O O
with O O
restoration O O
of O O
polyclonal O O
haemopoiesis O O
. O O

Prominent O O
sex O O
steroid O O
metabolism O O
in O O
human B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Steroid O O
metabolism O O
was O O
investigated O O
in O O
cultured B-cell_line B-cell_line
human I-cell_line I-cell_line
B-lymphoblastoid I-cell_line I-cell_line
cells I-cell_line I-cell_line
( O O
B-LCL B-cell_line B-cell_line
) O O
, O O
and O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
T I-cell_type I-cell_type
and I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Gene O O
expression O O
was O O
examined O O
by O O
reverse-transcription O O
polymerase O O
chain O O
reaction O O
amplification O O
( O O
RT-PCR O O
) O O
. O O

Appropriate O O
sized O O
transcripts B-RNA O
were O O
detected O O
in O O
both O O
cultured O O
and O O
fresh O O
peripheral B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
for O O
CYP11A B-protein O
, O O
CYP17 B-protein B-protein
, O O
HSD11L B-protein O
( O O
11beta-hydroxysteroid B-protein B-protein
dehydrogenase I-protein I-protein
I I-protein I-protein
) O O
, O O
HSD17B1 B-protein O
( O O
17beta-hydroxysteroid B-protein B-protein
dehydrogenase I-protein I-protein
type I-protein I-protein
I I-protein I-protein
) O O
and O O
SRD5A1 B-protein B-protein
( O O
5alpha-reductase B-protein O
I I-protein O
) O O
. O O

B-LCL O B-cell_line
, O I-cell_line
but O I-cell_line
not O I-cell_line
T B-cell_type I-cell_line
and I-cell_type I-cell_line
B I-cell_type I-cell_line
cells I-cell_type I-cell_line
, O O
expressed O O
CYP11B B-protein B-protein
. O O

There O O
was O O
minimal O O
expression O O
of O O
HSD3B1 B-protein B-protein
and O O
HSD3B2 B-protein B-protein
( O O
3beta-hydroxysteroid B-protein B-protein
dehydrogenase I-protein I-protein
I I-protein I-protein
and I-protein O
II I-protein O
) O O
in O O
B-LCL B-cell_line B-cell_line
and O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Transcripts O O
for O O
CYP19 B-protein B-protein
and O O
HSD11K B-protein B-protein
were O O
not O O
detected O O
. O O

Corresponding O O
enzymatic O O
activity O O
was O O
detectable O O
only O O
for O O
17-hydroxysteroid B-protein B-protein
dehydrogenase I-protein I-protein
and O O
5alpha-reductase B-protein B-protein
, O O
respectively O O
producing O O
testosterone O O
and O O
5alpha-dihydrotestosterone O O
. O O

Steroid O O
identities O O
were O O
confirmed O O
by O O
gas O O
chromatography/mass O O
spectrometry O O
( O O
GC/MS O O
) O O
. O O

One O O
metabolite O O
thought O O
to O O
be O O
deoxycorticosterone O O
was O O
identified O O
by O O
GC/MS O O
as O O
6alpha-hydroxypregnanolone O O
. O O

It O O
was O O
concluded O O
that O O
sex O O
hormone O O
metabolism O O
, O O
including O O
androgen O O
synthesis O O
, O O
occurs O O
in O O
lymphocytes O B-cell_type
, O O
and O O
may O O
modulate O O
immune O O
response O O
. O O

Human B-cell_type O
white I-cell_type O
blood I-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
hair O O
follicles O O
are O O
good O O
sources O O
of O O
mRNA B-RNA B-RNA
for O O
the O O
pterin B-protein B-protein
carbinolamine I-protein I-protein
dehydratase/dimerization I-protein I-protein
cofactor I-protein I-protein
of O O
HNF1 B-protein B-protein
for O O
mutation O O
detection O O
. O O

Pterin B-protein B-protein
carbinolamine I-protein I-protein
dehydratase/dimerization I-protein I-protein
cofactor I-protein I-protein
of O O
HNF1 B-protein B-protein
( O O
PCD/DCoH B-protein B-protein
) O O
is O O
a O O
protein O O
that O O
has O O
a O O
dual O O
function O O
. O O

It O O
is O O
a O O
pterin B-protein B-protein
4alpha-carbinolamine I-protein I-protein
dehydratase I-protein I-protein
that O O
is O O
involved O O
in O O
the O O
regeneration O O
of O O
the O O
cofactor B-protein O
tetrahydrobiopterin I-protein B-protein
during O O
the O O
phenylalanine O O
hydroxylase- O O
catalyzed O O
hydroxylation O O
of O O
phenylalanine O O
. O O

In O O
addition O O
, O O
it O O
is O O
the O O
dimerization O B-protein
cofactor O I-protein
of O O
HNF1 B-protein B-protein
that O O
is O O
able O O
to O O
activate O O
the O O
transcriptional O O
activity O O
of O O
HNF1 B-protein B-protein
. O O

Deficiencies O O
in O O
the O O
gene O O
for O O
this O O
dual B-protein O
functional I-protein O
protein I-protein O
result O O
in O O
hyperphenylalaninemia O O
. O O

Here O O
we O O
report O O
for O O
the O O
first O O
time O O
that O O
the O O
PCD/DCoH B-RNA B-RNA
mRNA I-RNA I-RNA
is O O
present O O
in O O
human B-cell_type B-cell_type
white I-cell_type I-cell_type
blood I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
hair O O
follicles O O
. O O

Taking O O
advantage O O
of O O
this O O
finding O O
, O O
a O O
sensitive O O
, O O
rapid O O
and O O
convenient O O
method O O
for O O
screening O O
mutations O O
occurring O O
in O O
the O O
coding O B-DNA
region O I-DNA
of O O
this O O
gene O O
has O O
been O O
described O O
. O O

Copyright O O
1998 O O
Academic O O
Press O O
. O O

Biochemical O O
characterization O O
of O O
the O O
NF-Y B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
complex I-protein I-protein
during O O
B O O
lymphocyte O O
development O O
. O O

The O O
transcription B-protein B-protein
factor I-protein I-protein
, O O
NF-Y B-protein B-protein
, O O
plays O O
a O O
critical O O
role O O
in O O
tissue-specific O B-DNA
major B-DNA I-DNA
histocompatibility I-DNA I-DNA
complex I-DNA I-DNA
class I-DNA I-DNA
II I-DNA I-DNA
gene I-DNA I-DNA
transcription O O
. O O

In O O
this O O
report O O
the O O
biochemical O O
properties O O
of O O
the O O
heterotrimeric B-protein B-protein
NF-Y I-protein I-protein
complex I-protein I-protein
have O O
been O O
characterized O O
during O O
stage-specific O O
B-cell O O
development O O
, O O
and O O
in O O
several O O
class B-cell_line B-cell_line
II- I-cell_line I-cell_line
mutant I-cell_line I-cell_line
B-cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
which O O
represent O O
distinct O O
bare O O
lymphocyte O O
syndrome O O
class O O
II O O
genetic O O
complementation O O
groups O O
. O O

The O O
NF-Y B-protein B-protein
complex I-protein I-protein
derived O O
from O O
class B-cell_type B-cell_type
II+ I-cell_type I-cell_type
mature I-cell_type I-cell_type
B-cells I-cell_type I-cell_type
bound O O
with O O
high O O
affinity O O
to O O
anion B-protein O
exchangers I-protein O
, O O
and O O
eluted O O
as O O
an O O
intact O B-protein
trimeric B-protein I-protein
complex I-protein I-protein
, O O
whereas O O
, O O
NF-Y B-protein B-protein
derived O O
from O O
class B-cell_type B-cell_type
II- I-cell_type I-cell_type
plasma I-cell_type I-cell_type
B-cells I-cell_type I-cell_type
, O O
and O O
from O O
bare B-cell_line B-cell_line
lymphocyte I-cell_line I-cell_line
syndrome I-cell_line I-cell_line
group I-cell_line I-cell_line
II I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
RJ2.2.5 B-cell_line B-cell_line
and O O
RM3 B-cell_line B-cell_line
, O O
dissociated O O
into O O
discrete O O
NF-YA B-protein B-protein
and O O
NF-YB B-protein B-protein
: I-protein I-protein
C I-protein I-protein
subunit B-protein I-protein
fractions I-protein I-protein
. O O

Recombination O O
of O O
the O O
MPC11 B-protein B-cell_line
plasma I-protein I-cell_line
B-cell I-protein I-cell_line
derived I-protein O
NF-Y I-protein B-protein
A I-protein I-protein
: I-protein I-protein
B I-protein I-protein
: I-protein I-protein
C I-protein I-protein
complex I-protein I-protein
with O O
the O O
low O O
molecular O O
mass O O
protein O O
fraction O O
, O O
NF-Y-associated B-protein B-protein
factors I-protein I-protein
( O O
YAFs B-protein B-protein
) O O
, O O
derived O O
from O O
mature O O
A20 O B-protein
B-cell O B-cell_type
nuclei O O
, O O
conferred O O
high O O
affinity O O
anion O O
exchange O O
binding O O
to O O
NF-Y B-protein B-protein
as O O
an O O
intact B-protein B-protein
trimeric I-protein I-protein
complex I-protein I-protein
. O O

Recombination O O
of O O
the O O
native B-protein O
NF-YA I-protein B-protein
: I-protein I-protein
B I-protein I-protein
: I-protein I-protein
C I-protein I-protein
complex I-protein I-protein
with O O
the O O
transcriptional B-protein B-protein
cofactor I-protein I-protein
, O O
PC4 B-protein B-protein
, O O
likewise O O
conferred O O
high B-protein O
affinity I-protein O
NF-Y I-protein B-protein
binding O O
to O O
anion B-protein O
exchangers I-protein O
, O O
and O O
stabilized O O
NF-Y B-protein B-protein
interaction O O
with O O
CCAAT-box B-DNA B-DNA
DNA I-DNA I-DNA
motifs I-DNA I-DNA
in O O
vitro O O
. O O

Interaction O O
between O O
PC4 B-protein B-protein
and O O
NF-Y B-protein B-protein
was O O
mapped O O
to O O
the O O
C-terminal B-protein B-protein
region I-protein I-protein
of O O
PC4 B-protein B-protein
, O O
and O O
the O O
subunit B-protein B-protein
interaction I-protein I-protein
subdomain I-protein I-protein
of O O
the O O
highly B-protein B-protein
conserved I-protein I-protein
DNA I-protein I-protein
binding-subunit I-protein I-protein
interaction I-protein I-protein
domain I-protein I-protein
( O O
DBD B-protein B-protein
) O O
of O O
NF-YA B-protein B-protein
. O O

These O O
results O O
suggest O O
that O O
in O O
class B-cell_type B-cell_type
II+ I-cell_type I-cell_type
mature I-cell_type I-cell_type
B-cells I-cell_type I-cell_type
NF-Y B-protein B-protein
is O O
associated O O
with O O
the O O
protein O B-protein
cofactor O I-protein
, O O
PC4 B-protein B-protein
, O O
which O O
may O O
play O O
an O O
important O O
role O O
in O O
NF-Y-mediated O O
transcriptional O O
control O O
of O O
class B-DNA B-DNA
II I-DNA I-DNA
genes I-DNA I-DNA
. O O

Arrest O O
of O O
B O B-cell_type
lymphocyte O I-cell_type
terminal O I-cell_type
differentiation O O
by O O
CD40 O B-protein
signaling O O
: O O
mechanism O O
for O O
lack O O
of O O
antibody-secreting B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
germinal O O
centers O O
. O O

Despite O O
extensive O O
research O O
, O O
the O O
role O O
of O O
CD40 B-protein B-protein
signaling O O
in O O
B O O
cell O O
terminal O O
differentiation O O
remains O O
controversial O O
. O O

Here O O
we O O
show O O
that O O
CD40 B-protein B-protein
engagement O O
arrests O O
B O O
cell O O
differentiation O O
prior O O
to O O
plasma O O
cell O O
formation O O
. O O

This O O
arrest O O
is O O
manifested O O
at O O
a O O
molecular O O
level O O
as O O
a O O
reduction O O
in O O
mRNA O O
levels O O
of O O
secretory O B-protein
immunoglobulin O I-protein
gene O I-protein
products O I-protein
such O O
as O O
mu O O
( O O
s O O
) O O
and O O
J O B-protein
chain O I-protein
as O O
well O O
as O O
the O O
loss O O
of O O
the O O
transcriptional B-protein B-protein
regulator I-protein I-protein
BLIMP-1 B-protein B-protein
. O O

Furthermore O O
, O O
the O O
inhibition O O
of O O
B O O
cell O O
differentiation O O
by O O
CD40 B-protein B-protein
engagement O O
could O O
not O O
be O O
overcome O O
by O O
either O O
mitogens B-protein O
or O O
cytokines B-protein B-protein
, O O
but O O
could O O
be O O
reversed O O
by O O
antibodies O B-protein
that O O
interfere O O
with O O
the O O
CD40 B-protein B-protein
/ O O
gp39 B-protein B-protein
interaction O O
. O O

These O O
data O O
suggest O O
that O O
secretory O B-protein
immunoglobulin O I-protein
is O O
not O O
produced O O
by O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
that O O
are O O
actively O O
engaged O O
by O O
gp39-expressing B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

A O O
positively O O
charged O O
alpha-lipoic O O
acid O O
analogue O O
with O O
increased O O
cellular O O
uptake O O
and O O
more O O
potent O O
immunomodulatory O O
activity O O
. O O

alpha-Lipoic O O
acid O O
( O O
LA O O
) O O
is O O
taken O O
up O O
by O O
cells O O
and O O
reduced O O
to O O
its O O
potent O O
dithiol O O
form O O
, O O
dihydrolipoate O O
( O O
DHLA O O
) O O
, O O
much O O
of O O
which O O
is O O
rapidly O O
effluxed O O
out O O
from O O
cells O O
. O O

To O O
improve O O
retention O O
in O O
cells O O
, O O
the O O
LA O O
molecule O O
was O O
modified O O
to O O
confer O O
a O O
positive O O
charge O O
at O O
physiological O O
pH O O
. O O

N O O
, O O
N-dimethyl O O
, O O
N'-2-amidoethyl-lipoate O O
was O O
synthesized O O
. O O

The O O
protonated O O
form O O
of O O
the O O
new O O
molecule O O
is O O
referred O O
to O O
as O O
LA-Plus O O
. O O

The O O
uptake O O
of O O
LA-Plus O O
by O O
human B-cell_type B-cell_line
Wurzburg I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
was O O
higher O O
compared O O
to O O
that O O
of O O
LA O O
. O O

Several-fold O O
higher O O
amounts O O
of O O
DHLA-Plus O B-protein
, O O
the O O
corresponding O O
reduced O O
form O O
of O O
LA-Plus O O
, O O
were O O
detected O O
in O O
LA-Plus O B-cell_line
treated O I-cell_line
cells O I-cell_line
compared O O
to O O
the O O
amount O O
of O O
DHLA O O
found O O
in O O
cells O O
treated O O
with O O
LA O O
. O O

At O O
100 O O
microM O O
, O O
LA O O
did O O
not O O
but O O
LA-Plus O O
inhibited O O
H2O2 O O
induced O O
NF-kappaB B-protein B-protein
activation O O
and O O
NF-kappaB B-protein B-protein
directed O O
IL-2 B-protein B-protein
receptor I-protein I-protein
expression O O
. O O

Both O O
LA O O
and O O
LA-Plus O O
synergised O O
with O O
selenium O O
in O O
inhibiting O O
H2O2 O O
induced O O
NF-kappaB B-protein B-protein
activation O O
. O O

At O O
150 O O
microM O O
LA-Plus O O
, O O
but O O
not O O
LA O O
, O O
inhibited O O
TNFalpha B-protein B-protein
induced O O
NF-kappaB B-protein B-protein
activation O O
. O O

At O O
5 O O
microM O O
LA-Plus O O
, O O
but O O
not O O
LA O O
, O O
protected O O
against O O
both O O
spontaneous O O
and O O
etoposide O O
induced O O
apoptosis O O
in O O
rat B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
. O O

LA-Plus O O
is O O
thus O O
an O O
improved O O
form O O
of O O
LA O O
with O O
increased O O
therapeutic O O
potential O O
. O O

Copyright O O
1998 O O
Academic O O
Press O O
. O O

Carrier O O
identification O O
in O O
X-linked O O
immunodeficiency O O
diseases O O
. O O

OBJECTIVE O O
: O O
Carrier O O
identification O O
in O O
X-linked O O
immunodeficiency O O
disorders O O
can O O
be O O
based O O
on O O
the O O
demonstration O O
of O O
non-random O O
X O O
inactivation O O
( O O
NRXI O O
) O O
in O O
affected B-cell_type B-cell_type
blood I-cell_type I-cell_type
cell I-cell_type I-cell_type
lineages I-cell_type I-cell_type
when O O
growth O O
is O O
impaired O O
in O O
cells O O
expressing O O
the O O
abnormal B-DNA O
gene I-DNA O
. O O

We O O
examined O O
the O O
utility O O
of O O
seeking O O
evidence O O
of O O
NRXI O B-protein
to O O
test O O
the O O
carrier O O
status O O
of O O
women O O
in O O
families O O
affected O O
by O O
X-linked O O
severe O O
combined O O
immunodeficiency O O
( O O
XSCID O O
) O O
and O O
X-linked O O
hypogammaglobulinaemia O O
( O O
XLH O O
) O O
, O O
to O O
identify O O
as O O
carriers O O
the O O
mothers O O
of O O
boys O O
with O O
SCID O O
or O O
hypogammaglobulinaemia O O
whose O O
phenotype O O
suggested O O
X-linkage O O
and O O
to O O
infer O O
X-linkage O O
in O O
boys O O
with O O
SCID O O
or O O
hypogammaglobulinaemia O O
whose O O
disease O O
was O O
not O O
clearly O O
X-linked O O
on O O
the O O
basis O O
either O O
of O O
family O O
history O O
or O O
clinical O O
and O O
immunological O O
characteristics O O
. O O

METHODOLOGY O O
: O O
A O O
polymerase O O
chain O O
reaction-based O O
method O O
was O O
used O O
to O O
amplify O O
a O O
polymorphic O B-DNA
CAG B-DNA I-DNA
repeat I-DNA I-DNA
in O O
the O O
first B-DNA O
exon I-DNA O
of O O
the O O
androgen B-DNA B-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
after O O
selective O O
digestion O O
of O O
the O O
active B-DNA O
X I-DNA B-DNA
chromosome I-DNA I-DNA
with O O
a O O
methylation-sensitive B-protein B-DNA
enzyme I-protein I-DNA
, O O
HpaII B-protein O
to O O
distinguish O O
between O O
the O O
paternal B-DNA B-DNA
and I-DNA I-DNA
maternal I-DNA I-DNA
alleles I-DNA I-DNA
and O O
to O O
identify O O
their O O
methylation O O
status O O
. O O

RESULTS O O
: O O
Heterozygosity O O
was O O
found O O
in O O
24 O O
of O O
31 O O
female O O
subjects O O
( O O
77 O O
% O O
) O O
. O O

As O O
anticipated O O
, O O
NRXI O O
could O O
be O O
demonstrated O O
in O O
all O O
lymphoid B-cell_type B-cell_type
cells I-cell_type I-cell_type
studied O O
from O O
obligate O O
carriers O O
of O O
XSCID O O
and O O
an O O
obligate O O
carrier O O
of O O
XLH O O
but O O
not O O
on O O
a O O
carrier O O
of O O
X-linked O O
immunodeficiency O O
with O O
hyper-IgM B-protein O
. O O

The O O
finding O O
of O O
NRXI O B-protein
in O O
the O O
mother O O
of O O
a O O
boy O O
with O O
a O O
SCID O O
variant O O
showed O O
her O O
to O O
be O O
a O O
carrier O O
of O O
XSCID O O
and O O
establishes O O
that O O
her O O
son O O
has O O
XSCID O O
, O O
not O O
otherwise O O
evident O O
from O O
available O O
data O O
. O O

CONCLUSIONS O O
: O O
This O O
PCR O O
assay O O
provides O O
a O O
rapid O O
method O O
for O O
carrier O O
detection O O
of O O
X-linked O O
immunodeficiencies O O
, O O
and O O
has O O
allowed O O
us O O
to O O
expand O O
the O O
phenotype O O
of O O
XSCID O B-protein

Leukocyte-endothelial O O
interaction O O
is O O
augmented O O
by O O
high O O
glucose O O
concentrations O O
and O O
hyperglycemia O O
in O O
a O O
NF-kB-dependent O O
fashion O O
. O O

We O O
addressed O O
the O O
role O O
of O O
hyperglycemia O O
in O O
leukocyte-endothelium O O
interaction O O
under O O
flow O O
conditions O O
by O O
exposing O O
human B-cell_type B-cell_type
umbilical I-cell_type I-cell_type
vein I-cell_type I-cell_type
endothelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
for O O
24 O O
h O O
to O O
normal O O
( O O
5 O O
mM O O
) O O
, O O
high O O
concentration O O
of O O
glucose O O
( O O
30 O O
mM O O
) O O
, O O
advanced O O
glycosylation O O
end O O
product-albumin B-protein O
( O O
100 O O
microg/ml O O
) O O
, O O
or O O
hyperglycemic O O
( O O
174-316 O O
mg/dl O O
) O O
sera O O
from O O
patients O O
with O O
diabetes O O
and O O
abnormal O O
hemoglobin O B-protein
A1c O O
( O O
8.1+/-1.4 O O
% O O
) O O
. O O

At O O
the O O
end O O
of O O
incubation O B-cell_type
endothelial B-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
perfused O O
with O O
total O O
leukocyte O O
suspension O O
in O O
a O O
parallel O O
plate O O
flow O O
chamber O O
under O O
laminar O O
flow O O
( O O
1.5 O O
dyn/cm2 O O
) O O
. O O

Rolling O O
and O O
adherent B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
evaluated O O
by O O
digital O O
image O O
processing O O
. O O

Results O O
showed O O
that O O
30 O O
mM O O
glucose O O
significantly O O
( O O
P O O
< O O
0.01 O O
) O O
increased O O
the O O
number O O
of O O
adherent B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
to O O
endothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
respect O O
to O O
control O O
( O O
5 O O
mM O O
glucose O O
; O O
151+/-19 O O
versus O O
33+/-8 O O
cells/mm2 O O
) O O
. O O

A O O
similar O O
response O O
was O O
induced O O
by O O
endothelial O O
stimulation O O
with O O
IL-1beta B-protein B-protein
, O O
here O O
used O O
as O O
positive O O
control O O
( O O
195+/-20 O O
cells/mm2 O O
) O O
. O O

The O O
number O O
of O O
rolling B-cell_type B-cell_type
cells I-cell_type I-cell_type
on O O
endothelial O B-cell_type
surface O I-cell_type
was O O
not O O
affected O O
by O O
high O O
glucose O O
level O O
. O O

Stable O O
adhesion O O
of O O
leukocytes B-cell_type B-cell_type
to O O
glucose-treated O O
as O O
well O O
as O O
to O O
IL-1beta-stimulated B-cell_type B-cell_line
endothelial I-cell_type I-cell_line
cells I-cell_type I-cell_line
was O O
preceded O O
by O O
short O O
interaction O O
of O O
leukocytes B-cell_type B-cell_type
with O O
the O O
endothelial O O
surface O O
. O O

The O O
distance O O
travelled O O
by O O
leukocytes B-cell_type B-cell_type
before O O
arrest O O
on O O
30 O O
mM O O
glucose O O
, O O
or O O
on O O
IL-1beta-treated B-cell_type B-cell_line
endothelial I-cell_type I-cell_line
cells I-cell_type I-cell_line
, O O
was O O
significantly O O
( O O
P O O
< O O
0.01 O O
) O O
higher O O
than O O
that O O
observed O O
for O O
leukocytes B-cell_type B-cell_type
adhering O O
on O O
control O O
endothelium O O
( O O
30 O O
mM O O
glucose O O
: O O
76.7+/-3.5 O O
; O O
IL1beta O B-protein
: O O
69.7+/-4 O O
versus O O
5 O O
mM O O
glucose O O
: O O
21.5+/-5 O O
microm O O
) O O
. O O

Functional O O
blocking O O
of O O
E-selectin B-protein B-protein
, O O
intercellular B-protein B-protein
cell I-protein I-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
, O O
and O O
vascular B-protein B-protein
cell I-protein I-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
on O O
endothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
with O O
the O O
corresponding O O
mouse B-protein O
mAb I-protein O
significantly O O
inhibited O O
glucose-induced O O
increase O O
in O O
leukocyte O O
adhesion O O
( O O
67+/-16 O O
, O O
83+/-12 O O
, O O
62+/-8 O O
versus O O
144+/-21 O O
cells/ O O
mm2 O O
) O O
. O O

Confocal O O
fluorescence O O
microscopy O O
studies O O
showed O O
that O O
30 O O
mM O O
glucose O O
induced O O
an O O
increase O O
in O O
endothelial O O
surface O O
expression O O
of O O
E-selectin B-protein B-protein
, O O
intercellular B-protein B-protein
cell I-protein I-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
, O O
and O O
vascular B-protein B-protein
cell I-protein I-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
. O O

Electrophoretic O O
mobility O O
shift O O
assay O O
of O O
nuclear O O
extracts O O
of O O
human B-cell_type B-cell_line
umbilical I-cell_type I-cell_line
vein I-cell_type I-cell_line
endothelial I-cell_type I-cell_line
cells I-cell_type I-cell_line
( O O
HUVEC O B-cell_type
) O O
exposed O O
for O O
1 O O
h O O
to O O
30 O O
mM O O
glucose O O
revealed O O
an O O
intense O O
NF-kB B-protein B-protein
activation O O
. O O

Treatment O O
of O O
HUVEC O B-cell_line
exposed O O
to O O
high O O
glucose O O
with O O
the O O
NF-kB B-protein O
inhibitors I-protein O
pyrrolidinedithiocarbamate O O
( O O
100 O O
microM O O
) O O
and O O
tosyl-phe-chloromethylketone O O
( O O
25 O O
microM O O
) O O
significantly O O
reduced O O
( O O
P O O
< O O
0.05 O O
) O O
leukocyte O O
adhesion O O
in O O
respect O O
to O O
HUVEC O B-cell_type
treated O O
with O O
glucose O O
alone O O
. O O

A O O
significant O O
( O O
P O O
< O O
0.01 O O
) O O
inhibitory O O
effect O O
on O O
glucose-induced O O
leukocyte O O
adhesion O O
was O O
observed O O
after O O
blocking O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
activity O O
with O O
staurosporine O O
( O O
5 O O
nM O O
) O O
. O O

When O O
HUVEC O B-cell_line
were O O
treated O O
with O O
specific O O
antisense O O
oligodesoxynucleotides O O
against O O
PKCalpha B-protein B-protein
and I-protein O
PKCepsilon I-protein B-protein
isoforms I-protein I-protein
before O O
the O O
addition O O
of O O
30 O O
mM O O
glucose O O
, O O
a O O
significant O O
( O O
P O O
< O O
0.05 O O
) O O
reduction O O
in O O
the O O
adhesion O O
was O O
also O O
seen O O
. O O

Advanced O O
glycosylation O B-protein
end O I-protein
product-albumin B-protein I-protein
significantly O O
increased O O
the O O
number O O
of O O
adhering B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
in O O
respect O O
to O O
native B-protein O
albumin I-protein B-protein
used O O
as O O
control O O
( O O
110+/-16 O O
versus O O
66+/-7 O O
, O O
P O O
< O O
0.01 O O
) O O
. O O

Sera O O
from O O
diabetic O O
patients O O
significantly O O
( O O
P O O
< O O
0.01 O O
) O O
enhanced O O
leukocyte O O
adhesion O O
as O O
compared O O
with O O
controls O O
, O O
despite O O
normal O O
levels O O
of O O
IL-1beta B-protein B-protein
and O O
TNFalpha B-protein B-protein
in O O
these O O
sera O O
. O O

These O O
data O O
indicate O O
that O O
high O O
glucose O O
concentration O O
and O O
hyperglycemia O O
promote O O
leukocyte O O
adhesion O O
to O O
the O O
endothelium O O
through O O
upregulation O O
of O O
cell O O
surface O O
expression O O
of O O
adhesive O B-protein
proteins O I-protein
, O O
possibly O O
depending O O
on O O
NF-kB B-protein B-protein
activation O O
. O O

Ikaros B-protein B-protein
in O O
hemopoietic O B-cell_type
lineage O I-cell_type
determination O O
and O O
homeostasis O O
. O O

Studies O O
on O O
the O O
molecular O O
mechanisms O O
that O O
control O O
hemopoietic O O
differentiation O O
have O O
focused O O
on O O
signaling O O
cascades O O
and O O
nuclear O B-protein
effectors O I-protein
that O O
drive O O
this O O
complex O O
developmental O O
system O O
in O O
a O O
regulated O O
fashion O O
. O O

Here O O
we O O
review O O
the O O
role O O
of O O
Ikaros B-protein B-protein
, O O
the O O
founding O O
member O O
of O O
a O O
unique O O
family O O
of O O
zinc B-protein B-protein
finger I-protein I-protein
transcription I-protein I-protein
factors I-protein I-protein
in O O
this O O
developmental O O
process O O
. O O

Studies O O
on O O
an O O
Ikaros B-protein B-protein
null O I-protein
mutation O I-protein
have O O
revealed O O
an O O
essential O O
role O O
for O O
this O O
factor O O
in O O
lymphoid O O
cell O O
fate O O
determination O O
and O O
at O O
subsequent O O
branch O O
points O O
of O O
the O O
T O O
cell O O
differentiation O O
pathway O O
. O O

Differences O O
in O O
the O O
phenotypes O O
of O O
a O O
null O O
and O O
a O O
dominant B-DNA O
negative I-DNA O
( I-DNA O
DN I-DNA O
) I-DNA O
Ikaros I-DNA B-protein
mutation I-DNA O
provide O O
insight O O
into O O
a O O
regulatory O O
network O O
through O O
which O O
Ikaros B-protein B-protein
proteins I-protein I-protein
exert O O
their O O
effects O O
in O O
development O O
. O O

In O O
addition O O
a O O
comparative O O
analysis O O
of O O
the O O
hemopoietic B-cell_type B-cell_type
stem I-cell_type I-cell_type
cell I-cell_type I-cell_type
and O O
precursor O O
compartment O O
resulting O O
from O O
the O O
two O O
Ikaros B-DNA B-protein
mutations I-DNA O
reveals O O
a O O
profound O O
yet O O
not O O
absolute O O
requirement O O
for O O
Ikaros B-protein B-protein

Induction O O
of O O
early B-protein B-protein
B I-protein I-protein
cell I-protein I-protein
factor I-protein I-protein
( O O
EBF B-protein B-protein
) O O
and O O
multiple B-DNA O
B I-DNA B-DNA
lineage I-DNA I-DNA
genes I-DNA I-DNA
by O O
the O O
basic B-protein B-protein
helix-loop-helix I-protein I-protein
transcription I-protein I-protein
factor I-protein I-protein
E12 B-protein B-protein
. O O

The O O
transcription B-protein B-protein
factors I-protein I-protein
encoded O O
by O O
the O O
E2A B-protein B-DNA
and O I-DNA
early B-protein I-DNA
B I-protein I-DNA
cell I-protein I-DNA
factor I-protein I-DNA
( O I-DNA
EBF B-protein I-DNA
) O I-DNA
genes O I-DNA
are O O
required O O
for O O
the O O
proper O O
development O O
of O O
B B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

However O O
, O O
the O O
absence O O
of O O
B B-cell_type B-cell_type
lineage I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
E2A- O O
and O O
EBF-deficient O O
mice O O
has O O
made O O
it O O
difficult O O
to O O
determine O O
the O O
function O O
or O O
relationship O O
between O O
these O O
proteins O O
. O O

We O O
report O O
the O O
identification O O
of O O
a O O
novel O O
model O O
system O O
in O O
which O O
the O O
role O O
of O O
E2A B-protein B-protein
and O O
EBF B-protein B-protein
in O O
the O O
regulation O O
of O O
multiple O O
B O B-cell_type
lineage O I-cell_type
traits O O
can O O
be O O
studied O O
. O O

We O O
found O O
that O O
the O O
conversion O O
of O O
70Z/3 B-cell_line B-cell_line
pre-B I-cell_line I-cell_line
lymphocytes I-cell_line I-cell_line
to O O
cells O O
with O O
a O O
macrophage-like O O
phenotype O O
is O O
associated O O
with O O
the O O
loss O O
of O O
E2A B-protein B-protein
and O O
EBF B-protein B-protein
. O O

Moreover O O
, O O
we O O
show O O
that O O
ectopic O O
expression O O
of O O
the O O
E2A B-protein B-protein
protein O I-protein
E12 B-protein I-protein
in O O
this O O
macrophage B-cell_line B-cell_line
line I-cell_line I-cell_line
results O O
in O O
the O O
induction O O
of O O
many B-DNA O
B I-DNA B-DNA
lineage I-DNA I-DNA
genes I-DNA I-DNA
, O O
including O O
EBF B-protein B-protein
, O O
IL7Ralpha B-protein B-protein
, O O
lambda5 B-protein B-protein
, O O
and O O
Rag-1 O B-protein
, O O
and O O
the O O
ability O O
to O O
induce O O
kappa B-protein B-protein
light I-protein I-protein
chain I-protein I-protein
in O O
response O O
to O O
mitogen O B-protein
. O O

Activation O O
of O O
EBF B-protein B-protein
may O O
be O O
one O O
of O O
the O O
critical O O
functions O O
of O O
E12 B-protein B-protein
in O O
regulating O O
the O O
B O B-cell_type
lineage O I-cell_type
phenotype O I-cell_type
since O O
expression O O
of O O
EBF B-protein B-protein
alone O O
leads O O
to O O
the O O
activation O O
of O O
a O O
subset O O
of O O
E12 B-protein B-protein
-inducible O O
traits O O
. O O

Our O O
data O O
demonstrate O O
that O O
, O O
in O O
the O O
context O O
of O O
this O O
macrophage B-cell_line B-cell_line
line I-cell_line I-cell_line
, O O
E12 B-protein B-protein
induces O O
expression O O
of O O
EBF B-protein B-protein
and O O
together O O
these O O
transcription B-protein B-protein
factors I-protein I-protein
coordinately O O
regulate O O
numerous O O
B B-DNA B-DNA
lineage-associated I-DNA I-DNA
genes I-DNA I-DNA
. O O

Activation-induced O O
down-regulation O O
of O O
retinoid B-protein B-protein
receptor I-protein I-protein
RXRalpha I-protein B-protein
expression O O
in O O
human B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Role O O
of O O
cell O O
cycle O O
regulation O O
. O O

A O B-RNA
5.4-kilobase B-RNA I-RNA
mRNA I-RNA I-RNA
, O O
the O O
expression O O
of O O
which O O
is O O
down-regulated O O
after O O
treatment O O
of O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
PBMCs B-cell_type B-cell_type
) O O
with O O
various O O
T O O
cell-activating O O
agents O O
, O O
was O O
isolated O O
using O O
an O O
mRNA O O
differential O O
display O O
method O O
. O O

Nucleotide O B-DNA
sequence O I-DNA
analysis O O
identified O O
the O O
5 B-RNA B-DNA
' I-RNA I-DNA
end I-RNA I-DNA
of O O
this O O
RNA B-RNA O
as O O
human B-RNA B-RNA
retinoid I-RNA I-RNA
receptor I-RNA I-RNA
RXRalpha I-RNA I-RNA
mRNA I-RNA I-RNA
. O O

Here O O
, O O
we O O
report O O
the O O
nucleotide O B-DNA
sequence O I-DNA
of O O
3.6 B-DNA O
kilobases I-DNA O
of O O
this O O
RNA O B-RNA
, O O
which O O
represents O O
the O O
3 B-RNA O
' I-RNA O
end I-RNA O
of O O
RXRalpha B-RNA B-RNA
mRNA I-RNA I-RNA
, O O
the O O
sequence O O
of O O
which O O
has O O
not O O
been O O
previously O O
described O O
. O O

Activated O O
PBMCs B-cell_type B-cell_type
also O O
expressed O O
lower O O
levels O O
of O O
RXRalpha B-protein B-protein
protein O I-protein
, O O
and O O
a O O
DNA O O
binding O O
assay O O
showed O O
that O O
the O O
activation-induced O O
loss O O
of O O
RXRalpha B-RNA B-RNA
mRNA I-RNA I-RNA
and O O
protein O O
expression O O
correlated O O
with O O
the O O
loss O O
of O O
DNA O O
binding O O
activity O O
of O O
this O O
protein O O
. O O

We O O
present O O
evidence O O
that O O
the O O
transition O O
from O O
G0/G1 O O
to O O
S O O
phase O O
of O O
the O O
cell O O
cycle O O
results O O
in O O
the O O
down-regulation O O
of O O
RXRalpha B-protein B-protein
expression O O
and O O
that O O
cell O O
cycle O O
inhibitors O O
, O O
which O O
block O O
the O O
cells O O
in O O
G1 O O
phase O O
, O O
prevent O O
this O O
down-regulation O O
. O O

The O O
decrease O O
in O O
the O O
levels O O
of O O
RXRalpha B-RNA B-RNA
mRNA I-RNA I-RNA
was O O
found O O
to O O
be O O
regulated O O
at O O
the O O
post-transcriptional O O
level O O
and O O
involved O O
new O O
protein O O
synthesis O O
. O O

These O O
observations O O
indicate O O
that O O
the O O
levels O O
of O O
RXRalpha B-protein B-protein
expression O O
in O O
T O B-cell_type
lymphocytes O I-cell_type
are O O
coupled O O
to O O
cell O O
cycle O O
progression O O
, O O
and O O
there O O
is O O
tight O O
regulatory O O
control O O
of O O
RXRalpha B-protein B-protein
expression O O
during O O
the O O
transition O O
from O O
G0/G1 O O
to O O
S O O
phase O O
of O O
the O O
cell O O
cycle O O
. O O

Epidemiology O O
and O O
pathogenesis O O
of O O
AIDS-related O O
lymphomas O O
. O O

Among O O
patients O O
with O O
congenital O O
and O O
acquired O O
immunodeficiencies O O
, O O
non-Hodgkin O O
's O O
lymphoma O O
( O O
NHLs O O
) O O
are O O
the O O
most O O
common O O
tumors O O
of O O
the O O
immune O O
system O O
. O O

In O O
the O O
setting O O
of O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
infection O O
, O O
as O O
many O O
as O O
10 O O
% O O
to O O
20 O O
% O O
of O O
people O O
ultimately O O
developed O O
NHLs O O
. O O

These O O
tumors O O
are O O
clinically O O
aggressive O O
, O O
frequently O O
involve O O
extranodal O O
sites O O
, O O
and O O
often O O
exhibit O O
unique O O
features O O
that O O
distinguish O O
them O O
from O O
NHL O O
arising O O
in O O
individuals O O
with O O
other O O
forms O O
of O O
immunosuppression O O
. O O

Important O O
in O O
the O O
development O O
of O O
HIV-associated O O
NHL O O
are O O
cytokines B-protein B-protein
and O O
other O O
factors O O
that O O
induce O O
B-cell O B-cell_type
proliferation O O
and O O
increase O O
the O O
likelihood O O
of O O
mutations O O
of O O
c-myc B-DNA B-DNA
, O O
bcl-6 B-DNA B-protein
, O O
and O O
other O O
tumor-suppressor B-DNA B-DNA
genes I-DNA I-DNA
with O O
carcinogenic O O
potential O O
. O O

Specific O O
forms O O
of O O
HIV-associated O O
NHL O O
are O O
linked O O
to O O
expression O O
of O O
Epstein-Barr B-protein B-protein
virus I-protein I-protein
( I-protein I-protein
EBV I-protein I-protein
) I-protein I-protein
-latent I-protein I-protein
proteins I-protein I-protein
; O O
the O O
newly O O
described O O
DNA O O
virus O O
, O O
Karposi O O
's O O
sarcoma-associated O O
herpesvirus/human O O
herpesvirus-8 O O
( O O
KSHV/HHV-8 O O
) O O
; O O
and O O
perhaps O O
HIV O O
. O O

Elucidation O O
of O O
the O O
factors O O
that O O
contribute O O
to O O
the O O
high O O
incidence O O
of O O
NHL O O
among O O
patients O O
infected O O
with O O
HIV O O
provides O O
insights O O
into O O
important O O
elements O O
of O O
lymphomagenesis O O
. O O

Matrix B-protein B-protein
metalloproteinase I-protein I-protein
expression O O
in O O
human O O
breast O O
cancer O O
: O O
an O O
immunohistochemical O O
study O O
including O O
correlation O O
with O O
cathepsin B-protein B-protein
D I-protein I-protein
, O O
type B-protein B-protein
IV I-protein I-protein
collagen I-protein I-protein
, O O
laminin B-protein B-protein
, O O
fibronectin B-protein B-protein
, O O
EGFR B-protein B-protein
, O O
c-erbB-2 B-protein B-protein
oncoprotein I-protein I-protein
, O O
p53 B-protein B-protein
, O O
steroid O O
receptors O O
status O O
and O O
proliferative O O
indices O O
. O O

Matrix B-protein B-protein
metalloproteinase I-protein I-protein
s O O
( O O
MMPs B-protein B-protein
) O O
are O O
a O O
group O O
of O O
enzymes O B-protein
thought O O
to O O
be O O
responsible O O
for O O
both O O
normal O O
connective O O
tissue O O
matrix O O
remodelling O O
and O O
accelerated O O
breakdown O O
associated O O
with O O
tumour O O
development O O
. O O

The O O
current O O
study O O
aimed O O
to O O
investigate O O
the O O
immunohistochemical O O
expression O O
of O O
matrix B-protein B-protein
metalloproteinase I-protein I-protein
3 I-protein I-protein
( O O
MMP-3 B-protein B-protein
, O O
stromelysin-1 B-protein B-protein
) O O
in O O
correlation O O
with O O
the O O
expression O O
of O O
Basement B-protein B-protein
Membrane I-protein I-protein
( I-protein I-protein
BM I-protein I-protein
) I-protein I-protein
antigen I-protein I-protein
( O O
type B-protein B-protein
IV I-protein I-protein
collagen I-protein I-protein
, O O
laminin B-protein B-protein
) O O
, O O
fibronectin B-protein B-protein
, O O
cathepsin B-protein B-protein
D I-protein I-protein
, O O
p53 B-protein B-protein
, O O
c-erbB-2 B-protein B-protein
, O O
proliferative O O
activity O O
( O O
Ki-67 B-protein B-protein
, O O
PCNA B-protein B-protein
) O O
, O O
steroid O O
receptor O O
content O O
as O O
well O O
as O O
to O O
the O O
other O O
conventional O O
clinicopathological O O
parameters O O
in O O
breast O O
cancer O O
. O O

This O O
study O O
was O O
performed O O
on O O
a O O
series O O
of O O
frozen O O
and O O
paraffin O O
sections O O
from O O
84 O O
breast O O
cancer O O
specimens O O
by O O
immunohistochemistry O O
using O O
the O O
monoclonal B-protein B-protein
antibody I-protein I-protein
MMP-3 I-protein I-protein
( O O
Ab-1 B-protein B-protein
) O O
. O O

Stromelysin-1 B-protein B-protein
( O O
ST1 B-protein O
) O O
was O O
observed O O
in O O
about O O
10 O O
% O O
of O O
epithelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
the O O
control O O
groups O O
( O O
cases O O
of O O
fibrocystic O O
and O O
benign O O
proliferative O O
breast O O
disease O O
) O O
, O O
while O O
expression O O
( O O
> O O
10 O O
% O O
of O O
expression O O
) O O
was O O
detected O O
in O O
89.7 O O
% O O
of O O
tumours O O
. O O

The O O
expression O O
of O O
ST1 B-protein O
in O O
carcinoma O B-cell_type
cells O I-cell_type
was O O
strongly O O
associated O O
with O O
its O O
presence O O
in O O
the O O
stroma O O
( O O
p O O
< O O
0.001 O O
) O O
. O O

A O O
significantly O O
positive O O
correlation O O
was O O
found O O
between O O
ST1 B-protein O
expression O O
, O O
and O O
p53 B-protein B-protein
tumour O I-protein
suppressor O I-protein
gene O I-protein
product O I-protein
( O O
p O O
= O O
0.004 O O
) O O
, O O
and O O
a O O
relationship O O
with O O
c-erbB-2 B-protein B-protein
protein O O
and O O
progesterone O B-protein
receptor O I-protein
status O O
was O O
also O O
indicated O O
. O O

These O O
findings O O
suggest O O
that O O
ST1 B-protein O
expression O O
in O O
breast O O
cancer O O
tissue O O
is O O
irrespective O O
of O O
the O O
expression O O
of O O
the O O
extracellular O O
matrix O O
component O O
, O O
the O O
proteolytic B-protein B-protein
enzyme I-protein I-protein
cathepsin B-protein I-protein
D I-protein I-protein
and O O
the O O
growth O O
fraction O O
of O O
the O O
tumour O O
, O O
and O O
that O O
it O O
could O O
be O O
a O O
potential O O
new O O
prognostic O O
marker O O
in O O
breast O O
cancer O O
. O O

Use O O
of O O
transfected B-cell_line B-cell_line
liver I-cell_line I-cell_line
cells I-cell_line I-cell_line
to O O
evaluate O O
potential O O
mechanisms O O
of O O
alcohol-induced O O
liver O O
injury O O
[ O O
see O O
comments O O
] O O

There O O
is O O
increased O O
activity O O
of O O
the O O
proinflammatory B-protein B-protein
cytokine I-protein I-protein
, O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
( O O
TNF B-protein B-protein
) O O
in O O
alcoholic O O
liver O O
disease O O
( O O
ALD O O
) O O
. O O

Hepatic O B-cell_type
neutrophil O I-cell_type
infiltration O O
is O O
a O O
principal O O
injurious O O
manifestation O O
of O O
ALD O O
. O O

TNF B-protein B-protein
can O O
induce O O
cellular O O
oxidative O O
injury O O
directly O O
, O O
and O O
indirectly O O
by O O
inducing O O
neutrophil O B-protein
chemotactic O I-protein
factor O I-protein
( O O
IL-8 B-protein B-protein
) O O
production O O
by O O
hepatocytes O B-cell_type
. O O

IL-8 B-protein B-protein
activates O O
and O O
chemotactically O O
attracts O O
neutrophils O B-cell_type
to O O
the O O
liver O O
where O O
they O O
release O O
oxidizing O O
substances O O
. O O

Patients O O
with O O
ALD O O
also O O
have O O
decreased O O
protective B-protein O
factors I-protein O
for O O
cellular O O
oxidative O O
injury O O
. O O

Manganous B-protein B-protein
superoxide I-protein I-protein
dismutase I-protein I-protein
( O O
MnSOD B-protein B-protein
) O O
is O O
an O O
antioxidant B-protein B-protein
protective I-protein I-protein
factor I-protein I-protein
. O O

The O O
objectives O O
of O O
these O O
studies O O
were O O
to O O
investigate O O
mechanisms O O
for O O
induction O O
of O O
an O O
injurious B-protein O
factor I-protein O
( O O
IL-8 B-protein B-protein
) O O
and O O
a O O
protective B-protein O
factor I-protein O
( O O
MnSOD B-protein B-protein
) O O
in O O
the O O
HepG2 B-cell_line B-cell_line
human I-cell_line I-cell_line
hepatoma I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

In O O
the O O
first O O
set O O
of O O
experiments O O
, O O
IL-8 B-DNA B-DNA
gene I-DNA I-DNA
reporter I-DNA I-DNA
constructs I-DNA I-DNA
were O O
used O O
to O O
transiently O O
transfect O O
a O O
derivative O O
( O O
MVh2E1-9 B-cell_line O
) O O
of O O
the O O
HepG2 B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
which O O
expresses O O
P-4502E1 B-protein B-cell_line
and O O
metabolizes O O
ethanol O O
. O O

Inactivation O O
of O O
the O O
NF-kappaB B-DNA B-DNA
and I-DNA I-DNA
3'NF-IL-6 I-DNA I-DNA
DNA I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
decreased O O
IL-8 B-DNA B-DNA
gene I-DNA I-DNA
transcriptional O O
activation O O
in O O
response O O
to O O
TNF B-protein B-protein
while O O
inactivation O O
of O O
the O O
5'NF-IL-6 B-DNA B-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
increased O O
IL-8 B-DNA B-DNA
gene I-DNA I-DNA
transcriptional O O
activity O O
in O O
response O O
to O O
TNF B-protein B-protein
. O O

This O O
system O O
may O O
be O O
useful O O
to O O
assess O O
the O O
effects O O
of O O
ethanol O O
on O O
TNF B-protein B-protein
-induced O O
hepatocyte O O
IL-8 B-protein B-protein
production O O
. O O

In O O
the O O
second O O
set O O
of O O
experiments O O
, O O
HepG2 B-cell_line B-cell_line
cells I-cell_line I-cell_line
were O O
cultured O O
in O O
25 O O
to O O
100 O O
mmol O O
concentrations O O
of O O
ethanol O O
. O O

Both O O
TNF B-protein B-protein
and O O
ethanol O O
increased O O
HepG2 B-cell_line B-cell_line
cell I-cell_line I-cell_line
MnSOD B-protein B-protein
activity O O
in O O
short-term O O
( O O
72 O O
hr O O
) O O
cultures O O
with O O
ethanol O O
. O O

However O O
, O O
after O O
long-term O O
( O O
10 O O
weeks O O
) O O
culture O O
with O O
ethanol O O
, O O
there O O
was O O
no O O
induction O O
of O O
MnSOD B-protein B-protein
by O O
ethanol O O
and O O
there O O
was O O
a O O
diminished O O
induction O O
of O O
MnSOD B-protein B-protein
in O O
response O O
to O O
TNF B-protein B-protein
. O O

Further O O
studies O O
are O O
needed O O
to O O
assess O O
the O O
effect O O
of O O
this O O
diminished O O
induction O O
of O O
MnSOD B-protein B-protein
with O O
chronic O O
ethanol O O
culture O O
on O O
HepG2 B-cell_line O
cell I-cell_line O
susceptibility O O
to O O
TNF B-cell_line B-protein
cytotoxicity I-cell_line O
. O O

We O O
conclude O O
that O O
transfected O B-cell_line
liver B-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
can O O
be O O
used O O
to O O
evaluate O O
mechanisms O O
for O O
increased O O
injurious B-protein B-protein
factors I-protein I-protein
and O O
decreased O O
protective B-protein B-protein
factors I-protein I-protein
in O O
alcoholic O O
liver O O
injury O O
. O O

Tissue O B-protein
factor O I-protein
transcription O I-protein
driven O O
by O O
Egr-1 B-protein B-protein
is O O
a O O
critical O O
mechanism O O
of O O
murine B-protein O
pulmonary I-protein O
fibrin I-protein B-protein
deposition O O
in O O
hypoxia O O
. O O

Local O O
hypoxemia O O
and O O
stasis O O
trigger O O
thrombosis O O
. O O

We O O
have O O
demonstrated O O
previously O O
that O O
in O O
a O O
murine O O
model O O
of O O
normobaric O O
hypoxia O O
pulmonary O O
fibrin B-protein B-protein
deposition O O
is O O
a O O
result O O
of O O
expression O O
of O O
tissue B-protein B-protein
factor I-protein I-protein
, O O
especially O O
in O O
oxygen-deprived B-protein B-cell_type
mononuclear I-protein I-cell_type
phagocytes I-protein I-cell_type
( O O
MPs B-protein B-cell_type
) O O
. O O

We O O
now O O
show O O
that O O
transcription B-protein B-protein
factor I-protein I-protein
early-growth-response I-protein I-protein
gene I-protein I-protein
product I-protein I-protein
( O O
Egr-1 B-protein B-protein
) O O
is O O
rapidly O O
activated O O
in O O
hypoxia O O
, O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
, O O
and O O
is O O
responsible O O
for O O
transcription O O
and O O
expression O O
of O O
tissue B-protein B-protein
factor I-protein I-protein
in O O
hypoxic O O
lung O O
. O O

MPs B-protein O
and O O
HeLa B-cell_line B-cell_line
cells I-cell_line I-cell_line
subjected O O
to O O
hypoxia O O
( O O
pO2 O O
approximately O O
13 O O
torr O O
) O O
had O O
increased O O
levels O O
of O O
tissue B-RNA B-RNA
factor I-RNA I-RNA
transcripts I-RNA I-RNA
( O O
approximately O O
18-fold O O
) O O
and O O
an O O
increased O O
rate O O
of O O
transcription O O
( O O
approximately O O
15-fold O O
) O O
, O O
based O O
on O O
nuclear O O
run-on O O
analysis O O
. O O

Gel-shift O O
analysis O O
of O O
nuclear O O
extracts O O
from O O
hypoxic B-protein B-cell_type
MPs I-protein I-cell_type
and O O
HeLa B-cell_line B-cell_line
cells I-cell_line I-cell_line
demonstrated O O
increased O O
DNA-binding O O
activity O O
at O O
the O O
serum B-DNA B-DNA
response I-DNA I-DNA
region I-DNA I-DNA
( O O
SRR O B-protein
; O O
-111/+14 O O
bp O O
) O O
of O O
the O O
tissue B-DNA B-DNA
factor I-DNA I-DNA
promoter I-DNA I-DNA
at O O
Egr-1 B-DNA B-DNA
motifs I-DNA I-DNA
. O O

Using O O
32P-labeled O B-DNA
Egr O I-DNA
consensus O I-DNA
oligonucleotide O O
, O O
we O O
observed O O
induction O O
of O O
DNA-binding O O
activity O O
in O O
nuclear O O
extracts O O
from O O
hypoxic O O
lung O O
and O O
HeLa B-cell_line B-cell_line
cells I-cell_line I-cell_line
because O O
of O O
activation O O
of O O
Egr-1 B-protein B-protein
, O O
by O O
means O O
of O O
supershift O O
analysis O O
. O O

Transient O O
transfection O O
of O O
HeLa B-cell_line B-cell_line
cells I-cell_line I-cell_line
with O O
chimeric B-DNA B-protein
plasmids I-DNA I-protein
containing O O
wild-type B-protein O
or I-protein O
mutant I-protein B-protein
SRR I-protein I-protein
from O O
the O O
tissue B-DNA B-DNA
factor I-DNA I-DNA
promoter I-DNA I-DNA
showed O O
that O O
intact B-DNA O
Sp1 I-DNA B-DNA
sites I-DNA I-DNA
are O O
necessary O O
for O O
basal O O
promoter O O
activity O O
, O O
whereas O O
the O O
integrity O O
of O O
Egr-1 B-DNA B-DNA
sites I-DNA I-DNA
was O O
required O O
for O O
hypoxia-enhanced O O
expression O O
. O O

A O O
central O O
role O O
for O O
Egr-1 B-protein B-protein
in O O
hypoxia-mediated O O
tissue O B-protein
factor O I-protein
expression O O
was O O
confirmed O O
by O O
experiments O O
with O O
homozygous O O
Egr-1 B-protein B-protein
null O O
mice O O
; O O
wild-type O O
mice O O
subjected O O
to O O
oxygen B-protein O
deprivation I-protein O
expressed I-protein O
tissue I-protein B-protein
factor I-protein I-protein
and O O
showed O O
fibrin B-protein B-protein
deposition O O
, O O
but O O
hypoxic O O
homozygous O O
Egr-1 B-protein B-protein
null O O
mice O O
displayed O O
neither O O
tissue B-protein O
factor I-protein O
nor O O
fibrin B-protein B-protein
. O O

These O O
data O O
delineate O O
a O O
novel O O
biology O O
for O O
hypoxia-induced O O
fibrin B-protein B-protein
deposition O O
, O O
in O O
which O O
oxygen O O
deprivation-induced O O
activation O O
of O O
Egr-1 B-protein B-protein
, O O
resulting O O
in O O
expression O O
of O O
tissue B-protein B-protein
factor I-protein I-protein
, O O
has O O
an O O
unexpected O O
and O O
central O O
role O O
. O O

Kinetics O O
of O O
cytokine O B-protein
and O O
NFAT O B-protein
gene O O
expression O O
in O O
human B-cell_line B-cell_type
interleukin-2-dependent I-cell_line I-cell_type
T I-cell_line I-cell_type
lymphoblasts I-cell_line I-cell_type
stimulated O O
via O O
T-cell B-protein B-protein
receptor I-protein I-protein
. O O

T B-cell_type B-cell_type
cells I-cell_type I-cell_type
respond O O
to O O
mitogenic O O
or O O
antigenic O O
stimulation O O
by O O
proliferation O O
and O O
by O O
turning O O
on O O
cytokine O B-DNA
gene O I-DNA
expression O O
. O O

Here O O
we O O
have O O
analysed O O
the O O
kinetics O O
and O O
nature O O
of O O
cytokine O B-protein
production O O
in O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood-derived I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphoblasts I-cell_type I-cell_type
stimulated O O
with O O
anti-CD3 B-protein B-protein
antibodies I-protein I-protein
or O O
Lens B-protein B-protein
culinaris I-protein I-protein
lectin I-protein I-protein
( O O
LCL B-protein B-cell_line
) O O
. O O

T B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
purified O O
from O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
PBMC B-cell_type B-cell_type
) O O
and O O
primarily O O
activated O O
with O O
anti-CD3 B-protein B-protein
antibodies I-protein I-protein
and O O
cultured O O
in O O
the O O
presence O O
of O O
interleukin-2 B-protein B-protein
( O O
IL-2 B-protein B-protein
) O O
. O O

Anti-CD3-restimulated O B-cell_type
T B-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
mainly O O
CD8+ O O
) O O
produced O O
IL-2 B-protein B-protein
, O O
interferon-gamma B-protein B-protein
( O O
IFN-gamma B-protein B-protein
) O O
and O O
tumour B-protein B-protein
necrosis I-protein I-protein
factor-alpha I-protein I-protein
( O O
TNF-alpha B-protein B-protein
) O O
and O O
low O O
levels O O
of O O
IL-4 B-RNA B-RNA
and I-RNA I-RNA
IL-10 I-RNA I-RNA
transcripts I-RNA I-RNA
and O O
proteins O O
. O O

No O O
IL-6 B-DNA B-protein
gene I-DNA O
expression O O
was O O
observed O O
. O O

In O O
LCL-stimulated B-cell_type B-cell_line
cells I-cell_type I-cell_line
the O O
cytokine O B-protein
production O O
pattern O O
was O O
very O O
similar O O
. O O

Steady-state O O
mRNA O O
levels O O
of O O
IL-2 B-protein B-protein
, O O
IL-10 B-protein B-protein
and O O
IFN-gamma B-protein B-protein
peaked O O
at O O
3 O O
hr O O
after O O
anti-CD3 O B-protein
stimulation O O
and O O
declined O O
rapidly O O
thereafter O O
. O O

The O O
kinetics O O
of O O
TNF-alpha B-RNA B-RNA
mRNA I-RNA I-RNA
expression O O
was O O
faster O O
, O O
being O O
at O O
its O O
peak O O
level O O
1 O O
hr O O
after O O
stimulation O O
. O O

Anti-CD3-stimulated O O
IL-2 B-DNA B-protein
gene I-DNA O
expression O O
was O O
down-regulated O O
by O O
protein O O
synthesis O O
inhibitor O O
, O O
whereas O O
IL-10 B-DNA B-protein
, I-DNA O
IFN-gamma I-DNA B-protein
and I-DNA O
TNF-alpha I-DNA B-protein
genes I-DNA I-DNA
were O O
readily O O
induced O O
independent O O
of O O
ongoing O O
protein O O
synthesis O O
. O O

T-cell B-protein B-protein
receptor I-protein I-protein
stimulation O O
also O O
induced O O
a O O
very O O
rapid O O
expression O O
of O O
c-jun B-DNA B-DNA
, I-DNA O
c-fos I-DNA O
and I-DNA O
NFATc1 I-DNA B-DNA
( I-DNA I-DNA
NFATc I-DNA I-DNA
) I-DNA I-DNA
genes I-DNA I-DNA
, O O
the O O
gene O B-protein
products O I-protein
of O O
which O O
are O O
involved O O
in O O
cytokine O B-DNA
gene O I-DNA
expression O O
. O O

In O O
conclusion O O
, O O
the O O
cytokines B-protein B-protein
synthesized O O
by O O
IL-2-dependent B-cell_type B-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
were O O
predominantly O O
IL-2 B-protein B-protein
, O O
IFN-gamma B-protein B-protein
and O O
TNF-alpha B-protein B-protein
. O O

An O O
animal O O
model O O
to O O
study O O
local O O
oxidation O O
of O O
LDL O B-protein
and O O
its O O
biological O O
effects O O
in O O
the O O
arterial O O
wall O O
. O O

Oxidized O O
LDL O O
( O O
oxLDL O B-protein
) O O
is O O
present O O
in O O
atherosclerotic O O
lesions O O
and O O
is O O
believed O O
to O O
play O O
a O O
key O O
role O O
in O O
atherogenesis O O
. O O

Mainly O O
on O O
the O O
basis O O
of O O
cell O O
culture O O
studies O O
, O O
oxLDL O B-protein
has O O
been O O
shown O O
to O O
produce O O
many O O
biological O O
effects O O
that O O
influence O O
the O O
atherosclerotic O O
process O O
. O O

To O O
study O O
LDL O B-protein
oxidation O O
in O O
vivo O O
, O O
we O O
have O O
established O O
a O O
model O O
in O O
which O O
Sprague-Dawley O O
rats O O
are O O
given O O
a O O
single O O
injection O O
of O O
unmodified O O
human O O
LDL O O
( O O
> O O
or O O
= O O
4 O O
mg/kg O O
body O O
weight O O
) O O
. O O

Within O O
6 O O
hours O O
, O O
an O O
accumulation O O
of O O
apolipoprotein O B-protein
B O I-protein
and O O
epitopes B-protein B-protein
present O O
on O O
oxLDL O B-protein
are O O
detected O O
in O O
the O O
arterial O O
endothelium O O
and O O
media O O
. O O

The O O
presence O O
of O O
oxLDL O B-protein
is O O
associated O O
with O O
activation O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
in O O
the O O
endothelium O O
as O O
well O O
as O O
endothelial O O
expression O O
of O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
. O O

Injection O O
of O O
LDL O B-protein
enriched O O
with O O
the O O
antioxidant O O
probucol O O
resulted O O
in O O
arterial O O
accumulation O O
of O O
apolipoprotein O B-protein
B O I-protein
, O O
but O O
the O O
expression O O
of O O
oxLDL-specific O B-protein
epitopes O I-protein
was O O
reduced O O
at O O
24 O O
hours O O
. O O

Thus O O
, O O
this O O
simple O O
model O O
has O O
the O O
potential O O
to O O
analyze O O
the O O
mechanisms O O
behind O O
and O O
biological O O
effects O O
of O O
LDL O B-protein
oxidation O O
in O O
vivo O O
. O O

Molecular O O
mechanisms O O
of O O
promoter O O
regulation O O
of O O
the O O
gp34 B-DNA B-DNA
gene I-DNA I-DNA
that O O
is O O
trans-activated O O
by O O
an O O
oncoprotein B-protein B-protein
Tax I-protein I-protein
of O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
I O O
. O O

We O O
investigated O O
the O O
molecular O O
mechanism O O
of O O
transcriptional O O
activation O O
of O O
the O O
gp34 B-DNA B-DNA
gene I-DNA I-DNA
by O O
the O O
Tax B-protein B-protein
oncoprotein I-protein I-protein
of O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV-I O O
) O O
. O O

gp34 B-protein B-protein
is O O
a O O
type B-protein B-protein
II I-protein I-protein
transmembrane I-protein I-protein
molecule I-protein I-protein
belonging O O
to O O
the O O
tumor O B-protein
necrosis O I-protein
factor O I-protein
family O I-protein
and O O
is O O
constitutively O O
expressed O O
on O O
HTLV-I-producing B-cell_type B-cell_line
cells I-cell_type I-cell_line
but O O
not O O
normal B-cell_type B-cell_type
resting I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
transcriptional O B-DNA
regulatory O I-DNA
region O I-DNA
of O O
the O O
gp34 B-DNA B-DNA
gene I-DNA I-DNA
was O O
activated O O
by O O
HTLV-I O O
Tax B-protein B-protein
in O O
the O O
human B-cell_line B-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
Jurkat I-cell_line I-cell_line
, O O
in O O
which O O
endogenous O B-protein
gp34 B-protein I-protein
is O O
induced O O
by O O
Tax B-protein B-protein
. O O

Sequence O O
analysis O O
demonstrated O O
that O O
two O O
NF-kappaB-like B-DNA B-DNA
elements I-DNA I-DNA
( O O
1 O O
and O O
2 O O
) O O
were O O
present O O
in O O
the O O
regulatory B-DNA B-DNA
region I-DNA I-DNA
. O O

Both O O
NF-kappaB-like B-DNA B-DNA
elements I-DNA I-DNA
were O O
able O O
to O O
bind O O
to O O
NF-kappaB B-protein B-protein
or O O
its O O
related O O
factor O O
( O O
s O O
) O O
in O O
a O O
Tax B-protein B-protein
-dependent O O
manner O O
. O O

Chloramphenicol B-protein B-protein
acetyltransferase I-protein I-protein
assays O O
indicated O O
that O O
NF-kappaB-like B-DNA B-DNA
element I-DNA I-DNA
1 I-DNA I-DNA
was O O
Tax B-protein B-protein
-responsive O O
, O O
although O O
the O O
activity O O
was O O
lower O O
than O O
that O O
the O O
native B-DNA B-DNA
promoter I-DNA I-DNA
. O O

NF-kappaB B-protein B-protein
-like O B-DNA
element O I-DNA
2 O I-DNA
elevated O O
promoter O O
activity O O
when O O
combined O O
with O O
NF-kappaB-like B-DNA B-DNA
element I-DNA I-DNA
1 I-DNA I-DNA
, O O
indicating O O
cooperative O O
function O O
of O O
the O O
elements O O
for O O
maximum O O
promoter O O
function O O
. O O

Unlike O O
typical O O
NF-kappaB B-DNA B-DNA
elements I-DNA I-DNA
, O O
the O O
NF-kappaB-like B-DNA B-DNA
elements I-DNA I-DNA
in O O
gp34 B-protein B-protein
were O O
not O O
activated O O
by O O
treatment O O
of O O
Jurkat B-cell_line B-cell_line
cells I-cell_line I-cell_line
with O O
phorbol O O
ester O O
despite O O
induction O O
of O O
the O O
NF-kappaB B-protein B-protein
-like O O
binding O O
activity O O
. O O

Chloramphenicol B-protein B-DNA
acetyltransferase I-protein I-DNA
reporter O I-DNA
assays O O
using O O
the O O
region O O
upstream O O
of O O
the O O
NF-kappaB-like B-DNA B-DNA
elements I-DNA I-DNA
identified O O
an O O
upstream O B-DNA
region O I-DNA
that O O
reduced O O
transcription O O
from O O
cognate B-DNA B-DNA
and I-DNA I-DNA
noncognate I-DNA I-DNA
core I-DNA I-DNA
promoters I-DNA I-DNA
in O O
a O O
Tax-independent O O
manner O O
. O O

Our O O
results O O
imply O O
complex O O
regulation O O
of O O
expression O O
of O O
the O O
gp34 B-DNA B-DNA
gene I-DNA I-DNA
and O O
suggest O O
implication O O
of O O
gp34 B-protein B-protein
in O O
proliferation O O
of O O
HTLV-I O B-cell_type
infected O I-cell_type
T O I-cell_type
cells O I-cell_type
. O O

beta-Amyloid B-protein O
fibrils I-protein O
activate O O
parallel O O
mitogen-activated B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
pathways O O
in O O
microglia B-cell_type B-cell_type
and O O
THP1 B-cell_line B-cell_line
monocytes I-cell_line I-cell_line
. O O

The O O
senile O O
plaques O O
of O O
Alzheimer O O
's O O
disease O O
are O O
foci O O
of O O
local O O
inflammatory O O
responses O O
, O O
as O O
evidenced O O
by O O
the O O
presence O O
of O O
acute B-protein B-protein
phase I-protein I-protein
proteins I-protein I-protein
and O O
oxidative O O
damage O O
. O O

Fibrillar B-protein O
forms I-protein O
of O O
beta-amyloid B-protein O
( O O
Abeta B-protein O
) O O
, O O
which O O
are O O
the O O
primary O O
constituents O O
of O O
senile O O
plaques O O
, O O
have O O
been O O
shown O O
to O O
activate O O
tyrosine O O
kinase-dependent O O
signal O O
transduction O O
cascades O O
, O O
resulting O O
in O O
inflammatory O O
responses O O
in O O
microglia B-cell_type B-cell_type
. O O

However O O
, O O
the O O
downstream O O
signaling O O
pathways O O
mediating O O
Abeta B-protein B-protein
-induced O O
inflammatory O O
events O O
are O O
not O O
well O O
characterized O O
. O O

We O O
report O O
that O O
exposure O O
of O O
primary B-cell_type B-cell_type
rat I-cell_type I-cell_type
microglia I-cell_type I-cell_type
and O O
human B-cell_line B-cell_type
THP1 I-cell_line I-cell_type
monocytes I-cell_line I-cell_type
to O O
fibrillar B-protein B-protein
Abeta I-protein I-protein
results O O
in O O
the O O
tyrosine B-protein B-protein
kinase I-protein I-protein
-dependent O O
activation O O
of O O
two O O
parallel O O
signal O O
transduction O O
cascades O O
involving O O
members O O
of O O
the O O
mitogen-activated B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
( I-protein I-protein
MAPK I-protein I-protein
) I-protein I-protein
superfamily I-protein I-protein
. O O

Abeta B-protein O
stimulated O O
the O O
rapid O O
, O O
transient O O
activation O O
of O O
extracellular B-protein B-protein
signal-regulated I-protein I-protein
kinase I-protein I-protein
1 I-protein I-protein
( O O
ERK1 B-protein B-protein
) O O
and O O
ERK2 B-protein B-protein
in O O
microglia B-cell_type B-cell_type
and O O
ERK2 B-protein B-protein
in O O
THP1 B-cell_line B-cell_line
monocytes I-cell_line I-cell_line
. O O

A O O
second O O
superfamily B-protein O
member I-protein O
, O O
p38 B-protein B-protein
MAPK I-protein I-protein
, O O
was O O
also O O
activated O O
with O O
similar O O
kinetics O O
. O O

Scavenger B-protein B-protein
receptor I-protein I-protein
and O O
receptor B-protein O
for I-protein O
advanced I-protein O
glycated I-protein B-protein
end I-protein I-protein
products I-protein I-protein
( O I-protein
RAGE B-protein I-protein
) O I-protein
ligands O I-protein
failed O O
to O O
activate O O
ERK B-protein B-protein
and O I-protein
p38 B-protein I-protein
MAPK I-protein I-protein
in O O
the O O
absence O O
of O O
significant O O
increases O O
in O O
protein O O
tyrosine O O
phosphorylation O O
, O O
demonstrating O O
that O O
scavenger B-protein B-protein
receptors I-protein I-protein
and O O
RAGE B-protein B-protein
are O O
not O O
linked O O
to O O
these O O
pathways O O
. O O

Importantly O O
, O O
the O O
stress-activated B-protein B-protein
protein I-protein I-protein
kinases I-protein I-protein
( O O
SAPKs B-protein B-protein
) O O
were O O
not O O
significantly O O
activated O O
in O O
response O O
to O O
Abeta B-protein B-protein
. O O

Downstream O O
effectors O O
of O O
the O O
MAPK O B-protein
signal O O
transduction O O
cascades O O
include O O
MAPKAP B-protein B-protein
kinases I-protein I-protein
, O O
such O O
as O O
RSK1 B-protein B-protein
and O O
RSK2 B-protein B-protein
, O O
as O O
well O O
as O O
transcription B-protein B-protein
factors I-protein I-protein
. O O

Exposure O O
of O O
microglia B-cell_type B-cell_type
and O O
THP1 B-cell_line B-cell_line
monocytes I-cell_line I-cell_line
to O O
Abeta B-protein O
resulted O O
in O O
the O O
activation O O
of O O
RSK1 B-protein B-protein
and O O
RSK2 B-protein B-protein
and O O
phosphorylation O O
of O O
cAMP B-protein B-protein
response I-protein I-protein
element-binding I-protein I-protein
protein I-protein I-protein
at O O
Ser133 O B-protein
, O O
providing O O
a O O
mechanism O O
for O O
Abeta B-protein B-protein
-induced O O
changes O O
in O O
gene O O
expression O O

Regulation O O
of O O
cellular B-protein B-protein
retinoic I-protein I-protein
acid I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
( O O
CRABP B-protein B-protein
II I-protein I-protein
) O O
during O O
human B-cell_type O
monocyte I-cell_type O
differentiation O O
in O O
vitro O O
. O O

Cellular B-protein B-protein
retinoic I-protein I-protein
acid I-protein I-protein
binding I-protein I-protein
proteins I-protein I-protein
( O O
CRABP B-protein B-protein
) O O
are O O
low B-protein O
molecular I-protein O
weight I-protein O
proteins I-protein O
whose O O
precise O O
function O O
remains O O
unknown O O
. O O

They O O
bind O O
retinoids O O
and O O
may O O
thereby O O
modulate O O
the O O
intracellular O O
steady-state O O
concentration O O
of O O
retinoids O O
. O O

Whereas O O
CRABP B-protein B-protein
I I-protein I-protein
is O O
ubiquitously O O
expressed O O
, O O
CRABP B-protein B-protein
II I-protein I-protein
is O O
mainly O O
detected O O
in O O
various O O
cell O O
types O O
of O O
the O O
skin O O
. O O

By O O
representative O O
difference O O
analysis O O
we O O
found O O
that O O
CRABP B-protein B-protein
II I-protein I-protein
is O O
also O O
strongly O O
expressed O O
in O O
human B-cell_type B-cell_line
monocyte-derived I-cell_type I-cell_line
macrophages I-cell_type I-cell_line
( O O
MAC B-cell_type O
) O O
but O O
not O O
in O O
freshly B-cell_type B-cell_type
isolated I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
( O O
MO B-cell_type O
) O O
. O O

The O O
CRABP B-RNA B-RNA
II I-RNA I-RNA
mRNA I-RNA I-RNA
was O O
gradually O O
upregulated O O
during O O
differentiation O O
from O O
MO B-cell_type O
to O O
MAC B-cell_type O
in O O
the O O
presence O O
of O O
2 O O
% O O
serum O O
. O O

Adherence O O
, O O
which O O
is O O
important O O
for O O
MO B-cell_type O
differentiation O O
, O O
induced O O
CRABP B-protein B-protein
II I-protein I-protein
expression O O
, O O
but O O
the O O
addition O O
of O O
10 O O
( O O
-7 O O
) O O
M O O
retinoic O O
acid O O
inhibited O O
the O O
upregulation O O
of O O
CRABP B-protein B-protein
II I-protein I-protein
expression O O
during O O
MO/MAC O O
differentiation O O
. O O

As O O
MO B-cell_type O
can O O
differentiate O O
along O O
the O O
classical O O
pathway O O
not O O
only O O
to O O
MAC B-cell_type O
but O O
also O O
to O O
dendritic O B-cell_type
cells O I-cell_type
we O O
analyzed O O
the O O
expression O O
of O O
CRABP B-protein B-protein
II I-protein I-protein
in O O
MO-derived B-cell_type B-cell_type
dendritic I-cell_type I-cell_type
cells I-cell_type I-cell_type
cultured O O
with O O
10 O O
% O O
FCS B-protein O
, O O
IL-4 B-protein B-protein
, O O
and O O
GM-CSF B-protein B-protein
. O O

In O O
contrast O O
to O O
MAC B-cell_type O
, O O
MO-derived B-cell_type B-cell_type
dendritic I-cell_type I-cell_type
cells I-cell_type I-cell_type
showed O O
an O O
extremely O O
low O O
expression O O
of O O
CRABP B-protein B-protein
II I-protein I-protein
. O O

From O O
these O O
results O O
we O O
conclude O O
( O O
1 O O
) O O
that O O
the O O
availability O O
and O O
the O O
metabolism O O
of O O
retinoids O O
may O O
be O O
different O O
in O O
MAC B-cell_type O
compared O O
to O O
MO B-cell_type O
and O O
dendritic B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
( O O
2 O O
) O O
that O O
this O O
may O O
influence O O
differentiation O O
and O O
activation O O
of O O
those O O
cells O O
. O O

Transcription B-protein B-protein
factor I-protein I-protein
B-cell-specific I-protein I-protein
activator I-protein I-protein
protein I-protein I-protein
( O O
BSAP B-protein B-protein
) O O
is O O
differentially O O
expressed O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
in O O
subsets O O
of O O
B-cell O B-cell_type
lymphomas O I-cell_type
. O O

The O O
paired B-DNA B-DNA
box I-DNA I-DNA
containing I-DNA I-DNA
gene I-DNA I-DNA
PAX-5 B-DNA I-DNA
encodes O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
BSAP B-protein B-protein
( O O
B-cell-specific B-protein B-protein
activator I-protein I-protein
protein I-protein I-protein
) O O
, O O
which O O
plays O O
a O O
key O O
role O O
in O O
B-lymphocyte O B-cell_type
development O O
. O O

Despite O O
its O O
known O O
involvement O O
in O O
a O O
rare O O
subtype O O
of O O
non-Hodgkin O O
's O O
lymphoma O O
( O O
NHL O O
) O O
, O O
a O O
detailed O O
examination O O
of O O
BSAP B-protein B-protein
expression O O
in O O
NHL O O
has O O
not O O
been O O
previously O O
reported O O
. O O

In O O
this O O
study O O
, O O
we O O
analyzed O O
normal O O
and O O
malignant O B-cell_line
lymphoid O I-cell_line
tissues O I-cell_line
and O I-cell_line
cell B-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
including O O
102 O O
cases O O
of O O
B-cell O O
NHL O O
, O O
23 O O
cases O O
of O O
T- O O
and O O
null-cell O O
NHL O O
, O O
and O O
18 O O
cases O O
of O O
Hodgkin O O
's O O
disease O O
. O O

Normal O O
lymphoid O O
tissues O O
showed O O
strong O O
nuclear O O
BSAP B-protein B-protein
expression O O
in O O
mantle B-cell_type B-cell_type
zone I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
less O O
intense O O
reactivity O O
in O O
follicular B-cell_type B-cell_type
center I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
and O O
no O O
expression O O
in O O
cells O O
of O O
the O O
T-cell-rich O O
zones O O
. O O

Monocytoid B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
showed O O
weak O O
expression O O
, O O
whereas O O
plasma B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
extrafollicular B-cell_type B-cell_type
large I-cell_type I-cell_type
transformed I-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
negative O O
. O O

Of O O
the O O
102 O O
B-cell O O
NHLs O O
, O O
83 O O
( O O
81 O O
% O O
) O O
demonstrated O O
BSAP B-protein B-protein
expression O O
. O O

All O O
of O O
the O O
13 O O
( O O
100 O O
% O O
) O O
B-cell O O
chronic O O
lymphocytic O O
leukemias O O
( O O
B-CLLs O O
) O O
, O O
21 O O
of O O
( O O
100 O O
% O O
) O O
mantle B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
MCLs B-cell_type O
) O O
, O O
and O O
20 O O
of O O
21 O O
( O O
95 O O
% O O
) O O
follicular O O
lymphomas O O
( O O
FLs O O
) O O
were O O
positive O O
. O O

Moderate O O
staining O O
intensities O O
were O O
found O O
in O O
most O O
B-CLL O O
and O O
FL O O
cases O O
, O O
whereas O O
most O O
MCLs B-cell_type O
showed O O
strong O O
reactions O O
, O O
paralleling O O
the O O
strong O O
reactivity O O
of O O
nonmalignant B-cell_type B-cell_type
mantle I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Eight O O
of O O
12 O O
( O O
67 O O
% O O
) O O
marginal O O
zone O O
lymphoma O O
cases O O
showed O O
negative O O
or O O
low O O
BSAP B-protein B-protein
levels O O
, O O
and O O
17 O O
of O O
24 O O
( O O
71 O O
% O O
) O O
large O O
B-cell O B-cell_type
lymphomas O I-cell_type
displayed O O
moderate O O
to O O
strong O O
expression O O
. O O

None O O
of O O
the O O
23 O O
T- O O
and O O
null-cell O O
lymphomas O O
reacted O O
with O O
the O O
BSAP B-protein B-protein
antisera O I-protein
, O O
whereas O O
in O O
Hodgkin O O
's O O
disease O O
, O O
2 O O
of O O
4 O O
( O O
50 O O
% O O
) O O
nodular O O
lymphocytic O O
predominance O O
and O O
5 O O
of O O
14 O O
( O O
36 O O
% O O
) O O
classical O O
cases O O
showed O O
weak O O
nuclear O O
or O O
nucleolar O O
BSAP B-protein B-protein
reactions O O
in O O
a O O
fraction O O
of O O
the O O
tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Western O O
blot O O
analysis O O
showed O O
a O O
52-kD O B-protein
BSAP B-protein I-protein
band O O
in O O
B-cell B-cell_line B-cell_line
lines I-cell_line I-cell_line
, O O
but O O
not O O
in O O
non-B-cell B-cell_line B-cell_line
or I-cell_line I-cell_line
plasma I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

We O O
conclude O O
that O O
BSAP B-protein B-protein
expression O O
is O O
largely O O
restricted O O
to O O
lymphomas O O
of O O
B-cell B-cell_type B-cell_type
lineage I-cell_type I-cell_type
and O O
that O O
BSAP B-protein B-protein
expression O O
varies O O
in O O
B-cell B-cell_type B-cell_type
subsets I-cell_type I-cell_type
and O O
subtypes O O
of O O
B-cell O O
NHL O O
. O O

The O O
high O O
levels O O
of O O
BSAP B-protein B-protein
, O O
especially O O
those O O
found O O
in O O
large-cell B-cell_type O
lymphomas I-cell_type O
and O O
in O O
some O O
follicular B-cell_type O
lymphomas I-cell_type O
, O O
may O O
be O O
a O O
consequence O O
of O O
deregulated O O
gene O O
expression O O
and O O
suggest O O
a O O
possible O O
involvement O O
of O O
PAX-5 B-DNA B-protein
in O O
certain O O
B-cell O O
malignancies O O
. O O

This O O
is O O
a O O
US O O
government O O
work O O
. O O

There O O
are O O
no O O
restrictions O O
on O O
its O O
use O O
. O O

Mitogen O O
and O O
growth O O
factor-induced O O
activation O O
of O O
a O O
STAT-like B-protein B-protein
molecule I-protein I-protein
in O O
channel B-cell_type B-cell_type
catfish I-cell_type I-cell_type
lymphoid I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

This O O
article O O
describes O O
the O O
identification O O
of O O
a O O
putative B-protein O
STAT I-protein B-protein
molecule I-protein I-protein
in O O
the O O
channel O O
catfish O O
( O O
Ictalurus O O
punctatus O O
) O O
, O O
the O O
first O O
report O O
of O O
such O O
a O O
molecule O O
in O O
a O O
'lower O O
' O O
vertebrate O O
. O O

A O O
monoclonal B-protein B-protein
antibody I-protein I-protein
against O O
human B-protein B-protein
STAT6 I-protein I-protein
recognizes O O
an O O
approximately O O
100 B-protein B-protein
kDa I-protein I-protein
molecule I-protein I-protein
that O O
becomes O O
activated O O
and O O
translocates O O
to O O
the O O
nucleus O O
upon O O
both O O
growth O B-protein
factor O I-protein
and O O
mitogen O B-protein
stimulation O O
of O O
catfish O B-cell_type
leukocytes O I-cell_type
. O O

This O O
presumed O O
catfish B-protein O
STAT I-protein B-protein
binds O O
the O O
mammalian B-DNA B-DNA
interferon-gamma I-DNA I-DNA
activation I-DNA I-DNA
site I-DNA I-DNA
, O O
a O O
known O O
motif O O
of O O
mammalian O O
STAT O B-protein
binding O O
, O O
as O O
shown O O
by O O
electromobility O O
shift O O
assays O O
. O O

Purification O O
of O O
the O O
proteins O O
present O O
in O O
these O O
DNA B-protein B-protein
complexes I-protein I-protein
confirms O O
that O O
the O O
catfish O B-protein
reactive O I-protein
molecule O I-protein
binds O O
to O O
the O O
interferon-gamma B-DNA B-DNA
activation I-DNA I-DNA
site I-DNA I-DNA
sequence I-DNA I-DNA
. O O

These O O
results O O
suggest O O
that O O
STAT B-protein B-protein
molecules I-protein I-protein
have O O
been O O
highly O O
conserved O O
in O O
vertebrate O O
evolution O O
. O O

Isolation O O
and O O
analysis O O
of O O
a O O
T B-cell_line B-cell_line
cell I-cell_line I-cell_line
clone I-cell_line I-cell_line
variant I-cell_line I-cell_line
exhibiting O O
constitutively O O
phosphorylated B-protein O
Ser133 I-protein B-protein
cAMP I-protein I-protein
response I-protein I-protein
element-binding I-protein I-protein
protein I-protein I-protein
. O O

In O O
driving O O
T O O
cell O O
proliferation O O
, O O
IL-2 B-protein B-protein
stimulates O O
a O O
new O O
program O O
of O O
gene O O
expression O O
that O O
includes O O
proliferating B-protein B-protein
cell I-protein I-protein
nuclear I-protein I-protein
antigen I-protein I-protein
( O O
PCNA B-protein B-protein
) O O
, O O
a O O
requisite O O
processivity O B-protein
factor O I-protein
for O O
DNA B-protein B-protein
polymerase I-protein I-protein
delta I-protein I-protein
. O O

PCNA B-protein B-protein
transcription O O
is O O
regulated O O
in O O
part O O
through O O
tandem O O
CRE B-DNA B-DNA
sequences I-DNA I-DNA
in O O
the O O
promoter B-protein O
and I-protein O
CRE I-protein B-protein
binding I-protein I-protein
proteins I-protein I-protein
; O O
IL-2 B-protein B-protein
stimulates O O
CREB O B-protein
phosphorylation O O
in O O
the O O
resting B-cell_line B-cell_type
cloned I-cell_line I-cell_type
T I-cell_line I-cell_type
lymphocyte I-cell_line I-cell_type
, O O
L2 B-cell_line O
. O O

After O O
culturing O B-cell_line
L2 B-cell_line I-cell_line
cells I-cell_line I-cell_line
for O O
greater O O
than O O
91 O O
days O O
, O O
we O O
consistently O O
isolate O O
a O O
stable O O
variant O O
that O O
exhibits O O
constitutive O O
CREB O B-protein
phosphorylation O O
. O O

L2 B-cell_line B-cell_line
and I-cell_line I-cell_line
L2 I-cell_line I-cell_line
variant I-cell_line I-cell_line
cells I-cell_line I-cell_line
were O O
tested O O
for O O
IL-2 B-protein B-protein
responsiveness O O
and O O
rapamycin O O
sensitivity O O
with O O
respect O O
to O O
specific O O
kinase O O
activity O O
, O O
PCNA O B-protein
expression O O
and O O
proliferation O O
. O O

In O O
L2 B-cell_line B-cell_type
cells I-cell_line I-cell_type
, O O
IL-2 B-protein B-protein
stimulated O O
and O O
rapamycin O O
inhibited O O
the O O
following O O
: O O
cAMP-independent O O
CREB B-protein B-protein
kinase I-protein O
activity O O
, O O
PCNA O O
expression O O
and O O
proliferation O O
. O O

In O O
L2 B-cell_line B-cell_line
variant I-cell_line I-cell_line
cells I-cell_line I-cell_line
, O O
CREB B-protein B-protein
kinase I-protein O
activity O O
was O O
constitutively O O
high O O
; O O
IL-2 B-protein B-protein
stimulated O O
and O O
rapamycin O O
blocked O O
PCNA O B-protein
expression O O
and O O
proliferation O O
. O O

These O O
results O O
indicate O O
that O O
IL-2 B-protein B-protein
induces O O
a O O
rapamycin-sensitive O O
, O O
cAMP-independent O O
CREB B-protein B-protein
kinase I-protein I-protein
activity O O
in O O
L2 B-cell_line B-cell_type
cells I-cell_line I-cell_type
. O O

However O O
, O O
phosphorylation O O
of O O
CREB B-protein B-protein
alone O O
is O O
not O O
sufficient O O
to O O
drive O O
PCNA B-protein B-protein
expression O O
and O O
L2 O O
cell O O
proliferation O O
in O O
the O O
absence O O
of O O
IL-2 B-protein B-protein
. O O

Serotonin O O
derivative O O
, O O
N- O O
( O O
p-coumaroyl O O
) O O
serotonin O O
, O O
inhibits O O
the O O
production O O
of O O
TNF-alpha B-protein B-protein
, O O
IL-1alpha B-protein B-protein
, O O
IL-1beta B-protein B-protein
, O O
and O O
IL-6 B-protein B-protein
by O O
endotoxin-stimulated B-cell_type B-cell_type
human I-cell_type I-cell_type
blood I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
. O O

We O O
have O O
reported O O
that O O
N- O O
( O O
p-coumaroyl O O
) O O
serotonin O O
( O O
CS O O
) O O
and O O
its O O
derivatives O O
with O O
antioxidative O O
activity O O
are O O
present O O
in O O
safflower O O
seeds O O
. O O

As O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
are O O
implicated O O
in O O
the O O
signaling O O
of O O
lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
we O O
examined O O
whether O O
CS O O
has O O
a O O
suppressive O O
effect O O
on O O
inflammatory B-protein O
cytokine I-protein B-protein
generation O O
from O O
human B-cell_type O
monocyte I-cell_type O
s O O
in O O
vitro O O
. O O

CS O O
at O O
50-200 O O
microM O O
reduced O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
( O O
TNF B-protein B-protein
) O O
, O O
interleukin-1 B-protein B-protein
( O O
IL-1 B-protein B-protein
) O O
, O O
and O O
IL-6 B-protein B-protein
activities O O
in O O
the O O
culture O O
supernatants O O
from O O
LPS-stimulated B-cell_line B-cell_line
human I-cell_line I-cell_line
blood I-cell_line I-cell_line
monocytes I-cell_line I-cell_line
without O O
cytotoxicity O O
. O O

ELISA O O
assay O O
revealed O O
that O O
the O O
production O O
of O O
TNF-alpha B-protein B-protein
, O O
IL-1alpha B-protein B-protein
, O O
IL-1beta B-protein B-protein
, O O
and O O
IL-6 B-protein B-protein
was O O
inhibited O O
by O O
CS O O
. O O

Northern O O
blot O O
analysis O O
showed O O
that O O
LPS-induced O O
expression O O
of O O
these O O
cytokine B-RNA B-RNA
mRNA I-RNA I-RNA
in O O
monocytes B-cell_type B-cell_type
was O O
suppressed O O
by O O
CS O O
. O O

NF-kappaB O B-protein
activation O O
was O O
also O O
inhibited O O
by O O
CS O O
. O O

These O O
findings O O
indicate O O
that O O
CS O O
has O O
a O O
suppressive O O
effect O O
on O O
proinflammatory O B-protein
cytokine O I-protein
production O O
from O O
monocytes B-cell_type B-cell_type
, O O
and O O
this O O
effect O O
is O O
based O O
in O O
part O O
on O O
the O O
suppression O O
of O O
cytokine B-RNA B-RNA
mRNA I-RNA I-RNA
expression O O
through O O
inhibition O O
of O O
NF-kappaB B-protein B-protein
activation O O
. O O

Elevated O O
expression O O
of O O
differentiation B-RNA B-RNA
inhibitory I-RNA I-RNA
factor I-RNA I-RNA
nm23 I-RNA I-RNA
mRNA I-RNA I-RNA
in O O
monoblastic O O
crisis O O
of O O
a O O
patient O O
with O O
chronic O O
myelogenous O O
leukemia O O
. O O

Differentiation B-protein O
inhibitory I-protein B-DNA
factor I-protein I-DNA
nm23 B-DNA I-DNA
gene I-DNA I-DNA
has O O
been O O
found O O
to O O
be O O
expressed O O
in O O
high O O
quantities O O
in O O
acute O O
myelogenous O O
leukemia O O
( O O
AML O O
) O O
, O O
especially O O
in O O
acute O O
monocytic O O
leukemia O O
( O O
AML-M5 O O
) O O
and O O
is O O
suggested O O
as O O
a O O
new O O
prognostic O O
factor O O
in O O
AML-M5 O B-cell_line
. O O

We O O
report O O
an O O
example O O
of O O
elevated O O
expression O O
of O O
nm23 B-RNA B-RNA
mRNA I-RNA I-RNA
in O O
a O O
patient O O
with O O
chronic O O
myelogenous O O
leukemia O O
( O O
CML O O
) O O
who O O
developed O O
monoblastic O O
crisis O O
. O O

Relative O O
levels O O
of O O
nm23-H1 B-RNA B-protein
and I-RNA O
-H2 I-RNA O
mRNA I-RNA O
extracted O O
from O O
the O O
patient O O
's O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
bone B-cell_type B-cell_type
marrow I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
measured O O
by O O
quantitative O O
reverse O B-protein
transcriptase O I-protein
polymerase O O
chain O O
reaction O O
. O O

The O O
level O O
of O O
nm23-H1 B-RNA B-RNA
mRNA I-RNA I-RNA
in O O
CML B-cell_line B-cell_type
cells I-cell_line I-cell_type
at O O
the O O
chronic O O
phase O O
was O O
as O O
high O O
as O O
that O O
in O O
bone B-cell_type B-cell_type
marrow I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
healthy O O
volunteers O O
. O O

The O O
mRNA O O
level O O
of O O
nm23-H2 B-protein B-protein
was O O
slightly O O
below O O
the O O
normal O O
level O O
. O O

At O O
blastic O O
crisis O O
, O O
however O O
, O O
expression O O
of O O
both O O
nm23-H1 B-RNA B-RNA
and I-RNA I-RNA
-H2 I-RNA I-RNA
mRNA I-RNA I-RNA
was O O
elevated O O
to O O
about O O
three O O
to O O
nine O O
times O O
of O O
that O O
at O O
the O O
chronic O O
phase O O
. O O

Proliferated B-cell_type B-cell_type
blastic I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
positive O O
for O O
non-specific B-protein O
esterase I-protein B-protein
, O O
and O O
the O O
serum O B-protein
lysozyme O I-protein
level O O
was O O
elevated O O
and O O
diagnosed O O
as O O
monoblastic O O
crisis O O
. O O

The O O
patient O O
received O O
combined O O
chemotherapy O O
but O O
response O O
was O O
partial O O
. O O

These O O
findings O O
are O O
compatible O O
with O O
our O O
previous O O
report O O
that O O
nm23 B-DNA B-DNA
gene I-DNA I-DNA
is O O
overexpressed O O
in O O
monocytic O O
leukemia O O
. O O

Increased O O
transcription O O
decreases O O
the O O
spontaneous O O
mutation O O
rate O O
at O O
the O O
thymidine B-DNA B-DNA
kinase I-DNA I-DNA
locus I-DNA I-DNA
in O O
human B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Transcription O O
increases O O
DNA O O
repair O O
efficiency O O
and O O
modulates O O
the O O
distribution O O
of O O
certain O O
types O O
of O O
DNA O O
damage O O
. O O

Furthermore O O
, O O
increased O O
transcription O O
level O O
stimulates O O
spontaneous O O
mutation O O
rate O O
in O O
yeast O O
. O O

We O O
explored O O
whether O O
transcription O O
level O O
affects O O
spontaneous O O
mutation O O
rate O O
in O O
human B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

We O O
first O O
developed O O
two O O
thymidine B-cell_line B-protein
kinase I-cell_line I-cell_line
( I-cell_line I-cell_line
tk I-cell_line I-cell_line
) I-cell_line I-cell_line
inducible I-cell_line I-cell_line
human I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
using O O
the O O
Gal4-Estrogen O B-protein
receptor O I-protein
system O O
. O O

In O O
our O O
TK6i-G3 B-cell_line B-cell_line
and I-cell_line I-cell_line
G9 I-cell_line I-cell_line
tk I-cell_line I-cell_line
heterozygous I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
the O O
active O O
tk B-DNA B-DNA
allele I-DNA I-DNA
is O O
linked O O
to O O
an O O
inducible O B-DNA
promoter B-DNA I-DNA
element I-DNA I-DNA
. O O

Tk B-RNA B-RNA
mRNA I-RNA I-RNA
is O O
induced O O
following O O
treatment O O
with O O
estrogen O O
. O O

Spontaneous O O
mutation O O
rate O O
was O O
significantly O O
decreased O O
in O O
human B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
after O O
induction O O
in O O
contrast O O
to O O
the O O
report O O
in O O
yeast O O
. O O

Thus O O
, O O
humans O O
may O O
have O O
evolved O O
different O O
or O O
additional O O
mechanisms O O
to O O
deal O O
with O O
transcription O O
related O O
spontaneous O O
mutagenesis O O
. O O

Copyright O O
1998 O O
Elsevier O O
Science O O
B.V O O
. O O

All O O
rights O O
reserved O O
. O O

Mutation O O
of O O
BCL-6 B-DNA B-DNA
gene I-DNA I-DNA
in O O
normal O B-cell_type
B B-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
the O O
process O O
of O O
somatic O O
hypermutation O O
of O O
Ig B-DNA B-DNA
genes I-DNA I-DNA
. O O

Immunoglobulin B-DNA B-protein
( I-DNA B-DNA
Ig I-DNA I-DNA
) I-DNA I-DNA
genes I-DNA I-DNA
are O O
hypermutated O O
in O O
B B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
that O O
are O O
the O O
precursors O O
to O O
memory B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
mutations O O
are O O
linked O O
to O O
transcription O O
initiation O O
, O O
but O O
non-Ig B-DNA B-DNA
promoters I-DNA I-DNA
are O O
permissible O O
for O O
the O O
mutation O O
process O O
; O O
thus O O
, O O
other O O
genes O O
expressed O O
in O O
mutating O B-cell_type
B B-cell_type I-cell_type
cells I-cell_type I-cell_type
may O O
also O O
be O O
subject O O
to O O
somatic O O
hypermutation O O
. O O

Significant O O
mutations O O
were O O
not O O
observed O O
in O O
c-MYC B-DNA B-DNA
, I-DNA I-DNA
S14 I-DNA I-DNA
, I-DNA I-DNA
or I-DNA I-DNA
alpha-fetoprotein I-DNA I-DNA
( I-DNA I-DNA
AFP I-DNA I-DNA
) I-DNA I-DNA
genes I-DNA I-DNA
, O O
but O O
BCL-6 B-protein B-protein
was O O
highly O O
mutated O O
in O O
a O O
large O O
proportion O O
of O O
memory B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
of O O
normal O O
individuals O O
. O O

The O O
mutation O O
pattern O O
was O O
similar O O
to O O
that O O
of O O
Ig B-DNA B-DNA
genes I-DNA I-DNA
. O O

CD28-mediated O O
activation O O
in O O
CD45RA+ B-cell_type B-cell_type
and I-cell_type O
CD45RO+ I-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
: O O
enhanced O O
levels O O
of O O
reactive O O
oxygen O O
intermediates O O
and O O
c-Rel O B-protein
nuclear O O
translocation O O
in O O
CD45RA+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

We O O
have O O
analyzed O O
the O O
effect O O
of O O
complete O O
T O O
cell O O
activation O O
( O O
anti-CD3 O B-protein
plus O O
anti-CD28 O B-protein
) O O
on O O
the O O
activation O O
of O O
NF-kappaB B-protein B-protein
in O O
CD45RA+ B-cell_type B-cell_type
( I-cell_type I-cell_type
naive I-cell_type I-cell_type
) I-cell_type I-cell_type
and I-cell_type I-cell_type
CD45RO+ I-cell_type I-cell_type
( I-cell_type I-cell_type
memory/effector I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Long O O
exposure O O
( O O
24 O O
h O O
) O O
induced O O
stronger O O
NF-kappaB B-protein B-protein
DNA O O
binding O O
in O O
CD45RA+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
than O O
in O O
CD45RO+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Analysis O O
of O O
the O O
nuclear B-protein B-protein
c-Rel I-protein I-protein
protein I-protein I-protein
indicated O O
that O O
after O O
anti-CD3+anti-CD28 O O
stimulation O O
the O O
level O O
of O O
c-Rel B-protein B-protein
was O O
higher O O
in O O
CD45RA+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Analysis O O
of O O
the O O
cytoplasmic B-protein B-protein
inhibitor I-protein I-protein
IkappaBalpha B-protein B-protein
indicated O O
that O O
anti-CD3+anti-CD28 O O
stimulation O O
induced O O
a O O
long-lasting O O
degradation O O
in O O
CD45RA+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
but O O
in O O
CD45RO+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
the O O
degradation O O
process O O
was O O
more O O
rapid O O
. O O

Because O O
the O O
CD28 B-protein B-protein
costimulus O O
is O O
known O O
to O O
induce O O
the O O
production O O
of O O
reactive O O
oxygen O O
intermediates O O
( O O
ROIs O O
) O O
, O O
the O O
intracellular O O
ROI O O
levels O O
in O O
CD45RA+ B-cell_type B-cell_type
and I-cell_type O
CD45RO+ I-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
compared O O
by O O
flow O O
cytometry O O
. O O

ROIs O O
were O O
produced O O
in O O
both O O
cell O O
types O O
, O O
but O O
more O O
strongly O O
in O O
CD45RA+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
data O O
presented O O
in O O
this O O
study O O
further O O
emphasize O O
the O O
differences O O
between O O
CD45RA+ B-cell_type O
and I-cell_type O
CD45RO+ I-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
in O O
ROI-dependent O O
signaling O O
pathways O O
. O O

Non-Hodgkin O O
's O O
lymphoma O O
involving O O
bilateral O O
breasts O O
[ O O
see O O
comments O O
] O O

We O O
describe O O
here O O
two O O
cases O O
of O O
diffuse O O
large O O
cell O O
type O O
non-Hodgkin O O
's O O
lymphoma O O
affecting O O
the O O
bilateral O O
breasts O O
. O O

The O O
contralateral O O
tumor O O
in O O
one O O
case O O
appeared O O
17 O O
months O O
after O O
the O O
first O O
mastectomy O O
, O O
whereas O O
the O O
bilateral O O
tumors O O
occurred O O
concurrently O O
in O O
the O O
other O O
patient O O
who O O
was O O
pregnant O O
and O O
showed O O
widespread O O
dissemination O O
at O O
initial O O
presentation O O
. O O

Lymphoma B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
both O O
cases O O
showed O O
the O O
mature O O
B-cell O B-cell_type
immunophenotype O I-cell_type
and O O
had O O
rearrangements O O
of O O
the O O
BCL6 B-DNA B-DNA
gene I-DNA I-DNA
. O O

Both O O
patients O O
developed O O
progressive O O
disease O O
despite O O
chemo-radiotherapy O O
and O O
died O O
of O O
leukemic O O
manifestations O O
. O O

There O O
were O O
no O O
apparent O O
pathological O O
features O O
of O O
lymphomas O O
of O O
mucosa-associated O B-cell_type
lymphoid O I-cell_type
tissue O I-cell_type
origin O I-cell_type

Biochemical O O
characterization O O
of O O
MIP-1 B-protein B-protein
alpha I-protein I-protein
nuclear I-protein I-protein
protein I-protein I-protein
. O O

A O O
family O O
of O O
hematopoietic B-protein O
specific I-protein O
transcription I-protein B-protein
factors I-protein I-protein
, O O
MIP-1 B-protein B-protein
alpha I-protein I-protein
nuclear I-protein I-protein
protein I-protein I-protein
( I-protein I-protein
MNP I-protein I-protein
) I-protein I-protein
family I-protein I-protein
, O O
has O O
recently O O
been O O
identified O O
. O O

They O O
are O O
intimately O O
involved O O
in O O
regulating O O
the O O
transcription O O
of O O
the O O
huMIP-1 B-DNA B-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
in O O
monocytes B-cell_type B-cell_type
, O O
T-cells B-cell_type B-cell_type
, O O
and O O
transformed B-cell_type B-cell_line
B-cells I-cell_type I-cell_line
. O O

One O O
member O O
of O O
the O O
family O O
( O O
MNP-1 B-protein B-protein
) O O
is O O
essential O O
for O O
promoter O O
activity O O
in O O
monocytes B-cell_type B-cell_type
and O O
B-cells B-cell_type B-cell_type
, O O
while O O
another O O
( O O
MNP-2 B-protein B-protein
) O O
is O O
required O O
for O O
full O O
promotor O O
activity O O
in O O
T-cells B-cell_type B-cell_type
. O O

A O O
third O O
member O O
of O O
the O O
family O O
( O O
MNP-3 B-protein B-protein
) O O
is O O
expressed O O
in O O
PMA B-cell_line O
induced I-cell_line O
HL60 I-cell_line B-cell_line
cells I-cell_line I-cell_line
and O O
probably O O
has O O
a O O
role O O
in O O
monocyte O O
differentiation O O
. O O

In O O
this O O
communication O O
we O O
demonstrate O O
by O O
two O O
techniques O O
that O O
MNP-1 B-protein B-protein
and O O
MNP-2 B-protein B-protein
are O O
distinct O O
but O O
related O O
factors O O
, O O
and O O
we O O
present O O
further O O
evidence O O
to O O
show O O
that O O
MNP-1 B-protein B-protein
acts O O
as O O
a O O
heterodimer B-protein B-protein
. O O

Bcl-3 B-protein B-protein
expression O O
and O O
nuclear O O
translocation O O
are O O
induced O O
by O O
granulocyte-macrophage B-protein B-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
and O O
erythropoietin B-protein B-protein
in O O
proliferating B-cell_type B-cell_type
human I-cell_type I-cell_type
erythroid I-cell_type I-cell_type
precursors I-cell_type I-cell_type
. O O

Bcl-3 B-protein B-protein
is O O
a O O
proto-oncogene B-DNA B-DNA
involved O O
in O O
the O O
chromosomal O B-DNA
translocation O I-DNA
t B-DNA I-DNA
( I-DNA I-DNA
14 I-DNA I-DNA
; I-DNA I-DNA
19 I-DNA I-DNA
) I-DNA O
found O O
in O O
some O O
patients O O
with O O
chronic O O
lymphocytic O O
leukemia O O
. O O

It O O
shares O O
structural O O
similarities O O
with O O
and O O
is O O
a O O
member O O
of O O
the O O
IkappaB B-protein B-protein
family I-protein I-protein
of O O
proteins O O
. O O

In O O
this O O
report O O
, O O
involvement O O
of O O
Bcl-3 B-protein B-protein
in O O
hematopoietic O O
growth O O
factor-stimulated O O
erythroid O O
proliferation O O
and O O
differentiation O O
was O O
examined O O
. O O

In O O
TF-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
an O O
erythroleukemia B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
, O O
granulocyte-macrophage B-protein B-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
( O O
GM-CSF B-protein B-protein
) O O
and O O
erythropoietin B-protein B-protein
( O O
Epo B-protein B-protein
) O O
greatly O O
enhanced O O
Bcl-3 B-protein B-protein
expression O O
at O O
both O O
the O O
protein O O
and O O
mRNA O O
levels O O
in O O
association O O
with O O
stimulation O O
of O O
proliferation O O
. O O

Bcl-3 B-protein B-protein
protein O I-protein
was O O
also O O
highly O O
expressed O O
in O O
early B-cell_type B-cell_line
burst-forming I-cell_type I-cell_line
unit-erythroid I-cell_type I-cell_line
( I-cell_type I-cell_line
BFU-E I-cell_type I-cell_line
) I-cell_type I-cell_line
-derived I-cell_type I-cell_line
erythroid I-cell_type I-cell_line
precursors I-cell_type I-cell_line
( O O
day O O
7 O O
) O O
and O O
decreased O O
during O O
maturation O O
( O O
days O O
10 O O
and O O
14 O O
) O O
, O O
suggesting O O
that O O
Bcl-3 B-protein B-protein
is O O
involved O O
in O O
normal O O
erythroid O O
proliferation O O
. O O

In O O
these O O
hematopoietic B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
Bcl-3 B-protein B-protein
was O O
hyperphosphorylated O O
. O O

GM-CSF B-protein B-protein
and O O
Epo B-protein B-protein
modulated O O
the O O
subcellular O O
localization O O
of O O
Bcl-3 B-protein B-protein
. O O

Upon O O
stimulation O O
of O O
TF-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
with O O
GM-CSF B-protein B-protein
or O O
Epo B-protein B-protein
, O O
the O O
nuclear O O
translocation O O
of O O
Bcl-3 B-protein B-protein
was O O
dramatically O O
enhanced O O
. O O

Overexpression O O
of O O
Bcl-3 B-protein B-protein
in O O
TF-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
by O O
transient O O
transfection O O
along O O
with O O
the O O
NF-kappaB B-protein B-protein
factors I-protein I-protein
p50 I-protein B-protein
or I-protein O
p52 I-protein B-protein
resulted O O
in O O
significant O O
induction O O
of O O
an O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus-type I-DNA I-DNA
1 I-DNA I-DNA
( I-DNA I-DNA
HIV-1 I-DNA I-DNA
) I-DNA I-DNA
kappaB-TATA-luceriferase I-DNA I-DNA
reporter I-DNA I-DNA
plasmid I-DNA I-DNA
, O O
demonstrating O O
that O O
Bcl-3 B-protein B-protein
has O O
a O O
positive O O
role O O
in O O
transactivation O O
of O O
kappaB-containing B-DNA B-DNA
genes I-DNA I-DNA
in O O
erythroid B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Stimulation O O
with O O
GM-CSF B-protein B-protein
enhanced O O
c-myb B-RNA O
mRNA I-RNA O
expression O O
in O O
these O O
cells O O
. O O

Bcl-3 B-protein B-protein
in O O
nuclear O O
extracts O O
of O O
TF-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
bound O O
to O O
a O O
kappaB B-DNA B-DNA
enhancer I-DNA I-DNA
in O O
the O O
c-myb B-DNA B-DNA
promoter I-DNA I-DNA
together O O
with O O
NF-kappaB2/p52 B-protein B-protein
and O O
this O O
binding O O
activity O O
was O O
enhanced O O
by O O
GM-CSF B-protein B-protein
stimulation O O
. O O

Furthermore O O
, O O
cotransfection O O
of O O
Bcl-3 B-protein B-protein
with O O
p52 B-protein B-protein
or O O
p50 B-protein B-protein
in O O
TF-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
resulted O O
in O O
significant O O
activation O O
of O O
a O O
c-myb B-DNA B-DNA
kappaB-TATA-luceriferase I-DNA I-DNA
reporter I-DNA I-DNA
plasmid I-DNA I-DNA
. O O

These O O
findings O O
suggest O O
that O O
Bcl-3 B-protein B-protein
may O O
participate O O
in O O
the O O
transcriptional O O
regulation O O
of O O
certain O O
kappaB-containing B-DNA B-DNA
genes I-DNA I-DNA
involved O O
in O O
hematopoiesis O O
, O O
including O O
c-myb B-DNA B-DNA
. O O

Copyright O O
1998 O O
by O O
The O O
American O O
Society O O
of O O
Hematology O O
. O O

5-Lipoxygenase B-protein B-protein
compartmentalization O O
in O O
granulocytic O B-cell_type
cells O I-cell_type
is O O
modulated O O
by O O
an O O
internal B-protein B-DNA
bipartite I-protein I-DNA
nuclear I-protein I-DNA
localizing I-protein I-DNA
sequence I-protein I-DNA
and O O
nuclear B-protein B-protein
factor I-protein I-protein
kappa I-protein I-protein
B I-protein I-protein
complex I-protein I-protein
formation O O
. O O

A O O
region O O
of O O
basic O B-protein
amino O I-protein
acids O I-protein
spanning O I-protein
residues B-protein I-protein
639-656 I-protein I-protein
in O O
the O O
human B-protein B-DNA
5-lipoxygenase I-protein I-DNA
sequence I-protein I-DNA
resembles O O
a O O
consensus B-protein B-DNA
bipartite I-protein I-DNA
nuclear I-protein I-DNA
localizing I-protein I-DNA
sequence I-protein I-DNA
. O O

A O O
synthetic O O
peptide O O
consisting O O
of O O
the O O
Kaposi B-protein B-DNA
fibroblast I-protein I-DNA
growth I-protein I-DNA
factor I-protein I-DNA
signal I-protein I-DNA
sequence I-protein I-DNA
fused O O
to O O
the O O
5-lipoxygenase639-656 B-protein B-DNA
bipartite I-protein I-DNA
nuclear I-protein I-DNA
localizing I-protein I-DNA
sequence I-protein I-DNA
has O O
a O O
prominent O O
inhibitory O O
effect O O
on O O
5-lipoxygenase B-protein O
catalysis O O
in O O
granulocytic O B-cell_line
HL-60 B-cell_line I-cell_line
cells I-cell_line I-cell_line
activated O O
by O O
calcium O O
ionophor O O
A23187 O O
. O O

Recombinant O O
5-lipoxygenase B-protein B-protein
was O O
not O O
affected O O
by O O
the O O
peptide O O
. O O

The O O
peptide O O
also O O
inhibited O O
redistribution O O
of O O
5-lipoxygenase B-protein B-protein
from O O
the O O
cytosol O O
to O O
the O O
nuclear O O
membrane O O
of O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
stimulated O O
by O O
A23187 O O
. O O

5-Lipoxygenase B-protein B-protein
protein I-protein I-protein
was O O
detected O O
in O O
nuclear B-protein B-protein
factor I-protein I-protein
kappaB I-protein I-protein
( I-protein I-protein
NF-kappaB I-protein I-protein
) I-protein I-protein
p65 I-protein I-protein
subunit I-protein I-protein
immunoprecipitate O O
fractions O O
prepared O O
from O O
HL-60 B-cell_line O
cell I-cell_line O
lysates O O
. O O

The O O
amount O O
of O O
5-lipoxygenase B-protein B-protein
protein I-protein I-protein
coimmunoprecipitated O O
by O O
NF-kappaB O B-protein
antiserum O O
was O O
increased O O
following O O
A23187 O O
stimulation O O
. O O

In O O
cells O O
treated O O
with O O
agents O O
that O O
block O O
5-lipoxygenase B-protein B-protein
translocation O O
to O O
the O O
nucleus O O
, O O
5-lipoxygenase B-protein B-protein
protein O I-protein
appearing O O
in O O
the O O
NF-kappaB B-protein B-protein
immunoprecipitate O O
was O O
diminished O O
. O O

Our O O
results O O
implicate O O
an O O
internal B-protein B-DNA
bipartite I-protein I-DNA
nuclear I-protein I-DNA
localizing I-protein I-DNA
sequence I-protein I-DNA
as O O
a O O
regulatory O B-protein
domain O I-protein
that O O
modulates O O
5-lipoxygenase B-protein B-protein
redistribution O O
and O O
catalysis O O
in O O
granulocytic B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Additionally O O
, O O
our O O
results O O
suggest O O
that O O
molecular O O
determinants O O
which O O
govern O O
5-lipoxygenase O B-protein
and O O
NF-kappaB O B-protein
redistribution O O
to O O
the O O
nucleus O O
may O O
be O O
coordinately O O
controlled O O
in O O
granulocytic B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Copyright O O
1998 O O
Academic O O
Press O O
. O O

Inhibition O O
of O O
CD28/CD3-mediated O O
costimulation O O
of O O
naive B-cell_type B-cell_type
and I-cell_type I-cell_type
memory I-cell_type I-cell_type
human I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
by O O
intracellular O O
incorporation O O
of O O
polyclonal B-protein O
antibodies I-protein O
specific O O
for O O
the O O
activator B-protein B-protein
protein-1 I-protein I-protein
transcriptional I-protein I-protein
complex I-protein I-protein
. O O

A O O
number O O
of O O
indirect O O
methods O O
have O O
been O O
utilized O O
in O O
demonstrating O O
activator B-protein B-protein
protein-1 I-protein I-protein
transcription O I-protein
factor O I-protein
function O O
in O O
IL-2 O B-DNA
promoter O I-DNA
activity O O
. O O

However O O
, O O
there O O
has O O
been O O
no O O
direct O O
demonstration O O
that O O
activator B-protein B-protein
protein-1 I-protein I-protein
is O O
involved O O
in O O
CD28-dependent O O
costimulation O O
of O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
transcription O O
in O O
freshly O B-cell_type
isolated O I-cell_type
naive B-cell_type I-cell_type
and I-cell_type I-cell_type
memory I-cell_type I-cell_type
human I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

To O O
address O O
this O O
issue O O
, O O
the O O
method O O
of O O
scrape O O
loading O O
was O O
applied O O
to O O
purified B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Since O O
scrape O O
loading O O
relies O O
on O O
adherent B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
human I-cell_type I-cell_type
T I-cell_type I-cell_type
( I-cell_type I-cell_type
PB-T I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
immobilized O O
on O O
the O O
nonspecific O O
cell O O
attachment O O
factor O O
poly-L-lysine O O
. O O

Cells O O
scraped O O
off O O
poly-L-lysine O O
in O O
the O O
presence O O
of O O
Ig B-protein B-protein
FITC I-protein O
efficiently O O
incorporated O O
Ig O B-protein
, O O
with O O
relatively O O
uniform O O
fluorescence O O
. O O

T O B-cell_type
cells O I-cell_type
retained O O
their O O
physical O O
parameters O O
as O O
measured O O
by O O
forward O O
and O O
side O O
light O O
scatter O O
, O O
and O O
functional O O
activity O O
as O O
measured O O
by O O
costimulation O O
of O O
proliferation O O
and O O
IL-2 B-protein B-protein
production O O
after O O
being O O
scraped O O
off O O
this O O
substrate O O
. O O

CD28/CD3-costimulated B-cell_type B-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
produced O O
intracellular O B-protein
IL-2 B-protein I-protein
from O O
all O O
subsets O O
measured O O
( O O
CD4+ B-cell_type B-protein
, O O
CD4- B-cell_type O
, O O
CD45RO+ B-cell_type O
, O O
and O O
CD45RO- B-cell_type O
) O O
. O O

IL-2 B-protein B-protein
production O O
and O O
intracellular O O
accumulation O O
in O O
nonscraped O B-cell_line
PB-T B-cell_type I-cell_line
cells I-cell_type I-cell_line
activated O O
with O O
CD28/CD3 O O
coligation O O
were O O
skewed O O
favoring O O
CD45RO+ B-cell_type B-cell_type
and I-cell_type I-cell_type
CD4+ I-cell_type I-cell_type
subsets I-cell_type I-cell_type
, O O
as O O
was O O
IL-2 B-protein B-protein
production O O
in O O
scraped O B-cell_type
PB-T B-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
intracellular O O
incorporation O O
of O O
Abs O B-protein
specific O O
for O O
c-Fos B-protein B-protein
and I-protein O
c-Jun I-protein B-protein
family I-protein I-protein
members I-protein I-protein
by O O
scrape O O
loading O O
inhibited O O
the O O
production O O
and O O
intracellular O O
accumulation O O
of O O
IL-2 B-protein B-protein
within O O
6 O O
h O O
of O O
costimulation O O
with O O
PMA/ionomycin O O
, O O
or O O
costimulation O O
by O O
CD28 O B-protein
and O O
CD3 O B-protein
ligation O O
. O O

Scrape O O
loading O O
thus O O
provides O O
an O O
efficient O O
mechanism O O
for O O
intracellular O O
incorporation O O
of O O
macromolecules O O
, O O
and O O
the O O
first O O
direct O O
evidence O O
that O O
c-Fos B-protein B-protein
and O O
c-Jun B-protein B-protein
are O O
involved O O
in O O
transcription O O
of O O
the O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
within O O
its O O
correct O O
chromosomal O O
context O O
, O O
in O O
resting O B-cell_type
human O I-cell_type
T O I-cell_type
lymphocyte O I-cell_type
subpopulations O I-cell_type
. O O

Differential O O
expression O O
of O O
Nur77 B-protein B-protein
family I-protein I-protein
members I-protein I-protein
in O O
human B-cell_type B-cell_type
T-lymphotropic I-cell_type I-cell_type
virus I-cell_type I-cell_type
type I-cell_type I-cell_type
1-infected I-cell_type I-cell_type
cells I-cell_type I-cell_type
: O O
transactivation O O
of O O
the O O
TR3/nur77 B-DNA B-DNA
gene I-DNA I-DNA
by O O
Tax B-protein B-protein
protein I-protein I-protein
. O O

We O O
analyzed O O
the O O
differential O O
expression O O
and O O
regulation O O
of O O
three O O
members O O
of O O
the O O
Nur77 B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
family I-protein I-protein
by O O
the O O
human O B-protein
T-lymphotropic O I-protein
virus O I-protein
type O I-protein
1 O I-protein
( O I-protein
HTLV-1 O I-protein
) O I-protein
Tax B-protein I-protein
protein I-protein I-protein
. O O

We O O
have O O
demonstrated O O
that O O
in O O
both O O
HTLV-1-infected B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
Tax-expressing B-cell_line B-cell_line
JPX-9 I-cell_line I-cell_line
cells I-cell_line I-cell_line
, O O
TR3/nur77 B-protein B-protein
is O O
highly O O
expressed O O
, O O
whereas O O
neither O O
NOR-1 O B-protein
nor O O
NOT O O
expression O O
is O O
detectable O O
. O O

Transient O O
transfection O O
analysis O O
further O O
confirmed O O
the O O
Tax B-protein B-protein
transactivation O O
of O O
the O O
TR3/nur77 B-protein B-DNA
promoter O I-DNA
but O O
not O O
the O O
NOR-1 B-DNA B-DNA
promoter I-DNA I-DNA
in O O
different O O
cell O O
types O O
. O O

Furthermore O O
, O O
expression O O
of O O
a O O
luciferase B-DNA B-DNA
reporter I-DNA I-DNA
gene I-DNA I-DNA
driven O O
by O O
the O O
NGFI-B B-DNA B-DNA
( I-DNA I-DNA
rat I-DNA I-DNA
homolog I-DNA I-DNA
of I-DNA I-DNA
TR3/Nur77 I-DNA I-DNA
) I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
( O O
NBRE B-DNA B-DNA
) O O
provided O O
evidence O O
that O O
Tax B-protein B-protein
-mediated O O
transactivation O O
resulted O O
in O O
the O O
induction O O
of O O
a O O
functional O O
protein O O
. O O

Cotransfection O O
assays O O
with O O
the O O
TR3/nur77 B-DNA B-DNA
promoter I-DNA I-DNA
sequence I-DNA I-DNA
or O O
the O O
NBRE B-DNA B-DNA
binding O I-DNA
motif O I-DNA
together O O
with O O
a O O
series O O
of O O
Tax B-protein B-protein
mutants O I-protein
have O O
shown O O
that O O
Tax B-protein B-protein
-induced O O
TR3/nur77 B-protein B-protein
expression O O
is O O
mediated O O
by O O
CREB/ATF-related B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
. O O

Negative O O
regulation O O
of O O
the O O
heat O O
shock O O
transcriptional O O
response O O
by O O
HSBP1 B-protein B-protein
. O O

In O O
response O O
to O O
stress O O
, O O
heat B-protein B-protein
shock I-protein I-protein
factor I-protein I-protein
1 I-protein I-protein
( O O
HSF1 B-protein B-protein
) O O
acquires O O
rapid O O
DNA O O
binding O O
and O O
transient O O
transcriptional O O
activity O O
while O O
undergoing O O
conformational O O
transition O O
from O O
an O O
inert O O
non-DNA-binding B-protein B-protein
monomer I-protein I-protein
to O O
active O B-protein
functional O I-protein
trimers O I-protein
. O O

Attenuation O O
of O O
the O O
inducible O O
transcriptional O O
response O O
occurs O O
during O O
heat O O
shock O O
or O O
upon O O
recovery O O
at O O
non-stress O O
conditions O O
and O O
involves O O
dissociation O O
of O O
the O O
HSF1 B-protein B-protein
trimer I-protein I-protein
and O O
loss O O
of O O
activity O O
. O O

We O O
have O O
used O O
the O O
hydrophobic B-protein O
repeats I-protein O
of O O
the O O
HSF1 B-protein B-protein
trimerization O I-protein
domain O I-protein
in O O
the O O
yeast O O
two-hybrid O O
protein O O
interaction O O
assay O O
to O O
identify O O
heat B-protein B-protein
shock I-protein I-protein
factor I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
1 I-protein I-protein
( O O
HSBP1 B-protein B-protein
) O O
, O O
a O O
novel O O
, O O
conserved O O
, O O
76-amino-acid B-protein B-protein
protein I-protein I-protein
that O O
contains O O
two O O
extended O O
arrays O O
of O O
hydrophobic B-protein B-DNA
repeats I-protein I-DNA
that O O
interact O O
with O O
the O O
HSF1 B-protein B-DNA
heptad I-protein I-DNA
repeats I-protein I-DNA
. O O

HSBP1 B-protein B-protein
is O O
nuclear-localized O O
and O O
interacts O O
in O O
vivo O O
with O O
the O O
active O B-protein
trimeric O I-protein
state O I-protein
of O O
HSF1 B-protein B-protein
that O O
appears O O
during O O
heat O O
shock O O
. O O

During O O
attenuation O O
of O O
HSF1 B-protein B-protein
to O O
the O O
inert O O
monomer O O
, O O
HSBP1 B-protein B-protein
associates O O
with O O
Hsp70 O B-protein
. O O

HSBP1 B-protein B-protein
negatively O O
affects O O
HSF1 B-protein B-protein
DNA-binding O O
activity O O
, O O
and O O
overexpression O O
of O O
HSBP1 B-protein B-protein
in O O
mammalian B-cell_type B-cell_type
cells I-cell_type I-cell_type
represses O O
the O O
transactivation O O
activity O O
of O O
HSF1 B-protein B-protein
. O O

To O O
establish O O
a O O
biological O O
role O O
for O O
HSBP1 B-protein B-protein
, O O
the O O
homologous O B-protein
Caenorhabditis B-protein I-protein
elegans I-protein I-protein
protein I-protein I-protein
was O O
overexpressed O O
in O O
body B-cell_type B-cell_type
wall I-cell_type I-cell_type
muscle I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
was O O
shown O O
to O O
block O O
activation O O
of O O
the O O
heat O O
shock O O
response O O
from O O
a O O
heat B-DNA B-DNA
shock I-DNA I-DNA
promoter-reporter I-DNA I-DNA
construct I-DNA I-DNA
. O O

Alteration O O
in O O
the O O
level O O
of O O
HSBP1 B-protein B-protein
expression O O
in O O
C. O O
elegans O O
has O O
severe O O
effects O O
on O O
survival O O
of O O
the O O
animals O O
after O O
thermal O O
and O O
chemical O O
stress O O
, O O
consistent O O
with O O
a O O
role O O
for O O
HSBP1 B-protein B-protein
as O O
a O O
negative O O
regulator O O
of O O
the O O
heat O O
shock O O
response O O
. O O

Long-range O O
transcriptional O O
regulation O O
of O O
cytokine O B-DNA
gene O I-DNA
expression O O
. O O

Most O O
studies O O
on O O
the O O
control O O
of O O
cytokine O B-DNA
gene O I-DNA
expression O O
have O O
involved O O
the O O
functional O O
analysis O O
of O O
proximal B-DNA B-DNA
promoters I-DNA I-DNA
. O O

Recent O O
work O O
has O O
identified O O
distal B-DNA B-DNA
elements I-DNA I-DNA
that O O
mediate O O
long-range O O
cytokine O B-DNA
gene O I-DNA
regulation O O
and O O
has O O
implicated O O
chromatin O O
reorganization O O
in O O
regulation O O
of O O
cytokine B-DNA B-DNA
gene I-DNA I-DNA
loci I-DNA I-DNA
. O O

These O O
studies O O
have O O
begun O O
to O O
elucidate O O
the O O
basis O O
for O O
cell-specificity O O
and O O
high-level O O
expression O O
of O O
cytokine B-DNA B-DNA
genes I-DNA I-DNA
. O O

A O O
signaling O O
complex O O
of O O
Ca2+-calmodulin-dependent B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
IV I-protein I-protein
and O O
protein B-protein B-protein
phosphatase I-protein I-protein
2A I-protein I-protein
[ O O
see O O
comments O O
] O O

Stimulation O O
of O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
results O O
in O O
a O O
rapid O O
increase O O
in O O
intracellular O O
calcium O O
concentration O O
( O O
[ O O
Ca2+ O O
] O O
i O O
) O O
that O O
parallels O O
the O O
activation O O
of O O
Ca2+-calmodulin-dependent B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
IV I-protein I-protein
( O O
CaMKIV B-protein B-protein
) O O
, O O
a O O
nuclear B-protein B-protein
enzyme I-protein I-protein
that O O
can O O
phosphorylate O O
and O O
activate O O
the O O
cyclic B-protein B-protein
adenosine I-protein I-protein
monophosphate I-protein I-protein
( I-protein I-protein
cAMP I-protein I-protein
) I-protein I-protein
response I-protein I-protein
element-binding I-protein I-protein
protein I-protein I-protein
( O O
CREB B-protein B-protein
) O O
. O O

However O O
, O O
inactivation O O
of O O
CaMKIV B-protein B-protein
occurs O O
despite O O
the O O
sustained O O
increase O O
in O O
[ O O
Ca2+ O O
] O O
i O O
that O O
is O O
required O O
for O O
T O O
cell O O
activation O O
. O O

A O O
stable O O
and O O
stoichiometric O B-protein
complex O I-protein
of O O
CaMKIV B-protein B-protein
with O O
protein B-protein B-protein
serine-threonine I-protein I-protein
phosphatase I-protein I-protein
2A I-protein I-protein
( O O
PP2A B-protein B-protein
) O O
was O O
identified O O
in O O
which O O
PP2A B-protein B-protein
dephosphorylates O O
CaMKIV B-protein B-protein
and O O
functions O O
as O O
a O O
negative O O
regulator O O
of O O
CaMKIV B-protein B-protein
signaling O O
. O O

In O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
, O O
inhibition O O
of O O
PP2A B-protein B-protein
activity O O
by O O
small O B-protein
t O I-protein
antigen O I-protein
enhanced O O
activation O O
of O O
CREB B-protein B-protein
-mediated O O
transcription O O
by O O
CaMKIV B-protein B-protein
. O O

These O O
findings O O
reveal O O
an O O
intracellular O O
signaling O O
mechanism O O
whereby O O
a O O
protein B-protein B-protein
serine-threonine I-protein I-protein
kinase I-protein I-protein
( O O
CaMKIV B-protein B-protein
) O O
is O O
regulated O O
by O O
a O O
tightly O O
associated O O
protein B-protein B-protein
serine-threonine I-protein I-protein
phosphatase I-protein I-protein
( O O
PP2A B-protein B-protein
) O O
. O O

Hypoxia O O
down-regulates O O
MCP-1 B-protein B-protein
expression O O
: O O
implications O O
for O O
macrophage O O
distribution O O
in O O
tumors O O
. O O

Monocyte B-protein B-protein
chemoattractant I-protein I-protein
protein I-protein I-protein
1 I-protein I-protein
( O O
MCP-1 B-protein B-protein
) O O
is O O
likely O O
to O O
contribute O O
to O O
the O O
macrophage B-cell_type O
infiltrate I-cell_type O
in O O
human O O
ovarian O O
carcinomas O O
. O O

Although O O
MCP-1 B-protein B-protein
is O O
predominantly O O
expressed O O
by O O
the O O
tumor O O
parenchyma O O
, O O
macrophages O B-cell_type
accumulate O O
at O O
highest O O
density O O
in O O
necrotic O O
regions O O
, O O
which O O
are O O
associated O O
with O O
low O O
oxygen O O
tensions O O
. O O

Tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
alpha I-protein I-protein
( O O
TNF-alpha B-protein B-protein
) O O
can O O
stimulate O O
MCP-1 B-protein B-protein
production O O
and O O
is O O
also O O
present O O
within O O
ovarian O O
carcinomas O O
. O O

We O O
have O O
investigated O O
the O O
effect O O
of O O
hypoxia O O
both O O
on O O
MCP-1 B-protein B-protein
expression O O
in O O
ovarian B-cell_line B-cell_line
cancer I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
and O O
monocyte O O
migration O O
. O O

Hypoxia O O
down-regulated O O
TNF-alpha-induced B-RNA B-protein
MCP-1 I-RNA I-protein
mRNA I-RNA O
and O O
protein O O
production O O
by O O
ovarian B-cell_type B-cell_type
cancer I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
effect O O
was O O
mimicked O O
by O O
cobalt O O
chloride O O
and O O
desferrioxamine O O
, O O
consistent O O
with O O
a O O
specific O O
oxygen-sensing O O
mechanism O O
. O O

Unlike O O
antioxidants O O
, O O
hypoxia O O
did O O
not O O
inhibit O O
nuclear O O
factor O O
KB O O
mobilization O O
. O O

Monocyte O O
migration O O
in O O
response O O
to O O
MCP-1 B-protein B-protein
was O O
also O O
diminished O O
under O O
hypoxic O O
conditions O O
. O O

Down-regulation O O
of O O
MCP-1 B-protein B-protein
expression O O
and O O
the O O
inhibition O O
of O O
monocyte O O
migration O O
are O O
independent O O
effects O O
of O O
hypoxia O O
that O O
may O O
contribute O O
to O O
the O O
distribution O O
of O O
macrophages B-cell_type B-cell_type
within O O
ovarian O O
tumors O O
. O O

Activation O O
of O O
nuclear B-protein B-protein
factor I-protein I-protein
kappa I-protein I-protein
B I-protein I-protein
inflammatory O O
bowel O O
disease O O
[ O O
see O O
comments O O
] O O

BACKGROUND O O
: O O
Expression O O
of O O
pro-inflammatory B-protein B-protein
cytokines I-protein I-protein
is O O
increased O O
in O O
the O O
intestinal O O
lamina O O
propria O O
of O O
patients O O
with O O
inflammatory O O
bowel O O
disease O O
( O O
IBD O O
) O O
. O O

Nuclear B-protein B-protein
factor I-protein I-protein
kappa I-protein I-protein
B I-protein I-protein
( O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
) O O
controls O O
transcription O O
of O O
inflammation B-DNA B-DNA
genes I-DNA I-DNA
. O O

On O O
activation O O
, O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
is O O
rapidly O O
released O O
from O O
its O O
cytoplasmic B-protein O
inhibitor I-protein O
( O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
) O O
, O O
transmigrates O O
into O O
the O O
nucleus O O
, O O
and O O
binds O O
to O O
DNA B-DNA B-DNA
response I-DNA I-DNA
elements I-DNA I-DNA
in O O
gene O B-DNA
promoter O I-DNA
regions O I-DNA
. O O

AIMS O O
: O O
To O O
investigate O O
whether O O
increased O O
activation O O
of O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
is O O
important O O
in O O
IBD O O
and O O
may O O
be O O
down-regulated O O
by O O
anti-inflammatory O O
treatment O O
. O O

METHODS O O
: O O
Activation O O
of O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
was O O
determined O O
by O O
western O O
blot O O
assessment O O
and O O
electrophoretic O O
mobility O O
shift O O
assay O O
in O O
nuclear O O
extracts O O
of O O
colonic O O
biopsy O O
samples O O
as O O
well O O
as O O
lamina B-cell_type B-cell_type
propria I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

RESULTS O O
: O O
Nuclear O O
levels O O
of O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
p65 B-protein I-protein
are O O
increased O O
in O O
lamina O O
propria O O
biopsy O O
specimens O O
from O O
patients O O
with O O
Crohn O O
's O O
disease O O
in O O
comparison O O
with O O
patients O O
with O O
ulcerative O O
colitis O O
and O O
controls O O
. O O

Increased O O
activation O O
of O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
was O O
detected O O
in O O
lamina B-cell_type B-cell_type
propria I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
patients O O
with O O
active O O
IBD O O
. O O

Corticosteroids O O
strongly O O
inhibit O O
intestinal O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
activation O O
in O O
IBD O O
in O O
vivo O O
and O O
in O O
vitro O O
by O O
stabilising O O
the O O
cytosolic B-protein O
inhibitor I-protein O
I B-protein O
kappa I-protein O
B I-protein O
alpha O O
against O O
activation O O
induced O O
degradation O O
. O O

CONCLUSIONS O O
: O O
In O O
both O O
IBDs O O
, O O
but O O
particularly O O
Crohn O O
's O O
disease O O
, O O
increased O O
activation O O
of O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
may O O
be O O
involved O O
in O O
the O O
regulation O O
of O O
the O O
inflammatory O O
response O O
. O O

Inhibition O O
of O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
activation O O
may O O
represent O O
a O O
mechanism O O
by O O
which O O
steroids O O
exert O O
an O O
anti-inflammatory O O
effect O O
in O O
IBD O B-protein

Insufficient O O
glycemic O O
control O O
increases O O
nuclear B-protein B-protein
factor-kappa I-protein I-protein
B I-protein I-protein
binding O O
activity O O
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
isolated O O
from O O
patients O O
with O O
type O O
1 O O
diabetes O O
. O O

OBJECTIVE O O
: O O
The O O
redox-sensitive B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
nuclear I-protein B-protein
factor-kappa I-protein I-protein
B I-protein I-protein
( O O
NF-kappa B-protein B-protein
B I-protein I-protein
) O O
is O O
believed O O
to O O
contribute O O
to O O
late O O
diabetic O O
complications O O
. O O

It O O
is O O
unknown O O
whether O O
NF-kappa B-protein B-protein
B I-protein I-protein
is O O
influenced O O
by O O
glycemic O O
control O O
. O O

RESEARCH O O
DESIGN O O
AND O O
METHODS O O
: O O
To O O
determine O O
whether O O
NF-kappa B-protein B-protein
B I-protein I-protein
is O O
activated O O
in O O
patients O O
with O O
insufficient O O
glycemic O O
control O O
( O O
HbA1c O O
> O O
10 O O
% O O
) O O
, O O
we O O
developed O O
a O O
tissue O O
culture-independent O O
electrophoretic O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
-based O O
semiquantitative O O
detection O O
system O O
that O O
allowed O O
us O O
to O O
determine O O
NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
in O O
ex O O
vivo-isolated O B-cell_type
peripheral B-cell_type I-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
PBMCs B-cell_type B-cell_type
) O O
. O O

We O O
included O O
43 O O
patients O O
with O O
type O O
1 O O
diabetes O O
in O O
this O O
cross-sectional O O
study O O
. O O

10 O O
of O O
those O O
received O O
the O O
antioxidant O O
thioctic O O
acid O O
( O O
600 O O
mg/day O O
p.o. O O
) O O
for O O
2 O O
weeks O O
. O O

RESULTS O O
: O O
Monocytes O B-cell_type
of O O
patients O O
with O O
HbA1c O O
levels O O
> O O
10 O O
% O O
demonstrated O O
significantly O O
higher O O
NF-kappa B-protein B-protein
B I-protein I-protein
binding O O
activity O O
in O O
an O O
EMSA O O
and O O
a O O
stronger O O
NF-kappa B-protein B-protein
B I-protein I-protein
staining O O
in O O
immunohistochemistry O O
than O O
monocytes B-cell_type B-cell_type
of O O
patients O O
with O O
HbA1c O O
levels O O
of O O
6-8 O O
% O O
. O O

The O O
increase O O
in O O
NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
correlated O O
with O O
an O O
increase O O
in O O
plasmatic O O
markers O O
of O O
lipid O O
peroxidation O O
. O O

Treatment O O
with O O
the O O
antioxidant O O
thioctic O O
acid O O
decreased O O
NF-kappa B-protein B-protein
B I-protein I-protein
binding O O
activity O O
. O O

CONCLUSIONS O O
: O O
Hyperglycemia O O
induces O O
activation O O
of O O
the O O
transcription O B-protein
factor O I-protein
NF-kappa B-protein B-protein
B I-protein I-protein
in O O
ex O O
vivo-isolated O O
PBMCs B-cell_type B-cell_type
of O O
patients O O
with O O
type O O
1 O O
diabetes O O
. O O

NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
is O O
at O O
least O O
partially O O
dependent O O
on O O
oxidative O O
stress O O
, O O
since O O
the O O
antioxidant O O
thioctic O O
acid O O
significantly O O
lowered O O
the O O
extent O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
binding O O
activity O O
. O O

Synergistic O O
activation O O
of O O
MAP B-protein B-protein
kinase I-protein I-protein
( O O
ERK1/2 B-protein B-protein
) O O
by O O
erythropoietin B-protein B-protein
and O O
stem B-protein B-protein
cell I-protein I-protein
factor I-protein I-protein
is O O
essential O O
for O O
expanded O O
erythropoiesis O O
. O O

Stem B-protein B-protein
cell I-protein I-protein
factor I-protein I-protein
( O O
SCF B-protein B-protein
) O O
and O O
erythropoietin B-protein B-protein
( O O
EPO B-protein B-protein
) O O
work O O
synergistically O O
to O O
support O O
erythropoiesis O O
, O O
but O O
the O O
mechanism O O
for O O
this O O
synergism O O
is O O
unknown O O
. O O

By O O
using O O
purified B-cell_line B-cell_line
human I-cell_line I-cell_line
erythroid I-cell_line I-cell_line
colony-forming I-cell_line I-cell_line
cells I-cell_line I-cell_line
( O O
ECFC B-cell_line B-cell_type
) O O
, O O
we O O
have O O
found O O
that O O
SCF B-protein B-protein
and O O
EPO B-protein B-protein
synergistically O O
activate O O
MAP B-protein B-protein
kinase I-protein I-protein
( O O
MAPK B-protein B-protein
, O O
ERK1/2 B-protein B-protein
) O O
, O O
which O O
correlates O O
with O O
the O O
cell O O
growth O O
and O O
thus O O
may O O
be O O
responsible O O
for O O
the O O
synergistic O O
effects O O
. O O

Treatment O O
of O O
the O O
cells O O
with O O
PD98059 O O
and O O
wortmannin O O
, O O
inhibitors O O
of O O
MEK B-protein B-protein
and O O
PI-3 B-protein B-protein
kinase I-protein I-protein
, O O
respectively O O
, O O
inhibited O O
the O O
synergistic O O
activation O O
of O O
MAPK B-protein B-protein
and O O
also O O
the O O
cell O O
growth O O
, O O
further O O
supporting O O
this O O
conclusion O O
. O O

Wortmannin O O
only O O
inhibits O O
MAPK B-protein B-protein
activation O O
induced O O
by O O
EPO B-protein B-protein
but O O
not O O
that O O
by O O
SCF B-protein B-protein
, O O
suggesting O O
that O O
SCF B-protein B-protein
and O O
EPO B-protein B-protein
may O O
activate O O
MAPK B-protein B-protein
through O O
different O O
pathways O O
, O O
which O O
would O O
facilitate O O
synergy O O
. O O

Furthermore O O
, O O
EPO B-protein B-protein
, O O
but O O
not O O
SCF B-protein B-protein
, O O
led O O
to O O
activation O O
of O O
STAT5 B-protein B-protein
, O O
whereas O O
SCF B-protein B-protein
and O O
wortmannin O O
had O O
no O O
effect O O
on O O
the O O
EPO B-protein B-protein
-induced O O
STAT5 B-protein B-protein
activation O O
, O O
suggesting O O
that O O
STAT5 B-protein B-protein
is O O
not O O
involved O O
in O O
the O O
synergistic O O
action O O
of O O
SCF B-protein B-protein
and O O
EPO B-protein B-protein
. O O

Together O O
, O O
the O O
data O O
suggest O O
that O O
synergistic O O
activation O O
of O O
MAPK B-protein B-protein
by O O
SCF B-protein B-protein
and O O
EPO B-protein B-protein
is O O
essential O O
for O O
expanded O O
erythropoiesis O O
. O O

Copyright O O
1998 O O
by O O
The O O
American O O
Society O O
of O O
Hematology O O
. O O

The O O
molecular O O
and O O
phenotypic O O
profile O O
of O O
primary O O
central O O
nervous O O
system O O
lymphoma O O
identifies O O
distinct O O
categories O O
of O O
the O O
disease O O
and O O
is O O
consistent O O
with O O
histogenetic O O
derivation O O
from O O
germinal B-cell_type B-cell_type
center-related I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Primary O O
central O O
nervous O O
system O O
lymphoma O O
( O O
PCNSL O O
) O O
is O O
a O O
major O O
cause O O
of O O
morbidity O O
and O O
mortality O O
among O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
-infected O O
individuals O O
. O O

The O O
precise O O
histogenetic O O
derivation O O
and O O
the O O
molecular O O
pathogenesis O O
of O O
PCNSL O O
is O O
poorly O O
understood O O
. O O

In O O
an O O
attempt O O
to O O
clarify O O
the O O
histogenesis O O
and O O
pathogenesis O O
of O O
these O O
lymphomas O O
, O O
49 O O
PCNSL O O
( O O
26 O O
acquired O O
immunodeficiency O O
syndrome O O
[ O O
AIDS O O
] O O
-related O O
and O O
23 O O
AIDS-unrelated O O
) O O
were O O
analyzed O O
for O O
multiple O O
biologic O O
markers O O
, O O
which O O
are O O
known O O
to O O
bear O O
histogenetic O O
and O O
pathogenetic O O
significance O O
for O O
mature O O
B-cell O B-cell_type
neoplasms O I-cell_type
. O O

PCNSL O O
associated O O
frequently O O
( O O
50.0 O O
% O O
) O O
with O O
mutations O O
of O O
BCL-6 B-DNA B-DNA
5 I-DNA I-DNA
' I-DNA I-DNA
noncoding I-DNA I-DNA
regions I-DNA I-DNA
, O O
which O O
are O O
regarded O O
as O O
a O O
marker O O
of O O
B-cell O O
transition O O
through O O
the O O
germinal O O
center O O
( O O
GC O O
) O O
. O O

Expression O O
of O O
BCL-6 B-protein B-protein
protein I-protein I-protein
, O O
which O O
is O O
restricted O O
to O O
GC B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
throughout O O
physiologic O O
B-cell O O
maturation O O
, O O
was O O
detected O O
in O O
100 O O
% O O
AIDS-unrelated O O
PCNSL O O
and O O
in O O
56.2 O O
% O O
AIDS-related O O
cases O O
. O O

Notably O O
, O O
among O O
AIDS-related O O
PCNSL O O
, O O
expression O O
of O O
BCL-6 B-protein B-protein
was O O
mutually O O
exclusive O O
with O O
expression O O
of O O
Epstein-Barr B-protein O
virus I-protein O
( I-protein O
EBV I-protein O
) I-protein O
-encoded I-protein O
latent I-protein B-protein
membrane I-protein I-protein
protein I-protein I-protein
( I-protein I-protein
LMP I-protein I-protein
) I-protein I-protein
-1 I-protein I-protein
and O O
, O O
with O O
few O O
exceptions O O
, O O
also O O
of O O
BCL-2 B-protein B-protein
. O O

All O O
but O O
one O O
PCNSL O O
expressed O O
hMSH2 O B-protein
, O O
which O O
among O O
mature B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
selectively O O
stains O B-cell_type
GC B-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

These O O
data O O
suggest O O
that O O
PCNSL O O
may O O
be O O
frequently O O
related O O
to O O
GC B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
may O O
be O O
segregated O O
into O O
two O O
major O O
biologic O O
categories O O
based O O
on O O
the O O
expression O O
pattern O O
of O O
BCL-6 B-protein B-protein
, O O
LMP-1 B-protein B-protein
, O O
and O O
BCL-2 B-protein B-protein
. O O

BCL-6 B-protein B-protein
( O O
+ O O
) O O
/ O O
LMP-1 B-protein B-protein
( O O
- O O
) O O
/ O O
BCL-2 B-protein B-protein
( O O
- O O
) O O
PCNSL O O
occur O O
both O O
in O O
the O O
presence O O
and O O
in O O
the O O
absence O O
of O O
HIV O O
infection O O
and O O
consistently O O
display O O
a O O
large O O
noncleaved O O
cell O O
morphology O O
. O O

Conversely O O
, O O
BCL-6 B-protein B-protein
( O O
- O O
) O O
/ O O
LMP-1 B-protein B-protein
( O O
+ O O
) O O
/ O O
BCL-2 B-protein B-protein
( O O
+ O O
) O O
PCNSL O O
are O O
restricted O O
to O O
HIV-infected O O
hosts O O
and O O
are O O
represented O O
by O O
lymphomas O O
with O O
immunoblastic O O
features O O
. O O

These O O
data O O
are O O
relevant O O
for O O
the O O
pathogenesis O O
and O O
histogenesis O O
of O O
PCNSL O O
and O O
may O O
be O O
helpful O O
to O O
segregate O O
distinct O O
biologic O O
and O O
prognostic O O
categories O O
of O O
these O O
lymphomas O O
. O O

Copyright O O
1998 O O
by O O
The O O
American O O
Society O O
of O O
Hematology O O
. O O

Antioxidant O O
regulation O O
of O O
phorbol O O
ester-induced O O
adhesion O O
of O O
human B-cell_line B-cell_line
Jurkat I-cell_line I-cell_line
T-cells I-cell_line I-cell_line
to O O
endothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Regulation O O
of O O
adhesion O B-protein
molecule O I-protein
expression O O
and O O
function O O
by O O
reactive O O
oxygen O O
species O O
via O O
specific O O
redox O O
sensitive O O
mechanisms O O
have O O
been O O
reported O O
. O O

The O O
effects O O
of O O
clinically O O
safe O O
antioxidants O O
in O O
the O O
regulation O O
of O O
adhesion O B-protein
molecule O I-protein
expression O O
in O O
human B-cell_type B-cell_type
endothelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
ECV O O
) O O
, O O
and O O
adherence O O
of O O
human B-cell_line B-cell_line
Jurkat I-cell_line I-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
to O O
ECV B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
investigated O O
. O O

The O O
thiol O O
antioxidant O O
, O O
alpha-lipoate O O
, O O
at O O
clinically O O
relevant O O
doses O O
down-regulated O O
phorbol O O
12-myristate O O
13-acetate O O
( O O
PMA O O
) O O
-induced O O
adhesion O B-protein
molecule O I-protein
expression O O
and O O
cell-cell O O
adhesion O O
. O O

Inhibition O O
of O O
PMA-induced O O
ICAM-1 O B-protein
and O O
VCAM-1 O B-protein
expression O O
as O O
well O O
as O O
PMA-induced O O
adhesion O O
of O O
Jurkat B-cell_line B-cell_line
T-cells I-cell_line I-cell_line
to O O
ECV B-cell_type B-cell_line
cells I-cell_type I-cell_line
by O O
alpha-lipoate O O
was O O
dose O O
dependent O O
( O O
50-250 O O
microM O O
) O O
. O O

The O O
effect O O
was O O
significant O O
for O O
ICAM-1 B-protein B-protein
( O O
p O O
< O O
.01 O O
) O O
and O O
VCAM-1 B-protein B-protein
( O O
p O O
< O O
.01 O O
) O O
expression O O
in O O
cells O O
pretreated O O
with O O
100 O O
microM O O
alpha-lipoate O O
compared O O
to O O
PMA-activated B-cell_type B-cell_line
untreated I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

Inhibition O O
of O O
PMA-induced O O
adhesion O B-protein
molecule O I-protein
expression O O
and O O
cell-cell O O
adhesion O O
was O O
more O O
pronounced O O
when O O
a O O
combination O O
of O O
antioxidants O O
, O O
alpha-lipoate O O
and O O
alpha-tocopherol O O
, O O
were O O
used O O
compared O O
to O O
the O O
use O O
of O O
either O O
of O O
these O O
antioxidant O O
alone O O
. O O

The O O
regulation O O
of O O
adhesion O B-protein
molecule O I-protein
expression O O
and O O
function O O
by O O
low O O
concentration O O
of O O
antioxidants O O
investigated O O
does O O
not O O
appear O O
to O O
be O O
NF-kappaB B-protein B-protein
regulated O O
or O O
transcription O O
dependent O O
because O O
no O O
change O O
in O O
the O O
mRNA O O
response O O
was O O
observed O O
. O O

Protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
( O O
PKC B-protein B-protein
) O O
has O O
been O O
suggested O O
to O O
regulate O O
PMA-induced O O
adhesion O B-protein
molecule O I-protein
expression O O
by O O
post-transcriptional O O
stabilization O O
of O O
adhesion B-RNA B-RNA
molecule I-RNA I-RNA
mRNA I-RNA I-RNA
. O O

Alpha-lipoate O O
pretreatment O O
did O O
not O O
influence O O
the O O
response O O
of O O
PKC B-protein B-protein
activity O O
to O O
PMA O O
. O O

Oxidants O O
are O O
known O O
to O O
be O O
involved O O
in O O
the O O
regulation O O
of O O
cell O O
adhesion O O
processes O O
. O O

Treatment O O
of O O
ECV B-cell_type B-cell_type
cells I-cell_type I-cell_type
with O O
PMA O O
induced O O
generation O O
of O O
intracellular O O
oxidants O O
. O O

Alpha-lipoate O O
( O O
100 O O
or O O
250 O O
microM O O
) O O
treatment O O
decreased O O
PMA-induced O O
generation O O
of O O
intracellular O O
oxidants O O
. O O

The O O
inhibitory O O
effect O O
of O O
low O O
concentration O O
of O O
alpha-lipaote O O
alone O O
or O O
in O O
combination O O
with O O
alpha-tocopherol O O
on O O
agonist-induced O O
adhesion O O
processes O O
observed O O
in O O
this O O
study O O
may O O
be O O
of O O
potential O O
therapeutic O O
value O O
. O O

Binding O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
to O O
CD4 B-protein B-protein
and I-protein O
CXCR4 I-protein B-protein
receptors I-protein I-protein
differentially O O
regulates O O
expression O O
of O O
inflammatory B-DNA B-DNA
genes I-DNA I-DNA
and O O
activates O O
the O O
MEK B-protein B-protein
/ERK O B-protein
signaling O O
pathway O O
. O O

We O O
have O O
previously O O
shown O O
that O O
binding O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
virions O O
to O O
CD4 B-protein B-protein
receptors I-protein I-protein
stimulates O O
association O O
of O O
Lck B-protein B-protein
with O O
Raf-1 B-protein B-protein
and O O
results O O
in O O
the O O
activation O O
of O O
Raf-1 B-protein B-protein
kinase O I-protein
in O O
a O O
Ras-independent O O
manner O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
demonstrate O O
that O O
HIV-1 B-protein B-protein
envelope I-protein I-protein
glycoproteins I-protein I-protein
of O O
both O O
T-cell-tropic O O
and O O
macrophagetropic O O
strains O O
rapidly O O
activate O O
the O O
ERK/mitogen-activated O B-protein
protein O I-protein
( O I-protein
MAP O I-protein
) O I-protein
kinase O I-protein
pathway O O
and O O
the O O
binding O O
of O O
nuclear B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
( O O
AP-1 B-protein B-protein
, O O
NF-kappaB B-protein B-protein
, O O
and O O
C/EBP B-protein B-protein
) O O
and O O
stimulate O O
expression O O
of O O
cytokine B-DNA B-DNA
and I-DNA I-DNA
chemokine I-DNA I-DNA
genes I-DNA I-DNA
. O O

The O O
activation O O
of O O
this O O
signaling O O
pathway O O
requires O O
functional O O
CD4 B-protein B-protein
receptors I-protein I-protein
and O O
is O O
independent O O
of O O
binding O O
to O O
CXCR4 B-protein B-protein
. O O

Binding O O
of O O
the O O
natural O B-protein
ligand O I-protein
stromal B-protein I-protein
cell-derived I-protein I-protein
factor I-protein I-protein
1 I-protein I-protein
( O O
SDF-1 B-protein B-protein
) O O
to O O
CXCR4 B-protein B-protein
, O O
which O O
inhibits O O
entry O O
of O O
T-cell-tropic O O
HIV-1 O O
, O O
activates O O
also O O
the O O
ERK/ O B-protein
MAP B-protein I-protein
kinase I-protein I-protein
pathway O O
. O O

However O O
, O O
SDF-1 B-protein B-protein
did O O
not O O
affect O O
the O O
CD4-mediated O O
expression O O
of O O
cytokine B-DNA B-DNA
and I-DNA I-DNA
chemokine I-DNA I-DNA
genes I-DNA I-DNA
. O O

These O O
results O O
provide O O
firm O O
molecular O O
evidence O O
that O O
binding O O
of O O
HIV-1 B-protein B-protein
envelope I-protein I-protein
glycoproteins I-protein I-protein
to O O
CD4 B-protein B-protein
receptor I-protein I-protein
initiates O O
a O O
signaling O O
pathway O O
( O O
s O O
) O O
independent O O
of O O
the O O
binding O O
to O O
the O O
chemokine B-protein B-protein
receptor I-protein I-protein
that O O
leads O O
to O O
the O O
aberrant O O
expression O O
of O O
inflammatory B-DNA B-DNA
genes I-DNA I-DNA
and O O
may O O
contribute O O
significantly O O
to O O
HIV-1 O O
replication O O
as O O
well O O
as O O
to O O
deregulation O O
of O O
the O O
immune O O
system O O
. O O

Antigen O B-protein
receptor O I-protein
signaling O I-protein
induces O O
MAP O O
kinase-mediated O O
phosphorylation O O
and O O
degradation O O
of O O
the O O
BCL-6 B-protein B-protein
transcription B-protein I-protein
factor I-protein I-protein
. O O

The O O
bcl-6 B-DNA B-DNA
proto-oncogene I-DNA I-DNA
encodes O O
a O O
POZ/zinc B-protein B-protein
finger I-protein I-protein
transcriptional I-protein I-protein
repressor I-protein I-protein
expressed O O
in O O
germinal B-cell_type B-cell_type
center I-cell_type I-cell_type
( I-cell_type I-cell_type
GC I-cell_type I-cell_type
) I-cell_type I-cell_type
B I-cell_type I-cell_type
and I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
required O O
for O O
GC O O
formation O O
and O O
antibody O O
affinity O O
maturation O O
. O O

Deregulation O O
of O O
bcl-6 B-DNA B-protein
expression O O
by O O
chromosomal O O
rearrangements O O
and O O
point O O
mutations O O
of O O
the O O
bcl-6 B-DNA B-DNA
promoter I-DNA I-DNA
region I-DNA I-DNA
are O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
B-cell O O
lymphoma O O
. O O

The O O
signals O O
regulating O O
bcl-6 B-DNA B-protein
expression O O
are O O
not O O
known O O
. O O

Here O O
we O O
show O O
that O O
antigen O O
receptor O O
activation O O
leads O O
to O O
BCL-6 B-protein B-protein
phosphorylation O O
by O O
mitogen-activated B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
( O O
MAPK B-protein B-protein
) O O
. O O

Phosphorylation O O
, O O
in O O
turn O O
, O O
targets O O
BCL-6 B-protein B-protein
for O O
rapid O O
degradation O O
by O O
the O O
ubiquitin B-protein B-protein
/ O O
proteasome B-protein B-protein
pathway O O
. O O

These O O
findings O O
indicate O O
that O O
BCL-6 B-protein B-protein
expression O O
is O O
directly O O
controlled O O
by O O
the O O
antigen O O
receptor O O
via O O
MAPK B-protein B-protein
activation O O
. O O

This O O
signaling O O
pathway O O
may O O
be O O
crucial O O
for O O
the O O
control O O
of O O
B-cell O O
differentiation O O
and O O
antibody O O
response O O
and O O
has O O
implications O O
for O O
the O O
regulation O O
of O O
other O O
POZ/zinc B-protein B-protein
finger I-protein I-protein
transcription I-protein I-protein
factors I-protein I-protein
in O O
other O O
tissues O O
. O O

Glucocorticoid B-protein B-protein
receptors I-protein I-protein
are O O
differentially O O
expressed O O
in O O
the O O
cells O O
and O O
tissues O O
of O O
the O O
immune O O
system O O
. O O

Cytosolic B-protein B-protein
glucocorticoid I-protein I-protein
receptor I-protein I-protein
( O O
GR B-protein B-protein
) O O
binding O O
studies O O
on O O
immune O O
tissues O O
demonstrate O O
that O O
the O O
thymus O O
exhibits O O
three O O
to O O
four O O
times O O
higher O O
levels O O
of O O
GR B-protein B-protein
protein I-protein I-protein
than O O
the O O
spleen O O
. O O

High O O
levels O O
of O O
GR B-protein B-protein
are O O
consistent O O
with O O
the O O
exquisite O O
sensitivity O O
of O O
the O O
thymus O O
to O O
glucocorticoid O O
exposure O O
. O O

Nevertheless O O
, O O
whole O O
cell O O
binding O O
studies O O
reveal O O
similar O O
levels O O
of O O
GR B-protein B-protein
in O O
immature B-cell_type B-cell_type
thymic I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
more O O
mature O O
, O O
splenic B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Moreover O O
, O O
whole O O
cell O O
binding O O
techniques O O
indicate O O
that O O
neutrophils B-cell_type B-cell_type
( O O
which O O
represent O O
roughly O O
30 O O
% O O
of O O
splenic B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
) O O
exhibit O O
higher O O
GR B-protein B-protein
than O O
both O O
T B-cell_type B-cell_type
and I-cell_type I-cell_type
B I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
, O O
further O O
contradicting O O
results O O
from O O
cytosolic O O
binding O O
studies O O
. O O

To O O
address O O
these O O
inconsistencies O O
, O O
GR B-protein B-protein
protein I-protein I-protein
was O O
assessed O O
in O O
immune B-cell_type B-cell_type
cells I-cell_type I-cell_type
and I-cell_type O
tissues I-cell_type O
using O O
cytosolic O O
radioligand O O
binding O O
. O O

Western O O
blot O O
analysis O O
, O O
and O O
immunocytochemistry O O
. O O

Consistent O O
with O O
previous O O
cytosolic O B-protein
receptor O I-protein
binding O O
studies O O
on O O
immune O O
tissue O O
homogenates O O
, O O
thymic O B-cell_type
T B-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
found O O
to O O
have O O
higher O O
levels O O
of O O
GR B-protein B-protein
than O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
isolated O O
from O O
the O O
spleen O O
. O O

In O O
addition O O
, O O
neutrophils O B-cell_type
were O O
found O O
to O O
have O O
fewer O O
GR B-protein B-protein
than O O
lymphocytes B-cell_type B-cell_type
and O O
monocytes B-cell_type B-cell_type
. O O

These O O
results O O
indicate O O
a O O
meaningful O O
relationship O O
between O O
receptor O O
expression O O
and O O
known O O
sensitivity O O
to O O
glucocorticoids O O
. O O

Functional O O
replacement O O
of O O
the O O
mouse B-DNA B-DNA
E2A I-DNA I-DNA
gene I-DNA I-DNA
with O O
a O O
human B-DNA B-DNA
HEB I-DNA I-DNA
cDNA I-DNA I-DNA
. O O

The O O
mammalian B-DNA B-DNA
E2A I-DNA I-DNA
, I-DNA I-DNA
HEB I-DNA I-DNA
, I-DNA I-DNA
and I-DNA I-DNA
E2-2 I-DNA I-DNA
genes I-DNA I-DNA
encode O O
a O O
unique O O
class O O
of O O
basic B-protein O
helix-loop-helix I-protein B-protein
( I-protein I-protein
bHLH I-protein I-protein
) I-protein I-protein
transcription I-protein I-protein
factors I-protein I-protein
that O O
are O O
evolutionarily O O
conserved O O
and O O
essential O O
for O O
embryonic O O
and O O
postnatal O O
development O O
. O O

While O O
the O O
structural O O
and O O
functional O O
similarities O O
among O O
the O O
gene B-protein B-protein
products I-protein I-protein
are O O
well O O
demonstrated O O
, O O
it O O
is O O
not O O
clear O O
why O O
deletion O O
of O O
E2A B-DNA B-protein
, O O
but O O
not O O
HEB B-DNA B-protein
or O O
E2-2 B-DNA B-protein
, O O
leads O O
to O O
a O O
complete O O
arrest O O
in O O
B-lymphocyte O O
development O O
. O O

To O O
understand O O
the O O
molecular O O
basis O O
of O O
the O O
functional O O
specificity O O
between O O
E2A B-DNA B-protein
and O O
HEB B-DNA B-protein
/ O O
E2-2 B-DNA B-protein
in O O
mammalian O O
development O O
, O O
we O O
generated O O
and O O
tested O O
a O O
panel O O
of O O
E2A B-DNA B-protein
knockin O I-protein
mutations O I-protein
including O O
subtle O O
mutations O O
in O O
the O O
E12 B-DNA B-DNA
and I-DNA I-DNA
E47 I-DNA I-DNA
exons I-DNA I-DNA
and O O
substitution O O
of O O
both O O
E12 B-DNA B-DNA
and I-DNA I-DNA
E47 I-DNA I-DNA
exons I-DNA I-DNA
with O O
a O O
human B-DNA B-DNA
HEB I-DNA I-DNA
cDNA I-DNA I-DNA
. O O

We O O
find O O
that O O
the O O
alternatively O O
spliced O O
E12 B-protein B-protein
and I-protein I-protein
E47 I-protein I-protein
bHLH I-protein I-protein
proteins I-protein I-protein
of O O
the O O
E2A B-DNA B-DNA
gene I-DNA I-DNA
play O O
similar O O
and O O
additive O O
roles O O
in O O
supporting O O
B B-cell_type B-cell_type
lymphopoiesis I-cell_type I-cell_type
. O O

Further O O
, O O
we O O
find O O
that O O
HEB B-DNA B-protein
driven O O
by O O
the O O
endogenous B-DNA B-DNA
E2A I-DNA I-DNA
promoter I-DNA I-DNA
can O O
functionally O O
replace O O
E2A B-DNA B-protein
in O O
supporting O O
B-cell O O
commitment O O
and O O
differentiation O O
toward O O
completion O O
. O O

Finally O O
, O O
the O O
postnatal O O
lethality O O
associated O O
with O O
E2A B-DNA B-protein
disruption O O
is O O
fully O O
rescued O O
by O O
the O O
addition O O
of O O
HEB B-DNA B-protein
. O O

This O O
study O O
suggests O O
that O O
the O O
functional O O
divergence O O
among O O
E12 B-DNA B-protein
, O O
E47 B-DNA B-protein
, O O
and O O
HEB B-DNA B-protein
in O O
different O O
cell O O
types O O
is O O
partially O O
defined O O
by O O
the O O
context O O
of O O
gene O O
expression O O
. O O

Biased O O
dependency O O
of O O
CD80 B-protein B-protein
versus O O
CD86 B-protein B-protein
in O O
the O O
induction O O
of O O
transcription B-protein B-protein
factors I-protein I-protein
regulating O O
the O O
human B-DNA B-DNA
IL-2 I-DNA I-DNA
promoter I-DNA I-DNA
. O O

In O O
addition O O
to O O
the O O
signals O O
obtained O O
by O O
ligation O O
of O O
the O O
TCR O B-protein
, O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
need O O
additional O O
, O O
co-stimulatory O O
signals O O
to O O
be O O
activated O O
. O O

One O O
such O O
co-stimulatory O O
signal O O
is O O
delivered O O
when O O
CD28 B-protein B-protein
on O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
binds O O
to O O
CD80 B-protein B-protein
or O O
CD86 B-protein B-protein
on O O
antigen-presenting B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
APC B-cell_type B-cell_type
) O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
analyzed O O
the O O
ability O O
of O O
CD80 B-protein B-protein
and O O
CD86 B-protein B-protein
to O O
co-stimulate B-cell_type B-cell_type
human I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
activated O O
by O O
superantigen O O
. O O

Using O O
the O O
Raji B-cell_line B-cell_line
B I-cell_line I-cell_line
cell I-cell_line I-cell_line
lymphoma I-cell_line O
, O O
which O O
express O O
similar O O
levels O O
of O O
CD80 B-protein B-protein
and O O
CD86 B-protein B-protein
, O O
it O O
was O O
found O O
that O O
T O O
cell O O
proliferation O O
was O O
mainly O O
co-stimulated O O
by O O
CD80 B-protein B-protein
. O O

To O O
further O O
characterize O O
the O O
consequences O O
of O O
this O O
biased O O
co-stimulatory O O
dependency O O
, O O
we O O
employed O O
a O O
well-defined O O
system O O
of O O
transfected O B-cell_line
CHO B-cell_line I-cell_line
cells I-cell_line I-cell_line
expressing O O
human B-protein B-protein
MHC I-protein I-protein
class I-protein I-protein
II I-protein I-protein
together O O
with O O
CD80 B-protein B-protein
, O O
CD86 B-protein B-protein
or O O
CD80 B-protein B-protein
and O O
CD86 B-protein B-protein
. O O

Proliferation O O
of O O
freshly O O
prepared O O
CD4+ B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
required O O
the O O
presence O O
of O O
either O O
CD80 B-protein B-protein
or O O
CD86 B-protein B-protein
. O O

However O O
, O O
IL-2 B-protein B-protein
production O O
reached O O
only O O
suboptimal O O
levels O O
in O O
the O O
presence O O
of O O
CD86 B-protein B-protein
but O O
optimal O O
levels O O
with O O
CD80 B-protein B-protein
. O O

To O O
analyze O O
IL-2 B-protein B-protein
transcriptional O O
activity O O
in O O
CD80 B-protein B-protein
and O O
CD86 B-protein B-protein
co-stimulated O I-cell_type
T B-cell_type I-cell_type
cells I-cell_type I-cell_type
we O O
used O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
transfected O O
with O O
luciferase B-DNA B-DNA
reporter I-DNA I-DNA
gene I-DNA I-DNA
constructs I-DNA I-DNA
. O O

CD80 B-protein B-protein
induced O O
higher O O
levels O O
of O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
-enhancer O O
activity O O
compared O O
to O O
CD86 B-protein B-protein
. O O

Furthermore O O
, O O
the O O
activity O O
of O O
transcription B-protein B-protein
factors I-protein I-protein
regulating O O
the O O
IL-2 B-DNA B-DNA
promoter-enhancer I-DNA I-DNA
region I-DNA I-DNA
including O O
activation B-protein B-DNA
protein-1 I-protein I-DNA
, O I-DNA
CD28 B-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
and O O
nuclear B-protein B-protein
factor I-protein I-protein
kappaB I-protein I-protein
were O O
4-8 O O
times O O
higher O O
after O O
CD80 B-protein B-protein
compared O O
to O O
CD86 B-protein B-protein
ligation O O
. O O

Our O O
results O O
suggest O O
that O O
the O O
eventual O O
appearance O O
of O O
CD80 B-protein B-protein
on O O
recently O O
activated O B-cell_type
CD86+ B-cell_type I-cell_type
APC I-cell_type I-cell_type
is O O
important O O
for O O
the O O
superinduction O O
of O O
IL-2 B-protein B-protein
production O O
and O O
to O O
support O O
vigorous O O
T O O
cell O O
proliferation O O
. O O

Duplication O O
of O O
the O O
DR3 B-DNA B-DNA
gene I-DNA I-DNA
on O O
human B-DNA B-DNA
chromosome I-DNA I-DNA
1p36 I-DNA I-DNA
and O O
its O O
deletion O O
in O O
human B-cell_type B-cell_type
neuroblastoma I-cell_type I-cell_type
. O O

The O O
human B-DNA B-DNA
DR3 I-DNA I-DNA
gene I-DNA I-DNA
, O O
whose O O
product O O
is O O
also O O
known O O
as O O
Wsl-1/APO-3/TRAMP/LARD B-protein B-protein
, O O
encodes O O
a O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor-related I-protein I-protein
receptor I-protein I-protein
that O O
is O O
expressed O O
primarily O O
on O O
the O O
surface O O
of O O
thymocytes B-cell_type B-cell_type
and O O
lymphocytes B-cell_type B-cell_type
. O O

DR3 B-protein B-protein
is O O
capable O O
of O O
inducing O O
both O O
NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
and O O
apoptosis O O
when O O
overexpressed O O
in O O
mammalian B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
although O O
its O O
ligand O O
has O O
not O O
yet O O
been O O
identified O O
. O O

We O O
report O O
here O O
that O O
the O O
DR3 B-DNA B-DNA
gene I-DNA I-DNA
locus I-DNA I-DNA
is O O
tandemly O O
duplicated O O
on O O
human B-DNA B-DNA
chromosome I-DNA I-DNA
band I-DNA I-DNA
1p36.2-p36.3 I-DNA I-DNA
and O O
that O O
these O O
genes O O
are O O
hemizygously O O
deleted O O
and/or O O
translocated O O
to O O
another O O
chromosome O B-DNA
in O O
neuroblastoma B-cell_line B-cell_line
( I-cell_line I-cell_line
NB I-cell_line I-cell_line
) I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
with O O
amplified O O
MYCN O B-protein
. O O

Duplication O O
of O O
at O O
least O O
a O O
portion O O
of O O
the O O
DR3 B-DNA B-DNA
gene I-DNA I-DNA
, O O
including O O
the O O
extracellular B-protein O
and I-protein O
transmembrane I-protein B-protein
regions I-protein I-protein
but O O
not O O
the O O
cytoplasmic B-protein B-protein
domain I-protein I-protein
, O O
was O O
demonstrated O O
by O O
both O O
fluorescence O O
in O O
situ O O
hybridization O O
and O O
genomic O O
Southern O O
blotting O O
. O O

In O O
most O O
NB B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
both O O
the O O
DR3 B-DNA B-protein
and I-DNA O
the I-DNA O
DR3L I-DNA B-DNA
sequences I-DNA I-DNA
are O O
simultaneously O O
deleted O O
and/or O O
translocated O O
to O O
another O O
chromosome B-DNA B-DNA
. O O

Finally O O
, O O
DR3/ B-protein O
Wsl-1 I-protein O
protein I-protein O
expression O O
is O O
quite O O
variable O O
among O O
these O O
NB B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
with O O
very O O
low O O
or O O
undetectable O O
levels O O
in O O
7 O O
of O O
17 O B-cell_line
NB B-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line

Differential O O
protection O O
of O O
normal B-cell_type O
and I-cell_type O
malignant I-cell_type B-cell_type
human I-cell_type I-cell_type
myeloid I-cell_type I-cell_type
progenitors I-cell_type I-cell_type
( O O
CFU-GM B-cell_type B-cell_type
) O O
from O O
Ara-C O O
toxicity O O
using O O
cycloheximide O O
. O O

Cycloheximide O O
, O O
a O O
reversible O O
protein O O
synthesis O O
inhibitor O O
, O O
is O O
thought O O
to O O
block O O
DNA O O
replication O O
in O O
normal B-cell_type B-cell_type
cells I-cell_type I-cell_type
by O O
preventing O O
synthesis O O
of O O
a O O
labile B-protein B-protein
protein I-protein I-protein
. O O

In O O
animal O O
systems O O
, O O
cycloheximide O O
protects O O
normal B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
cytotoxic O O
S-phase O O
specific O O
agents O O
, O O
such O O
as O O
cytosine O O
arabinoside O O
( O O
Ara-C O O
) O O
. O O

Malignant B-cell_type B-cell_type
cells I-cell_type I-cell_type
appear O O
not O O
to O O
be O O
susceptible O O
to O O
cycloheximide-induced O O
cycle O O
arrest O O
and O O
, O O
subsequently O O
, O O
may O O
not O O
be O O
protected O O
from O O
Ara-C O O
cytotoxicity O O
. O O

The O O
effect O O
of O O
cycloheximide O O
on O O
granulocyte/macrophage B-cell_type B-cell_type
progenitors I-cell_type I-cell_type
( O O
CFU-GM B-cell_type O
) O O
after O O
in O O
vitro O O
Ara-C O O
exposure O O
was O O
examined O O
using O O
normal O O
human O O
bone O O
marrow O O
, O O
malignant B-cell_type B-cell_type
progenitors I-cell_type I-cell_type
from O O
patients O O
with O O
chronic O O
myelogenous O O
leukemia O O
( O O
CML O O
) O O
, O O
and O O
clonogenic B-cell_line B-cell_type
cells I-cell_line I-cell_type
from O O
the O O
human B-cell_line B-cell_line
acute I-cell_line I-cell_line
nonlymphocytic I-cell_line I-cell_line
leukemia I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
HL-60 I-cell_line B-cell_line
and I-cell_line O
KG-1 I-cell_line B-cell_line
. O O

Mononuclear B-cell_line O
or I-cell_line O
clonogenic I-cell_line B-cell_type
cells I-cell_line I-cell_type
were O O
incubated O O
for O O
one O O
hour O O
with O O
cycloheximide O O
, O O
followed O O
by O O
the O O
addition O O
, O O
for O O
three O O
or O O
17 O O
hours O O
, O O
of O O
Ara-C O O
before O O
being O O
plated O O
in O O
a O O
methylcellulose O O
culture O O
system O O
. O O

CFU-GM O O
survival O O
was O O
significantly O O
increase O O
if O O
normal O B-cell_type
cells O I-cell_type
were O O
treated O O
with O O
cycloheximide O O
before O O
Ara-C O O
exposure O O
. O O

Similar O O
cycloheximide O O
pretreatment O O
of O O
CML B-cell_type B-cell_type
progenitors I-cell_type I-cell_type
and O O
clonogenic B-cell_line B-cell_line
HL-60 I-cell_line I-cell_line
and I-cell_line O
KG-1 I-cell_line B-cell_line
cells I-cell_line I-cell_line
failed O O
to O O
protect O O
CFU-GM B-cell_type O
from O O
Ara-C-induced O O
cytotoxicity O O
. O O

Primary O O
cortisol O O
resistance O O
accompanied O O
by O O
a O O
reduction O O
in O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
two O O
members O O
of O O
the O O
same O O
family O O
. O O

This O O
report O O
describes O O
studies O O
of O O
a O O
man O O
suspected O O
of O O
having O O
primary O O
cortisol O O
resistance O O
. O O

This O O
conclusion O O
is O O
based O O
on O O
his O O
high O O
plasma O O
cortisol O O
levels O O
and O O
high O O
24-h O O
urinary O O
17-hydroxycorticosteroid O O
and O O
cortisol O O
excretion O O
, O O
plus O O
the O O
fact O O
that O O
he O O
had O O
no O O
manifestations O O
of O O
Cushing O O
's O O
syndrome O O
. O O

Among O O
family O O
members O O
tested O O
, O O
his O O
mother O O
also O O
had O O
hypercortisolemia O O
. O O

Both O O
mother O O
and O O
son O O
had O O
high O O
levels O O
of O O
unbound O O
plasma O O
cortisol O O
, O O
but O O
their O O
plasma O O
ACTH O O
concentrations O O
were O O
within O O
the O O
normal O O
range O O
. O O

Both O O
were O O
partially O O
resistant O O
to O O
dexamethasone O O
adrenal O O
suppression O O
, O O
and O O
both O O
had O O
mild O O
hypertension O O
without O O
hypokalemia O O
. O O

To O O
study O O
this O O
apparent O O
end-organ O O
resistance O O
to O O
cortisol O O
, O O
we O O
examined O O
the O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
peripheral B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Using O O
whole O O
cell O O
assays O O
, O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
both O O
patients O O
were O O
found O O
to O O
have O O
reduced O O
total O O
binding O O
capacity O O
. O O

We O O
conclude O O
that O O
these O O
two O O
patients O O
, O O
members O O
of O O
the O O
same O O
family O O
, O O
have O O
primary O O
cortisol O O
resistance O O
accompanied O O
by O O
a O O
reduced O O
number O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
. O O

[ O O
Glucocorticoid B-protein B-protein
receptors I-protein I-protein
and O O
response O O
to O O
polychemotherapy O O
in O O
acute O O
lymphatic O O
leukemia O O
] O O

Glucocorticoid B-protein B-protein
receptor I-protein I-protein
( O O
GR B-protein B-protein
) O O
levels O O
were O O
quantified O O
in O O
leukemic B-cell_type B-cell_type
blasts I-cell_type I-cell_type
from O O
peripheral O O
blood O O
of O O
86 O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
. O O

The O O
subsequent O O
achievement O O
of O O
complete O O
remission O O
after O O
combination O O
chemotherapy O O
was O O
correlated O O
with O O
high O O
receptor O O
levels O O
. O O

Forty-seven O O
of O O
50 O O
patients O O
with O O
leukemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
containing O O
more O O
than O O
6 O B-DNA
, O I-DNA
000 O I-DNA
receptor O I-DNA
sites O I-DNA
and O O
22 O O
of O O
36 O O
patients O O
with O O
cells O O
containing O O
less O O
than O O
6 O O
, O O
000 O O
receptor O O
sites O O
achieved O O
remission O O
. O O

The O O
study O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
leukemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
may O O
predict O O
response O O
to O O
combination O O
chemotherapy O O
in O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
. O O

Specific O O
uptake O O
of O O
1 O O
, O O
25-dihydroxycholecalciferol O O
by O O
human B-cell_type B-cell_type
chronic I-cell_type I-cell_type
myeloid I-cell_type I-cell_type
leukemia I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

We O O
have O O
examined O O
mononuclear B-cell_line O
cell I-cell_line O
preparations I-cell_line O
from O O
patients O O
with O O
chronic O O
myeloid O O
leukemia O O
[ O O
CML O O
] O O
for O O
binding O O
of O O
and O O
response O O
to O O
1 O O
, O O
25-dihydroxycholecalciferol O O
[ O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
] O O
. O O

Whole O B-cell_type
cells O I-cell_type
specifically O O
took O O
up O O
[ O O
3H O O
] O O
-1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
with O O
high O O
affinity O O
( O O
Kd O O
3.6 O O
X O O
10 O O
( O O
-11 O O
) O O
M O O
) O O
and O O
low O O
capacity O O
. O O

Subcellular O O
fractionation O O
of O O
labeled B-cell_line B-cell_type
cells I-cell_line I-cell_type
showed O O
that O O
binding O O
was O O
restricted O O
to O O
cytosols O O
and O O
nuclei O O
. O O

Sucrose O O
gradient O O
centrifugation O O
of O O
cells O O
preincubated O O
with O O
[ O O
3H O O
] O O
-1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
revealed O O
a O O
single O O
3.6S O O
peak O O
which O O
was O O
totally O O
displaced O O
with O O
100-fold O O
excess O O
nonradioactive O O
hormone O O
. O O

However O O
, O O
we O O
were O O
unable O O
to O O
demonstrate O O
specific O O
binding O O
of O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
by O O
postlabeling O O
standard O O
cytosol O O
preparations O O
. O O

In O O
addition O O
, O O
cytosols O O
prepared O O
from O O
a O O
mixture O O
of O O
CML B-cell_line B-cell_type
cells I-cell_line I-cell_type
and O O
1 B-cell_line O
, I-cell_line O
25- I-cell_line O
( I-cell_line O
OH I-cell_line O
) I-cell_line O
2D3 I-cell_line O
receptor-positive I-cell_line O
T47D I-cell_line O
( O O
human O B-cell_line
breast O I-cell_line
cancer O I-cell_line
) O I-cell_line
cells O I-cell_line
had O O
less O O
than O O
10 O O
% O O
of O O
the O O
binding O O
measured O O
in O O
T47D B-cell_line O
cytosol O O
alone O O
. O O

However O O
, O O
the O O
levels O O
of O O
binding O O
in O O
T47D B-cell_line O
cytosols O O
were O O
not O O
reduced O O
if O O
the O O
receptors O O
were O O
occupied O O
with O O
[ O O
3H O O
] O O
-1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
prior O O
to O O
the O O
addition O O
of O O
the O O
CML B-cell_line O
cytosols O O
. O O

Thus O O
, O O
CML B-cell_line B-cell_type
cells I-cell_line I-cell_type
appear O O
to O O
contain O O
both O O
the O O
receptor O O
for O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
and O O
an O O
unknown O O
substance O O
which O O
prevents O O
its O O
detection O O
following O O
the O O
preparation O O
of O O
cytosol O O
. O O

Cells O O
from O O
patients O O
with O O
CML O O
in O O
the O O
chronic O O
phase O O
specifically O O
bound O O
more O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
[ O O
18.0 O O
+/- O O
3.2 O O
( O O
S.E. O O
) O O
fmol/10 O O
( O O
7 O O
) O O
cells O O
] O O
than O O
did O O
those O O
in O O
acute O O
myeloid O O
transformation O O
[ O O
7.2 O O
+/- O O
1.5 O O
] O O
or O O
than O O
did O O
cells O O
from O O
patients O O
with O O
acute O O
myeloid O O
leukemia O O
[ O O
2.6 O O
+/- O O
0.8 O O
] O O
. O O

Only O O
cells O O
from O O
the O O
first O O
group O O
of O O
patients O O
responded O O
to O O
the O O
addition O O
of O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
by O O
differentiating O O
along O O
the O O
monocyte-macrophage O O
pathway O O
. O O

We O O
conclude O O
that O O
the O O
differentiation-induction O O
effect O O
of O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
is O O
likely O O
to O O
depend O O
on O O
adequate O O
levels O O
of O O
receptor O O
and O O
that O O
intact B-cell_type B-cell_type
cells I-cell_type I-cell_type
rather O O
than O O
cytosol O O
preparations O O
should O O
be O O
studied O O
before O O
cells O O
of O O
a O O
particular O O
tissue O O
are O O
designated O O
as O O
receptor O O
negative O O
. O O

Effect O O
of O O
cell O O
cycle O O
position O O
on O O
dexamethasone O O
binding O O
by O O
mouse B-cell_line B-cell_line
and I-cell_line I-cell_line
human I-cell_line I-cell_line
lymphoid I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
: O O
correlation O O
between O O
an O O
increase O O
in O O
dexamethasone O O
binding O O
during O O
S O O
phase O O
and O O
dexamethasone O O
sensitivity O O
. O O

We O O
determined O O
the O O
effect O O
of O O
cell O O
cycle O O
position O O
on O O
the O O
amount O O
of O O
dexamethasone O O
that O O
was O O
specifically O O
bound O O
by O O
mouse B-cell_line B-cell_line
and I-cell_line I-cell_line
human I-cell_line I-cell_line
lymphoid I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

Cell B-cell_line O
lines I-cell_line O
that O O
were O O
either O O
sensitive O O
or O O
resistant O O
to O O
growth O O
inhibition O O
by O O
dexamethasone O O
were O O
compared O O
. O O

Exponentially B-cell_type B-cell_type
growing I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
separated O O
by O O
centrifugal O O
elutriation O O
into O O
fractions O O
that O O
corresponded O O
to O O
different O O
positions O O
in O O
the O O
cell O O
cycle O O
. O O

The O O
cell O O
cycle O O
phase O O
distribution O O
of O O
each O O
fraction O O
was O O
estimated O O
by O O
flow O O
cytometry O O
and O O
autoradiography O O
. O O

The O O
amount O O
of O O
dexamethasone O O
bound O O
per O O
cell O O
in O O
each O O
fraction O O
was O O
measured O O
by O O
a O O
whole O O
cell O O
binding O O
assay O O
. O O

In O O
three O O
dexamethasone-sensitive B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
( O O
two O O
mouse O O
and O O
one O O
human O O
) O O
, O O
we O O
found O O
that O O
the O O
amount O O
of O O
dexamethasone O O
bound O O
per O O
cell O O
increased O O
2-4-fold O O
between O O
G1 O O
phase O O
and O O
S O O
phase O O
, O O
and O O
then O O
decreased O O
during O O
G2/M O O
phase O O
. O O

Results O O
were O O
the O O
same O O
when O O
the O O
amount O O
of O O
dexamethasone O O
bound O O
per O O
milligram O O
of O O
cell B-protein O
protein I-protein O
was O O
measured O O
. O O

Binding O O
affinity O O
was O O
the O O
same O O
during O O
G1 O O
phase O O
and O O
S O O
phase O O
, O O
but O O
the O O
proportion O O
of O O
bound O O
dexamethasone O O
that O O
translocated O O
to O O
the O O
nucleus O O
was O O
greater O O
during O O
S O O
phase O O
. O O

In O O
contrast O O
, O O
we O O
found O O
that O O
the O O
amount O O
of O O
dexamethasone O O
bound O O
per O O
cell O O
by O O
three O O
dexamethasone-resistant B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
( O O
two O O
mouse O O
and O O
one O O
human O O
) O O
did O O
not O O
increase O O
during O O
S O O
phase O O
. O O

Our O O
results O O
indicate O O
that O O
cell O O
cycle O O
changes O O
in O O
dexamethasone O O
binding O O
are O O
not O O
simply O O
related O O
to O O
changes O O
in O O
cell B-protein O
protein I-protein O
or O O
cell O O
volume O O
during O O
the O O
cell O O
cycle O O
. O O

An O O
increase O O
in O O
dexamethasone O O
binding O O
during O O
S O O
phase O O
may O O
be O O
required O O
for O O
dexamethasone O O
to O O
inhibit O O
cell O O
growth O O
, O O
and O O
a O O
failure O O
of O O
dexamethasone O O
binding O O
to O O
increase O O
during O O
S O O
phase O O
might O O
represent O O
a O O
new O O
mechanism O O
of O O
dexamethasone O O
resistance O O
in O O
lymphoid B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Presence O O
and O O
steroid O O
inducibility O O
of O O
glutamine B-protein B-protein
synthetase I-protein I-protein
in O O
human B-cell_type B-cell_type
leukemic I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Glutamine B-protein B-protein
synthetase I-protein I-protein
( O O
EC O B-protein
6.3.1.2 O I-protein
; O O
GS O B-protein
) O O
is O O
present O O
in O O
lymphoblasts B-cell_type B-cell_type
from O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
( O O
ALL O O
) O O
as O O
well O O
as O O
in O O
normal B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

In O O
16 O O
out O O
of O O
20 O O
ALL O O
patients O O
studied O O
exposure O O
of O O
the O O
cells O O
to O O
physiological O O
concentrations O O
of O O
dexamethasone O O
in O O
vitro O O
increased O O
enzyme B-protein B-protein
activity O O
above O O
the O O
control O O
levels O O
. O O

The O O
increase O O
was O O
specific O O
for O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
ligands O I-protein
. O O

A O O
direct O O
correlation O O
was O O
found O O
between O O
the O O
magnitude O O
of O O
glucocorticoid-mediated O O
increase O O
of O O
GS O O
activity O O
and O O
the O O
cellular O O
levels O O
of O O
specific O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
assayed O O
in O O
the O O
same O O
cell B-cell_type O
specimen I-cell_type O
. O O

Moreover O O
, O O
the O O
basal O O
levels O O
of O O
the O O
enzyme B-protein O
measured O O
in O O
cells O O
prior O O
to O O
exposure O O
to O O
dexamethasone O O
correlated O O
negatively O O
with O O
receptor O O
density O O
. O O

It O O
is O O
suggested O O
that O O
the O O
presence O O
of O O
steroid-inducible B-protein B-protein
GS I-protein I-protein
in O O
ALL B-cell_type B-cell_type
cells I-cell_type I-cell_type
may O O
prove O O
to O O
be O O
a O O
marker O O
for O O
functional B-protein B-DNA
receptor I-protein I-DNA
sites I-protein I-DNA
. O O

Binding O O
of O O
progestins O O
to O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
. O O

Correlation O O
to O O
their O O
glucocorticoid-like O O
effects O O
on O O
in O O
vitro O O
functions O O
of O O
human B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
. O O

A O O
number O O
of O O
physiological O O
and O O
synthetic O O
progestins O O
were O O
tested O O
for O O
their O O
ability O O
to O O
compete O O
with O O
[ O O
3H O O
] O O
dexamethasone O O
for O O
the O O
binding O O
to O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
of O O
human B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
and O O
their O O
ability O O
to O O
elicit O O
glucocorticoid-like O O
effects O O
on O O
the O O
same O O
cells O O
. O O

As O O
compared O O
to O O
the O O
reference O O
compound O O
dexamethasone O O
( O O
relative O O
receptor O O
binding O O
affinity O O
defined O O
as O O
100 O O
% O O
) O O
, O O
two O O
potent O O
synthetic O O
progestins O O
with O O
a O O
pregnane-type O O
structure O O
, O O
megestrol O O
acetate O O
and O O
medroxyprogesterone O O
acetate O O
, O O
were O O
found O O
to O O
display O O
a O O
considerable O O
binding O O
affinity O O
towards O O
the O O
receptor O O
( O O
46 O O
and O O
42 O O
% O O
, O O
respectively O O
) O O
. O O

The O O
relative O O
binding O O
affinity O O
of O O
the O O
naturally O O
occurring O O
ligand O O
, O O
cortisol O O
, O O
to O O
the O O
receptor O O
was O O
clearly O O
lower O O
( O O
25 O O
% O O
) O O
. O O

The O O
effective O O
binding O O
of O O
medroxyprogesterone O O
acetate O O
to O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
was O O
confirmed O O
by O O
direct O O
binding O O
studies O O
utilizing O O
a O O
tritiated O O
derivative O O
of O O
this O O
steroid O O
. O O

No O O
evidence O O
for O O
the O O
existence O O
of O O
a O O
specific O O
progesterone B-protein B-protein
receptor I-protein I-protein
in O O
human B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
was O O
obtained O O
as O O
judged O O
by O O
the O O
results O O
of O O
competition O O
experiments O O
where O O
a O O
progesterone O O
receptor-specific O O
ligand O O
[ O O
3H O O
] O O
Org O O
2058 O O
was O O
used O O
. O O

Medroxyprogesterone O O
acetate O O
and O O
megestrol O O
acetate O O
also O O
induced O O
glucocorticoid-like O O
effects O O
on O O
the O O
lymphocyte B-cell_type O
functions O O
. O O

These O O
included O O
inhibition O O
of O O
the O O
proliferative O O
responses O O
to O O
the O O
T-cell B-protein B-protein
mitogens I-protein I-protein
concanavalin B-protein I-protein
A I-protein I-protein
and O O
phytohaemagglutinin B-protein B-protein
and O O
an O O
enhanced O O
accumulation O O
of O O
immunoglobulin B-cell_type B-cell_type
secreting I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
pokeweed B-cell_line B-cell_line
mitogen-stimulated I-cell_line I-cell_line
cultures I-cell_line I-cell_line
. O O

The O O
progestin O O
effect O O
appears O O
to O O
be O O
mediated O O
through O O
a O O
radiosensitive O O
( O O
suppressor O O
) O O
subpopulation O O
of O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

In O O
contrast O O
, O O
the O O
synthetic O O
progestins O O
related O O
structurally O O
to O O
19-nortestosterone O O
, O O
norethisterone O O
and O O
d-norgestrel O O
, O O
were O O
virtually O O
devoid O O
of O O
binding O O
affinity O O
towards O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
nor O O
did O O
they O O
measurably O O
influence O O
the O O
in O O
vitro O O
lymphocyte B-cell_type O
functions O O
. O O

These O O
studies O O
demonstrate O O
that O O
certain O O
progestins O O
in O O
common O O
clinical O O
use O O
probably O O
possess O O
inherent O O
glucocorticoid O O
activity O O
and O O
suggest O O
that O O
side O O
effects O O
attributable O O
to O O
this O O
character O O
( O O
e.g. O O
suppression O O
of O O
the O O
pituitary-adrenal O O
axis O O
) O O
might O O
be O O
expected O O
when O O
these O O
compounds O O
are O O
used O O
in O O
pharmacological O O
doses O O
. O O

Metabolic O O
and O O
ultrastructural O O
aspects O O
of O O
the O O
in O O
vitro O O
lysis O O
of O O
chronic B-cell_type B-cell_type
lymphocytic I-cell_type I-cell_type
leukemia I-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
glucocorticoids O O
. O O

Human B-cell_type O
chronic I-cell_type O
lymphocytic I-cell_type B-cell_line
leukemia I-cell_type I-cell_line
( I-cell_type I-cell_line
CLL I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
like O O
prothymocytes B-cell_type B-cell_type
and O O
immunoactivated B-cell_type B-cell_type
T-lymphocytes I-cell_type I-cell_type
are O O
readily O O
lysed O O
in O O
vitro O O
by O O
pharmacological O O
concentrations O O
of O O
glucocorticoids O O
such O O
as O O
cortisol O O
, O O
whereas O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
thymocytes B-cell_type B-cell_type
are O O
unaffected O O
by O O
the O O
hormone B-protein O
. O O

In O O
this O O
study O O
, O O
metabolic O O
and O O
ultrastructural O O
aspects O O
of O O
the O O
cortisol-induced O O
killing O O
process O O
of O O
CLL B-cell_type B-cell_line
cells I-cell_type I-cell_line
are O O
recorded O O
. O O

In O O
vitro O O
lysis O O
was O O
found O O
to O O
be O O
temperature O O
dependent O O
and O O
was O O
detected O O
only O O
after O O
6 O O
to O O
8 O O
hr O O
incubation O O
with O O
cortisol O O
by O O
means O O
of O O
the O O
trypan O O
blue O O
exclusion O O
test O O
. O O

However O O
, O O
30 O O
min O O
of O O
incubation O O
with O O
cortisol O O
at O O
either O O
37 O O
degrees O O
or O O
4 O O
degrees O O
followed O O
by O O
the O O
removal O O
of O O
the O O
hormone B-protein O
was O O
still O O
sufficient O O
to O O
induce O O
the O O
lytic O O
process O O
. O O

Ultrastructural O O
studies O O
demonstrated O O
sequential O O
changes O O
in O O
the O O
cytoplasm O O
, O O
including O O
swelling O O
of O O
mitochondria O O
and O O
cytoplasmic O O
decompartmentalization O O
, O O
followed O O
by O O
loss O O
of O O
surface O O
microvilli O O
with O O
the O O
appearance O O
of O O
`` O O
holes O O
'' O O
in O O
the O O
cell O O
membrane O O
, O O
and O O
subsequent O O
condensation O O
of O O
nuclear B-DNA O
chromatin I-DNA O
. O O

The O O
large O O
holes O O
in O O
the O O
membrane O O
appearing O O
after O O
6 O O
hr O O
of O O
incubation O O
with O O
the O O
hormone B-protein O
may O O
be O O
the O O
cause O O
for O O
the O O
penetration O O
of O O
the O O
viable O O
stain O O
into O O
the O O
dead B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
as O O
seen O O
by O O
light O O
microscopy O O
. O O

Addition O O
of O O
metabolic O O
inhibitors O O
including O O
actinomycin O O
D O O
, O O
puromycin O O
, O O
and O O
cycloheximide O O
following O O
administration O O
of O O
cortisol O O
resulted O O
in O O
inhibition O O
of O O
the O O
cell O O
lysis O O
. O O

An O O
excess O O
of O O
an O O
antagonist O O
such O O
as O O
cortexolone O O
was O O
found O O
to O O
inhibit O O
the O O
cortisol-induced O O
cytolysis O O
of O O
the O O
CLL B-cell_line B-cell_type
cells I-cell_line I-cell_type
. O O

It O O
is O O
suggested O O
that O O
the O O
glucocorticoid-induced O O
lysis O O
of O O
human B-cell_line B-cell_type
CLL I-cell_line I-cell_type
cells I-cell_line I-cell_type
is O O
similar O O
to O O
the O O
phenomenon O O
observed O O
in O O
rat B-cell_type B-cell_type
or I-cell_type I-cell_type
murine I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
is O O
mediated O O
by O O
interaction O O
of O O
the O O
steroid O B-protein
molecule O I-protein
with O O
the O O
cytoplasmic B-protein B-protein
receptor I-protein I-protein
. O O

The O O
resulting O O
complex O O
appears O O
to O O
activate O O
specific O O
gene B-DNA O
( O O
s O O
) O O
the O O
products O O
of O O
which O O
eventually O O
cause O O
cytolysis O O
. O O

Glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
lymphoid O O
tumors O O
. O O

There O O
is O O
a O O
range O O
of O O
levels O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
numbers O O
seen O O
in O O
the O O
various O O
subclasses O O
of O O
acute O O
lymphatic O O
leukemia O O
( O O
ALL O O
) O O
. O O

This O O
variability O O
can O O
not O O
be O O
explained O O
by O O
the O O
known O O
correlation O O
between O O
active O O
cell O O
proliferation O O
and O O
an O O
increase O O
in O O
the O O
number O O
of O O
receptors O O
, O O
since O O
the O O
tumors O O
with O O
the O O
highest O O
growth O O
fraction O O
( O O
i.e. O O
, O O
Burkitt O O
's O O
lymphoma O O
and O O
T-cell O O
leukemia O O
) O O
tend O O
to O O
have O O
lower O O
average O O
receptor O O
numbers O O
than O O
do O O
tumors O O
with O O
lower O O
growth O O
fractions O O
such O O
as O O
common O O
ALL O O
. O O

All O O
clinical O O
specimens O O
from O O
patients O O
with O O
lymphatic O O
leukemia O O
have O O
some O O
measurable O O
level O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
; O O
therefore O O
, O O
the O O
resistance O O
seen O O
in O O
vivo O O
can O O
not O O
be O O
explained O O
by O O
the O O
lack O O
of O O
receptors O O
. O O

However O O
, O O
there O O
has O O
been O O
a O O
positive O O
correlation O O
, O O
in O O
our O O
hands O O
, O O
with O O
receptor O O
level O O
and O O
prognosis O O
. O O

On O O
the O O
basis O O
of O O
in O O
vitro O O
models O O
, O O
it O O
is O O
proposed O O
that O O
perhaps O O
the O O
high B-cell_line B-cell_line
receptor I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
( O O
i.e. O O
, O O
common O O
ALL O O
of O O
childhood O O
) O O
have O O
relative O O
stability O O
of O O
their O O
genetic O O
material O O
making O O
glucocorticoid-resistant O O
mutations O O
less O O
likely O O
to O O
occur O O
in O O
patients O O
with O O
these O O
cells O O
than O O
in O O
low-receptor B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
( O O
i.e. O O
, O O
T-cell O O
leukemia O O
) O O
. O O

This O O
greater O O
genetic O O
variability O O
in O O
the O O
low-receptor B-cell_line B-cell_line
lines I-cell_line I-cell_line
could O O
account O O
for O O
the O O
earlier O O
emergence O O
of O O
clinical O O
glucocorticoid O O
resistance O O
in O O
these O O
patients O O
. O O

[ O O
Tumor O O
histology O O
and O O
steroid B-protein B-protein
receptors I-protein I-protein
in O O
breast O O
carcinoma O O
] O O

In O O
Specimens O O
of O O
115 O O
patients O O
with O O
breast O O
cancer O O
4 O O
tumorparameters O O
( O O
tumorsize O O
, O O
tumorboder O O
, O O
nucleargrade O O
, O O
lymphocytic O O
stromal O O
reaction O O
) O O
3 O O
features O O
of O O
regional O O
lymphnodes O O
( O O
sinushistiocytosis O O
, O O
T-cellreaction O O
, O O
lymphnode O O
metastases O O
) O O
and O O
estrogen B-protein O
and I-protein O
progesteron I-protein B-protein
receptors I-protein I-protein
were O O
determined O O
. O O

A O O
strong O O
sinushistiocytosis O O
and O O
T-cellreaction O O
could O O
be O O
verified O O
mainly O O
in O O
metastases O O
in O O
free O O
lymphnodes O O
. O O

The O O
steroid B-protein O
receptor I-protein O
content O O
does O O
not O O
correlate O O
with O O
histological O O
parameters O O

Aldosterone-receptor B-protein O
deficiency O O
in O O
pseudohypoaldosteronism O O
. O O

Pseudohypoaldosteronism O O
, O O
a O O
syndrome O O
characterized O O
by O O
salt O O
wasting O O
and O O
failure O O
to O O
thrive O O
, O O
usually O O
presents O O
in O O
infancy O O
as O O
high O O
urinary O O
levels O O
of O O
sodium O O
despite O O
hyponatremia O O
, O O
hyperkalemia O O
, O O
hyperreninemia O O
, O O
and O O
elevated O O
aldosterone O O
levels O O
. O O

We O O
have O O
investigated O O
this O O
syndrome O O
for O O
the O O
possibility O O
of O O
abnormal B-protein O
Type I-protein B-protein
I I-protein I-protein
or O I-protein
`` B-protein I-protein
mineralocorticoid-like I-protein I-protein
'' I-protein I-protein
receptors I-protein I-protein
, O O
which O O
have O O
intrinsic O O
steroid O O
specificity O O
indistinguishable O O
from O O
that O O
of O O
renal B-protein B-protein
mineralocorticoid I-protein I-protein
receptors I-protein I-protein
and O O
are O O
found O O
in O O
many O O
tissues O O
and O O
cells B-cell_type O
, O O
including O O
mononuclear B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
. O O

We O O
have O O
studied O O
three O O
patients O O
with O O
pseudohypoaldosteronism O O
: O O
the O O
28-year-old O O
index O O
case O O
in O O
Melbourne O O
( O O
Patient O O
1 O O
) O O
and O O
two O O
siblings O O
in O O
Munich O O
, O O
eight O O
and O O
two O O
years O O
of O O
age O O
( O O
Patients O O
2 O O
and O O
3 O O
) O O
; O O
clinically O O
, O O
Patient O O
3 O O
had O O
a O O
less O O
severe O O
case O O
than O O
his O O
sister O O
. O O

Percoll-separated B-cell_type O
control I-cell_type O
monocytes I-cell_type B-cell_type
bound O O
[ O O
3H O O
] O O
aldosterone O O
with O O
high O O
affinity O O
( O O
Kd O O
approximately O O
3 O O
nM O O
) O O
and O O
limited O O
capacity O O
( O O
150 O B-DNA
to O I-DNA
600 O I-DNA
sites O I-DNA
per O O
cell O O
) O O
. O O

On O O
repeated O O
examination O O
, O O
no O O
[ O O
3H O O
] O O
aldosterone O O
binding O O
was O O
found O O
in O O
monocytes B-cell_type B-cell_type
from O O
Patients O O
1 O O
and O O
2 O O
; O O
in O O
Patient O O
3 O O
, O O
the O O
levels O O
were O O
62 O B-cell_line
sites O I-cell_line
per O I-cell_line
cell O I-cell_line
, O O
more O O
than O O
2 O O
S.D. O O
below O O
those O O
of O O
the O O
control O O
. O O

Levels O O
in O O
the O O
parents O O
of O O
the O O
Munich O O
patients O O
( O O
first O O
cousins O O
) O O
were O O
normal O O
. O O

It O O
appears O O
that O O
pseudohypoaldosteronism O O
is O O
caused O O
by O O
a O O
Type O B-protein
I O I-protein
receptor O I-protein
defect O O
, O O
that O O
the O O
defect O O
may O O
be O O
complete O O
or O O
partial O O
, O O
that O O
transmission O O
may O O
be O O
autosomal O O
recessive O O
, O O
and O O
that O O
the O O
study O O
of O O
patients O O
with O O
pseudohypoaldosteronism O O
may O O
indicate O O
physiologic O O
roles O O
for O O
Type B-protein B-protein
I I-protein I-protein
receptors I-protein I-protein
in O O
nonepithelial O O
tissues O O
. O O

Glucocorticoid O O
inhibition O O
of O O
urokinase-like B-protein B-protein
plasminogen I-protein I-protein
activators I-protein I-protein
in O O
cultured B-cell_line B-cell_line
human I-cell_line I-cell_line
lymphoblasts I-cell_line I-cell_line
. O O

Two O O
human B-cell_line B-cell_line
lymphoblast I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
LICR-LON-HMy2 B-cell_line B-cell_line
( O O
HMy2 B-cell_line B-cell_line
cells I-cell_line I-cell_line
) O O
and O O
GM4672A B-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
are O O
moderately O O
growth O O
inhibited O O
by O O
dexamethasone O O
( O O
1 O O
, O O
4-pregnadien-9-fluoro-16 O O
alpha-methyl-11 O O
beta O O
, O O
17 O O
alpha O O
, O O
21-triol-3 O O
, O O
20-dione O O
) O O
( O O
Dex O O
) O O
. O O

Both O O
cell O O
types O O
secrete O O
a O O
urokinase B-protein B-protein
( I-protein O
UK I-protein O
) I-protein O
-like I-protein O
plasminogen I-protein B-protein
activator I-protein I-protein
( O O
PA B-protein O
) O O
. O O

Treatment O O
of O O
both O O
HMy2 B-cell_line B-cell_line
and I-cell_line I-cell_line
GM4672A I-cell_line I-cell_line
cells I-cell_line I-cell_line
with O O
Dex O O
for O O
1-4 O O
days O O
inhibits O O
extracellular O O
PA B-protein O
activity O O
in O O
a O O
concentration-dependent O O
manner O O
, O O
being O O
half-maximal O O
at O O
approximately O O
1 O O
X O O
10 O O
( O O
-9 O O
) O O
M O O
. O O

Inhibition O O
of O O
PA B-protein O
in O O
both O O
cell O O
types O O
is O O
specific O O
for O O
active O O
glucocorticoids O O
, O O
and O O
this O O
specificity O O
parallels O O
the O O
ability O O
of O O
various O O
steroids O O
to O O
bind O O
to O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
. O O

HMy2 B-cell_line O
cell I-cell_line O
PA B-protein O
is O O
fully O O
suppressible O O
by O O
Dex O O
, O O
whereas O O
up O O
to O O
one O O
third O O
of O O
the O O
activator O O
expressed O O
by O O
GM4672A B-cell_line B-cell_line
cells I-cell_line I-cell_line
is O O
resistant O O
to O O
glucocorticoid O O
inhibition O O
. O O

Mixing O O
experiments O O
using O O
a O O
UK O O
standard O O
and O O
conditioned O O
media O O
from O O
Dex-treated B-cell_line B-cell_type
cells I-cell_line I-cell_type
suggest O O
an O O
absence O O
of O O
glucocorticoid-inducible B-protein O
inhibitors I-protein O
to O O
UK B-protein O
or O O
plasmin B-protein B-protein
in O O
both O O
cell O O
types O O
. O O

However O O
, O O
conditioned O O
media O O
from O O
Dex-treated B-cell_line B-cell_line
GM4672A I-cell_line I-cell_line
cells I-cell_line I-cell_line
inhibits O O
a O O
portion O O
of O O
the O O
homologous O O
cellular O O
activator O O
in O O
conditioned O O
media O O
from O O
control O B-cell_line
GM4672A B-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Thus O O
, O O
low O O
levels O O
of O O
glucocorticoid-inducible B-protein O
inhibitors I-protein O
may O O
contribute O O
to O O
, O O
but O O
can O O
not O O
fully O O
account O O
for O O
, O O
Dex O O
inhibition O O
of O O
GM4672A B-protein O
PA I-protein O
activity O O
. O O

Glucocorticoid-inducible B-protein O
inhibitors I-protein O
in O O
HMy2 B-cell_line B-cell_line
cells I-cell_line I-cell_line
are O O
either O O
totally O O
absent O O
or O O
are O O
present O O
at O O
undetectable O O
levels O O
. O O

Thus O O
, O O
regulation O O
of O O
UK-like B-protein O
PAs I-protein O
in O O
HMy2 B-cell_line B-cell_line
and I-cell_line I-cell_line
GM4672A I-cell_line I-cell_line
cells I-cell_line I-cell_line
differs O O
with O O
respect O O
to O O
the O O
extent O O
to O O
which O O
glucocorticoids O O
inhibit O O
constitutively B-protein O
expressed I-protein O
activator I-protein O
levels O O
, O O
as O O
well O O
as O O
the O O
possible O O
contribution O O
of O O
glucocorticoid-inducible B-protein O
inhibitors I-protein O
to O O
the O O
regulatory O O
process O O
in O O
GM4672A B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

Characterization O O
of O O
aldosterone O B-DNA
binding O I-DNA
sites O I-DNA
in O O
circulating B-cell_type B-cell_type
human I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
. O O

Aldosterone O B-protein
binding O I-protein
sites O I-protein
in O O
human B-cell_line B-cell_type
mononuclear I-cell_line I-cell_type
leukocytes I-cell_line I-cell_type
were O O
characterized O O
after O O
separation O O
of O O
cells O O
from O O
blood O O
by O O
a O O
Percoll O O
gradient O O
. O O

After O O
washing O O
and O O
resuspension O O
in O O
RPMI-1640 O B-cell_line
medium O I-cell_line
, O I-cell_line
cells O I-cell_line
were O O
incubated O O
at O O
37 O O
degrees O O
C O O
for O O
1 O O
h O O
with O O
different O O
concentrations O O
of O O
[ O O
3H O O
] O O
aldosterone O O
plus O O
a O O
100-fold O O
concentration O O
of O O
RU-26988 O O
( O O
11 O O
alpha O O
, O O
17 O O
alpha-dihydroxy-17 O O
beta-propynylandrost-1 O O
, O O
4 O O
, O O
6-trien-3-one O O
) O O
, O O
with O O
or O O
without O O
an O O
excess O O
of O O
unlabeled O O
aldosterone O O
. O O

Aldosterone O O
binds O O
to O O
a O O
single O O
class O O
of O O
receptors O O
with O O
an O O
affinity O O
of O O
2.7 O O
+/- O O
0.5 O O
nM O O
( O O
means O O
+/- O O
SD O O
, O O
n O O
= O O
14 O O
) O O
and O O
a O O
capacity O O
of O O
290 O O
+/- O O
108 O O
sites/cell O O
( O O
n O O
= O O
14 O O
) O O
. O O

The O O
specificity O O
data O O
show O O
a O O
hierarchy O O
of O O
affinity O O
of O O
desoxycorticosterone O O
= O O
corticosterone O O
= O O
aldosterone O O
greater O O
than O O
hydrocortisone O O
greater O O
than O O
dexamethasone O O
. O O

The O O
results O O
indicate O O
that O O
mononuclear B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
could O O
be O O
useful O O
for O O
studying O O
the O O
physiological O O
significance O O
of O O
these O O
mineralocorticoid B-protein B-protein
receptors I-protein I-protein
and O O
their O O
regulation O O
in O O
humans O O
. O O

Mineralocorticoid B-protein O
and I-protein O
glucocorticoid I-protein B-protein
receptors I-protein I-protein
in O O
circulating B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
of O O
patients O O
with O O
primary O O
hyperaldosteronism O O
. O O

Mineralocorticoid B-protein O
and I-protein O
glucocorticoid I-protein B-protein
receptors I-protein I-protein
were O O
measured O O
in O O
circulating B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
in O O
5 O O
patients O O
affected O O
by O O
Conn O O
's O O
syndrome O O
( O O
3 O O
cases O O
of O O
bilateral O O
adrenal O O
hyperplasia O O
and O O
2 O O
cases O O
of O O
adenoma O O
plus O O
unilateral O O
hyperplasia O O
) O O
. O O

The O O
number O O
of O O
the O O
binding O B-DNA
sites O I-DNA
per O O
cell O O
resulted O O
significantly O O
lower O O
( O O
189 O O
+/- O O
114 O O
, O O
mean O O
+/- O O
SD O O
) O O
, O O
as O O
compared O O
with O O
the O O
normal O O
controls O O
( O O
298 O O
+/- O O
105 O O
) O O
. O O

The O O
affinity O O
of O O
aldosterone O O
for O O
the O O
receptor O O
was O O
found O O
to O O
be O O
not O O
different O O
than O O
that O O
of O O
healthy O O
control O O
subjects O O
. O O

The O O
capacity O O
and O O
the O O
affinity O O
of O O
dexamethasone O O
for O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
ranged O O
in O O
the O O
normal O O
values O O
. O O

These O O
data O O
suggest O O
a O O
possible O O
down-regulation O O
of O O
mineralocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
humans O O
. O O

Short-term O O
and O O
long-term O O
effects O O
of O O
estrogen O O
on O O
lymphoid O B-cell_type
tissues O I-cell_type
and O I-cell_type
lymphoid B-cell_type I-cell_type
cells I-cell_type I-cell_type
with O O
some O O
remarks O O
on O O
the O O
significance O O
for O O
carcinogenesis O O
. O O

Estrogens O O
have O O
long O O
been O O
thought O O
to O O
play O O
a O O
role O O
in O O
regulating O O
the O O
immune O O
system O O
. O O

The O O
difference O O
in O O
some O O
types O O
of O O
immune O O
responses O O
between O O
males O O
and O O
females O O
is O O
well-known O O
, O O
as O O
is O O
the O O
pronounced O O
thymic O O
involution O O
induced O O
by O O
exogenous O O
estrogens O O
. O O

Estrogens O O
stimulate O O
some O O
aspects O O
of O O
macrophage B-cell_type O
activity O O
and O O
, O O
depending O O
on O O
dose O O
and O O
mitogen B-protein B-protein
, O O
inhibit O O
or O O
stimulate O O
lymphocyte O O
proliferative O O
response O O
in O O
vitro O O
. O O

Another O O
example O O
is O O
the O O
estrogen O O
effect O O
on O O
the O O
delayed O O
type O O
hypersensitivity O O
response O O
. O O

A O O
broad O O
review O O
is O O
given O O
of O O
such O O
estrogen O O
effects O O
on O O
lymphoid B-cell_type O
tissue I-cell_type O
and O O
immune O O
response O O
. O O

Most O O
of O O
the O O
studies O O
published O O
so O O
far O O
are O O
phenomenological O O
. O O

However O O
, O O
the O O
recent O O
description O O
of O O
estrogen B-protein B-protein
receptors I-protein I-protein
in O O
the O O
thymus O O
and O O
in O O
some O O
lymphocyte B-cell_line B-cell_type
subpopulations I-cell_line I-cell_type
, O O
as O O
well O O
as O O
a O O
deeper O O
understanding O O
of O O
regulating O B-protein
factors O I-protein
in O O
the O O
immune O O
system O O
, O O
open O O
the O O
possibility O O
of O O
a O O
more O O
detailed O O
understanding O O
of O O
the O O
estrogen O O
mechanism O O
of O O
interference O O
. O O

Estrogen O O
effects O O
in O O
adults O O
are O O
reversible O O
. O O

After O O
treating O O
neonatal O O
mice O O
with O O
the O O
synthetic O O
estrogen O O
diethylstilbestrol O O
( O O
DES O O
) O O
, O O
disturbances O O
are O O
induced O O
in O O
lymphocyte B-cell_line B-cell_type
populations I-cell_line I-cell_type
and O O
lymphocyte B-cell_type O
functions O O
which O O
are O O
permanent O O
and O O
irreversible O O
. O O

Lymphocytes B-cell_type B-cell_type
from O O
adult O O
, O O
neonatally O O
DES-treated O O
female O O
mice O O
have O O
a O O
reduced O O
mitogen O B-protein
response O O
to O O
ConA B-protein O
and O O
LPS B-protein O
( O O
T B-protein O
and I-protein O
B I-protein B-cell_type
cell I-protein I-cell_type
mitogen I-protein B-protein
) O O
and O O
the O O
delayed O O
type O O
hypersensitivity O O
response O O
is O O
depressed O O
. O O

A O O
detailed O O
analysis O O
demonstrated O O
a O O
decreased O O
T B-cell_type B-cell_type
helper I-cell_type I-cell_type
cell I-cell_type I-cell_type
population O I-cell_type
. O O

The O O
activity O O
of O O
Natural B-cell_type B-cell_type
Killer I-cell_type I-cell_type
cells I-cell_type I-cell_type
is O O
permanently O O
reduced O O
and O O
this O O
functional O O
impairment O O
is O O
related O O
to O O
a O O
decreased O O
number O O
of O O
these O O
cells O O
, O O
in O O
turn O O
determined O O
at O O
the O O
bone O O
marrow O O
level O O
. O O

The O O
same O O
animals O O
have O O
an O O
increased O O
sensitivity O O
to O O
chemical O O
carcinogens O O
( O O
methylcholanthrene O O
) O O
and O O
they O O
spontaneously O O
develop O O
epithelial O O
changes O O
in O O
the O O
uterine O O
cervix O O
which O O
morphologically O O
are O O
similar O O
to O O
adenocarcinoma O O
. O O

The O O
association O O
between O O
estrogen-associated O O
malignancy O O
and O O
estrogen O O
effects O O
in O O
lymphocyte B-cell_type O
functions O O
deserves O O
further O O
study O O
. O O

Drugs O O
affecting O O
the O O
hormonal O O
receptors O O
of O O
normal B-cell_type O
and I-cell_type O
leukaemic I-cell_type B-cell_type
peripheral I-cell_type I-cell_type
leucocytes I-cell_type I-cell_type
. O O

The O O
authors O O
investigated O O
the O O
behaviour O O
of O O
steroid O O
hormone O O
uptake O O
in O O
leukaemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
CML B-cell_line O
, O O
CLL B-cell_line O
, O O
AML B-cell_line O
, O O
ALL B-cell_line O
) O O
, O O
in O O
basal O O
conditions O O
and O O
after O O
incubation O O
with O O
drugs O O
which O O
modify O O
the O O
cellular O O
concentration O O
of O O
cAMP O O
, O O
PGE O O
and O O
PGF O O
. O O

The O O
results O O
demonstrated O O
the O O
presence O O
in O O
leukaemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
of O O
an O O
alteration O O
in O O
the O O
incorporation O O
of O O
steroid O O
hormones O O
. O O

This O O
alteration O O
was O O
scarcely O O
modified O O
by O O
incubation O O
with O O
theophylline B-protein O
, O O
which O O
increases O O
cellular O O
concentration O O
of O O
cAMP O O
. O O

On O O
the O O
other O O
hand O O
, O O
it O O
was O O
moderately O O
counteracted O O
by O O
thioproline O O
and O O
was O O
evidently O O
inhibited O O
by O O
flurbiprofen O O
, O O
which O O
also O O
reduced O O
cellular O O
concentrations O O
of O O
prostaglandins O O
, O O
particularly O O
PGE2 O O
, O O
with O O
the O O
exception O O
of O O
PGF2 O O
which O O
showed O O
a O O
poor O O
response O O
. O O

Differences O O
were O O
observed O O
in O O
the O O
behavior O O
of O O
hormonal O O
uptake O O
of O O
CML B-cell_line O
, O O
in O O
contrast O O
to O O
that O O
of O O
AML B-cell_line O
, I-cell_line O
CLL I-cell_line O
and I-cell_line O
ALL I-cell_line B-cell_type
peripheral I-cell_line I-cell_type
leucocytes I-cell_line I-cell_type
. O O

Human O O
breast O O
cancer O O
and O O
impaired O O
NK B-cell_type O
cell I-cell_type O
function O O
. O O

Recent O O
advances O O
in O O
tumor O O
immunology O O
have O O
led O O
to O O
the O O
discovery O O
of O O
a O O
new O O
lymphoid B-cell_type O
cell I-cell_type O
with O O
unique O O
antitumor O O
activity O O
. O O

Natural B-cell_type I-cell_line
killer I-cell_type I-cell_line
( I-cell_type I-cell_line
NK I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
form O O
an O O
antitumor O O
surveillance O O
system O O
and O O
appear O O
to O O
be O O
vital O O
in O O
preventing O O
tumor O O
growth O O
and O O
metastasis O O
in O O
animal O O
models O O
. O O

We O O
studied O O
NK B-cell_type O
activity O O
in O O
patients O O
with O O
benign O O
and O O
malignant O O
breast O O
disease O O
, O O
using O O
a O O
chromium-51 O O
release O O
microtiter O O
cytotoxicity O O
assay O O
with O O
K562 B-cell_line B-cell_line
cells I-cell_line I-cell_line
as O O
targets O O
. O O

Compared O O
with O O
benign O O
controls O O
, O O
patients O O
with O O
malignancies O O
had O O
significantly O O
depressed O O
NK B-cell_type O
-mediated O O
lysis O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
. O O

Furthermore O O
, O O
lysis O O
in O O
those O O
with O O
advanced O O
disease O O
( O O
stages O O
II O O
, O O
III O O
, O O
and O O
IV O O
) O O
was O O
significantly O O
less O O
than O O
in O O
those O O
with O O
limited O O
disease O O
( O O
stage O O
I O O
) O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
. O O

NK B-cell_type B-protein
activity O O
was O O
not O O
correlated O O
to O O
estrogen O O
or O O
progesterone O B-protein
receptor O I-protein
states O O
. O O

Positive O O
correlation O O
of O O
a O O
depressed O O
natural O O
killer O O
activity O O
with O O
the O O
extent O O
of O O
tumor O O
spread O O
supports O O
the O O
concept O O
of O O
an O O
NK B-cell_type O
cell I-cell_type O
immune O O
surveillance O O
system O O
in O O
breast O O
cancer O O
and O O
emphasizes O O
its O O
importance O O
in O O
this O O
malignancy O O
. O O

Immunosuppressive O O
effect O O
of O O
serum O O
progesterone O O
during O O
pregnancy O O
depends O O
on O O
the O O
progesterone O O
binding O O
capacity O O
of O O
the O O
lymphocytes B-cell_type B-cell_type
. O O

Cytotoxic O O
activity O O
and O O
progesterone O O
binding O O
capacity O O
of O O
the O O
lymphocytes B-cell_type B-cell_type
, O O
together O O
with O O
serum O O
progesterone O O
concentrations O O
, O O
were O O
determined O O
in O O
women O O
with O O
normal O O
pregnancy O O
or O O
with O O
a O O
clinical O O
diagnosis O O
of O O
threatened O O
abortion O O
or O O
threatened O O
premature O O
labour O O
. O O

The O O
lymphocytes O B-cell_type
of O O
women O O
with O O
threatened O O
abortion O O
or O O
threatened O O
premature O O
labour O O
showed O O
significantly O O
higher O O
cytotoxic O O
activity O O
( O O
P O O
less O O
than O O
0.001 O O
) O O
and O O
significantly O O
lower O O
progesterone O O
binding O O
capacity O O
( O O
P O O
less O O
than O O
0.001 O O
) O O
than O O
did O O
lymphocytes B-cell_type B-cell_type
obtained O O
from O O
the O O
healthy O O
pregnant O O
women O O
. O O

Significant O O
inverse O O
correlation O O
was O O
found O O
between O O
progesterone O O
binding O O
capacity O O
and O O
cytotoxic O O
activity O O
of O O
the O O
lymphocytes B-cell_type B-cell_type
( O O
P O O
less O O
than O O
0.001 O O
) O O
, O O
but O O
the O O
progesterone O O
concentration O O
of O O
the O O
pregnancy O O
serum O O
appeared O O
to O O
have O O
no O O
influence O O
on O O
the O O
other O O
two O O
parameters O O
. O O

The O O
findings O O
indicate O O
that O O
intact O O
progesterone O O
binding O O
capacity O O
of O O
the O O
lymphocytes B-cell_type B-cell_type
is O O
an O O
essential O O
factor O O
for O O
the O O
manifestation O O
of O O
the O O
blocking O O
effect O O
exerted O O
by O O
pregnancy O O
serum O O
on O O
lymphocyte B-cell_type O
cytotoxicity O O
in O O
vitro O O
. O O

Serum O O
sex O O
steroid O O
and O O
peptide O O
hormone O O
concentrations O O
, O O
and O O
endometrial O O
estrogen O O
and O O
progestin O B-protein
receptor O I-protein
levels O O
during O O
administration O O
of O O
human B-protein O
leukocyte I-protein O
interferon I-protein O
. O O

Five O O
normally O O
cycling O O
healthy O O
women O O
were O O
given O O
daily O O
subcutaneous O O
injections O O
of O O
human B-protein O
leukocyte I-protein O
interferon I-protein O
( O O
3 O O
X O O
10 O O
( O O
6 O O
) O O
units/day O O
) O O
from O O
the O O
3rd O O
through O O
23rd O O
day O O
of O O
the O O
menstrual O O
cycle O O
, O O
and O O
serum O O
steroid O O
and O O
peptide O O
hormone O O
concentrations O O
monitored O O
at O O
3-day O O
intervals O O
during O O
the O O
treatment O O
and O O
the O O
preceding O O
control O O
cycle O O
. O O

Concentrations O O
of O O
cytosol B-protein O
and I-protein O
nuclear I-protein B-protein
estrogen I-protein I-protein
receptors I-protein I-protein
( O O
ERC B-protein O
and O O
ERN B-protein B-protein
, O O
respectively O O
) O O
and O O
progestin B-protein B-protein
receptors I-protein I-protein
( O O
PRC B-protein O
and O O
PRN B-protein O
) O O
were O O
also O O
measured O O
from O O
endometrial O O
biopsies O O
taken O O
on O O
the O O
24th O O
day O O
of O O
the O O
control O O
and O O
treatment O O
cycle O O
. O O

In O O
addition O O
, O O
an O O
extensive O O
monitoring O O
of O O
clinical O O
chemical O O
and O O
hematological O O
tests O O
from O O
the O O
blood O O
samples O O
were O O
performed O O
. O O

Serum O O
estradiol O O
and O O
progesterone O O
concentrations O O
were O O
significantly O O
decreased O O
during O O
the O O
treatment O O
cycle O O
, O O
suggesting O O
that O O
interferon B-protein B-protein
interacts O O
in O O
vivo O O
with O O
the O O
function O O
of O O
both O O
FSH O O
and O O
LH O O
. O O

No O O
significant O O
changes O O
were O O
observed O O
in O O
the O O
serum O O
peptide O O
hormone O O
concentrations O O
measured O O
( O O
FSH O O
, O O
LH O O
, O O
prolactin O O
, O O
insulin O O
, O O
growth O O
hormone O O
and O O
TSH O O
) O O
; O O
neither O O
were O O
the O O
levels O O
of O O
endometrial B-protein O
ERC I-protein O
, I-protein O
ERN I-protein O
, I-protein O
PRC I-protein O
and I-protein O
PRN I-protein O
affected O O
by O O
interferon B-protein B-protein
administration O O
. O O

As O O
expected O O
, O O
interferon B-protein B-protein
administration O O
resulted O O
in O O
decreased O O
leukocyte B-cell_type O
counts O O
. O O

Moreover O O
, O O
an O O
increasing O O
tendency O O
in O O
the O O
activities O O
of O O
serum B-protein B-protein
alkaline I-protein I-protein
phosphatase I-protein I-protein
and O O
gamma-glutamyltransferase B-protein B-protein
during O O
the O O
interferon B-protein B-protein
therapy O O
shows O O
that O O
interferon B-protein B-protein
may O O
slightly O O
interfere O O
with O O
the O O
liver O O
function O O
. O O

These O O
results O O
suggest O O
that O O
one O O
of O O
the O O
mechanisms O O
by O O
which O O
interferon B-protein B-protein
treatment O O
may O O
affect O O
the O O
growth O O
of O O
hormone-dependent O O
neoplasms O O
could O O
be O O
the O O
interaction O O
with O O
production O O
and/or O O
function O O
of O O
circulating O O
hormonal O O
compounds O O
. O O

[ O O
Glucocorticoid B-protein B-protein
receptor I-protein I-protein
level O O
in O O
the O O
blood B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
in O O
different O O
acute O O
diseases O O
] O O

Content O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
cytosol O O
of O O
blood B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
, O O
concentration O O
of O O
cortisol O O
and O O
amount O O
of O O
leukocytes B-cell_type B-cell_type
in O O
blood O O
were O O
studied O O
in O O
20 O O
patients O O
with O O
acute O O
impairments O O
within O O
the O O
second O O
day O O
of O O
the O O
disease O O
. O O

Content O O
of O O
receptors O O
in O O
cytosol O O
of O O
blood O B-cell_type
leukocytes O I-cell_type
was O O
studied O O
using O O
3H-triamcinolone O O
acetonide O O
. O O

Distinct O O
increase O O
in O O
amount O O
of O O
the O O
leukocyte B-protein B-protein
glucocorticoid I-protein I-protein
receptors I-protein I-protein
was O O
found O O
in O O
patients O O
with O O
poisoning O O
by O O
dichlorethane O O
and O O
hypnotic O O
drugs O O
under O O
conditions O O
of O O
acute O O
myocardial O O
infarction O O
. O O

In O O
acute O O
pancreatitis O O
content O O
of O O
the O O
leukocyte B-protein B-protein
receptors I-protein I-protein
was O O
not O O
altered O O
as O O
compared O O
with O O
controls O O
. O O

Concentration O O
of O O
endogenous O O
cortisol O O
was O O
increased O O
in O O
blood O O
of O O
all O O
the O O
patients O O
, O O
except O O
of O O
the O O
cases O O
of O O
acetate O O
intoxication O O
. O O

Reverse O O
correlation O O
was O O
observed O O
between O O
concentration O O
of O O
cortisol O O
in O O
blood O O
and O O
content O O
of O O
glucocorticoid O B-protein
receptors O I-protein
in O O
leukocytes B-cell_type B-cell_type
. O O

But O O
in O O
the O O
patients O O
with O O
acute O O
pancreatitis O O
the O O
decrease O O
in O O
content O O
of O O
leukocyte B-protein B-protein
glucocorticoid I-protein I-protein
receptors I-protein I-protein
was O O
not O O
observed O O
although O O
there O O
was O O
an O O
increase O O
in O O
cortisol O O
concentration O O
in O O
blood O O
. O O

The O O
role O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
immunological O O
processes O O
under O O
conditions O O
of O O
purulent O O
complications O O
and O O
possibility O O
to O O
regulate O O
the O O
metabolism O O
in O O
leukocytes B-cell_type B-cell_type

Therapeutic O O
concentrations O O
of O O
glucocorticoids O O
suppress O O
the O O
antimicrobial O O
activity O O
of O O
human B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
without O O
impairing O O
their O O
responsiveness O O
to O O
gamma B-protein B-protein
interferon I-protein I-protein
. O O

By O O
exposing O O
human B-cell_type B-cell_type
blood-derived I-cell_type I-cell_type
macrophages I-cell_type I-cell_type
and I-cell_type O
alveolar I-cell_type B-cell_type
macrophages I-cell_type I-cell_type
in O O
vitro O O
to O O
dexamethasone O O
, O O
we O O
showed O O
in O O
these O O
studies O O
that O O
glucocorticoids O O
markedly O O
suppress O O
the O O
antimicrobial O O
activity O O
of O O
macrophages B-cell_type B-cell_type
but O O
not O O
macrophage B-cell_type O
activation O O
by O O
lymphokines B-cell_type B-protein
. O O

As O O
little O O
as O O
2.5 O O
X O O
10 O O
( O O
-8 O O
) O O
mol/liter O O
of O O
dexamethasone O O
prevented O O
macrophages B-cell_type B-cell_type
from O O
inhibiting O O
germination O O
of O O
Aspergillus O O
spores O O
or O O
from O O
eliminating O O
ingested O O
bacteria O O
such O O
as O O
Listeria O O
, O O
Nocardia O O
, O O
or O O
Salmonella O O
. O O

Damage O O
to O O
macrophage B-cell_type O
function O O
was O O
inhibited O O
by O O
progesterone O O
and O O
appeared O O
to O O
be O O
receptor-mediated O O
. O O

In O O
accordance O O
with O O
in O O
vivo O O
observations O O
, O O
dexamethasone O O
required O O
24-36 O O
h O O
to O O
suppress O O
antimicrobial O O
activity O O
. O O

While O O
glucocorticoids O O
interfered O O
with O O
base-line O O
activity O O
of O O
macrophages B-cell_type B-cell_type
, O O
dexamethasone O O
concentrations O O
comparable O O
to O O
drug O O
levels O O
in O O
patients O O
had O O
no O O
effect O O
on O O
macrophage B-cell_type O
activation O O
. O O

Proliferating O B-cell_type
lymphocytes B-cell_type I-cell_type
and O O
gamma-interferon B-protein B-protein
thus O O
increased O O
the O O
antimicrobial O O
activity O O
of O O
phagocytes B-cell_type B-cell_type
exposed O O
to O O
glucocorticoids O O
over O O
that O O
of O O
control O B-cell_type
cells O I-cell_type
. O O

Macrophage O O
activation O O
and O O
correction O O
of O O
the O O
dexamethasone O O
effect O O
by O O
gamma-interferon B-protein B-protein
, O O
however O O
, O O
was O O
dependent O O
on O O
the O O
pathogen O O
. O O

The O O
lymphokine B-protein B-protein
enhanced O O
the O O
antimicrobial O O
activity O O
of O O
dexamethasone-treated B-cell_line B-cell_type
macrophages I-cell_line I-cell_type
against O O
Listeria O O
and O O
Salmonella O O
but O O
not O O
against O O
Aspergillus O O
or O O
Nocardia O O
. O O

Dexamethasone-induced O O
damage O O
to O O
the O O
antimicrobial O O
activity O O
of O O
human B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
in O O
vitro O O
parallels O O
observations O O
that O O
glucocorticoids O O
render O O
laboratory O O
animals O O
susceptible O O
to O O
listeriosis O O
and O O
aspergillosis O O
by O O
damaging O O
resident O B-cell_type
macrophages B-cell_line I-cell_type
. O O

Suppression O O
of O O
macrophage B-cell_type O
antimicrobial O O
activity O O
should O O
thus O O
be O O
considered O O
when O O
treating O O
patients O O
with O O
glucocorticoids O O
; O O
its O O
prevention O O
by O O
gamma-interferon B-protein B-protein
might O O
be O O
beneficial O O
for O O
some O O
but O O
not O O
all O O
pathogens O O
. O O

Interleukin B-protein B-protein
2 I-protein I-protein
receptor I-protein I-protein
( O O
Tac B-protein B-protein
antigen I-protein I-protein
) O O
expression O O
in O O
HTLV-I-associated O O
adult O O
T-cell B-cell_type O
leukemia O O
. O O

Interleukin-2 B-protein B-protein
( O O
IL-2 B-protein B-protein
) O O
is O O
a O O
lymphokine B-protein B-protein
synthesized O O
by O O
some O O
T-cells B-cell_type B-cell_type
following O O
activation O O
. O O

Resting O O
T-cells B-cell_type O
do O O
not O O
express O O
IL-2 B-protein B-protein
receptors I-protein I-protein
, O O
but O O
receptors O O
are O O
rapidly O O
expressed O O
on O O
T-cells B-cell_type B-cell_type
following O O
interaction O O
of O O
antigens O B-protein
, O O
mitogens O O
, O O
or O O
monoclonal B-protein B-protein
antibodies I-protein I-protein
with O O
the O O
antigen-specific B-protein B-protein
T-cell I-protein I-protein
receptor I-protein I-protein
complex I-protein I-protein
. O O

Using O O
anti-Tac B-protein B-protein
, O O
a O O
monoclonal B-protein B-protein
antibody I-protein I-protein
that O O
recognizes O O
the O O
IL-2 B-protein B-protein
receptor I-protein I-protein
, O O
the O O
receptor O O
has O O
been O O
purified O O
and O O
shown O O
to O O
be O O
a O O
Mr O O
33 O O
, O O
000 O O
peptide O O
that O O
is O O
posttranslationally O O
glycosylated O O
to O O
a O O
Mr O O
55 O O
, O O
000 O O
mature O O
form O O
. O O

Normal O B-cell_type
resting O I-cell_type
T-cells B-cell_type I-cell_type
and O O
most O O
leukemic B-cell_line B-cell_type
T-cell I-cell_line I-cell_type
populations I-cell_line I-cell_type
do O O
not O O
express O O
IL-2 B-protein B-protein
receptors I-protein I-protein
; O O
however O O
, O O
the O O
leukemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
of O O
the O O
11 O O
patients O O
examined O O
who O O
had O O
human O O
T-cell O O
lymphotropic O O
virus-associated O O
adult O O
T-cell O O
leukemia O O
expressed O O
the O O
Tac B-protein B-protein
antigen I-protein I-protein
. O O

In O O
human B-cell_type B-cell_type
T-cell I-cell_type I-cell_type
lymphotropic I-cell_type I-cell_type
virus-I I-cell_type I-cell_type
infected I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
the O O
Mr O B-DNA
42 O I-DNA
, O I-DNA
000 O I-DNA
long O I-DNA
open B-protein I-DNA
reading I-protein I-DNA
frame I-protein I-DNA
protein I-protein B-protein
encoded O O
in O O
part O O
by O O
the O O
pX B-DNA B-DNA
region I-DNA I-DNA
of O O
this O O
virus O O
may O O
act O O
as O O
a O O
transacting B-protein B-DNA
transcriptional I-protein I-DNA
activator I-protein I-DNA
that O O
induces O O
IL-2 B-DNA B-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
transcription O O
, O O
thus O O
providing O O
an O O
explanation O O
for O O
the O O
constant O O
association O O
of O O
IL-2 B-protein B-protein
receptor I-protein I-protein
expression O O
with O O
adult O O
T-cell O O
lymphotropic O O
virus-I O O
infection O O
of O O
lymphoid B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
constant O O
expression O O
of O O
large O O
numbers O O
of O O
IL-2 B-protein B-protein
receptors I-protein I-protein
which O O
may O O
be O O
aberrant O O
may O O
play O O
a O O
role O O
in O O
the O O
uncontrolled O O
growth O O
of O O
adult B-cell_type B-cell_type
T-cell I-cell_type I-cell_type
leukemia I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Two O O
patients O O
with O O
Tac-positive O O
adult O O
T-cell O O
leukemia O O
have O O
been O O
treated O O
with O O
the O O
anti-Tac B-protein B-protein
. O O

One O O
of O O
the O O
patients O O
had O O
6- O O
and O O
3-mo O O
remissions O O
of O O
his O O
leukemia O O
following O O
two O O
courses O O
of O O
therapy O O
with O O
this O O
monoclonal B-protein B-protein
antibody I-protein I-protein
directed O O
toward O O
this O O
growth B-protein B-protein
factor I-protein I-protein
receptor I-protein I-protein
. O O

Lymphocyte B-cell_type B-protein
glucocorticoid B-protein I-protein
receptor I-protein I-protein
binding O O
in O O
depressed O O
patients O O
with O O
hypercortisolemia O O
. O O

Despite O O
elevated O O
levels O O
of O O
serum O O
and O O
urinary O O
cortisol O O
, O O
patients O O
with O O
depressive O O
illness O O
manifest O O
none O O
of O O
the O O
clinical O O
stigmata O O
of O O
glucocorticoid O O
excess O O
. O O

This O O
hypercortisolemia O O
in O O
the O O
absence O O
of O O
clinical O O
effects O O
suggests O O
a O O
state O O
of O O
hormone O O
resistance O O
and O O
could O O
be O O
mediated O O
by O O
alterations O O
in O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
. O O

Earlier O O
studies O O
have O O
shown O O
that O O
small O O
doses O O
of O O
glucocorticoids O O
cause O O
a O O
decrease O O
in O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
binding O O
in O O
normal O B-cell_type
human B-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

White O B-cell_type
cells O I-cell_type
from O O
depressed O O
patients O O
with O O
significant O O
hypercortisolemia O O
would O O
be O O
expected O O
to O O
show O O
a O O
similar O O
change O O
in O O
receptor O O
concentration O O
if O O
peripheral O O
tissues O O
are O O
adequately O O
exposed O O
to O O
and O O
sensitive O O
to O O
the O O
hormone O O
. O O

In O O
this O O
study O O
we O O
compared O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
dexamethasone O O
to O O
lymphocytes B-cell_type B-cell_type
from O O
normal O O
subjects O O
and O O
depressed O O
patients O O
with O O
hypercortisolemia O O
. O O

Lymphocytes B-cell_type B-cell_type
from O O
normal O O
subjects O O
had O O
a O O
mean O O
receptor O O
concentration O O
of O O
10.2 O O
+/- O O
0.66 O O
fm/10 O O
( O O
6 O O
) O O
cells O O
( O O
S.E.M. O O
) O O
and O O
a O O
dissociation O O
constant O O
of O O
4.8 O O
+/- O O
0.47 O O
nM O O
. O O

Lymphocytes B-cell_type B-cell_type
from O O
depressed O O
patients O O
with O O
abnormal O O
0800 O O
h O O
serum O O
cortisol O O
after O O
dexamethasone O O
had O O
a O O
mean O O
receptor O O
concentration O O
of O O
8.8 O O
+/- O O
0.75 O O
fm/10 O O
( O O
6 O O
) O O
cells O O
, O O
which O O
was O O
not O O
significantly O O
different O O
from O O
that O O
in O O
lymphocytes B-cell_type B-cell_type
from O O
normal O O
subjects O O
or O O
from O O
depressed O O
subjects O O
with O O
normal O O
post-dexamethasone O O
cortisol O O
levels O O
( O O
9.4 O O
+/- O O
0.95 O O
fm/10 O O
( O O
6 O O
) O O
cells O O
) O O
. O O

Lymphocytes B-cell_type B-cell_type
from O O
depressed O O
patients O O
with O O
elevated O O
urinary O O
free O O
cortisol O O
excretion O O
( O O
UFC O O
) O O
also O O
had O O
normal O O
receptor O O
concentration O O
and O O
binding O O
affinity O O
for O O
dexamethasone O O
. O O

The O O
lack O O
of O O
a O O
change O O
in O O
lymphocyte B-cell_type B-cell_type
glucocorticoid B-protein B-protein
receptor I-protein I-protein
concentration O O
in O O
the O O
presence O O
of O O
cortisol O O
excess O O
suggests O O
the O O
possibility O O
that O O
hypercortisolemia O O
in O O
depressive O O
illness O O
represents O O
a O O
state O O
of O O
peripheral O O
glucocorticoid O O
resistance O O
. O O

Structure O O
and O O
regulation O O
of O O
the O O
glucocorticoid B-protein B-protein
hormone I-protein I-protein
receptor I-protein I-protein
. O O

The O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
is O O
an O O
intracellular B-protein B-protein
protein I-protein I-protein
which O O
possesses O O
three O O
distinct O O
domains O O
, O O
one O O
that O O
binds O O
agonist O O
and O O
antagonist O O
steroids O O
, O O
one O O
that O O
binds O O
DNA O O
, O O
and O O
one O O
that O O
binds O O
anti-receptor B-protein B-protein
antibodies I-protein I-protein
and O O
is O O
required O O
for O O
glucocorticoid O O
modulation O O
of O O
gene O O
expression O O
. O O

In O O
intact O O
cells O O
, O O
receptor O O
number O O
, O O
affinity O O
and O O
activity O O
can O O
change O O
in O O
response O O
to O O
factors O O
that O O
bind O O
to O O
the O O
receptor O O
, O O
or O O
that O O
act O O
indirectly O O
through O O
ill-defined O O
mechanisms O O
which O O
may O O
include O O
resumption O O
or O O
arrest O O
of O O
cell O O
cycling O O
and O O
variations O O
in O O
intracellular O O
calcium O O
ion O O
concentrations O O
. O O

Some O O
of O O
these O O
factors O O
appear O O
to O O
exert O O
their O O
effect O O
by O O
controlling O O
critical O O
receptor O O
properties O O
such O O
as O O
ATP-dependent O O
phosphorylation O O
, O O
integrity O O
of O O
thiol B-protein O
groups I-protein O
, O O
and O O
exposure O O
of O O
key B-protein O
amino I-protein O
acid I-protein O
residues I-protein O
. O O

Glucocorticoid O O
agonists O O
promote O O
the O O
'transformation O O
' O O
of O O
the O O
receptor O O
into O O
the O O
DNA-binding O O
state O O
, O O
which O O
is O O
competent O O
for O O
modulating O O
gene O O
expression O O
. O O

Glucocorticoid O O
antagonists O O
are O O
steroids O O
that O O
interact O O
with O O
the O O
receptor O O
but O O
either O O
fail O O
to O O
produce O O
a O O
stable B-protein O
complex I-protein O
or O O
produce O O
a O O
stable B-protein O
but I-protein O
inefficient I-protein O
complex I-protein O
. O O

Although O O
substituent O O
groups O O
that O O
confer O O
agonist O O
or O O
antagonist O O
activity O O
to O O
the O O
steroid O O
have O O
been O O
identified O O
, O O
the O O
molecular O O
determinants O O
of O O
this O O
difference O O
at O O
the O O
receptor O O
level O O
remain O O
unknown O O
. O O

Most O O
in O O
vitro O O
and O O
in O O
vivo O O
data O O
on O O
receptor O O
regulation O O
can O O
be O O
accommodated O O
by O O
postulating O O
the O O
existence O O
of O O
an O O
intracellular O O
cycle O O
that O O
involves O O
five O O
states O O
of O O
the O O
receptor O O
. O O

The O O
active O O
free O O
receptor O O
is O O
phosphorylated O O
, O O
reduced O O
, O O
and O O
presumably O O
oligomeric O O
( O O
state O O
A O O
) O O
. O O

Following O O
binding O O
of O O
an O O
agonist O O
( O O
state O O
B O O
) O O
, O O
it O O
can O O
become O O
transformed O O
by O O
dissociation O O
into O O
its O O
subunits O O
and O O
dephosphorylation O O
( O O
state O O
C O O
) O O
. O O

The O O
transformed B-protein B-protein
receptor I-protein I-protein
then O O
interacts O O
with O O
chromatin B-DNA B-DNA
( O O
state O O
D O O
) O O
. O O

Dissociation O O
of O O
the O O
steroid O O
and O O
oxidation O O
of O O
receptor B-protein B-protein
thiol I-protein I-protein
group I-protein I-protein
( O O
s O O
) O O
lead O O
to O O
the O O
inactive O B-protein
receptor O I-protein
form O I-protein
( O O
state O O
E O O
) O O
. O O

Reduction O O
and O O
rephosphorylation O O
of O O
the O O
receptor O O
enable O O
it O O
to O O
bind O O
steroids O O
again O O
so O O
that O O
the O O
cycle O O
is O O
closed O O
. O O

Thermodynamics O O
of O O
steroid O O
binding O O
to O O
the O O
human B-protein B-protein
glucocorticoid I-protein I-protein
receptor I-protein I-protein
. O O

The O O
thermodynamics O O
of O O
the O O
interaction O O
of O O
glucocorticoids O O
with O O
their O O
receptor O O
were O O
studied O O
in O O
cytosol O O
from O O
human B-cell_type B-cell_type
lymphoblastoid I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
rate O O
and O O
affinity O O
constants O O
of O O
dexamethasone O O
and O O
cortisol O O
between O O
0 O O
degree O O
and O O
25 O O
degrees O O
C O O
were O O
calculated O O
by O O
curve-fitting O O
from O O
time-course O O
and O O
equilibrium O O
kinetics O O
. O O

The O O
data O O
were O O
consistent O O
with O O
a O O
simple O O
reversible O O
bimolecular O O
interaction O O
. O O

Arrhenius O O
and O O
Va O O
n't O O
Hoff O O
plots O O
were O O
curvilinear O O
for O O
both O O
steroids O O
. O O

At O O
equilibrium O O
, O O
the O O
solution O O
for O O
the O O
equation O O
delta O O
G O O
= O O
delta O O
H O O
- O O
T O O
X O O
delta O O
S O O
( O O
eqn. O O
1 O O
) O O
was O O
( O O
in O O
kJ O O
X O O
mol-1 O O
) O O
-47 O O
= O O
36 O O
- O O
83 O O
( O O
dexamethasone O O
) O O
and O O
-42 O O
= O O
-9 O O
- O O
33 O O
( O O
cortisol O O
) O O
at O O
0 O O
degree O O
C O O
. O O

Enthalpy O O
and O O
entropy O O
changes O O
decreased O O
quasi-linearly O O
with O O
temperature O O
such O O
that O O
, O O
at O O
25 O O
degrees O O
C O O
, O O
the O O
respective O O
values O O
were O O
-50 O O
= O O
-75 O O
+ O O
25 O O
and O O
-43 O O
= O O
-48 O O
+ O O
5 O O
. O O

Thus O O
, O O
for O O
both O O
steroids O O
, O O
the O O
interaction O O
was O O
entropy-driven O O
at O O
low O O
temperature O O
and O O
became O O
entirely O O
enthalpy-driven O O
at O O
20 O O
degrees O O
C O O
. O O

Thermodynamic O O
values O O
for O O
the O O
transition O O
state O O
were O O
calculated O O
from O O
the O O
rate O O
constants O O
. O O

For O O
the O O
forward O O
reaction O O
, O O
eqn. O O
( O O
1 O O
) O O
gave O O
45 O O
= O O
84 O O
- O O
39 O O
( O O
dexamethasone O O
) O O
and O O
46 O O
= O O
60 O O
- O O
14 O O
( O O
cortisol O O
) O O
at O O
0 O O
degree O O
C O O
, O O
and O O
44 O O
= O O
24 O O
+ O O
20 O O
( O O
dexamethasone O O
) O O
and O O
46 O O
= O O
28 O O
+ O O
18 O O
( O O
cortisol O O
) O O
at O O
25 O O
degrees O O
C O O
. O O

These O O
data O O
fit O O
quite O O
well O O
with O O
a O O
two-step O O
model O O
[ O O
Ross O O
& O O
Subramanian O O
( O O
1981 O O
) O O
Biochemistry O O
20 O O
, O O
3096-3102 O O
] O O
proposed O O
for O O
ligand-protein O O
interactions O O
, O O
which O O
involves O O
a O O
partial O O
immobilization O O
of O O
the O O
reacting O O
species O O
governed O O
by O O
hydrophobic O O
forces O O
, O O
followed O O
by O O
stabilization O O
of O O
the O O
complex O O
by O O
short-range O O
interactions O O
. O O

On O O
the O O
basis O O
of O O
this O O
model O O
, O O
an O O
analysis O O
of O O
the O O
transition-state O O
thermodynamics O O
led O O
to O O
the O O
conclusion O O
that O O
no O O
more O O
than O O
half O O
of O O
the O O
steroid O O
molecular O O
area O O
is O O
engaged O O
in O O
the O O
binding O O
process O O
. O O

Cell O O
cycle-related O O
changes O O
in O O
number O O
of O O
T-lymphocyte B-protein B-protein
receptors I-protein I-protein
for O O
glucocorticoids O O
and O O
insulin O O
. O O

Enriched O B-cell_type
human B-cell_type I-cell_type
peripheral I-cell_type I-cell_type
T-lymphocytes I-cell_type I-cell_type
were O O
stimulated O O
with O O
PHA O B-protein
and O O
examined O O
for O O
variations O O
in O O
insulin O O
and O O
glucocorticoid O O
( O O
dexamethasone O O
) O O
receptor O O
numbers O O
during O O
the O O
early O O
phases O O
of O O
the O O
cell O O
cycle O O
. O O

Cells O O
in O O
G0 O O
, O O
G1a O O
and O O
G1b O O
phases O O
, O O
where O O
the O O
G1a O O
- O O
G1b O O
transition O O
is O O
an O O
Interleukin B-protein B-protein
2 I-protein I-protein
dependent O O
event O O
, O O
were O O
quantitated O O
by O O
flow O O
cytometry O O
. O O

Few O O
but O O
significant O O
numbers O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
( O O
2700/cell O B-protein
) O O
and O O
no O O
insulin B-protein B-protein
receptors I-protein I-protein
( O O
-1/cell O B-protein
) O O
were O O
found O O
in O O
the O O
resting O O
( O O
G0 O O
) O O
phase O O
. O O

As O O
cells O O
entered O O
the O O
G1a O O
phase O O
the O O
specific O O
binding O O
of O O
dexamethasone O O
increased O O
and O O
of O O
insulin O O
took O O
place O O
. O O

Although O O
the O O
specific O O
binding O O
further O O
increased O O
as O O
T-cells B-cell_type B-cell_type
entered O O
the O O
G1b O O
phase O O
( O O
as O O
measured O O
at O O
44 O O
h O O
of O O
incubation O O
and O O
using O O
hydroxyurea-treated B-cell_line B-cell_type
cells I-cell_line I-cell_type
) O O
, O O
the O O
major O O
changes O O
in O O
the O O
specific O O
binding O O
of O O
dexamethasone O O
took O O
place O O
during O O
the O O
period O O
16 O O
- O O
20 O O
h O O
after O O
stimulation O O
. O O

Based O O
on O O
these O O
findings O O
, O O
it O O
is O O
concluded O O
that O O
both O O
receptor O O
types O O
( O O
cell B-protein O
membrane I-protein O
and I-protein O
cytoplasmic I-protein B-protein
receptors I-protein I-protein
) O O
are O O
being O O
formed O O
and O O
increased O O
at O O
G1 O O
phase O O
prior O O
to O O
cell O O
proliferation O O
, O O
indicating O O
the O O
importance O O
of O O
G1 O O
phase O O
in O O
immunoregulation O O
. O O

Glucocorticoid B-protein B-protein
receptors I-protein I-protein
and O O
cortico-sensitivity O O
in O O
a O O
human B-cell_line B-cell_line
clonal I-cell_line I-cell_line
monocytic I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
, O O
CM-SM B-cell_line B-cell_line
. O O

CM-SM B-cell_line B-cell_line
is O O
a O O
clonal B-cell_line O
line I-cell_line O
of O O
human B-cell_type B-cell_type
precursor I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
phagocytes I-cell_type I-cell_type
inducible O O
to O O
macrophage B-cell_type O
differentiation O O
in O O
response O O
to O O
the O O
tumor O B-DNA
promoter O I-DNA
phorbol O O
ester O O
12-O-tetradecanoyl-phorbol-13-acetate O O
( O O
TPA O O
) O O
. O O

Untreated O O
CM-SM O B-cell_line
cells O I-cell_line
contain O O
single O O
class O O
, O O
high-affinity O O
( O O
KD O O
= O O
4.0 O O
X O O
10 O O
( O O
-9 O O
) O O
M O O
) O O
glucocorticoid-specific O B-DNA
receptor O I-DNA
sites O I-DNA
( O O
approximately O O
60 O O
, O O
000 O O
per O O
cell O O
) O O
, O O
as O O
measured O O
by O O
a O O
whole O O
cell O O
assay O O
, O O
at O O
37 O O
degrees O O
C O O
, O O
using O O
[ O O
3H O O
] O O
triamcinolone O O
acetonide O O
( O O
TA O O
) O O
. O O

Exposure O O
of O O
CM-SM B-cell_line O
to O O
dexamethasone O O
( O O
DEX O O
) O O
produced O O
a O O
progressive O O
, O O
dose- O O
and O O
time-related O O
series O O
of O O
changes O O
in O O
CM-SM B-cell_line O
cell O O
growth O O
, O O
saturation O O
density O O
, O O
morphology O O
, O O
and O O
functional O O
properties O O
, O O
with O O
half-maximal O O
effects O O
at O O
about O O
10 O O
( O O
-9 O O
) O O
M O O
for O O
DEX O O
. O O

TA-receptor O B-protein
sites O I-protein
rapidly O O
decreased O O
( O O
about O O
70 O O
% O O
) O O
after O O
DEX O O
treatment O O
, O O
without O O
any O O
apparent O O
change O O
in O O
steroid O O
specificity O O
and O O
affinity O O
. O O

After O O
5 O O
days O O
in O O
culture O O
with O O
a O O
saturating O O
concentration O O
( O O
3.6 O O
X O O
10 O O
( O O
-8 O O
) O O
M O O
) O O
of O O
hormone O O
, O O
the O O
cells O O
reached O O
a O O
saturation O O
density O O
of O O
about O O
9.0 O O
X O O
10 O O
( O O
6 O O
) O O
viable O O
cells/ml O O
( O O
about O O
4.0 O O
X O O
10 O O
( O O
6 O O
) O O
viable O O
cells/ml O O
in O O
the O O
controls O O
) O O
, O O
while O O
the O O
modal O O
volume O O
of O O
the O O
resulting O O
cell B-cell_line O
population I-cell_line O
was O O
approximately O O
60 O O
% O O
, O O
as O O
compared O O
to O O
the O O
volume O O
of O O
untreated B-cell_line B-cell_type
cells I-cell_line I-cell_type
. O O

DEX-treated B-cell_line B-cell_line
cells I-cell_line I-cell_line
appeared O O
less O O
differentiated O O
than O O
controls O O
, O O
as O O
assessed O O
by O O
combined O O
morphologic O O
, O O
antigenic O O
, O O
and O O
cytoenzymatic O O
analyses O O
. O O

DEX O O
almost O O
completely O O
inhibited O O
TPA O O
activation O O
of O O
the O O
following O O
macrophage B-cell_type O
functions O O
: O O
adherency O O
to O O
the O O
culture O O
plate O O
, O O
expression O O
of O O
lysosomal B-protein B-protein
enzymes I-protein I-protein
, O O
Fc B-protein B-protein
and I-protein I-protein
C3 I-protein I-protein
receptors I-protein I-protein
, O O
and O O
stimulation O O
of O O
phagocytosis O O
. O O

After O O
removal O O
of O O
DEX O O
, O O
the O O
cells O O
, O O
within O O
a O O
few O O
passages O O
, O O
returned O O
to O O
a O O
state O O
apparently O O
identical O O
to O O
the O O
untreated O O
controls O O
and O O
could O O
be O O
induced O O
to O O
macrophage B-cell_type O
differentiation O O
in O O
response O O
to O O
TPA O O
. O O

Acute O O
lymphoblastic O O
leukemia O O
in O O
children O O
: O O
current O O
status O O
, O O
controversies O O
, O O
and O O
future O O
perspective O O
. O O

Disease-free O O
survival O O
( O O
DFS O O
) O O
in O O
childhood O O
ALL O O
is O O
60 O O
% O O
, O O
and O O
survival O O
in O O
good O O
, O O
average O O
, O O
and O O
poor O O
prognostic O O
groups O O
defined O O
by O O
initial O O
WBC O B-cell_type
and O O
age O O
is O O
90 O O
, O O
60 O O
, O O
and O O
45 O O
% O O
, O O
respectively O O
. O O

Additional O O
immunological O O
, O O
morphological O O
, O O
biochemical O O
, O O
cytokinetic O O
, O O
and O O
cytogenetic O O
factors O O
have O O
been O O
identified O O
, O O
illustrating O O
the O O
heterogeneity O O
of O O
ALL O O
and O O
its O O
derivation O O
from O O
malignant B-cell_line B-cell_line
clones I-cell_line I-cell_line
at O O
various O O
stages O O
of O O
differentiation O O
and O O
with O O
varying O O
rates O O
of O O
proliferation O O
. O O

Of O O
biologic O O
importance O O
, O O
these O O
factors O O
may O O
refine O O
further O O
the O O
characteristic O O
features O O
of O O
clinically-determined O O
prognostic O O
groups O O
. O O

Multivariate O O
analysis O O
of O O
large O O
prospective O O
trials O O
with O O
homogeneous O O
therapy O O
will O O
be O O
required O O
to O O
determine O O
the O O
independent O O
prognostic O O
importance O O
of O O
these O O
factors O O
. O O

Current O O
treatment O O
strategies O O
in O O
ALL O O
include O O
( O O
1 O O
) O O
tailoring O O
therapy O O
and O O
its O O
intensity O O
to O O
prognostic O O
groups O O
; O O
( O O
2 O O
) O O
multiple-drug O O
combinations O O
in O O
induction O O
; O O
( O O
3 O O
) O O
early O O
use O O
of O O
intrathecal O O
( O O
IT O O
) O O
methotrexate O O
( O O
MTX O O
) O O
; O O
( O O
4 O O
) O O
CNS O O
prophylaxis O O
with O O
IT O O
MTX O O
alone O O
in O O
good O O
prognosis O O
patients O O
and O O
combined O O
cranial O O
radiation O O
( O O
CXRT O O
) O O
, O O
1800 O O
rads O O
plus O O
IT O O
MTX O O
, O O
in O O
average O O
and O O
poor O O
prognosis O O
patients O O
. O O

Current O O
studies O O
show O O
a O O
CNS O O
relapse O O
rate O O
of O O
5 O O
% O O
in O O
all O O
prognostic O O
groups O O
. O O

Late O O
neuropsychological O O
defects O O
caused O O
by O O
cranial O O
XRT O O
and O O
IT O O
MTX O O
have O O
prompted O O
programs O O
designed O O
to O O
reduce O O
the O O
potential O O
late O O
toxicity O O
of O O
CNS O O
prophylaxis O O
. O O

More O O
pronounced O O
in O O
younger O O
children O O
, O O
these O O
abnormalities O O
include O O
decreased O O
IQ O O
, O O
visual-motor O O
incoordination O O
, O O
poor O O
performance O O
in O O
mathematics O O
, O O
and O O
memory O O
dysfunction O O
. O O

Until O O
1980 O O
, O O
more O O
intensive O O
induction O O
, O O
consolidation O O
, O O
and O O
maintenance O O
therapy O O
had O O
failed O O
to O O
prolong O O
DFS O O
in O O
children O O
with O O
a O O
poor O O
prognosis O O
. O O

In O O
West O O
Germany O O
( O O
Berlin-Frankfurt-Muenster O O
protocol O O
) O O
a O O
70 O O
to O O
75 O O
% O O
DFS O O
is O O
seen O O
in O O
all O O
patients O O
regardless O O
of O O
initial O O
WBC O B-cell_type
, O O
suggesting O O
that O O
effective O O
therapy O O
will O O
override O O
prognostic O O
factors O O
. O O

Ultra-high-dose O O
MTX O O
, O O
without O O
cranial O O
radiation O O
, O O
is O O
also O O
showing O O
promise O O
in O O
poor O O
prognosis O O
patients O O
. O O

Other O O
issues O O
include O O
the O O
optimal O O
duration O O
of O O
therapy O O
, O O
the O O
role O O
of O O
testicular O O
biopsies O O
, O O
and O O
prophylactic O O
testicular O O
radiation O O
. O O

Recent O O
studies O O
suggest O O
that O O
prognostic O O
factors O O
lose O O
their O O
significance O O
after O O
2 O O
years O O
of O O
continuous O O
complete O O
remission O O
and O O
that O O
2 O O
years O O
of O O
maintenance O O
therapy O O
is O O
adequate O O
. O O

Bilateral O O
open-wedge O O
testicular O O
biopsies O O
have O O
identified O O
occult O O
testicular O O
disease O O
in O O
8 O O
to O O
10 O O
% O O
of O O
males O O
. O O

A O O
unified O O
approach O O
to O O
children O O
with O O
leukemia/lymphoma O O
, O O
a O O
group O O
with O O
a O O
particularly O O
poor O O
prognosis O O
, O O
utilizing O O
NHL-type O O
therapy O O
may O O
be O O
more O O
effective O O
than O O
conventional O O
ALL O O
therapy O O
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

Glucocorticoid B-protein B-protein
receptor I-protein I-protein
and O O
in O O
vitro O O
sensitivity O O
to O O
steroid O O
hormones O O
in O O
human O O
lymphoproliferative O O
diseases O O
and O O
myeloid O O
leukemia O O
. O O

The O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
( O O
GR B-protein B-protein
) O O
quantitation O O
by O O
a O O
whole-cell O O
assay O O
and/or O O
cytosol O O
technique O O
and O O
the O O
in O O
vitro O O
sensitivity O O
to O O
steroids O O
have O O
been O O
assessed O O
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
normal O O
donors O O
and O O
patients O O
with O O
chronic O O
lymphatic O O
leukemia O O
( O O
CLL O O
) O O
, O O
acute O O
lymphoblastic O O
leukemia O O
( O O
ALL O O
) O O
, O O
lymphosarcoma O O
cell O O
leukemia O O
( O O
LSCL O O
) O O
, O O
acute O O
nonlymphatic O O
leukemia O O
( O O
ANLL O O
) O O
, O O
and O O
chronic O O
myeloid O O
leukemia O O
( O O
CML O O
) O O
. O O

Within O O
the O O
lymphoproliferative O O
diseases O O
, O O
ALL B-cell_line B-cell_type
cells I-cell_line I-cell_type
exhibited O O
the O O
highest O O
GR B-protein B-protein
concentration O O
( O O
regardless O O
of O O
the O O
method O O
used O O
) O O
and O O
the O O
highest O O
in O O
vitro O O
inhibition O O
of O O
spontaneous O O
[ O O
3H O O
] O O
thymidine O O
( O O
[ O O
3H O O
] O O
TdR O O
) O O
uptake O O
by O O
glucocorticoids O O
. O O

A O O
significant O O
relationship O O
between O O
GR B-protein B-protein
concentration O O
( O O
whole-cell O O
assay O O
) O O
and O O
in O O
vitro O O
sensitivity O O
to O O
dexamethasone O O
was O O
also O O
found O O
. O O

On O O
the O O
contrary O O
, O O
CLL B-cell_line B-cell_type
cells I-cell_line I-cell_type
presented O O
the O O
highest O O
sensitivity O O
to O O
glucocorticoids O O
in O O
PHA-stimulated B-cell_line B-cell_line
cell I-cell_line I-cell_line
cultures I-cell_line I-cell_line
. O O

Cells O O
from O O
the O O
only O O
two O O
ALL O O
patients O O
who O O
did O O
not O O
undergo O O
a O O
remission O O
after O O
glucocorticoid-inclusive O O
chemotherapy O O
had O O
both O O
the O O
lowest O O
in O O
vitro O O
sensitivity O O
to O O
dexamethasone O O
and O O
the O O
lowest O O
GR O B-protein
concentration O O
with O O
whole-cell O O
assay O O
. O O

Concerning O O
myeloid O O
leukemia O O
, O O
ANLL O O
patients O O
had O O
GR B-protein B-protein
concentrations O O
slightly O O
higher O O
than O O
those O O
found O O
in O O
the O O
ALL O O
group O O
but O O
exhibited O O
the O O
lowest O O
degree O O
of O O
inhibition O O
of O O
spontaneous O O
[ O O
3H O O
] O O
TdR O O
uptake O O
by O O
dexamethasone O O
( O O
stimulatory O O
effects O O
occurred O O
in O O
some O O
cases O O
) O O
. O O

CML B-cell_line B-cell_type
cells I-cell_line I-cell_type
exhibited O O
an O O
inhibition O O
degree O O
by O O
in O O
vitro O O
glucocorticoids O O
significantly O O
higher O O
than O O
that O O
of O O
ANLL B-cell_line B-cell_type
cells I-cell_line I-cell_type
but O O
not O O
different O O
from O O
that O O
of O O
lymphoproliferative O O
diseases O O
. O O

No O O
clear O O
relationship O O
among O O
GR O B-protein
pattern O O
, O O
in O O
vitro O O
cell O O
sensitivity O O
to O O
glucocorticoids O O
, O O
and O O
clinicohematologic O O
parameters O O
was O O
observed O O
in O O
myeloid O O
leukemia-bearing O O
patients O O
. O O

Glucocorticoid B-protein B-protein
receptors I-protein I-protein
and O O
in O O
vitro O O
corticosensitivity O O
of O O
peanut-positive B-cell_line B-cell_line
and I-cell_line I-cell_line
peanut-negative I-cell_line I-cell_line
human I-cell_line I-cell_line
thymocyte I-cell_line I-cell_line
subpopulations I-cell_line I-cell_line
. O O

In O O
6 O O
human O O
thymus O O
glands O O
, O O
the O O
immature O O
subset O O
of O O
thymocytes B-cell_type B-cell_type
was O O
separated O O
from O O
the O O
more O O
mature O O
one O O
, O O
by O O
differential O O
peanut O O
lectin O B-protein
agglutination O O
. O O

These O O
2 O O
cell O O
subpopulations O O
were O O
analyzed O O
for O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
content O O
by O O
using O O
a O O
whole O O
cell O O
assay O O
, O O
with O O
( O O
3H O O
) O O
-triamcinolone O O
acetonide O O
as O O
tracer O O
. O O

The O O
unagglutinated B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
( O O
peanut O O
negative O O
) O O
contained O O
about O O
2 O O
times O O
more O O
receptor O B-protein
sites O I-cell_line
per O I-cell_line
cell O I-cell_line
than O O
agglutinated O O
( O O
peanut O O
positive O O
) O O
ones O O
( O O
7650 O O
+/- O O
1550 O O
S.D. O O
verus O O
3195 O O
+/- O O
896 O O
S.D. O O
) O O
. O O

The O O
affinity O O
for O O
steroid O O
was O O
similar O O
in O O
both O O
cell O O
subsets O O
, O O
as O O
was O O
the O O
stereospecificity O O
for O O
glucocorticoids O O
, O O
the O O
time-course O O
of O O
steroid-receptor O O
association O O
, O O
and O O
cytoplasmic O O
to O O
nuclear O O
translocation O O
. O O

Despite O O
the O O
greater O O
number O O
of O O
glucocorticoid B-protein B-DNA
receptor I-protein I-DNA
sites O I-DNA
, O O
the O O
peanut-negative B-cell_line B-cell_type
thymocyte I-cell_line I-cell_type
subpopulation I-cell_line I-cell_type
did O O
not O O
differ O O
from O O
the O O
peanut-positive B-cell_line O
one O O
in O O
its O O
sensitivity O O
to O O
the O O
inhibitory O O
effects O O
of O O
triamcinolone O O
acetonide O O
, O O
as O O
determined O O
by O O
measurements O O
of O O
the O O
incorporation O O
of O O
radiolabeled O O
precursors O O
of O O
protein O O
and O O
DNA O O
. O O

Moreover O O
, O O
the O O
peanut-negative B-cell_line O
subset I-cell_line O
appeared O O
more O O
resistant O O
in O O
vitro O O
to O O
the O O
steroid-induced O B-cell_type
cell O I-cell_type
lysis O I-cell_type
as O O
compared O O
to O O
the O O
peanut-positive B-cell_line O
one O O
. O O

Thus O O
, O O
our O O
data O O
suggest O O
that O O
glucocorticoid O B-protein
receptor O I-protein
density O O
and O O
corticosensitivity O O
are O O
not O O
directly O O
correlated O O
and O O
that O O
the O O
number O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
sites O I-protein
may O O
be O O
dependent O O
on O O
the O O
degree O O
of O O
immunologic O O
maturation O O

Defective O O
binding O O
and O O
function O O
of O O
1 B-protein O
, I-protein O
25-dihydroxyvitamin I-protein O
D3 I-protein O
receptors I-protein O
in O O
peripheral B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
of O O
patients O O
with O O
end-organ O O
resistance O O
to O O
1 O O
, O O
25-dihydroxyvitamin O O
D O O
. O O

Lectin-induced O O
DNA O O
synthesis O O
by O O
peripheral B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
17 O O
normal O O
donors O O
was O O
inhibited O O
( O O
40-60 O O
% O O
) O O
by O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
( O O
1 O O
, O O
25 O O
[ O O
OH O O
] O O
2D3 O O
) O O
at O O
physiological O O
concentrations O O
( O O
10 O O
( O O
-10 O O
) O O
-10 O O
( O O
-9 O O
) O O
M O O
) O O
. O O

The O O
lymphocytes B-cell_type B-cell_type
acquire O O
specific O O
receptors O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
upon O O
activation O O
by O O
the O O
lectins B-protein B-protein
. O O

This O O
process O O
precedes O O
the O O
inhibitory O O
effect O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
. O O

We O O
studied O O
lymphocytes B-cell_type B-cell_type
from O O
six O O
patients O O
from O O
four O O
different O O
kindreds O O
with O O
the O O
syndrome O O
of O O
hereditary O O
end-organ O O
resistance O O
to O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D O O
( O O
the O O
so-called O O
vitamin O O
D-dependent O O
rickets O O
type O O
II O O
) O O
. O O

In O O
five O O
patients O O
( O O
three O O
kindreds O O
) O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
did O O
not O O
acquire O O
receptors O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
upon O O
phytohemagglutinin-induced O O
activation O O
. O O

Moreover O O
, O O
in O O
contrast O O
to O O
normal B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
, O O
the O O
mitogenic O O
stimulation O O
of O O
these O O
patients O O
' O O
lymphocytes B-cell_type B-cell_type
by O O
phytohemagglutinin B-protein B-protein
and O O
concanavalin O O
A O O
was O O
not O O
inhibited O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
. O O

Activated O B-cell_type
lymphocytes B-cell_type I-cell_type
of O O
the O O
sixth O O
patient O O
from O O
a O O
fourth O O
kindred O O
exhibited O O
normal O O
binding O O
of O O
[ O O
3H O O
] O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
but O O
the O O
hormone O O
failed O O
to O O
inhibit O O
the O O
mitogenic O O
stimulation O O
. O O

A O O
similar O O
pattern O O
of O O
the O O
vitamin O O
D O O
effector O O
system O O
was O O
previously O O
observed O O
in O O
fibroblasts O B-cell_type
cultured O O
from O O
skin O O
biopsies O O
of O O
the O O
same O O
group O O
of O O
patients O O
. O O

The O O
conclusions O O
from O O
these O O
findings O O
are O O
: O O
( O O
a O O
) O O
the O O
inhibition O O
of O O
mitogenic O O
stimulation O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
is O O
mediated O O
by O O
specific B-protein O
functional I-protein B-protein
receptors I-protein I-protein
to O O
the O O
hormone O O
; O O
and O O
( O O
b O O
) O O
the O O
receptors O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
in O O
mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
are O O
probably O O
controlled O O
genetically O O
by O O
the O O
same O O
mechanisms O O
as O O
the O O
effector O O
system O O
in O O
well-characterized O O
target O O
organs O O
of O O
the O O
hormone O O
, O O
such O O
as O O
intestine O O
and O O
kidney O O
. O O

Glucocorticoid B-protein B-protein
receptors I-protein I-protein
of O O
mononuclear B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
from O O
myasthenia O O
gravis O O
patients O O
. O O

The O O
present O O
study O O
was O O
performed O O
to O O
analyse O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
( O O
GR B-protein B-protein
) O O
binding O O
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
( O O
MNL B-cell_type B-cell_type
) O O
from O O
39 O O
myasthenia O O
gravis O O
( O O
MG O O
) O O
patients O O
( O O
unoperated O O
patients O O
( O O
n O O
= O O
13 O O
) O O
, O O
thymectomized O O
patients O O
( O O
n O O
= O O
14 O O
) O O
and O O
patients O O
receiving O O
glucocorticoids O O
: O O
thymectomized O O
( O O
n O O
= O O
11 O O
) O O
and O O
unoperated O O
( O O
n O O
= O O
6 O O
] O O
. O O

A O O
whole O O
cell O O
binding O O
assay O O
with O O
3 O O
( O O
H O O
) O O
dexamethasone O O
was O O
used O O
. O O

GR B-protein B-protein
mean O O
values O O
were O O
significantly O O
higher O O
in O O
the O O
MNL B-cell_type B-cell_type
of O O
MG O O
patients O O
( O O
thymectomized O O
or O O
not O O
) O O
not O O
receiving O O
glucocorticoid O O
than O O
in O O
the O O
MNL B-cell_type B-cell_type
of O O
healthy O O
donors O O
. O O

Affinity O O
was O O
within O O
the O O
normal O O
range O O
. O O

Sex O O
, O O
age O O
or O O
clinical O O
forms O O
of O O
illness O O
did O O
not O O
influence O O
the O O
results O O
. O O

In O O
patients O O
receiving O O
prednisone O O
( O O
Pd O O
) O O
the O O
GR B-protein B-protein
values O O
were O O
significantly O O
lower O O
than O O
in O O
MG O O
patients O O
without O O
Pd O O
therapy O O
, O O
independent O O
of O O
Pd O O
dose O O
or O O
time O O
of O O
administration O O
. O O

No O O
differences O O
in O O
receptor O O
binding O O
between O O
normal O O
subjects O O
and O O
MG O O
patients O O
receiving O O
Pd O O
have O O
been O O
found O O
. O O

Immunological O O
interference O O
of O O
high O O
dose O O
corticosteroids O O
. O O

High-dose O O
corticosteroids O O
( O O
HDC O O
) O O
will O O
influence O O
cellular O O
as O O
well O O
as O O
humoral O O
participants O O
of O O
the O O
immune O O
response O O
. O O

The O O
lymphoid O O
tissue O O
will O O
decrease O O
in O O
size O O
and O O
weight O O
after O O
prolonged O O
treatment O O
with O O
HDC O O
. O O

Lymphocyte O O
functions O O
will O O
be O O
impaired O O
. O O

Reduced O O
synthesis O O
of O O
B- B-cell_type O
as I-cell_type O
well I-cell_type O
as I-cell_type O
T-lymphocytes I-cell_type B-cell_type
will O O
be O O
seen O O
. O O

The O O
inhibitory O O
effect O O
on O O
B-cell B-cell_type O
function O O
can O O
be O O
observed O O
both O O
as O O
decreased O O
serum O O
levels O O
of O O
immunoglobulins B-protein B-protein
and O O
as O O
impaired O O
binding O O
of O O
antibodies B-protein B-protein
and O O
complement O O
to O O
the O O
cellular O O
surface O O
. O O

Reduced O O
T-cell B-cell_type O
function O O
indicated O O
by O O
impaired O O
stimulation O O
by O O
PHA B-protein B-protein
and O O
porkweed B-protein O
as O O
well O O
as O O
by O O
impaired O O
lymphokinin O O
effects O O
on O O
leukocyte B-cell_type O
migration O O
inhibition O O
has O O
been O O
reported O O
. O O

Reduced O O
lymphocyte O O
adherence O O
to O O
antigen O O
and O O
suppressed O O
lymphocyte O O
reaction O O
have O O
also O O
been O O
observed O O
. O O

Humoral O B-protein
factors O I-protein
involved O O
in O O
chemotaxis O O
, O O
opsonisation O O
, O O
phagocytosis O O
, O O
vascular O O
permeability O O
leading O O
to O O
leakage O O
of O O
fluid O O
and O O
cells O O
and O O
factors O O
involved O O
in O O
lysis O O
of O O
antigens O O
are O O
impaired O O
. O O

This O O
can O O
be O O
explained O O
partly O O
by O O
the O O
observed O O
reduced O O
complement O O
activation O O
via O O
the O O
alternative O O
as O O
well O O
as O O
the O O
classical O O
pathway O O
in O O
association O O
with O O
HDC O O
therapy O O
. O O

Acute O O
processes O O
with O O
increased O O
vascular O O
permeability O O
and O O
accumulation O O
of O O
leukocytes B-cell_type B-cell_type
as O O
impairing O O
factors O O
could O O
be O O
influenced O O
beneficially O O
by O O
HDC O O
therapy O O
. O O

This O O
positive O O
effect O O
can O O
be O O
seen O O
in O O
treatment O O
of O O
septic O O
shock O O
or O O
rejection O O
of O O
a O O
transplant O O
. O O

However O O
, O O
if O O
sepsis O O
or O O
rejection O O
is O O
not O O
rapidly O O
reversed O O
, O O
complications O O
such O O
as O O
multisystem O O
organ O O
failure O O
and O O
bacteremia O O
are O O
prone O O
to O O
appear O O
. O O

Identification O O
of O O
human B-protein B-protein
leukemic I-protein I-protein
glucocorticoid I-protein I-protein
receptors I-protein I-protein
using O O
affinity O O
labeling O O
and O O
anti-human B-protein B-protein
glucocorticoid I-protein I-protein
receptor I-protein I-protein
antibodies I-protein I-protein
. O O

Antisera O O
raised O O
against O O
human B-protein B-protein
lymphoid I-protein I-protein
glucocorticoid I-protein I-protein
receptors I-protein I-protein
were O O
used O O
in O O
combination O O
with O O
the O O
glucocorticoid O B-protein
receptor O I-protein
affinity O O
label O O
[ O O
3H O O
] O O
dexamethasone O O
21-mesylate O O
[ O O
( O O
3H O O
] O O
DM O O
) O O
to O O
identify O O
the O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
of O O
the O O
human B-cell_line B-cell_line
B-lymphoblastoid I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
IM-9 B-cell_line I-cell_line
and O O
the O O
human B-cell_line B-cell_line
T-cell I-cell_line I-cell_line
leukemic I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
CEM-C7 B-cell_line I-cell_line
. O O

Antisera O O
were O O
obtained O O
following O O
immunization O O
of O O
New O O
Zealand O O
White O O
rabbits O O
with O O
[ B-protein O
3H I-protein O
] I-protein O
triamcinolone I-protein O
acetonide I-protein O
[ I-protein O
( I-protein O
3H I-protein O
] I-protein O
TA I-protein O
) I-protein O
-glucocorticoid I-protein B-protein
receptor I-protein I-protein
complexes I-protein I-protein
partially O O
purified O O
by O O
two-stage O O
DNA-cellulose O O
chromatography O O
. O O

The O O
presence O O
of O O
anti-human B-protein B-protein
glucocorticoid I-protein I-protein
receptor I-protein I-protein
antibodies I-protein I-protein
was O O
verified O O
by O O
: O O
( O O
a O O
) O O
adsorption O O
of O O
[ B-protein O
3H I-protein O
] I-protein O
TA-receptor-antibody I-protein B-protein
complexes I-protein I-protein
to O O
Protein B-protein O
A I-protein O
; O O
( O O
b O O
) O O
a O O
shift O O
to O O
higher O O
apparent O O
molecular O O
weight O O
in O O
the O O
elution O O
position O O
from O O
Sephacryl O O
S300 O O
of O O
[ B-protein O
3H I-protein O
] I-protein O
TA-receptor I-protein B-protein
complexes I-protein I-protein
incubated O O
with O O
immune O O
serum O O
; O O
and O O
( O O
c O O
) O O
the O O
ability O O
of O O
immune O O
serum O O
to O O
displace O O
[ B-protein O
3H I-protein O
] I-protein O
TA-receptor I-protein B-protein
complexes I-protein I-protein
on O O
sucrose O O
gradients O O
. O O

These O O
antibodies B-protein B-protein
also O O
recognized O O
rat O B-protein
liver O I-protein
and O I-protein
murine B-protein I-protein
S49 I-protein I-protein
cell I-protein I-protein
glucocorticoid I-protein I-protein
receptors I-protein I-protein
. O O

Sodium O O
dodecyl O O
sulfate-polyacrylamide O O
gel O O
electrophoresis O O
of O O
[ O O
3H O O
] O O
DM-labeled O O
IM-9 O O
cytosol O O
identified O O
a O O
major O O
competable O O
band O O
with O O
a O O
molecular O O
weight O O
of O O
approximately O O
90 O O
, O O
000 O O
, O O
three O O
minor O O
competable O O
components O O
with O O
molecular O O
weights O O
of O O
approximately O O
78 O O
, O O
000 O O
, O O
approximately O O
51 O O
, O O
000 O O
, O O
and O O
approximately O O
38 O O
, O O
500 O O
, O O
and O O
at O O
least O O
21 O O
other O O
noncompetable O O
components O O
. O O

Following O O
immunoprecipitation O O
of O O
[ O O
3H O O
] O O
DM-labeled O O
cytosol O O
with O O
immune O O
serum O O
, O O
only O O
the O O
Mr O O
90 O O
, O O
000 O O
and O O
78 O O
, O O
000 O O
components O O
were O O
seen O O
. O O

Sodium O O
dodecyl O O
sulfate-polyacrylamide O O
gel O O
electrophoresis O O
of O O
[ O O
3H O O
] O O
DM-labeled O O
CEM-C7 O O
cytosol O O
revealed O O
a O O
larger O O
number O O
of O O
[ O O
3H O O
] O O
DM-labeled O O
components O O
. O O

However O O
, O O
after O O
immunoprecipitation O O
of O O
[ O O
3H O O
] O O
DM-labeled O O
CEM-C7 O O
cytosol O O
, O O
a O O
predominant O O
competable O O
component O O
with O O
a O O
molecular O O
weight O O
of O O
90 O O
, O O
000 O O
was O O
easily O O
identified O O
. O O

This O O
component O O
was O O
markedly O O
diminished O O
when O O
cytosols O O
from O O
the O O
glucocorticoid B-cell_line B-cell_line
receptor-deficient I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
ICR-27 B-cell_line I-cell_line
were O O
used O O
. O O

Thus O O
, O O
the O O
combination O O
of O O
affinity O O
labeling O O
and O O
anti-human B-protein O
glucocorticoid I-protein B-protein
receptor I-protein I-protein
antibodies I-protein I-protein
is O O
capable O O
of O O
providing O O
direct O O
physical O O
identification O O
of O O
human B-protein B-protein
lymphoid I-protein I-protein
glucocorticoid I-protein I-protein
receptors I-protein I-protein
. O O

Effect O O
of O O
thymosin O O
on O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
activity O O
and O O
glucocorticoid O O
sensitivity O O
of O O
human B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
. O O

Incubation O O
with O O
thymosin O O
fraction O O
5 O O
, O O
( O O
TMS O O
F5 O O
at O O
300 O O
micrograms/ml O O
) O O
a O O
partially O O
purified O O
thymic O B-protein
factor O I-protein
, O O
reduced O O
the O O
steroid O O
binding O O
activity O O
of O O
human B-cell_type B-cell_type
infant I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
from O O
9.6 O O
+/- O O
2.1 O O
fmole/ml O O
to O O
5.0 O O
+/- O O
2.0 O O
fmole/ml O O
. O O

The O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
activity O O
in O O
normal O B-cell_type
infant O I-cell_type
thymocytes O I-cell_type
was O O
found O O
to O O
be O O
2 O O
, O O
146 O O
+/- O O
726 O O
( O O
s.d. O O
) O O
sites O O
per O O
cell O O
with O O
dissociation O O
constant O O
of O O
1.4 O O
+/- O O
0.6 O O
X O O
10 O O
( O O
-8 O O
) O O
M O O
. O O

TMS O O
F5 O O
also O O
increased O O
the O O
resistance O O
of O O
human O B-cell_type
thymocytes O I-cell_type
to O O
the O O
cytolytic O O
effect O O
of O O
dexamethasone O O
( O O
2.5 O O
X O O
10 O O
( O O
-8 O O
) O O
M O O
) O O
to O O
168.6 O O
+/- O O
30.2 O O
% O O
of O O
control O O
( O O
P O O
less O O
than O O
0.01 O O
) O O
. O O

In O O
animals O O
, O O
medullary B-cell_type B-cell_type
and I-cell_type I-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
are O O
more O O
resistant O O
to O O
glucocorticoids O O
than O O
immature B-cell_type B-cell_type
thymic I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
results O O
show O O
that O O
thymosin O O
can O O
induce O O
changes O O
consistent O O
with O O
differentiation O O
in O O
human B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
. O O

These O O
in O O
vitro O O
results O O
are O O
consistent O O
with O O
a O O
physiological O O
role O O
of O O
thymosin O O
in O O
intrathymic O O
T O O
cell O O
maturation O O
in O O
man O O
. O O

Incubation O O
of O O
a O O
human B-cell_line B-cell_line
malignant I-cell_line I-cell_line
thymus I-cell_line I-cell_line
derived I-cell_line I-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
( O O
MOLT B-cell_line B-cell_line
3 I-cell_line I-cell_line
) O O
with O O
TMS O O
F5 O O
also O O
resulted O O
in O O
a O O
significant O O
reduction O O
of O O
the O O
number O O
of O O
steroid O B-DNA
binding O I-DNA
sites O I-DNA
to O O
44.2 O O
+/- O O
15.3 O O
% O O
of O O
control O O
( O O
P O O
less O O
than O O
0.05 O O
) O O
, O O
but O O
TMS O O
F5 O O
did O O
not O O
significantly O O
reduce O O
the O O
glucocorticoid O O
sensitivity O O
of O O
MOLT B-cell_line B-cell_line
3 I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Specific B-protein O
high-affinity I-protein O
receptors I-protein O
for O O
1 O O
, O O
25-dihydroxyvitamin O O
D3 O O
in O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
: O O
presence O O
in O O
monocytes B-cell_type B-cell_type
and O O
induction O O
in O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
following O O
activation O O
. O O

Human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
have O O
high O O
affinity O O
binding O B-DNA
sites O I-DNA
for O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
( O O
Kd O O
0.14 O O
nM O O
, O O
sedimentation O O
coefficient O O
3.7S O O
) O O
. O O

Resting B-cell_type B-cell_type
human I-cell_type I-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
, O O
however O O
, O O
do O O
not O O
have O O
a O O
demonstrable O O
1 B-protein O
, I-protein O
25- I-protein O
( I-protein O
OH I-protein O
) I-protein O
2D3 I-protein O
receptor I-protein O
. O O

After O O
activation O O
with O O
phytohemagglutinin B-protein B-protein
the O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
exhibit O O
the O O
receptor O O
within O O
24 O O
h O O
, O O
and O O
this O O
expression O O
is O O
blocked O O
by O O
cycloheximide O O
. O O

The O O
receptor O O
in O O
activated B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
has O O
a O O
sedimentation O O
coefficient O O
of O O
3.7S O O
and O O
a O O
high O O
affinity O O
( O O
Kd O O
0.10 O O
nM O O
) O O
for O O
the O O
ligand O O
. O O

Effects O O
of O O
chronic O O
glucocorticoid O O
excess O O
in O O
man O O
on O O
insulin O O
binding O O
to O O
circulating B-cell_type B-cell_type
cells I-cell_type I-cell_type
: O O
differences O O
between O O
endogenous O O
and O O
exogenous O O
hypercorticism O O
. O O

We O O
measured O O
[ O O
125I O O
] O O
insulin O O
binding O O
to O O
circulating B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
or I-cell_type O
erythrocytes I-cell_type B-cell_type
from O O
16 O O
patients O O
with O O
chronic O O
glucocorticoid O O
excess O O
, O O
9 O O
chronically O O
treated O O
with O O
prednisone O O
and O O
7 O O
with O O
adrenocortical O O
hyperfunction O O
. O O

With O O
monocytes B-cell_type B-cell_type
, O O
[ O O
125I O O
] O O
insulin O O
binding O O
was O O
iincreased O O
in O O
all O O
patients O O
. O O

Analysis O O
of O O
binding O O
data O O
indicated O O
that O O
increased O O
binding O O
in O O
patients O O
treated O O
with O O
prednisone O O
was O O
due O O
to O O
an O O
ncrease O O
in O O
receptor O O
concentration O O
, O O
whereas O O
in O O
patients O O
with O O
adrenocortical O O
hyperfunction O O
, O O
it O O
was O O
due O O
to O O
an O O
increase O O
in O O
receptor O O
affinity O O
. O O

With O O
erythrocytes O B-cell_type
from O O
patients O O
with O O
adrenocortical O O
hyperfunction O O
there O O
was O O
an O O
increase O O
in O O
receptor O O
affinity O O
and O O
a O O
decrease O O
in O O
receptor O O
concentration O O
, O O
so O O
that O O
the O O
binding O O
of O O
[ O O
125I O O
] O O
insulin O O
was O O
normal O O
. O O

The O O
disparity O O
of O O
results O O
between O O
endogenous O O
and O O
exogenous O O
hypercorticism O O
, O O
between O O
the O O
two O O
cell O O
types O O
, O O
and O O
between O O
the O O
present O O
studies O O
and O O
previous O O
studies O O
suggest O O
that O O
the O O
effects O O
of O O
glucocorticoid O O
excess O O
on O O
the O O
insulin B-protein B-protein
receptor I-protein I-protein
are O O
extremely O O
complex O O
and O O
wide-ranging O O
and O O
that O O
in O O
this O O
condition O O
, O O
extrapolations O O
in O O
humans O O
from O O
data O O
with O O
circulating B-cell_type B-cell_type
cells I-cell_type I-cell_type
to O O
liver O O
and O O
muscle O O
may O O
not O O
be O O
appropriate O O
. O O

Reduced O O
level O O
of O O
cellular B-protein B-protein
glucocorticoid I-protein I-protein
receptors I-protein I-protein
in O O
patients O O
with O O
anorexia O O
nervosa O O
. O O

Specific O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
were O O
measured O O
in O O
circulating O B-cell_type
mononuclear B-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
from O O
12 O O
patients O O
with O O
anorexia O O
nervosa O O
and O O
21 O O
healthy O O
control O O
subjects O O
. O O

Cells O O
from O O
patients O O
were O O
found O O
to O O
contain O O
a O O
significantly O O
( O O
p O O
less O O
than O O
0.01 O O
) O O
lower O O
level O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
( O O
3830 O O
+/- O O
210 O O
sites/cell O O
, O O
mean O O
+/- O O
SE O O
) O O
than O O
those O O
from O O
controls O O
( O O
4930 O O
+/- O O
250 O O
sites/cell O O
) O O
. O O

A O O
partial O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
defect O O
may O O
well O O
explain O O
the O O
abnormal O O
cortisol O O
metabolism O O
and O O
glucocorticoid O O
resistance O O
commonly O O
found O O
in O O
patients O O
with O O
anorexia O O
nervosa O O
. O O

Regulation O O
of O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
in O O
human B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

The O O
presence O O
of O O
a O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
in O O
human B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
is O O
well O O
established O O
, O O
but O O
factors O O
affecting O O
its O O
regulation O O
have O O
not O O
been O O
described O O
. O O

Using O O
a O O
competitive O O
binding O O
whole O O
cell O O
assay O O
, O O
we O O
have O O
examined O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
-dexamethasone O O
at O O
24 O O
and O O
37 O O
degrees O O
C O O
in O O
untreated O O
normal O O
subjects O O
and O O
in O O
healthy O O
subjects O O
taking O O
various O O
glucocorticoid O O
preparations O O
. O O

At O O
24 O O
degrees O O
C O B-cell_type
normal B-cell_type I-cell_type
human I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
had O O
6000 O O
binding O O
sites/cell O O
and O O
a O O
dissociation O O
constant O O
of O O
4 O O
x O O
10 O O
( O O
-9 O O
) O O
M O O
. O O

The O O
administration O O
of O O
1 O O
mg O O
of O O
dexamethasone O O
, O O
5 O O
mg O O
of O O
prednisone O O
, O O
and O O
37.5 O O
mg O O
of O O
cortisone O O
acetate O O
resulted O O
in O O
a O O
30 O O
% O O
decrease O O
in O O
binding O B-DNA
sites O I-DNA
after O O
1 O O
week O O
with O O
no O O
change O O
in O O
binding O O
affinity O O
. O O

No O O
changes O O
in O O
the O O
number O O
of O O
binding O B-DNA
sites O I-DNA
was O O
noted O O
before O O
1 O O
week O O
and O O
the O O
diminished O O
number O O
persisted O O
for O O
1 O O
week O O
after O O
discontinuation O O
of O O
glucocorticoid O O
treatment O O
. O O

Lymphocytes B-cell_type B-cell_type
from O O
hospitalized O O
patients O O
taking O O
40-60 O O
mg O O
of O O
dexamethasone O O
daily O O
demonstrated O O
the O O
same O O
change O O
in O O
number O O
of O O
binding O B-DNA
sites O I-DNA
that O O
was O O
seen O O
in O O
normal O O
subjects O O
taking O O
1 O O
mg O O
of O O
dexamethasone O O
. O O

When O O
binding O O
assays O O
were O O
carried O O
out O O
at O O
physiologic O O
temperature O O
there O O
was O O
the O O
same O O
decrease O O
in O O
number O O
of O O
binding O B-DNA
sites O I-DNA
after O O
dexamethasone O O
administration O O
, O O
and O O
in O O
addition O O
, O O
there O O
was O O
a O O
two-fold O O
increase O O
in O O
binding O O
affinity O O
. O O

Glucocorticoid O O
administration O O
results O O
in O O
a O O
time-dependent O O
decrease O O
in O O
the O O
number O O
of O O
lymphocyte O B-DNA
glucocorticoid O I-DNA
binding O I-DNA
sites O I-DNA
that O O
is O O
independent O O
of O O
the O O
type O O
of O O
glucocorticoid O O
administered O O
. O O

This O O
is O O
the O O
first O O
in O O
vivo O O
demonstration O O
that O O
glucocorticoids O O
modulate O O
their O O
own O O
receptors O O
in O O
man O O
. O O

Immunoglobulin O B-protein
localization O O
in O O
benign O O
and O O
malignant O O
lesions O O
of O O
the O O
human O O
mammary O O
gland O O
. O O

Using O O
direct O O
imunofluorescence O O
, O O
lesions O O
from O O
266 O O
human O O
breast O O
specimens O O
were O O
studied O O
for O O
the O O
presence O O
of O O
IgA O B-protein
, O O
IgM O B-protein
, O O
or O O
IgG O B-protein
localization O O
. O O

The O O
lesions O O
included O O
benign O O
elements O O
from O O
66 O O
subcutaneous O O
mastectomy O O
specimens O O
in O O
which O O
the O O
absence O O
of O O
simultaneous O O
breast O O
malignancy O O
was O O
documented O O
, O O
primary O O
breast O O
carcinomas O O
from O O
153 O O
mastectomy O O
specimens O O
, O O
and O O
47 O O
biopsies O O
containing O O
metastatic O O
breast O O
cancer O O
. O O

A O O
statistically O O
significant O O
association O O
of O O
IgA B-protein B-protein
and O O
IgM B-protein B-protein
with O O
benign O O
lesions O O
was O O
contrasted O O
to O O
the O O
association O O
of O O
IgG B-protein B-protein
with O O
malignant O O
lesions O O
. O O

In O O
both O O
primary O O
and O O
metastatic O O
lesions O O
, O O
IgG B-protein B-protein
localization O O
was O O
associated O O
with O O
estrogen-receptor-poor O O
primary O O
cancers O O
as O O
compared O O
with O O
estrogen-receptor-rich O O
primary O O
cancers O O
. O O

Among O O
primary O O
breast O O
cancer O O
patients O O
, O O
IgG B-protein B-protein
localization O O
in O O
the O O
tumor O O
correlated O O
with O O
relative O O
lymphopenia O O
. O O

A O O
shorter O O
disease-free O O
interval O O
was O O
noted O O
in O O
association O O
with O O
IgG B-protein B-protein
localization O O
among O O
the O O
metastatic O O
breast O O
lesions O O
. O O

No O O
statistically O O
significant O O
association O O
between O O
stage O O
of O O
disease O O
and O O
immunoglobulin O B-protein
presence O O
was O O
demonstrable O O
. O O

Moderate-to-severe O O
intraductal O O
epithelial O O
hyperplasias O O
were O O
more O O
often O O
associated O O
with O O
immunoglobulin B-protein B-protein
G I-protein I-protein
localization O O
that O O
were O O
other O O
benign O B-cell_type
lesions O I-cell_type

Correlation O O
of O O
steroid B-protein B-protein
receptors I-protein I-protein
with O O
histologic O O
differentiation O O
in O O
mammary O O
carcinoma O O
. O O

A O O
Singapore O O
experience O O
. O O

Cancer O O
of O O
the O O
breast O O
is O O
the O O
most O O
common O O
tumor O O
in O O
females O O
in O O
Singapore O O
, O O
with O O
the O O
rate O O
of O O
20.7 O O
per O O
100 O O
, O O
000 O O
per O O
year O O
( O O
1977 O O
estimate O O
) O O
, O O
which O O
is O O
predicted O O
to O O
increase O O
to O O
29.8 O O
per O O
100 O O
, O O
000 O O
women O O
per O O
year O O
by O O
1995 O O
. O O

A O O
detailed O O
histopathologic O O
review O O
of O O
50 O O
primary O O
breast O O
cancer O O
tumors O O
analyzed O O
for O O
estrogen B-protein O
receptor I-protein O
( O O
ER B-protein B-protein
) O O
level O O
was O O
carried O O
out O O
and O O
a O O
variety O O
of O O
morphologic O O
features O O
correlated O O
with O O
ER B-protein B-protein
results O O
to O O
identify O O
any O O
factors O O
that O O
will O O
improve O O
the O O
management O O
and O O
prognosis O O
for O O
breast O O
cancer O O
. O O

Cytosol O O
was O O
incubated O O
with O O
3H-estradiol O O
in O O
the O O
presence O O
and O O
absence O O
of O O
cold O O
diethylstilbestrol O O
, O O
and O O
bound O O
and O O
free O O
hormone O O
were O O
separated O O
by O O
Dextran-coated O O
charcoal O O
method O O
. O O

Tumors O O
binding O O
more O O
than O O
5 O O
fmol/mg O O
cytosol B-protein B-protein
protein I-protein I-protein
were O O
classified O O
as O O
ER B-protein B-protein
-positive O O
. O O

Progesterone B-protein B-protein
receptor I-protein I-protein
( O O
PR B-protein B-protein
) O O
level O O
was O O
analyzed O O
in O O
some O O
specimens O O
with O O
the O O
use O O
of O O
a O O
similar O O
method O O
. O O

Most O O
of O O
the O O
patients O O
were O O
Chinese O O
( O O
90 O O
% O O
) O O
. O O

Three O O
patients O O
were O O
Malays O O
, O O
one O O
was O O
Indian O O
, O O
and O O
one O O
was O O
European O O
in O O
this O O
series O O
. O O

Results O O
indicated O O
that O O
there O O
was O O
strong O O
correlation O O
between O O
ER B-protein B-protein
level O O
, O O
age O O
, O O
and O O
histologic O O
grade O O
of O O
the O O
tumors O O
. O O

No O O
correlation O O
existed O O
between O O
absence O O
or O O
presence O O
of O O
lymph O O
node O O
metastases O O
and O O
ER B-protein B-protein
. O O

Although O O
there O O
was O O
a O O
trend O O
for O O
ER B-protein B-protein
-positive O O
tumors O O
to O O
have O O
a O O
low-grade O O
lymphocytic O O
infiltration O O
, O O
the O O
difference O O
was O O
not O O
statistically O O
significant O O
. O O

Mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
infiltrating O O
human O O
mammary O O
carcinomas O O
: O O
immunohistochemical O O
analysis O O
with O O
monoclonal B-protein B-protein
antibodies I-protein I-protein
. O O

Breast O O
carcinomas O O
were O O
examined O O
by O O
the O O
immunoperoxidase O O
technique O O
using O O
antisera O O
specific O O
for O O
lymphocyte B-cell_type B-cell_type
subsets I-cell_type I-cell_type
, O O
monocytes B-cell_type B-cell_type
, O O
NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
major B-protein B-protein
histocompatibility I-protein I-protein
antigens I-protein I-protein
( O O
HLA-A B-protein B-protein
, O I-protein
-B B-protein I-protein
, O I-protein
-C O I-protein
; O I-protein
Ia-like B-protein I-protein
) O O
. O O

Sixty-four O O
per O O
cent O O
of O O
the O O
patients O O
had O O
a O O
moderate O O
or O O
strong O O
mononuclear O O
cell O O
infiltration O O
, O O
77 O O
% O O
of O O
the O O
patients O O
without O O
mononuclear B-cell_type O
cell I-cell_type O
infiltration O O
had O O
receptors O O
for O O
estrogens O O
as O O
compared O O
to O O
51 O O
% O O
of O O
the O O
patients O O
with O O
infiltration O O
. O O

The O O
majority O O
of O O
the O O
infiltrating B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
; O O
generally O O
the O O
OKT8 B-cell_line B-cell_type
cells I-cell_line I-cell_type
were O O
predominant O O
. O O

The O O
Leu O O
3A/OKT8 O O
cell O O
ratio O O
was O O
not O O
related O O
to O O
histological O O
type O O
, O O
tumor O O
size O O
, O O
age O O
of O O
the O O
patient O O
or O O
presence O O
of O O
metastases O O
. O O

Some O O
of O O
the O O
T O B-cell_type
cells O I-cell_type
had O O
the O O
Ia B-protein B-protein
antigen I-protein I-protein
and O O
were O O
thus O O
probably O O
activated O O
. O O

The O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
either O O
absent O O
or O O
less O O
numerous O O
than O O
the O O
T O B-cell_type
cells O I-cell_type
. O O

There O O
was O O
no O O
relation O O
between O O
their O O
distribution O O
and O O
the O O
various O O
parameters O O
studied O O
. O O

A O O
few O O
monocytes B-cell_type B-cell_type
were O O
heterogeneous O O
according O O
to O O
their O O
markers O O
( O O
OKM B-protein B-protein
I I-protein I-protein
and O O
acid O O
phosphatase O O
) O O
. O O

In O O
6 O O
cases O O
only O O
there O O
was O O
a O O
strong O O
infiltration O O
of O O
mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
positive O O
for O O
acid B-protein O
phosphatase I-protein O
. O O

The O O
number O O
of O O
the O O
natural B-cell_type B-cell_type
killer I-cell_type I-cell_type
cells I-cell_type I-cell_type
was O O
also O O
low O O
. O O

Only O O
a O O
few O O
mononuclear O B-cell_type
infiltrating O I-cell_type
cells O I-cell_type
had O O
receptors O O
for O O
transferrin O B-protein
. O O

There O O
was O O
a O O
positive O O
correlation O O
between O O
the O O
inflammatory O O
infiltration O O
and O O
the O O
presence O O
of O O
HLA B-protein B-protein
class-I I-protein I-protein
antigens I-protein I-protein
on O O
tumor B-cell_type O
cell I-cell_type O
s O O
. O O

Some O O
of O O
the O O
antisera O O
specific O O
for O O
lymphocyte B-cell_type B-cell_type
subsets I-cell_type I-cell_type
also O O
stained O O
the O O
breast B-cell_type B-cell_type
carcinoma I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
great O O
variations O O
in O O
the O O
subsets O O
of O O
mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
breast O O
carcinomas O O
may O O
correspond O O
to O O
various O O
systems O O
of O O
defense O O
against O O
neoplasm O O
. O O

A O O
case O O
of O O
male O O
pseudohermaphroditism O O
with O O
normal O O
androgen B-protein B-protein
receptor I-protein I-protein
binding O O
and O O
47 O O
, O O
XYY O O
karyotype O O
. O O

A O O
case O O
of O O
male O O
pseudohermaphroditism O O
with O O
47 O O
, O O
XYY O O
karyotype O O
in O O
blood O B-cell_type
and O I-cell_type
cutaneous B-cell_type I-cell_type
fibroblasts I-cell_type I-cell_type
is O O
described O O
. O O

The O O
plasma O O
testosterone O O
response O O
to O O
HCG O O
stimulation O O
was O O
slightly O O
below O O
the O O
normal O O
range O O
on O O
two O O
occasions O O
suggesting O O
a O O
deficit O O
of O O
gonadal O O
function O O
. O O

A O O
study O O
of O O
the O O
receptors O O
for O O
dihydrotestosterone O O
in O O
fibroblasts B-cell_type B-cell_type
of O O
genital O O
and O O
nongenital O O
skin O O
showed O O
a O O
normal O O
concentration O O
of O O
receptors O O
in O O
genital O O
skin O O
; O O
5-alpha-reductase B-protein O
activity O O
in O O
fibroblasts B-cell_type B-cell_type
of O O
the O O
genital O O
skin O O
was O O
low O O
, O O
but O O
the O O
plasma O O
relationship O O
testosterone/dihydrotestosterone O O
under O O
HCG O O
stimulation O O
was O O
normal O O
. O O

The O O
diagnostic O O
possibility O O
of O O
a O O
complete O O
testicular O O
feminization O O
syndrome O O
with O O
normal O O
receptors O O
for O O
dihydrotestosterone O O
is O O
commented O O
on O O
. O O

1 O O
, O O
25-Dihydroxyvitamin O O
D3 O O
inhibits O O
antigen-induced O O
T B-cell_type O
cell I-cell_type O
activation O O
. O O

The O O
proliferative O O
response O O
of O O
murine B-cell_type B-cell_type
spleen I-cell_type I-cell_type
and I-cell_type I-cell_type
thymus I-cell_type I-cell_type
cells I-cell_type I-cell_type
to O O
antigen B-protein O
but O O
not O O
to O O
lectin B-protein B-protein
was O O
inhibited O O
by O O
the O O
active O O
metabolite O O
of O O
vitamin O O
D3 O O
, O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
. O O

To O O
directly O O
examine O O
the O O
effect O O
of O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
on O O
T B-cell_type O
cell I-cell_type O
activation O O
in O O
the O O
absence O O
of O O
other O O
complicating O O
interactions O O
, O O
we O O
utilized O O
a O O
panel O O
of O O
cloned O O
Ia-restricted B-cell_line B-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
hybridomas I-cell_line I-cell_line
that O O
secrete O B-cell_line
IL B-protein I-cell_line
2 I-protein I-cell_line
on O O
activation O O
by O O
cloned O B-cell_line
Ia-bearing B-cell_type I-cell_line
stimulator I-cell_type I-cell_line
cells I-cell_type I-cell_line
( O O
TA3 B-cell_type B-cell_line
) O O
or O O
when O O
stimulated O O
by O O
mitogen O B-protein
. O O

Physiologic O O
concentrations O O
of O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
( O O
0.01 O O
to O O
0.1 O O
nm O O
) O O
inhibited O O
the O O
antigen-induced O O
secretion O O
of O O
IL O B-protein
2 O I-protein
by O O
several O O
of O O
these O O
T B-cell_line B-cell_line
cell I-cell_line I-cell_line
hybridomas I-cell_line I-cell_line
. O O

This O O
inhibition O O
was O O
dependent O O
on O O
the O O
concentration O O
of O O
the O O
free O O
hormone O O
and O O
could O O
be O O
overcome O O
by O O
increasing O O
the O O
number O O
of O O
Ia-bearing B-cell_line B-cell_type
stimulator I-cell_line I-cell_type
cells I-cell_line I-cell_type
used O O
. O O

Pretreatment O O
of O O
the O O
T B-cell_line B-cell_line
hybridoma I-cell_line I-cell_line
but O O
not O O
the O O
TA3 B-cell_line B-cell_line
stimulator I-cell_line I-cell_line
cell I-cell_line I-cell_line
with O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
resulted O O
in O O
inhibition O O
of O O
activation O O
. O O

These O O
results O O
are O O
consistent O O
with O O
the O O
finding O O
that O O
specific O O
1 B-protein O
, I-protein O
25- I-protein O
( I-protein O
OH I-protein O
) I-protein O
2D3 I-protein O
receptors I-protein O
are O O
present O O
on O O
the O O
T O B-cell_line
cell O I-cell_line
hybridomas O I-cell_line
but O O
are O O
lacking O O
in O O
TA3 B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
failed O O
, O O
however O O
, O O
to O O
inhibit O O
the O O
activation O O
of O O
the O O
T B-cell_line B-cell_line
cell I-cell_line I-cell_line
hybridomas I-cell_line I-cell_line
by O O
lectin B-protein B-protein
or O O
by O O
an O O
anti-Thy-1 B-protein B-protein
antibody I-protein I-protein
. O O

These O O
findings O O
suggest O O
that O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
may O O
be O O
interfering O O
with O O
early O O
events O O
of O O
antigen-induced O O
T B-cell_type O
cell I-cell_type O
activation O O
, O O
perhaps O O
by O O
hindering O O
T B-cell_type O
cell I-cell_type O
recognition O O
of O O
the O O
relevant O O
antigen O O
on O O
stimulator O O
cell O O
surfaces O O
. O O

This O O
system O O
should O O
prove O O
useful O O
in O O
studying O O
the O O
molecular O O
mechanisms O O
by O O
which O O
1 O O
, O O
25- O O
( O O
OH O O
) O O
2D3 O O
acts O O
to O O
inhibit O O
T O O
cell O O
activation O O
and O O
subsequent O O
IL B-protein O
2 I-protein O
production O O
. O O

Glucocorticoid B-protein B-protein
receptors I-protein I-protein
and O O
steroid O O
sensitivity O O
in O O
normal O O
and O O
neoplastic O O
human O O
lymphoid O O
tissues O O
: O O
a O O
review O O
. O O

The O O
determination O O
of O O
estrogen B-protein B-protein
and I-protein I-protein
progesterone I-protein I-protein
receptors I-protein I-protein
in O O
breast O O
cancer O O
has O O
been O O
shown O O
to O O
be O O
useful O O
in O O
predicting O O
the O O
response O O
to O O
endocrine O O
therapy O O
. O O

Given O O
their O O
well-known O O
inhibitory O O
effects O O
on O O
lymphoid O O
tissue O O
, O O
glucocorticoids O O
have O O
been O O
used O O
widely O O
in O O
the O O
treatment O O
of O O
leukemia O O
. O O

Given O O
these O O
facts O O
, O O
over O O
the O O
last O O
10 O O
years O O
, O O
several O O
investigators O O
have O O
measured O O
the O O
number O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
normal O O
and O O
neoplastic O O
lymphoid O O
tissue O O
to O O
see O O
whether O O
their O O
number O O
correlated O O
with O O
glucocorticoid O O
responsiveness O O
in O O
vitro O O
or O O
in O O
vivo O O
. O O

No O O
clear O O
correlation O O
could O O
be O O
established O O
between O O
the O O
level O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
and O O
the O O
in O O
vitro O O
action O O
of O O
steroids O O
in O O
normal O O
and O O
neoplastic O O
lymphoid O O
tissue O O
. O O

In O O
contrast O O
, O O
attempts O O
to O O
correlate O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
levels O O
in O O
acute O O
lymphocytic O O
leukemia O O
to O O
in O O
vivo O O
steroid O O
responsiveness O O
and O O
immunological O O
type O O
using O O
the O O
whole-cell-binding O O
assay O O
for O O
receptor O O
determination O O
and O O
selecting O O
the O O
patients O O
according O O
to O O
age O O
and O O
immunological O O
criteria O O
have O O
been O O
more O O
successful O O
. O O

[ O O
Glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
normal B-cell_type B-cell_type
human I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
] O O

Glucocorticoid B-cell_type O
( I-cell_type O
GC I-cell_type O
) I-cell_type O
receptors I-cell_type O
were O O
studied O O
in O O
intact O B-cell_type
lymphocytes B-cell_type I-cell_type
from O O
11 O O
donors O O
. O O

GC O O
binding O O
parameters O O
were O O
found O O
to O O
be O O
highly O O
reproducible O O
in O O
repeated O O
experiments O O
with O O
lymphocytes B-cell_type B-cell_type
. O O

It O O
was O O
shown O O
that O O
GC B-protein B-protein
receptors I-protein I-protein
in O O
donors O O
' O O
lymphocytes B-cell_type B-cell_type
could O O
be O O
distributed O O
into O O
two O O
different O O
classes O O
similarly O O
to O O
the O O
pattern O O
seen O O
in O O
skin B-cell_type B-cell_type
fibroblasts I-cell_type I-cell_type
. O O

Human B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
are O O
an O O
adequate O O
object O O
for O O
studying O O
genetically O O
determined O O
variability O O
of O O
GC B-protein B-protein
receptors I-protein I-protein
and O O
its O O
clinical O O
importance O O
. O O

Specific O O
estrogen B-protein B-protein
binding I-protein I-protein
sites I-protein I-protein
in O O
human B-cell_type B-cell_type
lymphoid I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
thymic B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
binding O O
of O O
estrogen O O
in O O
preparations O O
of O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
, I-cell_type O
as O O
well O O
as O O
by O O
splenic B-cell_type O
and I-cell_type O
thymic I-cell_type B-cell_type
cells I-cell_type I-cell_type
is O O
demonstrated O O
by O O
three O O
different O O
approaches O O
( O O
Dextran-coated O O
charcoal O O
method O O
, O O
whole O O
cell O O
assay O O
, O O
and O O
gel O O
filtration O O
on O O
a O O
sepharose O O
4B O O
column O O
) O O
. O O

Scatchard O O
's O O
analysis O O
of O O
[ O O
3H O O
] O O
-moxestrol O O
( O O
R2858 O O
) O O
and O O
[ O O
3H O O
] O O
-estradiol O O
binding O O
proves O O
the O O
existence O O
of O O
a O O
single O O
class O O
of O O
receptor B-protein B-DNA
sites I-protein I-DNA
having O O
a O O
dissociation O O
constant O O
of O O
0.18-2.4 O O
X O O
10 O O
( O O
-9 O O
) O O
M O O
. O O

Physicochemical O O
properties O O
of O O
the O O
binder O O
, O O
including O O
binding O O
capacity O O
and O O
steroid O O
specificity O O
, O O
are O O
quite O O
similar O O
to O O
those O O
reported O O
for O O
the O O
thymus O O
of O O
small O O
mammalian O O
species O O
or O O
human O O
thymoma O O
. O O

Administration O O
of O O
fibroblast B-protein B-protein
interferon I-protein I-protein
to O O
patients O O
with O O
advanced O O
breast O O
cancer O O
: O O
possible O O
effects O O
on O O
skin O O
metastasis O O
and O O
on O O
hormone B-protein O
receptors I-protein O
. O O

Eleven O O
patients O O
with O O
metastasized O O
breast O O
cancer O O
received O O
8 O O
intramuscular O O
injections O O
of O O
6 O O
x O O
10 O O
( O O
6 O O
) O O
units O O
of O O
human B-protein B-protein
fibroblast I-protein I-protein
interferon I-protein I-protein
over O O
a O O
period O O
of O O
40 O O
days O O
. O O

The O O
injections O O
did O O
not O O
cause O O
local O O
irritation O O
or O O
inflammation O O
. O O

Fever O O
occurred O O
in O O
only O O
1 O O
of O O
the O O
11 O O
patients O O
. O O

Although O O
several O O
types O O
of O O
metastases O O
were O O
monitored O O
, O O
only O O
skin O O
nodules O O
consistently O O
( O O
10 O O
out O O
of O O
11 O O
patients O O
) O O
exhibited O O
changes O O
that O O
were O O
suggestive O O
of O O
a O O
therapeutic O O
effect O O
of O O
the O O
treatment O O
regimen O O
: O O
either O O
a O O
simple O O
decrease O O
in O O
size O O
of O O
some O O
nodules O O
or O O
central O O
necrosis O O
accompanied O O
by O O
an O O
inflammatory O O
reaction O O
. O O

NK-activity O O
of O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
was O O
significantly O O
increased O O
after O O
administration O O
of O O
the O O
first O O
dose O O
; O O
the O O
effect O O
of O O
subsequent O O
injections O O
was O O
less O O
clear O O
. O O

Receptors O O
for O O
estrogens O O
and O O
progestogens O O
were O O
increased O O
in O O
the O O
tumor O O
biopsies O O
of O O
2 O O
out O O
of O O
2 O O
and O O
5 O O
out O O
of O O
6 O O
patients O O
tested O O
respectively O O
. O O

Decreased O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
binding O O
in O O
adrenal O O
insufficiency O O
. O O

To O O
examine O O
the O O
effect O O
of O O
glucocorticoid O O
deficiency O O
on O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
, O O
we O O
examine O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
dexamethasone O O
to O O
lymphocytes B-cell_type B-cell_type
in O O
normal O O
subjects O O
and O O
patients O O
with O O
adrenal O O
insufficiency O O
before O O
and O O
after O O
glucocorticoid O O
replacement O O
therapy O O
. O O

Using O O
a O O
whole O O
cell O O
competitive O O
binding O O
assay O O
, O O
normal B-cell_type B-cell_type
human I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
had O O
5977 O O
+/- O O
1487 O O
( O O
mean O O
+/- O O
SD O O
) O O
binding O O
sites/cell O O
and O O
a O O
dissociation O O
constant O O
of O O
10 O O
+/- O O
2 O O
nM O O
. O O

Lymphocytes B-cell_type B-cell_type
from O O
patients O O
with O O
untreated O O
adrenal O O
insufficiency O O
had O O
fewer O O
binding B-protein B-DNA
sites I-protein I-DNA
( O O
3364 O O
+/-322 O O
) O O
and O O
a O O
2-fold O O
increase O O
in O O
binding O O
affinity O O
( O O
5.4 O O
+/- O O
0.9 O O
mM O O
) O O
. O O

The O O
administration O O
of O O
conventional O O
replacement O O
doses O O
of O O
cortisone O O
acetate O O
for O O
6 O O
months O O
caused O O
no O O
change O O
in O O
receptor O O
number O O
, O O
but O O
was O O
associated O O
with O O
a O O
decrease O O
in O O
binding O O
affinity O O
toward O O
normal O O
. O O

After O O
long O O
term O O
glucocorticoid O O
replacement O O
therapy O O
, O O
binding O O
parameters O O
were O O
similar O O
to O O
those O O
in O O
patients O O
before O O
treatment O O
. O O

The O O
physiological O O
implications O O
of O O
the O O
decreased O O
receptor O O
number O O
and O O
increased O O
binding O O
affinity O O
in O O
adrenal O O
insufficiency O O
remain O O
to O O
be O O
elucidated O O
. O O

Glucocorticoid B-protein B-protein
receptor I-protein I-protein
concentrations O O
and O O
terminal O B-protein
transferase B-protein I-protein
activity O O
as O O
indicators O O
of O O
prognosis O O
in O O
acute O O
non-lymphocytic O O
leukaemia O O
. O O

Activity O O
of O O
terminal B-protein B-protein
deoxynucleotidyl I-protein I-protein
transferase I-protein I-protein
( O O
TdT B-protein B-protein
) O O
, O O
adenosine B-protein B-protein
deaminase I-protein I-protein
, O O
and O O
5'nucleotidase B-protein B-protein
and O O
the O O
cellular O O
concentration O O
of O O
glucocorticoid B-protein B-protein
( I-protein I-protein
dexamethasone I-protein I-protein
) I-protein I-protein
receptor I-protein I-protein
were O O
determined O O
in O O
25 O O
patients O O
with O O
acute O O
non-lymphocytic O O
leukaemia O O
. O O

All O O
patients O O
were O O
treated O O
according O O
to O O
a O O
common O O
protocol O O
. O O

Increased O O
activity O O
of O O
TdT B-protein B-protein
( O O
greater O O
than O O
0.1 O O
unit/microgram O O
DNA O O
) O O
was O O
found O O
in O O
11 O O
patients O O
. O O

This O O
group O O
of O O
patients O O
was O O
shown O O
to O O
have O O
higher O O
remission O O
and O O
survival O O
rates O O
( O O
p O O
= O O
0.06 O O
) O O
compared O O
with O O
patients O O
with O O
low O O
activity O O
of O O
TdT O B-protein
. O O

The O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
concentration O O
of O O
the O O
leukaemic B-cell_type B-cell_type
blast I-cell_type I-cell_type
cells I-cell_type I-cell_type
ranged O O
from O O
0 O O
to O O
0.94 O O
fmol/microgram O O
DNA O O
. O O

Thirteen O O
patients O O
had O O
blast B-cell_type B-cell_type
cells I-cell_type I-cell_type
with O O
a O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
concentration O O
over O O
0.22 O O
fmol/microgram O O
DNA O O
. O O

These O O
patients O O
had O O
significantly O O
increased O O
remission O O
and O O
survival O O
rates O O
( O O
p O O
= O O
0.006 O O
) O O
compared O O
with O O
those O O
with O O
a O O
low O O
receptor O O
concentration O O
. O O

This O O
finding O O
can O O
not O O
be O O
explained O O
by O O
a O O
difference O O
in O O
sensitivity O O
to O O
glucocorticoids O O
since O O
these O O
were O O
not O O
used O O
as O O
therapeutic O O
agents O O
. O O

Adenosine B-protein O
deaminase I-protein O
and O O
5'nucleotidase B-protein O
activities O O
both O O
varied O O
within O O
two O O
orders O O
of O O
magnitude O O
. O O

No O O
correlation O O
could O O
be O O
found O O
between O O
activities O O
of O O
these O O
enzymes O B-protein
and O O
remission O O
or O O
survival O O
rate O O
. O O

These O O
results O O
show O O
that O O
measurements O O
of O O
TdT B-protein O
activity O O
and O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
concentration O O
yield O O
valuable O O
prognostic O O
information O O
in O O
acute O O
non-lymphocytic O O
leukaemia O O

[ O O
3H O O
] O O
cortivazol O O
: O O
a O O
unique O O
high O O
affinity O O
ligand O O
for O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
. O O

Cortivazol O O
( O O
CVZ O O
) O O
and O O
deacylcortivazol O O
( O O
DAC O O
) O O
are O O
pyrazolosteroids O O
with O O
potent O O
glucocorticoid O O
activity O O
. O O

In O O
previous O O
work O O
we O O
showed O O
that O O
DAC O O
is O O
40-fold O O
more O O
potent O O
than O O
dexamethasone O O
( O O
DEX O O
) O O
in O O
lysing O B-cell_type
leukemic B-cell_type I-cell_type
lymphoblasts I-cell_type I-cell_type
. O O

To O O
assess O O
the O O
interaction O O
between O O
these O O
atypical O O
steroids O O
and O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
, O O
we O O
examined O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
CVZ O O
to O O
cytosol O O
from O O
glucocorticoid-sensitive B-cell_line B-cell_line
and I-cell_line I-cell_line
-resistant I-cell_line I-cell_line
variants I-cell_line I-cell_line
of O O
the O O
human B-cell_line B-cell_line
leukemic I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
CEM B-cell_line I-cell_line
C7 I-cell_line I-cell_line
. O O

In O O
glucocorticoid-sensitive B-cell_line B-cell_line
cells I-cell_line I-cell_line
[ O O
3H O O
] O O
CVZ O O
causes O O
a O O
2-fold O O
induction O O
of O O
glutamine B-protein B-protein
synthetase I-protein I-protein
and O O
binds O O
to O O
a O O
protein O O
in O O
the O O
4.6 O B-protein
S O I-protein
region O I-protein
of O O
high O O
salt O O
sucrose O O
gradients O O
. O O

On O O
DEAE-cellulose O O
chromatography O O
, O O
[ B-protein O
3H I-protein O
] I-protein O
CVZ-receptor I-protein O
complexes I-protein O
show O O
a O O
shift O O
from O O
high O O
( O O
0.25 O O
M O O
KP O O
) O O
to O O
low O O
salt O O
( O O
0.09 O O
M O O
KP O O
) O O
eluting O O
forms O O
upon O O
activation O O
. O O

CVZ O O
competes O O
for O O
a O O
97 O O
, O O
000-dalton O B-protein
protein O I-protein
labeled O O
by O O
[ O O
3H O O
] O O
dexamethasone O O
mesylate O O
. O O

Scatchard O O
analysis O O
of O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
CVZ O O
in O O
glucocorticoid-sensitive B-cell_line B-cell_line
cells I-cell_line I-cell_line
revealed O O
a O O
curvilinear O O
plot O O
which O O
resolved O O
into O O
high O O
( O O
0.4 O O
nM O O
) O O
and O O
low O O
( O O
11 O O
nM O O
) O O
affinity O O
components O O
. O O

The O O
receptor O O
concentration O O
of O O
the O O
low O B-DNA
affinity O I-DNA
site O I-DNA
( O O
0.30 O B-protein
pmol/mg O I-protein
protein O I-protein
) O O
was O O
approximately O O
twice O O
that O O
of O O
the O O
high B-protein B-DNA
affinity I-protein I-DNA
site I-protein I-DNA
( O O
0.14 O O
pmol/mg O O
protein O O
) O O
. O O

Dissociation O O
experiments O O
with O O
dilution O O
and/or O O
excess O O
unlabeled O O
CVZ O O
supported O O
the O O
presence O O
of O O
independent O O
sites O O
. O O

In O O
contrast O O
, O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
DEX O O
to O O
C7 O O
cytosol O O
revealed O O
a O O
single O O
class O O
of O O
binding O B-DNA
sites O I-DNA
( O O
Kd O O
= O O
1.9 O O
nM O O
; O O
receptor O O
concentration O O
, O O
0.46 O O
pmol/mg O O
protein O O
) O O
. O O

Examination O O
of O O
the O O
binding O O
of O O
[ O O
3H O O
] O O
CVZ O O
using O O
10 O O
( O O
-5 O O
) O O
M O O
DEX O O
as O O
the O O
competing O O
ligand O O
showed O O
that O O
DEX O O
binds O O
only O O
to O O
the O O
low O B-DNA
affinity O I-DNA
site O I-DNA
detected O O
by O O
[ O O
3H O O
] O O
CVZ O O
. O O

In O O
cytosol O O
from O O
a O O
glucocorticoid-resistant B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
with O O
virtually O O
no O O
[ O O
3H O O
] O O
DEX O O
binding O O
, O O
[ O O
3H O O
] O O
CVZ O O
detected O O
a O O
single O O
high B-protein O
affinity I-protein B-DNA
binding I-protein I-DNA
site I-protein I-DNA
that O O
was O O
similar O O
in O O
dissociation O O
constant O O
( O O
0.8 O O
nM O O
) O O
and O O
receptor O O
concentration O O
( O O
0.13 O O
pmol/mg O O
protein O O
) O O
to O O
the O O
high B-protein O
affinity I-protein O
site I-protein O
detected O O
in O O
the O O
glucocorticoid-sensitive B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
C7 B-cell_line I-cell_line
. O O

A O O
controlled O O
pore O O
glass O O
bead O O
assay O O
for O O
the O O
measurement O O
of O O
cytoplasmic B-protein B-protein
and I-protein I-protein
nuclear I-protein I-protein
glucocorticoid I-protein I-protein
receptors I-protein I-protein
. O O

An O O
assay O O
for O O
the O O
quantitation O O
of O O
cytoplasmic B-protein B-protein
and I-protein I-protein
nuclear I-protein I-protein
glucocorticoid I-protein I-protein
receptors I-protein I-protein
in O O
lymphoid O O
tissue O O
has O O
been O O
developed O O
using O O
controlled O O
pore O O
glass O O
( O O
CPG O O
) O O
beads O O
. O O

Soluble O B-protein
receptor B-protein I-protein
-- I-protein O
3H-steroid I-protein B-protein
complex I-protein I-protein
( O O
cytosol O O
or O O
nuclear O O
extract O O
) O O
is O O
adsorbed O O
quantitatively O O
within O O
the O O
crevasses O O
of O O
porous O O
glass O O
beads O O
. O O

Excess O O
labeled O O
steroid O O
as O O
well O O
as O O
most O O
non-specifically O O
bound O O
steroid O O
is O O
easily O O
washed O O
away O O
, O O
leaving O O
the O O
hormone-receptor B-protein B-protein
complex I-protein I-protein
retained O O
by O O
the O O
beads O O
. O O

Bound O O
3H-steroid O O
is O O
eluted O O
with O O
ethanol O O
and O O
measured O O
for O O
radioactivity O O
. O O

This O O
procedure O O
which O O
is O O
simple O O
, O O
rapid O O
, O O
and O O
highly O O
reproducible O O
is O O
carried O O
out O O
using O O
frozen O O
samples O O
( O O
stable O O
for O O
many O O
months O O
) O O
containing O O
as O O
few O O
as O O
1 O O
X O O
10 O O
( O O
7 O O
) O O
cells O O
. O O

A O O
comparison O O
of O O
the O O
CPG O O
assay O O
to O O
dextran O O
coated O O
charcoal O O
and O O
a O O
whole O O
cell O O
assay O O
demonstrates O O
that O O
CPG O O
and O O
dextran O O
coated O O
charcoal O O
give O O
equivalent O O
measurements O O
of O O
cytosolic B-protein B-protein
receptor I-protein I-protein
concentration O O
, O O
while O O
the O O
CPG O O
and O O
whole O O
cell O O
assays O O
provide O O
equivalent O O
values O O
for O O
total O O
receptor O O
content O O
. O O

Plasmacytoid O O
blast O O
crisis O O
in O O
B-cell B-cell_type O
chronic O O
lymphocytic O O
leukemia O O
: O O
effect O O
of O O
estradiol O O
on O O
growth O O
and O O
differentiation O O
in O O
vitro O O
. O O

Evolution O O
of O O
a O O
case O O
of O O
chronic O O
lymphocytic O O
leukemia O O
( O O
CLL O O
) O O
into O O
blast O O
crisis O O
was O O
found O O
to O O
be O O
characterized O O
by O O
three O O
unusual O O
features O O
( O O
1 O O
) O O
the O O
phenotype O O
of O O
the O O
emerging B-cell_type B-cell_type
blast I-cell_type I-cell_type
cells I-cell_type I-cell_type
was O O
that O O
of O O
pre-plasmacytoid B-cell_type B-cell_type
cells I-cell_type I-cell_type
as O O
shown O O
by O O
plasma O O
cell O O
morphology O O
and O O
an O O
immunological O O
phenotype O O
corresponding O O
partially O O
with O O
CLL- B-cell_type B-cell_line
or I-cell_type I-cell_line
intermediate I-cell_type I-cell_line
B-cells I-cell_type I-cell_line
, O O
partially O O
with O O
plasma B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
terminal B-protein B-protein
transferase I-protein I-protein
- O O
, O O
common O O
acute B-protein O
lymphocytic I-protein B-protein
leukemia I-protein I-protein
antigen I-protein I-protein
- O I-protein
, O I-protein
Ia+ B-protein I-protein
, O I-protein
surface B-protein I-protein
immunoglobulin I-protein I-protein
heavy I-protein I-protein
chains I-protein I-protein
- O O
, O O
surface B-protein B-protein
kappa I-protein I-protein
light I-protein I-protein
chains I-protein I-protein
+ O O
, O O
intracytoplasmic B-protein B-protein
immunoglobulin I-protein I-protein
A+ I-protein O
and I-protein O
G+ I-protein O
, O O
BA-1+ B-protein O
, O O
polyclonal O O
gammaglobulin O B-protein
production O O
) O O
; O O
( O O
2 O O
) O O
cytogenetic O O
analysis O O
of O O
spontaneous O O
metaphases O O
revealed O O
that O O
in O O
addition O O
to O O
the O O
typical O O
CLL O O
abnormality O O
, O O
trisomy O O
12 O O
, O O
in O O
all O O
of O O
the O O
cells O O
, O O
an O O
additional O O
translocation O O
between O O
chromosomes B-DNA B-DNA
14 I-DNA I-DNA
and I-DNA I-DNA
17 I-DNA I-DNA
was O O
present O O
in O O
40 O O
% O O
with O O
a O O
presumptive O O
breakpoint O O
on O O
chromosome B-DNA B-DNA
14 I-DNA I-DNA
( O O
q12-3 O O
) O O
never O O
described O O
before O O
( O O
commonly O O
q32 O O
) O O
and O O
( O O
3 O O
) O O
the O O
progression O O
of O O
the O O
disease O O
was O O
associated O O
with O O
a O O
striking O O
increase O O
in O O
the O O
expression O O
by O O
the O O
transformed B-cell_type B-cell_type
cells I-cell_type I-cell_type
of O O
specific O B-DNA
binding O I-DNA
sites O I-DNA
for O O
estradiol O O
( O O
E2 O O
) O O
due O O
to O O
an O O
actual O O
increase O O
in O O
total O B-protein
cellular B-protein I-protein
receptor I-protein I-protein
proteins I-protein I-protein
and O O
not O O
to O O
a O O
change O O
in O O
receptor O O
affinity O O
for O O
E2 O O
. O O

The O O
functional O O
status O O
of O O
the O O
steroid B-protein B-protein
receptors I-protein I-protein
was O O
confirmed O O
by O O
nuclear O O
transfer O O
of O O
the O O
cytoplasmic B-protein B-protein
hormone-receptor I-protein I-protein
complex I-protein I-protein
upon O O
temperature O O
activation O O
. O O

Since O O
the O O
rise O O
in O O
E2-receptor B-protein O
display O O
paralleled O O
a O O
large O O
increase O O
in O O
the O O
proliferative O O
activity O O
of O O
the O O
cells O O
as O O
well O O
as O O
a O O
change O O
in O O
their O O
maturation O O
status O O
the O O
question O O
was O O
raised O O
as O O
to O O
whether O O
the O O
E2-receptor B-protein O
should O O
be O O
considered O O
as O O
a O O
physiological O O
marker O O
of O O
growth O O
rate O O
or O O
of O O
cellular O O
differentiation O O
. O O

Exposure O O
of O O
the O O
patient O O
's O O
blast B-cell_type B-cell_type
cells I-cell_type I-cell_type
to O O
E2 O O
in O O
vitro O O
resulted O O
in O O
cessation O O
of O O
cell O O
growth O O
following O O
at O O
least O O
one O O
mitosis O O
after O O
addition O O
of O O
the O O
inducer O O
as O O
seen O O
from O O
the O O
replacement O O
of O O
the O O
large B-cell_type B-cell_type
blasts I-cell_type I-cell_type
by O O
small O B-cell_type
CLL-like B-cell_type I-cell_type
cells I-cell_type I-cell_type
without O O
definite O O
signs O O
of O O
alteration O O
of O O
the O O
differentiation O O
status O O
. O O

This O O
suggests O O
the O O
association O O
of O O
E2-receptor B-protein O
expression O O
with O O
control O O
of O O
growth O O
rather O O
than O O
cell O O
maturation O O
. O O

Multiple O O
forms O O
and O O
fragments O O
of O O
cytosolic B-protein B-protein
glucocorticoid I-protein I-protein
receptors I-protein I-protein
from O O
human B-cell_type B-cell_type
leukemic I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
normal B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Therapy O O
with O O
glucocorticoids O O
is O O
generally O O
more O O
effective O O
in O O
acute O O
lymphoblastic O O
leukemia O O
than O O
in O O
other O O
types O O
of O O
human O O
leukemia O O
. O O

Previous O O
studies O O
, O O
however O O
, O O
have O O
not O O
revealed O O
any O O
consistent O O
relationship O O
between O O
clinical O O
responsiveness O O
and O O
the O O
cellular O O
or O O
cytosolic O O
concentration O O
of O O
glucocorticoid-binding B-protein B-protein
sites I-protein I-protein
. O O

The O O
objectives O O
of O O
this O O
study O O
were O O
to O O
determine O O
whether O O
there O O
are O O
intrinsic O O
structural O O
differences O O
among O O
the O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
various O O
types O O
of O O
leukemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
normal B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
and O O
to O O
investigate O O
the O O
role O O
of O O
endogenous B-protein O
peptidases I-protein O
in O O
receptor O O
degradation O O
. O O

Cytosols O O
were O O
prepared O O
from O O
fresh B-cell_type O
or I-cell_type O
rapidly I-cell_type O
frozen I-cell_type O
leukocytes I-cell_type B-cell_type
from O O
6 O O
healthy O O
adults O O
and O O
35 O O
high-risk O O
leukemia O O
patients O O
( O O
median O O
white O O
blood O O
cell O O
count O O
, O O
150 O O
, O O
000 O O
cells/microliter O O
; O O
median O O
age O O
, O O
13 O O
years O O
) O O
. O O

Receptors O O
were O O
labeled O O
with O O
[ O O
3H O O
] O O
triamcinolone O O
acetonide O O
and O O
quantitated O O
by O O
charcoal-dextran O O
treatment O O
or O O
Sephadex O O
LH-20 O O
chromatography O O
. O O

Mean O O
and O O
median O O
cytosolic O O
receptor O O
concentrations O O
in O O
12 O O
acute O O
lymphoblastic O O
leukemia O O
specimens O O
lacking O O
the O O
standard O B-cell_type
B-cell O I-cell_type
or O I-cell_type
T-cell O I-cell_type
markers O I-cell_type
( O I-cell_type
`` O I-cell_type
null O I-cell_type
cells O I-cell_type
'' O O
) O O
were O O
approximately O O
4-fold O O
higher O O
than O O
in O O
23 O O
other O O
leukemic B-cell_type O
cell I-cell_type O
specimens I-cell_type O
. O O

No O O
other O O
consistent O O
differences O O
in O O
receptor O O
content O O
were O O
observed O O
. O O

Agarose O O
filtration O O
and O O
ultracentrifugation O O
in O O
hypotonic O O
buffers O O
containing O O
20 O O
mM O O
Na2MoO4 O O
revealed O O
complexes O O
of O O
similar O O
size O O
and O O
shape O O
in O O
all O O
clinical O O
specimens O O
tested O O
and O O
two O O
established O B-cell_line
leukemic B-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

They O O
had O O
Stokes O O
radii O O
( O O
Rs O O
) O O
of O O
8.1 O O
+/- O O
0.5 O O
( O O
S.D. O O
) O O
nm O O
( O O
n O O
= O O
50 O O
) O O
, O O
sedimentation O O
coefficients O O
of O O
9.5 O O
+/- O O
0.3S O O
( O O
n O O
= O O
40 O O
) O O
, O O
molecular O O
weights O O
of O O
approximately O O
330 O O
, O O
000 O O
, O O
and O O
axial O O
ratios O O
( O O
a/b O O
) O O
of O O
approximately O O
12 O O
. O O

In O O
hypertonic O O
, O O
molybdate-free O O
buffer O O
, O O
these O O
oligomeric B-protein B-protein
complexes I-protein I-protein
were O O
dissociated O O
into O O
subunits O O
with O O
Rs O O
of O O
5.9 O O
+/- O O
0.3 O O
nm O O
( O O
n O O
= O O
12 O O
) O O
and O O
a/b O O
of O O
11 O O
to O O
12 O O
, O O
as O O
observed O O
previously O O
for O O
other O O
receptors O O
. O O

Fragmentation O O
of O O
the O O
oligomer B-protein O
and O O
the O O
subunit B-protein O
was O O
evident O O
in O O
some O O
cytosols O O
. O O

High O O
activities O O
of O O
peptidases B-protein O
of O O
various O O
specificities O O
were O O
detected O O
in O O
leukemic O O
cell O O
cytosols O O
, O O
as O O
in O O
other O O
cytosols O O
, O O
by O O
fluorometric O O
assays O O
with O O
derivatives O O
of O O
7-amino-4-methylcoumarin O O
. O O

Receptor O O
cleavage O O
by O O
these O O
and O O
other O O
endogenous B-protein B-protein
enzymes I-protein I-protein
may O O
account O O
for O O
previous O O
observations O O
of O O
`` O O
abnormal O O
'' O O
receptors O O
in O O
cytosols O O
from O O
some O O
leukemic B-cell_type O
specimens I-cell_type O
. O O

We O O
conclude O O
that O O
intrinsic O O
structural O O
defects O O
in O O
the O O
receptors O O
are O O
unlikely O O
explanations O O
for O O
the O O
unresponsiveness O O
of O O
some O O
types O O
of O O
leukemia O O
to O O
steroid O O
therapy O O
. O O

Glucocorticoid B-protein B-protein
receptor I-protein I-protein
number O O
and O O
intracellular O O
water O O
space O O
. O O

In O O
order O O
to O O
elucidate O O
the O O
relationship O O
between O O
cell O O
water O O
content O O
and O O
number O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
, O O
eleven O O
normal O O
and O O
malignant B-cell_type B-cell_type
lymphoid I-cell_type I-cell_type
or I-cell_type I-cell_type
myelomonocytic I-cell_type I-cell_type
cell I-cell_type I-cell_type
types I-cell_type I-cell_type
originating O O
from O O
mouse O O
, O O
rat O O
and O O
man O O
were O O
investigated O O
. O O

The O O
cellular O O
water O O
space O O
was O O
measured O O
with O O
3H2O O O
, O O
and O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
number O O
was O O
measured O O
in O O
a O O
whole-cell O O
binding O O
assay O O
with O O
[ O O
3H O O
] O O
dexamethasone O O
at O O
30 O O
and O O
37 O O
degrees O O
C O O
. O O

The O O
intracellular O O
water O O
phase O O
concentration O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
( O O
around O O
40 O O
nmol/l O O
cell O O
water O O
) O O
, O O
and O O
the O O
dependence O O
of O O
receptor O O
affinity O O
on O O
temperature O O
were O O
similar O O
in O O
normal B-cell_type O
and I-cell_type O
malignant I-cell_type B-cell_type
rodent I-cell_type I-cell_type
and I-cell_type I-cell_type
human I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

It O O
is O O
concluded O O
that O O
comparisons O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
levels O O
are O O
best O O
made O O
on O O
the O O
basis O O
of O O
intracellular B-protein O
receptor I-protein O
concentrations O O
. O O

Covalent O O
labeling O O
of O O
rat B-cell_type B-cell_type
thymocyte I-cell_type I-cell_type
and O O
human B-protein B-protein
lymphoid I-protein I-protein
glucocorticoid I-protein I-protein
receptor I-protein I-protein
. O O

Lymphoid B-cell_type B-cell_type
cells I-cell_type I-cell_type
contain O O
specific O O
receptors B-protein O
for O O
glucocorticoids O O
. O O

We O O
have O O
used O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
to O O
label O O
covalently O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
rat B-cell_type B-cell_type
thymic I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
in O O
neoplastic B-cell_type B-cell_type
cells I-cell_type I-cell_type
obtained O O
from O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
and O O
malignant O O
lymphoma O O
. O O

The O O
covalently O O
labeled O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
were O O
identified O O
by O O
polyacrylamide O O
gel O O
electrophoresis O O
( O O
in O O
the O O
presence O O
of O O
0.1 O O
% O O
sodium O O
dodecyl O O
sulfate O O
) O O
. O O

In O O
cytosolic O O
fractions O O
prepared O O
from O O
rat B-cell_type B-cell_type
thymic I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
, O O
[ O O
3H O O
] O O
-dexamethasone-21-mesylate O O
labels O O
a O O
protein O O
( O O
Mr O O
approximately O O
equal O O
to O O
95 O O
, O O
000 O O
) O O
which O O
was O O
identified O O
as O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
by O O
the O O
following O O
criteria O O
: O O
( O O
a O O
) O O
labeling O O
of O O
this O O
moiety O O
is O O
inhibited O O
by O O
treatment O O
with O O
a O O
100-fold O O
molar O O
excess O O
of O O
glucocorticoids O O
, O O
such O O
as O O
dexamethasone O O
and O O
triamcinolone O O
acetonide O O
; O O
and O O
( O O
b O O
) O O
the O O
covalently O O
labeled O O
Mr O O
approximately O O
equal O O
to O O
95 O B-protein
, O I-protein
000 O I-protein
protein O I-protein
is O O
activated O O
( O O
by O O
heating O O
at O O
20 O O
degrees O O
for O O
30 O O
min O O
) O O
to O O
a O O
form O O
that O O
binds O O
to O O
DNA-cellulose O O
. O O

When O O
intact B-cell_type O
thymocytes I-cell_type B-cell_type
are O O
treated O O
with O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
, O O
an O O
Mr O O
approximately O O
equal O O
to O O
95 O O
, O O
000 O O
moiety O O
is O O
also O O
labeled O O
covalently O O
. O O

Approximately O O
35 O O
% O O
of O O
the O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
can O O
be O O
labeled O O
covalently O O
when O O
intact O B-cell_type
thymocytes B-cell_type I-cell_type
are O O
treated O O
with O O
100 O O
nM O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
for O O
30 O O
min O O
at O O
4 O O
degrees O O
. O O

Neoplastic B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
acute O O
lymphoblastic O O
leukemia O O
and O O
malignant O O
lymphoma O O
were O O
treated O O
with O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
. O O

In O O
all O O
samples O O
, O O
an O O
Mr O O
approximately O O
equal O O
to O O
95 O O
, O O
000 O O
moiety O O
was O O
labeled O O
covalently O O
; O O
labeling O O
was O O
inhibited O O
by O O
excess O O
glucocorticoid O O
. O O

Smaller B-protein O
moieties I-protein O
were O O
also O O
identified O O
by O O
competition O O
experiments O O
; O O
these O O
may O O
represent O O
proteolytic B-protein B-protein
fragments I-protein I-protein
of O O
the O O
Mr O O
approximately O O
equal O O
to O O
95 O B-protein
, O I-protein
000 O I-protein
receptor O I-protein
. O O

Thus O O
, O O
in O O
rat B-cell_type O
and I-cell_type O
human I-cell_type B-cell_type
lymphoid I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
can O O
be O O
used O O
to O O
label O O
covalently O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
. O O

The O O
association O O
of O O
cytosol O B-protein
oestrogen B-protein I-protein
and I-protein I-protein
progesterone I-protein I-protein
receptors I-protein I-protein
with O O
histological O O
features O O
of O O
breast O O
cancer O O
and O O
early O O
recurrence O O
of O O
disease O O
. O O

Two O O
hundred O O
and O O
eighty-eight O O
primary O O
breast O O
tumours O O
were O O
examined O O
for O O
the O O
presence O O
or O O
absence O O
of O O
oestrogen B-protein O
( I-protein O
REc I-protein O
) I-protein O
and I-protein O
progesterone I-protein B-protein
( I-protein I-protein
RPc I-protein I-protein
) I-protein I-protein
receptors I-protein I-protein
. O O

Analysis O O
has O O
shown O O
a O O
relative O O
interdependence O O
between O O
the O O
steroid B-protein O
receptor I-protein O
status O O
of O O
primary O O
breast O O
cancer O O
and O O
other O O
prognostic O O
variables O O
such O O
as O O
histological O O
grade O O
, O O
lymphocytic O O
infiltration O O
and O O
tumour O O
elastosis O O
. O O

There O O
were O O
significant O O
associations O O
between O O
epithelial O O
cellularity O O
, O O
stromal O O
fibrosis O O
and O O
the O O
value O O
of O O
REc B-protein O
in O O
those O O
tumours O O
in O O
which O O
the O O
receptor O O
was O O
present O O
. O O

Cellularity O O
and O O
fibrosis O O
were O O
unrelated O O
to O O
the O O
presence O O
or O O
absence O O
of O O
oestrogen B-protein B-protein
receptor I-protein I-protein
. O O

By O O
contrast O O
, O O
neither O O
the O O
presence O O
or O O
absence O O
nor O O
the O O
value O O
of O O
RPc B-protein O
could O O
be O O
related O O
to O O
cellularity O O
or O O
fibrosis O O
. O O

The O O
value O O
of O O
REc B-protein O
and O O
RPc B-protein O
analysis O O
as O O
an O O
indicator O O
of O O
prognosis O O
was O O
examined O O
in O O
a O O
sub-group O O
of O O
175 O O
patients O O
receiving O O
no O O
additional O O
treatment O O
following O O
mastectomy O O
. O O

Overall O O
relapse-free O O
survival O O
( O O
RFS O O
) O O
was O O
no O O
different O O
for O O
those O O
patients O O
with O O
receptors O O
compared O O
to O O
those O O
without O O
them O O
( O O
REc B-protein O
P O O
= O O
0.11 O O
, O O
RPc O O
P O O
= O O
0.7 O O
) O O
. O O

There O O
was O O
no O O
difference O O
in O O
RFS O O
of O O
receptor O O
positive O O
and O O
negative O O
tumours O O
when O O
the O O
axillary O O
node O O
status O O
was O O
taken O O
into O O
account O O
. O O

Clinical O O
implications O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
human O O
leukemia O O
. O O

Normal B-cell_type O
lymphoid I-cell_type O
cells I-cell_type O
contain O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
. O O

A O O
variety O O
of O O
stimuli O O
that O O
activate O O
these O O
cells O O
also O O
induce O O
increases O O
in O O
receptor O O
concentration O O
. O O

Similar O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
can O O
be O O
detected O O
in O O
lymphoid B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
( O O
ALL O O
) O O
. O O

Absence O O
of O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
( O O
usually O O
found O O
in O O
treated O O
patients O O
) O O
predicts O O
lack O O
of O O
glucocorticoid O O
responsiveness O O
. O O

Furthermore O O
, O O
in O O
our O O
hands O O
, O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
levels O O
correlate O O
with O O
the O O
duration O O
of O O
complete O O
remission O O
in O O
ALL O O
( O O
though O O
not O O
in O O
other O O
forms O O
of O O
leukemia O O
) O O
. O O

This O O
association O O
is O O
independent O O
of O O
cell O O
type O O
, O O
age O O
, O O
sex O O
, O O
or O O
initial O O
leukocyte B-cell_type O
count O O
. O O

The O O
level O O
of O O
receptor O O
shows O O
a O O
negative O O
correlation O O
with O O
increasing O O
aggressiveness O O
of O O
the O O
tumor O O
( O O
null-cell O O
leukemia O O
greater O O
than O O
T-cell O O
leukemia O O
greater O O
than O O
Burkitt O O
's O O
lymphoma O O
) O O
. O O

Corticosteroid-mediated O O
immunoregulation O O
in O O
man O O
. O O

Glucocorticoids O O
have O O
profound O O
and O O
complex O O
effects O O
on O O
the O O
human O O
immune O O
response O O
. O O

However O O
, O O
the O O
precise O O
mechanisms O O
of O O
the O O
corticosteroid-induced O O
immunoregulation O O
in O O
man O O
have O O
not O O
been O O
precisely O O
defined O O
. O O

Intracytoplasmic B-protein B-protein
corticosteroid-specific I-protein I-protein
receptors I-protein I-protein
appear O O
to O O
be O O
an O O
important O O
common O O
pathway O O
for O O
steroid-induced O O
changes O O
, O O
but O O
variations O O
of O O
receptor O O
parameters O O
do O O
not O O
account O O
for O O
the O O
multifaceted O O
effects O O
on O O
the O O
immune O O
system O O
. O O

Human B-cell_type B-cell_type
circulating I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
redistribute O O
out O O
of O O
the O O
intravascular O O
compartment O O
following O O
treatment O O
with O O
corticosteroids O O
. O O

Although O O
certain O O
components O O
at O O
this O O
redistribution O O
phenomenon O O
have O O
been O O
well-characterized O O
, O O
the O O
importance O O
of O O
this O O
compartmental O O
cellular O O
shift O O
with O O
respect O O
to O O
the O O
mechanisms O O
of O O
corticosteroid-induced O O
immunoregulation O O
are O O
less O O
well-defined O O
. O O

Recent O O
observations O O
that O O
activated B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
may O O
be O O
sensitive O O
to O O
the O O
lytic O O
effects O O
of O O
glucocorticoids O O
suggest O O
that O O
under O O
certain O O
situations O O
the O O
elimination O O
of O O
selected O O
subsets O O
of O O
cells O O
may O O
be O O
a O O
relevant O O
mechanism O O
of O O
corticosteroid-mediated O O
immunoregulation O O
in O O
man O O
. O O

Corticosteroid-mediated O O
effects O O
on O O
monocyte B-cell_type O
function O O
may O O
be O O
an O O
important O O
mechanism O O
of O O
drug-induced B-cell_type O
immunoregulation I-cell_type O
in O O
monocyte-dependent B-cell_type O
responses I-cell_type O
. O O

In O O
some O O
experimental O O
conditions O O
, O O
corticosteroids O O
inhibit O O
Interleukin B-protein B-protein
1 I-protein I-protein
production O O
by O O
monocytes B-cell_type B-cell_type
. O O

The O O
immunoregulatory O O
effects O O
of O O
corticosteroids O O
on O O
lymphocyte B-cell_type O
immune O O
responses O O
are O O
complex O O
. O O

In O O
vitro O O
corticosteroids O O
appear O O
to O O
selectively O O
affect O O
early O O
immunoregulatory O O
events O O
as O O
opposed O O
to O O
altering O O
an O O
established O O
response O O
. O O

Multiple O O
sites O O
of O O
steroid-induced O O
modulations O O
of O O
human B-cell_type O
B I-cell_type O
cell I-cell_type O
responses O O
have O O
been O O
defined O O
. O O

Human B-cell_line B-cell_line
lymphoid I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
and O O
glucocorticoids O O
: O O
II O O
. O O

Whole O O
cell O O
and O O
cytoplasmic O O
binding O O
properties O O
of O O
lymphoblastoid B-cell_line B-cell_line
, I-cell_line I-cell_line
leukaemia I-cell_line I-cell_line
and I-cell_line I-cell_line
lymphoma I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

The O O
glucocorticoid O O
binding O O
properties O O
of O O
18 O B-cell_line
human B-cell_line I-cell_line
lymphoid I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
( O O
HLCL B-cell_line B-cell_line
) O O
have O O
been O O
investigated O O
. O O

The O O
specificity O O
of O O
steroid O O
binding O O
was O O
confirmed O O
with O O
various O O
glucocorticoid O O
agonists O O
and O O
antagonists O O
. O O

A O O
gradation O O
in O O
whole O O
cell O O
and O O
cytoplasmic O O
glucocorticoid O O
binding O O
capacity O O
was O O
observed O O
in O O
the O O
different O O
cell O B-cell_line
line O I-cell_line
types O I-cell_line
: O O
lymphoblastoid B-cell_line O
greater O O
than O O
lymphoma B-cell_line O
greater O O
than O O
leukaemia B-cell_line O
. O O

The O O
cytoplasmic B-protein B-protein
receptors I-protein I-protein
of O O
leukaemia B-cell_line B-cell_line
and I-cell_line I-cell_line
lymphoblastoid I-cell_line I-cell_line
lines I-cell_line I-cell_line
appeared O O
to O O
contain O O
both O O
proteinaceous O O
and O O
phospholipid O O
components O O
. O O

Cytoplasmic B-protein B-protein
steroid-receptor I-protein I-protein
complexes I-protein I-protein
exhibited O O
a O O
wide O O
range O O
of O O
sedimentation O O
coefficients O O
( O O
8.5-11.3S O O
) O O
in O O
low O O
ionic O O
strength O O
buffer O O
but O O
there O O
was O O
no O O
correlation O O
with O O
cell O O
line O O
type O O
or O O
glucocorticoid O O
sensitivity O O
. O O

Activation O O
of O O
these O O
complexes O O
by O O
heat O O
( O O
37 O O
degrees O O
C O O
) O O
or O O
exposure O O
to O O
high O O
ionic O O
strength O O
buffer O O
( O O
0.3 O O
M O O
NaCl O O
) O O
induced O O
nuclear O O
binding O O
of O O
steroid O O
but O O
only O O
complexes O O
in O O
high O O
ionic O O
strength O O
buffer O O
manifested O O
changes O O
in O O
sedimentation O O
coefficient O O
. O O

No O O
correlation O O
was O O
observed O O
between O O
the O O
level O O
or O O
nature O O
of O O
glucocorticoid O O
binding O O
and O O
the O O
cytolethal O O
or O O
cytostatic O O
responsiveness O O
of O O
HLCL B-cell_line O
to O O
glucocorticoid O O
treatment O O
in O O
vitro O O
. O O

The O O
resistance O O
to O O
cytolethal O O
effects O O
can O O
not O O
be O O
ascribed O O
to O O
a O O
failure O O
of O O
cells O O
to O O
take O O
up O O
and O O
bind O O
steroid O O
or O O
to O O
significant O O
differences O O
in O O
the O O
molecular O O
species O O
of O O
cytoplasmic B-protein B-protein
receptors I-protein I-protein
present O O
. O O

The O O
molecular O O
mechanisms O O
by O O
which O O
glucocorticoids O O
achieve O O
cytolethal O O
responses O O
in O O
human B-cell_type B-cell_type
lymphoid I-cell_type I-cell_type
cells I-cell_type I-cell_type

CD28 B-protein B-protein
-mediated O O
activation O O
in O O
CD45RA+ B-cell_type B-cell_type
and I-cell_type O
CD45RO+ I-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
: O O
enhanced O O
levels O O
of O O
reactive O O
oxygen O O
intermediates O O
and O O
c-Rel B-protein B-protein
nuclear O O
translocation O O
in O O
CD45RA+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

We O O
have O O
analyzed O O
the O O
effect O O
of O O
complete O O
T O O
cell O O
activation O O
( O O
anti-CD3 B-protein B-protein
plus O O
anti-CD28 B-protein B-protein
) O O
on O O
the O O
activation O O
of O O
NF-kappaB B-protein B-protein
in O O
CD45RA+ B-cell_type B-cell_type
( I-cell_type I-cell_type
naive I-cell_type I-cell_type
) I-cell_type I-cell_type
and I-cell_type I-cell_type
CD45RO+ I-cell_type I-cell_type
( I-cell_type I-cell_type
memory/effector I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Long O O
exposure O O
( O O
24 O O
h O O
) O O
induced O O
stronger O O
NF-kappaB B-protein B-protein
DNA O O
binding O O
in O O
CD45RA+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
than O O
in O O
CD45RO+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Analysis O O
of O O
the O O
nuclear B-protein B-protein
c-Rel I-protein I-protein
protein I-protein I-protein
indicated O O
that O O
after O O
anti-CD3+anti-CD28 O O
stimulation O O
the O O
level O O
of O O
c-Rel B-protein B-protein
was O O
higher O O
in O O
CD45RA+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Analysis O O
of O O
the O O
cytoplasmic O B-protein
inhibitor O I-protein
IkappaBalpha B-protein B-protein
indicated O O
that O O
anti-CD3+anti-CD28 O O
stimulation O O
induced O O
a O O
long-lasting O O
degradation O O
in O O
CD45RA+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
but O O
in O O
CD45RO+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
the O O
degradation O O
process O O
was O O
more O O
rapid O O
. O O

Because O O
the O O
CD28 O B-protein
costimulus O O
is O O
known O O
to O O
induce O O
the O O
production O O
of O O
reactive O O
oxygen O O
intermediates O O
( O O
ROIs O O
) O O
, O O
the O O
intracellular O O
ROI O O
levels O O
in O O
CD45RA+ B-cell_type B-cell_type
and I-cell_type O
CD45RO+ I-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
compared O O
by O O
flow O O
cytometry O O
. O O

ROIs O O
were O O
produced O O
in O O
both O O
cell O O
types O O
, O O
but O O
more O O
strongly O O
in O O
CD45RA+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
data O O
presented O O
in O O
this O O
study O O
further O O
emphasize O O
the O O
differences O O
between O O
CD45RA+ B-cell_type O
and I-cell_type O
CD45RO+ I-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
in O O
ROI-dependent O O
signaling O O
pathways O O
. O O

Ikaros B-protein B-protein
in O O
hemopoietic B-cell_line B-cell_type
lineage I-cell_line I-cell_type
determination O O
and O O
homeostasis O O
. O O

Studies O O
on O O
the O O
molecular O O
mechanisms O O
that O O
control O O
hemopoietic O O
differentiation O O
have O O
focused O O
on O O
signaling O O
cascades O O
and O O
nuclear O B-protein
effectors O I-protein
that O O
drive O O
this O O
complex O O
developmental O O
system O O
in O O
a O O
regulated O O
fashion O O
. O O

Here O O
we O O
review O O
the O O
role O O
of O O
Ikaros B-protein B-protein
, O O
the O O
founding O O
member O O
of O O
a O O
unique O O
family O O
of O O
zinc B-protein B-protein
finger I-protein I-protein
transcription I-protein I-protein
factors I-protein I-protein
in O O
this O O
developmental O O
process O O
. O O

Studies O O
on O O
an O O
Ikaros B-protein B-protein
null O I-protein
mutation O I-protein
have O O
revealed O O
an O O
essential O O
role O O
for O O
this O O
factor O O
in O O
lymphoid B-cell_type O
cell I-cell_type O
fate O O
determination O O
and O O
at O O
subsequent O O
branch O O
points O O
of O O
the O O
T B-cell_type O
cell I-cell_type O
differentiation O O
pathway O O
. O O

Differences O O
in O O
the O O
phenotypes O O
of O O
a O O
null O O
and O O
a O O
dominant O O
negative O O
( O O
DN O O
) O O
Ikaros O B-protein
mutation O O
provide O O
insight O O
into O O
a O O
regulatory O O
network O O
through O O
which O O
Ikaros B-protein B-protein
proteins I-protein I-protein
exert O O
their O O
effects O O
in O O
development O O
. O O

In O O
addition O O
a O O
comparative O O
analysis O O
of O O
the O O
hemopoietic B-cell_type B-cell_type
stem I-cell_type I-cell_type
cell I-cell_type I-cell_type
and O O
precursor O O
compartment O O
resulting O O
from O O
the O O
two O O
Ikaros B-protein B-protein
mutations O O
reveals O O
a O O
profound O O
yet O O
not O O
absolute O O
requirement O O
for O O
Ikaros B-protein B-protein
in O O
the O O
production O O
and O O
differentiation O O
of O O
these O O
populations O O
. O O

Overexpression O O
of O O
p65 O B-protein
and O O
c-Jun O B-protein
substitutes O O
for O O
B7-1 O B-protein
costimulation O O
by O O
targeting O O
the O O
CD28RE B-DNA B-DNA
within O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

The O O
role O O
of O O
Rel B-protein B-protein
and O O
activation B-protein B-protein
protein-1 I-protein I-protein
( O O
AP-1 B-protein B-protein
) O O
in O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
activity O O
in O O
B7-1- B-cell_type B-cell_line
and I-cell_type I-cell_line
leukocyte I-cell_type I-cell_line
function-associated I-cell_type I-cell_line
Ag-3 I-cell_type I-cell_line
( I-cell_type I-cell_line
LFA. I-cell_type I-cell_line
3 I-cell_type I-cell_line
) I-cell_type I-cell_line
-costimulated I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
has O O
been O O
evaluated O O
. O O

We O O
demonstrate O O
that O O
overexpression O O
of O O
c-Jun B-protein B-protein
but O O
not O O
c-Fos B-protein B-protein
increases O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
activity O O
in O O
both O O
B7-1- B-cell_type B-cell_line
and I-cell_type I-cell_line
LFA-3-costimulated I-cell_type I-cell_line
Jurkat I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

Cotransfection O O
of O O
both O O
c-Jun O B-protein
and O I-protein
c-Fos O I-protein
substitutes O I-protein
for O O
B7-1 O B-protein
costimulation O O
in O O
driving O O
an O O
activation B-DNA B-DNA
protein-1 I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
but O O
not O O
for O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Overexpression O O
of O O
Rel B-protein B-protein
proteins I-protein I-protein
demonstrated O O
that O O
p65-expressing B-cell_line B-cell_line
Jurkat I-cell_line I-cell_line
cells I-cell_line I-cell_line
transcribed O O
equally O O
well O O
a O O
nuclear B-DNA B-DNA
factor I-DNA I-DNA
kappabeta I-DNA I-DNA
reporter I-DNA I-DNA
construct I-DNA I-DNA
when O O
costimulated O O
with O O
B7-1 B-protein B-protein
or O O
LFA-3 B-protein B-protein
, O O
but O O
transcription O O
of O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
or O O
CD28 B-DNA B-DNA
response I-DNA I-DNA
element I-DNA I-DNA
( I-DNA O
CD28RE I-DNA B-DNA
) I-DNA I-DNA
-driven I-DNA I-DNA
reporters I-DNA I-DNA
was O O
superior O O
in O O
B7-1-costimulated B-cell_line B-cell_type
cells I-cell_line I-cell_type
. O O

Combined O O
expression O O
of O O
c-Jun B-protein B-protein
and O O
p65 B-protein B-protein
induced O O
vigorous O O
transcription O O
of O O
IL-2 B-DNA B-DNA
promoter- I-DNA I-DNA
and I-DNA O
CD28RE-driven I-DNA B-DNA
reporter I-DNA I-DNA
constructs I-DNA I-DNA
in O O
both O O
LFA-3- B-cell_type B-cell_line
and I-cell_type I-cell_line
B7-1-costimulated I-cell_type I-cell_line
Jurkat I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

Mutating O O
the O O
CD28RE B-DNA B-DNA
but O O
not O O
the O O
upstream B-DNA B-DNA
nuclear I-DNA I-DNA
factor I-DNA I-DNA
kappabeta-binding I-DNA I-DNA
site I-DNA I-DNA
in O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
reduced O O
B7-1 B-protein B-protein
-driven O O
transcription O O
> O O
90 O O
% O O
. O O

The O O
results O O
implicates O O
a O O
major O O
role O O
of O O
the O O
CD28RE B-DNA B-DNA
in O O
the O O
integration O O
of O O
p65 B-protein B-protein
/ O O
c-Jun B-protein B-protein
-mediated O O
transcription O O
within O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

We O O
suggest O O
that O O
the O O
transition O O
from O O
an O O
autocrine O O
LFA-3 B-protein B-protein
-driven O O
immune O O
response O O
to O O
a O O
B7 O B-protein
-- O O
induced O O
paracrine O O
immune O O
response O O
involves O O
the O O
activation O O
of O O
c-Jun B-protein B-protein
and O O
p65 B-protein B-protein
, O O
which O O
target O O
the O O
CD28RE B-DNA B-DNA
region O I-DNA
of O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Defects O O
in O O
actin-cap O O
formation O O
in O O
Vav-deficient O O
mice O O
implicate O O
an O O
actin O B-protein
requirement O O
for O O
lymphocyte O O
signal O O
transduction O O
. O O

BACKGROUND O O
: O O
Antigen-receptor O O
interactions O O
on O O
lymphocytes B-cell_type B-cell_type
result O O
in O O
local O O
clustering O O
of O O
actin B-protein B-protein
, O O
receptors O O
and O O
signaling O B-protein
molecules O I-protein
into O O
an O O
asymmetric O O
membrane O O
structure O O
termed O O
a O O
cap O O
. O O

Although O O
actin O B-protein
polymerization O O
is O O
known O O
to O O
be O O
required O O
, O O
the O O
mechanisms O O
underlying O O
cap O O
formation O O
are O O
unclear O O
. O O

We O O
have O O
studied O O
the O O
events O O
underlying O O
cap O O
formation O O
using O O
mice O O
bearing O O
a O O
null O O
mutation O O
in O O
vav B-DNA B-protein
( O O
vav B-DNA B-protein
-/- O O
) O O
, O O
a O O
gene O O
that O O
encodes O O
a O O
guanine-nucleotide B-protein B-protein
exchange I-protein I-protein
factor I-protein I-protein
for O O
the O O
GTPase B-protein B-protein
Rac I-protein I-protein
. O O

RESULTS O O
: O O
Lymphocytes B-cell_type B-cell_type
from O O
vav B-DNA B-protein
-/- O O
mice O O
failed O O
to O O
form O O
T-cell O B-cell_type
receptor O B-protein
caps O O
following O O
activation O O
and O O
had O O
a O O
defective O O
actin O B-protein
cytoskeleton O O
. O O

The O O
vav-/- B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
deficient O O
in O O
interleukin-2 O B-protein
( O O
IL-2 O B-protein
) O O
production O O
and O O
proliferation O O
, O O
and O O
the O O
peak O O
of O O
Ca2+ O O
mobilization O O
was O O
reduced O O
although O O
of O O
normal O O
duration O O
. O O

Activation O O
of O O
Jun B-protein B-protein
N-terminal I-protein I-protein
kinase I-protein I-protein
or O O
stress-activated B-protein B-protein
kinase I-protein I-protein
( O O
JNK B-protein B-protein
or O O
SAPK B-protein B-protein
) O O
and O O
mitogen-activated B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
( O O
MAPK B-protein B-protein
) O O
and O O
the O O
induction O O
of O O
the O O
transcription B-protein B-DNA
factor I-protein I-DNA
NF-ATc1 B-DNA I-DNA
and I-DNA I-DNA
egr-1 I-DNA I-DNA
genes I-DNA I-DNA
was O O
normal O O
. O O

Despite O O
the O O
reduced O O
Ca2+ O O
mobilization O O
, O O
translocation O O
of O O
cytoplasmic B-protein B-protein
NF-ATc I-protein I-protein
to O O
the O O
nucleus O O
was O O
normal O O
, O O
reflecting O O
that O O
the O O
lower O O
levels O O
of O O
Ca2+ O O
in O O
vav-/- B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
still O O
sufficient O O
to O O
activate O O
calcineurin B-protein B-protein
. O O

Treatment O O
of O O
lymphocytes B-cell_type B-cell_type
with O O
cytochalasin O O
D O O
, O O
which O O
blocks O O
actin O B-protein
polymerization O O
, O O
inhibited O O
cap O O
formation O O
and O O
produced O O
defects O O
in O O
signaling O O
and O O
IL-2 O B-protein
transcriptional O O
induction O O
in O O
response O O
to O O
antigen-receptor O O
signaling O O
that O O
were O O
nearly O O
identical O O
to O O
those O O
seen O O
in O O
vav-/- B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

In O O
transfection O O
studies O O
, O O
either O O
constitutively O O
active O O
Vav B-protein B-protein
or O O
Rac B-protein B-protein
could O O
complement O O
constitutively O O
active O O
calcineurin B-protein B-protein
to O O
activate O O
NF-AT-dependent O O
transcription O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
indicate O O
that O O
Vav B-protein B-protein
is O O
required O O
for O O
cap O O
formation O O
in O O
lymphocytes B-cell_type B-cell_type
. O O

Furthermore O O
, O O
the O O
correlation O O
between O O
cap O O
formation O O
, O O
IL-2 O B-protein
production O O
and O O
proliferation O O
supports O O
the O O
hypothesis O O
that O O
an O O
actin-dependent O O
pathway O O
is O O
a O O
source O O
of O O
specialized O O
growth O O
regulatory O O
signals O O
. O O

CD14 B-protein B-protein
-dependent O O
activation O O
of O O
human B-cell_type B-cell_type
endothelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
Bacteroides O O
fragilis O O
outer O O
membrane O O
. O O

We O O
studied O O
the O O
capacity O O
of O O
isolated O O
Bacteriodes O O
fragilis O O
outer O O
membrane O O
, O O
B. O O
fragilis O O
NCTC9343 O O
lipopolysaccharide O O
( O O
LPS O O
; O O
endotoxin O O
) O O
, O O
and O O
B. O O
fragilis O O
NCTC9343 O O
capsular O O
polysaccharides O O
to O O
activate O O
human O B-cell_line
umbilical O I-cell_line
vein O I-cell_line
endothelial O I-cell_line
cell O I-cell_line
( O I-cell_line
HUVEC O I-cell_line
) O I-cell_line
monolayers O I-cell_line
. O O

To O O
assess O O
HUVEC O B-cell_line
activation O O
, O O
E-selectin B-protein B-protein
expression O O
was O O
measured O O
by O O
enzyme-linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
, O O
Northern O O
blot O O
analysis O O
for O O
E-selectin-specific B-RNA B-RNA
mRNA I-RNA I-RNA
, O O
and O O
electrophoretic O O
gel O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
for O O
NF-kappa B-protein B-protein
B I-protein I-protein
, O O
a O O
transcription B-protein B-protein
factor I-protein I-protein
necessary O O
for O O
E-selectin B-DNA B-DNA
gene I-DNA I-DNA
activation O O
. O O

Exposure O O
of O O
HUVECs B-cell_type B-cell_line
to O O
B. O O
fragilis O O
outer O O
membrane O O
fractions O O
, O O
separated O O
from O O
other O O
components O O
of O O
the O O
B. O O
fragilis O O
cell O O
wall O O
by O O
isopycnic O O
, O O
sucrose O O
gradient O O
centrifugation O O
, O O
significantly O O
increased O O
surface O O
expression O O
of O O
E-selectin B-protein B-protein
and O O
induced O O
functional O O
endothelial B-cell_type O
cell I-cell_type O
-dependent O O
leukocyte O O
adhesion O O
. O O

B. O O
fragilis O O
outer O O
membranes O O
induced O O
translocation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
to O O
HUVEC O B-cell_type
nuclei O O
and O O
accumulation O O
of O O
E-selectin B-RNA B-RNA
mRNA I-RNA I-RNA
in O O
HUVEC O B-cell_type
cytoplasm O O
. O O

E-selectin O B-protein
expression O O
induced O O
by O O
B. O O
fragilis O O
outer O O
membranes O O
was O O
not O O
blocked O O
by O O
polymixin O O
B O O
. O O

In O O
contrast O O
, O O
E-selectin O B-protein
expression O O
induced O O
by O O
outer O O
membrane O O
fractions O O
purified O O
from O O
E. O O
coli O O
was O O
competitively O O
inhibited O O
by O O
polymixin O O
B O O
. O O

Neither O O
purified O O
B. O O
fragilis O O
LPS O O
, O O
a O O
prominent O O
constituent O O
of O O
the O O
outer O O
membrane O O
, O O
nor O O
purified O O
B. O O
fragilis O O
capsular O O
polysaccharides O O
induced O O
HUVEC O B-cell_type
activation O O
. O O

Two O O
different O O
monoclonal B-protein B-protein
antibodies I-protein I-protein
directed O O
against O O
human B-protein O
CD14 I-protein B-protein
completely O O
inhibited O O
B. O O
fragilis O O
outer O O
membrane-induced O O
NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
, O O
E-selectin O B-protein
transcription O O
, O O
and O O
E-selectin O B-protein
surface O O
expression O O
. O O

We O O
conclude O O
that O O
the O O
outer O O
membrane O O
component O O
of O O
the O O
B. O O
fragilis O O
cell O O
wall O O
contains O O
a O O
proinflammatory O B-protein
factor O I-protein
( O O
s O O
) O O
, O O
that O O
is O O
not O O
LPS O O
, O O
which O O
induces O O
human B-cell_type O
endothelial I-cell_type O
cell I-cell_type O
activation O O
by O O
a O O
soluble O O
CD14 B-protein B-protein
-dependent O O
mechanism O O
. O O

NF-kappaB B-protein B-protein
protects O O
HIV-1-infected O B-cell_type
myeloid B-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
apoptosis O O
. O O

HIV-1 O O
infection O O
of O O
primary B-cell_type B-cell_type
monocytic I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
myeloid B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
results O O
in O O
sustained O O
NF-kappaB O B-protein
activation O O
. O O

Recently O O
, O O
NF-kappaB O B-protein
induction O O
has O O
been O O
shown O O
to O O
play O O
a O O
role O O
in O O
protecting O O
cells O O
from O O
programmed O O
cell O O
death O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
sought O O
to O O
investigate O O
whether O O
constitutive O O
NF-kappaB B-protein B-protein
activity O O
in O O
chronically O O
HIV-1-infected O B-cell_line
promonocytic B-cell_line I-cell_line
U937 I-cell_line I-cell_line
( I-cell_line O
U9-IIIB I-cell_line B-cell_line
) I-cell_line I-cell_line
and I-cell_line I-cell_line
myeloblastic I-cell_line I-cell_line
PLB-985 I-cell_line I-cell_line
( I-cell_line I-cell_line
PLB-IIIB I-cell_line I-cell_line
) I-cell_line I-cell_line
cells I-cell_line I-cell_line
affects O O
apoptotic O O
signaling O O
. O O

TNFalpha B-protein B-protein
and O O
cycloheximide O O
caused O O
infected O B-cell_type
cells O I-cell_type
to O O
undergo O O
apoptosis O O
more O O
rapidly O O
than O O
parental B-cell_line O
U937 I-cell_line B-cell_line
and O O
PLB-985 B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

Inhibition O O
of O O
TNFalpha B-protein B-protein
-induced O O
NF-kappaB O B-protein
activation O O
using O O
the O O
antioxidant O O
N-acetylcysteine O O
( O O
NAC O O
) O O
resulted O O
in O O
increased O O
apoptosis O O
in O O
both O O
U937 B-cell_line B-cell_line
and I-cell_line O
U9-IIIB I-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
while O O
preactivation O O
of O O
NF-kappaB B-protein B-protein
with O O
the O O
non-apoptotic B-protein O
inducer I-protein O
IL-1beta I-protein B-protein
caused O O
a O O
relative O O
decrease O O
in O O
apoptosis O O
. O O

Inhibition O O
of O O
constitutive O O
NF-kappaB B-protein B-protein
activity O O
in O O
U9-IIIB B-cell_line B-cell_line
and I-cell_line I-cell_line
PLB-IIIB I-cell_line I-cell_line
cells I-cell_line I-cell_line
also O O
induced O O
apoptosis O O
, O O
suggesting O O
that O O
NF-kappaB B-cell_type B-protein
protects I-cell_type O
cells I-cell_type O
from O O
a O O
persistent O O
apoptotic O O
signal O O
. O O

TNFalpha B-protein B-protein
plus O O
NAC O O
treatment O O
resulted O O
in O O
a O O
marked O O
decrease O O
in O O
Bcl-2 B-protein B-protein
protein I-protein O
levels O O
in O O
HIV-1-infected B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
coupled O O
with O O
an O O
increase O O
in O O
Bax B-protein B-protein
protein I-protein I-protein
compared O O
to O O
uninfected O B-cell_type
cells O I-cell_type
, O O
suggesting O O
that O O
the O O
difference O O
in O O
susceptibility O O
to O O
TNFalpha B-protein B-protein
-induced O O
apoptosis O O
may O O
relate O O
to O O
the O O
differences O O
in O O
relative O O
levels O O
of O O
Bcl-2 B-protein B-protein
and O O
Bax B-protein B-protein
. O O

The O O
protective O O
role O O
of O O
NF-kappaB B-protein B-protein
in O O
blocking O O
TNFalpha- O O
and O O
HIV-1-induced O O
apoptosis O O
was O O
supported O O
by O O
studies O O
in O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
engineered O O
to O O
express O O
IkappaB B-protein B-protein
alpha I-protein I-protein
repressor I-protein I-protein
mutants I-protein I-protein
( O O
TD-IkappaB B-protein B-protein
) O O
under O O
the O O
control O O
of O O
a O O
tetracycline-responsive B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Cells O O
underwent O O
apoptosis O O
in O O
response O O
to O O
TNFalpha B-protein B-protein
only O O
when O O
NF-kappaB O B-protein
activation O O
was O O
inhibited O O
by O O
TD-IkappaB B-protein B-protein
expression O O
. O O

As O O
was O O
observed O O
for O O
the O O
U9-IIIB B-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
TNFalpha B-protein B-protein
treatment O O
also O O
induced O O
a O O
marked O O
decrease O O
in O O
Bcl-2 B-protein B-protein
protein I-protein O
levels O O
in O O
TD-IkappaB B-cell_type B-cell_line
expressing I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

These O O
experiments O O
demonstrate O O
that O O
apoptotic O O
signaling O O
is O O
perturbed O O
in O O
HIV-1-infected O B-cell_type
U9-IIIB B-cell_line I-cell_type
cells I-cell_line I-cell_type
and O O
indicate O O
that O O
NF-kappaB O B-protein
activation O O
may O O
play O O
an O O
additional O O
protective O O
role O O
against O O
HIV-1-induced O O
apoptosis O O
in O O
myeloid B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Human B-cell_type B-cell_type
normal I-cell_type I-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
B-lymphocytes I-cell_type I-cell_type
are O O
deficient O O
in O O
DNA-dependent O O
protein O O
kinase O O
activity O O
due O O
to O O
the O O
expression O O
of O O
a O O
variant O O
form O O
of O O
the O O
Ku86 B-protein B-protein
protein I-protein I-protein
. O O

The O O
heterodimeric O B-protein
Ku B-protein I-protein
protein I-protein I-protein
, O O
which O O
comprises O O
a O O
86 B-protein O
kDa I-protein O
( I-protein O
Ku86 I-protein B-protein
) I-protein O
amd O O
a O O
70 B-protein B-protein
kDa I-protein I-protein
( I-protein I-protein
Ku70 I-protein I-protein
) I-protein I-protein
subunits I-protein I-protein
, O O
is O O
an O O
abundant O B-protein
nuclear B-protein I-protein
DNA-binding I-protein I-protein
protein I-protein I-protein
which O O
binds O O
in O O
vitro O O
to O O
DNA B-DNA O
termini I-DNA O
without O O
sequence O O
specificity O O
. O O

Ku B-protein B-protein
is O O
the O O
DNA-targeting B-protein O
component I-protein O
of O O
the O O
large O O
catalytic B-protein B-protein
sub-unit I-protein I-protein
of O O
the O O
DNA-dependent B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
complex I-protein I-protein
( O O
DNA-PK B-protein B-protein
[ I-protein O
CS I-protein O
] I-protein O
) O O
, O O
that O O
plays O O
a O O
critical O O
role O O
in O O
mammalian O O
double-strand O O
break O O
repair O O
and O O
lymphoid O O
V O O
( O O
D O O
) O O
J O O
recombination O O
. O O

By O O
using O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
we O O
demonstrated O O
that O O
in O O
addition O O
to O O
the O O
major B-protein O
Ku I-protein B-protein
x I-protein I-protein
DNA I-protein I-protein
complex I-protein I-protein
usually O O
detected O O
in O O
cell O O
line O O
extracts O O
, O O
a O O
second O O
complex O O
with O O
faster O O
electrophoretic O O
mobility O O
was O O
observed O O
in O O
normal O B-cell_type
peripheral B-cell_type I-cell_type
blood I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
( O O
PBL B-cell_type B-cell_type
) O O
extracts O O
. O O

The O O
presence O O
of O O
this O O
faster B-protein O
migrating I-protein O
complex I-protein O
was O O
restricted O O
to O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
among O O
the O O
circulating B-cell_type O
lymphocyte I-cell_type O
population I-cell_type O
. O O

Western O O
blot O O
analysis O O
revealed O O
that O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
express O O
a O O
variant O O
form O O
of O O
the O O
Ku86 B-protein B-protein
protein I-protein I-protein
with O O
an O O
apparent O O
molecular O O
weight O O
of O O
69 O O
kDa O O
, O O
and O O
not O O
the O O
86 B-protein B-protein
kDa- I-protein I-protein
full-length I-protein I-protein
protein I-protein I-protein
. O O

Although O O
the O O
heterodimer B-protein B-protein
Ku70/variant-Ku86 I-protein I-protein
binds O O
to O O
DNA-ends B-DNA O
, O O
this O O
altered O O
form O O
of O O
the O O
Ku B-protein B-protein
heterodimer I-protein I-protein
has O O
a O O
decreased O O
ability O O
to O O
recruit O O
the O O
catalytic B-protein B-protein
component I-protein I-protein
of O O
the O O
complex O O
, O O
DNA-PK B-protein B-protein
( I-protein I-protein
CS I-protein I-protein
) I-protein I-protein
, O O
which O O
contributes O O
to O O
an O O
absence O O
of O O
detectable O O
DNA-PK O B-protein
activity O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

These O O
data O O
provide O O
a O O
molecular O O
basis O O
for O O
the O O
increased O O
sensitivity O O
of O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
to O O
ionizing O O
radiation O O
and O O
identify O O
a O O
new O O
mechanism O O
of O O
regulation O O
of O O
DNA-PK O B-protein
activity O O
that O O
operates O O
in O O
vivo O O
. O O

Co-stimulation O O
of O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
with O O
IL-2 B-protein B-protein
and O O
anti-CD3 B-protein B-protein
monoclonal I-protein I-protein
antibodies I-protein I-protein
induces O O
phosphorylation O O
of O O
CREB B-protein B-protein
. O O

Phosphorylation O O
of O O
the O O
cAMP-response B-protein B-protein
element I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
CREB I-protein B-protein
within O O
1 O O
h O O
of O O
CD2 B-protein B-protein
but O O
not O O
CD3 B-protein B-protein
cross-linking O O
of O O
human B-cell_type B-cell_type
PBMC I-cell_type I-cell_type
was O O
recently O O
demonstrated O O
. O O

The O O
absence O O
of O O
P-CREB B-protein B-protein
following O O
CD3 O B-protein
cross-linking O O
was O O
unexpected O O
, O O
as O O
other O O
laboratories O O
reported O O
increased O O
phosphorylation O O
of O O
CREB B-protein B-protein
following O O
CD3 O B-protein
cross-linking O O
of O O
the O O
Jurkat B-cell_line B-cell_line
lymphocyte I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

Due O O
to O O
Jurkat B-cell_line B-cell_line
T-cells I-cell_line I-cell_line
being O O
IL-2-independent O O
, O O
it O O
was O O
postulated O O
that O O
IL-2 B-protein B-protein
might O O
provide O O
a O O
necessary O O
co-stimulus O O
for O O
phosphorylation O O
of O O
CREB B-protein B-protein
in O O
primary B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Therefore O O
, O O
P-CREB B-protein B-protein
was O O
evaluated O O
following O O
co-stimulation O O
of O O
human B-cell_type B-cell_type
PBMC I-cell_type I-cell_type
through O O
the O O
IL-2 B-protein B-protein
and I-protein O
CD2 I-protein B-protein
or I-protein O
CD3 I-protein B-protein
receptors I-protein I-protein
. O O

IL-2 B-protein B-protein
did O O
not O O
further O O
augment O O
phosphorylation O O
of O O
CREB B-protein B-protein
following O O
CD2 O B-protein
cross-linking O O
. O O

However O O
, O O
while O O
neither O O
IL-2 B-protein B-protein
nor O O
CD3 O B-protein
cross-linking O O
alone O O
induced O O
P-CREB B-protein B-protein
, O O
a O O
4.5-fold O O
increase O O
in O O
phosphorylation O O
of O O
CREB B-protein B-protein
within O O
1 O O
h O O
of O O
IL-2/CD3 O O
co-stimulation O O
was O O
observed O O
. O O

Phosphorylation O O
was O O
not O O
associated O O
with O O
the O O
induction O O
of O O
cAMP O O
, O O
and O O
inhibition O O
of O O
PKA O B-protein
signaling O O
had O O
no O O
effect O O
on O O
P-CREB B-protein B-protein
. O O

Consistent O O
with O O
signal O O
transduction O O
through O O
p56lck B-protein B-protein
or O O
p59fyn B-protein B-protein
, O O
inhibition O O
of O O
PTK O B-protein
signaling O O
reduced O O
phosphorylation O O
50 O O
% O O
. O O

Interestingly O O
, O O
inhibiting O O
PKC O B-protein
signaling O O
with O O
calphostin O O
C O O
further O O
increased O O
P-CREB O B-protein
levels O O
3-fold O O
over O O
that O O
observed O O
in O O
IL-2/CD3 B-cell_type B-cell_line
co-stimulated I-cell_type I-cell_line
cells I-cell_type I-cell_line
not O O
pretreated O O
with O O
a O O
PKC O B-protein
inhibitor O O
. O O

In O O
contrast O O
to O O
previous O O
studies O O
performed O O
in O O
the O O
absence O O
of O O
exogenous B-protein O
IL-2 I-protein B-protein
, O O
no O O
increase O O
in O O
binding O O
of O O
CREB B-protein B-protein
to O O
a O O
32P-labeled O B-DNA
oligonucleotide O I-DNA
probe O I-DNA
was O O
observed O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

These O O
data O O
suggest O O
that O O
the O O
IL-2 B-protein B-protein
and O O
CD3 B-protein B-protein
signaling O O
pathways O O
provide O O
a O O
necessary O O
and O O
co-operative O O
stimulus O O
promoting O O
phosphorylation O O
of O O
CREB B-protein B-protein
following O O
receptor O O
cross-linking O O
. O O

HIV-1 O O
infection O O
induces O O
a O O
selective O O
reduction O O
in O O
STAT5 O B-protein
protein O O
expression O O
. O O

HIV-1 O O
infection O O
is O O
accompanied O O
by O O
qualitative O O
and O O
quantitative O O
defects O O
in O O
CD4+ B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Loss O O
of O O
immune O O
function O O
in O O
HIV O O
patients O O
is O O
usually O O
associated O O
with O O
a O O
profound O O
dysregulation O O
of O O
cytokine B-protein B-protein
production O O
. O O

To O O
investigate O O
whether O O
cytokine B-protein B-protein
signaling O O
defects O O
occur O O
during O O
HIV O O
infection O O
, O O
PHA B-cell_type B-cell_type
blasts I-cell_type I-cell_type
from O O
healthy O O
human O O
donors O O
were O O
infected O O
with O O
two O O
strains O O
of O O
HIV-1 O O
and O O
screened O O
for O O
the O O
expression O O
of O O
STAT B-protein B-protein
proteins I-protein I-protein
used O O
in O O
cytokine B-protein B-protein
signaling O O
. O O

A O O
selective O O
decrease O O
in O O
STAT5B B-protein B-protein
was O O
seen O O
8 O O
days O O
after O O
infection O O
with O O
the O O
BZ167 O O
dual-tropic O O
HIV O O
isolate O O
, O O
but O O
not O O
with O O
the O O
Ba-L O O
, O O
M-tropic O O
strain O O
. O O

Based O O
on O O
these O O
findings O O
, O O
purified B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
HIV-infected O O
patients O O
in O O
different O O
stages O O
of O O
disease O O
were O O
also O O
tested O O
for O O
STAT O B-protein
expression O O
; O O
decreases O O
in O O
STAT5A B-protein B-protein
, O O
STAT5B B-protein B-protein
, O O
and O O
STAT1alpha B-protein B-protein
were O O
observed O O
in O O
all O O
patients O O
. O O

The O O
reduction O O
in O O
STATs B-protein B-protein
seen O O
in O O
vivo O O
and O O
in O O
vitro O O
after O O
HIV O O
infection O O
may O O
contribute O O
to O O
the O O
loss O O
of O O
T B-cell_type O
cell I-cell_type O
function O O
in O O
HIV O O
disease O O
. O O

Transcription B-protein B-protein
factors I-protein I-protein
that O O
regulate O O
monocyte B-cell_type B-cell_type
/ O O
macrophage B-cell_type O
differentiation O O
. O O

Although O O
all O O
the O O
cells O O
in O O
an O O
organism O O
contain O O
the O O
same O O
genetic O O
information O O
, O O
differences O O
in O O
the O O
cell O O
phenotype O O
arise O O
from O O
the O O
expression O O
of O O
lineage-specific B-DNA B-DNA
genes I-DNA I-DNA
. O O

During O O
myelopoiesis O O
, O O
external O O
differentiating O O
signals O O
regulate O O
the O O
expression O O
of O O
a O O
set O O
of O O
transcription B-protein B-protein
factors I-protein I-protein
. O O

The O O
combined O O
action O O
of O O
these O O
transcription B-protein B-protein
factors I-protein I-protein
subsequently O O
determines O O
the O O
expression O O
of O O
myeloid-specific B-DNA B-DNA
genes I-DNA I-DNA
and O O
the O O
generation O O
of O O
monocytes B-cell_type B-cell_type
and O O
macrophages B-cell_type B-cell_type
. O O

In O O
particular O O
, O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
PU.1 I-protein B-protein
has O O
a O O
critical O O
role O O
in O O
this O O
process O O
. O O

We O O
review O O
the O O
contribution O O
of O O
several O O
transcription B-protein B-protein
factors I-protein I-protein
to O O
the O O
control O O
of O O
macrophage B-cell_type O
development O O

Transcription B-protein B-protein
factor I-protein I-protein
LKLF I-protein B-protein
is O O
sufficient O O
to O O
program O O
T O O
cell O O
quiescence O O
via O O
a O O
c-Myc O B-protein
-- O O
dependent O O
pathway O O
. O O

T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
circulate O I-cell_type
in O O
a O O
quiescent O O
state O O
until O O
they O O
encounter O O
cognate B-protein O
antigen I-protein O
bound O O
to O O
the O O
surface O O
of O O
an O O
antigen-presenting B-cell_type B-cell_type
cell I-cell_type I-cell_type
. O O

The O O
molecular O O
pathways O O
that O O
regulate O O
T O O
cell O O
quiescence O O
remain O O
largely O O
unknown O O
. O O

Here O O
we O O
show O O
that O O
forced O O
expression O O
of O O
the O O
lung B-protein B-protein
Kruppel-like I-protein I-protein
transcription I-protein I-protein
factor I-protein I-protein
( O O
LKLF B-protein B-protein
) O O
in O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
is O O
sufficient O O
to O O
program O O
a O O
quiescent O O
phenotype O O
characterized O O
by O O
decreased O O
proliferation O O
, O O
reduced O O
cell O O
size O O
and O O
protein O O
synthesis O O
and O O
decreased O O
surface O O
expression O O
of O O
activation O B-protein
markers O I-protein
. O O

Conversely O O
, O O
LKLF-deficient B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
produced O O
by O O
gene O O
targeting O O
showed O O
increased O O
proliferation O O
, O O
increased O O
cell O O
size O O
and O O
enhanced O O
expression O O
of O O
surface O B-protein
activation O I-protein
markers O I-protein
in O O
vivo O O
. O O

LKLF B-protein B-protein
appeared O O
to O O
function O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
decreasing O O
expression O O
of O O
the O O
proto-oncogene B-DNA B-DNA
encoding O O
c-Myc B-protein B-protein
. O O

Forced O O
expression O O
of O O
LKLF B-protein B-protein
was O O
associated O O
with O O
markedly O O
decreased O O
c-Myc B-protein B-protein
expression O O
. O O

In O O
addition O O
, O O
many O O
effects O O
of O O
LKLF B-protein B-protein
expression O O
were O O
mimicked O O
by O O
expression O O
of O O
the O O
dominant-negative B-protein B-protein
MadMyc I-protein I-protein
protein I-protein I-protein
and O O
rescued O O
by O O
overexpression O O
of O O
c-Myc B-protein B-protein
. O O

Thus O O
, O O
LKLF B-protein B-protein
is O O
both O O
necessary O O
and O O
sufficient O O
to O O
program O O
quiescence O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
functions O O
, O O
in O O
part O O
, O O
by O O
negatively O O
regulating O O
a O O
c-Myc O B-protein
-- O O
dependent O O
pathway O O
. O O

HTLV-1 B-protein B-protein
p12 I-protein I-protein
( I-protein I-protein
I I-protein I-protein
) I-protein I-protein
protein I-protein I-protein
enhances O O
STAT5 O B-protein
activation O O
and O O
decreases O O
the O O
interleukin-2 B-protein B-protein
requirement O O
for O O
proliferation O O
of O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
p12 B-protein B-protein
( I-protein I-protein
I I-protein I-protein
) I-protein I-protein
protein I-protein I-protein
, O O
encoded O O
by O O
the O O
pX B-DNA B-DNA
open I-DNA I-DNA
reading I-DNA I-DNA
frame I-DNA I-DNA
I I-DNA I-DNA
of O O
the O O
human O O
T-lymphotropic O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
, O O
is O O
a O O
hydrophobic B-protein O
protein I-protein O
that O O
localizes O O
to O O
the O O
endoplasmic O O
reticulum O O
and O O
the O O
Golgi O O
. O O

Although O O
p12 B-protein B-protein
( I-protein I-protein
I I-protein I-protein
) I-protein I-protein
contains O O
4 O B-DNA
minimal O I-DNA
proline-rich O I-DNA
, O I-DNA
src B-protein I-DNA
homology I-protein I-DNA
3-binding I-protein I-DNA
motifs I-protein I-DNA
( O O
PXXP B-protein B-protein
) O O
, O O
a O O
characteristic O O
commonly O O
found O O
in O O
proteins O O
involved O O
in O O
signaling O O
pathways O O
, O O
it O O
has O O
not O O
been O O
known O O
whether O O
p12 B-protein B-protein
( I-protein I-protein
I I-protein I-protein
) I-protein I-protein
has O O
a O O
role O O
in O O
modulating O O
intracellular O O
signaling O O
pathways O O
. O O

This O O
study O O
demonstrated O O
that O O
p12 B-protein B-protein
( I-protein I-protein
I I-protein I-protein
) I-protein I-protein
binds O O
to O O
the O O
cytoplasmic B-protein B-protein
domain I-protein I-protein
of O O
the O O
interleukin-2 B-protein B-protein
receptor I-protein I-protein
( I-protein I-protein
IL-2R I-protein I-protein
) I-protein I-protein
beta I-protein I-protein
chain I-protein I-protein
that O O
is O O
involved O O
in O O
the O O
recruitment O O
of O O
the O O
Jak1 B-protein B-protein
and I-protein I-protein
Jak3 I-protein I-protein
kinases I-protein I-protein
. O O

As O O
a O O
result O O
of O O
this O O
interaction O O
, O O
p12 B-protein B-protein
( I-protein I-protein
I I-protein I-protein
) I-protein I-protein
increases O I-protein
signal B-protein I-protein
transducers I-protein I-protein
and I-protein I-protein
activators I-protein I-protein
of I-protein I-protein
transcription I-protein I-protein
5 I-protein I-protein
( O O
STAT5 B-protein B-protein
) O O
DNA O O
binding O O
and O O
transcriptional O O
activity O O
and O O
this O O
effect O O
depends O O
on O O
the O O
presence O O
of O O
both O O
IL-2R B-protein B-protein
beta I-protein I-protein
and I-protein O
gamma I-protein B-protein
( I-protein I-protein
c I-protein I-protein
) I-protein I-protein
chains I-protein I-protein
and O O
Jak3 B-protein B-protein
. O O

Transduction O O
of O O
primary B-cell_line B-cell_type
human I-cell_line I-cell_type
peripheral I-cell_line I-cell_type
blood I-cell_line I-cell_type
mononuclear I-cell_line I-cell_type
cells I-cell_line I-cell_type
( O O
PBMCs B-cell_type B-cell_type
) O O
with O O
a O O
human B-DNA O
immunodeficiency I-DNA O
virus I-DNA O
type I-DNA O
1-based I-DNA O
retroviral I-DNA O
vector I-DNA O
expressing O O
p12 B-protein B-protein
( I-protein I-protein
I I-protein I-protein
) I-protein I-protein
also O O
resulted O O
in O O
increased O O
STAT5 B-protein B-protein
phosphorylation O O
and O O
DNA O O
binding O O
. O O

However O O
, O O
p12 B-protein B-protein
( I-protein I-protein
I I-protein I-protein
) I-protein I-protein
could O O
increase O O
proliferation O O
of O O
human B-cell_type B-cell_type
PBMCs I-cell_type I-cell_type
only O O
after O O
stimulation O O
of O O
T-cell B-protein B-protein
receptors I-protein I-protein
by O O
treatment O O
of O O
cells O O
with O O
low O O
concentrations O O
of O O
alphaCD3 B-protein B-protein
and I-protein O
alphaCD28 I-protein B-protein
antibodies I-protein I-protein
. O O

In O O
addition O O
, O O
the O O
proliferative O O
advantage O O
of O O
p12 B-cell_type B-protein
( I-cell_type I-protein
I I-cell_type I-protein
) I-cell_type I-cell_type
-transduced I-cell_type I-cell_type
PBMCs I-cell_type I-cell_type
was O O
evident O O
mainly O O
at O O
low O O
concentrations O O
of O O
IL-2 B-protein B-protein
. O O

Together O O
, O O
these O O
data O O
indicate O O
that O O
p12 B-protein B-protein
( I-protein I-protein
I I-protein I-protein
) I-protein I-protein
may O O
confer O O
a O O
proliferative O O
advantage O O
on O O
HTLV-1-infected B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
the O O
presence O O
of O O
suboptimal O O
antigen O O
stimulation O O
and O O
that O O
this O O
event O O
may O O
account O O
for O O
the O O
clonal O O
proliferation O O
of O O
infected B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
vivo O O
. O O

( O O
Blood. O O
2001 O O
; O O
98 O O
: O O
823-829 O O
) O O

Single O O
dose O O
intranasal O O
administration O O
of O O
retinal B-protein B-protein
autoantigen I-protein I-protein
generates O O
a O O
rapid O O
accumulation O O
and O O
cell O O
activation O O
in O O
draining O O
lymph O O
node O O
and O O
spleen O O
: O O
implications O O
for O O
tolerance O O
therapy O O
. O O

BACKGROUND/AIMS O O
: O O
A O O
single O O
intranasal O O
delivery O O
of O O
retinal B-protein O
autoantigen I-protein O
suppresses O O
effectively O O
experimental O O
autoimmune O O
uveoretinitis O O
( O O
EAU O O
) O O
. O O

To O O
further O O
unravel O O
underlying O O
mechanisms O O
the O O
authors O O
wished O O
to O O
determine O O
, O O
firstly O O
, O O
the O O
kinetics O O
of O O
antigen O O
delivery O O
and O O
, O O
secondly O O
, O O
the O O
early O O
cellular O O
responses O O
involved O O
in O O
the O O
initial O O
stages O O
of O O
nasal O O
mucosal O O
tolerance O O
induction O O
. O O

METHODS O O
: O O
Flow O O
cytometry O O
, O O
cell O O
proliferation O O
assays O O
, O O
and O O
microscopy O O
were O O
used O O
to O O
track O O
antigen B-protein O
following O O
a O O
single O O
, O O
intranasal O O
dose O O
of O O
Alexa-488 B-protein B-protein
labelled I-protein I-protein
retinal I-protein I-protein
antigen I-protein I-protein
. O O

RESULTS O O
: O O
A O O
rapid O O
accumulation O O
of O O
antigen B-protein O
within O O
both O O
superficial O O
cervical O O
lymph O O
nodes O O
( O O
SCLN O O
) O O
and O O
spleen O O
was O O
observed O O
after O O
30 O O
minutes O O
. O O

Significant O O
proliferative O O
responses O O
to O O
IRBP O B-protein
were O O
elicited O O
by O O
48 O O
hours O O
indicating O O
that O O
systemic O O
priming O O
of O O
naive B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
to O O
retinal B-protein B-protein
antigen I-protein I-protein
had O O
occurred O O
. O O

Cell O O
activation O O
was O O
further O O
confirmed O O
by O O
immunoprecipitation O O
studies O O
, O O
which O O
demonstrated O O
phosphorylation O O
of O O
STAT4 B-protein B-protein
but O O
not O O
STAT6 B-protein B-protein
in O O
both O O
lymph O O
nodes O O
and O O
spleen O O
. O O

However O O
, O O
at O O
24 O O
hours O O
, O O
STAT4 O B-protein
heterodimerisation O O
with O O
STAT B-protein B-protein
3 I-protein I-protein
was O O
only O O
observed O O
in O O
spleen O O
. O O

CONCLUSIONS O O
: O O
The O O
results O O
provide O O
novel O O
evidence O O
that O O
following O O
a O O
single O O
intranasal O O
application O O
rapid O O
transfer O O
of O O
antigen B-protein O
occurs O O
. O O

Resulting O O
T O O
cell O O
proliferation O O
develops O O
consequent O O
to O O
differential O O
cell O O
signalling O O
in O O
SCLN O O
and O O
spleen O O
. O O

Further O O
understanding O O
of O O
these O O
underlying O O
cellular O O
mechanisms O O
, O O
in O O
particular O O
as O O
is O O
inferred O O
by O O
the O O
results O O
the O O
contribution O O
of O O
local O O
versus O O
systemic O O
tolerance O O
induction O O
, O O
may O O
assist O O
in O O
strategies O O
to O O
clinically O O
apply O O
mucosal O O
tolerance O O
therapy O O
successfully O O
. O O

Regulation O O
of O O
interleukin B-protein B-protein
( I-protein I-protein
IL I-protein I-protein
) I-protein I-protein
-18 I-protein I-protein
receptor I-protein I-protein
alpha I-protein I-protein
chain I-protein I-protein
expression O O
on O O
CD4 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
during O I-cell_type
T O I-cell_type
helper O I-cell_type
( O I-cell_type
Th O I-cell_type
) O I-cell_type
1/Th2 O I-cell_type
differentiation O O
. O O

Critical O O
downregulatory O O
role O O
of O O
IL-4 B-protein B-protein
. O O

Interleukin B-protein B-protein
( I-protein I-protein
IL I-protein I-protein
) I-protein I-protein
-18 I-protein I-protein
has O O
been O O
well O O
characterized O O
as O O
a O O
costimulatory B-protein O
factor I-protein O
for O O
the O O
induction O O
of O O
IL-12-mediated B-protein B-protein
interferon I-protein I-protein
( I-protein I-protein
IFN I-protein I-protein
) I-protein I-protein
-gamma I-protein I-protein
production O O
by O O
T B-cell_type B-cell_type
helper I-cell_type I-cell_type
( I-cell_type I-cell_type
Th I-cell_type I-cell_type
) I-cell_type I-cell_type
1 I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
but O O
also O O
can O O
induce O O
IL-4 O B-protein
production O O
and O O
thus O O
facilitate O O
the O O
differentiation O O
of O O
Th2 B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

To O O
determine O O
the O O
mechanisms O O
by O O
which O O
IL-18 B-protein B-protein
might O O
regulate O O
these O O
diametrically O O
distinct O O
immune O O
responses O O
, O O
we O O
have O O
analyzed O O
the O O
role O O
of O O
cytokines B-protein B-protein
in O O
the O O
regulation O O
of O O
IL-18 B-protein B-protein
receptor I-protein I-protein
alpha I-protein I-protein
chain I-protein I-protein
( O O
IL-18Ralpha B-protein B-protein
) O O
expression O O
. O O

The O O
majority O O
of O O
peripheral B-cell_type B-cell_type
CD4 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
constitutively O O
expressed O O
the O O
IL-18Ralpha B-protein B-protein
. O O

Upon O O
antigen O O
stimulation O O
in O O
the O O
presence O O
of O O
IL-12 B-protein B-protein
, O O
marked O O
enhancement O O
of O O
IL-18Ralpha B-protein B-protein
expression O O
was O O
observed O O
. O O

IL-12 B-protein B-protein
-mediated O O
upregulation O O
of O O
IL-18Ralpha B-protein B-protein
required O O
IFN-gamma B-protein B-protein
. O O

Activated B-cell_type O
CD4 I-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
that O O
expressed O O
low O O
levels O O
of O O
IL-18Ralpha B-protein B-protein
could O O
produce O O
IFN-gamma B-protein B-protein
when O O
stimulated O O
with O O
the O O
combination O O
of O O
IL-12 B-protein B-protein
and O O
IL-18 B-protein B-protein
, O O
while O O
CD4 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
which O O
expressed O O
high O O
levels O O
of O O
IL-18Ralpha B-protein B-protein
could O O
respond O O
to O O
IL-18 B-protein B-protein
alone O O
. O O

In O O
contrast O O
, O O
T O O
cell O O
stimulation O O
in O O
the O O
presence O O
of O O
IL-4 B-protein B-protein
resulted O O
in O O
a O O
downregulation O O
of O O
IL-18Ralpha B-protein B-protein
expression O O
. O O

Both O O
IL-4 B-cell_type B-protein
( I-cell_type O
-/ I-cell_type O
) I-cell_type O
- I-cell_type O
and I-cell_type O
signal I-cell_type B-protein
transducer I-cell_type I-protein
and I-cell_type I-protein
activator I-cell_type I-protein
of I-cell_type I-protein
transcription I-cell_type I-protein
( I-cell_type I-protein
Stat I-cell_type I-protein
) I-cell_type I-protein
6 I-cell_type I-protein
( I-cell_type I-cell_type
-/ I-cell_type I-cell_type
) I-cell_type I-cell_type
- I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
expressed O O
higher O O
levels O O
of O O
IL-18Ralpha B-protein B-protein
after O O
TCR O B-protein
stimulation O O
. O O

Furthermore O O
, O O
activated B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
Stat6 O B-protein
( O O
-/ O O
) O O
- O O
mice O O
produced O O
more O O
IFN-gamma B-protein B-protein
in O O
response O O
to O O
IL-18 B-protein B-protein
than O O
wild-type O O
controls O O
. O O

Thus O O
, O O
positive/negative O O
regulation O O
of O O
the O O
IL-18Ralpha B-protein B-protein
by O O
the O O
major O O
inductive O O
cytokines B-protein B-protein
( O O
IL-12 B-protein B-protein
and O O
IL-4 B-protein B-protein
) O O
determines O O
the O O
capacity O O
of O O
IL-18 B-protein B-protein
to O O
polarize O O
an O O
immune O O
response O O
. O O

Glucocorticoid-regulated B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
. O O

Glucocorticoids O O
are O O
the O O
most O O
effective O O
antiinflammatory O O
drugs O O
used O O
in O O
the O O
treatment O O
of O O
asthma O O
. O O

They O O
act O O
by O O
binding O O
to O O
a O O
specific O O
receptor O O
( O O
GR B-protein B-protein
) O O
that O O
, O O
upon O O
activation O O
, O O
translocates O O
to O O
the O O
nucleus O O
and O O
either O O
increases O O
( O O
transactivates O O
) O O
or O O
decreases O O
( O O
transrepresses O O
) O O
gene O O
expression O O
. O O

Inhibition O O
of O O
pro-inflammatory B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
such O O
as O O
activator B-protein B-protein
protein I-protein I-protein
( I-protein I-protein
AP I-protein I-protein
) I-protein I-protein
-1 I-protein I-protein
, O O
signal B-protein B-protein
transducers I-protein I-protein
and I-protein I-protein
activators I-protein I-protein
of I-protein I-protein
transcription I-protein I-protein
( O O
STATs B-protein B-protein
) O O
, O O
nuclear B-protein B-protein
factor I-protein I-protein
of I-protein I-protein
activated I-protein I-protein
T I-protein I-protein
cells I-protein I-protein
( O O
NFAT B-protein B-protein
) O O
and O O
nuclear B-protein B-protein
factor I-protein I-protein
( I-protein I-protein
NF I-protein I-protein
) I-protein I-protein
-kappa I-protein I-protein
B I-protein I-protein
is O O
thought O O
to O O
be O O
a O O
major O O
action O O
of O O
glucocorticoids O O
. O O

Acetylation O O
of O O
histones B-protein B-protein
allows O O
unwinding O O
of O O
the O O
local B-DNA O
DNA I-DNA O
structure I-DNA O
and O O
enables O O
RNA B-protein B-protein
polymerase I-protein I-protein
II I-protein I-protein
to O O
enhance O O
gene O O
transcription O O
. O O

Histone O O
acetylation O O
is O O
regulated O O
by O O
a O O
balance O O
between O O
the O O
activity O O
of O O
histone B-protein B-protein
acetyltransferases I-protein I-protein
( O O
HATs B-protein B-protein
) O O
and O O
histone B-protein B-protein
deacetylases I-protein I-protein
( O O
HDACs B-protein B-protein
) O O
. O O

GR B-protein B-protein
acts O O
as O O
a O O
direct O O
inhibitor O O
of O O
NF-kappa O B-protein
B-induced O O
HAT O O
activity O O
and O O
also O O
by O O
recruiting O O
HDAC2 B-protein B-protein
to O O
the O O
NF-kappa B-protein B-protein
B/HAT I-protein I-protein
complex I-protein I-protein
. O O

A O O
sub-group O O
of O O
patients O O
with O O
glucocorticoid-insensitive O O
asthma O O
have O O
an O O
inability O O
to O O
induce O O
histone O B-protein
acetylation O O
in O O
response O O
to O O
dexamethasone O O
suggesting O O
reduced O O
expression O O
of O O
a O O
GR-specific B-protein O
HAT I-protein O
. O O

This O O
suggests O O
that O O
pharmacological O O
manipulation O O
of O O
specific O O
histone O B-protein
acetylation O O
status O O
is O O
a O O
potentially O O
useful O O
approach O O
for O O
the O O
treatment O O
of O O
inflammatory O O
diseases O O
. O O

Identification O O
of O O
the O O
precise O O
mechanism O O
by O O
which O O
activated B-protein O
GR I-protein B-protein
recruits O O
HDAC2 B-protein B-protein
may O O
reveal O O
new O O
targets O O
for O O
the O O
development O O
of O O
drugs O O
that O O
may O O
dissociate O O
the O O
antiinflammatory O O
actions O O
of O O
glucocorticoids O O
from O O
their O O
side O O
effects O O
that O O
are O O
largely O O
due O O
to O O
gene O O
induction O O
. O O

Copyright O O
Academic O O
Press O O
. O O

Differential O O
ultraviolet-B-induced O O
immunomodulation O O
in O O
XPA O O
, O O
XPC O O
, O O
and O O
CSB O O
DNA O O
repair-deficient O O
mice O O
. O O

Ultraviolet O O
B O O
irradiation O O
has O O
serious O O
consequences O O
for O O
cellular O O
immunity O O
and O O
can O O
suppress O O
the O O
rejection O O
of O O
skin O O
tumors O O
and O O
the O O
resistance O O
to O O
infectious O O
diseases O O
. O O

DNA O O
damage O O
plays O O
a O O
crucial O O
role O O
in O O
these O O
immunomodulatory O O
effects O O
of O O
ultraviolet O O
B O O
, O O
as O O
impaired O O
repair O O
of O O
ultraviolet-B-induced O O
DNA O O
damage O O
has O O
been O O
shown O O
to O O
cause O O
suppression O O
of O O
cellular O O
immunity O O
. O O

Ultraviolet-B-induced O O
DNA O O
damage O O
is O O
repaired O O
by O O
the O O
nucleotide O O
excision O O
repair O O
mechanism O O
very O O
efficiently O O
. O O

Nucleotide O O
excision O O
repair O O
comprises O O
two O O
subpathways O O
: O O
transcription-coupled O O
and O O
global O O
genome O O
repair O O
. O O

In O O
this O O
study O O
the O O
immunologic O O
consequences O O
of O O
specific O O
nucleotide O O
excision O O
repair O O
defects O O
in O O
three O O
mouse O O
models O O
, O O
XPA O O
, O O
XPC O O
, O O
and O O
CSB O O
mutant O O
mice O O
, O O
were O O
investigated O O
. O O

XPA O O
mice O O
carry O O
a O O
total O O
nucleotide O O
excision O O
repair O O
defect O O
, O O
whereas O O
XPC O B-protein
and O O
CSB O O
mice O O
only O O
lack O O
global O B-DNA
genome O I-DNA
and O O
transcription-coupled O O
nucleotide O O
excision O O
repair O O
, O O
respectively O O
. O O

Our O O
data O O
demonstrate O O
that O O
cellular O O
immune O O
parameters O O
in O O
XPA O O
, O O
XPC O B-protein
, O O
and O O
CSB O O
mice O O
are O O
normal O O
compared O O
with O O
their O O
wild-type O O
( O O
control O O
) O O
littermates O O
. O O

This O O
may O O
indicate O O
that O O
the O O
reported O O
altered O O
cellular O O
responses O O
in O O
xeroderma O O
pigmentosum O O
patients O O
are O O
not O O
constitutive O O
but O O
could O O
be O O
due O O
to O O
external O B-protein
factors O I-protein
, O O
such O O
as O O
ultraviolet O O
B O O
. O O

Upon O O
exposure O O
to O O
ultraviolet O O
B O O
, O O
only O O
XPA O O
mice O O
are O O
very O O
sensitive O O
to O O
ultraviolet-B-induced O O
inhibition O O
of O O
Th1-mediated O O
contact O O
hypersensitivity O O
responses O O
and O O
interferon-gamma B-protein B-protein
production O O
in O O
skin O O
draining O O
lymph O O
nodes O O
. O O

Lipopolysaccharide-stimulated O B-protein
tumor B-protein I-protein
necrosis I-protein I-protein
factor I-protein I-protein
alpha I-protein I-protein
and O O
interleukin-10 B-protein B-protein
production O O
are O O
significantly O O
augmented O O
in O O
both O O
XPA O O
and O O
CSB O O
mice O O
after O O
ultraviolet O O
B O O
exposure O O
. O O

Lymph O O
node O O
cell O O
numbers O O
were O O
increased O O
very O O
significantly O O
in O O
XPA O O
, O O
mildly O O
increased O O
in O O
CSB O B-protein
, O O
and O O
not O O
in O O
XPC O O
mice O O
. O O

In O O
general O O
XPC O O
mice O O
do O O
not O O
exhibit O O
any O O
indication O O
of O O
enhanced O O
ultraviolet O O
B O O
susceptibility O O
with O O
regard O O
to O O
the O O
immune O O
parameters O O
analyzed O O
. O O

These O O
data O O
suggest O O
that O O
both O O
global O O
genome O O
repair O O
and O O
transcription-coupled O O
repair O O
are O O
needed O O
to O O
prevent O O
immunomodulation O O
by O O
ultraviolet O O
B O O
, O O
whereas O O
transcription-coupled O O
repair O O
is O O
the O O
major O O
DNA O O
repair O O
subpathway O O
of O O
nucleotide O O
excision O O
repair O O
that O O
prevents O O
the O O
acute O O
ultraviolet-B-induced O O
effects O O
such O O
as O O
erythema O O
. O O

Biomechanical O O
strain O O
induces O O
class O O
a O O
scavenger B-protein O
receptor I-protein O
expression O O
in O O
human B-cell_type B-cell_type
monocyte/macrophages I-cell_type I-cell_type
and O O
THP-1 B-cell_type B-cell_line
cells I-cell_type I-cell_line
: O O
a O O
potential O O
mechanism O O
of O O
increased O O
atherosclerosis O O
in O O
hypertension O O
. O O

BACKGROUND O O
: O O
Although O O
hypertension O O
is O O
an O O
important O O
risk O O
factor O O
for O O
the O O
development O O
of O O
atherosclerosis O O
, O O
the O O
mechanisms O O
for O O
this O O
interaction O O
are O O
incompletely O O
described O O
. O O

Previous O O
studies O O
have O O
suggested O O
that O O
biomechanical O O
strain O O
regulates O O
macrophage O O
phenotype O O
. O O

We O O
tested O O
the O O
hypothesis O O
that O O
biomechanical O O
strain O O
can O O
induce O O
expression O O
of O O
the O O
class B-protein B-protein
A I-protein I-protein
scavenger I-protein I-protein
receptor I-protein I-protein
( O O
SRA B-protein B-protein
) O O
, O O
an O O
important O O
lipoprotein B-protein O
receptor I-protein O
in O O
atherogenesis O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Human B-cell_type B-cell_type
monocyte/macrophages I-cell_type I-cell_type
or O O
THP-1 B-cell_type B-cell_line
cells I-cell_type I-cell_line
were O O
cultured O O
in O O
a O O
device O O
that O O
imposes O O
uniform O O
biaxial O O
cyclic O O
1-Hz O O
strains O O
of O O
0 O O
% O O
, O O
1 O O
% O O
, O O
2 O O
% O O
, O O
or O O
3 O O
% O O
, O O
and O O
SRA B-protein O
expression O O
was O O
analyzed O O
. O O

Mechanical O O
strains O O
induced O O
SRA B-RNA B-RNA
mRNA I-RNA I-RNA
( O O
3.5+/-0.6-fold O O
at O O
3 O O
% O O
strain O O
for O O
48 O O
hours O O
, O O
P O O
< O O
0.01 O O
) O O
and O O
SRA B-protein B-protein
protein I-protein I-protein
in O O
THP-1 B-cell_type B-cell_line
cells I-cell_type I-cell_line
in O O
an O O
amplitude-dependent O O
manner O O
. O O

This O O
induction O O
was O O
accompanied O O
by O O
augmented O O
expression O O
of O O
the O O
class B-protein B-protein
B I-protein I-protein
scavenger I-protein I-protein
receptor I-protein I-protein
CD36 I-protein B-protein
( O O
2.8+/-0.3-fold O O
, O O
P O O
< O O
0.001 O O
) O O
but O O
not O O
by O O
increased O O
peroxisome B-protein B-protein
proliferator-activated I-protein I-protein
receptor-gamma I-protein I-protein
expression O O
. O O

To O O
evaluate O O
this O O
effect O O
in O O
vivo O O
, O O
apolipoprotein O O
E O O
( O O
-/- O O
) O O
mice O O
were O O
randomly O O
assigned O O
to O O
receive O O
standard O O
chow O O
, O O
a O O
high-cholesterol O O
diet O O
, O O
or O O
a O O
high-cholesterol O O
diet O O
with O O
hypertension O O
induced O O
by O O
angiotensin O O
II O O
infusion O O
for O O
8 O O
weeks O O
. O O

Immunohistochemistry O O
revealed O O
that O O
among O O
macrophages B-cell_type B-cell_type
in O O
atherosclerotic O O
lesions O O
of O O
the O O
aorta O O
, O O
the O O
proportion O O
of O O
macrophages B-cell_type B-cell_type
with O O
SRA B-protein O
expression O O
was O O
highest O O
in O O
hypertensive O O
animals O O
on O O
a O O
high-cholesterol O O
diet O O
( O O
43.9+/-0.7 O O
% O O
, O O
versus O O
12.0+/-2.0 O O
% O O
for O O
normotensive O O
animals O O
on O O
a O O
high-cholesterol O O
diet O O
and O O
4.7+/-4.7 O O
% O O
for O O
animals O O
on O O
standard O O
chow O O
; O O
P O O
< O O
0.001 O O
) O O
. O O

CONCLUSIONS O O
: O O
Biomechanical O O
strain O O
induces O O
SRA B-protein B-protein
expression O O
by O O
monocyte/macrophages B-cell_type B-cell_type
, O O
suggesting O O
a O O
novel O O
mechanism O O
for O O
promotion O O
of O O
atherosclerosis O O
in O O
hypertensive O O
patients O O
. O O

High O O
glucose O O
induces O O
MCP-1 O B-protein
expression O O
partly O O
via O O
tyrosine O B-protein
kinase-AP-1 O I-protein
pathway O O
in O O
peritoneal B-cell_type B-cell_type
mesothelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

BACKGROUND O O
: O O
High O O
glucose O O
in O O
peritoneal O O
dialysis O O
solutions O O
has O O
been O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
peritoneal O O
fibrosis O O
in O O
chronic O O
ambulatory O O
peritoneal O O
dialysis O O
( O O
CAPD O O
) O O
patients O O
. O O

However O O
, O O
the O O
mechanisms O O
are O O
not O O
very O O
clear O O
. O O

Peritoneal B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
seem O O
to O O
participate O O
in O O
the O O
process O O
of O O
peritoneal O O
fibrosis O O
and O O
monocyte B-protein B-protein
chemoattractant I-protein I-protein
protein-1 I-protein I-protein
( O O
MCP-1 B-protein B-protein
) O O
plays O O
a O O
key O O
role O O
in O O
the O O
recruitment O O
of O O
monocytes B-cell_type B-cell_type
toward O O
the O O
peritoneal O O
cavity O O
. O O

However O O
, O O
little O O
is O O
known O O
about O O
the O O
effect O O
of O O
high O O
glucose O O
on O O
MCP-1 B-protein B-protein
expression O O
and O O
its O O
signal O O
transduction O O
pathway O O
in O O
human B-cell_type B-cell_type
peritoneal I-cell_type I-cell_type
mesothelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

METHODS O O
: O O
Mesothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
cultured O O
with O O
glucose O O
( O O
5 O O
to O O
100 O O
mmol/L O O
) O O
or O O
mannitol O O
chronically O O
for O O
up O O
to O O
seven O O
days O O
. O O

MCP-1 B-protein B-protein
expression O O
of O O
mRNA O B-RNA
and O O
protein O O
was O O
measured O O
by O O
Northern O O
blot O O
analysis O O
and O O
enzyme-linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
. O O

Chemotactic O O
activity O O
of O O
high-glucose-conditioned O B-cell_line
culture O I-cell_line
supernatant O I-cell_line
was O O
measured O O
by O O
chemotactic O O
assay O O
. O O

To O O
examine O O
the O O
roles O O
of O O
the O O
transcription B-protein B-protein
factors I-protein I-protein
activator B-protein I-protein
protein-1 I-protein I-protein
( O O
AP-1 B-protein B-protein
) O O
and O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
( O O
NF-kappaB B-protein B-protein
) O O
, O O
electrophoretic O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
was O O
performed O O
. O O

RESULTS O O
: O O
Glucose O O
induced O O
MCP-1 B-RNA B-RNA
mRNA I-RNA I-RNA
expression O O
in O O
a O O
time- O O
and O O
dose-dependent O O
manner O O
. O O

MCP-1 B-protein B-protein
protein I-protein I-protein
in O O
cell O O
culture O O
supernant O O
was O O
also O O
increased O O
. O O

Equivalent O O
concentrations O O
of O O
mannitol O O
had O O
no O O
significant O O
effect O O
. O O

High-glucose-conditioned O O
supernatant O O
possessed O O
an O O
increased O O
chemotactic O O
activity O O
for O O
monocytes B-cell_type B-cell_type
, O O
which O O
was O O
neutralized O O
by O O
anti-MCP-1 B-protein B-protein
antibody I-protein I-protein
. O O

EMSA O O
revealed O O
that O O
glucose O O
increased O O
the O O
AP-1 B-protein B-protein
binding O O
activity O O
in O O
a O O
time- O O
and O O
dose-dependent O O
manner O O
, O O
but O O
not O O
NF-kappaB B-protein B-protein
. O O

Curcumin O O
, O O
an O O
inhibitor O O
of O O
AP-1 B-protein B-protein
, O O
dose-dependently O O
suppressed O O
the O O
induction O O
of O O
MCP-1 B-RNA B-RNA
mRNA I-RNA I-RNA
by O O
high O O
glucose O O
. O O

Tyrosine O O
kinase O O
inhibitors O O
such O O
as O O
genistein O O
( O O
12.5 O O
to O O
50 O O
micromol/L O O
) O O
and O O
herbimycin O O
A O O
( O O
0.1 O O
to O O
1 O O
micromol/L O O
) O O
inhibited O O
the O O
high-glucose-induced O O
MCP-1 B-RNA O
mRNA I-RNA O
expression O O
in O O
a O O
dose-dependent O O
manner O O
, O O
and O O
also O O
suppressed O O
the O O
high-glucose-induced O O
AP-1 B-protein B-protein
binding O O
activity O O
. O O

CONCLUSIONS O O
: O O
: O O
High O O
glucose O O
induced O O
mesothelial O O
MCP-1 B-protein B-protein
expression O O
partly O O
via O O
the O O
tyrosine O O
kinase- O O
AP-1 B-protein B-protein
pathway O O
. O O

Signal O O
thresholds O O
and O O
modular O O
synergy O O
during O O
expression O O
of O O
costimulatory O O
molecules O O
in O O
B B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

We O O
analyzed O O
intracellular O O
pathways O O
modulating O O
surface O O
densities O O
of O O
CD80 B-protein B-protein
and O O
CD86 B-protein B-protein
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
activated O O
through O O
ligation O O
of O O
the O O
Ag B-protein B-protein
receptor I-protein I-protein
, O O
and O O
the O O
adhesion B-protein B-protein
molecule I-protein I-protein
CD54 B-protein B-protein
. O O

Whereas O O
B B-protein B-protein
cell I-protein I-protein
Ag I-protein I-protein
receptor I-protein I-protein
( O O
BCR B-protein B-protein
) O O
cross-linking O O
alone O O
stimulated O O
increased O O
expression O O
of O O
CD86 B-protein B-protein
, O O
up-regulation O O
of O O
CD80 B-protein B-protein
required O O
dual O O
stimulation O O
with O O
anti-IgM B-protein B-protein
and O O
anti-CD54 B-protein B-protein
. O O

The O O
principal O O
downstream O O
component O O
contributed O O
by O O
BCR B-protein B-protein
signaling O O
, O O
toward O O
both O O
CD80 B-protein B-protein
and O O
CD86 B-protein B-protein
induction O O
, O O
was O O
the O O
elevated O O
concentration O O
of O O
free O O
cytoplasmic O O
Ca O O
( O O
2+ O O
) O O
, O O
recruited O O
by O O
way O O
of O O
capacitative O O
influx O O
. O O

This O O
alone O O
was O O
sufficient O O
to O O
generate O O
an O O
increase O O
in O O
CD86 B-protein B-protein
levels O O
. O O

However O O
, O O
CD80 B-protein B-protein
enhancement O O
required O O
the O O
concerted O O
action O O
of O O
both O O
intracellular O O
Ca O O
( O O
2+ O O
) O O
concentration O O
and O O
CD54-initiated O O
pathways O O
. O O

The O O
nexus O O
between O O
anti-IgM O B-protein
and O O
anti-CD54 O B-protein
stimulation O O
, O O
in O O
the O O
context O O
of O O
CD80 B-protein B-protein
regulation O O
, O O
was O O
identified O O
to O O
involve O O
a O O
self-propagating O O
process O O
of O O
sequential O O
synergy O O
. O O

The O O
first O O
step O O
involved O O
amplified O O
accumulation O O
of O O
intracellular O O
cAMP O O
, O O
as O O
a O O
result O O
of O O
cross-talk O O
between O O
BCR B-protein O
-mobilized O O
Ca O O
( O O
2+ O O
) O O
and O O
CD54-derived O O
signals O O
. O O

This O O
then O O
facilitated O O
a O O
second O O
synergistic O O
interaction O O
between O O
Ca O O
( O O
2+ O O
) O O
and O O
cAMP O O
, O O
culminating O O
in O O
CD80 B-protein B-protein
expression O O
. O O

Our O O
findings O O
of O O
distinct O O
signal O O
transducer O O
requirements O O
, O O
with O O
the O O
added O O
consequences O O
of O O
cross-talk O O
, O O
offers O O
an O O
explanation O O
for O O
variable O O
modulation O O
of O O
costimulatory O B-protein
molecule O I-protein
expression O O
in O O
response O O
to O O
diverse O O
physiological O O
stimuli O O
. O O

Importantly O O
, O O
these O O
results O O
also O O
reveal O O
how O O
concentration O O
threshold O O
barriers O O
for O O
recruitment O O
of O O
individual O O
second O O
messengers O O
can O O
be O O
overcome O O
by O O
constructive O O
convergence O O
of O O
signaling O B-protein
modules O I-protein
. O O

The O O
role O O
of O O
Epstein-Barr O O
virus O O
in O O
neoplastic O O
transformation O O
. O O

In O O
this O O
review O O
, O O
we O O
focus O O
on O O
new O O
data O O
from O O
basic O O
, O O
translational O O
and O O
clinical O O
research O O
relating O O
to O O
the O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
. O O

Beside O O
its O O
well-known O O
tropism O O
for O O
B B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
and O O
epithelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
EBV O O
also O O
infects O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
, O O
monocytes B-cell_type B-cell_type
and O O
granulocytes B-cell_type B-cell_type
. O O

After O O
primary O O
infection O O
, O O
EBV O O
persists O O
throughout O O
the O O
life O O
span O O
in O O
resting B-cell_type B-cell_type
memory I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
from O O
where O O
it O O
is O O
reactivated O O
upon O O
breakdown O O
of O O
cellular O O
immunity O O
. O O

In O O
the O O
process O O
of O O
neoplastic O O
transformation O O
, O O
the O O
EBV-encoded B-DNA B-DNA
latent I-DNA I-DNA
membrane I-DNA I-DNA
protein I-DNA I-DNA
1 I-DNA I-DNA
( I-DNA I-DNA
LMP1 I-DNA I-DNA
) I-DNA I-DNA
oncogene I-DNA I-DNA
represents O O
the O O
major O O
driving O O
force O O
. O O

LMP1 B-protein B-protein
acts O O
like O O
a O O
constitutively B-protein B-protein
activated I-protein I-protein
receptor I-protein I-protein
of O O
the O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
receptor I-protein I-protein
family I-protein I-protein
and O O
allows O O
the O O
amplification O O
or O O
bypassing O O
of O O
physiological O O
regulatory O O
signals O O
through O O
direct O O
and O O
indirect O O
interactions O O
with O O
proteins O O
of O O
the O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
receptor-associated I-protein I-protein
factor I-protein I-protein
( I-protein I-protein
TRAF I-protein I-protein
) I-protein I-protein
family I-protein I-protein
. O O

TRAF2 B-protein B-protein
-mediated O O
NF-kappaB B-protein B-protein
activation O O
, O O
AP-1 B-protein B-protein
induction O O
and O O
JAK3 B-protein B-protein
/ O O
STAT B-protein B-protein
activation O O
may O O
result O O
in O O
sustained O O
proliferation O O
leading O O
to O O
lymphoma B-cell_line O
. O O

The O O
ability O O
of O O
LMP1 B-protein B-protein
to O O
suppress O O
germinal O O
center O O
formation O O
and O O
its O O
capacity O O
to O O
mediate O O
its O O
own O O
transcriptional O O
activation O O
shed O O
new O O
light O O
on O O
the O O
pathogenesis O O
of O O
EBV-associated O O
latency O O
type O O
II O O
lymphoproliferations O O
like O O
Hodgkin O O
's O O
disease O O
and O O
angioimmunoblastic O O
lymphadenopathy O O
. O O

The O O
carboxy B-protein B-protein
terminus I-protein I-protein
of O O
LMP1 B-protein B-protein
is O O
also O O
a O O
reliable O O
marker O O
for O O
individual O O
EBV O O
strain O O
identification O O
and O O
thus O O
offers O O
new O O
possibilities O O
in O O
tracing O O
the O O
molecular O O
events O O
leading O O
to O O
posttransplant O O
lymphoproliferative O O
disorders O O
( O O
PTLDs O O
) O O
. O O

Cytotoxic B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
directed O O
against O O
well-characterized O O
epitopes O B-protein
of O O
EBV B-DNA B-DNA
latency I-DNA I-DNA
genes I-DNA I-DNA
represent O O
an O O
already O O
successful O O
and O O
promising O O
therapeutic O O
approach O O
to O O
EBV-associated B-cell_line O
lymphomas I-cell_line O
, O O
in O O
particular O O
PTLDs O O

Interferon-alpha B-protein B-protein
drives O O
T O O
cell-mediated O O
immunopathology O O
in O O
the O O
intestine O O
. O O

The O O
ability O O
of O O
interferon B-protein B-protein
( I-protein I-protein
IFN I-protein I-protein
) I-protein I-protein
-alpha I-protein I-protein
to O O
induce O O
autoimmunity O O
and O O
exacerbate O O
Th1 O O
diseases O O
is O O
well O O
known O O
. O O

We O O
have O O
recently O O
described O O
enhanced O O
expression O O
of O O
IFN-alpha B-protein B-protein
in O O
the O O
mucosa O O
of O O
patients O O
with O O
celiac O O
disease O O
( O O
CD O O
) O O
, O O
a O O
gluten-sensitive O O
Th1-mediated O O
enteropathy O O
, O O
characterized O O
by O O
villous O O
atrophy O O
and O O
crypt O O
cell O O
hyperplasia O O
. O O

Previous O O
studies O O
from O O
this O O
laboratory O O
have O O
shown O O
that O O
T B-cell_type O
cell I-cell_type O
activation O O
in O O
explant O O
cultures O O
of O O
human O O
fetal O O
gut O O
can O O
also O O
result O O
in O O
villous O O
atrophy O O
and O O
crypt O O
cell O O
hyperplasia O O
. O O

We O O
have O O
, O O
therefore O O
, O O
examined O O
changes O O
that O O
take O O
place O O
in O O
explant O O
cultures O O
of O O
human O O
fetal O O
gut O O
after O O
activation O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
with O O
anti-CD3 B-protein B-protein
and/or O O
IFN-alpha B-protein B-protein
. O O

We O O
show O O
that O O
activation O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
with O O
anti-CD3 B-protein B-protein
alone O O
elicits O O
a O O
small O O
IFN-gamma B-protein B-protein
and O O
TNF-alpha B-protein B-protein
response O O
with O O
no O O
tissue O O
injury O O
. O O

Similarly O O
, O O
no O O
changes O O
are O O
seen O O
in O O
explants O O
cultured O O
with O O
IFN-alpha B-protein B-protein
alone O O
. O O

However O O
, O O
addition O O
of O O
IFN-alpha B-protein B-protein
with O O
anti-CD3 B-protein B-protein
results O O
in O O
enhanced O O
Th1 O O
response O O
and O O
crypt O O
cell O O
hyperplasia O O
. O O

This O O
is O O
associated O O
with O O
enhanced O O
phosphorylation O O
of O O
STAT1 B-protein B-protein
, O O
STAT3 B-protein B-protein
, O O
and O O
Fyn B-protein B-protein
, I-protein O
a I-protein O
Src I-protein B-protein
homology I-protein I-protein
tyrosine I-protein I-protein
kinase I-protein I-protein
, O O
which O O
interacts O O
with O O
both O O
TCR O B-protein
and O O
IFN-alpha O B-protein
signal O O
components O O
. O O

Together O O
these O O
data O O
indicate O O
that O O
IFN-alpha B-protein B-protein
can O O
facilitate O O
activation O O
of O O
Th1-reactive B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
the O O
gut O O
and O O
drive O O
immunopathology O O
. O O

Suppression O O
of O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
alpha I-protein I-protein
production O O
by O O
cAMP O O
in O O
human B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
: O O
dissociation O O
with O O
mRNA O O
level O O
and O O
independent O O
of O O
interleukin-10 B-protein B-protein
. O O

BACKGROUND O O
: O O
Elevation O O
of O O
cellular O O
cAMP O O
inhibits O O
lipopolysaccharide O O
( O O
LPS O O
) O O
-stimulated O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
alpha I-protein I-protein
( O O
TNF-alpha B-protein B-protein
) O O
production O O
and O O
increases O O
the O O
expression O O
of O O
interleukin B-protein B-protein
( I-protein I-protein
IL I-protein I-protein
) I-protein I-protein
-10 I-protein I-protein
in O O
mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

TNF-alpha B-DNA B-protein
gene I-DNA O
expression O O
obligates O O
activation O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
nuclear B-protein I-protein
factor I-protein I-protein
kappaB I-protein I-protein
( O O
NF-kappaB B-protein B-protein
) O O
. O O

Exogenous O O
IL-10 B-protein B-protein
inhibits O O
NF-kappaB B-protein B-protein
in O O
monocytes B-cell_type B-cell_type
and O O
thus O O
attenuates O O
TNF-alpha B-protein B-protein
production O O
. O O

We O O
examined O O
the O O
role O O
of O O
endogenous O B-protein
IL-10 B-protein I-protein
in O O
the O O
regulation O O
of O O
NF-kappaB B-protein B-protein
activation O O
and O O
TNF-alpha B-protein B-protein
production O O
in O O
human B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
by O O
cAMP O O
. O O

METHODS O O
: O O
Human B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
were O O
stimulated O O
with O O
Escherichia O O
coli O O
LPS O O
( O O
100 O O
ng/ml O O
) O O
with O O
and O O
without O O
forskolin O O
( O O
FSK O O
, O O
50 O O
microM O O
) O O
or O O
dibutyryl O O
cyclic O O
AMP O O
( O O
dbcAMP O O
, O O
100 O O
microM O O
) O O
. O O

Cytokine B-protein B-protein
( O O
TNF-alpha B-protein B-protein
and O O
IL-10 B-protein B-protein
) O O
release O O
was O O
measured O O
by O O
immunoassay O O
. O O

TNF-alpha B-RNA B-RNA
mRNA I-RNA I-RNA
was O O
measured O O
by O O
reverse O O
transcription O O
polymerase O O
chain O O
reaction O O
, O O
and O O
NF-kappaB B-protein B-protein
DNA O O
binding O O
activity O O
was O O
assessed O O
by O O
gel O O
mobility O O
shift O O
assay O O
. O O

RESULTS O O
: O O
cAMP-elevating O O
agents O O
inhibited O O
LPS-stimulated O O
TNF-alpha B-protein O
release O O
( O O
0.77 O O
+/- O O
0.13 O O
ng/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
dbcAMP O O
and O O
0.68 O O
+/- O O
0.19 O O
ng/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
FSK O O
, O O
both O O
P O O
< O O
0.05 O O
vs O O
1.61 O O
+/- O O
0.34 O O
ng/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
alone O O
) O O
. O O

Conversely O O
, O O
cAMP O O
enhanced O O
LPS-stimulated O O
IL-10 B-protein B-protein
release O O
( O O
100 O O
+/- O O
21.5 O O
pg/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
dbcAMP O O
and O O
110 O O
+/- O O
25.2 O O
pg/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
+ O O
FSK O O
, O O
both O O
P O O
< O O
0.05 O O
vs O O
53.3 O O
+/- O O
12.8 O O
pg/10 O O
( O O
6 O O
) O O
cells O O
in O O
LPS O O
alone O O
) O O
. O O

Neither O O
TNF-alpha B-RNA B-RNA
mRNA I-RNA I-RNA
expression O O
nor O O
NF-kappaB B-protein B-protein
activation O O
stimulated O O
by O O
LPS O O
was O O
inhibited O O
by O O
the O O
cAMP-elevating O O
agents O O
. O O

Neutralization O O
of O O
IL-10 B-protein B-protein
with O O
a O O
specific O O
antibody B-protein O
did O O
not O O
attenuate O O
the O O
effect O O
of O O
cAMP-elevating O O
agents O O
on O O
TNF-alpha B-protein B-protein
production O O
. O O

CONCLUSION O O
: O O
The O O
results O O
indicate O O
that O O
cAMP O O
inhibits O O
LPS-stimulated O O
TNF-alpha B-protein B-protein
production O O
through O O
a O O
posttranscriptional O O
mechanism O O
that O O
is O O
independent O O
of O O
endogenous O O
IL-10 B-protein B-protein
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

Activation O O
of O O
the O O
p21 B-DNA B-DNA
( I-DNA I-DNA
CIP1/WAF1 I-DNA I-DNA
) I-DNA I-DNA
promoter I-DNA I-DNA
by O O
bone B-protein B-protein
morphogenetic I-protein I-protein
protein-2 I-protein I-protein
in O O
mouse O B-cell_line
B B-cell_line I-cell_line
lineage I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

BMPs B-protein O
exert O O
a O O
negative O O
growth O O
effect O O
on O O
various O O
types O O
of O O
cells O O
. O O

We O O
have O O
previously O O
reported O O
that O O
BMP-2 B-protein B-protein
inhibited O O
the O O
growth O O
of O O
HS-72 B-cell_line B-cell_line
mouse I-cell_line I-cell_line
hybridoma I-cell_line I-cell_line
cells I-cell_line I-cell_line
by O O
inducing O O
p21 O B-protein
( O O
CIP1/WAF1 O B-protein
) O O
expression O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
demonstrated O O
that O O
BMP-2 B-protein B-protein
activated O O
the O O
mouse O B-DNA
p21 B-DNA I-DNA
( I-DNA I-DNA
CIP1/WAF1 I-DNA I-DNA
) I-DNA I-DNA
promoter I-DNA I-DNA
in O O
HS-72 B-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
and O O
that O O
a O O
29-base B-DNA B-DNA
pair I-DNA I-DNA
( I-DNA I-DNA
b I-DNA I-DNA
) I-DNA I-DNA
region I-DNA I-DNA
of O O
the O O
promoter O B-DNA
( O O
-1928/-1900 O O
relative O O
to O O
the O O
TATA B-DNA B-DNA
box I-DNA I-DNA
) O O
, O O
conserved O O
between O O
mice O O
and O O
humans O O
, O O
was O O
responsive O O
to O O
BMP-2 B-protein B-protein
as O O
well O O
as O O
expression O O
of O O
Smad1 B-protein B-protein
, O O
Smad4 B-protein B-protein
, O O
and O O
constitutively O O
active O O
mutants O O
of O O
BMP B-protein B-protein
type I-protein I-protein
I I-protein I-protein
receptors I-protein I-protein
. O O

Furthermore O O
, O O
an O O
oligonucleotide O O
containing O O
the O O
29-b B-DNA B-DNA
region I-DNA I-DNA
was O O
found O O
to O O
be O O
associated O O
with O O
Smad4 B-protein B-protein
and O O
phosphorylated B-protein O
Smad1 I-protein B-protein
in O O
the O O
nuclear O O
extract O O
of O O
BMP-2 B-protein B-cell_line
-stimulated O I-cell_line
HS-72 B-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

These O O
results O O
suggested O O
that O O
BMP-2 B-protein B-protein
might O O
activate O O
p21 O B-protein
( O O
CIP1/WAF1 O B-protein
) O O
transcription O O
by O O
inducing O O
a O O
binding O O
of O O
Smad4 B-protein B-protein
and O O
Smad1 B-protein B-protein
to O O
the O O
29-b B-DNA B-DNA
region I-DNA I-DNA
in O O
HS-72 B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

Dendritic B-cell_type O
cell I-cell_type O
development O O
from O O
common O B-cell_type
myeloid B-cell_type I-cell_type
progenitors I-cell_type I-cell_type
. O O

Dendritic B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
DCs B-cell_type B-cell_type
) O O
are O O
professional O B-cell_type
antigen-presenting B-cell_type I-cell_type
cells I-cell_type I-cell_type
which O O
both O O
initiate O O
adaptive O O
immune O O
responses O O
and O O
control O O
tolerance O O
to O O
self-antigens B-protein B-protein
. O O

It O O
has O O
been O O
suggested O O
that O O
these O O
different O O
effects O O
on O O
responder O B-cell_type
cells O I-cell_type
depend O O
on O O
subsets O O
of O O
DCs B-cell_type B-cell_type
arising O O
from O O
either O O
myeloid O B-cell_type
or O I-cell_type
lymphoid O I-cell_type
hematopoietic O I-cell_type
origins O I-cell_type
. O O

In O O
this O O
model O O
, O O
CD8 B-cell_type B-cell_type
alpha+ I-cell_type I-cell_type
Mac-1- I-cell_type I-cell_type
DCs I-cell_type I-cell_type
are O O
supposed O O
to O O
be O O
of O O
lymphoid O O
while O O
CD8 B-cell_type B-cell_type
alpha- I-cell_type I-cell_type
Mac-1+ I-cell_type I-cell_type
DCs I-cell_type I-cell_type
are O O
supposed O O
to O O
be O O
of O O
myeloid O O
origin O O
. O O

Here O O
we O O
summarize O O
our O O
findings O O
that O O
both O O
CD8 B-cell_type B-cell_type
alpha+ I-cell_type I-cell_type
and I-cell_type I-cell_type
CD8 I-cell_type I-cell_type
alpha- I-cell_type I-cell_type
DCs I-cell_type I-cell_type
can O O
arise O O
from O O
clonogenic B-cell_type B-cell_type
common I-cell_type I-cell_type
myeloid I-cell_type I-cell_type
progenitors I-cell_type I-cell_type
( O O
CMPs B-cell_type B-cell_type
) O O
in O O
both O O
thymus O O
and O O
spleen O O
. O O

Therefore O O
CD8 B-protein B-protein
alpha I-protein I-protein
expression O O
DCs B-cell_type B-cell_type
does O O
not O O
indicate O O
a O O
lymphoid O O
origin O O
and O O
differences O O
among O O
CD8 B-cell_type B-cell_type
alpha+ I-cell_type I-cell_type
and I-cell_type I-cell_type
CD8 I-cell_type I-cell_type
alpha- I-cell_type I-cell_type
DCs I-cell_type I-cell_type
might O O
rather O O
reflect O O
maturation O O
status O O
than O O
ontogeny O O
. O O

On O O
the O O
basis O O
of O O
transplantation O O
studies O O
, O O
it O O
seems O O
likely O O
that O O
most O O
of O O
the O O
DCs B-cell_type B-cell_type
in O O
secondary O O
lymphoid O O
organs O O
and O O
a O O
substantial O O
fraction O O
of O O
thymic B-cell_type B-cell_type
DCs I-cell_type I-cell_type
are O O
myeloid-derived O O
. O O

Macrophage O O
stimulation O O
with O O
Murabutide O O
, O O
an O O
HIV-suppressive O O
muramyl O O
peptide O O
derivative O O
, O O
selectively O O
activates O O
extracellular B-protein B-protein
signal-regulated I-protein I-protein
kinases I-protein I-protein
1 I-protein I-protein
and I-protein I-protein
2 I-protein I-protein
, O O
C/EBPbeta B-protein B-protein
and O O
STAT1 B-protein B-protein
: O O
role O O
of O O
CD14 B-protein B-protein
and O O
Toll-like B-protein B-protein
receptors I-protein I-protein
2 I-protein I-protein
and I-protein I-protein
4 I-protein I-protein
. O O

The O O
smallest O O
unit O O
of O O
bacterial O O
peptidoglycans O O
known O O
to O O
be O O
endowed O O
with O O
biological O O
activities O O
is O O
muramyl O O
dipeptide O O
( O O
MDP O O
) O O
. O O

A O O
clinically O O
acceptable O O
synthetic O O
derivative O O
of O O
MDP O O
, O O
namely O O
murabutide O O
( O O
MB O O
) O O
, O O
has O O
been O O
found O O
to O O
present O O
interesting O O
pharmacological O O
properties O O
and O O
to O O
suppress O O
HIV-1 O O
replication O O
in O O
monocyte-derived B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
( O O
MDM B-cell_type B-cell_type
) O O
. O O

We O O
have O O
addressed O O
the O O
signaling O O
events O O
activated O O
in O O
MDM B-cell_type O
following O O
stimulation O O
with O O
either O O
MB O O
or O O
the O O
potent O O
immunostimulant O O
LPS O O
. O O

We O O
also O O
examined O O
whether O O
signaling O O
by O O
muramyl O O
peptides O O
involves O O
the O O
use O O
of O O
cell B-protein B-protein
surface I-protein I-protein
receptors I-protein I-protein
, O O
including O O
CD14 B-protein B-protein
and O O
Toll-like B-protein B-protein
receptor I-protein I-protein
2 I-protein I-protein
( O O
TLR2 B-protein B-protein
) O O
or O O
TLR4 B-protein B-protein
that O O
are O O
known O O
to O O
be O O
signal-transducing B-protein B-protein
receptors I-protein I-protein
for O O
other O O
bacterial O O
cell O O
wall O O
components O O
. O O

We O O
demonstrate O O
that O O
, O O
unlike O O
LPS O O
, O O
the O O
safe O O
immunomodulator O O
MB O O
selectively O O
activates O O
extracellular B-protein B-protein
signal-regulated I-protein I-protein
kinases I-protein I-protein
( I-protein O
Erk I-protein B-protein
) I-protein I-protein
1/2 I-protein I-protein
, O O
in O O
the O O
absence O O
of O O
detectable O O
Jun B-protein B-protein
N-terminal I-protein I-protein
kinase I-protein I-protein
( O O
JNK B-protein B-protein
) O O
or O O
p38 B-protein B-protein
mitogen-activated I-protein I-protein
kinase I-protein I-protein
activation O O
. O O

Furthermore O O
, O O
STAT1 B-protein B-protein
activation O O
but O O
weak O O
or O O
no O O
activation O O
of O O
STAT3 B-protein B-protein
or O O
STAT5 B-protein B-protein
respectively O O
, O O
could O O
be O O
detected O O
in O O
MB-stimulated B-cell_type B-cell_line
MDM I-cell_type I-cell_line
. O O

Using O O
MonoMac6 B-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
we O O
observed O O
high O O
C/EBPbeta B-protein B-protein
and O O
AP-1 B-protein B-protein
but O O
weaker O O
and O O
transient O O
NF-kappaB B-protein B-protein
activation O O
by O O
MB O O
. O O

Moreover O O
, O O
the O O
truncated O O
form O O
of O O
C/EBPbeta B-protein B-protein
, O O
known O O
to O O
repress O O
HIV-1 O O
transcription O O
, O O
was O O
detected O O
in O O
extracts O O
from O O
MB-treated B-cell_line B-cell_line
THP-1 I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Surprisingly O O
, O O
neither O O
MB O O
nor O O
MDP O O
were O O
able O O
to O O
transduce O O
signals O O
via O O
CD14 B-protein B-protein
and O O
TLR2 B-protein B-protein
or I-protein I-protein
4 I-protein I-protein
. O O

These O O
findings O O
present O O
major O O
differences O O
in O O
the O O
early O O
cell O O
activation O O
process O O
between O O
LPS O O
and O O
muramyl O O
peptides O O
, O O
and O O
strongly O O
argue O O
for O O
the O O
implication O O
of O O
co-receptors B-protein O
other O O
than O O
TLR2 B-protein B-protein
and O O
TLR4 B-protein B-protein
in O O
mediating O O
the O O
signaling O O
events O O
induced O O
by O O
defined O O
subunits O O
of O O
bacterial O O
peptidoglycans O O
. O O

Nuclear B-protein B-protein
peroxisome I-protein I-protein
proliferator-activated I-protein I-protein
receptors I-protein I-protein
alpha I-protein I-protein
and I-protein O
gamma I-protein B-protein
have O O
opposing O O
effects O O
on O O
monocyte O O
chemotaxis O O
in O O
endometriosis O O
. O O

The O O
peroxisome B-protein B-protein
proliferator-activated I-protein I-protein
receptors I-protein I-protein
( I-protein O
PPARs I-protein B-protein
) I-protein I-protein
alpha I-protein I-protein
and I-protein I-protein
gamma I-protein I-protein
are O O
nuclear B-protein B-protein
receptors I-protein I-protein
that O O
play O O
important O O
roles O O
in O O
inflammatory O O
diseases O O
like O O
ulcerative O O
colitis O O
and O O
arthritis O O
. O O

In O O
this O O
study O O
, O O
we O O
examined O O
the O O
possible O O
role O O
of O O
PPARs B-protein B-protein
in O O
macrophage O O
attraction O O
into O O
the O O
peritoneal O O
cavity O O
of O O
patients O O
with O O
endometriosis O O
. O O

We O O
identified O O
PPAR-alpha B-RNA B-protein
and I-RNA O
-gamma I-RNA B-RNA
messenger O I-RNA
RNA O I-RNA
by O O
RT-PCR O O
and O O
protein O O
by O O
immunoblotting O O
of O O
lysates O O
of O O
peritoneal B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
and O O
monocytic B-cell_line B-cell_line
U937 I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Using O O
immunocytochemistry O O
, O O
we O O
localized O O
PPAR-alpha B-protein B-protein
and I-protein I-protein
-gamma I-protein I-protein
within O O
the O O
nuclei O O
of O O
both O O
cell O O
types O O
. O O

Monocyte O O
chemotactic O O
activity O O
of O O
peritoneal O O
fluid O O
from O O
patients O O
with O O
endometriosis O O
was O O
quantified O O
in O O
Boyden O O
chambers O O
. O O

Migration O O
of O O
U937 B-cell_line B-cell_line
cells I-cell_line I-cell_line
was O O
increased O O
by O O
WY O O
14643 O O
and O O
reduced O O
by O O
rosiglitazone O O
. O O

Peritoneal O O
fluid O O
from O O
patients O O
with O O
endometriosis O B-cell_line
activated O I-cell_line
U937 B-cell_line I-cell_line
cells I-cell_line I-cell_line
transiently O O
transfected O O
with O O
a O O
PPAR-alpha/GAL4 B-DNA B-DNA
luciferase I-DNA I-DNA
reporter I-DNA I-DNA
. O O

By O O
contrast O O
, O O
peritoneal O O
fluid O O
did O O
not O O
cause O O
significant O O
activation O O
of O O
PPAR-gamma/GAL4 B-DNA B-DNA
constructs I-DNA I-DNA
. O O

The O O
U937 B-cell_line B-cell_line
cells I-cell_line I-cell_line
transiently O O
transfected O O
with O O
a O O
PPAR B-DNA B-DNA
response I-DNA I-DNA
element I-DNA I-DNA
luciferase I-DNA B-protein
reporter I-DNA O
showed O O
disease O O
stage-dependent O O
up-regulation O O
when O O
treated O O
with O O
peritoneal O O
fluid O O
from O O
patients O O
with O O
endometriosis O O
. O O

Treatment O O
with O O
peritoneal O O
fluid O O
from O O
healthy O O
controls O O
down-regulated O O
PPAR O B-protein
response O O
element O O
transactivation O O
. O O

We O O
conclude O O
that O O
peritoneal O O
fluid O O
of O O
endometriosis O O
patients O O
contains O O
activators O O
of O O
PPAR-alpha B-protein B-protein
that O O
stimulate O O
macrophage O O
chemotaxis O O
. O O

Inhibitors O O
of O O
PPAR-alpha B-protein B-protein
or O O
activators O O
of O O
PPAR-gamma B-protein B-protein
could O O
be O O
developed O O
for O O
the O O
treatment O O
of O O
inflammation O O
associated O O
with O O
endometriosis O O
. O O

Long-term-impaired O O
expression O O
of O O
nuclear B-protein B-protein
factor-kappa I-protein I-protein
B I-protein I-protein
and O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
of O O
trauma O O
patients O O
. O O

Nuclear B-protein B-protein
factor I-protein I-protein
( I-protein I-protein
NF I-protein I-protein
) I-protein I-protein
-kappa I-protein I-protein
B I-protein I-protein
expression O O
and O O
dimer O B-protein
characteristics O O
were O O
studied O O
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
PBMCs B-cell_type B-cell_type
) O O
of O O
major-trauma O O
patients O O
and O O
healthy O O
controls O O
. O O

Analysis O O
of O O
PBMCs B-cell_type B-cell_type
on O O
days O O
1 O O
, O O
3 O O
, O O
5 O O
, O O
and O O
10 O O
after O O
trauma O O
revealed O O
that O O
expression O O
of O O
both O O
p65p50 B-protein B-protein
heterodimers I-protein I-protein
and O O
p50p50 B-protein B-protein
homodimers I-protein I-protein
was O O
significantly O O
reduced O O
compared O O
with O O
that O O
in O O
controls O O
. O O

In O O
vitro O O
lipopolysaccharide O O
( O O
LPS O O
) O O
stimulation O O
of O O
PBMCs B-cell_type B-cell_type
induced O O
NF-kappa O B-protein
B O I-protein
translocation O O
. O O

However O O
, O O
throughout O O
the O O
survey O O
, O O
p65p50 O B-protein
activation O O
remained O O
significantly O O
lower O O
in O O
trauma O O
patients O O
than O O
in O O
controls O O
. O O

After O O
LPS O O
stimulation O O
in O O
vitro O O
, O O
the O O
p65p50/p50p50 O O
ratio O O
was O O
significantly O O
lower O O
in O O
PBMCs B-cell_type B-cell_type
from O O
trauma O O
patients O O
than O O
from O O
healthy O O
controls O O
. O O

The O O
ex O O
vivo O O
expression O O
of O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
was O O
higher O O
in O O
PBMCs B-cell_type B-cell_type
of O O
controls O O
than O O
of O O
trauma O O
patients O O
. O O

LPS O O
did O O
not O O
induce O O
I O B-protein
kappa O I-protein
B O I-protein
expression O O
in O O
PBMCs B-cell_type B-cell_type
from O O
trauma O O
patients O O
, O O
but O O
strong O O
induction O O
was O O
obtained O O
with O O
staphylococci O O
, O O
suggesting O O
that O O
this O O
defect O O
is O O
not O O
universal O O
and O O
depends O O
on O O
the O O
nature O O
of O O
the O O
activating O O
signal O O
. O O

Although O O
no O O
direct O O
correlation O O
was O O
found O O
between O O
levels O O
of O O
interleukin-10 B-protein B-protein
or O O
transforming B-protein B-protein
growth I-protein I-protein
factor-beta I-protein I-protein
and O O
NF-kappa B-protein B-protein
B I-protein I-protein
, O O
these O O
immunosuppressive B-protein B-protein
cytokines I-protein I-protein
were O O
significantly O O
elevated O O
in O O
trauma O O
patients O O
by O O
10 O O
days O O
after O O
admission O O
. O O

The O O
long-term O O
low-basal O O
and O O
LPS-induced O O
nuclear O O
translocation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
recalled O O
long-term O O
immunoparalysis O O
observed O O
in O O
patients O O
with O O
severe O O
inflammatory O O
stress O O
such O O
as O O
trauma O O
. O O

Hepatic O O
ischemia-reperfusion O O
injury O O
. O O

BACKGROUND O O
: O O
The O O
morbidity O O
associated O O
with O O
liver O O
transplantation O O
and O O
major O O
hepatic O O
resections O O
is O O
partly O O
a O O
result O O
of O O
ischemia-reperfusion O O
injury O O
. O O

DATA O O
SOURCES O O
: O O
The O O
entire O O
world O O
literature O O
on O O
the O O
subject O O
was O O
searched O O
via O O
Medline O O
. O O

Keywords O O
included O O
reperfusion O O
injury O O
, O O
transplantation O O
, O O
liver O O
resection O O
, O O
nitric O O
oxide O O
, O O
endothelin O O
, O O
cytokines B-protein B-protein
, O O
Kupffer B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
ischemic/ischaemic O O
preconditioning O O
, O O
and O O
nuclear B-protein B-protein
factor-kappa I-protein I-protein
B I-protein I-protein
. O O

CONCLUSIONS O O
: O O
An O O
imbalance O O
between O O
endothelin O O
and O O
nitric O O
oxide O O
levels O O
results O O
in O O
failure O O
of O O
the O O
hepatic O O
microcirculation O O
at O O
the O O
onset O O
of O O
reperfusion O O
. O O

Activation O O
of O O
nuclear B-protein B-protein
factor-kappa I-protein I-protein
B I-protein I-protein
in O O
the O O
liver O O
promotes O O
proinflammatory B-protein B-protein
cytokine I-protein I-protein
and O O
adhesion B-protein B-protein
molecule I-protein I-protein
synthesis O O
. O O

These O O
result O O
in O O
oxygen-derived O O
free O O
radical O O
production O O
and O O
neutrophil O B-cell_type
recruitment O O
, O O
further O O
contributing O O
to O O
cellular O O
injury O O
. O O

Various O O
therapeutic O O
modalities O O
acting O O
on O O
the O O
above O O
mediators O B-protein
have O O
been O O
successfully O O
used O O
to O O
attenuate O O
reperfusion O O
injury O O
in O O
animal O O
models O O
of O O
hepatic O O
transplantation O O
and O O
resection O O
. O O

Application O O
of O O
the O O
knowledge O O
gained O O
from O O
animal O O
models O O
of O O
hepatic O O
ischemia-reperfusion O O
to O O
the O O
clinical O O
setting O O
will O O
improve O O
the O O
outcome O O
of O O
hepatic O O
surgery O O
. O O

Down-regulation O O
of O O
IL-12 B-DNA B-DNA
p40 I-DNA I-DNA
gene I-DNA I-DNA
in O O
Plasmodium O O
berghei-infected O O
mice O O
. O O

We O O
analyzed O O
the O O
mechanism O O
that O O
causes O O
suppression O O
of O O
IL-12 B-DNA B-protein
p40 I-DNA B-DNA
gene I-DNA I-DNA
induction O O
during O O
Plasmodium O O
berghei O O
infection O O
. O O

Although O O
IL-12 B-protein B-protein
together O O
with O O
IFN-gamma B-protein B-protein
plays O O
an O O
important O O
role O O
in O O
protection O O
against O O
pathogenic O O
infection O O
, O O
the O O
IL-12 B-protein B-protein
p70 I-protein B-protein
protein I-protein O
production O O
of O O
infected B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
is O O
lower O O
than O O
that O O
by O O
the O O
uninfected B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
. O O

We O O
showed O O
in O O
the O O
present O O
study O O
that O O
the O O
induction O O
of O O
IL-12 B-DNA B-DNA
p40 I-DNA I-DNA
gene I-DNA I-DNA
but O O
not O O
IL-12 B-DNA B-DNA
p35 I-DNA I-DNA
gene I-DNA I-DNA
in O O
macrophages B-cell_type B-cell_type
of O O
P. O O
berghei-infected O O
mice O O
was O O
profoundly O O
inhibited O O
. O O

The O O
inhibition O O
was O O
induced O O
by O O
interaction O O
with O O
macrophages B-cell_type B-cell_type
that O O
had O O
contacted O O
with O O
P. B-cell_type B-cell_type
berghei-infected I-cell_type I-cell_type
erythrocytes I-cell_type I-cell_type
and O O
was O O
mediated O O
by O O
a O O
soluble O B-protein
factor O I-protein
, O O
IL-10 B-protein B-protein
. O O

There O O
was O O
comparable O O
activation O O
of O O
NF-kappaB B-protein B-protein
in O O
uninfected B-cell_type O
and I-cell_type O
infected I-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
induction O O
of O O
IFN-regulatory B-DNA B-DNA
factor-1 I-DNA I-DNA
gene I-DNA I-DNA
was O O
comparable O O
in O O
transcription O O
level O O
in O O
uninfected B-cell_type B-cell_type
and I-cell_type I-cell_type
infected I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
while O O
the O O
unidentified O O
complex O O
formation O O
of O O
IFN-regulatory B-protein B-protein
factor-1 I-protein I-protein
was O O
observed O O
in O O
infected B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Therefore O O
, O O
the O O
inhibition O O
of O O
the O O
IL-12 B-DNA B-DNA
p40 I-DNA I-DNA
gene I-DNA I-DNA
induction O O
appeared O O
to O O
be O O
regulated O O
at O O
transcriptional O O
regulation O O
level O O
of O O
the O O
gene O O
. O O

The O O
Friend B-protein O
of I-protein O
GATA I-protein B-protein
proteins I-protein I-protein
U-shaped O O
, O O
FOG-1 B-protein B-protein
, O O
and O O
FOG-2 B-protein B-protein
function O O
as O O
negative O O
regulators O O
of O O
blood O O
, O O
heart O O
, O O
and O O
eye O O
development O O
in O O
Drosophila O O
. O O

Friend B-protein O
of I-protein O
GATA I-protein B-protein
( I-protein I-protein
FOG I-protein I-protein
) I-protein I-protein
proteins I-protein I-protein
regulate O O
GATA O B-DNA
factor-activated O I-DNA
gene O I-DNA
transcription O O
. O O

During O O
vertebrate O O
hematopoiesis O O
, O O
FOG B-protein B-protein
and I-protein O
GATA I-protein B-protein
proteins I-protein I-protein
cooperate O O
to O O
promote O O
erythrocyte O O
and O O
megakaryocyte O O
differentiation O O
. O O

The O O
Drosophila B-protein B-protein
FOG I-protein I-protein
homologue I-protein I-protein
U-shaped I-protein O
( O O
Ush B-protein O
) O O
is O O
expressed O O
similarly O O
in O O
the O O
blood O O
cell O O
anlage O O
during O O
embryogenesis O O
. O O

During O O
hematopoiesis O O
, O O
the O O
acute O B-cell_line
myeloid O I-cell_line
leukemia O I-cell_line
1 O I-cell_line
homologue O I-cell_line
Lozenge B-cell_type I-cell_line
and I-cell_type I-cell_line
Glial I-cell_type I-cell_line
cells I-cell_type I-cell_line
missing O O
are O O
required O O
for O O
the O O
production O O
of O O
crystal B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
plasmatocytes B-cell_type B-cell_type
, O O
respectively O O
. O O

However O O
, O O
additional O O
factors O O
have O O
been O O
predicted O O
to O O
control O O
crystal O O
cell O O
proliferation O O
. O O

In O O
this O O
report O O
, O O
we O O
show O O
that O O
Ush B-protein O
is O O
expressed O O
in O O
hemocyte B-cell_type B-cell_type
precursors I-cell_type I-cell_type
and O O
plasmatocytes B-cell_type B-cell_type
throughout O O
embryogenesis O O
and O O
larval O O
development O O
, O O
and O O
the O O
GATA B-protein B-protein
factor I-protein I-protein
Serpent I-protein O
is O O
essential O O
for O O
Ush B-protein O
embryonic O O
expression O O
. O O

Furthermore O O
, O O
loss O O
of O O
ush O O
function O O
results O O
in O O
an O O
overproduction O O
of O O
crystal B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
whereas O O
forced O O
expression O O
of O O
Ush B-protein O
reduces O O
this O O
cell O O
population O O
. O O

Murine B-protein O
FOG-1 I-protein O
and I-protein O
FOG-2 I-protein B-protein
also O O
can O O
repress O O
crystal O O
cell O O
production O O
, O O
but O O
a O O
mutant O O
version O O
of O O
FOG-2 B-protein B-protein
lacking O O
a O O
conserved O B-DNA
motif O I-DNA
that O O
binds O O
the O O
corepressor B-protein B-protein
C-terminal I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
fails O O
to O O
affect O O
the O O
cell O B-cell_type
lineage O I-cell_type
. O O

The O O
GATA B-protein B-protein
factor I-protein I-protein
Pannier I-protein I-protein
( O O
Pnr B-protein O
) O O
is O O
required O O
for O O
eye O O
and O O
heart O O
development O O
in O O
Drosophila O O
. O O

When O O
Ush B-protein O
, O O
FOG-1 B-protein B-protein
, O O
FOG-2 B-protein B-protein
, O O
or O O
mutant B-protein B-protein
FOG-2 I-protein I-protein
is O O
coexpressed O O
with O O
Pnr B-protein O
during O O
these O O
developmental O O
processes O O
, O O
severe O O
eye O O
and O O
heart O O
phenotypes O O
result O O
, O O
consistent O O
with O O
a O O
conserved O O
negative O O
regulation O O
of O O
Pnr B-protein O
function O O
. O O

These O O
results O O
indicate O O
that O O
the O O
fly O O
and O O
mouse O O
FOG B-protein B-protein
proteins I-protein I-protein
function O O
similarly O O
in O O
three O O
distinct O O
cellular O O
contexts O O
in O O
Drosophila O O
, O O
but O O
may O O
use O O
different O O
mechanisms O O
to O O
regulate O O
genetic O O
events O O
in O O
blood O O
vs O O
. O O
cardial B-cell_line B-cell_type
or I-cell_line I-cell_type
eye I-cell_line I-cell_type
cell I-cell_line I-cell_type
lineages I-cell_line I-cell_type

The O O
RING B-protein B-protein
finger I-protein I-protein
protein I-protein I-protein
Siah-1 B-protein I-protein
regulates O O
the O O
level O O
of O O
the O O
transcriptional B-protein B-protein
coactivator I-protein I-protein
OBF-1 B-protein B-protein
. O O

The O O
transcriptional B-protein B-protein
coactivator I-protein I-protein
OBF-1 B-protein B-protein
, O O
which O O
interacts O O
with O O
Oct-1 B-protein B-protein
and O O
Oct-2 B-protein B-protein
and O O
the O O
octamer B-DNA B-DNA
site I-DNA I-DNA
DNA I-DNA I-DNA
, O O
has O O
been O O
shown O O
to O O
be O O
critical O O
for O O
development O O
of O O
a O O
normal O O
immune O O
response O O
and O O
the O O
formation O O
of O O
germinal O O
centers O O
in O O
secondary O O
lymphoid O O
organs O O
. O O

Here O O
we O O
have O O
identified O O
the O O
RING B-protein B-protein
finger I-protein I-protein
protein I-protein I-protein
Siah-1 B-protein B-protein
as O O
a O O
protein O O
interacting O O
specifically O O
with O O
OBF-1 B-protein B-protein
. O O

This O O
interaction O O
is O O
mediated O O
by O O
the O O
C-terminal B-protein B-protein
part O I-protein
of O O
Siah-1 B-protein B-protein
and O O
by O O
residues O O
in O O
the O O
N-terminus B-protein O
of O O
OBF-1 B-protein B-protein
, O O
partly O O
distinct O O
from O O
the O O
residues O O
required O O
for O O
formation O O
of O O
a O O
complex O O
with O O
the O O
Oct B-protein B-protein
POU I-protein I-protein
domains I-protein I-protein
and O O
the O O
DNA O O
. O O

Interaction O O
between O O
Siah-1 B-protein B-protein
and O O
OBF-1 B-protein B-protein
leads O O
to O O
downregulation O O
of O O
OBF-1 O B-protein
protein O I-protein
level O O
but O O
not O O
mRNA O B-RNA
, O O
and O O
to O O
a O O
corresponding O O
reduction O O
in O O
octamer O B-DNA
site-dependent O O
transcription O O
activation O O
. O O

Inhibition O O
of O O
the O O
ubiquitin-proteasome O O
pathway O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
leads O O
to O O
elevated O O
levels O O
of O O
OBF-1 B-protein B-protein
protein I-protein I-protein
. O O

Furthermore O O
, O O
in O O
immunized O O
mice O O
, O O
OBF-1 B-protein B-protein
protein I-protein I-protein
amounts O O
are O O
dramatically O O
increased O O
in O O
primary B-cell_type B-cell_type
activated I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
without O O
concomitant O O
increase O O
in O O
OBF-1 B-RNA B-RNA
mRNA I-RNA I-RNA
. O O

These O O
data O O
suggest O O
that O O
Siah-1 B-protein B-protein
is O O
part O O
of O O
a O O
novel O O
regulatory O O
loop O O
controlling O O
the O O
level O O
of O O
OBF-1 B-protein B-protein
protein I-protein I-protein
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
beta-catenin O B-protein
-- O O
TCF-1 O B-protein
pathway O O
ensures O O
CD4 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
CD8 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
thymocyte I-cell_type I-cell_type
survival O O
. O O

The O O
association O O
of O O
trans-acting B-protein B-protein
T I-protein I-protein
cell I-protein I-protein
factors I-protein I-protein
( O O
TCFs B-protein B-protein
) O O
or O O
lymphoid B-protein B-protein
enhancer I-protein I-protein
factor I-protein I-protein
1 I-protein I-protein
( O O
LEF-1 B-protein B-protein
) O O
with O O
their O O
coactivator O B-protein
beta-catenin O I-protein
mediates O O
transient O O
transcriptional O O
responses O O
to O O
extracellular O O
Wnt O O
signals O O
. O O

We O O
show O O
here O O
that O O
T O O
cell O O
maturation O O
depends O O
on O O
the O O
presence O O
of O O
the O O
beta-catenin B-protein B-protein
-- I-protein I-protein
binding I-protein I-protein
domain I-protein I-protein
in O O
TCF-1 B-protein B-protein
. O O

This O O
domain O O
is O O
necessary O O
to O O
mediate O O
the O O
survival O O
of O O
immature O B-cell_type
CD4 B-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
CD8 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
double-positive I-cell_type I-cell_type
( I-cell_type I-cell_type
DP I-cell_type I-cell_type
) I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
. O O

Accelerated O O
spontaneous O O
thymocyte O O
death O O
in O O
the O O
absence O O
of O O
TCF-1 B-protein B-protein
correlates O O
with O O
aberrantly O O
low O O
expression O O
of O O
the O O
anti-apoptotic B-protein B-protein
protein I-protein I-protein
Bcl-x B-protein B-protein
( I-protein I-protein
L I-protein I-protein
) I-protein I-protein
. O O

Increasing O O
anti-apoptotic O B-protein
effectors O I-protein
in O O
thymocytes B-cell_type B-cell_type
by O O
the O O
use O O
of O O
a O O
Bcl-2 B-DNA B-DNA
transgene I-DNA I-DNA
rescued O O
TCF-1-deficient B-cell_type B-cell_type
DP I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
from O O
apoptosis O O
. O O

Thus O O
, O O
TCF-1 B-protein B-protein
, O O
upon O O
association O O
with O O
beta-catenin O B-protein
, O O
transiently O O
ensures O O
the O O
survival O O
of O O
immature B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
which O O
enables O O
them O O
to O O
generate O O
and O O
edit O O
T B-protein B-protein
cell I-protein I-protein
receptor I-protein I-protein
( I-protein I-protein
TCR I-protein I-protein
) I-protein I-protein
alpha I-protein I-protein
chains I-protein I-protein
and O O
attempt O O
TCR B-protein B-protein
-mediated O O
positive O O
selection O O
. O O

TRAIL/Apo2L B-protein B-protein
ligand I-protein O
selectively O O
induces O O
apoptosis O O
and O O
overcomes O O
drug O O
resistance O O
in O O
multiple O O
myeloma O O
: O O
therapeutic O O
applications O O
. O O

Multiple O O
myeloma O O
( O O
MM O O
) O O
remains O O
incurable O O
and O O
novel O O
treatments O O
are O O
urgently O O
needed O O
. O O

Preclinical O O
in O O
vitro O O
and O O
in O O
vivo O O
evaluations O O
were O O
performed O O
to O O
assess O O
the O O
potential O O
therapeutic O O
applications O O
of O O
human O B-protein
recombinant O I-protein
tumor B-protein I-protein
necrosis I-protein I-protein
factor I-protein I-protein
( I-protein O
TNF I-protein B-protein
) I-protein O
-related I-protein O
apoptosis-inducing I-protein B-protein
ligand/Apo2 I-protein I-protein
ligand I-protein I-protein
( O O
TRAIL/Apo2L B-protein B-protein
) O O
in O O
MM O O
. O O

TRAIL/Apo2L B-protein B-protein
potently O O
induced O O
apoptosis O O
of O O
MM B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
patients O O
and O O
the O O
majority O O
of O O
MM B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
including O O
cells O O
sensitive O O
or O O
resistant O O
to O O
dexamethasone O O
( O O
Dex O O
) O O
, O O
doxorubicin O O
( O O
Dox O O
) O O
, O O
melphalan O O
, O O
and O O
mitoxantrone O O
. O O

TRAIL/Apo2L B-protein B-protein
also O O
overcame O O
the O O
survival O O
effect O O
of O O
interleukin B-protein B-protein
6 I-protein I-protein
on O O
MM B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
did O O
not O O
affect O O
the O O
survival O O
of O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
and I-cell_type I-cell_type
bone I-cell_type I-cell_type
marrow I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
purified B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
healthy O O
donors O O
. O O

The O O
status O O
of O O
the O O
TRAIL B-protein B-protein
receptors I-protein I-protein
( O O
assessed O O
by O O
immunoblotting O O
and O O
flow O O
cytometry O O
) O O
could O O
not O O
predict O O
TRAIL O B-protein
sensitivity O O
of O O
MM B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
anti-MM O O
activity O O
of O O
TRAIL/Apo2L B-protein B-protein
was O O
confirmed O O
in O O
nu/xid/bg O O
mice O O
xenografted O O
with O O
human B-cell_type B-cell_type
MM I-cell_type I-cell_type
cells I-cell_type I-cell_type
; O O
TRAIL B-protein B-protein
( O O
500 O O
microg O O
intraperitoneally O O
daily O O
for O O
14 O O
days O O
) O O
was O O
well O O
tolerated O O
and O O
significantly O O
suppressed O O
the O O
growth O O
of O O
plasmacytomas B-cell_type O
. O O

Dox O O
up-regulated O O
the O O
expression O O
of O O
the O O
TRAIL B-protein B-protein
receptor I-protein I-protein
death B-protein I-protein
receptor I-protein I-protein
5 I-protein I-protein
( O O
DR5 B-protein B-protein
) O O
and O O
synergistically O O
enhanced O O
the O O
effect O O
of O O
TRAIL B-protein B-protein
not O O
only O O
against O O
MM B-cell_type B-cell_type
cells I-cell_type I-cell_type
sensitive O O
to O O
, O O
but O O
also O O
against O O
those O O
resistant O O
to O O
, O O
Dex- O O
or O O
Dox-induced O O
apoptosis O O
. O O

Nuclear O B-protein
factor O I-protein
( O I-protein
NF O I-protein
) O I-protein
-kappaB O I-protein
inhibitors O O
, O O
such O O
as O O
SN50 O O
( O O
a O O
cell-permeable O O
inhibitor O O
of O O
the O O
nuclear O O
translocation O O
and O O
transcriptional O O
activity O O
of O O
NF-kappaB B-protein B-protein
) O O
or O O
the O O
proteasome O B-protein
inhibitor O O
PS-341 O O
, O O
enhanced O O
the O O
proapoptotic O O
activity O O
of O O
TRAIL/Apo2L B-protein B-protein
against O O
TRAIL-sensitive B-cell_type B-cell_type
MM I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
whereas O O
SN50 O O
reversed O O
the O O
TRAIL O B-protein
resistance O O
of O O
ARH-77 B-cell_type B-cell_line
and I-cell_type O
IM-9 I-cell_type B-cell_line
MM I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

Importantly O O
, O O
normal B-cell_type B-cell_type
B I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
were O O
not O O
sensitized O O
to O O
TRAIL B-protein B-protein
by O O
either O O
Dox O O
, O O
SN50 O O
, O O
or O O
PS-341 O O
. O O

These O O
preclinical O O
studies O O
suggest O O
that O O
TRAIL/Apo2L B-protein B-protein
can O O
overcome O O
conventional O O
drug O O
resistance O O
and O O
provide O O
the O O
basis O O
for O O
clinical O O
trials O O
of O O
TRAIL B-protein B-protein
-based O O
treatment O O
regimens O O
to O O
improve O O
outcome O O
in O O
patients O O
with O O
MM O O
. O O

( O O
Blood. O O
2001 O O
; O O
98 O O
: O O
795-804 O O
) O O

CD28 B-protein B-protein
costimulation O O
is O O
required O O
not O O
only O O
to O O
induce O O
IL-12 B-protein B-protein
receptor I-protein I-protein
but O O
also O O
to O O
render O O
janus B-protein B-protein
kinases/STAT4 I-protein I-protein
responsive O O
to O O
IL-12 B-protein B-protein
stimulation O O
in O O
TCR-triggered B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
activation O O
of O O
resting B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
for O O
the O O
acquisition O O
of O O
various O O
functions O O
depends O O
on O O
whether O O
CD28 O B-protein
costimulatory O O
signals O O
are O O
provided O O
upon O O
T O O
cell O O
receptor O O
stimulation O O
. O O

Here O O
, O O
we O O
investigated O O
how O O
CD28 O B-protein
costimulation O O
functions O O
to O O
allow O O
TCR B-protein B-protein
-triggered O O
resting B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
to O O
acquire O O
IL-12 B-protein B-protein
responsiveness O O
. O O

When O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
are O O
stimulated O O
with O O
low O O
doses O O
of O O
anti-CD3 B-protein B-protein
mAb I-protein I-protein
, O O
CD28 O B-protein
costimulation O O
was O O
required O O
for O O
the O O
optimal O O
levels O O
of O O
IL-12 B-protein B-protein
receptor I-protein I-protein
( O O
IL-12R B-protein B-protein
) O O
expression O O
. O O

However O O
, O O
stimulation O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
with O O
high O O
doses O O
of O O
anti-CD3 B-protein B-protein
alone O O
induced O O
comparable O O
levels O O
of O O
IL-12R B-protein B-protein
expression O O
to O O
those O O
induced O O
upon O O
CD28 O B-protein
costimulation O O
. O O

Nevertheless O O
, O O
there O O
was O O
a O O
substantial O O
difference O O
in O O
IL-12 B-protein B-protein
responsiveness O O
between O O
these O O
two O O
groups O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
: O O
compared O O
to O O
anti-CD28-costimulated B-cell_type B-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
, O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
that O O
were O O
not O O
costimulated O O
with O O
anti-CD28 B-protein B-protein
exhibited O O
decreased O O
levels O O
of O O
Janus B-protein B-protein
kinases I-protein I-protein
( O I-protein
JAK B-protein I-protein
) O I-protein
JAK2/TYK2 B-protein B-protein
and O O
STAT4 B-protein B-protein
phosphorylation O O
and O O
IFN-y O B-protein
production O O
following O O
IL-12 B-protein B-protein
stimulation O O
. O O

Importantly O O
, O O
STAT6 O B-protein
phosphorylation O O
following O O
IL-4 O B-protein
stimulation O O
was O O
not O O
decreased O O
in O O
anti-CD28-uncostimulated B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

These O O
resutls O O
indicate O O
that O O
CD28 O B-protein
costimulation O O
not O O
only O O
contributes O O
to O O
up-regulating O O
IL-12R B-protein B-protein
expression O O
but O O
is O O
also O O
required O O
to O O
render O O
JAKs/STAT4 B-protein B-protein
responsive O O
to O O
IL-12 B-protein B-protein
stimulation O O
. O O

Constitutively O O
activated O O
Akt-1 B-protein B-protein
is O O
vital O O
for O O
the O O
survival O O
of O O
human B-cell_type B-cell_type
monocyte-differentiated I-cell_type I-cell_type
macrophages I-cell_type I-cell_type
. O O

Role O O
of O O
Mcl-1 B-protein B-protein
, O O
independent O O
of O O
nuclear B-protein B-protein
factor I-protein I-protein
( I-protein I-protein
NF I-protein I-protein
) I-protein I-protein
-kappaB I-protein I-protein
, O O
Bad B-protein B-protein
, O O
or O O
caspase O B-protein
activation O O
. O O

Recent O O
data O O
from O O
mice O O
deficient O O
for O O
phosphatase B-protein B-DNA
and O I-DNA
tensin B-DNA I-DNA
homologue I-DNA I-DNA
deleted O O
from O O
chromosome B-DNA B-DNA
10 I-DNA I-DNA
or O O
src B-protein B-protein
homology I-protein I-protein
2 I-protein I-protein
domain-containing I-protein I-protein
5 I-protein I-protein
' I-protein I-protein
inositol I-protein I-protein
phosphatase I-protein I-protein
, O O
phosphatases B-protein B-protein
that O O
negatively O O
regulate O O
the O O
phosphatidylinositol B-protein B-protein
3-kinase I-protein I-protein
( O O
PI3K B-protein B-protein
) O O
pathway O O
, O O
revealed O O
an O O
increased O O
number O O
of O O
macrophages B-cell_type B-cell_type
in O O
these O O
animals O O
, O O
suggesting O O
an O O
essential O O
role O O
for O O
the O O
PI3K B-protein B-protein
pathway O O
for O O
macro-phage B-cell_type O
survival O O
. O O

Here O O
, O O
we O O
focused O O
on O O
the O O
role O O
of O O
the O O
PI3K-regulated B-protein B-protein
serine/threonine I-protein I-protein
kinase I-protein I-protein
Akt-1 B-protein B-protein
in O O
modulating O O
macrophage B-cell_type O
survival O O
. O O

Akt-1 B-protein B-protein
was O O
constitutively O O
activated O O
in O O
human B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
and O O
addition O O
of O O
the O O
PI3K B-protein B-protein
inhibitor O O
, O O
LY294002 O O
, O O
suppressed O O
the O O
activation O O
of O O
Akt-1 B-protein B-protein
and O O
induced O O
cell O O
death O O
. O O

Furthermore O O
, O O
suppression O O
of O O
Akt-1 B-protein B-protein
by O O
inhibition O O
of O O
PI3K B-protein B-protein
or O O
a O O
dominant B-protein B-protein
negative I-protein I-protein
( I-protein I-protein
DN I-protein I-protein
) I-protein I-protein
Akt-1 I-protein I-protein
resulted O O
in O O
loss O O
of O O
mitochondrial O O
transmembrane O O
potential O O
, O O
activation O O
of O O
caspases-9 B-protein B-protein
and I-protein I-protein
-3 I-protein I-protein
, O O
and O O
DNA O O
fragmentation O O
. O O

The O O
effects O O
of O O
PI3K B-protein B-protein
inhibition O O
were O O
reversed O O
by O O
the O O
ectopic O O
expression O O
of O O
constitutively O O
activated O O
Akt-1 B-protein B-protein
or O O
Bcl-x B-protein B-protein
( I-protein I-protein
L I-protein I-protein
) I-protein I-protein
. O O

Inhibition O O
of O O
PI3K B-protein B-protein
/Akt-1 O B-protein
pathway O O
either O O
by O O
LY294002 O O
or O O
DN B-protein B-protein
Akt-1 I-protein I-protein
had O O
no O O
effect O O
on O O
the O O
constitutive O O
or O O
inducible O O
activation O O
of O O
nuclear B-protein B-protein
factor I-protein I-protein
( I-protein I-protein
NF I-protein I-protein
) I-protein I-protein
-kappaB I-protein I-protein
in O O
human B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
. O O

However O O
, O O
after O O
inhibition O O
of O O
the O O
PI3K B-protein B-protein
/ O O
Akt-1 B-protein B-protein
pathway O O
, O O
a O O
marked O O
decrease O O
in O O
the O O
expression O O
of O O
the O O
antiapoptotic B-protein B-protein
molecule I-protein I-protein
Mcl-1 B-protein B-protein
, O O
but O O
not O O
other O O
Bcl-2 B-protein B-protein
family I-protein I-protein
members I-protein I-protein
was O O
observed O O
, O O
and O O
Mcl-1 B-protein B-protein
rescued O O
macrophages B-cell_type B-cell_type
from O O
LY294002-induced O O
cell O O
death O O
. O O

Further O O
, O O
inhibition O O
of O O
Mcl-1 B-protein B-protein
by O O
antisense O O
oligonucleotides O O
, O O
also O O
resulted O O
in O O
macrophage B-cell_type O
apoptosis O O
. O O

Thus O O
, O O
our O O
findings O O
demonstrate O O
that O O
the O O
constitutive O O
activation O O
of O O
Akt-1 B-protein B-protein
regulates O O
macrophage B-cell_type O
survival O O
through O O
Mcl-1 B-protein B-protein
, O O
which O O
is O O
independent O O
of O O
caspases B-protein B-protein
, O O
NF-kappaB B-protein B-protein
, O O
or O O
Bad B-protein B-protein
. O O

GRbeta O B-protein
expression O O
in O O
nasal B-cell_type B-cell_type
polyp I-cell_type I-cell_type
inflammatory I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
its O O
relationship O O
to O O
the O O
anti-inflammatory O O
effects O O
of O O
intranasal O O
fluticasone O O
. O O

BACKGROUND O O
: O O
Nasal O O
polyposis O O
disease O O
is O O
an O O
inflammatory O O
disorder O O
with O O
intense O O
eosinophilic O O
infiltration O O
of O O
respiratory O O
mucosa O O
that O O
is O O
often O O
difficult O O
to O O
control O O
with O O
topical O O
steroids O O
. O O

Recent O O
evidence O O
suggests O O
that O O
overexpression O O
of O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-RNA
splice I-protein I-RNA
variant I-protein I-RNA
GRbeta B-protein B-protein
in O O
inflammatory B-cell_type B-cell_type
cells I-cell_type I-cell_type
might O O
contribute O O
to O O
steroid O O
insensitivity O O
in O O
diseases O O
such O O
as O O
asthma O O
. O O

OBJECTIVE O O
: O O
The O O
purposes O O
of O O
this O O
investigation O O
were O O
to O O
determine O O
whether O O
nasal B-cell_type O
polyp I-cell_type O
( I-cell_type O
NP I-cell_type O
) I-cell_type O
inflammatory I-cell_type B-cell_type
cells I-cell_type I-cell_type
overexpress O O
GRbeta B-protein B-protein
and O O
to O O
examine O O
whether O O
GRbeta B-protein B-protein
overexpression O O
is O O
associated O O
with O O
insensitivity O O
to O O
the O O
potent O O
topical O O
steroid O O
fluticasone O O
propionate O O
( O O
FP O O
) O O
. O O

METHODS O O
: O O
Biopsies O O
were O O
obtained O O
from O O
10 O O
subjects O O
with O O
NPs O O
before O O
and O O
4 O O
weeks O O
after O O
treatment O O
with O O
intranasal O O
FP O O
. O O

Middle O O
turbinates O O
biopsies O O
from O O
6 O O
healthy O O
, O O
nonallergic O O
subjects O O
served O O
as O O
normal O O
controls O O
. O O

Biopsies O O
were O O
immunostained O O
for O O
inflammatory O O
cell O O
markers O O
as O O
well O O
as O O
GRbeta B-protein B-protein
and O O
probed O O
for O O
various O O
cytokine B-RNA B-RNA
mRNA I-RNA I-RNA
. O O

The O O
anti-inflammatory O O
response O O
to O O
FP O O
was O O
examined O O
in O O
relation O O
to O O
pretreatment O O
levels O O
of O O
GRbeta O B-protein
expression O O
. O O

RESULTS O O
: O O
The O O
total O O
numbers O O
of O O
inflammatory B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
increased O O
in O O
NPs B-cell_type O
. O O

The O O
percentage O O
of O O
inflammatory B-cell_type B-cell_type
cells I-cell_type I-cell_type
expressing O O
GRbeta B-protein B-protein
was O O
also O O
increased O O
( O O
40.5 O O
% O O
+/- O O
19.2 O O
% O O
vs O O
16.1 O O
% O O
+/- O O
4.0 O O
% O O
, O O
P O O
=.009 O O
) O O
. O O

GRbeta B-protein B-protein
expression O O
in O O
NPs B-cell_type O
was O O
almost O O
exclusive O O
to O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
, O O
eosinophils B-cell_type B-cell_type
, O O
and O O
macrophages B-cell_type B-cell_type
. O O

An O O
inverse O O
correlation O O
was O O
observed O O
between O O
the O O
baseline O O
inflammatory O O
cell O O
GRbeta B-protein B-protein
expression O O
and O O
the O O
reduction O O
after O O
FP O O
treatment O O
in O O
EG2-positive B-cell_type B-cell_type
eosinophils I-cell_type I-cell_type
, O O
CD4-positive B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
, O O
endothelial O O
VCAM-1 B-protein B-protein
expression O O
, O O
and O O
IL-4 B-cell_type B-protein
mRNA-positive I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

NPs B-cell_type O
that O O
were O O
`` O O
FP-insensitive O O
'' O O
in O O
terms O O
of O O
suppression O O
of O O
eosinophil B-cell_type O
numbers O O
( O O
major B-protein O
basic I-protein O
protein I-protein O
-positive O O
) O O
had O O
a O O
significantly O O
greater O O
percentage O O
of O O
GRbeta-positive B-cell_type B-cell_type
inflammatory I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
a O O
higher O O
ratio O O
of O O
GRbeta-positive/GRalpha-positive B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
and O O
increased O O
numbers O O
of O O
GRbeta-positive B-cell_type B-cell_type
eosinophils I-cell_type I-cell_type
and O O
macrophages B-cell_type B-cell_type
in O O
comparison O O
with O O
those O O
that O O
were O O
`` O O
FP-sensitive. O O
'' O O

`` B-cell_type O
FP-insensitive I-cell_type O
'' I-cell_type O
NPs I-cell_type O
also O O
demonstrated O O
a O O
higher O O
percentage O O
of O O
IL-5-positive B-cell_type B-cell_type
inflammatory I-cell_type I-cell_type
cells I-cell_type I-cell_type
expressing O O
GRbeta B-protein B-protein
before O O
and O O
after O O
FP O O
treatment O O
. O O

CONCLUSION O O
: O O
GRbeta B-protein B-protein
expression O O
appears O O
to O O
be O O
a O O
marker O O
of O O
steroid O O
insensitivity O O
in O O
NPs B-cell_type O
. O O

Expression O O
of O O
GRbeta B-protein B-protein
by O O
NP B-cell_type B-cell_type
inflammatory I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
particularly O B-cell_type
T B-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
eosinophils B-cell_type B-cell_type
, O O
might O O
render O O
them O O
resistant O O
to O O
suppression O O
by O O
topical O O
steroids O O
and O O
thereby O O
contribute O O
to O O
persistent O O
NP B-cell_type O
inflammation O O
. O O

Transcriptional O O
regulation O O
of O O
galectin-10 B-protein B-protein
( O O
eosinophil B-protein B-protein
Charcot-Leyden I-protein I-protein
crystal I-protein I-protein
protein I-protein I-protein
) O O
: O O
a O O
GC B-DNA B-DNA
box I-DNA I-DNA
( O O
-44 O O
to O O
-50 O O
) O O
controls O O
butyric O O
acid O O
induction O O
of O O
gene O O
expression O O
. O O

Galectin-10 B-protein O
( O O
gal-10 B-protein O
, O O
also O O
known O O
as O O
Charcot-Leyden B-protein B-protein
crystal I-protein I-protein
protein I-protein I-protein
) O O
is O O
a O O
member O O
of O O
the O O
galectin B-protein B-protein
family I-protein I-protein
of O O
beta-galactoside B-protein B-protein
binding I-protein I-protein
proteins I-protein I-protein
that O O
is O O
expressed O O
uniquely O O
in O O
eosinophilic B-cell_type B-cell_type
and I-cell_type I-cell_type
basophilic I-cell_type I-cell_type
leukocytes I-cell_type I-cell_type
. O O

To O O
gain O O
a O O
better O O
understanding O O
of O O
galectin O B-DNA
gene O I-DNA
expression O O
, O O
we O O
present O O
an O O
analysis O O
of O O
the O O
transcriptional O O
regulation O O
of O O
the O O
gene O O
encoding O O
gal-10 B-protein B-DNA
. O O

Analysis O O
of O O
the O O
minimal B-DNA B-DNA
promoter I-DNA I-DNA
revealed O O
nine O O
consensus-binding B-DNA B-DNA
sites I-DNA I-DNA
for O O
transcription B-protein B-protein
factors I-protein I-protein
, O O
including O O
several O O
that O O
are O O
also O O
found O O
in O O
the O O
minimal B-DNA B-DNA
promoters I-DNA I-DNA
of O O
galectins B-DNA B-protein
-1 I-DNA I-protein
, I-DNA I-protein
-2 I-DNA I-protein
, I-DNA I-protein
and I-DNA I-protein
-3 I-DNA I-protein
. O O

The O O
decrease O O
in O O
gal-10 O B-DNA
promoter O I-DNA
activity O O
after O O
disruption O O
of O O
either O O
the O O
GC B-DNA B-DNA
box I-DNA I-DNA
( O I-DNA
-44 O I-DNA
to O I-DNA
-50 O I-DNA
) O O
or O O
the O O
Oct B-DNA B-DNA
site I-DNA I-DNA
( O O
-255 O B-DNA
to O I-DNA
-261 O I-DNA
) O O
suggests O O
that O O
these O O
sites O O
, O O
along O O
with O O
the O O
previously O O
characterized O O
GATA B-DNA B-DNA
and I-DNA I-DNA
EoTF I-DNA I-DNA
sites I-DNA I-DNA
, O O
are O O
necessary O O
for O O
full O O
promoter O O
activity O O
. O O

By O O
supershift O O
analysis O O
, O O
we O O
demonstrate O O
binding O O
of O O
the O O
transcription B-protein B-protein
factors I-protein I-protein
Sp1 B-protein B-protein
and O O
Oct1 B-protein B-protein
to O O
the O O
consensus B-DNA B-DNA
GC I-DNA I-DNA
box I-DNA I-DNA
and O O
the O O
Oct B-DNA B-DNA
site I-DNA I-DNA
, O O
respectively O O
. O O

Similar O O
to O O
gal-1 B-DNA B-protein
, O O
gal-10 O O
expression O O
is O O
induced O O
by O O
butyric O O
acid O O
, O O
an O O
effect O O
that O O
is O O
lost O O
upon O O
ablation O O
of O O
the O O
GC B-DNA B-DNA
box I-DNA I-DNA
. O O

Additionally O O
, O O
we O O
demonstrate O O
AML3 O B-DNA
binding O O
to O O
the O O
consensus B-DNA B-DNA
AML I-DNA I-DNA
site I-DNA I-DNA
and O O
YY1 B-protein B-protein
binding I-protein O
to O O
the O O
Inr B-DNA B-DNA
sequence I-DNA I-DNA
, O O
both O O
elements O O
functioning O O
as O O
silencers O O
in O O
the O O
gal-10 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Tumour-stromal O O
interactions O O
. O O

Role O O
of O O
the O O
stroma O O
in O O
mammary O O
development O O
. O O

Mammary O O
development O O
depends O O
on O O
branching O O
morphogenesis O O
, O O
namely O O
the O O
bifurcation O O
and O O
extension O O
of O O
ductal O O
growth O O
points O O
( O O
end O O
buds O O
) O O
and O O
secretory O O
lobules O O
into O O
a O O
more O O
or O O
less O O
fatty O O
stroma O O
. O O

Because O O
breast O O
carcinomas O O
are O O
overwhelmingly O O
ductal O O
in O O
origin O O
, O O
this O O
review O O
focuses O O
on O O
stromal O O
influences O O
guiding O O
postnatal O O
ductal O O
development O O
and O O
there O O
is O O
only O O
the O O
briefest O O
account O O
of O O
the O O
role O O
of O O
embryonic O O
stroma O O
( O O
mesenchyme O O
) O O
. O O

The O O
stroma O O
as O O
the O O
necessary O O
target O O
for O O
endocrine O O
mammogens O O
and O O
the O O
source O O
of O O
stimulatory O B-protein
growth O I-protein
factors O I-protein
is O O
described O O
and O O
the O O
importance O O
of O O
mammary O O
epithelium-induced O O
modifications O O
of O O
the O O
periductal O O
stroma O O
is O O
emphasized O O
. O O

Evidence O O
is O O
presented O O
that O O
if O O
they O O
are O O
to O O
grow O O
, O O
end O O
buds O O
must O O
condition O O
proximal O O
fatty O O
stroma O O
by O O
recruiting O O
white B-cell_type B-cell_type
blood I-cell_type I-cell_type
cells I-cell_type I-cell_type
as O O
well O O
as O O
inducing O O
stromal O O
cell O O
division O O
and O O
, O O
possibly O O
, O O
estrogen B-protein B-protein
receptors I-protein I-protein
. O O

The O O
induction O O
of O O
a O O
fibrous O O
stromal O O
tunic O O
around O O
the O O
end O O
bud O O
is O O
described O O
and O O
its O O
likely O O
role O O
as O O
a O O
complex O O
ductal O O
morphogen O O
is O O
discussed O O
; O O
a O O
possible O O
role O O
in O O
growth O O
inhibition O O
is O O
also O O
considered O O
. O O

Although O O
the O O
signals O O
governing O O
fibrotic O O
induction O O
, O O
ductal O O
morphogenesis O O
, O O
and O O
growth O O
inhibition O O
are O O
unknown O O
, O O
a O O
role O O
for O O
transforming O B-protein
growth B-protein I-protein
factor-beta I-protein I-protein
is O O
highly O O
likely O O
and O O
is O O
discussed O O
. O O

Finally O O
, O O
a O O
need O O
for O O
new O O
conceptual O O
and O O
experimental O O
approaches O O
to O O
understanding O O
stromal-epithelial O O
signaling O O
is O O
discussed O O
. O O

Adipophilin B-protein O
is O O
a O O
sensitive O O
marker O O
for O O
lipid O O
loading O O
in O O
human B-cell_type B-cell_type
blood I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
. O O

Adipophilin B-protein O
, O O
a O O
marker O O
of O O
lipid O O
accumulation O O
initially O O
described O O
in O O
adipocytes B-cell_type B-cell_type
, O O
was O O
recently O O
shown O O
to O O
be O O
induced O O
in O O
macrophage B-cell_type B-cell_type
foam I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

We O O
found O O
that O O
even O O
freshly B-cell_type B-cell_type
isolated I-cell_type I-cell_type
blood I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
express O O
adipophilin B-protein B-protein
and O O
that O O
the O O
amount O O
of O O
adipophilin B-protein B-protein
protein I-protein I-protein
is O O
variable O O
in O O
monocytes B-cell_type B-cell_type
from O O
different O O
healthy O O
individuals O O
. O O

However O O
, O O
the O O
physiological O O
expression O O
of O O
adipophilin B-protein B-protein
does O O
not O O
correlate O O
with O O
the O O
levels O O
of O O
free O O
fatty O O
acids O O
, O O
cholesterylesters O O
or O O
free O O
cholesterol O O
. O O

Enzymatically B-protein O
modified I-protein O
low-density I-protein B-protein
lipoprotein I-protein I-protein
( O O
E-LDL B-protein B-protein
) O O
induces O O
rapid O O
foam O O
cell O O
formation O O
in O O
monocytes B-cell_type B-cell_type
and O O
upregulates O O
adipophilin B-protein B-RNA
mRNA O I-RNA
and O O
protein O O
within O O
2 O O
h O O
of O O
incubation O O
. O O

This O O
rapid O O
induction O O
of O O
adipophilin B-protein B-protein
is O O
accompanied O O
by O O
a O O
significant O O
increase O O
of O O
free O O
fatty O O
acids O O
in O O
monocytes B-cell_type B-cell_type
incubated O O
with O O
E-LDL B-protein O
. O O

Adipophilin B-protein O
facilitates O O
the O O
uptake O O
of O O
free O O
fatty O O
acids O O
, O O
and O O
here O O
we O O
demonstrate O O
that O O
free O O
fatty O O
acids O O
increase O O
is O O
related O O
to O O
the O O
early O O
upregulation O O
of O O
adipophilin O B-protein
expression O O
in O O
blood B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
. O O

Fatty O O
acids O O
are O O
ligands O O
for O O
peroxisome B-protein B-protein
proliferator-activated I-protein I-protein
receptor-gamma I-protein I-protein
( O O
PPARgamma B-protein B-protein
) O O
, O O
and O O
the O O
upregulation O O
of O O
adipophilin B-RNA B-RNA
mRNA I-RNA I-RNA
by O O
PPARgamma B-protein B-protein
agonists O O
like O O
15d-PGJ O O
( O O
2 O O
) O O
and O O
ciglitazone O O
indicates O O
that O O
PPARgamma B-protein B-protein
may O O
mediate O O
the O O
induction O O
of O O
adipophilin O B-protein
expression O O
in O O
human B-cell_type B-cell_type
blood I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
. O O

Constitutive O O
expression O O
of O O
MHC B-DNA B-DNA
class I-DNA I-DNA
II I-DNA I-DNA
genes I-DNA I-DNA
in O O
melanoma B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
results O O
from O O
the O O
transcription O O
of O O
class B-DNA B-protein
II I-DNA I-protein
transactivator I-DNA I-protein
abnormally O O
initiated O O
from O O
its O O
B B-DNA B-DNA
cell-specific I-DNA I-DNA
promoter I-DNA I-DNA
. O O

In O O
melanoma B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
two O O
different O O
patterns O O
of O O
MHC O B-protein
class O I-protein
II O I-protein
expression O O
have O O
been O O
described O O
, O O
either O O
an O O
IFN O B-protein
gamma-inducible O I-protein
expression O O
of O O
HLA-DR B-DNA B-protein
and O O
HLA-DP B-DNA B-protein
, O O
with O O
a O O
faint O O
or O O
null O O
expression O O
of O O
HLA-DQ B-DNA B-DNA
, O O
resembling O O
that O O
described O O
for O O
melanocytes B-cell_type B-cell_type
, O O
or O O
a O O
constitutive O O
expression O O
, O O
i.e. O O
, O O
IFN-gamma O B-protein
independent O O
, O O
of O O
all O O
three O O
HLA-D B-DNA B-protein
isotypes I-DNA I-protein
. O O

As O O
this O O
latter O O
phenotype O O
has O O
been O O
associated O O
with O O
a O O
more O O
rapid O O
progression O O
of O O
melanoma O O
tumors O O
, O O
we O O
have O O
analyzed O O
in O O
different O O
melanoma B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
the O O
molecular O O
mechanisms O O
leading O O
to O O
this O O
abnormal O O
pattern O O
of O O
MHC O B-protein
class O I-protein
II O I-protein
expression O O
. O O

In O O
agreement O O
with O O
the O O
evidence O O
of O O
a O O
coordinate O O
transcription O O
of O O
the O O
HLA-D B-DNA B-DNA
genes I-DNA I-DNA
in O O
these O O
cell O B-cell_line
lines O I-cell_line
, O O
we O O
have O O
shown O O
the O O
constitutive O O
expression O O
of O O
CIITA B-RNA B-DNA
( I-RNA I-DNA
class I-RNA I-DNA
II I-RNA I-DNA
transactivator I-RNA I-DNA
) I-RNA O
transcripts I-RNA O
, O O
CIITA B-protein B-protein
being O O
known O O
as O O
the O O
master O O
switch O O
of O O
MHC O B-protein
class O I-protein
II O I-protein
expression O O
. O O

Unexpectedly O O
, O O
these O O
transcripts O O
initiate O O
from O O
promoter B-DNA B-DNA
III I-DNA I-DNA
of O O
the O O
CIITA B-DNA B-DNA
gene I-DNA I-DNA
, O O
a O O
promoter O O
that O O
is O O
mainly O O
used O O
constitutively O O
in O O
B B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

This O O
expression O O
was O O
further O O
shown O O
to O O
occur O O
through O O
factor O O
( O O
s O O
) O O
acting O O
on O O
the O O
enhancer O B-DNA
located O O
upstream O O
of O O
CIITA B-DNA B-DNA
promoter I-DNA I-DNA
III I-DNA I-DNA
, O O
which O O
was O O
previously O O
described O O
in O O
epithelioid B-cell_type B-cell_type
cells I-cell_type I-cell_type
as O O
an O O
IFN-gamma-response O B-DNA
sequence O I-DNA
. O O

The O O
hypothesis O O
of O O
a O O
general O O
abnormality O O
of O O
the O O
IFN-gamma O B-protein
transduction O O
pathway O O
was O O
dismissed O O
. O O

Constitutive O O
transcription O O
of O O
CIITA B-DNA B-protein
from O O
promoter B-DNA B-DNA
III I-DNA I-DNA
having O O
been O O
observed O O
in O O
unrelated O B-cell_line
melanoma B-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
we O O
propose O O
the O O
hypothesis O O
that O O
this O O
phenomenon O O
might O O
not O O
be O O
a O O
random O O
event O O
, O O
but O O
could O O
be O O
linked O O
to O O
the O O
neoplasic O O
state O O
of O O
the O O
melanoma B-cell_type B-cell_type
cells I-cell_type I-cell_type

Caspase B-protein B-protein
-mediated O O
calcineurin O B-protein
activation O O
contributes O O
to O O
IL-2 B-protein B-protein
release O O
during O O
T O O
cell O O
activation O O
. O O

Calcineurin B-protein B-protein
, O O
a O O
Ca B-protein B-protein
( I-protein I-protein
2+ I-protein I-protein
) I-protein I-protein
/calmodulin-dependent I-protein I-protein
Ser/Thr I-protein I-protein
phosphatase I-protein I-protein
( I-protein O
protein I-protein B-protein
phosphatase I-protein I-protein
2B I-protein I-protein
) I-protein O
, O O
plays O O
a O O
critical O O
role O O
in O O
IL-2 O B-protein
production O O
during O O
T O O
cell O O
activation O O
. O O

It O O
has O O
been O O
previously O O
reported O O
that O O
IL-2 B-protein B-protein
release O O
in O O
activated O O
Jurkat B-cell_line O
T I-cell_line O
requires O O
caspase-like O B-protein
activity O O
( O O
Posmantur O O
et O O
al. O O
( O O
1998 O O
) O O
Exp. O O
Cell. O O
Res. O O
244 O O
, O O
302-309 O O
) O O
. O O

We O O
report O O
here O O
that O O
the O O
60-kDa B-protein B-protein
catalytic I-protein I-protein
subunit I-protein I-protein
of O O
calcineurin B-protein B-protein
A I-protein I-protein
( O O
Cn B-protein B-protein
A I-protein I-protein
) O O
was O O
partially O O
cleaved O O
to O O
a O O
45-kDa B-protein O
form O O
in O O
phytohemagglutinin O B-protein
A O I-protein
( O O
PHA O O
) O O
or O O
phorbol O O
ester O O
+ O O
ionomycin O O
( O O
P O B-cell_line
+ O I-cell_line
I O I-cell_line
) O I-cell_line
-activated O I-cell_line
Jurkat B-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

In O O
parallel O O
, O O
proteolytic O O
activation O O
of O O
upstream O B-protein
caspases B-protein I-protein
( O O
caspase-8 O B-protein
and O I-protein
-9 O I-protein
) O O
as O O
well O O
as O O
effector B-protein B-protein
caspase-3 I-protein I-protein
was O O
also O O
observed O O
. O O

Cn B-protein O
A I-protein O
cleavage O O
was O O
caspase O B-protein
mediated O O
, O O
since O O
it O O
was O O
inhibitable O O
by O O
pan-caspase O B-protein
inhibitor O I-protein
Cbz-Asp-CH O I-protein
( O I-protein
2 O I-protein
) O I-protein
OC O I-protein
( O I-protein
O O I-protein
) O I-protein
-2 O I-protein
, O O
6-dichlorobenzene O O
( O O
Z-D-DCB O O
) O O
. O O

Cn B-protein O
A I-protein O
cleavage O O
was O O
also O O
observed O O
when O O
purified O O
calcineurin B-protein B-protein
was O O
digested O O
in O O
vitro O O
with O O
caspase-3 B-protein B-protein
. O O

Truncated B-protein B-protein
Cn I-protein I-protein
A I-protein I-protein
was O O
associated O O
with O O
enhanced O O
phosphatase O B-protein
activity O O
and O O
reduced O O
calmodulin O B-protein
sensitivity O O
. O O

Furthermore O O
, O O
in O O
PHA O B-cell_line
or O I-cell_line
P O I-cell_line
+ O I-cell_line
I-activated O I-cell_line
Jurkat B-cell_line I-cell_line
cells I-cell_line I-cell_line
, O O
dephosphorylation O O
of O O
calcineurin B-protein B-protein
substrate O I-protein
NFATc B-protein I-protein
( O O
a O O
transcription B-protein B-protein
factor I-protein I-protein
known O O
to O O
be O O
involved O O
in O O
transactivation O O
of O O
the O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
) O O
, O O
was O O
also O O
suppressed O O
by O O
Z-D-DCB O O
. O O

Taken O O
together O O
, O O
our O O
results O O
suggest O O
that O O
caspase-mediated O O
cleavage O O
of O O
Cn B-protein O
A I-protein O
contributes O O
to O O
IL-2 O B-protein
production O O
during O O
T O O
cell O O
activation O O
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

Maturation O O
of O O
human B-cell_type B-cell_type
dendritic I-cell_type I-cell_type
cells I-cell_type I-cell_type
as O O
sulfasalazine O O
target O O
. O O

AIM O O
: O O
Sulfasalazine O O
, O O
a O O
nonsteroidal O O
anti-inflammatory O O
drug O O
, O O
is O O
effective O O
in O O
treating O O
some O O
autoimmune O O
diseases O O
, O O
but O O
its O O
mechanism O O
of O O
action O O
is O O
unclear O O
. O O

To O O
determine O O
whether O O
dendritic B-cell_type B-cell_type
cells I-cell_type I-cell_type
could O O
be O O
a O O
possible O O
target O O
of O O
the O O
drug O O
, O O
we O O
studied O O
the O O
effects O O
of O O
sulfasalazine O O
and O O
its O O
metabolites O O
, O O
aminosalicylate O O
and O O
sulfapyridine O O
, O O
on O O
in O O
vitro O O
maturation O O
( O O
terminal O O
differentiation O O
) O O
of O O
human B-cell_type B-cell_type
myeloid I-cell_type I-cell_type
dendritic I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

METHODS O O
: O O
We O O
prepared O O
immature B-cell_type B-cell_type
dendritic I-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
incubating O B-cell_type
CD14-positive B-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
the O O
presence O O
of O O
granulocyte- B-protein B-protein
macrophage I-protein I-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
and O O
interleukin B-protein B-protein
( I-protein I-protein
IL I-protein I-protein
) I-protein I-protein
-4 I-protein I-protein
. O O

The O O
cells O O
were O O
matured O O
by O O
addition O O
of O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
( I-protein O
TNF I-protein B-protein
) I-protein I-protein
-a I-protein I-protein
, O O
IL-1 B-protein B-protein
beta I-protein I-protein
, O O
and O O
prostaglandin B-protein O
E2 I-protein O
in O O
the O O
presence O O
of O O
sulfasalazine O O
or O O
its O O
metabolites O O
-- O O
aminosalicylate O O
and O O
sulfapyridine O O
, O O
or O O
their O O
combinations O O
. O O

We O O
quantified O O
the O O
effect O O
of O O
drugs O O
on O O
the O O
dendritic O O
cell O O
characteristics O O
, O O
such O O
as O O
stimulation O O
of O O
autologous O O
and O O
allogeneic O O
pan-T O O
cell O O
proliferation O O
, O O
surface O O
marker O O
phenotype O O
, O O
IL-12 O B-protein
p40 O I-protein
subunit O I-protein
secretion O O
, O O
and O O
activation O O
of O O
nuclear B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
( I-protein I-protein
NF I-protein I-protein
) I-protein I-protein
-kappa I-protein I-protein
B I-protein I-protein
. O O

RESULTS O O
: O O
Dendritic B-cell_type B-cell_type
cells I-cell_type I-cell_type
treated O O
with O O
sulfasalazine O O
( O O
1.25 O O
micromol/L O O
or O O
2.5 O O
micromol/L O O
) O O
could O O
not O O
stimulate O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
p O O
< O O
0.028 O O
, O O
two-sided O O
paired O O
t-test O O
) O O
. O O

In O O
distinction O O
to O O
drug-free O B-cell_line
maturing O I-cell_line
dendritic B-cell_type I-cell_line
cells I-cell_type I-cell_line
, O O
2.5 O O
micromol/L O O
sulfasalazine O O
upregulated O O
the O O
levels O O
of O O
CD14 B-protein B-protein
and O O
CD68 B-protein B-protein
and O O
downregulated O O
the O O
levels O O
of O O
CD40 B-protein B-protein
, O O
CD80 B-protein B-protein
, O O
and O O
CD83 B-protein B-protein
( O O
for O O
all O O
CD O O
markers O O
, O O
p O O
< O O
0.03 O O
for O O
difference O O
between O O
measurements O O
in O O
the O O
absence O O
and O O
the O O
presence O O
of O O
sulfasalazine O O
) O O
. O O

From O O
concentration-dependent O O
changes O O
in O O
CD83 O B-protein
expression O O
, O O
we O O
found O O
an O O
apparent O O
ID50 O O
> O O
> O O
1.5 O O
micromol/L O O
sulfasalazine O O
. O O

The O O
apparent O O
ID50 O O
value O O
for O O
aminosalicylate-inhibited O O
maturation O O
was O O
4 O O
micromol/L O O
. O O

Sulfapyridine O O
had O O
no O O
effect O O
. O O

At O O
1.25 O O
micromol/L O O
, O O
sulfasalazine O O
largely O O
inhibited O O
NF-kB O B-protein
activation O O
in O O
dendritic B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

CONCLUSION O O
: O O
Maturing B-cell_type B-cell_type
human I-cell_type I-cell_type
dendritic I-cell_type I-cell_type
cells I-cell_type I-cell_type
are O O
hundred-fold O O
more O O
sensitive O O
to O O
sulfasalazine O O
than O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
the O O
most O O
sensitive O B-cell_type
human O I-cell_type
cells O I-cell_type
described O O
so O O
far O O
. O O

Thus O O
, O O
dendritic O O
cell O O
maturation O O
is O O
an O O
important O O
target O O
of O O
sulfasalazine O O
. O O

Because O O
of O O
the O O
role O O
of O O
dendritic B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
( O O
auto O O
) O O
immunity O O
, O O
inhibition O O
of O O
their O O
maturation O O
might O O
provide O O
a O O
target O O
for O O
further O O
optimization O O
of O O
sulfasalazine O O
therapy O O
. O O

Defective O O
function O O
of O O
the O O
proteasome B-protein B-protein
in O O
autoimmunity O O
: O O
involvement O O
of O O
impaired O O
NF-kappaB O B-protein
activation O O
. O O

Type O O
1 O O
diabetes O O
( O O
also O O
known O O
as O O
insulin-dependent O O
diabetes O O
mellitus O O
or O O
juvenile-onset O O
diabetes O O
) O O
is O O
usually O O
caused O O
by O O
T O O
cell-mediated O O
autoimmunity O O
, O O
with O O
a O O
prediabetic O O
state O O
characterized O O
by O O
the O O
production O O
of O O
autoantibodies B-protein O
specific O O
for O O
proteins O O
expressed O O
by O O
pancreatic B-cell_type B-cell_type
beta I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
nonobese O O
patient O O
with O O
diabetes O O
( O O
NOD O O
) O O
mouse O O
is O O
a O O
spontaneous O O
model O O
of O O
type O O
1 O O
diabetes O O
with O O
a O O
strong O O
genetic O O
component O O
that O O
maps O O
to O O
the O O
major B-DNA B-DNA
histocompatibility I-DNA I-DNA
complex I-DNA I-DNA
( I-DNA I-DNA
MHC I-DNA I-DNA
) I-DNA I-DNA
region I-DNA I-DNA
of O O
the O O
genome B-DNA B-DNA
. O O

A O O
specific O O
proteasome B-protein B-protein
defect O O
has O O
been O O
identified O O
in O O
NOD O O
mouse O O
in O O
select O O
lymphocytic B-cell_line B-cell_type
and I-cell_line I-cell_type
monocytic I-cell_line I-cell_type
lineages I-cell_line I-cell_type
that O O
results O O
from O O
down-regulation O O
of O O
expression O O
of O O
the O O
proteasome B-protein B-protein
subunit I-protein I-protein
LMP2 I-protein B-protein
, O O
which O O
is O O
encoded O O
by O O
a O O
gene O O
in O O
the O O
MHC B-DNA B-DNA
genomic I-DNA I-DNA
region I-DNA I-DNA
. O O

This O O
defect O O
prevents O O
the O O
proteolytic O O
processing O O
required O O
for O O
the O O
production O O
and O O
activation O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
nuclear I-protein B-protein
factor-kappaB I-protein I-protein
( O O
NF-kappaB B-protein B-protein
) O O
, O O
which O O
plays O O
important O O
roles O O
in O O
immune O O
and O O
inflammatory O O
responses O O
, O O
as O O
well O O
as O O
increases O O
the O O
susceptibility O O
of O O
the O O
affected O O
cells O O
to O O
apoptosis O O
induced O O
by O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor-alpha I-protein I-protein
( O O
TNF-alpha B-protein B-protein
) O O
. O O

The O O
novel O O
role O O
of O O
the O O
proteasome B-protein B-protein
in O O
dysfunction O O
in O O
autoimmunity O O
is O O
presented O O
and O O
documented O O
to O O
be O O
both O O
tissue O O
and O O
developmental O O
stage O O
specific O O
. O O

We O O
propose O O
a O O
role O O
of O O
the O O
proteasome B-protein B-protein
as O O
a O O
step O O
in O O
disease O O
pathogenesis O O
and O O
tissue O O
targeting O O
. O O

Down-regulation O O
of O O
TDT O O
transcription O O
in O O
CD4 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
CD8 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
by O O
Ikaros B-protein B-protein
proteins I-protein I-protein
in O O
direct O O
competition O O
with O O
an O O
Ets B-protein B-protein
activator I-protein I-protein
. O O

Ikaros B-protein B-protein
is O O
a O O
unique O O
regulator O O
of O O
lymphopoiesis O O
that O O
associates O O
with O O
pericentromeric B-DNA B-DNA
heterochromatin I-DNA I-DNA
and O O
has O O
been O O
implicated O O
in O O
heritable O O
gene O O
inactivation O O
. O O

Binding O O
and O O
competition O O
experiments O O
demonstrate O O
that O O
Ikaros B-protein B-protein
dimers I-protein I-protein
compete O O
with O O
an O O
Ets B-protein B-protein
activator I-protein I-protein
for O O
occupancy O O
of O O
the O O
lymphocyte-specific B-DNA B-DNA
TdT I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Mutations O O
that O O
selectively O O
disrupt O O
Ikaros O B-protein
binding O O
to O O
an O O
integrated B-DNA O
TdT I-DNA B-DNA
promoter I-DNA I-DNA
had O O
no O O
effect O O
on O O
promoter O O
function O O
in O O
a O O
CD4 B-cell_line B-cell_line
( I-cell_line I-cell_line
+ I-cell_line I-cell_line
) I-cell_line I-cell_line
CD8 I-cell_line I-cell_line
( I-cell_line I-cell_line
+ I-cell_line I-cell_line
) I-cell_line I-cell_line
thymocyte I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

However O O
, O O
these O O
mutations O O
abolished O O
down-regulation O O
on O O
differentiation O O
, O O
providing O O
evidence O O
that O O
Ikaros B-protein B-protein
plays O O
a O O
direct O O
role O O
in O O
repression O O
. O O

Reduced O O
access O O
to O O
restriction O O
enzyme O O
cleavage O O
suggested O O
that O O
chromatin O O
alterations O O
accompany O O
down-regulation O O
. O O

The O O
Ikaros-dependent O O
down-regulation O O
event O O
and O O
the O O
observed O O
chromatin O O
alterations O O
appear O O
to O O
precede O O
pericentromeric O O
repositioning O O
. O O

Current O O
models O O
propose O O
that O O
the O O
functions O O
of O O
Ikaros B-protein B-protein
should O O
be O O
disrupted O O
by O O
a O O
small O O
isoform B-protein O
that O O
retains O O
the O O
dimerization B-protein B-protein
domain I-protein I-protein
and O O
lacks O O
the O O
DNA-binding B-protein B-protein
domain I-protein I-protein
. O O

Surprisingly O O
, O O
in O O
the O O
CD4 B-cell_line B-cell_line
( I-cell_line I-cell_line
+ I-cell_line I-cell_line
) I-cell_line I-cell_line
CD8 I-cell_line I-cell_line
( I-cell_line I-cell_line
+ I-cell_line I-cell_line
) I-cell_line I-cell_line
thymocyte I-cell_line I-cell_line
line I-cell_line I-cell_line
, O O
overexpression O O
of O O
a O O
small B-protein B-protein
Ikaros I-protein I-protein
isoform I-protein I-protein
had O O
no O O
effect O O
on O O
differentiation O O
or O O
on O O
the O O
pericentromeric O O
targeting O O
and O O
DNA-binding O O
properties O O
of O O
Ikaros B-protein B-protein
. O O

Rather O O
, O O
the O O
small O O
isoform B-protein O
assembled O O
into O O
multimeric B-protein B-protein
complexes I-protein I-protein
with O O
DNA-bound B-protein B-protein
Ikaros I-protein I-protein
at O O
the O O
pericentromeric O O
foci O O
. O O

The O O
capacity O O
for O O
in O O
vivo O O
multimer O O
formation O O
suggests O O
that O O
interactions O O
between O O
Ikaros B-protein B-protein
dimers I-protein I-protein
bound O O
to O O
the O O
TdT B-DNA B-DNA
promoter I-DNA I-DNA
and O O
those O O
bound O O
to O O
pericentromeric B-DNA B-DNA
repeat I-DNA I-DNA
sequences I-DNA I-DNA
may O O
contribute O O
to O O
the O O
pericentromeric O O
repositioning O O
of O O
the O O
inactive B-DNA B-DNA
gene I-DNA I-DNA
. O O

Type B-protein B-protein
I I-protein I-protein
interferons I-protein I-protein
and O O
IL-12 B-protein B-protein
: O O
convergence O O
and O O
cross-regulation O O
among O O
mediators O O
of O O
cellular O O
immunity O O
. O O

Therapeutic O O
use O O
of O O
type B-protein B-protein
I I-protein I-protein
IFN I-protein I-protein
( O O
IFN-alpha/beta B-protein B-protein
) O O
has O O
become O O
common O O
. O O

Many O O
of O O
the O O
diverse O O
diseases O O
targeted O O
are O O
marked O O
by O O
pathogenetic O O
abnormalities O O
in O O
cell-mediated O O
immunity O O
( O O
CMI O O
) O O
, O O
these O O
cellular O O
immune O O
responses O O
either O O
causing O O
injury O O
to O O
the O O
host O O
, O O
lacking O O
sufficient O O
vigor O O
for O O
virus O O
or O O
tumor O O
clearance O O
, O O
or O O
both O O
. O O

In O O
general O O
, O O
therapeutic O O
efficacy O O
is O O
limited O O
. O O

It O O
is O O
thus O O
notable O O
that O O
the O O
pleiotropic O O
effects O O
of O O
type B-protein O
I I-protein B-protein
IFN I-protein I-protein
on O O
CMI O O
remain O O
poorly O O
understood O O
. O O

We O O
characterized O O
the O O
effects O O
of O O
type B-protein B-protein
I I-protein I-protein
IFN I-protein I-protein
on O O
the O O
production O O
of O O
IL-12 B-protein B-protein
, O O
the O O
central B-protein O
immunoregulatory I-protein B-protein
cytokine I-protein I-protein
of O O
the O O
CD4 B-protein B-cell_type
( I-protein I-cell_type
+ I-protein I-cell_type
) I-protein I-cell_type
T I-protein I-cell_type
cell I-protein I-cell_type
arm I-protein I-cell_type
of O O
CMI O O
. O O

We O O
show O O
that O O
type B-protein B-protein
I I-protein I-protein
IFN I-protein I-protein
are O O
potent O O
inhibitors O O
of O O
IL-12 O B-protein
production O O
by O O
human B-cell_type B-cell_type
monocytes/macrophages I-cell_type I-cell_type
. O O

The O O
underlying O O
mechanism O O
involves O O
transcriptional O O
inhibition O O
of O O
the O O
IL-12p40 B-DNA B-DNA
gene I-DNA I-DNA
, O O
marked O O
by O O
down-regulation O O
of O O
PU.1 O B-protein
binding O O
activity O O
at O O
the O O
upstream B-DNA B-DNA
Ets I-DNA I-DNA
site I-DNA I-DNA
of O O
the O O
IL-12p40 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Type B-protein B-protein
I I-protein I-protein
IFN I-protein I-protein
have O O
previously O O
been O O
shown O O
to O O
be O O
able O O
to O O
substitute O O
for O O
IL-12 B-protein B-protein
in O O
driving O O
IFN-gamma O B-protein
production O O
from O O
T B-cell_type B-cell_type
and I-cell_type I-cell_type
NK I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
ability O O
of O O
IFN-alpha/beta B-protein B-protein
to O O
suppress O O
IL-12 O B-protein
production O O
while O O
up-regulating O O
IFN-gamma O B-protein
production O O
suggests O O
a O O
possible O O
mechanistic O O
basis O O
for O O
the O O
difficulties O O
of O O
employing O O
these O O
cytokines B-protein B-protein
in O O
diseases O O
involving O O
abnormalities O O
of O O
CMI O O
. O O

Nuclear B-protein B-protein
factor-kappaB I-protein I-protein
suppressive O O
and O O
inhibitor-kappaB B-protein O
stimulatory O O
effects O O
of O O
troglitazone O O
in O O
obese O O
patients O O
with O O
type O O
2 O O
diabetes O O
: O O
evidence O O
of O O
an O O
antiinflammatory O O
action O O
? O O

It O O
has O O
been O O
shown O O
recently O O
that O O
troglitazone O O
exerts O O
an O O
anti-inflammatory O O
effect O O
, O O
in O O
vitro O O
, O O
and O O
in O O
experimental O O
animals O O
. O O

To O O
test O O
these O O
properties O O
in O O
humans O O
, O O
we O O
investigated O O
the O O
effect O O
of O O
troglitazone O O
on O O
the O O
proinflammatory B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
nuclear I-protein B-protein
factor-kappaB I-protein I-protein
and O O
its O O
inhibitory B-protein B-protein
protein I-protein I-protein
IkappaB I-protein B-protein
in O O
mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
MNC B-cell_type B-cell_type
) O O
and O O
plasma B-protein B-protein
soluble I-protein I-protein
intracellular I-protein I-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
, O O
monocyte B-protein B-protein
chemoattractant I-protein I-protein
protein-1 I-protein I-protein
, O O
plasminogen B-protein B-protein
activator I-protein I-protein
inhibitor-1 I-protein I-protein
, O O
and O O
C-reactive B-protein B-protein
protein I-protein I-protein
. O O

We O O
also O O
examined O O
the O O
effect O O
of O O
troglitazone O O
on O O
reactive O O
oxygen O O
species O O
generation O O
, O O
p47 O B-protein
( O I-protein
phox O I-protein
) O I-protein
subunit O I-protein
expression O O
, O O
9-hydroxyoctadecadienoic O O
acid O O
( O O
9-HODE O O
) O O
, O O
13-HODE O O
, O O
o-tyrosine O O
, O O
and O O
m-tyrosine O O
in O O
obese O O
patients O O
with O O
type O O
2 O O
diabetes O O
. O O

Seven O O
obese O O
patients O O
with O O
type O O
2 O O
diabetes O O
were O O
treated O O
with O O
troglitazone O O
( O O
400 O O
mg/day O O
) O O
for O O
4 O O
weeks O O
. O O

Blood O O
samples O O
were O O
obtained O O
at O O
weekly O O
intervals O O
. O O

Nuclear B-protein B-protein
factor-kappaB I-protein I-protein
binding O O
activity O O
in O O
MNC B-cell_type B-cell_type
nuclear O O
extracts O O
was O O
significantly O O
inhibited O O
after O O
troglitazone O O
treatment O O
at O O
week O O
1 O O
and O O
continued O O
to O O
be O O
inhibited O O
up O O
to O O
week O O
4 O O
. O O

On O O
the O O
other O O
hand O O
, O O
IkappaB O B-protein
protein O O
levels O O
increased O O
significantly O O
after O O
troglitazone O O
treatment O O
at O O
week O O
1 O O
, O O
and O O
this O O
increase O O
persisted O O
throughout O O
the O O
study O O
. O O

Plasma B-protein O
monocyte I-protein B-protein
chemoattractant I-protein I-protein
protein-1 I-protein I-protein
and O O
soluble B-protein B-protein
intracellular I-protein I-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
concentrations O O
did O O
not O O
decrease O O
significantly O O
after O O
troglitazone O O
treatment O O
, O O
although O O
there O O
was O O
a O O
trend O O
toward O O
inhibition O O
. O O

Reactive O O
oxygen O O
species O O
generation O O
by O O
polymorphonuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
MNC B-cell_type B-cell_type
, O O
p47 B-protein B-protein
( I-protein I-protein
phox I-protein I-protein
) I-protein I-protein
subunit I-protein I-protein
protein I-protein I-protein
quantities O O
, O O
plasminogen B-protein B-protein
activator I-protein I-protein
inhibitor-1 I-protein B-protein
, O O
and O O
C-reactive B-protein B-protein
protein I-protein I-protein
levels O O
decreased O O
significantly O O
after O O
troglitazone O O
intake O O
. O O

13-HODE/linoleic O O
acid O O
and O O
9-HODE/linoleic O O
acid O O
ratios O O
also O O
decreased O O
after O O
troglitazone O O
intake O O
. O O

However O O
, O O
o-tyrosine/phenylalanine O O
and O O
m-tyrosine/phenylalanine O O
ratios O O
did O O
not O O
change O O
significantly O O
. O O

These O O
data O O
show O O
that O O
troglitazone O O
has O O
profound O O
antiinflammatory O O
effects O O
in O O
addition O O
to O O
antioxidant O O
effects O O
in O O
obese O O
type O O
2 O O
diabetics O O
; O O
these O O
effects O O
may O O
be O O
relevant O O
to O O
the O O
recently O O
described O O
beneficial O O
antiatherosclerotic O O
effects O O
of O O
troglitazone O O
at O O
the O O
vascular O O
level O O
. O O

OX40 O B-protein
stimulation O O
by O O
gp34/OX40 B-protein B-protein
ligand I-protein I-protein
enhances O O
productive O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
infection O O
. O O

OX40 B-protein B-protein
is O O
a O O
member O O
of O O
the O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
( I-protein I-protein
TNF I-protein I-protein
) I-protein I-protein
receptor I-protein I-protein
superfamily I-protein I-protein
and O O
known O O
to O O
be O O
an O O
important O O
costimulatory B-protein O
molecule I-protein O
expressed O O
on O O
activated B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

To O O
investigate O O
the O O
role O O
of O O
costimulation O O
of O O
OX40 B-protein B-protein
in O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
infection O O
by O O
its O O
natural O O
ligand O O
, O O
gp34 B-protein B-protein
, O O
the O O
OX40-transfected B-cell_line B-cell_line
ACH-2 I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
, I-cell_line O
ACH-2/OX40 I-cell_line B-cell_line
, O O
chronically O O
infected O O
with O O
HIV-1 O O
, O O
was O O
cocultured O O
with O O
paraformaldehyde O O
( O O
PFA O O
) O O
-fixed O O
gp34-transfected B-cell_line B-cell_line
mouse I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
, I-cell_line O
SV-T2/gp34 I-cell_line B-cell_line
. O O

The O O
results O O
showed O O
that O O
HIV-1 O O
production O O
was O O
strongly O O
induced O O
. O O

This O O
was O O
followed O O
by O O
apparent O O
apoptosis O O
, O O
and O O
both O O
processes O O
were O O
specifically O O
inhibited O O
by O O
the O O
gp34 B-protein B-protein
-specific O O
neutralizing B-protein O
monoclonal I-protein B-protein
antibody I-protein I-protein
5A8 I-protein I-protein
. O O

Endogenous O B-protein
TNF B-protein I-protein
alpha I-protein I-protein
( O O
TNF-alpha B-protein B-protein
) O O
and O O
TNF-beta B-protein B-protein
production O O
were O O
not O O
involved O O
in O O
the O O
enhanced O O
HIV-1 O O
production O O
. O O

Furthermore O O
, O O
enhanced O O
HIV-1 O O
transcription O O
in O O
gp34 B-protein B-cell_line
-stimulated O I-cell_line
ACH-2/OX40 B-cell_line I-cell_line
cells I-cell_line I-cell_line
was O O
dependent O O
on O O
the O O
kappa B-DNA B-DNA
B I-DNA I-DNA
site I-DNA I-DNA
of O O
the O O
HIV-1 B-DNA B-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
, O O
and O O
the O O
OX40-gp34 O B-protein
interaction O I-protein
activated O I-protein
NF-kappa B-protein I-protein
B I-protein I-protein
consisting O O
of O O
p50 B-protein B-protein
and I-protein O
p65 I-protein B-protein
subunits I-protein I-protein
. O O

When O O
primary O B-cell_type
activated O I-cell_type
CD4 B-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
acutely O O
infected O O
with O O
HIV-1 O O
( O O
NL4-3 O O
) O O
( O O
CXCR4-using B-cell_line O
T-cell-line-tropic I-cell_line O
) O O
were O O
cocultured O O
with O O
PFA-fixed O O
gp34 B-cell_type B-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
human I-cell_type I-cell_line
T-cell I-cell_type I-cell_line
leukemia O I-cell_line
virus O I-cell_line
type O I-cell_line
1-bearing O I-cell_line
MT-2 B-cell_line I-cell_line
cells I-cell_line I-cell_line
or O O
SV-T2/gp34 B-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
HIV-1 O O
production O O
was O O
also O O
markedly O O
enhanced O O
. O O

The O O
enhancement O O
was O O
again O O
significantly O O
inhibited O O
by O O
5A8 B-protein B-protein
. O O

The O O
present O O
study O O
first O O
shows O O
that O O
OX40-gp34 O B-protein
interaction O O
stimulates O O
HIV-1 O O
expression O O
and O O
suggests O O
that O O
OX40 O B-protein
triggering O O
by O O
gp34 B-protein B-protein
may O O
play O O
an O O
important O O
role O O
in O O
enhancing O O
HIV-1 O O
production O O
in O O
both O O
acutely O O
and O O
latently O O
infected O O
CD4 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
vivo O O
. O O

Troglitazone O O
, O O
a O O
PPARgamma O B-protein
ligand O I-protein
, O O
inhibits O O
osteopontin O B-DNA
gene O I-DNA
expression O O
in O O
human B-cell_type B-cell_type
monocytes/macrophage I-cell_type I-cell_type
THP-1 I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Peroxizome B-protein B-protein
proliferator-activated I-protein I-protein
receptor-gamma I-protein I-protein
( O O
PPARgamma B-protein B-protein
) O O
is O O
a O O
member O O
of O O
the O O
nuclear B-protein B-protein
receptor I-protein I-protein
family I-protein I-protein
of O O
transcription B-protein B-protein
factors I-protein I-protein
that O O
regulate O O
adipocyte O B-cell_type
differentiation O O
. O O

Recent O O
studies O O
indicate O O
that O O
liganded B-protein B-protein
PPARgamma I-protein I-protein
not O O
only O O
promotes O O
differentiation O O
but O O
also O O
inhibits O O
the O O
activation O O
of O O
macrophages B-cell_type B-cell_type
. O O

Osteopontin B-protein O
, O O
a O O
component O O
of O O
extracellular O O
matrix O O
, O O
is O O
synthesized O O
by O O
macrophages B-cell_type B-cell_type
in O O
atherosclerotic O O
plaques O O
. O O

In O O
this O O
study O O
, O O
we O O
examined O O
whether O O
PPARgamma B-protein B-protein
ligand O I-protein
regulates O O
osteopontin O B-DNA
gene O I-DNA
expression O O
in O O
THP-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
a O O
cell O O
line O O
derived O O
from O O
human B-cell_type B-cell_type
monocytic I-cell_type I-cell_type
leukemia I-cell_type I-cell_type
cells I-cell_type I-cell_type
which O O
can O O
differentiate O O
to O O
macrophage B-cell_type O
upon O O
stimulation O O
with O O
phorbol O O
ester O O
PMA O O
. O O

Northern O O
blot O O
analysis O O
showed O O
that O O
osteopontin O B-protein
expression O O
is O O
markedly O O
induced O O
in O O
response O O
to O O
PMA O O
. O O

Troglitazone O O
, O O
a O O
PPARgamma B-protein B-protein
ligand O O
, O O
dramatically O O
attenuated O O
the O O
PMA-induced O O
osteopontin O B-protein
expression O O
. O O

Transient O O
transfection O O
assays O O
of O O
the O O
human B-DNA B-DNA
osteopontin I-DNA I-DNA
promoter/luciferase I-DNA I-DNA
construct I-DNA I-DNA
which O O
contains O O
a O O
5'-flanking B-DNA B-DNA
region I-DNA I-DNA
between O O
-1500 O O
and O O
+87 O O
relative O O
to O O
the O O
transcription B-DNA B-DNA
start I-DNA I-DNA
site I-DNA I-DNA
demonstrate O O
that O O
either O O
treatment O O
with O O
troglitazone O O
or O O
cotransfection O O
of O O
PPARgamma B-DNA B-DNA
expression I-DNA I-DNA
vector I-DNA I-DNA
inhibits O O
osteopontin O B-DNA
promoter O I-DNA
activity O O
. O O

These O O
data O O
indicate O O
that O O
troglitazone O O
reduces O O
osteopontin O B-DNA
gene O I-DNA
expression O O
at O O
transcriptional O O
level O O
through O O
PPARgamma B-protein B-protein
activation O O
, O O
and O O
suggest O O
the O O
role O O
of O O
troglitazone O O
in O O
inhibiting O O
the O O
ability O O
of O O
macrophages B-cell_type B-cell_type
to O O
produce O O
extracellular O O
matrix O O
, O O
which O O
is O O
particularly O O
relevant O O
to O O
atherosclerotic O O
plaque O O
formation O O
. O O

Transcription B-protein B-protein
factor I-protein I-protein
NF-kappa I-protein B-protein
B I-protein I-protein
regulates O O
Ig B-protein B-DNA
lambda I-protein I-DNA
light O I-DNA
chain O I-DNA
gene O I-DNA
rearrangement O O
. O O

The O O
tissue- O O
and O O
stage-specific O O
assembly O O
of O O
Ig B-DNA B-DNA
and I-DNA I-DNA
TCR I-DNA I-DNA
genes I-DNA I-DNA
is O O
mediated O O
by O O
a O O
common O B-protein
V B-protein I-protein
( I-protein I-protein
D I-protein I-protein
) I-protein I-protein
J I-protein I-protein
recombinase I-protein I-protein
complex I-protein I-protein
in O O
precursor B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Directed O O
alterations O O
in O O
the O O
accessibility O O
of O O
V B-DNA B-DNA
, I-DNA I-DNA
D I-DNA I-DNA
, I-DNA I-DNA
and I-DNA I-DNA
J I-DNA I-DNA
gene I-DNA I-DNA
segments I-DNA I-DNA
target O I-DNA
the O O
recombinase B-protein O
to O O
specific O O
Ag B-DNA B-DNA
receptor I-DNA I-DNA
loci I-DNA I-DNA
. O O

Accessibility O O
within O O
a O O
given O O
locus B-DNA O
is O O
regulated O O
by O O
the O O
functional O O
interaction O O
of O O
transcription B-protein B-protein
factors I-protein I-protein
with O O
cognate B-DNA B-DNA
enhancer I-DNA I-DNA
elements I-DNA I-DNA
and O O
correlates O O
with O O
the O O
transcriptional O O
activity O O
of O O
unrearranged O B-DNA
gene B-DNA I-DNA
segments I-DNA I-DNA
. O O

As O O
demonstrated O O
in O O
our O O
prior O O
studies O O
, O O
rearrangement O O
of O O
the O O
Igkappa B-DNA B-DNA
locus I-DNA I-DNA
is O O
regulated O O
by O O
the O O
inducible B-protein O
transcription I-protein B-protein
factor I-protein I-protein
NF-kappaB B-protein B-protein
. O O

In O O
contrast O O
to O O
the O O
Igkappa B-DNA B-DNA
locus I-DNA I-DNA
, O O
known O O
transcriptional B-DNA B-DNA
control I-DNA I-DNA
elements I-DNA I-DNA
in O O
the O O
Iglambda B-DNA B-DNA
locus I-DNA I-DNA
lack O O
functional O O
NF-kappaB B-DNA B-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
. O O

Consistent O O
with O O
this O O
observation O O
, O O
the O O
expression O O
of O O
assembled O O
Iglambda B-DNA B-DNA
genes I-DNA I-DNA
in O O
mature B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
has O O
been O O
shown O O
to O O
be O O
NF-kappaB B-protein B-protein
independent O O
. O O

Nonetheless O O
, O O
we O O
now O O
show O O
that O O
specific O O
repression O O
of O O
NF-kappaB B-protein B-protein
inhibits O O
germline O B-DNA
transcription O O
and O O
recombination O O
of O O
Iglambda B-DNA B-DNA
gene I-DNA I-DNA
segments I-DNA I-DNA
in O O
precursor B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Molecular O O
analyses O O
indicate O O
that O O
the O O
block O O
in O O
NF-kappaB B-protein B-protein
impairs O O
Iglambda O B-protein
rearrangement O O
at O O
the O O
level O O
of O O
recombinase B-protein B-protein
accessibility O O
. O O

In O O
contrast O O
, O O
the O O
activities O O
of O O
known O O
Iglambda B-DNA B-DNA
promoter I-DNA I-DNA
and O O
enhancer B-DNA B-DNA
elements I-DNA I-DNA
are O O
unaffected O O
in O O
the O O
same O O
cellular O O
background O O
. O O

These O O
findings O O
expand O O
the O O
range O O
of O O
NF-kappaB B-protein B-protein
action O O
in O O
precursor B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
beyond O O
Igkappa B-protein B-protein
to O O
include O O
the O O
control O O
of O O
recombinational O O
accessibility O O
at O O
both O O
L B-DNA B-DNA
chain I-DNA I-DNA
loci I-DNA I-DNA
. O O

Moreover O O
, O O
our O O
results O O
strongly O O
suggest O O
the O O
existence O O
of O O
a O O
novel O O
Iglambda B-DNA B-DNA
regulatory I-DNA I-DNA
element I-DNA I-DNA
that O O
is O O
either O O
directly O O
or O O
indirectly O O
activated O O
by O O
NF-kappaB B-protein B-protein
during O O
the O O
early O O
stages O O
of O O
B O O
cell O O
development O O
. O O

Transcription B-protein B-protein
factor I-protein I-protein
STAT5A B-protein I-protein
is O O
a O O
substrate O O
of O O
Bruton B-protein B-protein
's I-protein I-protein
tyrosine I-protein I-protein
kinase I-protein I-protein
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

STAT5A B-protein B-protein
is O O
a O O
molecular O B-protein
regulator O I-protein
of O O
proliferation O O
, O O
differentiation O O
, O O
and O O
apoptosis O O
in O O
lymphohematopoietic B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Here O O
we O O
show O O
that O O
STAT5A B-protein B-protein
can O O
serve O O
as O O
a O O
functional O O
substrate O O
of O O
Bruton B-protein B-protein
's I-protein I-protein
tyrosine I-protein I-protein
kinase I-protein I-protein
( O O
BTK B-protein B-protein
) O O
. O O

Purified B-protein O
recombinant I-protein O
BTK I-protein B-protein
was O O
capable O O
of O O
directly O O
binding O B-protein
purified B-protein I-protein
recombinant I-protein I-protein
STAT5A I-protein I-protein
with O O
high O O
affinity O O
( O O
K O O
( O O
d O O
) O O
= O O
44 O O
nm O O
) O O
, O O
as O O
determined O O
by O O
surface O O
plasmon O O
resonance O O
using O O
a O O
BIAcore O O
biosensor O O
system O O
. O O

BTK B-protein B-protein
was O O
also O O
capable O O
of O O
tyrosine-phosphorylating O B-protein
ectopically O I-protein
expressed O I-protein
recombinant B-protein I-protein
STAT5A I-protein I-protein
on O O
Tyr O O
( O O
694 O O
) O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
in O O
a O O
Janus B-protein B-protein
kinase I-protein I-protein
3 I-protein I-protein
-independent O O
fashion O O
. O O

BTK B-protein B-protein
phosphorylated O O
the O O
Y665F B-protein O
, I-protein O
Y668F I-protein O
, I-protein O
and I-protein O
Y682F I-protein B-protein
, I-protein O
Y683F I-protein O
mutants I-protein O
but O O
not O O
the O O
Y694F B-protein B-protein
mutant I-protein I-protein
of O O
STAT5A B-protein B-protein
. O O

STAT5A O B-protein
mutations O O
in O O
the O O
Src B-protein B-protein
homology I-protein I-protein
2 I-protein I-protein
( I-protein I-protein
SH2 I-protein I-protein
) I-protein O
and I-protein O
SH3 I-protein B-protein
domains I-protein I-protein
did O O
not O O
alter O O
the O O
BTK B-protein B-protein
-mediated O O
tyrosine O O
phosphorylation O O
. O O

Recombinant B-protein O
BTK I-protein B-protein
proteins I-protein I-protein
with O O
mutant O B-protein
pleckstrin O I-protein
homology O I-protein
, O O
SH2 B-protein B-protein
, I-protein O
or I-protein O
SH3 I-protein B-protein
domains I-protein I-protein
were O O
capable O O
of O O
phosphorylating O O
STAT5A B-protein B-protein
, O O
whereas O O
recombinant B-protein B-protein
BTK I-protein I-protein
proteins I-protein I-protein
with O O
SH1/kinase O B-protein
domain O I-protein
mutations O O
were O O
not O O
. O O

In O O
pull-down O O
experiments O O
, O O
only O O
full-length B-protein O
BTK I-protein B-protein
and O O
its O O
SH1/kinase B-protein B-protein
domain I-protein I-protein
( O O
but O O
not O O
the O O
pleckstrin O B-protein
homology O I-protein
, O O
SH2 B-protein B-protein
, I-protein O
or I-protein O
SH3 I-protein B-protein
domains I-protein I-protein
) O O
were O O
capable O O
of O O
binding O O
STAT5A B-protein B-protein
. O O

Ectopically O O
expressed O O
BTK B-protein B-protein
kinase I-protein I-protein
domain I-protein I-protein
was O O
capable O O
of O O
tyrosine-phosphorylating O B-protein
STAT5A B-protein I-protein
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

BTK B-protein B-protein
-mediated O O
tyrosine O O
phosphorylation O O
of O O
ectopically O O
expressed O O
wild O O
type O O
( O O
but O O
not O O
Tyr B-protein O
( I-protein O
694 I-protein O
) I-protein O
mutant I-protein O
) O O
STAT5A B-protein B-protein
enhanced O O
its O O
DNA O O
binding O O
activity O O
. O O

In O O
BTK B-protein B-cell_type
-competent O I-cell_type
chicken O I-cell_type
B B-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
anti-IgM-stimulated O O
tyrosine O O
phosphorylation O O
of O O
STAT5 B-protein B-protein
protein I-protein I-protein
was O O
prevented O O
by O O
pretreatment O O
with O O
the O O
BTK B-protein O
inhibitor O O
LFM-A13 O O
but O O
not O O
by O O
pretreatment O O
with O O
the O O
JAK3 O B-protein
inhibitor O O
HI-P131 O O
. O O

B O B-protein
cell O I-protein
antigen O I-protein
receptor O I-protein
ligation O O
resulted O O
in O O
enhanced O O
tyrosine O O
phosphorylation O O
of O O
STAT5 B-protein B-protein
in O O
BTK B-protein B-protein
-deficient O O
chicken O B-cell_type
B B-cell_type I-cell_type
cells I-cell_type I-cell_type
reconstituted O O
with O O
wild B-protein O
type I-protein O
human I-protein O
BTK I-protein B-protein
but O O
not O O
in O O
BTK B-protein B-protein
-deficient O O
chicken O B-cell_type
B B-cell_type I-cell_type
cells I-cell_type I-cell_type
reconstituted O O
with O O
kinase-inactive B-protein B-protein
mutant I-protein I-protein
BTK I-protein I-protein
. O O

Similarly O O
, O O
anti-IgM O B-protein
stimulation O O
resulted O O
in O O
enhanced O O
tyrosine O O
phosphorylation O O
of O O
STAT5A B-protein B-protein
in O O
BTK B-protein B-cell_type
-competent O I-cell_type
B B-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
wild O O
type O O
mice O O
but O O
not O O
in O O
BTK B-protein B-cell_line
-deficient O I-cell_line
B B-cell_type I-cell_line
cells I-cell_type I-cell_line
from O O
XID O O
mice O O
. O O

In O O
contrast O O
to O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
XID O O
mice O O
, O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
JAK3 O B-protein
knockout O O
mice O O
showed O O
a O O
normal O O
STAT5A O B-protein
phosphorylation O O
response O O
to O O
anti-IgM O B-protein
stimulation O O
. O O

These O O
findings O O
provide O O
unprecedented O O
experimental O O
evidence O O
that O O
BTK B-protein B-protein
plays O O
a O O
nonredundant O O
and O O
pivotal O O
role O O
in O O
B O O
cell O O
antigen O O
receptor-mediated O O
STAT5A O B-protein
activation O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type

Role O O
of O O
T-bet B-protein B-protein
in O O
commitment O O
of O O
TH1 B-cell_type B-cell_type
cells I-cell_type I-cell_type
before O O
IL-12 B-protein B-protein
-dependent O O
selection O O
. O O

How O O
cytokines B-protein B-protein
control O O
differentiation O O
of O O
helper B-cell_type B-cell_line
T I-cell_type I-cell_line
( I-cell_type I-cell_line
TH I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
is O O
controversial O O
. O O

We O O
show O O
that O O
T-bet B-protein B-protein
, O O
without O O
apparent O O
assistance O O
from O O
interleukin B-protein B-protein
12 I-protein I-protein
( I-protein O
IL-12 I-protein B-protein
) I-protein O
/ O O
STAT4 B-protein B-protein
, O O
specifies O O
TH1 B-cell_type O
effector O O
fate O O
by O O
targeting O O
chromatin O O
remodeling O O
to O O
individual O O
interferon-gamma B-DNA B-DNA
( I-DNA I-DNA
IFN-gamma I-DNA I-DNA
) I-DNA I-DNA
alleles I-DNA I-DNA
and O O
by O O
inducing O O
IL-12 B-DNA B-protein
receptor I-DNA I-protein
beta2 I-DNA I-protein
expression O O
. O O

Subsequently O O
, O O
it O O
appears O O
that O O
IL-12 B-protein B-protein
/ O O
STAT4 B-protein B-protein
serves O O
two O O
essential O O
functions O O
in O O
the O O
development O O
of O O
TH1 B-cell_type B-cell_type
cells I-cell_type I-cell_type
: O O
as O O
growth B-protein O
signal I-protein O
, O O
inducing O O
survival O O
and O O
cell O O
division O O
; O O
and O O
as O O
trans-activator B-protein O
, O O
prolonging O O
IFN-gamma B-protein B-protein
synthesis O O
through O O
a O O
genetic O O
interaction O O
with O O
the O O
coactivator B-protein O
, O O
CREB-binding B-protein B-protein
protein I-protein I-protein
. O O

These O O
results O O
suggest O O
that O O
a O O
cytokine B-protein B-protein
does O O
not O O
simply O O
induce O O
TH O O
fate O O
choice O O
but O O
instead O O
may O O
act O O
as O O
an O O
essential O O
secondary O O
stimulus O O
that O O
mediates O O
selective O O
survival O O
of O O
a O O
lineage O O
. O O

Stat6 B-protein B-protein
is O O
necessary O O
and O O
sufficient O O
for O O
IL-4 O B-protein
's O O
role O O
in O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
. O O

IL-4 B-protein B-protein
plays O O
a O O
critical O O
role O O
in O O
the O O
differentiation O O
of O O
T O B-cell_line
CR-stimulated B-cell_type I-cell_line
naive I-cell_type I-cell_line
CD4 I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
to O O
the O O
Th2 O O
phenotype O O
. O O

In O O
response O O
to O O
IL-4 B-protein B-protein
, O O
the O O
IL-4R B-protein B-protein
activates O O
a O O
set O O
of O O
phosphotyrosine B-protein B-protein
binding I-protein I-protein
domain-containing I-protein I-protein
proteins I-protein I-protein
, O O
including O O
insulin B-protein B-protein
receptor I-protein I-protein
substrate I-protein I-protein
1/2 I-protein I-protein
, O O
Shc B-protein B-protein
, O O
and O O
IL-4R B-protein B-protein
interacting I-protein I-protein
protein I-protein I-protein
, O O
as O O
well O O
as O O
Stat6 B-protein B-protein
. O O

Stat6 B-protein B-protein
has O O
been O O
shown O O
to O O
be O O
required O O
for O O
Th2 O O
differentiation O O
. O O

To O O
determine O O
the O O
roles O O
of O O
the O O
phosphotyrosine B-protein B-protein
binding I-protein I-protein
adaptors I-protein I-protein
in O O
Th2 O O
differentiation O O
, O O
we O O
prepared O O
a O O
retrovirus O O
containing O O
a O O
mutant O O
of O O
the O O
human B-protein B-protein
( I-protein I-protein
h I-protein I-protein
) I-protein I-protein
IL-4R I-protein I-protein
alpha-chain I-protein I-protein
, O O
Y497F B-protein O
, O O
which O O
is O O
unable O O
to O O
recruit O O
these O O
adaptors O O
. O O

The O O
mutant B-protein B-protein
hIL-4Ralpha I-protein I-protein
, O O
as O O
well O O
as O O
the O O
wild-type B-protein B-protein
( I-protein I-protein
WT I-protein I-protein
) I-protein I-protein
hIL-4Ralpha I-protein I-protein
, O O
was O O
introduced O O
into O O
naive B-cell_type B-cell_line
CD4 I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

Upon O O
hIL-4 O B-protein
stimulation O O
, O O
Y497F B-protein O
worked O O
as O O
well O O
as O O
the O O
WT B-protein B-protein
hIL-4Ralpha I-protein I-protein
in O O
driving O O
Th2 O O
differentiation O O
, O O
as O O
measured O O
by O O
Gata3 O B-protein
up-regulation O O
and O O
IL-4 O B-protein
production O O
. O O

Furthermore O O
, O O
IL-4-driven O O
cell O O
expansion O O
was O O
also O O
normal O O
in O O
the O O
cells O O
infected O O
with O O
Y497F B-protein O
, O O
although O O
cells O O
infected O O
with O O
Y497F B-protein O
were O O
not O O
capable O O
of O O
phosphorylating O B-protein
insulin B-protein I-protein
receptor I-protein I-protein
substrate I-protein I-protein
2 I-protein I-protein
. O O

These O O
results O O
suggest O O
that O O
the O O
signal O O
pathway O O
mediated O O
by O O
Y497 B-protein B-protein
is O O
dispensable O O
for O O
both O O
IL-4 B-protein B-protein
-driven O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
. O O

Both O O
WT B-protein B-protein
and I-protein I-protein
Y497F I-protein I-protein
hIL-4Ralpha I-protein I-protein
lose O O
the O O
ability O O
to O O
drive O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
in O O
Stat6-knockout B-cell_type B-cell_line
CD4 I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

A O O
constitutively O O
activated O O
form O O
of O O
Stat6 B-protein B-protein
introduced O O
into O O
CD4 B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
resulted O O
in O O
both O O
Th2 O O
differentiation O O
and O O
enhanced O O
cell O O
expansion O O
. O O

Thus O O
, O O
activated B-protein O
Stat6 I-protein B-protein
is O O
necessary O O
and O O
sufficient O O
to O O
mediate O O
both O O
IL-4 B-protein B-protein
-driven O O
Th2 O O
differentiation O O
and O O
cell O O
expansion O O
in O O
CD4 B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
effect O O
of O O
HIV-1 B-protein B-protein
regulatory I-protein I-protein
proteins I-protein I-protein
on O O
cellular O B-DNA
genes O I-DNA
: O O
derepression O O
of O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
by O O
Tat B-protein B-protein
. O O

In O O
HIV-infected O O
individuals O O
dysregulation O O
of O O
the O O
immune O O
system O O
is O O
characterized O O
by O O
severe O O
disorders O O
of O O
the O O
cytokine O B-protein
network O I-protein
. O O

Increase O O
secretion O O
of O O
IL-2 B-protein B-protein
, O O
the O O
major O O
T B-cell_type O
cell I-cell_type O
growth O O
and O O
differentiation O B-protein
cytokine B-protein I-protein
, O O
may O O
play O O
a O O
decisive O O
role O O
in O O
sensitization O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
for O O
activation O O
induced O O
apoptosis O O
and O O
indirect O O
death O O
of O O
activated B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
through O O
augmented O O
virus O O
replication O O
. O O

We O O
investigated O O
the O O
cause O O
of O O
enhanced O O
IL-2 O B-protein
secretion O O
and O O
found O O
that O O
the O O
HIV B-protein B-protein
Tat I-protein I-protein
induces O O
this O O
effect O O
. O O

We O O
demonstrate O O
that O O
increased O O
IL-2 O B-protein
secretion O O
is O O
due O O
to O O
Tat B-protein B-protein
-enhanced O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
activation O O
. O O

Tat B-protein B-protein
derepresses O O
and O O
activates O O
the O O
distal B-DNA B-DNA
AP-1 I-DNA I-DNA
site I-DNA I-DNA
( O O
position B-DNA B-DNA
-185 I-DNA I-DNA
to I-DNA I-DNA
-177 I-DNA I-DNA
) O O
in O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

In O O
nonstimulated B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
a O O
repressor O B-protein
complex O I-protein
containing O O
NF-IL6 B-protein B-protein
, O O
JunB B-protein B-protein
, O O
c-Fos B-protein B-protein
and O O
Fra-1 B-protein B-protein
is O O
formed O O
on O O
the O O
AP-1 B-DNA B-DNA
( I-DNA I-DNA
IL-2/d I-DNA I-DNA
) I-DNA I-DNA
site I-DNA I-DNA
and O O
represses O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
activity O O
. O O

After O O
T O O
cell O O
activation O O
, O O
a O O
heterodimeric B-protein B-protein
activator I-protein I-protein
containing O O
p65 B-protein B-protein
and O O
c-Jun B-protein B-protein
binds O O
to O O
the O O
AP-1 B-DNA B-DNA
( I-DNA I-DNA
IL-2/d I-DNA I-DNA
) I-DNA I-DNA
site I-DNA I-DNA
. O O

HIV B-protein B-protein
Tat I-protein I-protein
enhances O O
activation O O
of O O
NF-kappaB B-protein B-protein
and O O
consequently O O
, O O
activates O O
the O O
AP-1 B-DNA B-DNA
( I-DNA I-DNA
IL-2/d I-DNA I-DNA
) I-DNA I-DNA
site I-DNA I-DNA
. O O

Our O O
data O O
provide O O
evidence O O
for O O
a O O
novel O O
mechanism O O
by O O
which O O
HIV B-protein B-protein
Tat I-protein I-protein
dysregulates O O
IL-2 O B-protein
production O O
and O O
therefore O O
may O O
contribute O O
to O O
the O O
HIV-1 O O
infection O O
in O O
a O O
way O O
yet O O
to O O
be O O
clarified O O
. O O

Transforming B-protein B-protein
growth I-protein I-protein
factor-beta1 I-protein I-protein
interferes O O
with O O
thrombopoietin-induced O O
signal O O
transduction O O
in O O
megakaryoblastic B-cell_type O
and I-cell_type O
erythroleukemic I-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

OBJECTIVE O O
: O O
Thrombopoietin B-protein B-protein
( O O
TPO B-protein B-protein
) O O
and O O
transforming B-protein B-protein
growth I-protein I-protein
factor-beta I-protein I-protein
( I-protein O
1 I-protein O
) I-protein O
( O O
TGF-beta B-protein B-protein
( I-protein O
1 I-protein O
) I-protein O
) O O
have O O
been O O
shown O O
to O O
exert O O
opposite O O
effects O O
on O O
proliferation O O
and O O
megakaryocytic O O
differentiation O O
of O O
hematopoietic B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

To O O
determine O O
whether O O
TGF-beta B-protein B-protein
( I-protein I-protein
1 I-protein I-protein
) I-protein I-protein
interferes O O
directly O O
with O O
TPO B-protein B-protein
-induced O O
signal O O
transduction O O
in O O
hematopoietic B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
we O O
compared O O
the O O
regulatory O O
effects O O
in O O
the O O
TPO B-protein B-cell_line
-responsive O I-cell_line
cell O I-cell_line
lines O I-cell_line
Mo-7e O B-cell_line
and O O
HEL O B-cell_line
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
The O O
cells O O
were O O
stimulated O O
by O O
100 O O
ng/mL O O
TPO B-protein B-protein
and/or O O
100 O O
ng/mL O O
TGF-beta1 B-protein B-protein
and O O
analyzed O O
for O O
proliferation O O
( O O
3H O O
thymidine O O
incorporation O O
) O O
, O O
viability O O
( O O
trypan O O
blue O O
exclusion O O
) O O
, O O
and O O
protein O O
expression O O
and O O
phosphorylation O O
( O O
Western O O
blot O O
) O O
. O O

RESULTS O O
: O O
TPO B-protein B-protein
enhanced O O
the O O
proliferation O O
of O O
Mo-7e B-cell_line B-cell_type
cells I-cell_line I-cell_type
as O O
determined O O
by O O
3H-thymidine O O
incorporation O O
, O O
whereas O O
TGF-beta1 B-protein B-protein
suppressed O O
baseline O O
cell O O
growth O O
and O O
antagonized O O
the O O
proliferative O O
effect O O
of O O
TPO B-protein B-protein
. O O

TPO B-protein B-protein
-induced O O
proliferation O O
also O O
was O O
reduced O O
by O O
a O O
specific O O
inhibitor O O
of O O
the O O
mitogen-activated B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
( O O
MAPK B-protein B-protein
) O O
pathway O O
( O O
PD098059 O O
) O O
, O O
which O O
inhibits O O
activation O O
of O O
the O O
MAPK B-protein B-protein
extracellular I-protein I-protein
signal-regulated I-protein I-protein
kinases I-protein I-protein
( O I-protein
ERK B-protein I-protein
) O I-protein
ERK1 B-protein B-protein
and O O
ERK2 B-protein B-protein
, O O
and O O
AG490 O O
, O O
an O O
inhibitor O O
of O O
Janus B-protein B-protein
kinase-2 I-protein I-protein
, O O
which O O
completely O O
blocked O O
TPO B-protein B-protein
-induced O O
proliferation O O
. O O

As O O
demonstrated O O
by O O
Western O O
blotting O O
, O O
TGF-beta1 B-protein B-protein
reduced O O
the O O
TPO B-protein B-protein
-stimulated O O
ERK1 B-protein B-protein
/ O O
ERK2 B-protein B-protein
and O O
STAT5 O B-protein
phosphorylation O O
in O O
Mo-7e B-cell_line B-cell_line
and I-cell_line I-cell_line
HEL I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

This O O
effect O O
was O O
completely O O
reversed O O
by O O
preincubation O O
with O O
a O O
tyrosine O O
phosphatase O O
inhibitor O O
( O O
Na3VO4 O O
) O O
, O O
which O O
suggests O O
that O O
TGF-beta1 B-protein B-protein
activated O O
a O O
phosphatase B-protein B-protein
. O O

Although O O
STAT3 B-protein B-protein
also O O
was O O
activated O O
by O O
TPO B-protein B-protein
, O O
STAT3 B-protein B-protein
activation O O
remained O O
unaltered O O
by O O
TGF-beta1 B-protein B-protein
. O O

CONCLUSION O O
: O O
Taken O O
together O O
, O O
these O O
data O O
suggest O O
that O O
TGF-beta1 B-protein B-protein
modulates O O
TPO B-protein B-protein
-mediated O O
effects O O
on O O
megakaryocytic O O
proliferation O O
by O O
interfering O O
with O O
TPO B-protein B-protein
-induced O O
signal O O
transduction O O
, O O
particularly O O
by O O
reducing O O
the O O
activities O O
of O O
MAPK B-protein B-protein
ERK1/ERK2 I-protein B-protein
and I-protein O
STAT5 I-protein B-protein
. O O

Invariant B-protein O
chain I-protein O
induces O O
B O B-cell_type
cell O I-cell_type
maturation O O
by O O
activating O O
a O O
TAF B-protein B-protein
( I-protein I-protein
II I-protein I-protein
) I-protein I-protein
105-NF-kappaB I-protein B-protein
-dependent O O
transcription O O
program O O
. O O

Early O O
stages O O
of O O
B O O
cell O O
development O O
occur O O
in O O
the O O
bone O O
marrow O O
, O O
resulting O O
in O O
formation O O
of O O
immature B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

From O O
there O O
these O O
immature B-cell_type B-cell_type
cells I-cell_type I-cell_type
migrate O O
to O O
the O O
spleen O O
where O O
they O O
differentiate O O
to O O
mature B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

This O O
final O O
maturation O O
step O O
is O O
crucial O O
for O O
the O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
to O O
become O O
responsive O O
to O O
antigens B-protein B-protein
and O O
to O O
participate O O
in O O
the O O
immune O O
response O O
. O O

Recently O O
, O O
invariant B-protein B-protein
chain I-protein I-protein
( O O
Ii B-protein B-protein
) O O
, O O
a O O
major B-protein B-protein
histocompatibility I-protein I-protein
complex I-protein I-protein
class I-protein I-protein
II I-protein I-protein
chaperone I-protein I-protein
, O O
as O O
well O O
as O O
the O O
transcription B-protein B-protein
factors I-protein I-protein
c-Rel B-protein B-protein
and O O
p65/RelA B-protein B-protein
, O O
were O O
found O O
to O O
play O O
a O O
role O O
in O O
the O O
final O O
antigen-independent O O
differentiation O O
stage O O
of O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
the O O
spleen O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
a O O
possible O O
link O O
between O O
Ii B-protein B-protein
-dependent O O
B O O
cell O O
maturation O O
and O O
the O O
NF-kappaB O B-protein
pathway O O
. O O

Our O O
studies O O
indicate O O
that O O
Ii B-protein B-protein
-induced O O
B O O
cell O O
maturation O O
involves O O
activation O O
of O O
transcription O O
mediated O O
by O O
the O O
NF-kappaB B-protein B-protein
p65/RelA I-protein I-protein
homodimer I-protein I-protein
and O O
requires O O
the O O
B B-protein B-protein
cell-enriched I-protein I-protein
coactivator I-protein I-protein
TBP-associated B-protein I-protein
factor I-protein I-protein
( I-protein I-protein
II I-protein I-protein
) I-protein I-protein
105 I-protein I-protein
. O O

Androgens O O
indirectly O O
accelerate O O
thymocyte B-cell_type B-cell_type
apoptosis O O
. O O

Apoptotic O O
processes O O
, O O
or O O
the O O
disturbance O O
of O O
the O O
natural O O
regulation O O
of O O
these O O
processes O O
, O O
may O O
be O O
involved O O
in O O
the O O
pathogenesis O O
of O O
autoimmune O O
diseases O O
( O O
AID O O
) O O
. O O

Women O O
are O O
, O O
in O O
general O O
, O O
more O O
susceptible O O
than O O
men O O
to O O
develop O O
AID O O
like O O
rheumatoid O O
arthritis O O
. O O

Androgens O O
and O O
glucocorticoids O O
, O O
in O O
contrast O O
to O O
oestrogens O O
, O O
have O O
favourable O O
effects O O
in O O
AID O O
models O O
as O O
well O O
as O O
in O O
human O O
AID O O
. O O

It O O
is O O
known O O
that O O
glucocorticoids O O
( O O
GC O O
) O O
, O O
used O O
for O O
treatment O O
of O O
AID O O
, O O
increase O O
apoptosis O O
in O O
the O O
thymus O O
resulting O O
in O O
decreased O O
numbers O O
of O O
CD4+ B-cell_type B-cell_type
CD8+ I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
. O O

It O O
was O O
asked O O
whether O O
androgens O O
, O O
in O O
contrast O O
to O O
oestrogens O O
, O O
exert O O
their O O
favourable O O
effects O O
in O O
the O O
treatment O O
of O O
AID O O
by O O
a O O
mechanism O O
comparable O O
to O O
that O O
described O O
for O O
GC O O
by O O
eliminating O O
the O O
apoptosis O O
prone O O
CD4+ B-cell_type B-cell_type
CD8+ I-cell_type I-cell_type
population I-cell_type I-cell_type
in O O
the O O
thymus O O
. O O

Although O O
both O O
androgens O O
and O O
oestrogens O O
proved O O
thymolytic O O
, O O
a O O
significantly O O
decreased O O
percentage O O
of O O
CD4+ B-cell_type B-cell_type
CD8+ I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
was O O
observed O O
by O O
flow O O
cytometry O O
after O O
treatment O O
of O O
mice O O
with O O
the O O
androgen O O
methyltestosterone O O
, O O
but O O
not O O
with O O
the O O
oestrogen O O
ethinylestradiol O O
. O O

To O O
investigate O O
whether O O
the O O
observed O O
thymolytic O O
effects O O
were O O
due O O
to O O
the O O
presence O O
of O O
hormone B-protein B-protein
receptors I-protein I-protein
on O O
thymocytes B-cell_type B-cell_type
, O O
cells O O
were O O
isolated O O
from O O
the O O
thymus O O
and O O
incubated O O
with O O
androgens O O
or O O
oestrogens O O
to O O
measure O O
apoptosis O O
. O O

Several O O
techniques O O
were O O
used O O
to O O
determine O O
thymocyte B-cell_type O
apoptosis O O
in O O
vitro O O
, O O
but O O
no O O
enhanced O O
apoptotic O O
signal O O
was O O
observed O O
. O O

Using O O
the O O
very O O
sensitive O O
TUNEL O O
assay O O
, O O
no O O
direct O O
effect O O
of O O
androgens O O
on O O
thymocytes B-cell_type B-cell_type
in O O
vitro O O
could O O
be O O
observed O O
. O O

This O O
is O O
in O O
sharp O O
contrast O O
to O O
the O O
high O O
signal O O
observed O O
with O O
GC O O
. O O

Therefore O O
, O O
upon O O
in O O
vivo O O
androgen O O
treatment O O
, O O
other O O
cells O O
containing O O
androgen B-protein B-protein
receptors I-protein I-protein
than O O
thymocytes B-cell_type B-cell_type
are O O
probably O O
involved O O
in O O
inducing O O
the O O
increase O O
in O O
thymic O O
apoptosis O O
. O O

To O O
study O O
the O O
role O O
of O O
the O O
androgen B-protein B-protein
receptor I-protein I-protein
on O O
thymocyte B-cell_type O
apoptosis O O
, O O
androgen B-protein B-protein
receptor I-protein I-protein
mutant O I-protein
( O O
Tfm/Y O O
) O O
mice O O
were O O
treated O O
with O O
androgens O O
. O O

No O O
alterations O O
of O O
thymocyte B-cell_type B-cell_type
subpopulations I-cell_type I-cell_type
were O O
seen O O
, O O
suggesting O O
that O O
changes O O
in O O
the O O
percentage O O
of O O
CD4+ B-cell_type B-cell_type
CD8+ I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
after O O
administration O O
of O O
androgens O O
depend O O
on O O
the O O
presence O O
of O O
functional O O
androgen B-protein B-protein
receptors I-protein I-protein
. O O

Thus O O
, O O
it O O
is O O
concluded O O
that O O
androgens O O
indirectly O O
accelerate O O
thymocyte B-cell_type B-cell_type
apoptosis O O
in O O
vivo O O
. O O

Inhibition O O
of O O
the O O
transcription B-protein B-protein
factors I-protein I-protein
AP-1 B-protein B-protein
and O O
NF-kappaB B-protein B-protein
in O O
CD4 B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
peroxisome B-protein B-protein
proliferator-activated I-protein I-protein
receptor I-protein I-protein
gamma I-protein I-protein
ligands I-protein I-protein
. O O

The O O
peroxisome B-protein B-protein
proliferator-activated I-protein I-protein
receptor I-protein I-protein
gamma I-protein I-protein
( O O
PPARgamma B-protein B-protein
) O O
, O O
a O O
member O O
of O O
the O O
nuclear B-protein B-protein
hormone I-protein I-protein
receptor I-protein I-protein
superfamily I-protein I-protein
, O O
is O O
essential O O
for O O
adipocyte O B-cell_type
differentiation O O
and O O
glucose O O
homeostasis O O
. O O

PPARgamma B-protein B-protein
has O O
been O O
found O O
recently O O
to O O
regulate O O
macrophage O O
activation O O
in O O
response O O
to O O
mitogens B-protein O
and O O
inflammation O O
. O O

Our O O
study O O
shows O O
PPARgamma B-protein B-protein
to O O
be O O
preferentially O O
expressed O O
in O O
the O O
nuclei O O
of O O
resting B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
to O O
increase O O
upon O O
activation O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
by O O
either O O
anti-CD3 B-protein B-protein
and O O
anti-CD28 B-protein B-protein
or O O
phorbol O O
myristyl O O
acetate O O
( O O
PMA O O
) O O
. O O

We O O
also O O
found O O
the O O
PPARgamma B-protein B-protein
ligand I-protein I-protein
ciglitizone O O
to O O
attenuate O O
the O O
activation O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
by O O
inhibiting O O
cytokine O B-DNA
gene O I-DNA
expression O O
and O O
anti-CD3 B-protein B-protein
and O O
anti-CD28 B-protein B-protein
or O O
PMA-induced O O
proliferative O O
responses O O
. O O

Inhibition O O
of O O
both O O
the O O
proliferative O O
response O O
and O O
inflammatory O B-protein
cytokine O I-protein
expression O O
in O O
CD4 B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
was O O
correlated O O
with O O
suppression O O
of O O
the O O
activated O O
transcription B-protein B-protein
factors I-protein I-protein
AP1 B-protein B-protein
and O O
NF-kappaB B-protein B-protein
. O O

PPARgamma B-protein B-protein
ligands I-protein O
also O O
strongly O O
inhibited O O
SEA-induced O B-cell_line
Vbeta3 O I-cell_line
T O I-cell_line
cell O I-cell_line
activation O O
in O O
vivo O O
. O O

These O O
results O O
, O O
together O O
with O O
previous O O
findings O O
of O O
the O O
inhibitory O O
effect O O
of O O
PPARgamma B-protein B-protein
ligands I-protein O
on O O
activated B-cell_type O
macrophages I-cell_type B-cell_type
, O O
provide O O
clear O O
evidence O O
for O O
PPARgamma B-protein B-protein
as O O
a O O
negative B-protein O
regulator I-protein O
of O O
the O O
inflammatory O O
activation O O
of O O
both O O
macrophage B-cell_type B-cell_type
and O I-cell_type
T B-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

PPARgamma B-protein B-protein
may O O
thus O O
be O O
a O O
potential O O
therapeutic O O
target O O
for O O
the O O
treatment O O
of O O
autoimmunity O O
. O O

A O O
prominent O O
role O O
for O O
activator B-protein B-protein
protein-1 I-protein I-protein
in O O
the O O
transcription O O
of O O
the O O
human B-DNA B-DNA
2B4 I-DNA I-DNA
( I-DNA I-DNA
CD244 I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
in O O
NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
cell B-protein B-protein
surface I-protein I-protein
glycoprotein I-protein I-protein
2B4 I-protein I-protein
( O O
CD244 B-protein B-protein
) O O
of O O
the O O
Ig B-protein B-protein
superfamily I-protein I-protein
is O O
involved O O
in O O
the O O
regulation O O
of O O
NK B-cell_type B-cell_type
and O I-cell_type
T B-cell_type I-cell_type
lymphocyte I-cell_type I-cell_type
functions O O
. O O

We O O
have O O
recently O O
identified O O
CD48 B-protein B-protein
as O O
the O O
high B-protein B-protein
affinity I-protein I-protein
counterreceptor I-protein I-protein
for O O
2B4 B-protein B-protein
in O O
both O O
mice O O
and O O
humans O O
. O O

The O O
cytoplasmic B-protein B-protein
domain I-protein I-protein
of O O
2B4 B-protein B-protein
associates O O
with O O
src B-protein B-protein
homology I-protein I-protein
2 I-protein I-protein
domain-containing I-protein I-protein
protein I-protein I-protein
or O O
signaling B-protein B-protein
lymphocyte I-protein I-protein
activation I-protein I-protein
molecule-associated I-protein I-protein
protein I-protein I-protein
, O O
whose O O
mutation O O
is O O
the O O
underlying O O
genetic O O
defect O O
in O O
the O O
X-linked O O
lymphoproliferative O O
syndrome O O
. O O

In O O
this O O
study O O
, O O
we O O
report O O
the O O
molecular O O
cloning O O
and O O
characterization O O
of O O
the O O
human B-DNA B-DNA
2B4 I-DNA I-DNA
( I-DNA I-DNA
h2B4 I-DNA I-DNA
) I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Through O O
primer O O
extension O O
analysis O O
, O O
we O O
found O O
that O O
the O O
transcription O O
of O O
the O O
h2B4 B-DNA B-DNA
gene I-DNA I-DNA
initiates O O
at O O
multiple O B-DNA
start O I-DNA
sites O I-DNA
. O O

We O O
isolated O O
h2B4 B-DNA B-DNA
genomic I-DNA I-DNA
clones I-DNA I-DNA
and O O
PCR O O
amplified O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
untranslated I-DNA I-DNA
region I-DNA I-DNA
containing O O
the O O
promoter B-DNA B-DNA
elements I-DNA I-DNA
. O O

We O O
have O O
identified O O
a O O
functional O B-DNA
AP-1 B-DNA I-DNA
site I-DNA I-DNA
that O O
lies O O
between O O
( O O
-106 O B-DNA
to O I-DNA
-100 O I-DNA
) O O
through O O
transient O O
transfection O O
analysis O O
in O O
YT B-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
a O O
human B-cell_line B-cell_line
NK I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

EMSAs O O
with O O
Abs B-protein B-protein
specific O O
for O O
various O O
protein B-protein B-protein
factors I-protein I-protein
of O O
the O O
AP-1 B-protein B-protein
family I-protein I-protein
revealed O O
that O O
multiple O O
members O O
of O O
the O O
Jun B-protein B-protein
family I-protein I-protein
are O O
involved O O
in O O
the O O
regulation O O
of O O
the O O
h2B4 B-DNA B-DNA
gene I-DNA I-DNA
. O O

Mutation O O
of O O
the O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
not O O
only O O
abolishes O O
protein/DNA O O
interactions O O
but O O
also O O
promoter O O
activity O O
. O O

These O O
results O O
demonstrate O O
a O O
significant O O
role O O
for O O
AP-1 B-protein B-protein
in O O
the O O
transcriptional O O
regulation O O
of O O
the O O
h2B4 B-DNA B-DNA
gene I-DNA I-DNA
. O O

Functional O O
correction O O
of O O
FA-C B-cell_type B-cell_line
cells I-cell_type I-cell_line
with O O
FANCC B-protein B-protein
suppresses O O
the O O
expression O O
of O O
interferon B-DNA B-DNA
gamma-inducible I-DNA I-DNA
genes I-DNA I-DNA
. O O

Because O O
hematopoietic B-cell_type B-cell_type
cells I-cell_type I-cell_type
derived O O
from O O
Fanconi O O
anemia O O
( O O
FA O O
) O O
patients O O
of O O
the O O
C-complementation O O
group O O
( O O
FA-C O O
) O O
are O O
hypersensitive O O
to O O
the O O
inhibitory O O
effects O O
of O O
interferon B-protein B-protein
gamma I-protein I-protein
( O O
IFNgamma B-protein B-protein
) O O
, O O
the O O
products O O
of O O
certain O O
IFNgamma-inducible B-DNA B-DNA
genes I-DNA I-DNA
known O O
to O O
influence O O
hematopoietic O O
cell O O
survival O O
were O O
quantified O O
. O O

High O O
constitutive O O
expression O O
of O O
the O O
IFNgamma-inducible B-DNA B-DNA
genes I-DNA I-DNA
, O O
IFN-stimulated B-protein B-protein
gene I-protein I-protein
factor I-protein I-protein
3 I-protein I-protein
gamma I-protein I-protein
subunit I-protein I-protein
( O O
ISGF3gamma B-protein B-protein
) O O
, O O
IFN B-protein B-protein
regulatory I-protein I-protein
factor-1 I-protein I-protein
( O O
IRF-1 B-protein B-protein
) O O
, O O
and O O
the O O
cyclin-dependent B-protein B-protein
kinase I-protein I-protein
inhibitor I-protein I-protein
p21 I-protein B-protein
( O O
WAF1 B-protein B-protein
) O O
was O O
found O O
in O O
FANCC B-protein B-cell_line
mutant O I-cell_line
B B-cell_type I-cell_line
lymphoblasts I-cell_type I-cell_line
, O O
low-density B-cell_type B-cell_type
bone I-cell_type I-cell_type
marrow I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
and O O
murine B-cell_type B-cell_type
embryonic I-cell_type I-cell_type
fibroblasts I-cell_type I-cell_type
. O O

Paradoxically O O
, O O
these O O
cells O O
do O O
not O O
activate B-protein O
signal I-protein B-protein
transducer I-protein I-protein
and I-protein I-protein
activator I-protein I-protein
of I-protein I-protein
transcription I-protein I-protein
( I-protein I-protein
STAT I-protein I-protein
) I-protein I-protein
1 I-protein I-protein
properly O O
. O O

In O O
an O O
attempt O O
to O O
clarify O O
mechanisms O O
by O O
which O O
FA-C B-cell_type B-cell_line
cells I-cell_type I-cell_line
overexpress O O
IFNgamma-inducible B-DNA B-DNA
genes I-DNA I-DNA
in O O
the O O
face O O
of O O
defective O O
STAT1 O B-protein
phosphorylation O O
, O O
it O O
was O O
reasoned O O
that O O
decreased O O
levels O O
of O O
activated B-protein O
STAT1 I-protein B-protein
might O O
result O O
in O O
reduced O O
expression O O
of O O
a O O
hematopoietic B-protein B-protein
IFNgamma-responsive I-protein I-protein
protein I-protein I-protein
that O O
normally O O
modulates O O
expression O O
of O O
other O O
IFNgamma-responsive B-DNA B-DNA
genes I-DNA I-DNA
. O O

Levels O O
of O O
the O O
IFNgamma B-protein B-DNA
-inducible O I-DNA
factor O I-DNA
IFN B-protein I-DNA
consensus I-protein I-DNA
sequence I-protein I-DNA
binding I-protein B-protein
protein I-protein I-protein
( O O
ICSBP B-protein B-protein
) O O
, O O
a O O
negative B-protein B-DNA
trans-acting I-protein I-DNA
regulator I-protein I-DNA
of O O
some O O
IFNgamma-inducible B-DNA B-DNA
genes I-DNA I-DNA
, O O
were O O
quantified O O
. O O

ICSBP B-protein B-protein
levels O O
were O O
reduced O O
in O O
FA-C B-cell_type B-cell_line
B I-cell_type I-cell_line
lymphoblasts I-cell_type I-cell_line
and O O
MEFs B-cell_type B-cell_line
. O O

However O O
, O O
enforced O O
expression O O
of O O
ICSBP B-protein B-protein
failed O O
to O O
down-regulate O O
IRF-1 B-protein B-protein
, O O
ISGF3gamma B-protein B-protein
, O O
and O O
p21 B-protein B-protein
( I-protein O
WAF1 I-protein B-protein
) I-protein O
. O O

Thus O O
, O O
the O O
FANCC B-protein B-protein
protein I-protein I-protein
functions O O
to O O
modulate O O
expression O O
of O O
a O O
family O O
of O O
genes O O
that O O
in O O
normal O B-cell_type
cells O I-cell_type
are O O
inducible O O
only O O
by O O
specific O O
environmental O O
cues O O
for O O
apoptosis O O
or O O
mitogenic O O
inhibition O O
, O O
but O O
it O O
does O O
so O O
independently O O
of O O
the O O
classic O O
IFN-STAT1 O B-protein
pathway O O
and O O
is O O
not O O
the O O
direct O O
result O O
of O O
reduced O O
ICSBP B-protein B-protein
expression O O
. O O

A O O
genetic O O
investigation O O
of O O
E2A O B-protein
function O O
in O O
lymphocyte O O
development O O
. O O

Lymphocytes B-cell_type B-cell_type
are O O
derived O O
from O O
hematopoietic B-cell_type B-cell_type
stem I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
HSC B-cell_type B-cell_type
) O O
following O O
a O O
series O O
of O O
regulated O O
differentiation O O
events O O
. O O

Multipotent B-cell_type B-cell_type
HSCs I-cell_type I-cell_type
become O O
committed O O
to O O
the O O
B B-cell_line B-cell_type
cell I-cell_line I-cell_type
lineage I-cell_line I-cell_type
in O O
bone O O
marrow O O
and O O
the O O
T B-cell_line B-cell_type
cell I-cell_line I-cell_type
lineage I-cell_line I-cell_type
in O O
the O O
thymus O O
after O O
receiving O O
appropriate O O
signals O O
from O O
the O O
corresponding O O
microenvironment O O
. O O

These O O
committed O B-cell_type
lymphoid B-cell_type I-cell_type
cells I-cell_type I-cell_type
must O O
then O O
undergo O O
V O B-cell_line
( O I-cell_line
D O I-cell_line
) O I-cell_line
J O I-cell_line
recombination O O
at O O
the O O
immunoglobulin B-DNA B-DNA
gene I-DNA I-DNA
or O O
T B-DNA B-DNA
cell I-DNA I-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
locus I-DNA I-DNA
resulting O O
in O O
clonal O O
production O O
of O O
functional O B-cell_type
B B-cell_type I-cell_type
or I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
, O O
respectively O O
. O O

Lymphocyte O O
commitment O O
and O O
differentiation O O
are O O
accompanied O O
by O O
programmed O O
gene O O
expression O O
or O O
repression O O
events O O
which O O
are O O
driven O O
by O O
lineage B-protein O
and I-protein O
stage I-protein O
specific I-protein O
transcription I-protein B-protein
factors I-protein I-protein
. O O

The O O
basic-helix-loop-helix B-protein B-protein
( I-protein I-protein
bHLH I-protein I-protein
) I-protein I-protein
transcription I-protein I-protein
factors I-protein I-protein
encoded O O
by O O
the O O
E2A B-DNA B-DNA
gene I-DNA I-DNA
are O O
involved O O
in O O
several O O
differentiation O O
events O O
during O O
B O O
and O O
T O O
cell O O
development O O
, O O
including O O
lineage O O
commitment O O
, O O
initiation O O
of O O
V O O
( O O
D O O
) O O
J O O
recombination O O
, O O
and O O
antigen O B-protein
receptor O I-protein
mediated O O
proliferation O O
and O O
differentiation O O
. O O

Several O O
recent O O
reviews O O
have O O
provided O O
a O O
comprehensive O O
discussion O O
of O O
biochemical O O
, O O
cellular O O
, O O
and O O
genetic O O
research O O
on O O
E2A O B-protein
function O O
in O O
lymphocyte O O
development O O
( O O
1 O O
, O O
2 O O
) O O
. O O

Here O O
, O O
we O O
only O O
discuss O O
some O O
of O O
the O O
genetic O O
approaches O O
our O O
laboratory O O
( O O
except O O
where O O
it O O
is O O
noted O O
) O O
has O O
undertaken O O
to O O
investigate O O
the O O
molecular O O
pathways O O
mediated O O
by O O
E2A B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
in O O
lymphocyte O O
development O O

D609 O O
inhibits O O
ionizing O O
radiation-induced O O
oxidative O O
damage O O
by O O
acting O O
as O O
a O O
potent O O
antioxidant O O
. O O

Tricyclodecan-9-yl-xanthogenate O O
( O O
D609 O O
) O O
has O O
been O O
extensively O O
studied O O
in O O
biological O O
systems O O
and O O
exhibits O O
a O O
variety O O
of O O
biological O O
functions O O
, O O
including O O
antiviral O O
, O O
antitumor O O
, O O
and O O
anti-inflammatory O O
activities O O
. O O

Most O O
of O O
these O O
activities O O
have O O
been O O
largely O O
attributed O O
to O O
the O O
inhibitory O O
effect O O
of O O
D609 O O
on O O
phosphatidylcholine-specific O B-protein
phospholipase B-protein I-protein
C I-protein I-protein
. O O

However O O
, O O
as O O
a O O
xanthate O O
derivative O O
, O O
D609 O O
is O O
a O O
strong O O
electrolyte O O
and O O
readily O O
dissociates O O
to O O
xanthate O O
anions O O
and O O
cations O O
of O O
alkali O O
metals O O
in O O
solution O O
. O O

Xanthate O O
anions O O
and O O
protonated O O
xanthic O O
acid O O
contain O O
a O O
free O O
thiol O O
moiety O O
and O O
are O O
highly O O
reductive O O
. O O

This O O
implies O O
that O O
D609 O O
and O O
other O O
xanthate O O
derivatives O O
may O O
function O O
as O O
potent O O
antioxidants O O
. O O

Indeed O O
, O O
we O O
found O O
that O O
D609 O O
inhibited O O
the O O
Fenton O O
reaction-induced O O
oxidation O O
of O O
dihydrorhodamine O O
123 O O
in O O
a O O
dose-dependent O O
manner O O
similar O O
to O O
that O O
of O O
pyrrolidinedithiocarbamate O O
, O O
a O O
well O O
known O O
antioxidant O O
. O O

In O O
addition O O
, O O
D609 O O
inhibited O O
the O O
formation O O
of O O
the O O
alpha-phenyl-tert-butylnitrone-free O O
radical O O
spin O O
adducts O O
and O O
lipid O O
peroxidation O O
of O O
synaptosomal O O
membranes O O
by O O
the O O
Fenton O O
reagents O O
. O O

Furthermore O O
, O O
preincubation O O
of O O
lymphocytes B-cell_type B-cell_type
with O O
D609 O O
resulted O O
in O O
a O O
significant O O
diminution O O
of O O
ionizing O O
radiation O O
( O O
IR O O
) O O
-induced O O
1 O O
) O O
production O O
of O O
reactive O O
oxygen O O
species O O
; O O
2 O O
) O O
decrease O O
in O O
intracellular O O
reduced O O
glutathione O O
; O O
3 O O
) O O
oxidative O O
damage O O
to O O
proteins O O
and O O
lipids O O
; O O
and O O
4 O O
) O O
activation O O
of O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
. O O

Moreover O O
, O O
when O O
D609 O O
( O O
50 O O
mg/kg O O
i.v. O O
) O O
was O O
administered O O
to O O
mice O O
10 O O
min O O
prior O O
to O O
total O O
body O O
IR O O
( O O
6.5 O O
and O O
8.5 O O
Gy O O
) O O
, O O
it O O
protected O O
the O O
mice O O
from O O
IR-induced O O
lethality O O
. O O

Thus O O
, O O
these O O
results O O
indicate O O
that O O
D609 O O
is O O
a O O
potent O O
antioxidant O O
and O O
has O O
the O O
ability O O
to O O
inhibit O O
IR-induced O O
cellular O O
oxidative O O
stress O O
. O O

Inhibition O O
of O O
AP-1 B-protein B-protein
by O O
the O O
glucocorticoid-inducible O B-protein
protein B-protein I-protein
GILZ I-protein B-protein
. O O

The O O
immunosuppressive O O
effects O O
of O O
glucocorticoids O O
arise O O
largely O O
by O O
inhibition O O
of O O
cytokine O B-DNA
gene O I-DNA
expression O O
, O O
which O O
has O O
been O O
ascribed O O
to O O
interference O O
between O O
the O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
and O O
transcription B-protein B-protein
factors I-protein I-protein
such O O
as O O
AP-1 B-protein B-protein
and O O
NF-kappa B-protein B-protein
B I-protein I-protein
as O O
well O O
as O O
by O O
competition O O
for O O
common O B-protein
coactivators O I-protein
. O O

Here O O
we O O
show O O
that O O
glucocorticoid-induced O O
inhibition O O
of O O
interleukin-2 O B-RNA
mRNA O I-RNA
expression O O
in O O
activated B-cell_type B-cell_type
normal I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
required O O
new O O
protein O O
synthesis O O
, O O
suggesting O O
that O O
this O O
phenomenon O O
is O O
secondary O O
to O O
expression O O
of O O
glucocorticoid-regulated O B-DNA
genes B-DNA I-DNA
. O O

One O O
of O O
the O O
most O O
prominent O O
glucocorticoid-induced O B-DNA
genes B-DNA I-DNA
is O O
glucocorticoid-induced B-DNA B-protein
leucine I-DNA I-protein
zipper I-DNA I-protein
( O O
GILZ B-DNA B-protein
) O O
, O O
which O O
has O O
been O O
reported O O
to O O
inhibit O O
activation-induced O O
up-regulation O O
of O O
Fas B-RNA B-protein
ligand I-RNA I-RNA
( I-RNA I-RNA
FasL I-RNA I-RNA
) I-RNA I-RNA
mRNA I-RNA I-RNA
. O O

Indeed O O
, O O
transient O O
expression O O
of O O
GILZ B-DNA B-protein
in O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
blocked O O
induction O O
of O O
a O O
reporter B-DNA B-DNA
construct I-DNA I-DNA
driven O O
by O O
the O O
FasL B-DNA B-DNA
promoter I-DNA I-DNA
. O O

This O O
could O O
be O O
accounted O O
for O O
by O O
GILZ B-protein B-protein
-mediated O O
inhibition O O
of O O
Egr-2 B-protein B-protein
and O O
Egr-3 B-protein B-protein
, O O
NFAT/AP-1 B-protein B-protein
-inducible O I-protein
transcription B-protein B-protein
factors I-protein I-protein
that O O
bind O O
a O O
regulatory B-DNA B-DNA
element I-DNA I-DNA
in O O
the O O
FasL B-DNA B-DNA
promoter I-DNA I-DNA
and O O
up-regulate O O
FasL O B-protein
expression O O
. O O

GILZ B-protein B-protein
also O O
potently O O
inhibited O O
AP-1-driven B-DNA B-DNA
and I-DNA I-DNA
IL-2 I-DNA I-DNA
promoter-driven I-DNA I-DNA
reporter I-DNA I-DNA
constructs I-DNA I-DNA
, O O
and O O
recombinant O B-protein
GILZ B-protein I-protein
specifically O O
interacted O O
with O O
c-Fos B-protein B-protein
and O O
c-Jun B-protein B-protein
in O O
vitro O O
and O O
inhibited O O
the O O
binding O O
of O O
active B-protein O
AP-1 I-protein B-protein
to O O
its O O
target O O
DNA O O
. O O

Whereas O O
homodimerization O O
of O O
GILZ B-protein B-protein
required O O
the O O
presence O O
of O O
its O O
leucine B-protein B-protein
zipper I-protein I-protein
, O O
the O O
interaction O O
with O O
c-Fos B-protein B-protein
and O O
c-Jun B-protein B-protein
occurred O O
through O O
the O O
N-terminal B-protein B-protein
60-amino B-protein I-protein
acid I-protein I-protein
region I-protein I-protein
of O O
GILZ B-protein B-protein
. O O

Thus O O
, O O
GILZ B-protein B-protein
represents O O
a O O
glucocorticoid-induced O B-protein
gene O I-protein
product O I-protein
that O O
can O O
inhibit O O
a O O
variety O O
of O O
activation-induced O O
events O O
, O O
at O O
least O O
in O O
part O O
by O O
direct O O
interference O O
with O O
AP-1 B-protein B-protein
, O O
and O O
is O O
therefore O O
a O O
candidate O O
for O O
a O O
mediator O O
of O O
glucocorticoid-induced O O
immunosuppression O O
. O O

Pharmacokinetic O O
differences O O
between O O
a O O
T O O
cell-tolerizing O O
and O O
a O O
T O O
cell-activating O O
peptide O O
. O O

Vaccination O O
with O O
a O O
peptide O O
representing O O
a O O
CTL O B-protein
epitope O I-protein
from O O
the O O
human O O
papillomavirus O O
( O O
HPV O O
) O O
16 O O
E7 B-protein B-protein
protein I-protein I-protein
induces O O
a O O
specific O O
CTL O O
response O O
that O O
prevents O O
the O O
outgrowth O O
of O O
HPV16 O O
E7-expressing O O
tumors O O
. O O

In O O
contrast O O
, O O
vaccination O O
with O O
a O O
peptide O O
encoding O O
an O O
adenovirus O O
type O O
5 O O
( O O
Ad5 O O
) O O
E1A O B-protein
CTL O I-protein
epitope O I-protein
results O O
in O O
CTL O O
tolerance O O
and O O
enhanced O O
growth O O
of O O
an O O
Ad5 O O
E1A-expressing O O
tumor O O
. O O

It O O
is O O
unclear O O
why O O
these O O
peptides O O
induce O O
such O O
opposite O O
effects O O
. O O

To O O
determine O O
whether O O
a O O
difference O O
in O O
pharmacokinetics O O
can O O
explain O O
the O O
functional O O
contrasts O O
, O O
tritiated O O
Ad5 O O
E1A O B-protein
and O O
HPV16 O O
E7 O O
peptides O O
were O O
injected O O
into O O
mice O O
. O O

Results O O
show O O
that O O
the O O
tolerizing O O
peptide O O
spread O O
through O O
the O O
body O O
16 O O
times O O
faster O O
than O O
the O O
activating O O
peptide O O
and O O
was O O
cleared O O
at O O
least O O
2 O O
times O O
faster O O
. O O

The O O
HPV16 O O
E7 O O
peptide O O
kinetics O O
correlated O O
with O O
the O O
kinetics O O
of O O
HPV16 B-protein O
E7 I-protein O
-specific O O
CTL O O
induction O O
. O O

In O O
contrast O O
, O O
Ad5 O O
E1A O B-protein
peptide O O
injection O O
resulted O O
in O O
physical O O
deletion O O
of O O
preexisting O O
Ad5 B-protein O
E1A I-protein B-DNA
-specific O O
CTLs B-protein B-cell_type
within O O
24 O O
h O O
after O O
injection O O
. O O

This O O
tolerization O O
occurred O O
at O O
the O O
time O O
when O O
the O O
peptide O O
reached O O
its O O
maximum O O
peptide O O
concentration O O
in O O
the O O
organs O O
. O O

These O O
data O O
suggest O O
that O O
ubiquitous O O
expression O O
of O O
the O O
tolerizing O O
Ad5 O O
E1A O B-protein
peptide O O
within O O
a O O
short O O
period O O
of O O
time O O
causes O O
activation-induced O O
cell O O
death O O
of O O
Ad5 B-protein O
E1A I-protein B-protein
-specific O B-cell_type
CTLs B-protein I-cell_type
. O O

Therefore O O
, O O
information O O
on O O
the O O
pharmacokinetics O O
of O O
peptides O O
is O O
vital O O
for O O
the O O
safety O O
and O O
efficacy O O
of O O
peptide-based O O
vaccines O O
. O O

Smad3 B-protein B-protein
and O O
Smad4 B-protein B-protein
mediate O O
transforming B-protein B-protein
growth I-protein I-protein
factor-beta1 I-protein I-protein
-induced O O
IgA O B-protein
expression O O
in O O
murine B-cell_type B-cell_type
B I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Transforming B-protein B-protein
growth I-protein I-protein
factor I-protein I-protein
( I-protein I-protein
TGF I-protein I-protein
) I-protein I-protein
-beta1 I-protein I-protein
is O O
well O O
established O O
as O O
a O O
critical O O
IgA B-protein B-protein
isotype I-protein I-protein
switching I-protein I-protein
factor I-protein I-protein
and O O
Smad B-protein B-protein
molecules I-protein I-protein
have O O
been O O
reported O O
to O O
act O O
as O O
transducers B-protein O
and O O
transcriptional B-protein B-protein
factors I-protein I-protein
in O O
the O O
expression O O
of O O
TGF-beta1 B-protein B-DNA
-targeted O I-DNA
genes B-DNA I-DNA
. O O

We O O
examined O O
the O O
involvement O O
of O O
Smad B-protein B-protein
proteins I-protein I-protein
in O O
TGF-beta1 B-protein B-protein
-induced O O
IgA O B-protein
expression O O
. O O

First O O
, O O
we O O
found O O
that O O
TGF-beta1 B-protein B-protein
significantly O O
increases O O
endogenous B-RNA B-RNA
germ-line I-RNA I-RNA
( I-RNA I-RNA
GL I-RNA I-RNA
) I-RNA I-RNA
alpha I-RNA I-RNA
transcripts I-RNA I-RNA
by O O
LPS-stimulated O O
CH12.LX.4933 B-cell_line O
( I-cell_line O
mu I-cell_line O
( I-cell_line O
+ I-cell_line O
) I-cell_line O
) I-cell_line O
B I-cell_line B-cell_type
lymphoma I-cell_line I-cell_type
cells I-cell_line I-cell_type
. O O

To O O
investigate O O
its O O
signaling O O
mechanisms O O
, O O
the O O
lymphoma B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
was O O
transfected O O
with O O
pFL3 B-DNA B-protein
that O O
contains O O
the O O
TGF-beta-responsive B-DNA B-DNA
element I-DNA I-DNA
of O O
the O O
GLalpha B-DNA B-DNA
promoter I-DNA I-DNA
, O O
and O O
stimulated O O
with O O
TGF-beta1 B-protein B-protein
. O O

Similar O O
to O O
endogenous B-RNA B-protein
GLalpha I-RNA B-RNA
transcripts I-RNA I-RNA
, O O
TGF-beta1 B-protein B-protein
induces O O
GLalpha B-DNA B-DNA
promoter I-DNA I-DNA
activity O O
and O O
overexpression O O
of O O
Smad3 B-protein B-protein
markedly O O
enhances O O
the O O
promoter O O
activity O O
. O O

This O O
activity O O
is O O
further O O
augmented O O
by O O
cotransfected B-protein O
Smad4 I-protein B-protein
. O O

On O O
the O O
other O O
hand O O
, O O
Smad7 B-protein B-protein
substantially O O
abrogates O O
the O O
synergistic O O
effect O O
of O O
Smad3/4 B-protein B-protein
on O O
GLalpha B-DNA B-DNA
promoter I-DNA I-DNA
activity O O
. O O

In O O
addition O O
, O O
overexpression O O
of O O
Smad3/4 B-protein B-protein
enhances O O
TGF-beta1 B-protein B-protein
-induced O O
endogenous B-RNA O
GLalpha I-RNA B-RNA
transcripts I-RNA I-RNA
in O O
normal B-cell_type B-cell_type
spleen I-cell_type I-cell_type
B I-cell_type I-cell_type
cell I-cell_type I-cell_type
s O O
. O O

Finally O O
, O O
in O O
the O O
presence O O
of O O
TGF-beta1 B-protein B-protein
, O O
overexpression O O
of O O
Smad3/4 B-protein B-protein
selectively O O
increases O O
both O O
surface O O
IgA O B-protein
expression O O
and O O
IgA O B-protein
production O O
. O O

The O O
results O O
from O O
the O O
present O O
study O O
indicate O O
that O O
Smad3 B-protein B-protein
, O O
Smad4 B-protein B-protein
, O O
and O O
Smad7 B-protein B-protein
, O O
at O O
least O O
in O O
part O O
, O O
serve O O
as O O
mediators O O
linking O O
TGF-beta1 B-protein B-protein
to O O
transcriptional O O
regulation O O
of O O
IgA B-DNA B-protein
switching I-DNA O
related I-DNA O
gene I-DNA O
and O O
regulation O O
of O O
IgA O B-protein
class O O
switching O O
. O O

The O O
translesion B-protein B-protein
DNA I-protein I-protein
polymerase I-protein I-protein
zeta I-protein I-protein
plays O O
a O O
major O O
role O O
in O O
Ig O B-protein
and O O
bcl-6 O B-protein
somatic O O
hypermutation O O
. O O

Ig O B-protein
somatic O O
mutations O O
would O O
be O O
introduced O O
by O O
a O O
polymerase B-protein O
( O O
pol B-protein O
) O O
while O O
repairing O O
DNA O O
outside O O
main O O
DNA O O
replication O O
. O O

We O O
show O O
that O O
human B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
constitutively O O
express O O
the O O
translesion B-protein B-protein
pol I-protein I-protein
zeta I-protein I-protein
, O O
which O O
effectively O O
extends O O
DNA O O
past O O
mismatched O O
bases O O
( O O
mispair O O
extender O O
) O O
, O O
and O O
pol B-protein O
eta I-protein O
, O O
which O O
bypasses O O
DNA O O
lesions O O
in O O
an O O
error-free O O
fashion O O
. O O

Upon O O
B B-protein B-protein
cell I-protein I-protein
receptor I-protein I-protein
( O O
BCR B-protein B-protein
) O O
engagement O O
and O O
coculture O O
with O O
activated B-cell_type B-cell_type
CD4+ I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
these O O
lymphocytes B-cell_type B-cell_type
upregulated O O
pol B-protein B-protein
zeta I-protein I-protein
, O O
downregulated O O
pol B-protein B-protein
eta I-protein I-protein
, O O
and O O
mutated O O
the O O
Ig B-DNA B-DNA
and I-DNA I-DNA
bcl-6 I-DNA I-DNA
genes I-DNA I-DNA
. O O

Inhibition O O
of O O
the O O
pol B-protein B-protein
zeta I-protein I-protein
REV3 B-protein I-protein
catalytic I-protein I-protein
subunit I-protein I-protein
by O O
specific O O
phosphorothioate-modified O O
oligonucleotides O O
impaired O O
Ig O B-protein
and O O
bcl-6 O B-protein
hypermutation O O
and O O
UV O O
damage-induced O O
DNA O O
mutagenesis O O
, O O
without O O
affecting O O
cell O O
cycle O O
or O O
viability O O
. O O

Thus O O
, O O
pol B-protein B-protein
zeta I-protein I-protein
plays O O
a O O
critical O O
role O O
in O O
Ig O O
and O O
bcl-6 O B-protein
hypermutation O O
, O O
perhaps O O
facilitated O O
by O O
the O O
downregulation O O
of O O
pol B-protein B-protein
eta I-protein I-protein
. O O

Molecular O O
mechanism O O
of O O
cell O O
cycle O O
progression O O
induced O O
by O O
the O O
oncogene B-protein B-protein
product I-protein I-protein
Tax I-protein B-protein
of O O
human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
. O O

The O O
trans-activator B-protein B-protein
protein I-protein I-protein
Tax I-protein I-protein
of O O
human O O
T-cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV-I O O
) O O
plays O O
an O O
important O O
role O O
in O O
the O O
development O O
of O O
adult O O
T-cell O O
leukemia O O
through O O
, O O
at O O
least O O
in O O
part O O
, O O
its O O
ability O O
to O O
stimulate O O
cell O O
growth O O
. O O

We O O
previously O O
reported O O
that O O
Tax B-protein B-protein
induced O O
cell O O
cycle O O
progression O O
from O O
G0/G1 O O
phase O O
to O O
S O O
and O O
G2/M O O
phases O O
in O O
human B-cell_line B-cell_line
T-cell I-cell_line I-cell_line
line I-cell_line I-cell_line
Kit I-cell_line I-cell_line
225 I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

To O O
elucidate O O
molecular O O
mechanism O O
of O O
Tax B-protein B-protein
-induced O O
cell O O
cycle O O
progression O O
, O O
we O O
systematically O O
examined O O
the O O
effects O O
of O O
Tax B-protein B-protein
on O O
biochemical O O
events O O
associated O O
with O O
cell O O
cycle O O
progression O O
. O O

Introduction O O
of O O
Tax B-protein B-protein
into O O
resting B-cell_line B-cell_line
Kit I-cell_line I-cell_line
225 I-cell_line I-cell_line
cells I-cell_line I-cell_line
induced O O
activation O O
of O O
the O O
G1/S O O
transition O O
regulation O O
cascade O O
consisting O O
of O O
activation O O
of O O
cyclin B-protein B-protein
dependent I-protein I-protein
kinase I-protein I-protein
2 I-protein I-protein
( O O
CDK2 B-protein B-protein
) O O
and O O
CDK4 B-protein B-protein
, O O
phosphorylation O O
of O O
the O O
Rb B-protein B-protein
family I-protein I-protein
proteins I-protein I-protein
and O O
an O O
increase O O
in O O
free O O
E2F B-protein B-protein
. O O

The O O
kinase O O
activation O O
was O O
found O O
to O O
result O O
from O O
Tax B-protein B-protein
-induced O O
expression O O
of O O
genes O O
for O O
cell B-protein O
cycle I-protein O
regulatory I-protein B-protein
molecules I-protein I-protein
including O O
cyclin B-protein B-protein
D2 I-protein I-protein
, O O
cyclin B-protein B-protein
E I-protein I-protein
, O O
E2F1 B-protein B-protein
, O O
CDK2 B-protein B-protein
, O O
CDK4 B-protein B-protein
and O O
CDK6 B-protein B-protein
, O O
and O O
Tax B-protein B-protein
-induced O O
reduction O O
of O O
CDK B-protein B-protein
inhibitors I-protein I-protein
p19 I-protein B-protein
( O I-protein
INK4d B-protein I-protein
) O I-protein
and O O
p27 B-protein B-protein
( I-protein I-protein
Kip1 I-protein I-protein
) I-protein I-protein
. O O

These O O
modulations O O
by O O
Tax B-protein B-protein
always O O
paralleled O O
the O O
ability O O
of O O
Tax B-protein B-protein
to O O
activate O O
the O O
NF-kappaB O B-protein
transcription O O
pathway O O
. O O

These O O
results O O
indicate O O
the O O
important O O
role O O
of O O
Tax B-protein B-protein
-mediated O O
trans-activation O O
of O O
the O O
genes O O
for O O
cell B-protein B-protein
cycle I-protein I-protein
regulatory I-protein I-protein
molecules I-protein I-protein
in O O
Tax B-protein B-protein
-induced O O
cell O O
cycle O O
progression O O
. O O

Cot B-protein B-protein
kinase I-protein I-protein
induces O O
cyclooxygenase-2 O B-protein
expression O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
through O O
activation O O
of O O
the O O
nuclear B-protein B-protein
factor I-protein I-protein
of I-protein I-protein
activated I-protein I-protein
T I-protein I-protein
cells I-protein I-protein
. O O

Cyclooxygenase-2 B-protein B-protein
( O O
COX-2 B-protein B-protein
) O O
is O O
induced O O
in O O
human B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
upon O O
T B-protein B-protein
cell I-protein I-protein
receptor I-protein I-protein
triggering O O
. O O

Here O O
we O O
report O O
that O O
Cot B-protein B-protein
kinase I-protein I-protein
, O O
a O O
mitogen-activated B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
kinase I-protein I-protein
kinase I-protein I-protein
involved O O
in O O
T O O
cell O O
activation O O
, O O
up-regulates O O
COX-2 B-DNA B-DNA
gene I-DNA I-DNA
expression O O
in O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Induction O O
of O O
COX-2 O B-DNA
promoter O I-DNA
activity O O
by O O
Cot B-protein B-protein
kinase I-protein I-protein
occurred O O
mainly O O
through O O
activation O O
of O O
the O O
nuclear B-protein B-protein
factor I-protein I-protein
of I-protein I-protein
activated I-protein I-protein
T I-protein I-protein
cells I-protein I-protein
( O O
NFAT B-protein B-protein
) O O
. O O

Mutation O O
of O O
the O O
distal B-DNA O
( I-DNA O
-105/-97 I-DNA O
) I-DNA O
and O O
proximal B-DNA B-DNA
( I-DNA I-DNA
-76/-61 I-DNA I-DNA
) I-DNA I-DNA
NFAT B-DNA I-DNA
response I-DNA I-DNA
elements I-DNA I-DNA
in O O
the O O
COX-2 B-DNA B-DNA
promoter I-DNA I-DNA
abolished O O
the O O
activation O O
induced O O
by O O
Cot B-protein B-protein
kinase I-protein I-protein
. O O

Even O O
more O O
, O O
coexpression O O
of O O
a O O
dominant O O
negative O O
version O O
of O O
NFAT B-protein B-protein
inhibited O O
Cot B-protein B-protein
kinase I-protein I-protein
-mediated O O
COX-2 B-DNA B-DNA
promoter I-DNA I-DNA
activation O O
, O O
whereas O O
cotransfection O O
of O O
a O O
constitutively O O
active O O
version O O
of O O
the O O
calcium-dependent B-protein B-protein
phosphatase I-protein I-protein
calcineurin I-protein B-protein
synergizes O O
with O O
Cot B-protein B-protein
kinase I-protein I-protein
in O O
the O O
up-regulation O O
of O O
COX-2 B-DNA B-DNA
promoter I-DNA I-DNA
-driven O O
transcription O O
. O O

Strikingly O O
, O O
Cot B-protein B-protein
kinase I-protein I-protein
increased O O
transactivation O O
mediated O O
by O O
a O O
GAL4-NFAT B-protein B-protein
fusion I-protein I-protein
protein I-protein I-protein
containing O O
the O O
N-terminal B-protein B-protein
transactivation I-protein I-protein
domain I-protein I-protein
of O O
NFATp B-protein B-protein
. O O

In O O
contrast O O
to O O
phorbol O O
ester O O
plus O O
calcium O O
ionophore O O
A23187 O O
, O O
Cot B-protein B-protein
kinase I-protein I-protein
increases O O
both O O
COX-2 B-DNA B-DNA
promoter I-DNA I-DNA
activity O O
and O O
NFAT B-protein B-protein
-mediated O O
transactivation O O
in O O
a O O
cyclosporin O O
A-independent O O
manner O O
. O O

These O O
data O O
indicate O O
that O O
Cot B-protein B-protein
kinase I-protein I-protein
up-regulates O O
COX-2 B-DNA B-DNA
promoter I-DNA I-DNA
-driven O O
transcription O O
through O O
the O O
NFAT B-DNA B-DNA
response I-DNA I-DNA
elements I-DNA I-DNA
, O O
being O O
the O O
Cot B-protein B-protein
kinase I-protein I-protein
-induced O O
NFAT B-protein B-protein
-dependent O O
transactivation O O
presumably O O
implicated O O
in O O
this O O
up-regulation O O
. O O

Positive O O
and O O
negative O O
roles O O
of O O
the O O
trans-acting B-protein B-protein
T I-protein I-protein
cell I-protein I-protein
factor-1 I-protein I-protein
for O O
the O O
acquisition O O
of O O
distinct O O
Ly-49 B-protein B-protein
MHC I-protein I-protein
class I-protein I-protein
I I-protein I-protein
receptors I-protein I-protein
by O O
NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Members O O
of O O
the O O
Ly-49 B-DNA B-protein
gene I-DNA I-protein
family I-DNA I-protein
code O O
for O O
class B-protein B-protein
I I-protein I-protein
MHC-specific I-protein I-protein
receptors I-protein I-protein
that O O
regulate O O
NK O O
cell O O
function O O
. O O

Due O O
to O O
a O O
combinatorial O O
distribution O O
of O O
Ly-49 B-protein B-protein
receptors I-protein I-protein
, O O
NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
display O O
considerable O O
clonal O O
heterogeneity O O
. O O

The O O
acquisition O O
of O O
one O O
Ly-49 B-protein B-protein
receptor I-protein I-protein
, O O
Ly-49A B-protein B-protein
is O O
strictly O O
dependent O O
on O O
the O O
transcriptional B-protein B-protein
trans-acting I-protein I-protein
factor I-protein I-protein
T B-protein I-protein
cell-specific I-protein I-protein
factor-1 I-protein I-protein
( O O
TCF-1 B-protein B-protein
) O O
. O O

Indeed O O
, O O
TCF-1 B-protein B-protein
binds O O
to O O
two O O
sites O O
in O O
the O O
Ly-49a B-DNA B-DNA
promoter I-DNA I-DNA
and O O
regulates O O
its O O
activity O O
, O O
suggesting O O
that O O
the O O
Ly-49a B-DNA B-DNA
gene I-DNA I-DNA
is O O
a O O
direct O O
TCF-1 B-protein B-protein
target O O
. O O

TCF-1 B-protein B-protein
deficiency O O
resulted O O
in O O
the O O
altered O O
usage O O
of O O
additional O O
Ly-49 B-protein B-protein
receptors I-protein I-protein
. O O

We O O
show O O
in O O
this O O
study O O
, O O
using O O
TCF-1 B-protein B-protein
beta I-protein I-protein
( I-protein I-protein
2 I-protein I-protein
) I-protein I-protein
-microglobulin I-protein I-protein
double-deficient O O
mice O O
, O O
that O O
these O O
repertoire O O
alterations O O
are O O
not O O
due O O
to O O
Ly-49/MHC O O
class O O
I O O
interactions O O
. O O

Our O O
findings O O
rather O O
suggest O O
a O O
TCF-1 B-protein B-protein
-dependent O O
, O O
cell O O
autonomous O O
effect O O
on O O
the O O
acquisition O O
of O O
multiple O O
Ly-49 B-protein B-protein
receptors I-protein I-protein
. O O

Besides O O
reduced O O
receptor O O
usage O O
( O O
Ly-49A B-protein B-protein
and I-protein I-protein
D I-protein I-protein
) O O
, O O
we O O
also O O
observed O O
no O O
effect O O
( O O
Ly-49C B-protein O
) O O
and O O
significantly O O
expanded O O
( O O
Ly-49G B-protein B-protein
and I-protein I-protein
I I-protein I-protein
) O I-protein
receptor O I-protein
usage O O
in O O
the O O
absence O O
of O O
TCF-1 B-protein B-protein
. O O

These O O
effects O O
did O O
not O O
in O O
all O O
cases O O
correlate O O
with O O
the O O
presence O O
of O O
TCF B-DNA B-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
in O O
the O O
respective O O
proximal B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Therefore O O
, O O
besides O O
TCF-1 B-protein B-protein
binding O O
to O O
the O O
proximal B-DNA B-DNA
promoter I-DNA I-DNA
, O O
Ly-49 O B-protein
acquisition O O
may O O
also O O
be O O
regulated O O
by O O
TCF-1 B-protein B-protein
binding O O
to O O
more O O
distant O O
cis-acting B-DNA B-DNA
elements I-DNA I-DNA
and/or O O
by O O
regulating O O
the O O
expression O O
of O O
additional O O
trans-acting B-DNA B-protein
factors I-DNA I-protein
. O O

Consistent O O
with O O
the O O
observed O O
differential O O
, O O
positive O O
or O O
negative O O
role O O
of O O
TCF-1 B-protein B-protein
for O O
Ly-49 B-protein B-protein
receptor I-protein I-protein
acquisition O O
, O O
reporter O B-DNA
gene O I-DNA
assays O O
revealed O O
the O O
presence O O
of O O
an O O
inducing O O
as O O
well O O
as O O
a O O
repressing O O
TCF B-DNA B-DNA
site I-DNA I-DNA
in O O
certain O O
proximal O B-DNA
Ly-49 B-DNA I-DNA
promoters I-DNA I-DNA
. O O

These O O
findings O O
reveal O O
an O O
important O O
role O O
of O O
TCF-1 B-protein B-protein
for O O
the O O
formation O O
of O O
the O O
NK B-protein B-protein
cell I-protein I-protein
receptor I-protein I-protein
repertoire O I-protein
. O O

Ligation O O
of O O
CD11b B-protein B-protein
and O I-protein
CD11c B-protein I-protein
beta I-protein I-protein
( I-protein I-protein
2 I-protein I-protein
) I-protein I-protein
integrins B-protein I-protein
by O O
antibodies B-protein O
or O O
soluble B-protein O
CD23 I-protein B-protein
induces O O
macrophage B-protein B-protein
inflammatory I-protein I-protein
protein I-protein I-protein
1alpha I-protein I-protein
( O O
MIP-1alpha B-protein B-protein
) O O
and O O
MIP-1beta B-protein B-protein
production O O
in O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
through O O
a O O
pathway O O
dependent O O
on O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
. O O

Chemokines B-protein B-protein
and O O
adhesion B-protein B-protein
molecules I-protein I-protein
such O O
as O O
integrins B-protein B-protein
play O O
a O O
major O O
part O O
in O O
the O O
trafficking O O
, O O
extravasation O O
, O O
and O O
recruitment O O
of O O
leukocytes B-cell_type B-cell_type
to O O
inflammatory O O
sites O O
. O O

This O O
study O O
investigated O O
the O O
effects O O
of O O
beta O B-protein
( O I-protein
2 O I-protein
) O I-protein
integrin O I-protein
engagement O O
on O O
chemokine O B-protein
production O O
by O O
freshly B-cell_type O
isolated I-cell_type O
human I-cell_type B-cell_type
monocytes I-cell_type I-cell_type
. O O

We O O
found O O
that O O
ligation O O
of O O
CD11b B-protein B-protein
or O O
CD11c B-protein B-protein
but O O
not O O
CD11a B-protein B-protein
alpha I-protein I-protein
chains I-protein I-protein
of O I-protein
beta B-protein I-protein
( I-protein I-protein
2 I-protein I-protein
) I-protein I-protein
integrins I-protein I-protein
by O O
antibodies B-protein B-protein
or O O
soluble B-protein O
CD23 I-protein B-protein
( I-protein O
sCD23 I-protein B-protein
) I-protein I-protein
fusion I-protein I-protein
proteins I-protein I-protein
rapidly O O
induced O O
transcription O O
and O O
secretion O O
of O O
interleukin B-protein B-protein
8 I-protein I-protein
, O O
macrophage B-protein B-protein
inflammatory I-protein I-protein
protein I-protein I-protein
( I-protein I-protein
MIP I-protein I-protein
) I-protein I-protein
1alpha I-protein I-protein
, O O
and O O
MIP-1beta B-protein B-protein
. O O

Because O O
the O O
promoters B-DNA B-DNA
of O O
these O O
chemokine B-DNA B-DNA
genes I-DNA I-DNA
contain O O
kappaB B-DNA B-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
, O O
we O O
assessed O O
the O O
possible O O
role O O
of O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
( O O
NF-kappaB B-protein B-protein
) O O
in O O
controlling O O
induction O O
of O O
the O O
genes O O
through O O
beta O B-protein
( O I-protein
2 O I-protein
) O I-protein
integrin O I-protein
engagement O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
showed O O
that O O
sCD23 B-protein B-protein
or O O
antibodies B-protein O
to O O
CD11b B-protein B-protein
or O O
to O O
CD11c B-protein B-protein
up-regulated O O
DNA-binding O O
activity O O
of O O
NF-kappaB B-protein B-protein
. O O

Activation O O
of O O
NF-kappaB B-protein B-protein
was O O
accompanied O O
by O O
degradation O O
of O O
its O O
cytosolic B-protein B-protein
inhibitor I-protein I-protein
IkappaB-alpha I-protein B-protein
. O O

Blockade O O
of O O
depletion O O
of O O
IkappaB-alpha B-protein B-protein
by O O
proteasome O O
inhibitors O O
( O O
proteasome O O
inhibitor O O
I O O
or O O
acetyl-leucinyl-leucinyl-norleucinal O O
) O O
led O O
to O O
concomitant O O
inhibition O O
of O O
NF-kappaB O B-protein
DNA-binding O O
activity O O
and O O
expression O O
of O O
MIP-1alpha B-RNA B-protein
and I-RNA O
MIP-1beta I-RNA B-RNA
messenger I-RNA I-RNA
RNA I-RNA I-RNA
induced O O
by O O
beta O B-protein
( O I-protein
2 O I-protein
) O I-protein
integrin O I-protein
ligation O O
. O O

These O O
results O O
suggest O O
that O O
triggering O O
of O O
CD11b B-protein B-protein
or O O
CD11c B-protein B-protein
beta I-protein I-protein
( I-protein I-protein
2 I-protein I-protein
) I-protein I-protein
integrin O I-protein
on O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
provides O O
activation O O
signals O O
leading O O
to O O
nuclear O O
translocation O O
of O O
NF-kappaB B-protein B-protein
and O O
subsequent O O
secretion O O
of O O
MIP-1alpha B-protein B-protein
and O O
MIP-1beta B-protein B-protein
that O O
may O O
have O O
an O O
important O O
role O O
in O O
recruitment O O
of O O
other O O
inflammatory B-cell_type B-cell_type
cells I-cell_type I-cell_type
during O O
initiation O O
of O O
an O O
inflammatory O B-cell_type
response O I-cell_type

Synergistic O O
transcriptional O O
activation O O
of O O
human B-DNA O
Acyl-coenzyme I-DNA O
A I-DNA O
: I-DNA O
cholesterol I-DNA B-DNA
acyltransterase-1 I-DNA I-DNA
gene I-DNA I-DNA
by O O
interferon-gamma B-protein B-protein
and O O
all-trans-retinoic O B-cell_line
acid O I-cell_line
THP-1 B-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

Acyl-coenzyme B-protein B-protein
A I-protein I-protein
: I-protein O
cholesterol I-protein B-protein
acyltransferase I-protein I-protein
( O O
ACAT B-protein O
) O O
is O O
an O O
intracellular B-protein B-protein
enzyme I-protein I-protein
involved O O
in O O
cellular O O
cholesterol O O
homeostasis O O
and O O
in O O
atherosclerotic O O
foam O O
cell O O
formation O O
. O O

Human B-DNA B-DNA
ACAT-1 I-DNA I-DNA
gene I-DNA I-DNA
contains O O
two O O
promoters B-DNA B-DNA
( O O
P1 B-DNA B-DNA
and O O
P7 B-DNA O
) O O
, O O
each O O
located O O
in O O
a O O
different O O
chromosome B-DNA B-DNA
( I-DNA O
1 I-DNA O
and I-DNA O
7 I-DNA O
) I-DNA O
( O O
Li O O
, O O
B. O O
L. O O
, O O
Li O O
, O O
X. O O
L. O O
, O O
Duan O O
, O O
Z. O O
J. O O
, O O
Lee O O
, O O
O. O O
, O O
Lin O O
, O O
S. O O
, O O
Ma O O
, O O
Z. O O
M. O O
, O O
Chang O O
, O O
C. O O
C. O O
, O O
Yang O O
, O O
X. O O
Y. O O
, O O
Park O O
, O O
J. O O
P. O O
, O O
Mohandas O O
, O O
T. O O
K. O O
, O O
Noll O O
, O O
W. O O
, O O
Chan O O
, O O
L. O O
, O O
and O O
Chang O O
, O O
T. O O
Y. O O
( O O
1999 O O
) O O
J. O O
Biol O O
Chem. O O
274 O O
, O O
11060-11071 O O
) O O
. O O

Interferon-gamma B-protein B-protein
( O O
IFN-gamma B-protein B-protein
) O O
, O O
a O O
cytokine B-protein B-protein
that O O
exerts O O
many O O
pro-atherosclerotic O O
effects O O
in O O
vivo O O
, O O
causes O O
up-regulation O O
of O O
ACAT-1 B-RNA B-RNA
mRNA I-RNA I-RNA
in O O
human B-cell_type B-cell_type
blood I-cell_type I-cell_type
monocyte-derived I-cell_type I-cell_type
macrophages I-cell_type I-cell_type
and O O
macrophage-like B-cell_type B-cell_type
cells I-cell_type I-cell_type
but O O
not O O
in O O
other O O
cell O O
types O O
. O O

To O O
examine O O
the O O
molecular O O
nature O O
of O O
this O O
observation O O
, O O
we O O
identified O O
within O O
the O O
ACAT-1 B-DNA B-DNA
P1 I-DNA I-DNA
promoter I-DNA I-DNA
a O O
159-base B-DNA B-DNA
pair I-DNA I-DNA
core I-DNA I-DNA
region I-DNA I-DNA
. O O

This O O
region O O
contains O O
4 O B-DNA
Sp1 B-DNA I-DNA
elements I-DNA I-DNA
and O O
an O O
IFN-gamma B-DNA B-DNA
activated I-DNA I-DNA
sequence I-DNA I-DNA
( O O
GAS B-DNA B-DNA
) O O
that O O
overlaps O O
with O O
the O O
second O O
Sp1 B-DNA B-DNA
element I-DNA I-DNA
. O O

In O O
the O O
monocytic B-cell_type B-cell_line
cell I-cell_type I-cell_line
line I-cell_type I-cell_line
THP-1 I-cell_type B-cell_line
cell I-cell_type I-cell_line
, O O
the O O
combination O O
of O O
IFN-gamma B-protein B-protein
and O O
all-trans-retinoic O O
acid O O
( O O
a O O
known O O
differentiation O O
agent O O
) O O
enhances O O
the O O
ACAT-1 B-DNA B-DNA
P1 I-DNA I-DNA
promoter I-DNA I-DNA
but O O
not O O
the O O
P7 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Additional O O
experiments O O
showed O O
that O O
all-trans-retinoic O O
acid O O
causes O O
large O O
induction O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
STAT1 I-protein B-protein
, O O
while O O
IFN-gamma B-protein B-protein
causes O O
activation O O
of O O
STAT1 B-protein B-protein
such O O
that O O
it O O
binds O O
to O O
the O O
GAS/Sp1 B-DNA B-DNA
site I-DNA I-DNA
in O O
the O O
ACAT-1 B-DNA B-DNA
P1 I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Our O O
work O O
provides O O
a O O
molecular O O
mechanism O O
to O O
account O O
for O O
the O O
effect O O
of O O
IFN-gamma B-protein B-protein
in O O
causing O O
transcriptional O O
activation O O
of O O
ACAT-1 B-protein B-protein
in O O
macrophage-like B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Inhaled O O
nitric O O
oxide O O
down-regulates O O
intrapulmonary O O
nitric O O
oxide O O
production O O
in O O
lipopolysaccharide-induced O O
acute O O
lung O O
injury O O
. O O

OBJECTIVE O O
: O O
To O O
examine O O
whether O O
inhaled O O
nitric O O
oxide O O
( O O
NO O O
) O O
affected O O
the O O
intrapulmonary O O
production O O
of O O
NO O O
, O O
reactive O O
oxygen O O
species O O
, O O
and O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
in O O
a O O
lipopolysaccharide O O
( O O
LPS O O
) O O
-induced O O
model O O
of O O
acute O O
lung O O
injury O O
. O O

DESIGN O O
: O O
Prospective O O
, O O
randomized O O
, O O
laboratory O O
study O O
. O O

SETTING O O
: O O
Experimental O O
laboratory O O
at O O
a O O
biomedical O O
institute O O
. O O

SUBJECTS O O
: O O
Twenty O O
male O O
rabbits O O
weighing O O
2.5-3.5 O O
kg O O
. O O

INTERVENTIONS O O
: O O
Saline O O
or O O
LPS O O
( O O
5 O O
mg/kg O O
of O O
body O O
weight O O
) O O
was O O
administered O O
intravenously O O
with O O
or O O
without O O
NO O O
inhalation O O
( O O
10 O O
ppm O O
) O O
in O O
each O O
group O O
of O O
five O O
rabbits O O
. O O

MEASUREMENTS O O
AND O O
MAIN O O
RESULTS O O
: O O
LPS O O
increased O O
the O O
lung O O
leak O O
index O O
, O O
the O O
neutrophils B-cell_type B-cell_type
and O O
NO O O
levels O O
in O O
bronchoalveolar O O
lavage O O
fluid O O
, O O
and O O
NO O O
levels O O
produced O O
by O O
resting O O
and O O
stimulated O B-cell_type
alveolar B-cell_type I-cell_type
macrophages I-cell_type I-cell_type
. O O

Inhaled O O
NO O O
decreased O O
the O O
lung O O
leak O O
index O O
, O O
the O O
neutrophils B-cell_type B-cell_type
and O O
NO O O
levels O O
as O O
measured O O
by O O
nitrite O O
levels O O
in O O
the O O
lavage O O
fluid O O
, O O
and O O
NO O O
produced O O
by O O
the O O
resting O O
and O O
stimulated O B-cell_type
alveolar B-cell_type I-cell_type
macrophages I-cell_type I-cell_type
. O O

Inhaled O O
NO O O
also O O
blocked O O
the O O
activities O O
of O O
reactive O O
oxygen O O
species O O
and O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
binding O O
to O O
DNA O O
in O O
lavage B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
in O O
alveolar B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
. O O

CONCLUSION O O
: O O
Inhaled O O
NO O O
attenuates O O
LPS-induced O O
acute O O
lung O O
injury O O
, O O
possibly O O
by O O
decreasing O O
NO O O
production O O
in O O
the O O
lungs O O
. O O

The O O
mechanism O O
of O O
reducing O O
NO O O
production O O
resulting O O
from O O
inhaled O O
NO O O
may O O
involve O O
, O O
in O O
part O O
, O O
the O O
activities O O
of O O
reactive O O
oxygen O O
species O O
and/or O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
. O O

Treatment O O
of O O
allergic O O
airway O O
inflammation O O
and O O
hyperresponsiveness O O
by O O
antisense-induced O O
local O O
blockade O O
of O O
GATA-3 B-DNA B-protein
expression O O
. O O

Recent O O
studies O O
in O O
transgenic O O
mice O O
have O O
revealed O O
that O O
expression O O
of O O
a O O
dominant O O
negative O O
form O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
GATA-3 I-protein B-protein
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
can O O
prevent O O
T B-cell_type B-cell_type
helper I-cell_type I-cell_type
cell I-cell_type I-cell_type
type I-cell_type I-cell_type
2 I-cell_type I-cell_type
( O O
Th2 B-cell_type O
) O O
-mediated O O
allergic O O
airway O O
inflammation O O
in O O
mice O O
. O O

However O O
, O O
it O O
remains O O
unclear O O
whether O O
GATA-3 B-protein B-protein
plays O O
a O O
role O O
in O O
the O O
effector O O
phase O O
of O O
allergic O O
airway O O
inflammation O O
and O O
whether O O
antagonizing O O
the O O
expression O O
and/or O O
function O O
of O O
GATA-3 B-DNA B-protein
can O O
be O O
used O O
for O O
the O O
therapy O O
of O O
allergic O O
airway O O
inflammation O O
and O O
hyperresponsiveness O O
. O O

Here O O
, O O
we O O
analyzed O O
the O O
effects O O
of O O
locally O O
antagonizing O O
GATA-3 B-protein B-protein
function O O
in O O
a O O
murine O O
model O O
of O O
asthma O O
. O O

We O O
could O O
suppress O O
GATA-3 O B-protein
expression O O
in O O
interleukin B-protein B-protein
( I-protein I-cell_line
IL I-protein I-cell_line
) I-protein I-cell_line
-4 I-protein I-cell_line
-producing O I-cell_line
T B-cell_type I-cell_line
cells I-cell_type I-cell_line
in O O
vitro O O
and O O
in O O
vivo O O
by O O
an O O
antisense O B-DNA
phosphorothioate O I-DNA
oligonucleotide O I-DNA
overlapping O O
the O O
translation B-DNA B-DNA
start I-DNA I-DNA
site I-DNA I-DNA
of O O
GATA-3 B-DNA B-protein
, O O
whereas O O
nonsense O O
control O O
oligonucleotides O O
were O O
virtually O O
inactive O O
. O O

In O O
a O O
murine O O
model O O
of O O
asthma O O
associated O O
with O O
allergic O O
pulmonary O O
inflammation O O
and O O
hyperresponsiveness O O
in O O
ovalbumin O O
( O O
OVA O O
) O O
-sensitized O O
mice O O
, O O
local O O
intranasal O O
administration O O
of O O
fluorescein O O
isothiocyanate-labeled O O
GATA-3 O B-protein
antisense O O
oligonucleotides O O
led O O
to O O
DNA O O
uptake O O
in O O
lung B-cell_type B-cell_type
cells I-cell_type I-cell_type
associated O O
with O O
a O O
reduction O O
of O O
intracellular O O
GATA-3 O B-protein
expression O O
. O O

Such O O
intrapulmonary O O
blockade O O
of O O
GATA-3 O B-protein
expression O O
caused O O
an O O
abrogation O O
of O O
signs O O
of O O
lung O O
inflammation O O
including O O
infiltration O O
of O O
eosinophils B-cell_type B-cell_type
and O O
Th2 B-cell_type B-cell_type
cytokine O B-protein
production O O
. O O

Furthermore O O
, O O
treatment O O
with O O
antisense O O
but O O
not O O
nonsense O O
oligonucleotides O O
induced O O
a O O
significant O O
reduction O O
of O O
airway O O
hyperresponsiveness O O
in O O
OVA-sensitized O O
mice O O
to O O
levels O O
comparable O O
to O O
saline-treated O O
control O O
mice O O
, O O
as O O
assessed O O
by O O
both O O
enhanced O O
pause O O
( O O
PenH O O
) O O
responses O O
and O O
pulmonary O O
resistance O O
determined O O
by O O
body O O
plethysmography O O
. O O

These O O
data O O
indicate O O
a O O
critical O O
role O O
for O O
GATA-3 B-DNA B-protein
in O O
the O O
effector O O
phase O O
of O O
a O O
murine O O
asthma O O
model O O
and O O
suggest O O
that O O
local O O
delivery O O
of O O
GATA-3 O B-protein
antisense O O
oligonucleotides O O
may O O
be O O
a O O
novel O O
approach O O
for O O
the O O
treatment O O
of O O
airway O O
hyperresponsiveness O O
such O O
as O O
in O O
asthma O O
. O O

This O O
approach O O
has O O
the O O
potential O O
advantage O O
of O O
suppressing O O
the O O
expression O O
of O O
various O O
proinflammatory B-protein O
Th2 I-protein B-protein
cytokines I-protein B-protein
simultaneously O O
rather O O
than O O
suppressing O O
the O O
activity O O
of O O
a O O
single O O
cytokine B-protein B-protein
. O O

T O O
helper-cell O O
phenotype O O
regulates O O
atherosclerosis O O
in O O
mice O O
under O O
conditions O O
of O O
mild O O
hypercholesterolemia O O
. O O

BACKGROUND O O
: O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
are O O
implicated O O
in O O
atherosclerosis O O
, O O
but O O
little O O
is O O
known O O
about O O
the O O
genetic O O
control O O
or O O
molecular O O
pathways O O
, O O
especially O O
under O O
conditions O O
of O O
mild O O
hypercholesterolemia O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
BALB/c O O
mice O O
, O O
making O O
a O O
CD4+ O B-cell_type
Th2 O I-cell_type
( O O
IL-4+ O O
) O O
cell O O
response O O
, O O
express O O
both O O
MHC B-protein B-protein
class I-protein I-protein
II I-protein I-protein
antigens I-protein I-protein
( O O
IA B-protein O
( I-protein O
d I-protein O
) I-protein O
, O O
IE B-protein O
( I-protein O
d I-protein O
) I-protein O
) O O
and O O
are O O
atherosclerosis-resistant O O
. O O

C57Bl/6 O O
mice O O
produce O O
a O O
CD4+ O B-cell_type
Th1 O I-cell_type
( O O
interferon O B-protein
[ O O
IFN O B-protein
] O I-protein
gamma+ O I-protein
) O I-protein
response O O
, O O
express O O
IA B-protein B-protein
( I-protein I-protein
b I-protein I-protein
) I-protein I-protein
but O O
no O O
IE B-protein O
, O O
and O O
are O O
atherosclerosis-prone O O
. O O

To O O
evaluate O O
T O O
helper-cell O O
phenotype O O
in O O
fatty O O
streak O O
formation O O
, O O
wild-type O O
C57Bl/6 O O
mice O O
( O O
IA O O
( O O
b O O
) O O
+IE- O O
) O O
and O O
transgenic O O
mice O O
, O O
either O O
AB O O
( O O
o O O
) O O
, O O
IA O B-protein
( O I-protein
b O I-protein
) O I-protein
-IE- O I-protein
; O I-protein
ABEalpha O I-protein
, O I-protein
IA-IE O I-protein
( O I-protein
k O I-protein
) O I-protein
+ O O
; O O
or O O
BL O O
: O O
TG O O
: O O
Ealpha O B-protein
, O I-protein
IA O I-protein
( O I-protein
b O I-protein
) O I-protein
+IE O I-protein
( O I-protein
k O I-protein
) O I-protein
+ O O
, O O
were O O
fed O O
a O O
high-cholesterol O O
diet O O
for O O
16 O O
weeks O O
and O O
evaluated O O
histomorphometrically O O
for O O
aortic O O
lesions O O
. O O

Lesion O O
size O O
in O O
AB O O
( O O
o O O
) O O
, O O
ABEalpha O B-protein
, O O
and O O
BL O O
: O O
TG O O
: O O
Ealpha O O
strains O O
was O O
decreased O O
by O O
54 O O
% O O
, O O
79 O O
% O O
, O O
and O O
82 O O
% O O
, O O
respectively O O
, O O
compared O O
with O O
wild-type O O
, O O
correlating O O
with O O
decreased O O
Th1 B-cell_type O
and O O
increased O O
Th2 B-cell_type O
expression O O
and O O
suggesting O O
that O O
T O O
helper-cell O O
phenotype O O
is O O
important O O
in O O
fatty O O
lesion O O
development O O
. O O

Decreasing O O
Th1 B-cell_type B-cell_type
cells I-cell_type I-cell_type
by O O
antibodies B-protein B-protein
( O O
alpha-CD4 B-protein B-protein
) O O
or O O
cytokines B-protein B-protein
( O O
IL-4 B-protein B-protein
) O O
also O O
caused O O
> O O
/=80 O O
% O O
reductions O O
in O O
lesion O O
size O O
. O O

Immunohistology O O
revealed O O
IFN-gamma B-protein B-protein
, O O
but O O
not O O
IL-4 B-protein B-protein
, O O
colocalized O O
with O O
activated O B-cell_type
macrophages B-cell_type I-cell_type
. O O

Confirming O O
these O O
findings O O
in O O
a O O
different O O
mouse O O
strain O O
, O O
BALB/c O B-protein
Stat O I-protein
6 O I-protein
knockout O O
mice O O
( O O
Th2 O O
cell-deficient O O
) O O
developed O O
aortic O O
lesions O O
comparable O O
to O O
C57Bl/6 O O
mice O O
on O O
the O O
same O O
diet O O
. O O

CONCLUSIONS O O
: O O
In O O
mildly O O
hypercholesterolemic O O
C57Bl/6 O O
mice O O
, O O
presence O O
of O O
IA B-protein O
( I-protein O
b I-protein O
) I-protein O
and O O
absence O O
of O O
IE B-protein O
regulated O O
CD4+ O B-cell_type
T O I-cell_type
helper-cell O I-cell_type
phenotype O I-cell_type
; O O
fatty O O
lesions O O
were O O
proportional O O
to O O
IFNgamma+ B-cell_type B-cell_type
Th1 I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
both O O
C57Bl/6 O O
and O O
BALB/c O O
strains O O
. O O

IFN-gamma B-protein B-protein
may O O
participate O O
through O O
macrophage O O
activation O O
, O O
whereas O O
IL-4 B-protein B-protein
may O O
act O O
to O O
limit O O
Th1-cell O O
response O O
. O O

Requirement O O
for O O
p38 B-protein B-protein
and O O
p44/p42 B-protein B-protein
mitogen-activated B-protein I-protein
protein I-protein I-protein
kinases I-protein I-protein
in O O
RAGE B-protein B-protein
-mediated O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
transcriptional O O
activation O O
and O O
cytokine O B-protein
secretion O O
. O O

Advanced O B-protein
glycation O I-protein
end O I-protein
product O I-protein
( O O
AGE O O
) O O
activation O O
of O O
the O O
signal-transducing B-protein B-protein
receptor I-protein I-protein
for I-protein O
AGE I-protein B-protein
( O O
RAGE B-protein B-protein
) O O
has O O
been O O
linked O O
to O O
a O O
proinflammatory O O
phenotypic O O
change O O
within O O
cells O O
. O O

However O O
, O O
the O O
precise O O
intracellular O O
signaling O O
pathways O O
involved O O
have O O
not O O
been O O
elucidated O O
. O O

We O O
demonstrate O O
here O O
that O O
human O B-protein
serum O I-protein
albumin O I-protein
modified O O
with O O
N O O
( O O
varepsilon O O
) O O
- O O
( O O
carboxymethyl O O
) O O
lysine O O
( O O
CML O O
) O O
, O O
a O O
major O O
AGE O O
adduct O O
that O O
progressively O O
accumulates O O
with O O
aging O O
, O O
diabetes O O
, O O
and O O
renal O O
failure O O
, O O
induced O O
nuclear B-protein B-protein
factor I-protein I-protein
( I-protein I-protein
NF I-protein I-protein
) I-protein I-protein
-kappaB I-protein I-protein
-driven O O
reporter O B-DNA
gene O I-DNA
expression O O
in O O
human B-cell_type B-cell_type
monocytic I-cell_type I-cell_type
THP-1 I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
NF-kappaB O B-protein
response O O
was O O
blocked O O
with O O
a O O
synthetic O O
peptide O O
corresponding O O
to O O
the O O
putative B-protein B-protein
ligand-binding I-protein I-protein
domain I-protein I-protein
of O O
RAGE B-protein B-protein
, O O
with O O
anti- O O
RAGE B-protein B-protein
antiserum O I-protein
, O O
and O O
by O O
coexpression O O
of O O
truncated B-protein B-protein
receptors I-protein I-protein
lacking O O
the O O
intracellular B-protein B-protein
domain I-protein I-protein
. O O

Signal O O
transduction O O
from O O
RAGE B-protein B-protein
to O O
NF-kappaB B-protein B-protein
involved O O
the O O
generation O O
of O O
reactive O O
oxygen O O
species O O
, O O
since O O
reporter O O
gene O O
expression O O
was O O
blocked O O
with O O
the O O
antioxidant O O
N-acetyl-L-cysteine O O
. O O

CML-modified B-protein B-protein
albumin I-protein I-protein
produced O O
rapid O O
transient O O
activation O O
of O O
tyrosine O O
phosphorylation O O
, O O
extracellular B-protein B-protein
signal-regulated I-protein I-protein
kinase I-protein I-protein
1 I-protein I-protein
and I-protein I-protein
2 I-protein I-protein
, O I-protein
and O I-protein
p38 B-protein I-protein
mitogen-activated I-protein I-protein
protein I-protein I-protein
kinase I-protein I-protein
( O O
MAPK B-protein B-protein
) O O
, O O
but O O
not O O
c-Jun B-protein B-protein
NH I-protein I-protein
( I-protein I-protein
2 I-protein I-protein
) I-protein I-protein
-terminal I-protein I-protein
kinase I-protein I-protein
. O O

RAGE B-protein B-protein
-mediated O O
NF-kappaB O B-protein
activation O O
was O O
suppressed O O
by O O
the O O
selective O O
p38 B-protein B-protein
MAPK I-protein I-protein
inhibitor O O
SB203580 O O
and O O
by O O
coexpression O O
of O O
a O O
kinase-dead O O
p38 O B-protein
dominant-negative O I-protein
mutant O I-protein
. O O

Activation O O
of O O
NF-kappaB B-protein B-protein
by O O
CML-modified B-protein B-protein
albumin I-protein I-protein
increased O O
secretion O O
of O O
proinflammatory B-protein B-protein
cytokines I-protein I-protein
( O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor-alpha I-protein I-protein
, O O
interleukin-1beta B-protein B-protein
, O O
and O O
monocyte B-protein B-protein
chemoattractant I-protein I-protein
protein-1 I-protein I-protein
) O O
severalfold O O
, O O
and O O
inhibition O O
of O O
p38 B-protein B-protein
MAPK I-protein I-protein
blocked O O
these O O
increases O O
. O O

These O O
results O O
indicate O O
that O O
p38 B-protein B-protein
MAPK I-protein B-protein
activation O O
mediates O O
RAGE B-protein B-protein
-induced O O
NF-kappaB B-protein B-protein
-dependent O O
secretion O O
of O O
proinflammatory B-protein B-protein
cytokines I-protein I-protein
and O O
suggest O O
that O O
accelerated O O
inflammation O O
may O O
be O O
a O O
consequence O O
of O O
cellular O O
activation O O
induced O O
by O O
this O O
receptor O O
. O O

Antigen-receptor O O
cross-linking O O
and O O
lipopolysaccharide O O
trigger O O
distinct O O
phosphoinositide B-protein B-protein
3-kinase I-protein I-protein
-dependent O O
pathways O O
to O O
NF-kappa O B-protein
B O I-protein
activation O O
in O O
primary B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
NF-kappaB/Rel B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
play O O
an O O
important O O
role O O
in O O
the O O
expression O O
of O O
genes O O
involved O O
in O O
B O O
cell O O
development O O
, O O
differentiation O O
and O O
function O O
. O O

Nuclear B-protein B-protein
NF-kappaB I-protein I-protein
is O O
induced O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
by O O
engagement O O
of O O
either O O
the O O
BCR B-protein B-protein
or O O
CD40 B-protein B-protein
or O O
by O O
stimulation O O
with O O
lipopolysaccharide O O
( O O
LPS O O
) O O
. O O

Despite O O
the O O
importance O O
of O O
NF-kappaB B-protein B-protein
to O O
B O O
cell O O
function O O
, O O
little O O
is O O
known O O
about O O
the O O
signaling O O
pathways O O
leading O O
to O O
NF-kappaB O B-protein
activation O O
. O O

In O O
this O O
report O O
we O O
address O O
the O O
role O O
of O O
phosphoinositide B-protein B-protein
3'-kinase I-protein I-protein
( O O
PI B-protein B-protein
3-kinase I-protein I-protein
) O O
in O O
BCR B-protein B-protein
- O O
and O O
LPS-induced O O
NF-kappaB O B-protein
activation O O
using O O
populations O O
of O O
primary B-cell_type B-cell_type
murine I-cell_type I-cell_type
resting I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Using O O
the O O
specific O O
pharmacological O O
inhibitors O O
of O O
PI B-protein B-protein
3-kinase I-protein I-protein
, O O
Wortmannin O O
and O O
LY294002 O O
, O O
we O O
demonstrate O O
that O O
PI B-protein B-protein
3-kinase I-protein I-protein
activity O O
is O O
vital O O
for O O
BCR B-protein B-protein
-induced O O
NF-kappaB B-protein B-protein
DNA-binding O O
activity O O
. O O

Furthermore O O
, O O
we O O
show O O
that O O
this O O
is O O
achieved O O
via O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
-dependent O O
degradation O O
of O O
IkappaBalpha B-protein B-protein
. O O

Similar O O
analyses O O
reveal O O
that O O
PI B-protein B-protein
3-kinase I-protein I-protein
is O O
also O O
critical O O
in O O
triggering O O
NF-kappaB B-protein B-protein
DNA-binding O O
activity O O
and O O
IkappaBalpha B-protein B-protein
degradation O O
following O O
LPS O O
stimulation O O
. O O

Interestingly O O
, O O
a O O
PKC O B-protein
inhibitor O O
which O O
blocked O O
the O O
BCR B-protein B-protein
-induced O O
IkappaBalpha B-protein B-protein
degradation O O
had O O
no O O
effect O O
on O O
the O O
degradation O O
of O O
IkappaBalpha B-protein B-protein
after O O
LPS O O
stimulation O O
. O O

Taken O O
together O O
, O O
our O O
results O O
indicate O O
the O O
involvement O O
of O O
PI B-protein B-protein
3-kinase I-protein I-protein
in O O
at O O
least O O
two O O
distinct O O
signaling O O
pathways O O
leading O O
to O O
activation O O
of O O
NF-kappaB B-protein B-protein
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Tetramer-guided O O
epitope O O
mapping O O
: O O
rapid O O
identification O O
and O O
characterization O O
of O O
immunodominant B-cell_type B-protein
CD4+ I-cell_type I-protein
T I-cell_type I-protein
cell I-cell_type I-protein
epitopes I-cell_type I-protein
from O O
complex O B-protein
antigens B-protein I-protein
. O O

T O O
cell O O
responses O O
to O O
Ags B-protein B-protein
involve O O
recognition O O
of O O
selected O O
peptide B-protein B-protein
epitopes I-protein I-protein
contained O O
within O O
the O O
antigenic B-protein B-protein
protein I-protein I-protein
. O O

In O O
this O O
report O O
, O O
we O O
describe O O
a O O
new O O
approach O O
for O O
direct O O
identification O O
of O O
CD4+ B-cell_type B-protein
T I-cell_type I-protein
cell I-cell_type I-protein
epitopes I-cell_type I-protein
of O O
complex O B-protein
Ags B-protein B-protein
that O O
uses O O
human B-protein B-protein
class I-protein I-protein
II I-protein I-protein
tetramers I-protein I-protein
to O O
identify O O
reactive O B-cell_type
cells O I-cell_type
. O O

With O O
a O O
panel O O
of O O
60 O O
overlapping O O
peptides O O
covering O O
the O O
entire O O
sequence O O
of O O
the O O
VP16 B-protein B-protein
protein I-protein I-protein
, O O
a O O
major O B-protein
Ag B-protein I-protein
for O O
HSV-2 O O
, O O
we O O
generated O O
a O O
panel O O
of O O
class B-protein B-protein
II I-protein I-protein
MHC I-protein I-protein
tetramers I-protein I-protein
loaded O O
with O O
peptide O O
pools O O
that O O
were O O
used O O
to O O
stain O B-cell_type
peripheral B-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
of O O
an O O
HSV-2 O O
infected O O
individual O O
. O O

With O O
this O O
approach O O
, O O
we O O
identified O O
four O O
new O O
DRA1*0101/DRB1*0401- O B-protein
and O O
two O O
DRA1*0101/DRB1*0404-restricted O B-protein
, O I-protein
VP16-specific B-protein I-protein
epitopes I-protein I-protein
. O O

By O O
using O O
tetramers B-protein O
to O O
sort O O
individual O B-cell_type
cells O I-cell_type
, O O
we O O
easily O O
obtained O O
a O O
large O O
number O O
of O O
clones O O
specific O O
to O O
these O O
epitopes B-protein B-protein
. O O

Although O O
DRA1*0101/DRB1*0401 O B-protein
and O O
DRA1*0101/DRB1*0404 O B-protein
are O O
structurally O O
very O O
similar O O
, O O
nonoverlapping O O
VP16 B-protein B-protein
epitopes I-protein I-protein
were O O
identified O O
, O O
illustrating O O
high O O
selectivity O O
of O O
individual O O
allele O B-DNA
polymorphisms O I-DNA
within O O
common O O
MHC O B-cell_line
variants O I-cell_line
. O O

This O O
rapid O O
approach O O
to O O
detecting O O
CD4+ B-cell_type B-protein
T I-cell_type I-protein
cell I-cell_type I-protein
epitopes I-cell_type I-protein
from O O
complex O B-protein
Ags B-protein I-protein
can O O
be O O
applied O O
to O O
any O O
known O O
Ag B-protein B-protein
that O O
gives O O
a O O
T O O
cell O O
response O O
. O O

Localized O O
pancreatic O O
NF-kappaB O B-protein
activation O O
and O O
inflammatory O O
response O O
in O O
taurocholate-induced O O
pancreatitis O O
. O O

Transcription B-protein B-protein
factor I-protein I-protein
nuclear I-protein I-protein
factor-kappaB I-protein I-protein
( O O
NF-kappaB B-protein B-protein
) O O
is O O
activated O O
in O O
cerulein O O
pancreatitis O O
and O O
mediates O O
cytokine O B-protein
expression O O
. O O

The O O
role O O
of O O
transcription O B-protein
factor O I-protein
activation O O
in O O
other O O
models O O
of O O
pancreatitis O O
has O O
not O O
been O O
established O O
. O O

Here O O
we O O
report O O
upregulation O O
of O O
NF-kappaB B-protein B-protein
and O O
inflammatory B-protein B-protein
molecules I-protein I-protein
, O O
and O O
their O O
correlation O O
with O O
local O O
pancreatic O O
injury O O
, O O
in O O
a O O
model O O
of O O
severe O O
pancreatitis O O
. O O

Rats O O
received O O
intraductal O O
infusion O O
of O O
taurocholate O O
or O O
saline O O
, O O
and O O
the O O
pancreatic O O
head O O
and O O
tail O O
were O O
analyzed O O
separately O O
. O O

NF-kappaB B-protein B-protein
and O O
activator B-protein B-protein
protein-1 I-protein I-protein
( O O
AP-1 B-protein B-protein
) O O
activation O O
were O O
assessed O O
by O O
gel O O
shift O O
assay O O
, O O
and O O
mRNA O O
expression O O
of O O
interleukin-6 B-RNA B-protein
, O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor-alpha I-protein I-protein
, O O
KC O B-protein
, O O
monocyte B-protein B-protein
chemoattractant I-protein I-protein
protein-1 I-protein I-protein
, O O
and O O
inducible B-protein O
nitric I-protein B-protein
oxide I-protein I-protein
synthase I-protein I-protein
was O O
assessed O O
by O O
semiquantitative O O
RT-PCR O O
. O O

Morphological O O
damage O O
and O O
trypsin O B-protein
activation O O
were O O
much O O
greater O O
in O O
the O O
pancreatic O O
head O O
than O O
tail O O
, O O
in O O
parallel O O
with O O
a O O
stronger O O
activation O O
of O O
NF-kappaB B-RNA B-RNA
and I-RNA I-RNA
cytokine I-RNA I-RNA
mRNA I-RNA I-RNA
. O O

Saline O O
infusion O O
mildly O O
affected O O
these O O
parameters O O
. O O

AP-1 B-protein B-protein
was O O
strongly O O
activated O O
in O O
both O O
pancreatic O O
segments O O
after O O
either O O
taurocholate O O
or O O
saline O O
infusion O O
. O O

NF-kappaB B-protein B-protein
inhibition O O
with O O
N-acetylcysteine O O
ameliorated O O
the O O
local O O
inflammatory O O
response O O
. O O

Correlation O O
between O O
localized O O
NF-kappaB B-protein B-protein
activation O O
, O O
cytokine O B-protein
upregulation O O
, O O
and O O
tissue O O
damage O O
suggests O O
a O O
key O O
role O O
for O O
NF-kappaB B-protein B-protein
in O O
the O O
development O O
of O O
the O O
inflammatory O O
response O O
of O O
acute O O
pancreatitis O O
. O O

CD45 B-protein B-protein
tyrosine I-protein I-protein
phosphatase I-protein I-protein
controls O O
common O O
gamma-chain B-protein B-protein
cytokine I-protein I-protein
-mediated O O
STAT B-protein B-protein
and O O
extracellular O B-protein
signal-related O I-protein
kinase O I-protein
phosphorylation O O
in O O
activated B-cell_type B-cell_type
human I-cell_type I-cell_type
lymphoblasts I-cell_type I-cell_type
: O O
inhibition O O
of O O
proliferation O O
without O O
induction O O
of O O
apoptosis O O
. O O

The O O
objective O O
of O O
this O O
study O O
was O O
to O O
test O O
whether O O
CD45 O B-protein
signals O O
can O O
influence O O
signaling O O
processes O O
in O O
activated B-cell_type B-cell_type
human I-cell_type I-cell_type
lymphoblasts I-cell_type I-cell_type
. O O

To O O
this O O
end O O
, O O
we O O
generated O O
lymphoblasts B-cell_type B-cell_type
which O O
proliferate O O
in O O
response O O
to O O
common O O
gamma-chain B-protein B-protein
cytokines I-protein I-protein
, O O
but O O
readily O O
undergo O O
apoptosis O O
after O O
cytokine O B-protein
withdrawal O O
. O O

In O O
experiments O O
with O O
the O O
CD45R0 B-protein B-protein
mAb I-protein I-protein
UCHL-1 I-protein I-protein
, O O
but O O
not O O
control B-protein O
CD45 I-protein B-protein
mAbs I-protein I-protein
, O O
we O O
found O O
significant O O
inhibition O O
of O O
proliferation O O
. O O

Interestingly O O
, O O
the O O
pan-CD45 B-protein B-protein
mAb I-protein I-protein
GAP8.3 I-protein I-protein
, O O
which O O
is O O
most O O
effective O O
in O O
inhibition O O
of O O
OKT-3-mediated O O
proliferation O O
in O O
quiescent B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
, O O
was O O
ineffective O O
in O O
lymphoblasts B-cell_type B-cell_type
. O O

Addition O O
of O O
CD3 B-protein B-protein
mAb I-protein I-protein
OKT-3 I-protein I-protein
had O O
no O O
influence O O
on O O
IL-2-mediated O O
proliferation O O
( O O
with O O
or O O
without O O
UCHL-1 B-protein B-protein
) O O
. O O

In O O
contrast O O
, O O
after O O
addition O O
of O O
OKT-3 B-protein B-protein
to O O
IL-4 B-protein B-protein
- O O
and O O
IL-7 B-protein B-protein
-stimulated O O
proliferation O O
assays O O
, O O
UCHL-1 B-protein B-protein
signals O O
could O O
not O O
significantly O O
alter O O
cellular O O
proliferation O O
. O O

We O O
did O O
not O O
find O O
induction O O
of O O
apoptosis O O
following O O
CD45R0 O O
signaling O O
. O O

In O O
Western O O
blots O O
using O O
mAbs B-protein B-protein
detecting O O
phosphorylated B-protein O
STAT-3 I-protein B-protein
, I-protein O
STAT-5 I-protein B-protein
, I-protein O
STAT-6 I-protein B-protein
, O O
or O O
extracellular B-protein B-protein
signal-related I-protein I-protein
kinase I-protein I-protein
1/2 I-protein I-protein
, O O
we O O
found O O
that O O
CD45R0 O O
signaling O O
could O O
effectively O O
diminish O O
phosphorylation O O
of O O
these O O
intracellular O O
signaling O O
components O O
. O O

Using O O
RT-PCR O O
, O O
we O O
found O O
that O O
CD45R0 O O
signaling O O
inhibited O O
IL-2 O B-RNA
mRNA O I-RNA
production O O
without O O
major O O
influence O O
on O O
IL-13 B-protein B-protein
, O O
IL-5 B-protein B-protein
, O O
or O O
IFN-gamma B-RNA B-protein
mRNA I-RNA O
levels O O
. O O

Costimulation O O
with O O
OKT-3 B-protein B-protein
and O O
IL-2 B-protein B-protein
optimally O O
induced O O
secretion O O
of O O
IFN-gamma B-protein B-protein
, O O
TNF-alpha B-protein B-protein
, O O
and O O
IL-5 B-protein B-protein
, O O
which O O
was O O
not O O
decreased O O
by O O
CD45 O B-protein
signals O O
. O O

In O O
conclusion O O
, O O
we O O
illustrate O O
that O O
CD45R0 O O
signals O O
control O O
early O O
cytokine O B-protein
receptor-associated O O
signaling O O
processes O O
and O O
mRNA O B-RNA
and O O
DNA O O
synthesis O O
in O O
activated B-cell_type B-cell_type
human I-cell_type I-cell_type
lymphoblasts I-cell_type I-cell_type
. O O

Furthermore O O
, O O
we O O
show O O
the O O
existence O O
of O O
CD45 B-protein B-protein
epitopes I-protein I-protein
( O O
GAP8.3 B-protein B-protein
) O O
, O O
which O O
are O O
active O O
and O O
critical O O
for O O
signaling O O
in O O
quiescent B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
, O O
but O O
are O O
nonfunctional O O
in O O
activated B-cell_type B-cell_type
human I-cell_type I-cell_type
lymphoblasts I-cell_type I-cell_type
. O O

Pax5 B-DNA B-protein
determines O O
the O O
identity O O
of O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
the O O
beginning O O
to O O
the O O
end O O
of O O
B-lymphopoiesis O O
. O O

Despite O O
being O O
one O O
of O O
the O O
most O O
intensively O O
studied O O
cell O O
types O O
, O O
the O O
molecular O O
basis O O
of O O
B O O
cell O O
specification O O
is O O
largely O O
unknown O O
. O O

The O O
Pax5 B-DNA B-DNA
gene I-DNA I-DNA
encoding O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
BSAP I-protein B-protein
is O O
required O O
for O O
progression O O
of O O
B-lymphopoiesis O O
beyond O O
the O O
pro-B O O
cell O O
stage O O
. O O

Pax5-deficient B-cell_type B-cell_line
pro-B I-cell_type I-cell_line
cells I-cell_type I-cell_line
are O O
, O O
however O O
, O O
not O O
yet O O
committed O O
to O O
the O O
B-lymphoid B-cell_type B-cell_type
lineage I-cell_type I-cell_type
, O O
but O O
instead O O
have O O
a O O
broad O O
lymphomyeloid O O
developmental O O
potential O O
. O O

Pax5 B-DNA B-protein
appears O O
to O O
mediate O O
B-lineage O O
commitment O O
by O O
repressing O O
the O O
transcription O O
of O O
non-B-lymphoid B-DNA B-DNA
genes I-DNA I-DNA
and O O
by O O
simultaneously O O
activating O O
the O O
expression O O
of O O
B-lineage-specific B-DNA B-DNA
genes I-DNA I-DNA
. O O

Pax5 B-DNA B-protein
thus O O
functions O O
both O O
as O O
a O O
transcriptional O B-protein
repressor O I-protein
and O O
activator O O
, O O
depending O O
on O O
its O O
interactions O O
with O O
corepressors B-protein O
of O O
the O O
Groucho B-protein B-protein
protein I-protein I-protein
family I-protein I-protein
or O O
with O O
positive O B-protein
regulators O I-protein
such O O
as O O
the O O
TATA-binding B-protein B-protein
protein I-protein I-protein
. O O

Once O O
committed O O
to O O
the O O
B-lineage B-cell_type B-cell_type
, O I-cell_type
B B-cell_type I-cell_type
cells I-cell_type I-cell_type
require O O
Pax5 B-DNA B-protein
function O O
to O O
maintain O O
their O O
B-lymphoid O O
identity O O
throughout O O
B O O
cell O O
development O O

Partners O O
in O O
transcription O O
: O O
NFAT B-protein B-protein
and O O
AP-1 B-protein B-protein
. O O

Combinatorial O O
regulation O O
is O O
a O O
powerful O O
mechanism O O
that O O
enables O O
tight O O
control O O
of O O
gene O O
expression O O
, O O
via O O
integration O O
of O O
multiple O O
signaling O O
pathways O O
that O O
induce O O
different O O
transcription B-protein B-protein
factors I-protein I-protein
required O O
for O O
enhanceosome O B-protein
assembly O O
. O O

The O O
four O O
calcium-regulated O B-protein
transcription B-protein I-protein
factors I-protein I-protein
of O O
the O O
NFAT B-protein B-protein
family I-protein I-protein
act O O
synergistically O O
with O O
AP-1 B-protein B-protein
( I-protein I-protein
Fos/Jun I-protein I-protein
) I-protein I-protein
proteins I-protein I-protein
on O O
composite O B-DNA
DNA O I-DNA
elements O I-DNA
which O O
contain O O
adjacent O O
NFAT B-DNA B-DNA
and I-DNA I-DNA
AP-1 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
, O O
where O O
they O O
form O O
highly O O
stable O O
ternary O B-protein
complexes O I-protein
to O O
regulate O O
the O O
expression O O
of O O
diverse O O
inducible O B-DNA
genes O I-DNA
. O O

Concomitant O O
induction O O
of O O
NFAT B-protein B-protein
and O O
AP-1 B-protein B-protein
requires O O
concerted O O
activation O O
of O O
two O O
different O O
signaling O O
pathways O O
: O O
calcium/calcineurin O O
, O O
which O O
promotes O O
NFAT O B-protein
dephosphorylation O O
, O O
nuclear O O
translocation O O
and O O
activation O O
; O O
and O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
( I-protein I-protein
PKC I-protein I-protein
) I-protein I-protein
/Ras I-protein I-protein
, O O
which O O
promotes O O
the O O
synthesis O O
, O O
phosphorylation O O
and O O
activation O O
of O O
members O O
of O O
the O O
Fos B-protein B-protein
and I-protein I-protein
Jun I-protein I-protein
families I-protein I-protein
of O O
transcription B-protein B-protein
factors I-protein I-protein
. O O

A O O
fifth O O
member O O
of O O
the O O
NFAT B-protein B-protein
family I-protein I-protein
, O O
NFAT5 B-protein B-protein
, O O
controls O O
the O O
cellular O O
response O O
to O O
osmotic O O
stress O O
, O O
by O O
a O O
mechanism O O
that O O
requires O O
dimer O O
formation O O
and O O
is O O
independent O O
of O O
calcineurin B-protein B-protein
or O O
of O O
interaction O O
with O O
AP-1 B-protein B-protein
. O O

Pharmacological O O
interference O O
with O O
theNFAT O B-protein
: O O
AP-1 O B-protein
interaction O O
may O O
be O O
useful O O
in O O
selective O O
manipulation O O
of O O
the O O
immune O O
response O O
. O O

Balanced O O
activation O O
of O O
NFAT B-protein B-protein
and O O
AP-1 B-protein B-protein
is O O
known O O
to O O
be O O
required O O
for O O
productive O O
immune O O
responses O O
, O O
but O O
the O O
role O O
of O O
NFAT O B-protein
: O O
AP-1 O B-protein
interactions O O
in O O
other O O
cell O O
types O O
and O O
biological O O
processes O O
remains O O
to O O
be O O
understood O O
. O O

Cytokine O B-protein
production O O
by O O
Vgamma B-cell_type B-DNA
( I-cell_type I-DNA
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
-T-cell I-cell_type I-cell_type
subsets I-cell_type I-cell_type
is O O
an O O
important O O
factor O O
determining O O
CD4 O B-cell_type
( O O
+ O O
) O O
-Th-cell O O
phenotype O O
and O O
susceptibility O O
of O O
BALB/c O O
mice O O
to O O
coxsackievirus O O
B3-induced O O
myocarditis O O
. O O

Two O O
coxsackievirus O O
B3 O O
( O O
CVB3 O O
) O O
variants O O
( O O
H3 O O
and O O
H310A1 O O
) O O
differ O O
by O O
a O O
single O O
amino O O
acid O O
mutation O O
in O O
the O O
VP2 B-protein B-protein
capsid I-protein I-protein
protein I-protein I-protein
. O O

H3 O O
induces O O
severe O O
myocarditis O O
in O O
BALB/c O O
mice O O
, O O
but O O
H310A1 O O
is O O
amyocarditic O O
. O O

Infection O O
with O O
H3 O B-protein
, O O
but O O
not O O
H310A1 O B-protein
, O O
preferentially O O
activates O O
Vgamma4 B-cell_type B-cell_type
Vdelta4 I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
which O O
are O O
strongly O O
positive O O
for O O
gamma B-protein O
interferon I-protein O
( O O
IFN-gamma B-protein B-protein
) O O
, O O
whereas O O
Vgamma1 B-cell_type B-cell_type
Vdelta4 I-cell_type I-cell_type
cells I-cell_type I-cell_type
are O O
increased O O
in O O
both O O
H3 O B-protein
and O O
H310A1 O O
virus-infected O O
animals O O
. O O

Depletion O O
of O O
Vgamma1 B-cell_type B-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
using O O
monoclonal B-protein B-protein
anti-Vgamma1 I-protein I-protein
antibody I-protein I-protein
enhanced O O
myocarditis O O
and O O
CD4 O B-cell_type
( O O
+ O O
) O O
- O O
, O O
IFN-gamma B-protein B-protein
( O O
+ O O
) O O
-cell O O
responses O O
in O O
both O O
H3- O O
and O O
H310A1-infected O O
mice O O
yet O O
decreased O O
the O O
CD4 O B-protein
( O I-protein
+ O I-protein
) O I-protein
- O O
, O O
IL-4 O B-protein
( O O
+ O O
) O O
-cell O O
response O O
. O O

Depleting O B-cell_type
Vgamma4 B-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
suppressed O O
myocarditis O O
and O O
reduced O O
CD4 B-cell_type B-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
IFN-gamma I-cell_type I-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
but O O
increased O O
CD4 B-cell_type B-protein
( I-cell_type I-protein
+ I-cell_type I-protein
) I-cell_type I-protein
IL-4 I-cell_type I-protein
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
role O O
of O O
cytokine O B-protein
production O O
by O O
Vgamma1 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
and I-cell_type I-cell_type
Vgamma4 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
was O O
investigated O O
by O O
adoptively O O
transferring O O
these O O
cells O O
isolated O O
from O O
H3-infected O O
BALB/c O B-protein
Stat4 O I-protein
knockout O I-protein
( O O
Stat4ko O O
) O O
( O O
defective O O
in O O
IFN-gamma B-protein B-protein
expression O O
) O O
or O O
BALB/c O B-protein
Stat6ko O I-protein
( O O
defective O O
in O O
IL-4 O B-protein
expression O O
) O O
mice O O
into O O
H3 O O
virus-infected O O
wild-type O O
BALB/c O O
recipients O O
. O O

Vgamma4 B-cell_type B-protein
and I-cell_type O
Vgamma1 I-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
Stat4ko O O
mice O O
expressed O O
IL-4 B-protein B-protein
but O O
no O O
or O O
minimal O O
IFN-gamma B-protein B-protein
, O O
whereas O O
these O O
cell O O
populations O O
derived O O
from O O
Stat6ko O O
mice O O
expressed O O
IFN-gamma B-protein B-protein
but O O
no O O
IL-4 B-protein B-protein
. O O

Stat4ko B-cell_type B-cell_line
Vgamma1 I-cell_type I-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
( I-cell_type O
IL-4 I-cell_type B-protein
( I-cell_type O
+ I-cell_type O
) I-cell_type O
) O O
suppress O O
myocarditis O O
. O O

Stat6ko B-cell_type B-cell_line
Vgamma1 I-cell_type I-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
( I-cell_type O
IFN-gamma I-cell_type B-protein
( I-cell_type O
+ I-cell_type O
) I-cell_type O
) I-cell_type O
were O O
not O O
inhibitory O O
. O O

Stat6ko B-cell_type B-protein
Vgamma4 I-cell_type B-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
( I-cell_type O
IFN-gamma I-cell_type B-protein
( I-cell_type O
+ I-cell_type O
) I-cell_type O
) I-cell_type O
significantly O O
enhanced O O
myocarditis O O
. O O

Stat4ko B-cell_type B-cell_line
Vgamma4 I-cell_type I-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
( I-cell_type O
IL-4 I-cell_type B-protein
( I-cell_type O
+ I-cell_type O
) I-cell_type O
) I-cell_type O
neither O O
inhibited O O
nor O O
enhanced O O
disease O O
. O O

These O O
results O O
show O O
that O O
distinct O O
gammadelta-T-cell B-cell_type O
subsets I-cell_type O
control O O
myocarditis O O
susceptibility O O
and O O
bias O O
the O O
CD4 B-cell_type B-cell_type
( I-cell_type O
+ I-cell_type O
) I-cell_type O
-Th-cell I-cell_type O
response O O
. O O

The O O
cytokines B-protein B-protein
produced O O
by O O
the O O
Vgamma B-cell_type B-cell_type
subpopulation I-cell_type I-cell_type
have O O
a O O
significant O O
influence O O
on O O
the O O
CD4 B-protein O
( O O
+ O O
) O O
-Th-cell O O
phenotype O O
. O O

Plasmin B-protein B-protein
-induced O O
expression O O
of O O
cytokines B-protein B-protein
and O O
tissue B-protein B-protein
factor I-protein I-protein
in O O
human B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
involves O O
AP-1 B-protein B-protein
and O O
IKKbeta B-protein B-protein
-mediated O O
NF-kappaB O B-protein
activation O O
. O O

It O O
was O O
previously O O
shown O O
that O O
plasmin B-protein B-protein
activates O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
in O O
terms O O
of O O
lipid O O
mediator O O
release O O
and O O
chemotactic O O
migration O O
. O O

Here O O
it O O
is O O
demonstrated O O
that O O
plasmin B-protein B-protein
induces O O
proinflammatory B-protein B-protein
cytokine I-protein I-protein
release O O
and O O
tissue B-protein B-protein
factor I-protein I-protein
( O O
TF B-protein B-protein
) O O
expression O O
by O O
monocytes B-cell_type B-cell_type
. O O

Plasmin B-protein O
0.043 O O
to O O
1.43 O O
CTA O O
U/mL O O
, O O
but O O
not O O
active B-protein O
site-blocked I-protein B-protein
plasmin I-protein I-protein
, O O
triggered O O
concentration-dependent O O
expression O O
of O O
mRNA O B-RNA
for O O
interleukin-1alpha B-protein B-protein
( O O
IL-1alpha B-protein B-protein
) O O
, O O
IL-1beta B-protein B-protein
, O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor-alpha I-protein I-protein
( O O
TNF-alpha B-protein B-protein
) O O
, O O
and O O
TF B-protein B-protein
with O O
maximum O O
responses O O
after O O
4 O O
hours O O
. O O

Plasmin B-protein B-protein
-mediated O O
mRNA O O
expression O O
was O O
inhibited O O
in O O
a O O
concentration-dependent O O
manner O O
by O O
the O O
lysine O O
analogue O O
trans-4- O O
( O O
aminomethyl O O
) O O
cyclohexane-1-carboxylic O O
acid O O
( O O
t-AMCA O O
) O O
. O O

Increases O O
in O O
mRNA O O
levels O O
were O O
followed O O
by O O
concentration- O O
and O O
time-dependent O O
release O O
of O O
IL-1alpha B-protein B-protein
, O O
IL-1beta B-protein B-protein
and O O
TNF-alpha B-protein B-protein
and O O
by O O
TF B-protein B-protein
expression O O
on O O
monocyte O O
surfaces O O
. O O

Neither O O
cytokines B-protein B-protein
nor O O
TF B-protein B-protein
could O O
be O O
detected O O
when O O
monocytes B-cell_type B-cell_type
were O O
preincubated O O
with O O
actinomycin O O
D O O
or O O
cycloheximide O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
indicated O O
plasmin B-protein B-protein
-induced O O
activation O O
of O O
NF-kappaB B-protein B-protein
; O O
DNA-binding B-protein B-protein
complexes I-protein I-protein
were O O
composed O O
of O O
p50 B-protein B-protein
, O O
p65 B-protein B-protein
, O O
and O O
c-Rel B-protein B-protein
, O O
as O O
shown O O
by O O
supershift O O
experiments O O
. O O

Nuclear O O
translocation O O
of O O
NF-kappaB/Rel B-protein B-protein
proteins I-protein I-protein
coincided O O
with O O
IkappaBalpha O B-protein
degradation O O
. O O

At O O
variance O O
with O O
endotoxic O O
lipopolysaccharide O O
, O O
plasmin B-protein B-protein
elicited O O
the O O
rapid O O
degradation O O
of O O
another O O
cytoplasmic B-protein B-protein
NF-kappaB I-protein I-protein
inhibitor I-protein O
, I-protein O
p105 I-protein B-protein
. O O

Proteolysis O O
of O O
NF-kappaB O B-protein
inhibitors O O
was O O
apparently O O
due O O
to O O
transient O O
activation O O
of O O
IkappaB B-protein B-protein
kinase I-protein I-protein
( I-protein I-protein
IKK I-protein I-protein
) I-protein I-protein
beta I-protein I-protein
that O O
reached O O
maximum O O
activity O O
at O O
1 O O
hour O O
after O O
plasmin B-protein B-protein
stimulation O O
. O O

In O O
addition O O
, O O
AP-1 O B-protein
binding O O
was O O
increased O O
in O O
plasmin B-protein B-protein
-treated O O
monocytes B-cell_type B-cell_type
, O O
with O O
most O O
complexes O O
composed O O
of O O
JunD B-protein B-protein
, O O
c-Fos B-protein B-protein
, O O
and O O
FosB B-protein B-protein
. O O

These O O
findings O O
further O O
substantiate O O
the O O
role O O
of O O
plasmin B-protein B-protein
as O O
a O O
proinflammatory O O
activator O O
of O O
human B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
and O O
reveal O O
an O O
important O O
new O O
link O O
between O O
the O O
plasminogen-plasmin O O
system O O
and O O
inflammation O O
. O O

( O O
Blood. O O
2001 O O
; O O
97 O O
: O O
3941-3950 O O
) O O

STAT3 B-protein B-protein
is O O
constitutively O O
active O O
in O O
some O O
patients O O
with O O
Polycythemia O O
rubra O O
vera O O
. O O

OBJECTIVE O O
: O O
Polycythemia O O
vera O O
is O O
a O O
clonal O O
stem O O
cell O O
disorder O O
characterized O O
by O O
hyperproliferation O O
of O O
the O O
erythroid B-cell_type B-cell_type
, I-cell_type I-cell_type
myeloid I-cell_type I-cell_type
, I-cell_type I-cell_type
and I-cell_type I-cell_type
megakaryocytic I-cell_type I-cell_type
lineages I-cell_type I-cell_type
. O O

While O O
it O O
has O O
been O O
shown O O
that O O
progenitor B-cell_type B-cell_type
cells I-cell_type I-cell_type
of O O
P. O O
vera O O
patients O O
are O O
hypersensitive O O
to O O
several O O
growth O B-protein
factors O I-protein
including O O
erythropoietin B-protein B-protein
, O O
insulin-like B-protein B-protein
growth I-protein I-protein
factor-1 I-protein I-protein
, O O
thrombopoietin B-protein B-protein
, O O
interleukin-3 B-protein B-protein
, O O
and O O
granulocyte/monocyte B-protein B-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
, O O
the O O
molecular O O
pathogenesis O O
of O O
this O O
disease O O
remains O O
unknown O O
. O O

Growth O O
factor O O
hypersensitivity O O
could O O
be O O
mediated O O
by O O
changes O O
in O O
signal O O
transduction O O
pathways O O
. O O

We O O
therefore O O
investigated O O
a O O
common O B-protein
downstream O I-protein
effector O I-protein
of O O
cytokines B-protein B-protein
, O O
the O O
signal B-protein B-protein
transducers I-protein I-protein
and I-protein I-protein
activators I-protein I-protein
of I-protein I-protein
transcription I-protein I-protein
( O O
STATs B-protein B-protein
) O O
. O O

A O O
constitutive O O
activation O O
of O O
STAT B-protein B-protein
factors I-protein I-protein
could O O
explain O O
the O O
increased O O
proliferation O O
of O O
P. B-cell_type B-cell_type
vera I-cell_type I-cell_type
cells I-cell_type I-cell_type
even O O
in O O
the O O
absence O O
of O O
growth O B-protein
factor O I-protein
stimulation O O
. O O

METHODS O O
: O O
Peripheral B-cell_type B-cell_type
granulocytes I-cell_type I-cell_type
from O O
patients O O
with O O
P. O O
vera O O
and O O
from O O
healthy O O
volunteers O O
were O O
assayed O O
for O O
STAT1 B-protein B-protein
, I-protein O
3 I-protein O
, I-protein O
and I-protein O
5 I-protein O
DNA O O
binding O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

RESULTS O O
: O O
Four O O
of O O
14 O O
P. O O
vera O O
patients O O
analyzed O O
showed O O
constitutive O O
STAT3 O B-protein
DNA O O
binding O O
in O O
unstimulated B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
granulocytes I-cell_type I-cell_type
, O O
while O O
none O O
of O O
the O O
17 O O
healthy O O
volunteers O O
tested O O
did O O
. O O

None O O
of O O
the O O
subjects O O
showed O O
constitutive O O
STAT1 B-protein B-protein
or O O
STAT5 B-protein B-protein
activity O O
. O O

Western O O
blotting O O
demonstrated O O
that O O
, O O
in O O
the O O
three O O
patients O O
, O O
STAT3 B-protein B-protein
is O O
constitutively O O
phosphorylated O O
on O O
Tyr O O
705 O O
, O O
whereas O O
it O O
is O O
unphosphorylated O O
in O O
the O O
other O O
patients O O
and O O
in O O
controls O O
. O O

Interestingly O O
, O O
constitutive O O
STAT3 B-protein B-protein
activity O O
did O O
not O O
correlate O O
with O O
the O O
duration O O
of O O
disease O O
or O O
the O O
treatment O O
regimen O O
. O O

It O O
was O O
observed O O
in O O
a O O
recently O O
diagnosed O O
patient O O
and O O
in O O
two O O
patients O O
treated O O
only O O
with O O
phlebotomy O O
. O O

CONCLUSION O O
: O O
Our O O
data O O
suggest O O
that O O
constitutive O O
phosphorylation O O
and O O
activation O O
of O O
STAT3 B-protein B-protein
is O O
not O O
a O O
secondary O O
event O O
induced O O
by O O
mutagenizing O O
agents O O
or O O
by O O
prolonged O O
hyperproliferation O O
of O O
hematopoietic B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
but O O
rather O O
represents O O
a O O
primary O O
molecular O O
aberration O O
. O O

Constitutively B-protein O
active I-protein O
STAT3 I-protein B-protein
may O O
contribute O O
to O O
the O O
growth O O
factor O O
hypersensitivity O O
of O O
P. B-cell_type B-cell_type
vera I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Identification O O
of O O
phosphorylation B-protein B-DNA
sites I-protein I-DNA
for O O
Bruton B-protein B-protein
's I-protein O
tyrosine I-protein B-protein
kinase I-protein I-protein
within O O
the O O
transcriptional B-protein B-protein
regulator I-protein I-protein
BAP/TFII-I I-protein B-protein
. O O

Bruton B-protein B-protein
's I-protein O
tyrosine I-protein B-protein
kinase I-protein I-protein
( O O
Btk B-protein B-protein
) O O
, O O
a O O
member O O
of O O
the O O
Tec B-protein B-protein
family I-protein I-protein
of I-protein O
cytosolic I-protein B-protein
kinases I-protein I-protein
, O O
is O O
essential O O
for O O
B B-cell_type O
cell I-cell_type O
development O O
and O O
function O O
. O O

BAP/TFII-I B-protein B-protein
, O O
a O O
protein O O
implicated O O
in O O
transcriptional O O
regulation O O
, O O
is O O
associated O O
with O O
Btk B-protein B-protein
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
is O O
transiently O O
phosphorylated O O
on O O
tyrosine O O
following O O
B B-cell_type O
cell I-cell_type O
receptor O O
engagement O O
. O O

BAP/TFII-I B-protein B-protein
is O O
a O O
substrate O O
for O O
Btk B-protein B-protein
in O O
vitro O O
and O O
is O O
hyperphosphorylated O O
on O O
tyrosine O O
upon O O
coexpression O O
with O O
Btk B-protein B-protein
in O O
mammalian B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

In O O
an O O
effort O O
to O O
understand O O
the O O
physiologic O O
consequences O O
of O O
BAP/TFII-I B-protein B-protein
tyrosine O O
phosphorylation O O
following O O
B O O
cell O O
receptor O O
stimulation O O
, O O
site-directed O O
mutagenesis O O
and O O
phosphopeptide O O
mapping O O
were O O
used O O
to O O
locate O O
the O O
predominant O O
sites O O
of O O
BAP/TFII-I B-protein B-protein
phosphorylation O O
by O O
Btk B-protein B-protein
in O O
vitro O O
. O O

These O O
residues O O
, O O
Tyr248 O O
, O O
Tyr357 O O
, O O
and O O
Tyr462 O O
, O O
were O O
also O O
found O O
to O O
be O O
the O O
major O B-DNA
sites O I-DNA
for O O
Btk B-protein B-protein
-dependent O O
phosphorylation O O
of O O
BAP/TFII-I B-protein B-protein
in O O
vivo O O
. O O

Residues O O
Tyr357 O O
and O O
Tyr462 O O
are O O
contained O O
within O O
the O O
loop B-protein B-DNA
regions I-protein I-DNA
of O O
adjacent O O
helix-loop-helix-like B-protein B-DNA
repeats I-protein I-DNA
within O O
BAP/TFII-I B-protein B-DNA
. O O

Mutation O O
of O O
either O O
Tyr248 O O
, O O
Tyr357 O O
, O O
or O O
Tyr462 O O
to O O
phenylalanine O O
reduced O O
transcription O O
from O O
a O O
c-fos B-DNA B-DNA
promoter I-DNA I-DNA
relative O O
to O O
wild-type B-DNA B-protein
BAP/TFII-I I-DNA I-protein
in O O
transfected O B-cell_line
COS-7 B-cell_line I-cell_line
cells I-cell_line I-cell_line
, O O
consistent O O
with O O
the O O
interpretation O O
that O O
phosphorylation O O
at O O
these O O
sites O O
contributes O O
to O O
transcriptional O O
activation O O
. O O

Phosphorylation O O
of O O
BAP/TFII-I B-protein B-protein
by O O
Btk B-protein B-protein
may O O
link O O
engagement O O
of O O
receptors O O
such O O
as O O
surface O B-protein
immunoglobulin B-protein I-protein
to O O
modulation O O
of O O
gene O O
expression O O
. O O

Expression O O
of O O
interferon B-protein B-protein
consensus I-protein I-protein
sequence I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
induces O O
potent O O
immunity O O
against O O
BCR/ABL-induced O O
leukemia O O
. O O

Mice O O
deficient O O
in O O
the O O
interferon B-protein B-protein
consensus I-protein I-protein
sequence I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
( O O
ICSBP B-protein B-protein
) O O
develop O O
a O O
disease O O
resembling O O
chronic O O
myeloid O O
leukemia O O
( O O
CML O O
) O O
, O O
which O O
in O O
humans O O
is O O
caused O O
by O O
the O O
BCR/ABL B-protein B-protein
oncoprotein I-protein I-protein
. O O

Interferon-alpha B-protein B-protein
( O O
IFN-alpha B-protein B-protein
) O O
induces O O
ICSBP B-protein B-protein
expression O O
and O O
is O O
an O O
effective O O
therapy O O
for O O
CML O O
. O O

This O O
study O O
examined O O
whether O O
enforced O O
expression O O
of O O
ICSBP B-protein B-protein
might O O
antagonize O O
BCR/ABL-induced O O
leukemia O O
; O O
results O O
demonstrated O O
that O O
ICSBP-modified B-cell_type B-cell_type
cells I-cell_type I-cell_type
generated O O
a O O
protective O O
CD8 O O
( O O
+ O O
) O O
cytotoxic O O
T-cell O O
response O O
against O O
BCR/ABL-transformed B-cell_type B-cell_line
BaF3 I-cell_type I-cell_line
cells I-cell_type I-cell_line
in O O
a O O
murine O O
leukemia O O
model O O
. O O

ICSBP B-protein B-protein
expression O O
represents O O
a O O
novel O O
means O O
of O O
stimulating O O
a O O
host O O
immune O O
response O O
to O O
BCR/ABL B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
leukemia I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
a O O
potential O O
strategy O O
for O O
immunotherapy O O
of O O
CML O O
. O O

( O O
Blood. O O
2001 O O
; O O
97 O O
: O O
3491-3497 O O
) O O

A O O
transcriptional O O
block O O
in O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
at O O
the O O
-150 B-DNA B-DNA
AP-1 I-DNA I-DNA
site I-DNA I-DNA
in O O
effector B-cell_type B-cell_type
CD8+ I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Both O O
CD4+ B-cell_type B-cell_type
and I-cell_type I-cell_type
CD8+ I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
that O O
produce O O
IL-2 B-protein B-protein
in O O
response O O
to O O
Ag O O
recognition O O
have O O
been O O
isolated O O
. O O

However O O
, O O
most O O
effector B-cell_type B-cell_type
CD8+ I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
recovered O O
after O O
exposure O O
to O O
Ag B-protein B-protein
do O O
not O O
produce O O
sufficient O O
IL-2 B-protein B-protein
to O O
sustain O O
growth O O
, O O
and O O
depend O O
on O O
CD4+ B-cell_type B-cell_type
T I-cell_type I-cell_type
helper I-cell_type I-cell_type
cells I-cell_type I-cell_type
for O O
this O O
obligate O O
growth O B-protein
factor O I-protein
. O O

IL-2 O B-protein
expression O O
in O O
CD4+ B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
is O O
primarily O O
controlled O O
at O O
the O O
level O O
of O O
transcription O O
, O O
but O O
mechanisms O O
restricting O O
IL-2 O B-protein
production O O
in O O
CD8+ B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
have O O
not O O
been O O
elucidated O O
. O O

To O O
evaluate O O
transcriptional O O
regulation O O
of O O
the O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
in O O
CD8+ B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
we O O
stably O O
transfected O B-DNA
reporter B-DNA I-DNA
genes I-DNA I-DNA
into O O
Ag B-protein B-cell_line
-specific O I-cell_line
CD8+ B-cell_line I-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
clones I-cell_line I-cell_line
. O O

CD28+ B-cell_type B-cell_type
CD8 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
unable O O
to O O
transcribe O O
the O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
in O O
response O O
to O O
antigenic O O
stimulation O O
had O O
a O O
block O O
in O O
transactivation O O
of O O
the O O
-150 B-DNA B-DNA
CD28 I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
( I-DNA I-DNA
CD28RE I-DNA I-DNA
) I-DNA I-DNA
/AP-1 I-DNA I-DNA
site I-DNA I-DNA
of O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
, O O
but O O
did O O
transactivate O O
the O O
composite O O
NFAT/AP-1 B-DNA B-DNA
and I-DNA I-DNA
OCT/AP-1 I-DNA I-DNA
sites I-DNA I-DNA
, O O
and O O
a O O
consensus B-DNA B-DNA
AP-1 I-DNA I-DNA
motif I-DNA I-DNA
. O O

Mutation O O
of O O
the O O
nonconsensus B-DNA B-DNA
-150 I-DNA I-DNA
AP-1 I-DNA I-DNA
site I-DNA I-DNA
to O O
a O O
consensus B-DNA B-DNA
AP-1 I-DNA I-DNA
site I-DNA I-DNA
, O O
or O O
insertion O O
of O O
a O O
CD28RE/AP-1 B-DNA B-DNA
consensus I-DNA I-DNA
site I-DNA I-DNA
upstream O O
of O O
the O O
native O O
-150 B-DNA B-DNA
CD28RE/AP-1 I-DNA I-DNA
site I-DNA I-DNA
restored O O
transactivation O O
of O O
the O O
altered O B-DNA
promoter B-DNA I-DNA
. O O

These O O
results O O
suggest O O
that O O
the O O
defect O O
at O O
the O O
-150 B-DNA B-DNA
site I-DNA I-DNA
may O O
reflect O O
the O O
absence O O
or O O
inactivity O O
of O O
a O O
required O O
factor O O
rather O O
than O O
repression O O
of O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Stem B-protein B-protein
cell I-protein I-protein
factor I-protein I-protein
and O O
interleukin-3 B-protein B-protein
induce O O
stepwise O O
generation O O
of O O
erythroid B-cell_type B-cell_type
precursor I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
a O O
basic O B-cell_line
fibroblast B-protein I-cell_line
growth I-protein I-cell_line
factor I-protein I-cell_line
-dependent O I-cell_line
hematopoietic B-cell_line I-cell_line
stem I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
, I-cell_line O
A-6 I-cell_line O
. O O

A O O
m O B-cell_type
ultipotent B-cell_type I-cell_type
immature I-cell_type I-cell_type
myeloid I-cell_type I-cell_type
cell I-cell_type I-cell_type
population I-cell_type I-cell_type
was O O
produced O O
from O O
a O O
basic B-protein B-protein
fibroblast I-protein I-protein
growth I-protein I-protein
factor I-protein I-protein
( O O
bFGF B-protein B-protein
) O I-cell_line
-dependent O I-cell_line
hematopoietic B-cell_line I-cell_line
stem I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
, I-cell_line O
A-6 I-cell_line B-cell_line
, O O
when O O
cultured O O
with O O
stem B-protein B-protein
cell I-protein I-protein
factor I-protein I-protein
( O O
SCF B-protein B-protein
) O O
replacing O O
bFGF B-protein B-protein
. O O

Those O O
cells O O
were O O
positive O O
for O O
stem B-protein B-cell_type
cell I-protein I-cell_type
markers I-protein I-protein
, O O
c-kit B-protein B-protein
and O O
CD34 B-protein B-protein
, O O
and O O
a O O
myeloid B-protein B-cell_type
cell I-protein I-cell_type
marker I-protein I-cell_type
, I-protein O
F4/80 I-protein B-protein
. O O

Some O O
cell O O
fractions O O
were O O
also O O
positive O O
for O O
Mac-1 B-protein B-protein
, I-protein O
a I-protein O
macrophage I-protein O
marker I-protein O
or O O
Gr-1 B-protein B-protein
, I-protein O
a I-protein O
granulocytic I-protein O
maker I-protein O
, O O
but O O
negative O O
for O O
an O O
erythroid B-protein B-cell_type
marker I-protein I-cell_type
TER119 I-protein I-cell_type
. O O

They O O
also O O
showed O O
the O O
expression O O
of O O
mRNA O B-RNA
for O O
the O O
myeloid-specific B-protein B-protein
PU.1 I-protein I-protein
but O O
did O O
not O O
that O O
for O O
the O O
erythroid-specific B-protein B-protein
GATA-1 I-protein I-protein
. O O

Among O O
various O O
cytokines B-protein B-protein
, O O
interleukin-3 B-protein B-protein
( O O
IL-3 B-protein B-protein
) O O
induced O O
erythroid B-cell_type B-cell_type
precursor I-cell_type I-cell_type
cells I-cell_type I-cell_type
that O O
expressed O O
the O O
erythroid-specific B-protein B-protein
GATA-1 I-protein I-protein
and O O
beta-major B-protein B-DNA
globin I-protein I-DNA
. O O

The O O
quantitative O O
analysis O O
showed O O
that O O
erythroid B-cell_type B-cell_type
precursor I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
newly O O
produced O O
from O O
the O O
immature B-cell_type B-cell_type
myeloid I-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
cultivation O O
with O O
IL-3 B-protein B-protein
. O O

SCF B-protein B-protein
and O O
IL-3 B-protein B-protein
induced O O
stepwise O O
generation O O
of O O
erythroid B-cell_type B-cell_type
precursor I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
an O O
A-6 B-cell_line B-cell_line
hematopoietic I-cell_line I-cell_line
stem I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

Distinct O O
BMI-1 B-protein B-protein
and O O
EZH2 B-protein B-protein
expression O O
patterns O O
in O O
thymocytes B-cell_type B-cell_type
and O O
mature B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
suggest O O
a O O
role O O
for O O
Polycomb B-DNA B-DNA
genes I-DNA I-DNA
in O O
human O O
T O O
cell O O
differentiation O O
. O O

BMI-1 B-protein B-protein
and O O
EZH2 B-protein B-protein
Polycomb-group B-protein I-protein
( I-protein I-protein
PcG I-protein I-protein
) I-protein I-protein
proteins I-protein I-protein
belong O O
to O O
two O O
distinct O O
protein O B-protein
complexes O I-protein
involved O O
in O O
the O O
regulation O O
of O O
hematopoiesis O O
. O O

Using O O
unique O O
PcG-specific O O
antisera O O
and O O
triple O O
immunofluorescence O O
, O O
we O O
found O O
that O O
mature B-cell_type O
resting I-cell_type B-cell_type
peripheral I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
expressed O O
BMI-1 B-protein B-protein
, O O
whereas O O
dividing B-cell_type B-cell_type
blasts I-cell_type I-cell_type
were O O
EZH2 O B-protein
( O O
+ O O
) O O
. O O

By O O
contrast O O
, O O
subcapsular B-cell_type O
immature I-cell_type O
double-negative I-cell_type O
( I-cell_type O
DN I-cell_type O
) I-cell_type O
( I-cell_type O
CD4 I-cell_type B-cell_line
( I-cell_type I-cell_line
- I-cell_type I-cell_line
) I-cell_type I-cell_line
/CD8 I-cell_type I-cell_line
( I-cell_type I-cell_line
- I-cell_type I-cell_line
) I-cell_type I-cell_line
) I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
in O O
the O O
thymus O O
coexpressed O O
BMI-1 B-protein B-protein
and O O
EZH2 B-protein B-protein
or O O
were O O
BMI-1 O B-protein
single O O
positive O O
. O O

Their O O
descendants O O
, O O
double-positive B-cell_type B-cell_type
( I-cell_type I-cell_type
DP I-cell_type I-cell_type
; I-cell_type I-cell_type
CD4 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
/CD8 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
) I-cell_type I-cell_type
cortical I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
, O O
expressed O O
EZH2 B-protein B-protein
without O O
BMI-1 B-protein B-protein
. O O

Most O O
EZH2 B-cell_type B-protein
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
DN I-cell_type I-cell_type
and I-cell_type I-cell_type
DP I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
were O O
dividing O O
, O O
while O O
DN B-cell_type B-cell_type
BMI-1 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
/EZH2 I-cell_type I-cell_type
( I-cell_type I-cell_type
- I-cell_type I-cell_type
) I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
were O O
resting O O
and O O
proliferation O O
was O O
occasionally O O
noted O O
in O O
DN B-cell_type B-cell_type
BMI-1 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
/EZH2 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Maturation O O
of O O
DP B-cell_type B-cell_type
cortical I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
to O O
single-positive B-cell_type B-cell_line
( I-cell_type I-cell_line
CD4 I-cell_type I-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
/CD8 I-cell_type I-cell_line
( I-cell_type I-cell_line
- I-cell_type I-cell_line
) I-cell_type I-cell_line
or O I-cell_line
CD8 B-cell_type I-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
/CD4 I-cell_type I-cell_line
( I-cell_type I-cell_line
- I-cell_type I-cell_line
) I-cell_type I-cell_line
) I-cell_type I-cell_line
medullar I-cell_type I-cell_line
thymocytes I-cell_type I-cell_line
correlated O O
with O O
decreased O O
detectability O O
of O O
EZH2 B-protein B-protein
and O O
continued O O
relative O O
absence O O
of O O
BMI-1 B-protein B-protein
. O O

Our O O
data O O
show O O
that O O
BMI-1 B-protein B-protein
and O O
EZH2 B-protein B-protein
expression O O
in O O
mature B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
is O O
mutually O O
exclusive O O
and O O
linked O O
to O O
proliferation O O
status O O
, O O
and O O
that O O
this O O
pattern O O
is O O
not O O
yet O O
established O O
in O O
thymocytes B-cell_type B-cell_type
of O O
the O O
cortex O O
and O O
medulla O O
. O O

T B-cell_type B-protein
cell I-cell_type I-protein
stage-specific O I-protein
PcG O I-protein
expression O O
profiles O O
suggest O O
that O O
PcG B-DNA B-DNA
genes I-DNA I-DNA
contribute O O
to O O
regulation O O
of O O
T O O
cell O O
differentiation O O
. O O

They O O
probably O O
reflect O O
stabilization O O
of O O
cell O O
type-specific O O
gene O O
expression O O
and O O
irreversibility O O
of O O
lineage O O
choice O O
. O O

The O O
difference O O
in O O
PcG O B-protein
expression O O
between O O
medullar B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
and O O
mature B-cell_type B-cell_type
interfollicular I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
indicates O O
that O O
additional O O
maturation O O
processes O O
occur O O
after O O
thymocyte O B-cell_type
transportation O O
from O O
the O O
thymus O O
. O O

Stepwise O O
lineage O O
restriction O O
of O O
progenitors B-cell_type B-cell_type
in O O
lympho-myelopoiesis O B-cell_type
. O O

It O O
has O O
long O O
been O O
controversial O O
whether O O
hematopoiesis O O
progresses O O
through O O
ordered O O
stages O O
of O O
determination O O
as O O
in O O
embryonic O O
development O O
. O O

This O O
is O O
due O O
to O O
the O O
absence O O
of O O
a O O
methodology O O
capable O O
of O O
exactly O O
determining O O
the O O
developmental O O
potential O O
of O O
hematopoietic B-cell_type B-cell_type
stem/progenitor I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
multilineage O B-cell_type
progenitor O I-cell_type
( O O
MLP O O
) O O
assay O O
enabled O O
us O O
to O O
discriminate O O
among O O
seven O O
types O O
of O O
hematopoietic O B-cell_type
progenitors O I-cell_type
, O O
which O O
are O O
multipotent O O
progenitor O O
p-MTB O O
( O O
capable O O
of O O
generating O O
myeloid B-cell_type B-cell_type
, I-cell_type I-cell_type
T I-cell_type I-cell_type
and I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
) O O
, O O
bipotent O B-cell_type
progenitors O I-cell_type
p-MT O B-cell_type
, O O
p-MB O O
and O O
p-TB O B-cell_line
, O I-cell_line
and O I-cell_line
unipotent O I-cell_line
progenitors O I-cell_line
p-M O I-cell_line
, O O
p-T O O
and O O
p-B O O
. O O

Among O O
these O O
seven O O
types O O
, O O
the O O
p-TB O B-cell_type
type O I-cell_type
progenitor O I-cell_type
was O O
found O O
to O O
be O O
absent O O
. O O

These O O
findings O O
indicate O O
that O O
the O O
process O O
of O O
lineage O O
commitment O O
proceeds O O
through O O
an O O
ordered O O
but O O
not O O
random O O
process O O
. O O

By O O
extending O O
the O O
area O O
of O O
investigation O O
to O O
include O O
the O O
erythroid B-cell_type B-cell_type
lineage I-cell_type I-cell_type
, O O
more O O
convincing O O
evidence O O
for O O
the O O
ordered O O
process O O
was O O
obtained O O
. O O

Detailed O O
and O O
exact O O
illustration O O
of O O
the O O
process O O
of O O
hematopoiesis O O
will O O
provide O O
an O O
opportunity O O
to O O
revive O O
hematopoiesis O O
as O O
one O O
of O O
the O O
most O O
fascinating O O
targets O O
of O O
research O O
in O O
developmental O B-cell_type
biology O I-cell_type

Epstein-Barr O O
Virus O O
and O O
its O O
glycoprotein-350 B-protein O
upregulate O O
IL-6 B-protein B-protein
in O O
human B-cell_type B-cell_type
B-lymphocytes I-cell_type I-cell_type
via O O
CD21 B-protein B-protein
, O O
involving O O
activation O O
of O O
NF-kappaB B-protein B-protein
and O O
different O O
signaling O O
pathways O O
. O O

Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
is O O
a O O
ubiquitous O O
and O O
highly O O
immunotropic O O
gamma O O
herpesvirus O O
that O O
infects O O
more O O
than O O
90 O O
% O O
of O O
humans O O
worldwide O O
. O O

Its O O
pathogenicity O O
leads O O
to O O
a O O
number O O
of O O
diseases O O
including O O
tumors O O
that O O
result O O
from O O
EBV O O
's O O
ability O O
to O O
readily O O
transform O B-cell_type
B-lymphocytes B-cell_type I-cell_type
and O O
, O O
to O O
a O O
lesser O O
extent O O
, O O
epithelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

EBV O O
utilizes O O
CD21/CR2 B-protein B-protein
as O O
its O O
receptor O O
on O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
to O O
initiate O O
the O O
infection O O
process O O
. O O

EBV O O
binds O O
to O O
CR2 B-protein B-protein
through O O
its O O
major B-protein B-protein
envelope I-protein I-protein
glycoprotein-350 I-protein I-protein
( O O
gp350 B-protein O
) O O
and O O
is O O
also O O
a O O
remarkable O O
immunomodulating O O
agent O O
. O O

We O O
had O O
previously O O
shown O O
that O O
EBV O O
is O O
capable O O
of O O
modulating O O
the O O
synthesis O O
of O O
a O O
number O O
of O O
cytokines B-protein B-protein
. O O

We O O
now O O
show O O
that O O
while O O
both O O
purified O O
recombinant B-protein O
gp350 I-protein O
( O O
rgp350 B-protein O
) O O
and O O
EBV O O
upregulate O O
IL-6 B-RNA B-RNA
mRNA I-RNA I-RNA
synthesis O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
EBV-induced O O
IL-6 O B-protein
gene O O
activation O O
occurs O O
for O O
a O O
significantly O O
longer O O
period O O
of O O
time O O
( O O
i.e. O O
12 O O
hours O O
for O O
EBV O O
as O O
compared O O
to O O
6 O O
hours O O
for O O
rgp350 B-protein O
) O O
. O O

Moreover O O
, O O
the O O
half-life O O
of O O
EBV-induced O B-RNA
IL-6 B-RNA I-RNA
mRNA I-RNA I-RNA
was O O
also O O
significantly O O
longer O O
( O O
10 O O
hours O O
) O O
than O O
that O O
of O O
mRNA O B-RNA
induced O O
by O O
rgp350 B-protein O
( O O
about O O
6 O O
hours O O
) O O
. O O

Both O O
EBV O O
and O O
gp350 B-protein B-protein
enhance O O
the O O
binding O O
of O O
the O O
NF-kappaB B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
, O O
as O O
determined O O
by O O
band-shift O O
and O O
augment O O
NF-kappaB B-protein B-protein
-mediated O O
activation O O
of O O
a O O
CAT B-DNA B-DNA
reporter I-DNA I-DNA
plasmid I-DNA I-DNA
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
while O O
the O O
activation O O
of O O
IL-6 O B-DNA
gene O I-DNA
expression O O
by O O
gp350 B-protein B-protein
is O O
mediated O O
primarily O O
by O O
the O O
protein O B-protein
kinase O I-protein
C O I-protein
pathway O O
, O O
EBV O O
can O O
mediate O O
its O O
effects O O
through O O
multiple O O
signaling O O
pathways O O
. O O

To O O
our O O
knowledge O O
this O O
is O O
the O O
first O O
report O O
showing O O
that O O
the O O
binding O O
of O O
a O O
herpesvirus B-protein B-protein
envelope I-protein I-protein
glycoprotein I-protein I-protein
to O O
CR2 B-protein B-protein
on O O
human B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
results O O
in O O
the O O
activation O O
of O O
the O O
NF-kappaB B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
leading O O
to O O
the O O
upregulation O O
of O O
IL-6 O B-DNA
gene O I-DNA
expression O O
in O O
these O O
lymphocytes B-cell_type B-cell_type
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

Gene- O O
and O O
tissue-specificity O O
of O O
mutation O O
in O O
Big O O
Blue O O
rats O O
treated O O
with O O
the O O
hepatocarcinogen O O
N-hydroxy-2-acetylaminofluorene O O
. O O

In O O
a O O
previous O O
study O O
, O O
we O O
found O O
that O O
treating O O
transgenic O O
Big O O
Blue O O
rats O O
with O O
the O O
hepatocarcinogen O O
N-hydroxy-2-acetylaminofluorene O O
( O O
N-OH-AAF O O
) O O
produced O O
the O O
same O O
major O O
DNA O O
adduct O O
in O O
the O O
target O O
liver O O
and O O
the O O
nontarget B-cell_type B-cell_type
spleen I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
bone B-cell_type B-cell_type
marrow I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
induced O O
lacI B-cell_type O
mutants I-cell_type O
in O O
the O O
liver O O
, O O
and O O
induced O O
much O O
lower O O
frequencies O O
of O O
l O B-cell_line
acI B-cell_type I-cell_line
and I-cell_type I-cell_line
hprt I-cell_type I-cell_line
mutants I-cell_type I-cell_line
in O O
spleen B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

In O O
the O O
present O O
study O O
, O O
sequence O O
analysis O O
was O O
conducted O O
on O O
lacI B-DNA B-DNA
DNA I-DNA I-DNA
and O O
hprt B-DNA B-DNA
cDNA I-DNA I-DNA
from O O
the O O
mutants O O
, O O
to O O
determine O O
the O O
mutational O O
specificity O O
of O O
N-OH-AAF O O
in O O
the O O
rat O O
. O O

All O O
the O O
mutation O O
spectra O O
from O O
N-OH-AAF-treated O O
rats O O
differed O O
significantly O O
from O O
corresponding O O
mutation O O
profiles O O
from O O
untreated O O
animals O O
( O O
P O O
= O O
0.02 O O
to O O
P O O
< O O
0.0001 O O
) O O
. O O

Although O O
there O O
were O O
similarities O O
among O O
the O O
mutational O O
patterns O O
derived O O
from O O
N-OH-AAF-treated O O
rats O O
( O O
e.g. O O
, O O
G O O
: O O
C O O
-- O O
> O O
T O O
: O O
A O O
transversion O O
was O O
the O O
most O O
common O O
mutation O O
in O O
all O O
mutation O O
sets O O
) O O
, O O
there O O
were O O
significant O O
differences O O
in O O
the O O
patterns O O
of O O
basepair O O
substitution O O
and O O
frameshift O O
mutation O O
between O O
the O O
liver O O
and O O
spleen B-cell_type O
lymphocyte I-cell_type O
lacI I-cell_type O
mutants I-cell_type O
( O O
P O O
= O O
0.02 O O
) O O
and O O
between O O
the O O
spleen B-cell_type O
lymphocyte I-cell_type O
lacI B-cell_type O
and I-cell_type O
hprt I-cell_type O
mutants I-cell_type O
( O O
P O O
= O O
0.04 O O
) O O
. O O

Also O O
, O O
multiplex O O
PCR O O
analysis O O
of O O
genomic B-DNA B-DNA
DNA I-DNA I-DNA
from O O
the O O
hprt B-cell_type O
mutants I-cell_type O
indicated O O
that O O
12 O O
% O O
of O O
mutants O O
from O O
treated O O
rats O O
had O O
major O O
deletions O O
in O O
the O O
hprt B-DNA B-DNA
gene I-DNA I-DNA
; O O
no O O
corresponding O O
incidence O O
of O O
large O O
deletions O O
was O O
evident O O
among O O
lacI O O
mutations O O
. O O

All O O
the O O
mutation O O
profiles O O
reflect O O
the O O
general O O
mutational O O
specificity O O
of O O
the O O
major O O
DNA O O
adduct O O
formed O O
by O O
N-OH-AAF O O
. O O

The O O
differences O O
between O O
N-OH-AAF O O
mutation O O
in O O
the O O
endogenous B-DNA B-DNA
gene I-DNA I-DNA
and O O
transgene B-DNA O
can O O
be O O
partially O O
explained O O
by O O
the O O
structures O O
of O O
the O O
two O O
genes O O
. O O

The O O
tissue-specificity O O
of O O
the O O
mutation O O
spectra O O
may O O
contribute O O
to O O
targeting O O
tumor O O
formation O O
to O O
the O O
liver O O
. O O

Environ. O O
Mol. O O
Mutagen. O O
37 O O
: O O
203-214 O O
, O O
2001 O O
. O O

Published O O
2001 O O
Wiley-Liss O O
, O O
Inc O O
. O O

Caspase B-protein B-protein
-dependent O O
cleavage O O
of O O
the O O
hematopoietic B-protein B-protein
specific I-protein I-protein
adaptor I-protein I-protein
protein I-protein I-protein
Gads I-protein I-protein
alters O O
signalling O O
from O O
the O O
T B-protein B-protein
cell I-protein I-protein
receptor I-protein I-protein
. O O

Gads B-protein O
is O O
a O O
SH2 B-protein B-protein
and I-protein I-protein
SH3 I-protein I-protein
domain I-protein I-protein
-containing O O
, O O
hematopoietic-specific B-protein B-protein
adaptor I-protein I-protein
protein I-protein I-protein
that O O
functions O O
in O O
signalling O O
from O O
the O O
T B-protein B-protein
cell I-protein I-protein
receptor I-protein I-protein
. O O

Gads B-protein O
acts O O
by O O
linking O O
SLP-76 B-protein B-protein
, O O
bound O O
by O O
the O O
carboxy-terminal B-protein B-protein
Gads I-protein I-protein
SH3 I-protein I-protein
domain I-protein I-protein
, O O
to O O
tyrosine B-protein O
phosphorylated I-protein O
LAT I-protein B-protein
which O O
contains O O
binding O B-DNA
sites O I-DNA
for O O
the O O
Gads B-protein B-protein
SH2 I-protein I-protein
domain I-protein I-protein
. O O

Gads B-protein B-protein
is O O
distinguished O O
from O O
Grb2 B-protein B-protein
and O O
the O O
closely O O
related O O
Grap B-protein B-protein
protein I-protein I-protein
by O O
the O O
presence O O
of O O
a O O
120 B-protein B-protein
amino I-protein I-protein
acid I-protein I-protein
unique I-protein I-protein
region I-protein I-protein
between O O
the O O
SH2 B-protein B-protein
domain I-protein I-protein
and O O
the O O
carboxy B-protein B-protein
terminal I-protein I-protein
SH3 I-protein I-protein
domain I-protein I-protein
. O O

Here O O
we O O
demonstrate O O
that O O
the O O
unique O O
region O O
of O O
Gads B-protein B-protein
contains O O
a O O
capase B-protein B-DNA
cleavage I-protein I-DNA
site I-protein I-DNA
. O O

Induction O O
of O O
apoptosis O O
in O O
lymphocytes B-cell_type B-cell_type
results O O
in O O
detectable O O
Gads B-protein O
cleavage O O
by O O
60 O O
min O O
. O O

Gads B-protein O
cleavage O O
is O O
blocked O O
in O O
vivo O O
by O O
treating O O
cells O O
with O O
a O O
caspase O B-protein
3 O I-protein
inhibitor O O
. O O

A O O
putative B-protein O
caspase I-protein B-DNA
3 I-protein I-DNA
cleavage I-protein I-DNA
site I-protein I-DNA
was O O
identified O O
within O O
the O O
unique O O
region O O
and O O
mutation O O
of O O
this O O
site O O
prevented O O
Gads B-protein B-protein
cleavage O O
in O O
vitro O O
, O O
and O O
in O O
vivo O O
. O O

The O O
Gads B-protein B-protein
cleavage O I-protein
products O I-protein
retained O O
the O O
predicted O O
binding O O
specificity O O
for O O
SLP-76 B-protein B-protein
and O O
LAT B-protein B-protein
. O O

Expression O O
of O O
the O O
Gads B-protein B-protein
cleavage O I-protein
products O I-protein
in O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
inhibited O O
NFAT O B-protein
activation O O
following O O
TCR O B-protein
cross O O
linking O O
. O O

These O O
findings O O
indicate O O
that O O
cleavage O O
of O O
Gads B-protein O
in O O
vivo O O
could O O
function O O
to O O
alter O O
signalling O O
downstream O O
of O O
the O O
T B-protein B-protein
cell I-protein I-protein
receptor I-protein I-protein
by O O
disrupting O O
cross O O
talk O O
between O O
SLP-76 B-protein B-protein
and O O
LAT B-protein B-protein
. O O

Targeting O O
of O O
p300 B-protein B-protein
to O O
the O O
interleukin-2 B-DNA B-DNA
promoter I-DNA I-DNA
via O O
CREB-Rel O B-protein
cross-talk O O
during O O
mitogen B-protein B-protein
and O O
oncogenic O O
molecular O O
signaling O O
in O O
activated B-cell_type B-cell_type
T-cells I-cell_type I-cell_type
. O O

In O O
this O O
report O O
, O O
we O O
explore O O
the O O
mechanisms O O
of O O
targeting O O
of O O
p300 B-protein B-protein
to O O
the O O
interleukin-2 B-DNA B-DNA
( I-DNA I-DNA
IL-2 I-DNA I-DNA
) I-DNA I-DNA
promoter I-DNA I-DNA
in O O
response O O
to O O
mitogenic O O
and O O
oncogenic O O
molecular O O
signals O O
. O O

Recruitment O O
of O O
p300 B-protein B-protein
by O O
cAMP-responsive B-protein B-protein
element-binding I-protein I-protein
protein-Rel I-protein I-protein
cross-talk O O
at O O
the O O
composite B-protein B-DNA
CD28 I-protein I-DNA
response I-protein I-DNA
element I-protein I-DNA
( O O
CD28RE B-protein B-DNA
) O O
- O O
TRE B-DNA B-DNA
element I-DNA I-DNA
of O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
is O O
essential O O
for O O
promoter O O
inducibility O O
during O O
T-cell O O
activation O O
, O O
and O O
CD28RE-TRE B-DNA B-protein
is O O
the O O
exclusive O O
target O O
of O O
the O O
human B-cell_type B-protein
T-cell I-cell_type I-protein
lymphotropic O I-protein
virus O I-protein
type O I-protein
I O I-protein
oncoprotein B-protein I-protein
Tax I-protein I-protein
. O O

The O O
intrinsic O O
histone O B-protein
acetyltransferase O I-protein
activity O O
of O O
p300 B-protein B-protein
is O O
dispensable O O
for O O
activation O O
of O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
, O O
and O O
the O O
N-terminal B-protein B-protein
743 I-protein I-protein
residues I-protein I-protein
contain O O
the O O
minimal O O
structural O O
requirements O O
for O O
synergistic O O
transactivation O O
of O O
the O O
CD28RE-TRE B-DNA B-DNA
, O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
, O O
and O O
endogenous O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
expression O O
. O O

Mutational O O
analysis O O
of O O
p300 B-protein B-protein
reveals O O
differential O O
structural O O
requirements O O
for O O
the O O
N-terminal O B-protein
p300 O I-protein
module O I-protein
by O O
individual O O
cis-elements B-DNA B-DNA
within O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

These O O
findings O O
provide O O
evidence O O
that O O
p300 B-protein B-protein
assembles O O
at O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
to O O
form O O
an O O
enhanceosome-like O O
signal O O
transduction O O
target O O
that O O
is O O
centrally O O
integrated O O
at O O
the O O
CD28RE-TRE B-DNA B-DNA
element I-DNA I-DNA
of O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
through O O
specific O O
protein O O
module-targeted O O
associations O O
in O O
activated B-cell_type B-cell_type
T-cells I-cell_type I-cell_type
. O O

Regulation O O
of O O
cytokine O B-protein
production O O
in O O
T-cell B-cell_type O
responses O O
to O O
inhalant O O
allergen O O
: O O
GATA-3 B-protein B-protein
expression O O
distinguishes O O
between O O
Th1- O O
and O O
Th2-polarized O O
immunity O O
. O O

BACKGROUND O O
: O O
The O O
precise O O
nature O O
of O O
allergen-specific O O
cytokine O B-protein
responses O O
in O O
atopics O O
versus O O
non-atopics O O
, O O
in O O
particular O O
the O O
'Th1 O O
polarity O O
' O O
of O O
responses O O
in O O
non-atopics O O
, O O
remains O O
controversial O O
. O O

This O O
is O O
due O O
in O O
part O O
to O O
the O O
relative O O
insensitivity O O
of O O
cytokine O B-protein
detection O O
systems O O
, O O
and O O
associated O O
variations O O
in O O
kinetics O O
of O O
cytokine O B-protein
production O O
and O O
catabolism O O
in O O
in O O
vitro O O
culture O O
systems O O
. O O

As O O
an O O
alternative O O
to O O
cytokine O B-protein
measurement O O
, O O
this O O
study O O
focuses O O
on O O
expression O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
GATA-3 I-protein B-protein
for O O
analysis O O
of O O
allergen-specific O O
Th O O
cell O O
responses O O
. O O

METHODS O O
: O O
Cord B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
Th1- O O
or O O
Th2-polarized O O
by O O
culture O O
in O O
IL-12- O O
or O O
IL-4-employing O O
established O O
methods O O
; O O
PBMC B-cell_type B-cell_type
from O O
house O O
dust O O
mite O O
( O O
HDM O O
) O O
-sensitive O O
atopics O O
and O O
controls O O
were O O
stimulated O O
overnight O O
with O O
HDM O O
; O O
cytokine O B-protein
production O O
was O O
measured O O
by O O
ELISA O O
and O O
GATA-3 B-RNA B-protein
mRNA I-RNA O
expression O O
by O O
PCR O O
. O O

RESULTS O O
: O O
Cytokine B-protein B-protein
-driven O O
Th2 O O
polarization O O
of O O
naive B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
is O O
associated O O
with O O
marked O O
upregulation O O
of O O
GATA-3 B-protein B-protein
expression O O
, O O
whereas O O
a O O
reciprocal O O
expression O O
pattern O O
accompanies O O
differentiation O O
towards O O
the O O
Th1 O B-cell_type
cytokine O B-protein
phenotype O O
. O O

In O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
HDM O O
skin O O
prick O O
test-positive O O
( O O
HDM-SPT+/HDM-IgE+ O O
) O O
volunteers O O
, O O
overnight O O
stimulation O O
results O O
in O O
marked O O
upregulation O O
of O O
GATA-3 B-protein B-protein
expression O O
, O O
compared O O
to O O
an O O
equally O O
marked O O
downregulation O O
of O O
expression O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
SPT-/IgE- O O
subjects O O
. O O

In O O
subjects O O
who O O
are O O
HDM-SPT+ O O
but O O
IgE- O O
, O O
GATA-3 B-protein B-protein
expression O O
levels O O
remained O O
relatively O O
stable O O
during O O
culture O O
with O O
HDM O O
. O O

CONCLUSIONS O O
: O O
Upregulation O O
of O O
GATA-3 B-protein B-protein
expression O O
in O O
PBMC B-cell_type B-cell_type
is O O
a O O
hallmark O O
of O O
the O O
early O O
phase O O
of O O
Th2 O O
recall O O
responses O O
to O O
specific O O
allergen O O
in O O
atopics O B-cell_type
. O O

The O O
reciprocal O O
expression O O
pattern O O
observed O O
in O O
HDM-specific O O
recall O O
responses O O
of O O
non-atopics O O
provides O O
independent O O
confirmation O O
of O O
the O O
presence O O
of O O
underlying O O
Th1-like O O
immunity O O
in O O
these O O
subjects O O
. O O

The O O
parallel O O
findings O O
in O O
neonatal B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
suggest O O
that O O
the O O
same O O
approach O O
may O O
be O O
utilized O O
for O O
monitoring O O
the O O
progress O O
of O O
allergen-specific O O
Th1/Th2 O O
memory O O
development O O
during O O
early O O
childhood O O
, O O
and O O
hence O O
in O O
assessment O O
of O O
risk O O
for O O
future O O
allergic O O
disease O O
. O O

Copyright O O
2001 O O
S. O O
Karger O O
AG O O
, O O
Basel O O

The O O
heat O O
shock O O
response O O
reduces O O
myelin B-protein B-protein
oligodendrocyte I-protein I-protein
glycoprotein I-protein I-protein
-induced O O
experimental O O
autoimmune O O
encephalomyelitis O O
in O O
mice O O
. O O

The O O
stress O O
response O O
( O O
SR O O
) O O
can O O
block O O
inflammatory O O
gene O O
expression O O
by O O
preventing O O
activation O O
of O O
transcription B-protein B-protein
factor I-protein I-protein
nuclear B-protein B-protein
factor-kappa I-protein I-protein
B I-protein I-protein
( O O
NF-kappaB B-protein B-protein
) O O
. O O

As O O
inflammatory O O
gene O O
expression O O
contributes O O
to O O
the O O
pathogenesis O O
of O O
demyelinating O O
diseases O O
, O O
we O O
tested O O
the O O
effects O O
of O O
the O O
SR O O
on O O
the O O
progression O O
of O O
the O O
demyelinating O O
disease O O
experimental O O
autoimmune O O
encephalomyelitis O O
( O O
EAE O O
) O O
. O O

EAE O B-protein
was O O
actively O O
induced O O
in O O
C57BL/6 O O
mice O O
using O O
an O O
encephalitogenic O B-protein
myelin B-protein I-protein
oligodendrocyte I-protein I-protein
glycoprotein I-protein I-protein
( O O
MOG B-protein O
( I-protein O
35-55 I-protein O
) I-protein O
) O O
peptide O O
. O O

Whole O O
body O O
hyperthermia O O
was O O
used O O
to O O
induce O O
a O O
heat O O
shock O O
response O O
( O O
HSR O O
) O O
in O O
immunized O O
mice O O
2 O O
days O O
after O O
the O O
booster O O
MOG O O
( O O
35-55 O O
) O O
peptide O O
injection O O
. O O

The O O
HSR O B-DNA
reduced O O
the O O
incidence O O
of O O
EAE O O
by O O
70 O O
% O O
, O O
delayed O O
disease O O
onset O O
by O O
6 O O
days O O
, O O
and O O
attenuated O O
disease O O
severity O O
. O O

The O O
HSR O O
attenuated O O
leukocyte B-cell_type O
infiltration O O
into O O
CNS O O
assessed O O
by O O
quantitation O O
of O O
perivascular O O
infiltrates O O
, O O
and O O
by O O
reduced O O
staining O O
for O O
CD4 B-protein B-protein
and O O
CD25 B-protein B-protein
immunopositive O I-cell_type
T-cells B-cell_type I-cell_type
. O O

T-cell O O
activation O O
, O O
assessed O O
by O O
the O O
production O O
of O O
interferon B-protein B-protein
gamma I-protein I-protein
( O O
IFNgamma B-protein B-protein
) O O
in O O
response O O
to O O
MOG B-protein O
( I-protein O
35-55 I-protein O
) I-protein O
, O O
was O O
also O O
decreased O O
by O O
the O O
HSR O B-DNA
. O O

The O O
HSR O O
reduced O O
inflammatory O O
gene O O
expression O O
in O O
the O O
brain O O
that O O
normally O O
occurs O O
during O O
EAE O O
, O O
including O O
the O O
early O O
increase O O
in O O
RANTES B-protein B-protein
( O O
regulated B-protein O
on I-protein O
activation I-protein O
of I-protein O
normal I-protein O
T-cell I-protein O
expressed I-protein O
and I-protein O
secreted I-protein O
) O O
expression O O
, O O
and O O
the O O
later O O
expression O O
of O O
the O O
inducible O O
form O O
of O O
nitric B-protein B-protein
oxide I-protein I-protein
synthase I-protein I-protein
. O O

The O O
early O O
activation O O
of O O
transcription B-protein B-protein
factor I-protein I-protein
NF-kappaB B-protein B-protein
was O O
also O O
blocked O O
by O O
the O O
HSR O B-DNA
. O O

The O O
finding O O
that O O
the O O
SR O O
reduces O O
inflammation O O
in O O
the O O
brain O O
and O O
the O O
clinical O O
severity O O
of O O
EAE O O
opens O O
a O O
novel O O
therapeutic O O
approach O O
for O O
prevention O O
of O O
autoimmune O O
diseases O O
. O O

In O O
vivo O O
detection O O
of O O
intracellular O O
signaling O O
pathways O O
in O O
developing O B-cell_type
thymocytes B-cell_type I-cell_type
. O O

Information O O
regarding O O
the O O
intracellular O O
signaling O O
processes O O
that O O
occur O O
during O O
the O O
development O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
has O O
largely O O
been O O
obtained O O
with O O
the O O
use O O
of O O
transgenic O O
mouse O O
models O O
, O O
which O O
although O O
providing O O
invaluable O O
information O O
are O O
time O O
consuming O O
and O O
costly O O
. O O

To O O
this O O
end O O
, O O
we O O
have O O
developed O O
a O O
novel O O
system O O
that O O
facilitates O O
the O O
in O O
vivo O O
analysis O O
of O O
signal O O
transduction O O
pathways O O
during O O
T-lymphocyte B-cell_type O
development O O
. O O

This O O
approach O O
uses O O
reporter-plasmids B-DNA O
for O O
the O O
detection O O
of O O
intracellular O O
signals O O
mediated O O
by O O
the O O
mitogen-activated B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
or O O
cyclic B-protein B-protein
AMP-dependent I-protein I-protein
protein I-protein I-protein
kinase I-protein I-protein
. O O

Reporter-plasmids B-DNA O
are O O
transfected O O
into O O
thymocytes B-cell_type B-cell_type
in O O
fetal O B-cell_line
thymic O I-cell_line
organ O I-cell_line
culture O I-cell_line
by O O
accelerated O O
DNA/particle O O
bombardment O O
( O O
gene O O
gun O O
) O O
, O O
and O O
the O O
activation O O
of O O
a O O
signaling O O
pathway O O
is O O
determined O O
in O O
the O O
form O O
of O O
a O O
standard O O
luciferase O B-protein
assay O O
. O O

Importantly O O
, O O
this O O
powerful O O
technique O O
preserves O O
the O O
structural O O
integrity O O
of O O
the O O
thymus O O
, O O
and O O
will O O
provide O O
an O O
invaluable O O
tool O O
to O O
study O O
how O O
thymocytes B-cell_type B-cell_type
respond O O
to O O
normal O O
environmental O O
stimuli O O
encountered O O
during O O
differentiation O O
within O O
the O O
thymic O O
milieu O O
. O O

Thus O O
, O O
this O O
method O O
allows O O
for O O
the O O
monitoring O O
of O O
signals O O
that O O
occur O O
in O O
a O O
biological O O
time O O
frame O O
, O O
such O O
as O O
during O O
differentiation O O
, O O
and O O
within O O
the O O
natural O O
environment O O
of O O
differentiating B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Core-binding B-protein B-protein
factor I-protein I-protein
beta I-protein I-protein
( O O
CBFbeta B-protein B-protein
) O O
, O O
but O O
not O O
CBFbeta-smooth B-protein B-protein
muscle I-protein I-protein
myosin I-protein I-protein
heavy I-protein I-protein
chain I-protein I-protein
, O O
rescues O O
definitive O O
hematopoiesis O O
in O O
CBFbeta B-protein B-protein
-deficient O B-cell_type
embryonic B-cell_type I-cell_type
stem I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Core-binding B-protein B-protein
factor I-protein I-protein
beta I-protein I-protein
( O O
CBFbeta B-protein B-protein
) O O
is O O
the O O
non-DNA-binding B-protein B-protein
subunit I-protein I-protein
of O O
the O O
heterodimeric B-protein B-protein
CBFs I-protein I-protein
. O O

Genes B-DNA O
encoding I-DNA O
CBFbeta I-DNA B-protein
( O O
CBFB B-DNA B-protein
) O O
, O O
and O O
one O O
of O O
the O O
DNA-binding B-protein B-protein
CBFalpha I-protein I-protein
subunits I-protein I-protein
, I-protein O
Runx1 I-protein B-protein
( O O
also O O
known O O
as O O
CBFalpha2 B-protein B-protein
, O O
AML1 B-protein B-protein
, O O
and O O
PEBP2alphaB B-protein B-protein
) O O
, O O
are O O
required O O
for O O
normal O O
hematopoiesis O O
and O O
are O O
also O O
frequent O O
targets O O
of O O
chromosomal O O
translocations O O
in O O
acute O O
leukemias O O
in O O
humans O O
. O O

Homozygous O O
disruption O O
of O O
either O O
the O O
Runx1 B-DNA B-DNA
or I-DNA I-DNA
Cbfb I-DNA I-DNA
gene I-DNA I-DNA
in O O
mice O O
results O O
in O O
embryonic O O
lethality O O
at O O
midgestation O O
due O O
to O O
hemorrhaging O O
in O O
the O O
central O O
nervous O O
system O O
, O O
and O O
severely O O
impairs O O
fetal O O
liver O O
hematopoiesis O O
. O O

Results O O
of O O
this O O
study O O
show O O
that O O
Cbfb-deficient O B-cell_line
mouse O I-cell_line
embryonic B-cell_type I-cell_line
stem I-cell_type I-cell_line
( I-cell_type I-cell_line
ES I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
can O O
differentiate O O
into O O
primitive B-cell_type B-cell_line
erythroid I-cell_type I-cell_line
colonies I-cell_type I-cell_line
in O O
vitro O O
, O O
but O O
are O O
impaired O O
in O O
their O O
ability O O
to O O
produce O O
definitive O O
erythroid B-cell_type B-cell_type
and I-cell_type I-cell_type
myeloid I-cell_type I-cell_type
colonies I-cell_type I-cell_type
, O O
mimicking O O
the O O
in O O
vivo O O
defect O O
. O O

Definitive O O
hematopoiesis O O
is O O
restored O O
by O O
ectopic O O
expression O O
of O O
full-length B-DNA B-DNA
Cbfb I-DNA I-DNA
transgenes I-DNA I-DNA
, O O
as O O
well O O
as O O
by O O
a O O
transgene O O
encoding O O
only O O
the O O
heterodimerization B-protein B-protein
domain I-protein I-protein
of O O
CBFbeta B-protein B-protein
. O O

In O O
contrast O O
, O O
the O O
CBFbeta B-protein B-protein
- O O
smooth B-protein B-protein
muscle I-protein I-protein
myosin I-protein I-protein
heavy I-protein I-protein
chain I-protein I-protein
( I-protein I-protein
SMMHC I-protein I-protein
) I-protein I-protein
fusion I-protein I-protein
protein I-protein I-protein
generated O O
by O O
the O O
inv B-protein O
( I-protein O
16 I-protein O
) I-protein O
associated O O
with O O
acute B-cell_line O
myeloid I-cell_line O
leukemias I-cell_line O
( O O
M4Eo B-cell_line O
) O O
can O O
not O O
rescue O O
definitive O O
hematopoiesis O O
by O O
Cbfb-deficient B-cell_type B-cell_type
ES I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Sequences O O
responsible O O
for O O
the O O
inability O O
of O O
CBFbeta B-protein B-protein
-SMMHC O I-protein
to O O
rescue O O
definitive O O
hematopoiesis O O
reside O O
in O O
the O O
SMMHC B-protein B-protein
portion I-protein I-protein
of O O
the O O
fusion B-protein B-protein
protein I-protein I-protein
. O O

Results O O
also O O
show O O
that O O
the O O
CBFbeta-SMMHC B-protein B-protein
fusion I-protein I-protein
protein I-protein I-protein
transdominantly O O
inhibits O O
definitive O O
hematopoiesis O O
, O O
but O O
not O O
to O O
the O O
same O O
extent O O
as O O
homozygous O O
loss O O
of O O
Runx1 B-protein B-protein
or O O
Cbfb B-protein B-protein
. O O

CBFbeta-SMMHC B-protein B-protein
preferentially O O
inhibits O O
the O O
differentiation O O
of O O
myeloid B-cell_type B-cell_type
lineage I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
while O O
increasing O O
the O O
number O O
of O O
blastlike B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
culture O O
. O O

The O O
latency O O
pattern O O
of O O
Epstein-Barr O O
virus O O
infection O O
and O O
viral O O
IL-10 B-protein B-protein
expression O O
in O O
cutaneous B-cell_type O
natural I-cell_type O
killer/T-cell I-cell_type O
lymphomas I-cell_type O
. O O

The O O
nasal B-cell_type O
type I-cell_type O
, I-cell_type O
extranodal I-cell_type B-cell_type
natural I-cell_type I-cell_type
killer I-cell_type I-cell_type
or I-cell_type I-cell_type
T I-cell_type I-cell_type
( I-cell_type I-cell_type
NK/T I-cell_type I-cell_type
) I-cell_type I-cell_type
-cell I-cell_type I-cell_type
lymphoma I-cell_type I-cell_type
is O O
usually O O
associated O O
with O O
latent O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
infection O O
. O O

In O O
order O O
to O O
elucidate O O
the O O
EBV O O
gene O O
expression O O
patterns O O
in O O
vivo O O
, O O
we O O
examined O O
eight O O
patients O O
with O O
cutaneous O O
EBV-related O O
NK/T-cell O O
lymphomas O O
, O O
including O O
six O O
patients O O
with O O
a O O
NK-cell O O
phenotype O O
and O O
two O O
patients O O
with O O
a O O
T-cell O O
phenotype O O
. O O

The O O
implication O O
of O O
EBV O O
in O O
the O O
skin O O
lesions O O
was O O
determined O O
by O O
the O O
presence O O
of O O
EBV-DNA B-DNA O
, O O
EBV-encoded B-RNA B-RNA
nuclear I-RNA I-RNA
RNA I-RNA I-RNA
( O O
EBER B-RNA O
) O O
and O O
a O O
clonality O O
of O O
EBV-DNA B-DNA B-DNA
fragments I-DNA I-DNA
containing O O
the O O
terminal B-DNA B-DNA
repeats I-DNA I-DNA
. O O

Transcripts O O
of O O
EBV-encoded B-DNA B-DNA
genes I-DNA I-DNA
were O O
screened O O
by O O
reverse O B-protein
transcription- O I-protein
polymerase O I-protein
chain O I-protein
reaction O O
( O O
RT-PCR O O
) O O
, O O
and O O
confirmed O O
by O O
Southern O O
blot O O
hybridization O O
. O O

The O O
expression O O
of O O
EBV-related B-protein B-protein
antigens I-protein I-protein
was O O
examined O O
by O O
immunostaining O O
using O O
paraffin-embedded O O
tissue O O
sections O O
and O O
cell O O
pellets O O
of O O
EBV-positive B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

Our O O
study O O
demonstrated O O
that O O
all O O
samples O O
from O O
the O O
patients O O
contained O O
EBV B-RNA B-RNA
nuclear I-RNA I-RNA
antigen I-RNA I-RNA
( I-RNA I-RNA
EBNA I-RNA I-RNA
) I-RNA I-RNA
-1 I-RNA I-RNA
mRNA I-RNA I-RNA
which O O
was O O
transcribed O O
using O O
the O O
Q B-DNA B-DNA
promoter I-DNA I-DNA
, O O
whereas O O
both O O
the O O
Q B-DNA B-DNA
promoter I-DNA I-DNA
and O O
another O O
upstream B-DNA B-DNA
promoter I-DNA I-DNA
( O O
Cp/Wp B-DNA B-DNA
) O O
were O O
used O O
in O O
EBV-positive B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
B95.8 B-cell_line B-cell_line
, O O
Raji B-cell_line B-cell_line
and O O
Jiyoye B-cell_line O
. O O

Latent B-RNA B-RNA
membrane I-RNA I-RNA
protein-1 I-RNA I-RNA
( I-RNA I-RNA
LMP-1 I-RNA I-RNA
) I-RNA I-RNA
mRNA I-RNA I-RNA
was O O
detected O O
in O O
seven O O
of O O
eight O O
patients O O
and O O
all O O
cell B-cell_line O
lines I-cell_line O
, O O
whereas O O
EBNA-2 B-RNA B-RNA
transcripts I-RNA I-RNA
were O O
found O O
only O O
in O O
the O O
cell B-cell_line B-cell_line
lines I-cell_line I-cell_line
. O O

Immunostaining O O
showed O O
no O O
LMP-1 B-protein B-protein
, I-protein O
EBNA-2 I-protein B-protein
or I-protein O
ZEBRA I-protein B-protein
antigens I-protein I-protein
in O O
the O O
paraffin-embedded O O
tissue O O
sections O O
, O O
although O O
they O O
were O O
positive O O
in O O
the O O
cell B-cell_line B-cell_line
line I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Latent B-RNA B-protein
BHRF1 I-RNA B-RNA
transcripts I-RNA I-RNA
encoding O O
bcl-2 B-RNA B-protein
homologue I-RNA O
and O O
BCRF1 B-RNA B-RNA
transcripts I-RNA I-RNA
encoding O O
viral B-protein B-protein
interleukin I-protein I-protein
( I-protein I-protein
vIL I-protein I-protein
) I-protein I-protein
-10 I-protein I-protein
were O O
detected O O
in O O
one O O
and O O
two O O
of O O
eight O O
patients O O
, O O
respectively O O
. O O

A O O
patient O O
with O O
NK-cell O O
lymphoma O O
expressing O O
both O O
transcripts O O
died O O
of O O
rapid O O
progression O O
of O O
the O O
illness O O
. O O

Our O O
results O O
indicate O O
that O O
the O O
restricted O O
expression O O
of O O
the O O
latency-associated B-DNA B-DNA
EBV I-DNA I-DNA
genes I-DNA I-DNA
and O O
the O O
production O O
of O O
vIL-10 B-RNA B-protein
and I-RNA O
bcl-2 I-RNA B-protein
homologue I-RNA O
may O O
favour O O
tumour O O
growth O O
, O O
evading O O
the O O
host O O
immune O O
surveillance O O
. O O

Copyright O O
2001 O O
Cancer O O
Research O O
Campaign O O
. O O

Oxidized O O
alkyl O O
phospholipids O O
are O O
specific O O
, O O
high O O
affinity O B-protein
peroxisome O I-protein
proliferator-activated O I-protein
receptor O I-protein
gamma O I-protein
ligands O O
and O O
agonists O O
. O O

Synthetic O O
high O O
affinity O B-protein
peroxisome O I-protein
proliferator-activated O I-protein
receptor O I-protein
( O O
PPAR O B-protein
) O O
agonists O O
are O O
known O O
, O O
but O O
biologic O O
ligands O O
are O O
of O O
low O O
affinity O O
. O O

Oxidized B-protein B-protein
low I-protein I-protein
density I-protein I-protein
lipoprotein I-protein I-protein
( O O
oxLDL B-protein B-protein
) O O
is O O
inflammatory O O
and O O
signals O O
through O O
PPARs B-protein B-protein
. O O

We O O
showed O O
, O O
by O O
phospholipase O O
A O O
( O O
1 O O
) O O
digestion O O
, O O
that O O
PPARgamma O B-protein
agonists O O
in O O
oxLDL B-protein B-protein
arise O O
from O O
the O O
small O O
pool O O
of O O
alkyl O O
phosphatidylcholines O O
in O O
LDL B-protein O
. O O

We O O
identified O O
an O O
abundant O O
oxidatively O O
fragmented O O
alkyl O O
phospholipid O O
in O O
oxLDL B-protein B-protein
, O O
hexadecyl O O
azelaoyl O O
phosphatidylcholine O O
( O O
azPC O O
) O O
, O O
as O O
a O O
high O O
affinity O O
ligand O O
and O O
agonist O O
for O O
PPARgamma B-protein B-protein
. O O

[ O B-protein
( O I-protein
3 O I-protein
) O I-protein
H O I-protein
] O I-protein
azPC O I-protein
bound O I-protein
recombinant B-protein I-protein
PPARgamma I-protein I-protein
with O O
an O O
affinity O O
( O O
K O O
( O O
d O O
) O O
( O O
( O O
app O O
) O O
) O O
approximately O O
40 O O
nm O O
) O O
that O O
was O O
equivalent O O
to O O
rosiglitazone O O
( O O
BRL49653 O O
) O O
, O O
and O O
competition O O
with O O
rosiglitazone O O
showed O O
that O O
binding O O
occurred O O
in O O
the O O
ligand-binding B-protein B-protein
pocket I-protein I-protein
. O O

azPC O O
induced O O
PPRE O B-DNA
reporter O I-DNA
gene O I-DNA
expression O O
, O O
as O O
did O O
rosiglitazone O O
, O O
with O O
a O O
half-maximal O O
effect O O
at O O
100 O O
nm O O
. O O

Overexpression O O
of O O
PPARalpha B-protein B-protein
or O O
PPARgamma B-protein B-protein
revealed O O
that O O
azPC O O
was O O
a O O
specific O O
PPARgamma O B-protein
agonist O O
. O O

The O O
scavenger B-protein O
receptor I-protein B-protein
CD36 I-protein B-protein
is O O
encoded O O
by O O
a O O
PPRE-responsive B-DNA B-DNA
gene I-DNA I-DNA
, O O
and O O
azPC O O
enhanced O O
expression O O
of O O
CD36 B-protein B-protein
in O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
. O O

We O O
found O O
that O O
anti-CD36 B-protein B-protein
inhibited O O
azPC O O
uptake O O
, O O
and O O
it O O
inhibited O O
PPRE O B-DNA
reporter O I-DNA
induction O O
. O O

Results O O
with O O
a O O
small O B-protein
molecule O I-protein
phospholipid B-protein I-protein
flippase I-protein I-protein
mimetic I-protein O
suggest O O
azPC O O
acts O O
intracellularly O O
and O O
that O O
cellular O O
azPC O O
accumulation O O
was O O
efficient O O
. O O

Thus O O
, O O
certain O O
alkyl O B-protein
phospholipid O I-protein
oxidation O I-protein
products O I-protein
in O O
oxLDL B-protein B-protein
are O O
specific O O
, O O
high O O
affinity O O
extracellular O O
ligands O O
and O O
agonists O O
for O O
PPARgamma B-protein B-protein
that O O
induce O O
PPAR-responsive B-DNA B-DNA
genes I-DNA I-DNA

Regulation O O
of O O
the O O
human B-DNA B-DNA
MAT2B I-DNA I-DNA
gene I-DNA I-DNA
encoding O O
the O O
regulatory B-protein B-protein
beta I-protein I-protein
subunit I-protein I-protein
of O O
methionine B-protein O
adenosyltransferase I-protein O
, O O
MAT B-protein B-protein
II I-protein I-protein
. O O

Methionine B-protein O
adenosyltransferase I-protein O
( O O
MAT B-protein O
) O O
catalyzes O O
the O O
biosynthesis O O
of O O
S-adenosylmethionine B-protein O
( O O
AdoMet B-protein O
) O O
, O O
a O O
key O O
molecule O O
in O O
transmethylation O O
reactions O O
and O O
polyamine O O
biosynthesis O O
. O O

The O O
MAT B-protein B-protein
II I-protein I-protein
isozyme I-protein I-protein
consists O O
of O O
a O O
catalytic B-protein B-protein
alpha2 I-protein I-protein
and I-protein O
a I-protein O
regulatory I-protein B-protein
beta I-protein I-protein
subunit I-protein I-protein
. O O

Down-regulation O O
of O O
the O O
MAT B-protein B-protein
II I-protein I-protein
beta I-protein I-protein
subunit I-protein I-protein
expression O O
causes O O
a O O
6-10-fold O O
increase O O
in O O
intracellular O O
AdoMet B-protein O
levels O O
. O O

To O O
understand O O
the O O
mechanism O O
by O O
which O O
the O O
beta B-protein B-protein
subunit I-protein I-protein
expression O O
is O O
regulated O O
, O O
we O O
cloned O O
the O O
MAT2B B-DNA B-DNA
gene I-DNA I-DNA
, O O
determined O O
its O O
organization O O
, O O
characterized O O
its O O
5'-flanking B-DNA B-DNA
sequences I-DNA I-DNA
, O O
and O O
elucidated O O
the O O
in O O
vitro O O
and O O
in O O
vivo O O
regulation O O
of O O
its O O
promoter B-DNA B-DNA
. O O

Transcription O O
of O O
the O O
MAT2B B-DNA B-DNA
gene I-DNA I-DNA
initiates O O
at O O
position O B-DNA
-203 O I-DNA
relative O O
to O O
the O O
translation B-DNA B-DNA
start I-DNA I-DNA
site I-DNA I-DNA
. O O

Promoter B-DNA O
deletion I-DNA O
analysis I-DNA O
defined O O
a O O
minimal B-DNA B-DNA
promoter I-DNA I-DNA
between O O
positions B-DNA B-DNA
+52 I-DNA I-DNA
and I-DNA I-DNA
+93 I-DNA I-DNA
base O I-DNA
pairs O I-DNA
, O O
a O O
GC-rich B-DNA B-DNA
region I-DNA I-DNA
. O O

Inclusion O O
of O O
the O O
sequences O O
between O O
-4 O B-DNA
and O I-DNA
+52 O I-DNA
enhanced O O
promoter O O
activity O O
; O O
this O O
was O O
primarily O O
because O O
of O O
an O O
Sp1 B-DNA B-DNA
recognition I-DNA I-DNA
site I-DNA I-DNA
at O O
+9/+15 O O
. O O

The O O
inclusion O O
of O O
sequences O O
up O O
to O O
position O O
-115 O O
provided O O
full O O
activity O O
; O O
this O O
was O O
attributed O O
to O O
a O O
TATA B-DNA B-DNA
at O O
-32 O B-DNA
. O O

The O O
Sp1 B-DNA B-DNA
site I-DNA I-DNA
at O O
position O B-DNA
+9 O I-DNA
was O O
key O O
for O O
the O O
formation O O
of O O
protein.DNA O B-protein
complexes O I-protein
. O O

Mutation O O
of O O
both O O
the O O
Sp1 B-DNA B-DNA
site I-DNA I-DNA
at O O
+9 O O
and O O
the O O
TATA B-DNA B-DNA
at O O
-32 O O
reduced O O
promoter O O
activity O O
to O O
its O O
minimal O O
level O O
. O O

Supershift O O
assays O O
showed O O
no O O
effect O O
of O O
the O O
anti-Sp1 B-protein B-protein
antibody I-protein I-protein
on O O
complex O O
formation O O
, O O
whereas O O
the O O
anti-Sp3 B-protein B-protein
antibody I-protein I-protein
had O O
a O O
strong O O
effect O O
on O O
protein.DNA O B-protein
complex O I-protein
formation O O
, O O
suggesting O O
that O O
Sp3 B-protein B-protein
is O O
one O O
of O O
the O O
main O O
factors O O
binding O O
to O O
this O O
Sp1 B-DNA B-DNA
site I-DNA I-DNA
. O O

Chromatin O O
immunoprecipitation O O
assays O O
supported O O
the O O
involvement O O
of O O
both O O
Sp1 B-protein B-protein
and O O
Sp3 B-protein B-protein
in O O
complexes O O
formed O O
on O O
the O O
MAT2B B-DNA B-DNA
promoter I-DNA I-DNA
. O O

The O O
data O O
show O O
that O O
the O O
5'-untranslated B-DNA B-DNA
sequences I-DNA I-DNA
play O O
an O O
important O O
role O O
in O O
regulating O O
the O O
MAT2B B-DNA B-DNA
gene I-DNA I-DNA
and O O
identifies O O
the O O
Sp1 B-DNA B-DNA
site I-DNA I-DNA
at O O
+9 O O
as O O
a O O
potential O O
target O O
for O O
modulating O O
MAT2B O B-protein
expression O O
, O O
a O O
process O O
that O O
can O O
have O O
a O O
major O O
effect O O
on O O
intracellular O O
AdoMet B-protein O
levels O O
. O O

Molecular O O
pathogenesis O O
of O O
influenza O O
A O O
virus O O
infection O O
and O O
virus-induced O O
regulation O O
of O O
cytokine B-DNA B-DNA
gene I-DNA I-DNA
expression O O
. O O

Despite O O
vaccines O O
and O O
antiviral O O
substances O O
influenza O O
still O O
causes O O
significant O O
morbidity O O
and O O
mortality O O
world O O
wide O O
. O O

Better O O
understanding O O
of O O
the O O
molecular O O
mechanisms O O
of O O
influenza O O
virus O O
replication O O
, O O
pathogenesis O O
and O O
host O O
immune O O
responses O O
is O O
required O O
for O O
the O O
development O O
of O O
more O O
efficient O O
means O O
of O O
prevention O O
and O O
treatment O O
of O O
influenza O O
. O O

Influenza O O
A O O
virus O O
, O O
which O O
replicates O O
in O O
epithelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
leukocytes B-cell_type B-cell_type
, O O
regulates O O
host O O
cell O O
transcriptional O O
and O O
translational O O
systems O O
and O O
activates O O
, O O
as O O
well O O
as O O
downregulates O O
apoptotic O O
pathways O O
. O O

Influenza O O
A O O
virus O O
infection O O
results O O
in O O
the O O
production O O
of O O
chemotactic O O
( O O
RANTES B-protein B-protein
, O O
MIP-1 B-protein B-protein
alpha I-protein I-protein
, O O
MCP-1 B-protein B-protein
, O O
MCP-3 B-protein B-protein
, O O
and O O
IP-10 B-protein B-protein
) O O
, O O
pro-inflammatory O O
( O O
IL-1 B-protein B-protein
beta I-protein I-protein
, O O
IL-6 B-protein B-protein
, O O
IL-18 B-protein B-protein
, O O
and O O
TNF-alpha B-protein B-protein
) O O
, O O
and O O
antiviral B-protein O
( I-protein O
IFN-alpha/beta I-protein B-protein
) I-protein I-protein
cytokines I-protein I-protein
. O O

Cytokine O B-DNA
gene O I-DNA
expression O O
is O O
associated O O
with O O
the O O
activation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
, O O
AP-1 B-protein B-protein
, O O
STAT B-protein B-protein
and O O
IRF B-protein B-protein
signal I-protein I-protein
transducing I-protein I-protein
molecules I-protein I-protein
in O O
influenza O B-cell_type
A O I-cell_type
virus-infected O I-cell_type
cells O I-cell_type
. O O

In O O
addition O O
of O O
upregulating O O
cytokine B-DNA B-protein
gene I-DNA O
expression O O
, O O
influenza O O
A O O
virus O O
infection O O
activates O O
caspase-1 B-protein B-protein
enzyme I-protein I-protein
, O O
which O O
is O O
involved O O
in O O
the O O
proteolytic O O
processing O O
of O O
proIL-1 B-protein B-protein
beta I-protein I-protein
and O O
proIL-18 B-protein B-protein
into O O
their O O
biologically O O
active O O
forms O O
. O O

Influenza O B-protein
A O I-protein
virus-induced O I-protein
IFN-alpha/beta B-protein I-protein
is O O
essential O O
in O O
host O O
's O O
antiviral O O
defence O O
by O O
activating O O
the O O
expression O O
of O O
antiviral B-DNA B-DNA
Mx I-DNA I-DNA
, O I-DNA
PKR B-DNA I-DNA
and I-DNA I-DNA
oligoadenylate I-DNA I-DNA
synthetase I-DNA I-DNA
genes I-DNA I-DNA
. O O

IFN-alpha/beta B-protein B-protein
also O O
prolongs O O
T O O
cell O O
survival O O
, O O
upregulates O O
IL-12 O B-protein
and O O
IL-18 O B-protein
receptor O O
gene O O
expression O O
and O O
together O O
with O O
IL-18 B-protein B-protein
stimulates O O
NK B-cell_type O
and I-cell_type O
T I-cell_type O
cell I-cell_type O
IFN-gamma O B-protein
production O O
and O O
the O O
development O O
of O O
Th1-type O O
immune O O
response O O
. O O

Comparison O O
of O O
hprt O O
and O O
lacI O O
mutant O O
frequency O O
with O O
DNA O O
adduct O O
formation O O
in O O
N-hydroxy-2-acetylaminofluorene-treated O O
Big O O
Blue O O
rats O O
. O O

N-Hydroxy-2-acetylaminofluorene O O
( O O
N-OH-AAF O O
) O O
is O O
the O O
proximate O O
carcinogenic O O
metabolite O O
of O O
the O O
powerful O O
rat O O
liver O O
carcinogen O O
2-acetylaminofluorene O O
. O O

In O O
this O O
study O O
, O O
transgenic O O
Big O O
Blue O O
( O O
R O O
) O O
rats O O
were O O
used O O
to O O
examine O O
the O O
relationship O O
between O O
in O O
vivo O O
mutagenicity O O
and O O
DNA O O
adduct O O
formation O O
by O O
N-OH-AAF O O
in O O
the O O
target O O
liver O O
compared O O
with O O
that O O
in O O
nontarget O O
tissues O O
. O O

Male O O
rats O O
were O O
given O O
one O O
, O O
two O O
, O O
or O O
four O O
doses O O
of O O
25 O O
mg O O
N-OH-AAF/kg O O
body O O
weight O O
by O O
i.p. O O
injection O O
at O O
4-day O O
intervals O O
, O O
and O O
groups O O
of O O
treated O O
and O O
control O O
rats O O
were O O
euthanized O O
up O O
to O O
10 O O
weeks O O
after O O
beginning O O
the O O
dosing O O
. O O

Mutant O O
frequencies O O
were O O
measured O O
in O O
the O O
spleen B-DNA B-cell_type
lymphocyte I-DNA I-cell_type
hprt I-DNA I-DNA
gene I-DNA I-DNA
, O O
and O O
lacI O O
mutant O O
frequencies O O
were O O
determined O O
in O O
the O O
liver O B-cell_type
and O I-cell_type
spleen O I-cell_type
lymphocytes B-cell_type I-cell_type
. O O

At O O
6 O O
weeks O O
after O O
beginning O O
the O O
dosing O O
, O O
the O O
hprt O O
mutant O O
frequency O O
in O O
spleen B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
from O O
the O O
four-dose O O
group O O
was O O
16.5 O O
x O O
10 O O
( O O
-6 O O
) O O
compared O O
with O O
3.2 O O
x O O
10 O O
( O O
-6 O O
) O O
in O O
control O O
animals O O
. O O

Also O O
at O O
6 O O
weeks O O
, O O
rats O O
given O O
one O O
, O O
two O O
, O O
or O O
four O O
doses O O
of O O
N-OH-AAF O O
had O O
lacI O O
mutant O O
frequencies O O
in O O
the O O
liver O O
of O O
97.6 O O
, O O
155.6 O O
, O O
and O O
406.8 O O
x O O
10 O O
( O O
-6 O O
) O O
, O O
respectively O O
, O O
compared O O
with O O
a O O
control O O
frequency O O
of O O
25.7 O O
x O O
10 O O
( O O
-6 O O
) O O
; O O
rats O O
given O O
four O O
doses O O
had O O
lacI O O
mutant O O
frequencies O O
in O O
spleen B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
of O O
55.8 O O
x O O
10 O O
( O O
-6 O O
) O O
compared O O
with O O
a O O
control O O
frequency O O
of O O
20.4 O O
x O O
10 O O
( O O
-6 O O
) O O
. O O

Additional O O
rats O O
were O O
evaluated O O
for O O
DNA O O
adduct O O
formation O O
in O O
the O O
liver O O
, O O
spleen B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
, O O
and O O
bone O O
marrow O O
by O O
( O O
32 O O
) O O
P-postlabeling O O
. O O

Adduct O O
analysis O O
was O O
conducted O O
1 O O
day O O
after O O
one O O
, O O
two O O
, O O
and O O
four O O
treatments O O
with O O
N-OH-AAF O O
, O O
5 O O
days O O
after O O
one O O
treatment O O
, O O
and O O
9 O O
days O O
after O O
two O O
treatments O O
. O O

N- O O
( O O
Deoxyguanosin-8-yl O O
) O O
-2-aminofluorene O O
was O O
the O O
major O O
DNA O O
adduct O O
identified O O
in O O
all O O
the O O
tissues O O
examined O O
. O O

Adduct O O
concentrations O O
increased O O
with O O
total O O
dose O O
to O O
maximum O O
values O O
in O O
samples O O
taken O O
1 O O
day O O
after O O
two O O
doses O O
, O O
and O O
remained O O
essentially O O
the O O
same O O
after O O
four O O
doses O O
. O O

In O O
samples O O
taken O O
after O O
four O O
doses O O
, O O
adduct O O
levels O O
were O O
103 O O
, O O
28 O O
, O O
and O O
7 O O
fmol/microg O O
of O O
DNA O O
in O O
liver O B-cell_type
, O I-cell_type
spleen B-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
, O O
and O O
bone O O
marrow O O
, O O
respectively O O
. O O

The O O
results O O
indicate O O
that O O
the O O
extent O O
of O O
both O O
DNA O O
adduct O O
formation O O
and O O
mutant O O
induction O O
correlates O O
with O O
the O O
organ O O
specificity O O
for O O
N-OH-AAF O O
carcinogenesis O O
in O O
the O O
rat O O
. O O

Environ. O O
Mol. O O
Mutagen. O O
37 O O
: O O
195-202 O O
, O O
2001 O O
. O O

Published O O
2001 O O
Wiley-Liss O O
, O O
Inc O O
. O O

Expression O O
of O O
Mad1 B-protein B-protein
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
leads O O
to O O
reduced O O
thymic O O
cellularity O O
and O O
impaired O O
mitogen-induced O O
proliferation O O
. O O

To O O
investigate O O
Mad1 B-protein B-protein
function O O
in O O
vivo O O
, O O
transgenic O O
mice O O
were O O
generated O O
that O O
express O O
a O O
Mad1 B-DNA B-DNA
transgene I-DNA I-DNA
in O O
T B-cell_type B-cell_type
lineage I-cell_type I-cell_type
cells I-cell_type I-cell_type
under O O
the O O
control O O
of O O
the O O
proximal B-DNA B-DNA
lck I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Thymus O O
size O O
in O O
lck-Mad1 O O
transgenic O O
mice O O
is O O
drastically O O
reduced O O
although O O
representation O O
of O O
the O O
various O O
thymocyte B-cell_type B-cell_type
sub I-cell_type O
populations I-cell_type O
appears O O
normal O O
. O O

To O O
investigate O O
more O O
closely O O
any O O
effects O O
of O O
Mad1 O B-protein
expression O O
on O O
thymocytes B-cell_type B-cell_type
, O O
we O O
examined O O
thymic O O
selection O O
using O O
MHC O O
class O O
I-restricted O O
H-Y-TCR O O
transgenic O O
mice O O
. O O

Mad1 O B-protein
expression O O
in O O
vivo O O
reduces O O
the O O
efficiency O O
of O O
positive O O
selection O O
. O O

Furthermore O O
, O O
thymocytes B-cell_type B-cell_type
and O O
splenic B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
lck-Mad1 O O
transgenic O O
mice O O
display O O
a O O
profound O O
proliferative O O
defect O O
in O O
response O O
to O O
activation O O
with O O
either O O
PMA/Ionomycin O O
or O O
immobilized B-protein O
anti-CD3/CD28 I-protein B-protein
antibody I-protein I-protein
. O O

This O O
proliferative O O
defect O O
is O O
not O O
reversed O O
by O O
addition O O
of O O
exogenous B-protein O
IL-2 I-protein B-protein
and O O
is O O
p53-independent O O
. O O

The O O
growth O O
inhibition O O
caused O O
by O O
Mad1 B-protein B-protein
is O O
overcome O O
by O O
expression O O
of O O
active B-protein O
c-Myc I-protein B-protein
. O O

Differential O O
requirement O O
for O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
PU.1 I-protein B-protein
in O O
the O O
generation O O
of O O
natural B-cell_type B-cell_type
killer I-cell_type I-cell_type
cells I-cell_type I-cell_type
versus O B-cell_type
B B-cell_type I-cell_type
and I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

PU.1 B-protein B-protein
is O O
a O O
member O O
of O O
the O O
Ets B-protein B-protein
family I-protein I-protein
of I-protein O
transcription I-protein B-protein
factors I-protein I-protein
required O O
for O O
the O O
development O O
of O O
various O O
lymphoid B-cell_line B-cell_type
and I-cell_line I-cell_type
myeloid I-cell_line I-cell_type
cell I-cell_line I-cell_type
lineages I-cell_line I-cell_type
, O O
but O O
its O O
role O O
in O O
natural B-cell_type B-cell_type
killer I-cell_type I-cell_type
( I-cell_type O
NK I-cell_type O
) I-cell_type O
cell I-cell_type O
development O O
is O O
not O O
known O O
. O O

The O O
study O O
shows O O
that O O
PU.1 B-protein B-protein
is O O
expressed O O
in O O
NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
that O O
, O O
on O O
cell O O
transfer O O
into O O
alymphoid O O
Rag2/gammac O O
( O O
-/- O O
) O O
mice O O
, O O
hematopoietic B-cell_type B-cell_type
progenitors I-cell_type I-cell_type
of O O
PU.1 B-cell_type B-protein
( I-cell_type I-cell_type
-/- I-cell_type I-cell_type
) I-cell_type I-cell_type
fetal I-cell_type I-cell_type
liver I-cell_type I-cell_type
cells I-cell_type I-cell_type
could O O
generate O O
functional O O
NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
but O O
not O O
B B-cell_type B-cell_type
or I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Nevertheless O O
, O O
the O O
numbers O O
of O O
bone B-cell_type B-cell_type
marrow I-cell_type I-cell_type
NK I-cell_type I-cell_type
cell I-cell_type I-cell_type
precursors I-cell_type I-cell_type
and O O
splenic B-cell_type B-cell_type
mature I-cell_type I-cell_type
NK I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
reduced O O
compared O O
to O O
controls O O
. O O

Moreover O O
, O O
PU.1 B-cell_type B-protein
( I-cell_type O
-/- I-cell_type O
) I-cell_type O
NK I-cell_type B-cell_type
cells I-cell_type I-cell_type
displayed O O
reduced O O
expression O O
of O O
the O O
receptors O O
for O O
stem B-protein B-protein
cell I-protein I-protein
factor I-protein I-protein
and O O
interleukin B-protein B-protein
( I-protein I-protein
IL I-protein I-protein
) I-protein I-protein
-7 I-protein I-protein
, O O
suggesting O O
a O O
nonredundant O O
role O O
for O O
PU.1 B-protein B-protein
in O O
regulating O O
the O O
expression O O
of O O
these O O
cytokine B-DNA B-DNA
receptor I-DNA I-DNA
genes I-DNA I-DNA
during O O
NK O O
cell O O
development O O
. O O

PU.1 B-cell_type B-protein
( I-cell_type I-cell_line
-/- I-cell_type I-cell_line
) I-cell_type I-cell_line
NK I-cell_type I-cell_line
cells I-cell_type I-cell_line
also O O
showed O O
defective O O
expression O O
of O O
inhibitory O O
and O O
activating O O
members O O
of O O
the O O
Ly49 B-protein B-protein
family I-protein I-protein
and O O
failed O O
to O O
proliferate O O
in O O
response O O
to O O
IL-2 B-protein B-protein
and O O
IL-12 B-protein B-protein
. O O

Thus O O
, O O
despite O O
the O O
less O O
stringent O O
requirement O O
for O O
PU.1 B-protein B-protein
in O O
NK O O
cell O O
development O O
compared O O
to O O
B B-cell_type B-cell_type
and I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
PU.1 B-protein B-protein
regulates O O
NK O O
cell O O
differentiation O O
and O O
homeostasis O O
. O O

Benzene-extracted O O
components O O
are O O
important O O
for O O
the O O
major O O
activity O O
of O O
diesel O O
exhaust O O
particles O O
: O O
effect O O
on O O
interleukin-8 B-DNA B-protein
gene I-DNA O
expression O O
in O O
human B-cell_type B-cell_type
bronchial I-cell_type I-cell_type
epithelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Epidemiologic O O
and O O
experimental O O
studies O O
suggest O O
that O O
diesel O O
exhaust O O
particles O O
( O O
DEPs O O
) O O
may O O
be O O
related O O
to O O
increasing O O
respiratory O O
mortality O O
and O O
morbidity O O
. O O

We O O
have O O
shown O O
that O O
DEPs O O
augmented O O
the O O
production O O
of O O
inflammatory B-protein B-protein
cytokines I-protein I-protein
by O O
human B-cell_type B-cell_type
airway I-cell_type I-cell_type
epithelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
vitro O O
. O O

To O O
better O O
understand O O
the O O
mechanisms O O
of O O
their O O
proinflammatory O O
activities O O
, O O
we O O
studied O O
the O O
effects O O
of O O
several O O
components O O
extracted O O
from O O
DEPs O O
on O O
interleukin O B-protein
( O I-protein
IL O I-protein
) O I-protein
-8 O I-protein
expression O O
in O O
human B-cell_line B-cell_line
bronchial I-cell_line I-cell_line
epithelial I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
BEAS-2B I-cell_line I-cell_line
and O O
normal B-cell_type B-cell_type
human I-cell_type I-cell_type
airway I-cell_type I-cell_type
epithelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
obtained O O
from O O
very O O
peripheral O O
airways O O
by O O
an O O
ultrathin O O
bronchoscope O O
. O O

We O O
used O O
several O O
agents O O
active O O
on O O
signal O O
transduction O O
pathways O O
in O O
cytokine O B-protein
expression O O
, O O
such O O
as O O
the O O
protein O B-protein
kinase O I-protein
C O I-protein
inhibitor O O
staurosporin O O
, O O
antioxidant O O
agents O O
including O O
N-acetyl O O
cysteine O O
( O O
NAC O O
) O O
and O O
pyrrolidine O O
dithiocarbamate O O
( O O
PDTC O O
) O O
, O O
and O O
p38 B-protein B-protein
mitogen-activated I-protein I-protein
protein I-protein I-protein
kinase I-protein I-protein
( O O
MAPK B-protein B-protein
) O O
inhibitor O O
SB203580 O O
. O O

Benzene-extracted O O
components O O
showed O O
effects O O
mimicking O O
DEPs O O
on O O
IL-8 O B-protein
gene O O
expression O O
, O O
release O O
of O O
several O O
cytokines B-protein B-protein
( O O
IL-8 B-protein B-protein
; O O
granulocyte B-protein B-protein
macrophage I-protein I-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
; O O
and O O
regulated O O
on O O
activation O O
, O O
normal B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
expressed O O
and O O
secreted O O
) O O
and O O
nuclear O B-protein
factor O I-protein
( O I-protein
NF O I-protein
) O I-protein
-kappa O I-protein
B O I-protein
activation O O
. O O

We O O
also O O
found O O
that O O
NAC O O
, O O
PDTC O O
, O O
and O O
SB203580 O O
suppressed O O
the O O
activities O O
of O O
DEPs O O
and O O
their O O
benzene O O
extracts O O
, O O
suggesting O O
the O O
roles O O
of O O
oxidants-mediated O O
NF-kappa O B-protein
B O I-protein
activation O O
and O O
p38MAPK B-protein B-protein
pathways O O
. O O

Finally O O
, O O
benzo O O
[ O O
a O O
] O O
pyrene O O
, O O
one O O
of O O
the O O
important O O
compounds O O
included O O
in O O
the O O
benzene O O
component O O
, O O
replicated O O
the O O
activities O O
shown O O
by O O
DEPs O O
. O O

The O O
nuclear B-protein B-protein
receptor I-protein I-protein
PPAR I-protein I-protein
gamma I-protein I-protein
is O O
expressed O O
by O O
mouse B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
PPAR O B-protein
gamma O I-protein
agonists O O
induce O O
apoptosis O O
. O O

Peroxisome B-protein B-protein
proliferator-activated I-protein I-protein
receptor I-protein I-protein
( I-protein I-protein
PPAR I-protein I-protein
) I-protein I-protein
-gamma I-protein I-protein
is O O
a O O
nuclear B-protein B-protein
hormone I-protein I-protein
receptor I-protein I-protein
that O O
serves O O
as O O
a O O
trans O B-protein
factor O I-protein
to O O
regulate O O
lipid O O
metabolism O O
. O O

Intense O O
interest O O
is O O
focused O O
on O O
PPAR-gamma B-protein B-protein
and O O
its O O
ligands O O
owing O O
to O O
its O O
putative O O
role O O
in O O
adipocyte O B-cell_type
differentiation O O
. O O

Little O O
is O O
known O O
, O O
however O O
, O O
about O O
the O O
functions O O
of O O
PPAR-gamma B-protein B-protein
in O O
the O O
immune O O
system O O
, O O
especially O O
in O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

We O O
demonstrate O O
that O O
both O O
naive B-cell_type B-cell_type
and I-cell_type I-cell_type
activated I-cell_type I-cell_type
ovalbumin-specific I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
DO11.10-transgenic O O
mice O O
express O O
PPAR-gamma B-RNA B-RNA
mRNA O I-RNA
and O O
protein O O
. O O

In O O
order O O
to O O
determine O O
the O O
function O O
of O O
PPAR-gamma B-protein B-protein
, O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
stimulated O O
with O O
phorbol O O
12-myristate O O
13-acetate O O
and O O
ionomycin O O
or O O
antigen O O
and O O
antigen-presenting B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Simultaneous O O
exposure O O
to O O
PPAR-gamma O B-protein
ligands O O
( O O
e.g. O O
15-deoxy-Delta O O
( O O
12 O O
, O O
14 O O
) O O
-prostaglandin O O
J O O
( O O
2 O O
) O O
, O O
troglitazone O O
) O O
showed O O
drastic O O
inhibition O O
of O O
proliferation O O
and O O
significant O O
decreases O O
in O O
cell O O
viability O O
. O O

The O O
decrease O O
in O O
cell O O
viability O O
was O O
due O O
to O O
apoptosis O O
of O O
the O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
, O O
and O O
occurred O O
only O O
when O O
cells O O
were O O
treated O O
with O O
PPAR-gamma B-protein B-protein
, O O
and O O
not O O
PPAR-alpha O B-protein
agonists O O
, O O
revealing O O
specificity O O
of O O
this O O
response O O
for O O
PPAR-gamma B-protein B-protein
. O O

These O O
observations O O
suggest O O
that O O
PPAR-gamma O B-protein
agonists O O
play O O
an O O
important O O
role O O
in O O
regulating O O
T O O
cell-mediated O O
immune O O
responses O O
by O O
inducing O O
apoptosis O O
. O O

T O O
cell O O
death O O
via O O
PPAR-gamma O B-protein
ligation O O
may O O
act O O
as O O
a O O
potent O O
anti-inflammatory O O
signal O O
in O O
the O O
immune O O
system O O
, O O
and O O
ligands O O
could O O
possibly O O
be O O
used O O
to O O
control O O
disorders O O
in O O
which O O
excessive O O
inflammation O O
occurs O O
. O O

Suppression O O
of O O
lung O O
inflammation O O
in O O
rats O O
by O O
prevention O O
of O O
NF-kappaB O B-protein
activation O O
in O O
the O O
liver O O
. O O

Activation O O
of O O
NF-kappaB B-protein B-protein
and O O
production O O
of O O
NF-kappaB B-protein B-protein
-dependent O O
chemokines B-protein B-protein
are O O
thought O O
to O O
be O O
involved O O
in O O
the O O
pathogenesis O O
of O O
neutrophilic O O
lung O O
inflammation O O
. O O

Calpain-1 O B-protein
inhibitor O O
( O O
CI-1 O O
) O O
blocks O O
activation O O
of O O
NF-kappaB B-protein B-protein
by O O
preventing O O
proteolysis O O
of O O
the O O
inhibitory O B-protein
protein O I-protein
IkappaB-alpha B-protein B-protein
by O O
the O O
ubiquitin/proteasome O O
pathway O O
. O O

We O O
hypothesized O O
that O O
inhibition O O
of O O
proteasome O B-protein
function O O
with O O
CI-1 O B-protein
would O O
block O O
NF-kappaB O B-protein
activation O O
in O O
vivo O O
after O O
intraperitoneal O O
( O O
i.p. O O
) O O
treatment O O
with O O
bacterial O O
lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
and O O
that O O
NF-kappaB O B-protein
inhibition O O
would O O
be O O
associated O O
with O O
suppression O O
of O O
chemokine O B-DNA
gene O I-DNA
expression O O
and O O
attenuation O O
of O O
neutrophilic O O
alveolitis O O
. O O

We O O
treated O O
rats O O
with O O
a O O
single O O
i.p. O O
injection O O
of O O
CI-1 O O
( O O
10 O O
mg/kg O O
) O O
two O O
hours O O
prior O O
to O O
i.p. O O
LPS O O
( O O
7 O O
mg/kg O O
) O O
. O O

Treatment O O
with O O
Cl-1 O O
prevented O O
degradation O O
of O O
IkappaB-alpha B-protein B-protein
and O O
activation O O
of O O
NF-kappaB B-protein B-protein
in O O
the O O
liver O O
in O O
response O O
to O O
LPS O O
; O O
however O O
, O O
Cl-1 O O
treatment O O
had O O
no O O
detected O O
effect O O
on O O
NF-kappaB O B-protein
activation O O
in O O
lung O O
tissue O O
. O O

CI-1 O B-protein
treatment O O
prior O O
to O O
LPS O O
resulted O O
in O O
40 O O
% O O
lower O O
MIP-2 O B-protein
concentration O O
in O O
lung O O
lavage O O
fluid O O
compared O O
to O O
rats O O
treated O O
with O O
vehicle O O
prior O O
to O O
LPS O O
( O O
502 O O
+/- O O
112 O O
pg/ml O O
vs. O O
859 O O
+/-144 O O
pg/ml O O
, O O
P O O
< O O
0.05 O O
) O O
. O O

In O O
addition O O
, O O
CI-1 O O
treatment O O
substantially O O
inhibited O O
LPS-induced O O
neutrophilic O O
alveolitis O O
( O O
2.7+ O O
/- O O
1.2 O O
x O O
10 O O
( O O
5 O O
) O O
vs. O O
43.7 O O
+/- O O
12.2 O O
x O O
10 O O
( O O
5 O O
) O O
lung B-cell_type B-cell_type
lavage I-cell_type I-cell_type
neutrophils I-cell_type I-cell_type
, O O
P O O
< O O
0.01 O O
) O O
. O O

These O O
data O O
indicate O O
that O O
NF-kappaB O B-protein
inhibition O O
in O O
the O O
liver O O
can O O
alter O O
lung O O
inflammation O O
induced O O
by O O
systemic O O
LPS O O
treatment O O
and O O
suggest O O
that O O
a O O
liver-lung O O
interaction O O
contributes O O
to O O
the O O
inflammatory O O
response O O
of O O
the O O
lung O O
. O O

Notch1 B-protein B-protein
regulates O O
maturation O O
of O O
CD4+ B-cell_type B-cell_type
and I-cell_type I-cell_type
CD8+ I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
by O O
modulating O O
TCR O B-protein
signal O O
strength O O
. O O

Notch O O
signaling O O
regulates O O
cell O O
fate O O
decisions O O
in O O
multiple O B-cell_type
lineages O I-cell_type
. O O

We O O
demonstrate O O
in O O
this O O
report O O
that O O
retroviral O O
expression O O
of O O
activated O O
Notch1 B-protein B-protein
in O O
mouse B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
abrogates O O
differentiation O O
of O O
immature B-cell_type B-cell_type
CD4+CD8+ I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
into O O
both O O
CD4 B-cell_type B-protein
and I-cell_type O
CD8 I-cell_type B-cell_type
mature I-cell_type I-cell_type
single-positive I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
ability O O
of O O
Notch1 B-protein B-protein
to O O
inhibit O O
T O O
cell O O
development O O
was O O
observed O O
in O O
vitro O O
and O O
in O O
vivo O O
with O O
both O O
normal B-cell_type O
and I-cell_type O
TCR I-cell_type B-protein
transgenic I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
. O O

Notch1 B-protein B-protein
-mediated O O
developmental O O
arrest O O
was O O
dose O O
dependent O O
and O O
was O O
associated O O
with O O
impaired O O
thymocyte O O
responses O O
to O O
TCR O B-protein
stimulation O O
. O O

Notch1 B-protein B-protein
also O O
inhibited O O
TCR-mediated O O
signaling O O
in O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

These O O
data O O
indicate O O
that O O
constitutively O O
active O O
Notch1 B-protein B-protein
abrogates O B-cell_type
CD4+ O B-protein
and O O
CD8+ O O
maturation O O
by O O
interfering O O
with O O
TCR O B-protein
signal O O
strength O O
and O O
provide O O
an O O
explanation O O
for O O
the O O
physiological O O
regulation O O
of O O
Notch O O
expression O O
during O O
thymocyte O O
development O O
. O O

Expression O O
of O O
SART3 B-protein B-protein
antigen I-protein I-protein
and O O
induction O O
of O O
CTLs B-cell_type B-cell_type
by O O
SART3-derived O O
peptides O O
in O O
breast O O
cancer O O
patients O O
. O O

We O O
recently O O
reported O O
the O O
SART3 B-protein B-protein
tumour-rejection I-protein I-protein
antigen I-protein I-protein
as O O
possessing O O
tumour O B-protein
epitopes O I-protein
capable O O
of O O
inducing O O
HLA-class B-cell_type B-protein
I-restricted I-cell_type B-cell_type
cytotoxic I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
( O O
CTLs B-cell_type B-cell_type
) O O
. O O

This O O
study O O
investigated O O
expression O O
of O O
the O O
SART3 B-protein B-protein
antigen I-protein I-protein
in O O
breast O O
cancer O O
to O O
explore O O
an O O
appropriate O O
molecule O O
for O O
use O O
in O O
specific O O
immunotherapy O O
of O O
breast O O
cancer O O
patients O O
. O O

The O O
SART3 B-protein B-protein
antigen I-protein I-protein
was O O
detected O O
in O O
all O O
of O O
the O O
breast B-cell_line B-cell_line
cancer I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
tested O O
, O O
30 O O
of O O
40 O O
( O O
75 O O
% O O
) O O
breast O O
cancer O O
tissue O O
samples O O
, O O
and O O
0 O O
of O O
3 O O
non-tumourous O O
breast O O
tissue O O
samples O O
. O O

SART3 O O
derived O O
peptides O O
at O O
positions B-DNA B-cell_line
109-118 I-DNA I-cell_line
and I-DNA I-cell_line
315-323 I-DNA I-cell_line
induced O I-cell_line
HLA-A24 O I-cell_line
restricted O I-cell_line
CTLs B-cell_type I-cell_line
that O O
reacted O O
to O O
breast B-cell_type B-cell_type
cancer I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
the O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
PBMCs B-cell_type B-cell_type
) O O
of O O
breast O O
cancer O O
patients O O
. O O

Therefore O O
, O O
the O O
SART3 B-protein B-protein
antigen I-protein I-protein
and O O
its O O
peptides O O
could O O
be O O
an O O
appropriate O O
molecule O O
for O O
use O O
in O O
specific O O
immunotherapy O O
of O O
the O O
majority O O
of O O
HLA-A24-positive O O
breast O O
cancer O O
patients O O

Autostimulation O O
of O O
the O O
Epstein-Barr O B-DNA
virus O I-DNA
BRLF1 B-DNA I-DNA
promoter I-DNA I-DNA
is O O
mediated O O
through O O
consensus O B-DNA
Sp1 B-DNA I-DNA
and I-DNA I-DNA
Sp3 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
. O O

As O O
an O O
essential O O
step O O
in O O
the O O
lytic O O
cascade O O
, O O
the O O
Rta O B-protein
homologues O I-protein
of O O
gammaherpesviruses O O
all O O
activate O O
their O O
own O O
expression O O
. O O

Consistent O O
with O O
this O O
biologic O O
function O O
, O O
the O O
Epstein-Barr O B-protein
virus O I-protein
( O I-protein
EBV O I-protein
) O I-protein
Rta B-protein I-protein
protein I-protein I-protein
powerfully O O
stimulates O O
the O O
promoter B-DNA B-DNA
of O O
its O O
own O O
gene O O
, O O
Rp B-DNA O
, O O
in O O
EBV-positive B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
transient-transfection O O
reporter-based O O
assays O O
. O O

We O O
analyzed O O
the O O
activity O O
of O O
RpCAT B-DNA B-protein
in O O
response O O
to O O
Rta B-protein B-protein
by O O
deletional O O
and O O
site-directed O O
mutagenesis O O
. O O

Two O O
cognate B-DNA B-DNA
Sp1 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
located O O
at O O
-279 O B-DNA
and O I-DNA
-45 O I-DNA
relative O O
to O O
the O O
transcriptional B-DNA B-DNA
start I-DNA I-DNA
site I-DNA I-DNA
proved O O
crucial O O
for O O
Rta-mediated O O
activation O O
. O O

Previously O O
described O O
binding O B-DNA
sites O I-DNA
for O O
the O O
cellular O B-protein
transcription B-protein I-protein
factor I-protein I-protein
Zif268 I-protein B-protein
and O O
the O O
viral B-protein B-protein
transactivator I-protein I-protein
ZEBRA I-protein B-protein
were O O
found O O
to O O
be O O
dispensable O O
for O O
activation O O
of O O
RpCAT B-DNA B-protein
by O O
Rta B-protein B-protein
. O O

Gel O O
shift O O
analysis O O
, O O
using O O
extracts O O
of O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
latency O O
or O O
induced O O
into O O
the O O
lytic O O
cycle O O
, O O
identified O O
Sp1 B-protein B-protein
and O O
Sp3 B-protein B-protein
as O O
the O O
predominant O O
cellular B-protein B-protein
proteins I-protein I-protein
bound O O
to O O
Rp B-DNA O
near O O
-45 O O
. O O

During O O
the O O
lytic O O
cycle O O
, O O
ZEBRA B-protein B-protein
bound O O
Rp B-DNA O
near O O
the O O
Sp1/Sp3 B-DNA B-DNA
site I-DNA I-DNA
. O O

The O O
binding O O
of O O
Sp1 B-protein B-protein
and O O
Sp3 B-protein B-protein
to O O
Rp B-DNA O
correlated O O
with O O
the O O
reporter O O
activities O O
in O O
the O O
mutagenesis O O
study O O
, O O
establishing O O
a O O
direct O O
link O O
between O O
transcriptional O O
activation O O
of O O
Rp B-DNA O
by O O
Rta B-protein B-protein
and O O
DNA O O
binding O O
by O O
Sp1 B-protein B-protein
and/or O O
Sp3 B-protein B-protein
. O O

The O O
relative O O
abundance O O
or O O
functional O O
state O O
of O O
the O O
cellular O O
Sp1 B-protein B-protein
and O O
Sp3 B-protein B-protein
transcription B-protein B-protein
factors I-protein I-protein
may O O
be O O
altered O O
in O O
response O O
to O O
stimuli O O
that O O
induce O O
the O O
BRLF1 B-DNA B-DNA
promoter I-DNA I-DNA
and O O
thereby O O
contribute O O
to O O
the O O
activation O O
of O O
the O O
viral O O
lytic O O
cycle O O
. O O

Gene O O
transfer O O
of O O
antisense O B-RNA
hypoxia B-protein B-protein
inducible I-protein I-protein
factor-1 I-protein I-protein
alpha I-protein I-protein
enhances O O
the O O
therapeutic O O
efficacy O O
of O O
cancer O O
immunotherapy O O
. O O

Solid O O
tumors O O
meet O O
their O O
demands O O
for O O
nascent O O
blood O O
vessels O O
and O O
increased O O
glycolysis O O
, O O
to O O
combat O O
hypoxia O O
, O O
by O O
activating O O
multiple O O
genes O O
involved O O
in O O
angiogenesis O O
and O O
glucose O O
metabolism O O
. O O

Hypoxia B-protein B-protein
inducible I-protein I-protein
factor-1 I-protein I-protein
( O O
HIF-1 B-protein B-protein
) O O
is O O
a O O
constitutively O O
expressed O O
basic O O
helix-loop-helix B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
, O O
formed O O
by O O
the O O
assembly O O
of O O
HIF-1alpha B-protein B-protein
and O O
HIF-1beta B-protein B-protein
( O O
Arnt B-protein B-protein
) O O
, O O
that O O
is O O
stablized O O
in O O
response O O
to O O
hypoxia O O
, O O
and O O
rapidly O O
degraded O O
under O O
normoxic O O
conditions O O
. O O

It O O
activates O O
the O O
transcription O O
of O O
genes O O
important O O
for O O
maintaining O O
oxygen O O
homeostasis O O
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
engineered O O
down-regulation O O
of O O
HIF-1alpha B-protein B-protein
by O O
intratumoral O O
gene O O
transfer O O
of O O
an O O
antisense B-DNA O
HIF-1alpha I-DNA B-DNA
plasmid I-DNA I-DNA
leads O O
to O O
the O O
down-regulation O O
of O O
VEGF B-DNA B-protein
, O O
and O O
decreased O O
tumor O O
microvessel O O
density O O
. O O

Antisense O B-protein
HIF-1alpha O B-protein
monotherapy O O
resulted O O
in O O
the O O
complete O O
and O O
permanent O O
rejection O O
of O O
small O O
( O O
0.1 O O
cm O O
in O O
diameter O O
) O O
EL-4 O O
tumors O O
, O O
which O O
is O O
unusual O O
for O O
an O O
anti-angiogenic O O
agent O O
where O O
transient O O
suppression O O
of O O
tumor O O
growth O O
is O O
the O O
norm O O
. O O

It O O
induced O O
NK B-cell_type O
cell I-cell_type O
-dependent O O
rejection O O
of O O
tumors O O
, O O
but O O
failed O O
to O O
stimulate O O
systemic O O
T B-cell_type O
cell I-cell_type O
-mediated O O
anti-tumor O O
immunity O O
, O O
and O O
synergized O O
with O O
B7-1-mediated O O
immunotherapy O O
to O O
cause O O
the O O
NK B-cell_type B-cell_type
cell I-cell_type I-cell_type
and O I-cell_type
CD8 B-cell_type I-cell_type
T I-cell_type I-cell_type
cell I-cell_type I-cell_type
-dependent O O
rejection O O
of O O
larger O O
EL-4 O O
tumors O O
( O O
0.4 O O
cm O O
in O O
diameter O O
) O O
that O O
were O O
refractory O O
to O O
monotherapies O O
. O O

Mice O O
cured O O
of O O
their O O
tumors O O
by O O
combination O O
therapy O O
resisted O O
a O O
rechallenge O O
with O O
parental B-cell_type B-cell_type
tumor I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
indicating O O
systemic O O
antitumor O O
immunity O O
had O O
been O O
achieved O O
. O O

In O O
summary O O
, O O
whilst O O
intensive O O
investigations O O
are O O
in O O
progress O O
to O O
target O O
the O O
many O O
HIF-1 B-protein B-protein
effectors O I-protein
, O O
the O O
results O O
herein O O
indicate O O
that O O
blocking O O
hypoxia-inducible O O
pathways O O
and O O
enhancing O O
NK-mediated O O
antitumor O O
immunity O O
by O O
targeting O O
HIF-1 B-protein B-protein
itself O O
may O O
be O O
advantageous O O
, O O
especially O O
when O O
combined O O
with O O
cancer O O
immunotherapy O O
. O O

Runx2 B-DNA B-protein
: O O
a O O
novel O O
oncogenic O O
effector O O
revealed O O
by O O
in O O
vivo O O
complementation O O
and O O
retroviral O O
tagging O O
. O O

The O O
Runx2 B-DNA B-DNA
( O I-DNA
Cbfa1 B-DNA I-DNA
, O I-DNA
Pebp2alphaA B-DNA I-DNA
, O I-DNA
Aml3 B-DNA I-DNA
) O I-DNA
gene O I-DNA
was O O
previously O O
identified O O
as O O
a O O
frequent O O
target O O
for O O
transcriptional O O
activation O O
by O O
proviral O O
insertion O O
in O O
T-cell O O
lymphomas O O
of O O
CD2-MYC O O
transgenic O O
mice O O
. O O

We O O
have O O
recently O O
shown O O
that O O
over-expression O O
of O O
the O O
full-length O O
, O O
most O O
highly O O
expressed O O
Runx2 B-DNA B-protein
isoform O I-protein
in O O
the O O
thymus O O
perturbs O O
T-cell O O
development O O
, O O
leads O O
to O O
development O O
of O O
spontaneous O O
lymphomas O O
at O O
low O O
frequency O O
and O O
is O O
strongly O O
synergistic O O
with O O
Myc B-protein B-protein
. O O

To O O
gain O O
further O O
insight O O
into O O
the O O
relationship O O
of O O
Runx2 B-DNA B-protein
to O O
other O O
lymphomagenic O O
pathways O O
, O O
we O O
tested O O
the O O
effect O O
of O O
combining O O
the O O
CD2-Runx2 B-DNA B-DNA
transgene I-DNA I-DNA
either O O
with O O
a O O
Pim1 B-DNA B-DNA
transgene I-DNA I-DNA
( O O
E B-DNA B-protein
( I-DNA I-protein
mu I-DNA I-protein
) I-DNA I-protein
-Pim1 I-DNA I-protein
) O O
or O O
with O O
the O O
p53 B-DNA B-protein
null O O
genotype O O
, O O
as O O
each O O
of O O
these O O
displays O O
independent O O
synergy O O
with O O
Myc B-protein B-protein
. O O

In O O
both O O
cases O O
we O O
observed O O
synergistic O O
tumour O O
development O O
. O O

However O O
, O O
Runx2 B-protein B-protein
appeared O O
to O O
have O O
a O O
dominant O O
effect O O
on O O
the O O
tumour O O
phenotype O O
in O O
each O O
case O O
, O O
with O O
most O O
tumours O O
conforming O O
to O O
the O O
CD3 O B-cell_line
( O I-cell_line
+ O I-cell_line
) O I-cell_line
, O I-cell_line
CD8 O I-cell_line
( O I-cell_line
+ O I-cell_line
) O I-cell_line
, O I-cell_line
CD4 O I-cell_line
( O O
+/- O O
) O O
phenotype O O
seen O O
in O O
CD2-Runx2 O O
mice O O
. O O

Neonatal O O
infection O O
of O O
CD2-Runx2 O O
mice O O
with O O
Moloney O O
murine O O
leukaemia O O
virus O O
( O O
Moloney O O
MLV O O
) O O
also O O
led O O
to O O
a O O
dramatic O O
acceleration O O
of O O
tumour O O
onset O O
. O O

Analysis O O
of O O
known O O
Moloney B-DNA B-DNA
MLV I-DNA I-DNA
target I-DNA I-DNA
genes I-DNA I-DNA
in O O
these O O
lymphomas O O
showed O O
a O O
high O O
frequency O O
of O O
rearrangement O O
at O O
c-Myc B-DNA B-protein
or O O
N-Myc B-DNA B-protein
( O O
82 O O
% O O
) O O
, O O
and O O
a O O
significant O O
number O O
at O O
Pim1 B-DNA B-protein
or O O
Pim2 B-DNA O
( O O
23 O O
% O O
) O O
, O O
and O O
at O O
Pal1/Gfi1 B-DNA O
( O O
18 O O
% O O
) O O
. O O

These O O
results O O
indicate O O
that O O
Runx2 B-protein B-protein
makes O O
a O O
distinct O O
contribution O O
to O O
T-cell O O
lymphoma O O
development O O
which O O
does O O
not O O
coincide O O
with O O
any O O
of O O
the O O
oncogene O O
complementation O O
groups O O
previously O O
identified O O
by O O
retroviral O O
tagging O O
. O O

The O O
involvement O O
of O O
TNF-alpha B-protein B-protein
-related O O
apoptosis-inducing O B-protein
ligand O I-protein
in O O
the O O
enhanced O O
cytotoxicity O O
of O O
IFN-beta B-protein B-protein
-stimulated O O
human B-cell_type B-cell_type
dendritic I-cell_type I-cell_type
cells I-cell_type I-cell_type
to O O
tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

TNF-alpha B-protein B-protein
-related O O
apoptosis-inducing O B-protein
ligand O I-protein
( O O
TRAIL O B-protein
) O O
is O O
characterized O O
by O O
its O O
preferential O O
induction O O
of O O
apoptosis O O
of O O
tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
but O O
not O O
normal B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Dendritic B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
DCs B-cell_type B-cell_type
) O O
, O O
besides O O
their O O
role O O
as O O
APCs O B-cell_type
, O O
now O O
have O O
been O O
demonstrated O O
to O O
exert O O
cytotoxicity O O
or O O
cytostasis O O
on O O
some O O
tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Here O O
, O O
we O O
report O O
that O O
both O O
human B-cell_type B-cell_line
CD34 I-cell_type I-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
stem I-cell_type I-cell_line
cell I-cell_type I-cell_line
-derived O I-cell_line
DCs B-cell_type I-cell_line
( O O
CD34DCs B-cell_type B-cell_type
) O O
and O O
human B-cell_type B-cell_line
CD14 I-cell_type I-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
monocyte I-cell_type I-cell_line
-derived O I-cell_line
DCs B-cell_type I-cell_line
( O O
MoDCs B-cell_type B-cell_type
) O O
express O O
TRAIL O B-protein
and O O
exhibit O O
cytotoxicity O O
to O O
some O O
types O O
of O O
tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
partially O O
through O O
TRAIL O B-protein
. O O

Moderate O O
expression O O
of O O
TRAIL O B-protein
appeared O O
on O O
CD34DCs B-cell_type B-cell_type
from O O
the O O
8th O O
day O O
of O O
culture O O
and O O
was O O
also O O
seen O O
on O O
freshly B-cell_type B-cell_type
isolated I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
. O O

The O O
level O O
of O O
TRAIL O B-protein
expression O O
remained O O
constant O O
until O O
DC O B-cell_type
maturation O O
. O O

TRAIL O B-protein
expression O O
on O O
immature B-cell_type O
CD34DCs I-cell_type O
or O O
MoDCs B-cell_type B-cell_type
was O O
greatly O O
up-regulated O O
after O O
IFN-beta B-protein B-protein
stimulation O O
. O O

Moreover O O
, O O
IFN-beta B-protein B-protein
could O O
strikingly O O
enhance O O
the O O
ability O O
of O O
CD34DCs B-cell_type B-cell_type
or O O
MoDCs B-cell_type B-cell_type
to O O
kill O O
TRAIL-sensitive O B-cell_type
tumor B-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
but O O
LPS O O
did O O
not O O
have O O
such O O
an O O
effect O O
. O O

The O O
up-regulation O O
of O O
TRAIL O B-protein
on O O
IFN-beta B-protein B-protein
-stimulated O O
DCs B-cell_type B-cell_type
partially O O
contributed O O
to O O
the O O
increased O O
cytotoxicity O O
of O O
DCS B-cell_type O
: O O
Pretreatment O O
of O O
TRAIL-sensitive O B-cell_line
tumor B-cell_type I-cell_line
cells I-cell_type I-cell_line
with O O
caspase-3 O O
inhibitor O O
could O O
significantly O O
increase O O
their O O
resistance O O
to O O
the O O
cytotoxicity O O
of O O
IFN-beta B-protein B-protein
-stimulated O O
DCS B-cell_type O
: O O
In O O
contrast O O
, O O
NF-kappaB O B-protein
inhibitor O O
could O O
significantly O O
increase O O
the O O
sensitivity O O
of O O
tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
to O O
the O O
killing O O
by O O
nonstimulated O O
or O O
LPS-stimulated O O
DCS B-cell_type O
: O O
Our O O
studies O O
demonstrate O O
that O O
IFN-beta B-protein B-protein
-stimulated O O
DCs B-cell_type B-cell_type
are O O
functionally O O
cytotoxic O O
. O O

Thus O O
, O O
an O O
innate O O
mechanism O O
of O O
DC-mediated O O
antitumor O O
immunity O O
might O O
exist O O
in O O
vivo O O
in O O
which O O
DCs B-cell_type B-cell_type
act O O
as O O
effectors O O
to O O
directly O O
kill O O
tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
partially O O
via O O
TRAIL O B-protein
. O O

Subsequently O O
, O O
DCs B-cell_type B-cell_type
act O O
as O O
APCs O B-cell_type
involved O O
in O O
the O O
uptake O O
, O O
processing O O
, O O
and O O
presentation O O
of O O
apoptotic B-protein O
tumor I-protein O
Ags I-protein B-protein
to O O
cross-prime O B-cell_type
CD8 B-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
CTL I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
regulate O O
the O O
lytic O O
activity O O
of O O
tumor-specific B-cell_type B-cell_type
cytotoxic I-cell_type I-cell_type
t I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
by O O
modulating O O
the O O
inhibitory O O
natural O O
killer O O
receptor O O
function O O
. O O

Tumor-infiltrating B-cell_type B-cell_type
p58+ I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
from O O
a O O
renal O O
tumor O O
were O O
specifically O O
expanded O O
in O O
response O O
to O O
tumor O O
cell O O
stimulation O O
and O O
cloned O O
. O O

These O O
p58+ B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
found O O
to O O
express O O
a O O
memory B-cell_type O
phenotype I-cell_type O
and O O
corresponded O O
to O O
clonal O O
TCRBV3 O O
T-cell O O
expansion O O
. O O

Functionally O O
, O O
p58 B-cell_type B-protein
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
CTLs I-cell_type I-cell_type
displayed O O
a O O
low O O
lytic O O
activity O O
for O O
HLA-A2 B-cell_type B-cell_line
tumor I-cell_type I-cell_line
and I-cell_type I-cell_line
normal I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

However O O
, O O
this O O
lytic O O
activity O O
was O O
significantly O O
increased O O
after O O
blockade O O
of O O
p58 B-protein B-protein
with O O
specific O O
monoclonal B-protein B-protein
antibodies I-protein I-protein
. O O

Interestingly O O
, O O
we O O
demonstrated O O
that O O
stimulation O O
by O O
tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
was O O
required O O
to O O
trigger O O
the O O
inhibitory O O
effect O O
of O O
p58 B-protein B-protein
on O O
the O O
lytic O O
activity O O
of O O
antigen-specific B-cell_type B-cell_type
CTLs I-cell_type I-cell_type
and O O
that O O
stimulation O O
of O O
the O O
inhibitory O O
function O O
of O O
p58 B-protein B-protein
by O O
tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
correlated O O
with O O
an O O
inhibition O O
of O O
nuclear O B-protein
factor-kappaB O I-protein
activation O O
in O O
p58+ B-cell_type O
tumor-specific I-cell_type O
CTLS I-cell_type O
. O O

T-cell B-protein B-protein
factor-1 I-protein I-protein
expression O O
during O O
human B-cell_type B-cell_type
natural I-cell_type I-cell_type
killer I-cell_type I-cell_type
cell I-cell_type I-cell_type
development O O
and O O
in O O
circulating O B-cell_type
CD56 B-protein I-cell_type
( I-protein I-cell_type
+ I-protein I-cell_type
) I-protein I-cell_type
bright O I-cell_type
natural B-cell_type I-cell_type
killer I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Transcription B-protein B-protein
factors I-protein I-protein
are O O
essential O O
to O O
govern O O
differentiation O O
along O O
the O O
lymphoid B-cell_type B-cell_type
lineage I-cell_type I-cell_type
from O O
uncommitted B-cell_type B-cell_type
hematopoietic I-cell_type I-cell_type
stem I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Although O O
many O O
of O O
these O O
transcription B-protein B-protein
factors I-protein I-protein
have O O
putative O O
roles O O
based O O
on O O
murine O O
knockout O O
experiments O O
, O O
their O O
function O O
in O O
human O O
lymphoid O O
development O O
is O O
less O O
known O O
and O O
was O O
studied O O
further O O
. O O

Transcription O B-protein
factor O I-protein
expression O O
in O O
fresh O O
and O O
cultured O B-cell_type
adult B-cell_type I-cell_type
human I-cell_type I-cell_type
bone I-cell_type I-cell_type
marrow I-cell_type I-cell_type
and I-cell_type I-cell_type
umbilical I-cell_type I-cell_type
cord I-cell_type I-cell_type
blood I-cell_type I-cell_type
progenitors I-cell_type I-cell_type
was O O
evaluated O O
. O O

We O O
found O O
that O O
fresh B-cell_type O
CD34 I-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
Lin I-cell_type I-cell_type
( I-cell_type I-cell_type
- I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
that O O
are O O
human O B-cell_line
leukocyte O I-cell_line
antigen O I-cell_line
( O I-cell_line
HLA O I-cell_line
) O I-cell_line
-DR O I-cell_line
( O I-cell_line
- O I-cell_line
) O I-cell_line
or O I-cell_line
CD38 O I-cell_line
( O I-cell_line
- O I-cell_line
) O I-cell_line
constitutively O O
express O O
GATA-3 B-protein B-protein
but O O
not O O
T-cell B-protein B-protein
factor-1 I-protein I-protein
( O O
TCF-1 B-protein B-protein
) O O
or O O
Id-3 B-protein B-protein
. O O

Culture O O
with O O
the O O
murine B-cell_line B-cell_line
fetal I-cell_line I-cell_line
liver I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
AFT024 I-cell_line I-cell_line
and O O
defined O O
cytokines B-protein B-protein
was O O
capable O O
of O O
inducing O O
TCF-1 B-RNA B-RNA
mRNA I-RNA I-RNA
. O O

However O O
, O O
no O O
T-cell B-DNA B-protein
receptor I-DNA I-protein
gene I-DNA O
rearrangement O O
was O O
identified O O
in O O
cultured O B-cell_line
progeny O I-cell_line
. O O

Id-3 B-protein B-protein
, O O
a O O
basic B-protein B-protein
helix I-protein I-protein
loop I-protein I-protein
helix I-protein I-protein
factor I-protein I-protein
with O O
dominant O O
negative O O
function O O
for O O
T-cell O B-protein
differentiation O I-protein
transcription B-protein I-protein
factors I-protein I-protein
, O O
also O O
was O O
upregulated O O
and O O
may O O
explain O O
unsuccessful O O
T-cell O O
maturation O O
. O O

To O O
better O O
understand O O
the O O
developmental O O
link O O
between O O
natural B-cell_type B-cell_type
killer I-cell_type I-cell_type
( I-cell_type I-cell_type
NK I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
derived O O
from O O
progenitors B-cell_type B-cell_type
, O O
we O O
studied O O
NK B-cell_type B-cell_type
cell I-cell_type I-cell_type
subsets I-cell_type I-cell_type
circulating O O
in O O
blood O O
. O O

CD56 B-cell_type I-cell_line
( I-cell_type I-cell_line
+bright I-cell_type I-cell_line
) I-cell_type I-cell_line
, O I-cell_line
but O I-cell_line
not O I-cell_line
CD56 B-cell_type I-cell_line
( I-cell_type I-cell_line
+dim I-cell_type I-cell_line
) I-cell_type I-cell_line
, O I-cell_line
NK B-cell_type I-cell_line
cells I-cell_type I-cell_line
constitutively O O
express O O
TCF-1 B-protein B-protein
by O O
reverse O B-protein
transcriptase O I-protein
polymerase O O
chain O O
reaction O O
and O O
Western O O
blot O O
analysis O O
. O O

The O O
TCF-1 B-protein B-protein
isoform I-protein I-protein
found O O
in O O
CD56 B-cell_type B-cell_line
( I-cell_type I-cell_line
+bright I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
, O O
which O O
express O O
lectin B-protein B-protein
but O O
not O O
immunoglobulin B-protein B-protein
class I-protein I-protein
I I-protein I-protein
recognizing O I-protein
inhibitory B-protein I-protein
receptors I-protein I-protein
, O O
was O O
identical O O
to O O
that O O
induced O O
in O O
NK O B-cell_line
cell O I-cell_line
differentiation O I-cell_line
culture O I-cell_line
and O O
was O O
distinctly O O
different O O
from O O
isoforms O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

These O O
results O O
suggest O O
that O O
TCF-1 B-protein B-protein
does O O
not O O
target O B-DNA
human B-DNA I-DNA
killer I-DNA I-DNA
immunoglobulin I-DNA I-DNA
receptor I-DNA I-DNA
genes I-DNA I-DNA
, O O
TCF-1 B-protein B-protein
is O O
uniquely O O
expressed O O
in O O
circulating O B-cell_type
CD56 B-cell_type I-cell_type
( I-cell_type I-cell_type
+bright I-cell_type I-cell_type
) I-cell_type I-cell_type
NK I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
and O O
specific O O
TCF-1 B-protein B-protein
isoforms I-protein I-protein
may O O
play O O
an O O
important O O
role O O
in O O
regulating O O
NK O O
differentiation O O
from O O
a O O
common O B-cell_type
NK/T-cell B-cell_type I-cell_type
progenitor I-cell_type I-cell_type
. O O

Transcriptional O O
activation O O
by O O
a O O
matrix B-protein B-protein
associating I-protein I-protein
region-binding I-protein I-protein
protein I-protein I-protein
. O O

contextual O O
requirements O O
for O O
the O O
function O O
of O O
bright B-protein O
. O O

Bright B-protein O
( O O
B B-protein B-protein
cell I-protein I-protein
regulator I-protein I-protein
of I-protein O
IgH I-protein B-protein
transcription I-protein O
) O O
is O O
a O O
B B-cell_type O
cell I-cell_type O
-specific O O
, O O
matrix B-protein O
associating I-protein O
region-binding I-protein B-protein
protein I-protein I-protein
that O O
transactivates O O
gene O O
expression O O
from O O
the O O
IgH B-DNA B-DNA
intronic I-DNA I-DNA
enhancer I-DNA I-DNA
( O O
E B-DNA B-DNA
mu I-DNA I-DNA
) O O
. O O

We O O
show O O
here O O
that O O
Bright B-protein O
has O O
multiple O O
contextual O O
requirements O O
to O O
function O O
as O O
a O O
transcriptional B-protein O
activator I-protein O
. O O

Bright B-protein O
can O O
not O O
transactivate O O
via O O
out O O
of O O
context O O
, O O
concatenated B-protein O
binding I-protein B-protein
sites I-protein I-protein
. O O

Transactivation O O
is O O
maximal O O
on O O
integrated O O
substrates O O
. O O

Two O O
of O O
the O O
three O O
previously O O
identified O O
binding B-DNA B-DNA
sites I-DNA I-DNA
in O O
E B-DNA B-DNA
mu I-DNA I-DNA
are O O
required O O
for O O
full O O
Bright B-protein O
transactivation O O
. O O

The O O
Bright B-protein B-protein
DNA I-protein I-protein
binding I-protein I-protein
domain I-protein I-protein
defined O O
a O O
new O O
family O O
, O O
which O O
includes O O
SWI1 B-protein B-protein
, O O
a O O
component O O
of O O
the O O
SWI.SNF B-protein B-protein
complex I-protein I-protein
shown O O
to O O
have O O
high O O
mobility O O
group-like O O
DNA O O
binding O O
characteristics O O
. O O

Similar O O
to O O
one O O
group O O
of O O
high B-protein B-protein
mobility I-protein I-protein
group I-protein I-protein
box I-protein I-protein
proteins I-protein I-protein
, O O
Bright B-protein O
distorts O O
E B-DNA B-DNA
mu I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
-containing O B-DNA
DNA O I-DNA
on O O
binding O O
, O O
supporting O O
the O O
concept O O
that O O
it O O
mediates O O
E B-DNA O
mu I-DNA O
remodeling O O
. O O

Transfection O O
studies O O
further O O
implicate O O
Bright B-protein O
in O O
facilitating O O
spatially O O
separated O O
promoter-enhancer O O
interactions O O
in O O
both O O
transient O O
and O O
stable O O
assays O O
. O O

Finally O O
, O O
we O O
show O O
that O O
overexpression O O
of O O
Bright B-protein O
leads O O
to O O
enhanced O O
DNase O B-protein
I O I-protein
sensitivity O O
of O O
the O O
endogenous O B-DNA
E B-DNA I-DNA
mu I-DNA I-DNA
matrix O I-DNA
associating O I-DNA
regions O I-DNA
. O O

These O O
data O O
further O O
suggest O O
that O O
Bright B-protein O
may O O
contribute O O
to O O
increased O O
gene O O
expression O O
by O O
remodeling O O
the O O
immunoglobulin B-DNA B-DNA
locus I-DNA I-DNA
during O O
B B-cell_type O
cell I-cell_type O
development O O
. O O

Analysis O O
of O O
BCL-6 O B-protein
mutations O O
in O O
classic O O
Hodgkin O O
disease O O
of O O
the O O
B- B-cell_type O
and I-cell_type O
T-cell I-cell_type O
type I-cell_type O
. O O

BCL-6 B-DNA B-protein
is O O
essential O O
for O O
germinal O O
center O O
formation O O
and O O
thus O O
for O O
affinity O O
maturation O O
of O O
immunoglobulin B-DNA B-DNA
( I-DNA I-DNA
Ig I-DNA I-DNA
) I-DNA I-DNA
genes I-DNA I-DNA
by O O
somatic O O
mutations O O
. O O

The O O
5'-noncoding B-DNA B-DNA
region I-DNA I-DNA
of O O
the O O
BCL-6 B-DNA B-DNA
gene I-DNA I-DNA
is O O
even O O
a O O
target O O
for O O
the O O
mutation O O
machinery O O
. O O

Translocations O O
of O O
the O O
BCL-6 B-DNA B-DNA
gene I-DNA I-DNA
to O O
heterologous B-DNA B-DNA
promoters I-DNA I-DNA
and O O
mutations O O
of O O
its O O
5'-noncoding B-DNA B-DNA
regulatory I-DNA I-DNA
region I-DNA I-DNA
were O O
reported O O
to O O
be O O
potential O O
mechanisms O O
for O O
deregulating O O
BCL-6 B-DNA B-protein
expression O O
and O O
for O O
playing O O
a O O
role O O
in O O
the O O
genesis O O
of O O
non-Hodgkin O O
lymphoma O O
. O O

In O O
line O O
with O O
this O O
hypothesis O O
is O O
the O O
observation O O
that O O
B-cell O O
lymphoma O O
with O O
somatic O O
mutations O O
, O O
such O O
as O O
diffuse O O
large O O
B-cell O O
lymphoma O O
and O O
follicular O O
lymphoma O O
, O O
also O O
carry O O
BCL-6 O B-protein
mutations O O
, O O
some O O
of O O
which O O
are O O
recurrently O O
detectable O O
. O O

Classic O O
Hodgkin O O
disease O O
( O O
cHD O O
) O O
is O O
also O O
derived O O
from O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
with O O
high O O
loads O O
of O O
somatic O O
mutations O O
and O O
thus O O
a O O
further O O
candidate O O
for O O
BCL-6 O B-protein
mutations O O
. O O

To O O
determine O O
the O O
presence O O
and O O
potential O O
role O O
of O O
BCL-6 O B-protein
mutations O O
in O O
cHD O O
, O O
the O O
5'-noncoding B-DNA O
BCL-6 I-DNA O
proportion O O
of O O
single B-cell_type O
Hodgkin I-cell_type B-cell_line
and I-cell_type I-cell_line
Reed-Sternberg I-cell_type I-cell_line
( I-cell_type I-cell_line
HRS I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
from O O
6 O O
cases O O
of O O
cHD O O
and O O
6 O O
cases O O
of O O
HD-derived B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
was O O
analyzed O O
. O O

All O O
B-cell-derived O B-cell_line
HD O I-cell_line
cases O I-cell_line
and O I-cell_line
cell O I-cell_line
lines O I-cell_line
harbored O O
BCL-6 O B-protein
mutations O O
. O O

In O O
contrast O O
, O O
both O O
T-cell-derived O B-cell_line
HD O I-cell_line
cases O I-cell_line
and O I-cell_line
cell O I-cell_line
lines O I-cell_line
were O O
devoid O O
of O O
BCL-6 O B-protein
mutations O O
. O O

With O O
only O O
one O O
exception O O
, O O
there O O
were O O
no O O
lymphoma-specific O O
recurrent O O
BCL-6 O B-protein
mutations O O
detected O O
, O O
and O O
BCL-6 B-protein B-protein
protein I-protein I-protein
was O O
absent O O
from O O
the O O
HRS B-cell_type B-cell_line
cells I-cell_type I-cell_line
of O O
most O O
cases O O
. O O

In O O
conclusion O O
, O O
( O O
1 O O
) O O
somatic O O
BCL-6 O B-protein
mutations O O
are O O
restricted O O
to O O
cHD O O
cases O O
of O O
B-cell B-cell_type B-cell_type
origin O I-cell_type
, O O
and O O
( O O
2 O O
) O O
the O O
BCL-6 O B-protein
mutations O O
represent O O
mostly O O
irrelevant O O
somatic O O
base O O
substitutions O O
without O O
consequences O O
for O O
BCL-6 B-protein B-protein
protein I-protein O
expression O O
and O O
the O O
pathogenesis O O
of O O
cHD O O
. O O

Gadd45gamma B-DNA B-protein
is O O
dispensable O O
for O O
normal O O
mouse O O
development O O
and O O
T-cell O O
proliferation O O
. O O

Gadd45gamma B-DNA B-protein
, O O
a O O
family O O
member O O
of O O
the O O
growth B-DNA O
arrest I-DNA O
and I-DNA O
DNA I-DNA B-protein
damage-inducible I-DNA I-protein
gene I-DNA I-protein
family I-DNA I-protein
45 I-DNA I-protein
( O O
Gadd45 B-DNA B-protein
) O O
, O O
is O O
strongly O O
induced O O
by O O
interleukin-2 B-protein B-protein
( O O
IL-2 B-protein B-protein
) O O
in O O
peripheral B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

While O O
in O O
most O O
tissues O O
all O O
Gadd45 B-DNA B-protein
family I-DNA I-protein
members I-DNA I-protein
are O O
expressed O O
, O O
Gadd45gamma B-DNA B-protein
is O O
the O O
only O O
member O O
that O O
is O O
induced O O
by O O
IL-2 B-protein B-protein
. O O

Here O O
we O O
show O O
that O O
the O O
IL-2 B-protein B-protein
-induced O O
expression O O
of O O
Gadd45gamma B-DNA B-protein
is O O
dependent O O
on O O
a O O
signaling O O
pathway O O
mediated O O
by O O
the O O
tyrosine B-protein B-protein
kinase I-protein I-protein
Jak3 I-protein I-protein
and O O
the O O
transcription B-protein B-protein
factors I-protein I-protein
Stat5a B-protein B-protein
and O O
Stat5b B-protein B-protein
( O O
signal B-protein B-protein
transducer I-protein I-protein
and I-protein I-protein
activator I-protein I-protein
of I-protein I-protein
transcription I-protein I-protein
) O O
. O O

Previous O O
studies O O
with O O
ectopically O O
overexpressed O O
Gadd45gamma B-DNA B-protein
in O O
various O O
cell O O
lines O O
implicated O O
its O O
function O O
in O O
negative O O
growth O O
control O O
. O O

To O O
analyze O O
the O O
physiological O O
role O O
of O O
Gadd45gamma B-DNA B-protein
we O O
used O O
homologous O O
recombination O O
to O O
generate O O
mice O O
lacking O O
Gadd45gamma B-DNA B-protein
. O O

Gadd45gamma B-DNA B-protein
-deficient O O
mice O O
develop O O
normally O O
, O O
are O O
indistinguishable O O
from O O
their O O
littermates O O
, O O
and O O
are O O
fertile O O
. O O

Furthermore O O
, O O
hematopoiesis O O
in O O
mice O O
lacking O O
Gadd45gamma B-DNA B-protein
is O O
not O O
impaired O O
and O O
Gadd45gamma B-DNA B-protein
-deficient O I-cell_type
T B-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
show O O
normal O O
responses O O
to O O
IL-2 B-protein B-protein
. O O

These O O
data O O
demonstrate O O
that O O
Gadd45gamma B-DNA B-protein
is O O
not O O
essential O O
for O O
normal O O
mouse O O
development O O
and O O
hematopoiesis O O
, O O
possibly O O
due O O
to O O
functional O O
redundancy O O
among O O
the O O
Gadd45 B-DNA B-protein
family I-DNA I-protein
members I-DNA I-protein
. O O

Gadd45gamma B-DNA B-protein
is O O
also O O
dispensable O O
for O O
IL-2 B-protein B-protein
-induced O O
T-cell O O
proliferation O O
. O O

Decreased O O
expression O O
of O O
c-myc B-DNA B-DNA
family I-DNA I-DNA
genes I-DNA I-DNA
in O O
thymuses O B-cell_type
from O O
myasthenia O O
gravis O O
patients O O
. O O

The O O
thymus O O
is O O
a O O
critical O O
organ O O
for O O
the O O
elimination O O
of O O
autoreactive B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
apoptosis O O
. O O

We O O
studied O O
the O O
expression O O
of O O
apoptosis-associated O B-DNA
genes O I-DNA
, O O
bcl-xL B-DNA B-DNA
, O I-DNA
bad B-DNA I-DNA
, O I-DNA
caspase-3 B-DNA I-DNA
, O I-DNA
and O I-DNA
c-myc B-DNA I-DNA
family I-DNA I-DNA
genes I-DNA I-DNA
in O O
myasthenia O O
gravis O O
( O O
MG O O
) O O
thymuses O O
. O O

We O O
observed O O
that O O
the O O
mRNA O O
levels O O
of O O
myc B-DNA B-DNA
family I-DNA I-DNA
genes I-DNA I-DNA
, O O
c-myc B-DNA B-DNA
and O O
max B-DNA O
, O O
were O O
markedly O O
reduced O O
in O O
MG O O
thymuses O O
. O O

These O O
results O O
indicate O O
that O O
c-myc B-DNA B-DNA
-mediated O O
signaling O O
is O O
abnormal O O
in O O
MG O B-cell_type
thymuses O I-cell_type
. O O

The O O
levels O O
of O O
molecules O O
whose O O
expressions O O
are O O
associated O O
with O O
myc B-DNA B-DNA
, O O
such O O
as O O
STAM B-protein B-protein
, O O
prothymosin-alpha B-protein O
, O O
and O O
NFkappaB B-protein B-protein

Immunohistochemical O O
detection O O
of O O
interferon-gamma-producing B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
dermatophytosis O O
. O O

Skin O O
lesions O O
of O O
dermatophytosis O O
are O O
thought O O
to O O
be O O
a O O
result O O
of O O
a O O
T B-cell_type O
cell I-cell_type O
-dependent O O
inflammatory O O
response O O
that O O
is O O
mediated O O
by O O
various O O
cytokines B-protein B-protein
. O O

We O O
examined O O
whether O O
IFN-gamma-positive B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
as O O
expression O O
of O O
Th1 B-cell_type O
response O O
) O O
were O O
present O O
in O O
the O O
skin O O
lesions O O
of O O
dermatophytosis O O
in O O
situ O O
by O O
immunohistochemical O O
techniques O O
. O O

Mixtures O O
of O O
CD4-positive B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
CD8-positive B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
found O O
to O O
be O O
present O O
in O O
the O O
dermal O O
infiltrates O O
of O O
the O O
lesions O O
. O O

Considerable O O
numbers O O
of O O
CD1a-positive B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
detected O O
in O O
the O O
upper O O
dermis O O
and O O
epidermis O O
. O O

A O O
marked O O
accumulation O O
of O O
CD68-positive B-cell_type B-cell_type
cells I-cell_type I-cell_type
was O O
found O O
in O O
the O O
upper O O
dermis O O
. O O

IFN-gamma-positive B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
present O O
in O O
the O O
upper O O
dermis O O
of O O
the O O
lesions O O
. O O

The O O
pattern O O
of O O
IFN-gamma B-protein B-protein
staining O O
appeared O O
to O O
be O O
intracellular O O
in O O
mononuclear B-cell_type B-cell_type
lymphoid I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
staining O O
was O O
considered O O
to O O
be O O
highly O O
specific O O
because O O
it O O
could O O
be O O
completely O O
blocked O O
by O O
preabsorption O O
with O O
recombinant B-protein B-protein
IFN-gamma I-protein I-protein
. O O

Our O O
data O O
support O O
the O O
hypothesis O O
that O O
the O O
skin O O
lesions O O
of O O
dermatophytosis O O
may O O
be O O
associated O O
with O O
a O O
Th1 B-cell_type O
response O O
. O O

Th1 B-cell_type O
response O O
, O O
which O O
is O O
characterized O O
by O O
IFN-gamma B-protein B-protein
release O O
, O O
is O O
thought O O
to O O
be O O
involved O O
in O O
the O O
host O O
defense O O
against O O
dermatophytes O O
and O O
to O O
reflect O O
cutaneous O O
reaction O O
in O O
dermatophytosis O O
. O O

Regulation O O
of O O
the O O
helix-loop-helix B-protein B-protein
proteins I-protein I-protein
, O O
E2A B-protein B-protein
and O O
Id3 B-protein B-protein
, O O
by O O
the O O
Ras B-protein B-protein
- O O
ERK B-protein B-protein
MAPK B-protein I-protein
cascade O O
. O O

Activation O O
of O O
mitogen-activated B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
( O O
MAPK B-protein B-protein
) O O
pathways O O
leads O O
to O O
cellular O O
differentiation O O
and/or O O
proliferation O O
in O O
a O O
wide O O
variety O O
of O O
cell O O
types O O
, O O
including O O
developing B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
. O O

The O O
basic B-protein O
helix-loop-helix I-protein B-protein
( I-protein I-protein
bHLH I-protein I-protein
) I-protein I-protein
proteins I-protein I-protein
E12 B-protein B-protein
and O O
E47 B-protein B-protein
and O O
an O O
inhibitor B-protein B-protein
HLH I-protein I-protein
protein I-protein I-protein
, O O
Id3 B-protein B-protein
, O O
play O O
key O O
roles O O
in O O
thymocyte O B-cell_type
differentiation O O
. O O

We O O
show O O
here O O
that O O
E2A B-protein B-protein
DNA O O
binding O O
is O O
lowered O O
in O O
primary B-cell_type B-cell_type
immature I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
consequent O O
to O O
T O B-cell_type
cell O I-cell_type
receptor O B-protein
( O O
TCR O B-protein
) O O
-mediated O O
ligation O O
. O O

Whereas O O
expression O O
of O O
E2A O B-RNA
mRNA O I-RNA
and O O
protein O O
are O O
unaltered O O
, O O
Id3 B-RNA B-RNA
transcripts I-RNA I-RNA
are O O
rapidly O O
induced O O
upon O O
signaling O O
from O O
the O O
TCR B-protein B-protein
. O O

Activation O O
of O O
Id3 O B-protein
transcription O O
is O O
regulated O O
in O O
a O O
dose-dependent O O
manner O O
by O O
the O O
extracellular O B-protein
signal-regulated O I-protein
kinase O I-protein
( O I-protein
ERK B-protein I-protein
) O I-protein
MAPK B-protein I-protein
module O O
. O O

These O O
observations O O
directly O O
connect O O
the O O
ERK B-protein B-protein
MAPK B-protein I-protein
cascade O O
and O O
HLH B-protein B-protein
proteins I-protein I-protein
in O O
a O O
linear O O
pathway O O
. O O

Retinoic O O
acid O O
up-regulates O O
myeloid O O
ICAM-3 O B-protein
expression O O
and O O
function O O
in O O
a O O
cell-specific O O
fashion O O
-- O O
evidence O O
for O O
retinoid O O
signaling O O
pathways O O
in O O
the O O
mast B-cell_type B-cell_type
cell I-cell_type I-cell_type
lineage I-cell_type I-cell_type
. O O

Investigation O O
of O O
mast O O
cell O O
responsiveness O O
toward O O
retinoic O O
acid O O
( O O
RA O O
) O O
revealed O O
selective O O
promotion O O
of O O
ICAM-3 B-protein B-protein
expression O O
in O O
the O O
human B-cell_line B-cell_line
mast I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
HMC-1 I-cell_line I-cell_line
. O O

This O O
process O O
was O O
dose- O O
and O O
time-dependent O O
and O O
detectable O O
by O O
flow O O
cytometry O O
, O O
Western O O
blot O O
analysis O O
, O O
ELISA O O
, O O
and O O
Northern O O
blot O O
analysis O O
. O O

ICAM-3 B-protein B-protein
modulation O O
was O O
found O O
to O O
be O O
cell-type O O
dependent O O
, O O
detectable O O
also O O
for O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
and O O
monocytes B-cell_type B-cell_type
but O O
not O O
U-937 B-cell_line B-cell_line
and O O
only O O
weakly O O
for O O
KU812 B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

Terminally B-cell_type O
differentiated I-cell_type O
skin I-cell_type B-cell_type
mast I-cell_type I-cell_type
cells I-cell_type I-cell_type
also O O
failed O O
to O O
up-modulate O O
their O O
ICAM-3 B-protein B-protein
, O O
suggesting O O
the O O
requirement O O
for O O
some O O
degree O O
of O O
immaturity O O
for O O
the O O
process O O
. O O

RA-mediated O O
effects O O
on O O
ICAM-1 B-protein B-protein
expression O O
, O O
studied O O
in O O
parallel O O
, O O
were O O
clearly O O
distinct O O
from O O
those O O
on O O
ICAM-3 B-protein B-protein
. O O

Investigation O O
of O O
retinoid B-protein B-protein
receptor I-protein I-protein
expression O O
, O O
known O O
to O O
mediate O O
intracellular O O
RA O O
signaling O O
, O O
revealed O O
presence O O
of O O
RAR B-RNA B-protein
alpha I-RNA I-protein
, I-RNA O
RAR I-RNA B-protein
gamma I-RNA I-protein
, I-RNA O
RXR I-RNA B-protein
beta I-RNA I-protein
, I-RNA O
and I-RNA O
RXR I-RNA B-protein
gamma I-RNA I-RNA
transcripts I-RNA I-RNA
in O O
all O O
cell O O
lines O O
studied O O
, O O
and O O
HMC-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
were O O
the O O
only O O
line O O
lacking O O
RXR B-protein B-protein
alpha I-protein I-protein
. O O

RAR B-protein B-protein
beta I-protein I-protein
, O O
not O O
expressed O O
at O O
baseline O O
, O O
was O O
induced O O
by O O
RA O O
in O O
a O O
fashion O O
obviously O O
correlating O O
with O O
ICAM-3 B-protein B-protein
up-regulation O O
. O O

Increased O O
ICAM-3 B-protein B-protein
expression O O
was O O
of O O
functional O O
significance O O
, O O
such O O
that O O
processes O O
stimulated O O
or O O
co-stimulated O O
via O O
ICAM-3 B-protein B-protein
( O O
homotypic O O
aggregation O O
, O O
IL-8 O B-protein
secretion O O
) O O
were O O
clearly O O
enhanced O O
upon O O
RA O O
pretreatment O O
, O O
suggesting O O
that O O
RA O O
may O O
contribute O O
via O O
hitherto O O
unrecognized O O
pathways O O
to O O
immune O O
function O O
and O O
host O O
defense O O
. O O

CD28 B-protein B-protein
and O O
T B-cell_type O
cell I-cell_type O
co-stimulation O O
. O O

Over O O
the O O
last O O
decade O O
the O O
concept O O
of O O
T B-cell_type O
cell I-cell_type O
co-stimulation O O
has O O
emerged O O
to O O
take O O
a O O
central O O
role O O
in O O
the O O
process O O
of O O
T O O
cell O O
activation O O
. O O

However O O
, O O
the O O
exact O O
definition O O
of O O
co-stimulation O O
is O O
still O O
unclear O O
. O O

In O O
this O O
review O O
, O O
we O O
re-examine O O
the O O
concept O O
of O O
co-stimulation O O
. O O

We O O
suggest O O
that O O
while O O
co-stimulation O O
is O O
important O O
, O O
there O O
is O O
little O O
evidence O O
to O O
link O O
co-stimulation O O
with O O
T B-cell_type O
cell I-cell_type O
anergy O O
. O O

We O O
then O O
suggest O O
a O O
framework O O
for O O
studying O O
co-stimulation O O
. O O

Focusing O O
on O O
recent O O
advances O O
in O O
our O O
understanding O O
of O O
CD28 B-protein B-protein
, O O
we O O
discuss O O
four O O
areas O O
of O O
T B-cell_type O
cell I-cell_type O
activation O O
where O O
co-stimulation O O
may O O
play O O
a O O
role O O
. O O

Regulation O O
of O O
activator B-protein B-protein
protein-1 I-protein I-protein
and O O
NF-kappa B-protein B-protein
B I-protein I-protein
in O O
CD8+ B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
exposed O O
to O O
peripheral B-protein O
self-antigens I-protein B-protein
. O O

The O O
transcriptional O O
events O O
that O O
control O O
T B-cell_type O
cell I-cell_type O
tolerance O O
to O O
peripheral B-protein B-cell_type
self I-protein I-cell_type
Ags I-protein B-protein
are O O
still O O
unknown O O
. O O

In O O
this O O
study O O
, O O
we O O
analyzed O O
the O O
regulation O O
of O O
AP-1 B-protein B-protein
- O O
and O O
NF-kappa B-protein B-protein
B I-protein I-protein
-mediated O O
transcription O O
during O O
in O O
vivo O O
induction O O
of O O
tolerance O O
to O O
a O O
self B-protein O
Ag I-protein O
expressed O O
exclusively O O
on O O
hepatocytes B-cell_type B-cell_type
. O O

Naive B-cell_type B-cell_type
CD8 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
Desire I-cell_type I-cell_type
( I-cell_type I-cell_type
Des I-cell_type I-cell_type
) I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
isolated O O
from O O
the O O
Des O O
TCR-transgenic O O
mice O O
that O O
are O O
specific O O
for O O
the O O
H-2K B-protein B-protein
( I-protein I-protein
b I-protein I-protein
) I-protein I-protein
class I-protein I-protein
I I-protein I-protein
Ag I-protein I-protein
were O O
transferred O O
into O O
Alb-K O B-cell_line
( O I-cell_line
b O I-cell_line
) O I-cell_line
-transgenic O I-cell_line
mice O O
that O O
express O O
the O O
H-2K B-protein B-protein
( I-protein I-protein
b I-protein I-protein
) I-protein I-protein
Ag I-protein I-protein
on O O
hepatocytes B-cell_type B-cell_type
only O O
. O O

Tolerance O O
develops O O
in O O
these O O
mice O O
. O O

We O O
found O O
that O O
the O O
self-reactive B-cell_type B-cell_type
CD8 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
Des I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
transiently O O
activated O O
, O O
then O O
became O O
unresponsive O O
and O O
were O O
further O O
deleted O O
. O O

In O O
contrast O O
to O O
CD8 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
Des I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
activated O O
in O O
vivo O O
with O O
APCs O B-cell_type
, O O
which O O
express O O
high O O
AP-1 B-protein B-protein
and O O
high O O
NF-kappa B-protein B-protein
B I-protein I-protein
transcriptional O O
activity O O
, O O
the O O
unresponsive O B-cell_type
CD8 B-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
Des I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
expressed O O
no O O
AP-1 B-protein B-protein
and O O
only O O
weak O O
NF-kappa B-protein B-protein
B I-protein I-protein
transcriptional O O
activity O O
. O O

The O O
differences O O
in O O
NF-kappa B-protein B-protein
B I-protein I-protein
transcriptional O O
activity O O
correlated O O
with O O
the O O
generation O O
of O O
distinct O O
NF-kappa B-protein B-protein
B I-protein I-protein
complexes I-protein I-protein
. O O

Indeed O O
, O O
in O O
vivo O B-cell_type
primed B-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
predominantly O O
express O O
p50/p50 B-protein B-protein
and I-protein I-protein
p65/p50 I-protein I-protein
dimers I-protein I-protein
, O O
whereas O O
these O O
p50-containing B-protein B-protein
complexes I-protein I-protein
are O O
barely O O
detectable O O
in O O
tolerant B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
that O O
express O O
p65- B-protein B-protein
and I-protein I-protein
c-Rel-containing I-protein I-protein
complexes I-protein I-protein
. O O

These O O
observations O O
suggest O O
that O O
fine O O
regulation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
complex I-protein I-protein
formation O O
may O O
determine O O
T B-cell_type O
cell I-cell_type O
fate O O
. O O

Transcriptional O O
regulation O O
in O O
lymphocytes B-cell_type B-cell_type
. O O

Lymphocytes B-cell_type B-cell_type
have O O
been O O
used O O
to O O
investigate O O
many O O
cellular O O
processes O O
, O O
including O O
lineage O O
commitment O O
, O O
differentiation O O
, O O
proliferation O O
and O O
apoptosis O O
. O O

The O O
transcription B-protein B-protein
factors I-protein I-protein
that O O
mediate O O
these O O
processes O O
are O O
often O O
expressed O O
broadly O O
in O O
many O O
cell O O
types O O
. O O

The O O
emerging O O
theme O O
is O O
one O O
of O O
cell-type-specific O O
regulation O O
, O O
affecting O O
not O O
only O O
the O O
functional O O
activation O O
of O O
transcription B-protein B-protein
factors I-protein I-protein
but O O
also O O
their O O
access O O
to O O
appropriate O O
regions O O
of O O
DNA O O
. O O

Existence O O
of O O
retinoic B-protein B-protein
acid-receptor I-protein I-protein
-independent O I-protein
retinoid B-protein I-protein
X-receptor I-protein I-protein
-dependent O O
pathway O O
in O O
myeloid B-cell_type O
cell I-cell_type O
function O O
. O O

We O O
previously O O
reported O O
that O O
ER-27191 O O
( O O
4- O O
[ O O
4 O O
, O O
5 O O
, O O
7 O O
, O O
8 O O
, O O
9 O O
, O O
10-hexahydro-7 O O
, O O
7 O O
, O O
10 O O
, O O
10-tetramethyl-1- O O
( O O
3-pyridylmethyl O O
) O O
anthra O O
[ O O
1 O O
, O O
2-b O O
] O O
pyrrol-3-yl O O
] O O
benzoic O O
acid O O
) O O
is O O
a O O
potent O O
antagonist O O
of O O
retinoic B-protein B-protein
acid I-protein I-protein
receptor I-protein I-protein
( O O
RAR B-protein B-protein
) O O
, O O
and O O
ER-35795 O O
( O O
( O O
2E O O
, O O
4E O O
, O O
6E O O
) O O
-7- O O
[ O O
1- O O
( O O
1-methylethyl O O
) O O
-8-chloro-1 O O
, O O
2 O O
, O O
3 O O
, O O
4-tetrahydroquinolin-6-yl O O
] O O
-6-fluoro-3-methyl-2 O O
, O O
4 O O
, O O
6-nonatrienoic O O
acid O O
) O O
is O O
a O O
novel O O
retinoid B-protein B-protein
X I-protein I-protein
receptor I-protein I-protein
( O O
RXR B-protein B-protein
) O O
-specific O O
agonist O O
. O O

By O O
using O O
these O O
compounds O O
, O O
we O O
investigated O O
whether O O
distinct O O
RAR B-protein B-protein
-dependent O O
and O O
RXR B-protein B-protein
-dependent O O
pathways O O
operate O O
to O O
mediate O O
the O O
diverse O O
activities O O
of O O
retinoids O O
, O O
particularly O O
, O O
the O O
effects O O
of O O
the O O
RXR B-protein B-protein
pathway O O
on O O
cellular O O
function O O
. O O

ER-27191 O O
completely O O
antagonized O O
HL60 B-cell_line B-cell_line
cell I-cell_line I-cell_line
differentiation O O
induced O O
by O O
all-trans-retinoic O O
acid O O
( O O
atRA O O
) O O
. O O

However O O
, O O
the O O
differentiation O O
induced O O
by O O
the O O
ER-35795 O O
was O O
not O O
antagonized O O
at O O
all O O
by O O
the O O
RAR B-protein B-protein
antagonist O O
, O O
but O O
was O O
inhibited O O
by O O
an O O
RXR B-protein B-protein
homodimer I-protein I-protein
antagonist O O
( O O
LGD100754 O O
, O O
( O O
2E O O
, O O
4E O O
, O O
6Z O O
) O O
-7- O O
( O O
3-n-propoxy-5 O O
, O O
6 O O
, O O
7 O O
, O O
8-tetrahydro-5 O O
, O O
5 O O
, O O
8 O O
, O O
8-tetramethylnaphthalen-2-yl O O
) O O
-3-methylocta-2 O O
, O O
4 O O
, O O
6-trienoic O O
acid O O
) O O
. O O

Its O O
agonistic O O
action O O
on O O
RXR/RAR B-protein B-protein
heterodimer I-protein I-protein
, O O
on O O
the O O
other O O
hand O O
, O O
was O O
neutralized O O
by O O
the O O
RAR B-protein B-protein
antagonist O O
. O O

During O O
HL60 B-cell_line B-cell_line
cell I-cell_line I-cell_line
differentiation O O
, O O
atRA O O
induced O O
RARbeta B-RNA B-RNA
mRNA I-RNA I-RNA
, O O
while O O
the O O
RXR B-protein B-protein
had O O
no O O
effect O O
. O O

Interestingly O O
, O O
a O O
functional O O
RXR B-protein B-protein
-pathway O O
was O O
also O O
seen O O
in O O
lipopolysaccharide-induced O O
inhibition O O
of O O
mouse B-cell_type O
splenocyte I-cell_type O
proliferation O O
. O O

These O O
results O O
strongly O O
suggest O O
the O O
existence O O
of O O
a O O
pharmacological O O
RXR B-protein B-protein
-dependent O O
pathway O O
that O O
is O O
activated O O
by O O
a O O
ligand O O
that O O
can O O
bind O O
to O O
RXR B-protein B-protein
. O O

Targeting O O
Src B-protein B-protein
homology I-protein I-protein
2 I-protein I-protein
domain-containing I-protein I-protein
tyrosine I-protein I-protein
phosphatase I-protein I-protein
( O O
SHP-1 B-protein B-protein
) O O
into O O
lipid O O
rafts O O
inhibits O O
CD3 B-protein B-protein
-induced O O
T B-cell_type O
cell I-cell_type O
activation O O
. O O

To O O
study O O
the O O
mechanism O O
by O O
which O O
protein B-protein B-protein
tyrosine I-protein I-protein
phosphatases I-protein I-protein
( O O
PTPs B-protein B-protein
) O O
regulate O O
CD3 B-protein B-protein
-induced O O
tyrosine O O
phosphorylation O O
, O O
we O O
investigated O O
the O O
distribution O O
of O O
PTPs B-protein B-protein
in O O
subdomains O O
of O O
plasma O O
membrane O O
. O O

We O O
report O O
here O O
that O O
the O O
bulk O O
PTP B-protein O
activity O O
associated O O
with O O
T B-cell_type O
cell I-cell_type O
membrane O O
is O O
present O O
outside O O
the O O
lipid O O
rafts O O
, O O
as O O
determined O O
by O O
sucrose O O
density O O
gradient O O
sedimentation O O
. O O

In O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
, O O
approximately O O
5 O O
-- O O
10 O O
% O O
of O O
Src B-protein B-protein
homology I-protein I-protein
2 I-protein I-protein
domain-containing I-protein I-protein
tyrosine I-protein I-protein
phosphatase I-protein I-protein
( O O
SHP-1 B-protein B-protein
) O O
is O O
constitutively O O
associated O O
with O O
plasma O O
membrane O O
, O O
and O O
nearly O O
50 O O
% O O
of O O
SHP-2 B-protein B-protein
is O O
translocated O O
to O O
plasma O O
membrane O O
after O O
vanadate O O
treatment O O
. O O

Similar O O
to O O
transmembrane B-protein O
PTP I-protein O
, O O
CD45 B-protein B-protein
, O O
the O O
membrane-associated O B-protein
populations O I-cell_type
of O O
SHP-1 B-protein B-protein
and O O
SHP-2 B-protein B-protein
are O O
essentially O O
excluded O O
from O O
lipid O O
rafts O O
, O O
where O O
other O O
signaling B-protein B-protein
molecules I-protein I-protein
such O O
as O O
Lck B-protein B-protein
, I-protein O
linker I-protein O
for I-protein O
activation I-protein O
of I-protein O
T I-protein B-cell_type
cells I-protein I-cell_type
, O O
and O O
CD3 B-protein B-protein
zeta I-protein I-protein
are O O
enriched O O
. O O

We O O
further O O
demonstrated O O
that O O
CD3 B-protein B-protein
-induced O O
tyrosine O O
phosphorylation O O
of O O
these O O
substrates O O
is O O
largely O O
restricted O O
to O O
lipid O O
rafts O O
, O O
unless O O
PTPs B-protein B-protein
are O O
inhibited O O
. O O

It O O
suggests O O
that O O
a O O
restricted O O
partition O O
of O O
PTPs B-protein B-protein
among O O
membrane O O
subdomains O B-protein
may O O
regulate O O
protein O O
tyrosine O O
phosphorylation O O
in O O
T B-cell_type O
cell I-cell_type O
membrane O O
. O O

To O O
test O O
this O O
hypothesis O O
, O O
we O O
targeted O O
SHP-1 B-protein B-protein
into O O
lipid O O
rafts O O
by O O
using O O
the O O
N-terminal B-protein B-protein
region I-protein I-protein
of I-protein O
Lck I-protein B-protein
( O O
residues B-protein B-protein
1 I-protein I-protein
-- I-protein O
14 I-protein O
) O O
. O O

The O O
results O O
indicate O O
that O O
the O O
expression O O
of O O
Lck/SHP-1 B-protein B-protein
chimera I-protein I-protein
inside O O
lipid O O
rafts O O
profoundly O O
inhibits O O
CD3 B-protein B-protein
-induced O O
tyrosine O O
phosphorylation O O
of O O
CD3 B-protein B-protein
zeta/epsilon I-protein I-protein
, O O
IL-2 O B-protein
generation O O
, O O
and O O
nuclear O O
mobilization O O
of O O
NF-AT B-protein B-protein
. O O

Collectively O O
, O O
these O O
results O O
suggest O O
that O O
the O O
exclusion O O
of O O
PTPs B-protein B-protein
from O O
lipid O O
rafts O O
may O O
be O O
a O O
mechanism O O
that O O
potentiates O O
TCR B-protein B-protein
/ O O
CD3 B-protein B-protein
activation O O

An O O
instructive O O
component O O
in O O
T B-cell_type B-cell_type
helper I-cell_type I-cell_type
cell I-cell_type I-cell_type
type I-cell_type I-cell_type
2 I-cell_type I-cell_type
( O O
Th2 B-cell_type O
) O O
development O O
mediated O O
by O O
GATA-3 B-protein B-protein
. O O

Although O O
interleukin B-protein B-protein
( I-protein I-protein
IL I-protein I-protein
) I-protein I-protein
-12 I-protein I-protein
and O O
IL-4 B-protein B-protein
polarize O I-cell_type
naive B-cell_type I-cell_type
CD4 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
toward O O
T O B-cell_type
helper O I-cell_type
cell O I-cell_type
type O I-cell_type
1 O I-cell_type
( O O
Th1 O O
) O O
or O O
Th2 O O
phenotypes O O
, O O
it O O
is O O
not O O
known O O
whether O O
cytokines B-protein B-protein
instruct O O
the O O
developmental O O
fate O O
in O O
uncommitted B-cell_type B-cell_type
progenitors I-cell_type I-cell_type
or O O
select O O
for O O
outgrowth O O
of O O
cells O O
that O O
have O O
stochastically O O
committed O O
to O O
a O O
particular O O
fate O O
. O O

To O O
distinguish O O
these O O
instructive O O
and O O
selective O O
models O O
, O O
we O O
used O O
surface O O
affinity O O
matrix O O
technology O O
to O O
isolate O O
committed B-cell_type B-cell_type
progenitors I-cell_type I-cell_type
based O O
on O O
cytokine O B-protein
secretion O O
phenotype O O
and O O
developed O O
retroviral-based O O
tagging O O
approaches O O
to O O
directly O O
monitor O O
individual O O
progenitor O O
fate O O
decisions O O
at O O
the O O
clonal O O
and O O
population O O
levels O O
. O O

We O O
observe O O
IL-4 B-protein B-protein
-dependent O O
redirection O O
of O O
phenotype O O
in O O
cells O O
that O O
have O O
already O O
committed O O
to O O
a O O
non-IL-4-producing O O
fate O O
, O O
inconsistent O O
with O O
predictions O O
of O O
the O O
selective O O
model O O
. O O

Further O O
, O O
retroviral O O
tagging O O
of O O
naive B-cell_type B-cell_type
progenitors I-cell_type I-cell_type
with O O
the O O
Th2-specific B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
GATA-3 I-protein B-protein
provided O O
direct O O
evidence O O
for O O
instructive O O
differentiation O O
, O O
and O O
no O O
evidence O O
for O O
the O O
selective O O
outgrowth O O
of O O
cells O O
committed O O
to O O
either O O
the O O
Th1 O B-cell_type
or O I-cell_type
Th2 O I-cell_type
fate O I-cell_type
. O O

These O O
data O O
would O O
seem O O
to O O
exclude O O
selection O O
as O O
an O O
exclusive O O
mechanism O O
in O O
Th1 B-cell_type O
/ O O
Th2 B-cell_type O
differentiation O O
, O O
and O O
support O O
an O O
instructive O O
model O O
of O O
cytokine-driven O O
transcriptional O O
programming O O
of O O
cell O O
fate O O
decisions O O
. O O

In O O
vitro-activated O B-cell_type
human B-cell_type I-cell_type
lupus I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
express O O
normal O O
estrogen B-protein B-protein
receptor I-protein I-protein
proteins I-protein I-protein
which O O
bind O O
to O O
the O O
estrogen B-protein B-DNA
response I-protein I-DNA
element I-protein I-DNA
. O O

We O O
have O O
shown O O
that O O
estrogen B-protein B-RNA
receptor I-protein I-RNA
( O I-RNA
ERalpha B-protein I-RNA
, O I-RNA
ERbeta B-protein I-RNA
) O I-RNA
transcripts O I-RNA
are O O
expressed O O
in O O
SLE B-cell_type O
and I-cell_type O
normal I-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

In O O
this O O
study O O
, O O
T O O
cell O O
nuclear O O
extracts O O
from O O
female O O
lupus O O
patients O O
and O O
normal O O
donors O O
were O O
tested O O
for O O
biologically O O
active O O
ER B-protein B-protein
proteins I-protein I-protein
capable O O
of O O
binding O O
to O O
the O O
human B-DNA B-DNA
estrogen I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
( O O
hERE B-DNA B-DNA
) O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
. O O

When O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
stimulated O O
with O O
17beta-estradiol O O
( O O
E2 O O
) O O
, O O
PMA O O
and O O
ionomycin O O
, O O
two O O
major O O
retarded O O
bands O O
in O O
T O O
cell O O
nuclear O O
extracts O O
exhibited O O
a O O
migration O O
pattern O O
similar O O
to O O
slow O O
migrating O O
protein-ERE B-protein B-protein
complexes I-protein I-protein
in O O
human O O
breast O O
cancer O O
cell O O
extracts O O
. O O

T B-cell_type B-cell_type
cells I-cell_type I-cell_type
cultured O O
only O O
with O O
E2 O O
did O O
not O O
have O O
these O O
complexes O O
. O O

The O O
formation O O
of O O
the O O
complexes O O
was O O
inhibited O O
by O O
competition O O
with O O
the O O
hERE O B-DNA
cold O O
oligonucleotide O O
and O O
partially O O
with O O
anti-ERalpha B-protein B-protein
antibodies I-protein I-protein
. O O

There O O
was O O
no O O
notable O O
difference O O
in O O
the O O
migration O O
pattern O O
of O O
ERE-binding B-protein B-protein
proteins I-protein I-protein
between O O
the O O
SLE O O
and O O
normal O O
T O O
cell O O
extracts O O
. O O

Together O O
, O O
these O O
results O O
suggest O O
that O O
activated B-cell_type O
human I-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
whether O O
lupus-derived O O
or O O
normal-derived O O
, O O
contain O O
biologically O O
active O O
ERalpha B-protein B-protein
proteins I-protein I-protein
. O O

Other O O
factors O O
may O O
be O O
responsible O O
for O O
differential O O
sensitivity O O
of O O
lupus B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
to O O
estrogen O O
. O O

Mechanism O O
of O O
the O O
inhibitory O O
effect O O
of O O
protease O O
inhibitor O O
on O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
alpha I-protein I-protein
production O O
of O O
monocytes B-cell_type B-cell_type
. O O

If O O
the O O
inflammatory O O
response O O
becomes O O
excessive O O
or O O
uncontrolled O O
by O O
some O O
stimuli O O
, O O
inappropriate O O
inflammatory O O
responses O O
occur O O
. O O

Monocytes B-cell_type B-cell_type
are O O
extremely O O
important O O
cells O O
for O O
regulating O O
the O O
cytokine O B-protein
network O I-protein
and O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
alpha I-protein I-protein
( O O
TNFalpha B-protein B-protein
) O O
and O O
interleukin- B-protein B-protein
( I-protein I-protein
IL I-protein I-protein
) I-protein I-protein
10 I-protein I-protein
, O O
which O O
are O O
mainly O O
synthesized O O
by O O
monocytes B-cell_type B-cell_type
, O O
are O O
representative O O
cytokines B-protein B-protein
that O O
play O O
a O O
central O O
role O O
in O O
the O O
cytokine O B-protein
network O I-protein
. O O

Protease O O
inhibitors O O
such O O
as O O
gabexate O O
mesilate O O
( O O
GM O O
) O O
and O O
ulinastatin O O
( O O
UTI O O
) O O
have O O
been O O
shown O O
to O O
have O O
various O O
beneficial O O
effects O O
by O O
inhibiting O O
the O O
activation O O
of O O
leukocytes B-cell_type B-cell_type
, O O
but O O
the O O
mechanism O O
for O O
this O O
has O O
yet O O
to O O
be O O
fully O O
elucidated O O
. O O

In O O
this O O
study O O
we O O
investigated O O
the O O
mechanism O O
of O O
the O O
inhibitory O O
effect O O
of O O
protease O O
inhibitors O O
on O O
the O O
proinflammatory O O
cytokine O B-protein
production O O
of O O
lipopolysaccharide- O B-cell_line
( O I-cell_line
LPS O I-cell_line
) O I-cell_line
stimulated O I-cell_line
monocytes B-cell_type I-cell_line
. O O

LPS-stimulated O B-cell_type
monocytes B-cell_type I-cell_type
were O O
treated O O
with O O
GM O O
or O O
UTI O O
. O O

The O O
value O O
of O O
TNFalpha B-protein B-protein
and O O
IL-10 B-protein B-protein
in O O
the O O
culture O O
medium O O
of O O
monocytes B-cell_type B-cell_type
was O O
measured O O
and O O
each O O
mRNA O O
expression O O
was O O
assayed O O
. O O

The O O
inhibitory O O
effect O O
of O O
protease O B-protein
inhibitors O O
on O O
the O O
activity O O
of O O
intracellular O O
signal O O
transduction O O
pathways O O
such O O
as O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
( O O
PKC B-protein B-protein
) O O
and O O
nuclear B-protein B-protein
factor I-protein I-protein
kappa I-protein I-protein
B I-protein I-protein
( O O
NFkappaB B-protein B-protein
) O O
were O O
also O O
evaluated O O
. O O

GM O O
decreased O O
the O O
TNFalpha B-protein B-protein
production O O
of O O
LPS-stimulated O B-cell_line
monocytes B-cell_type I-cell_line
as O O
shown O O
by O O
the O O
inhibition O O
of O O
mRNA O O
expression O O
and O O
increased O O
the O O
IL-10 B-protein B-protein
production O O
of O O
LPS-stimulated O B-cell_line
monocytes B-cell_type I-cell_line
. O O

GM O O
also O O
suppressed O O
the O O
NFkappaB B-protein B-protein
activity O O
of O O
LPS-stimulated O B-cell_type
monocytes B-cell_type I-cell_type
. O O

UTI O O
decreased O O
the O O
TNFalpha B-protein B-protein
production O O
of O O
LPS-stimulated O B-cell_line
monocytes B-cell_type I-cell_line
, O O
but O O
did O O
not O O
inhibit O O
the O O
TNFalpha B-RNA B-RNA
mRNA I-RNA I-RNA
expression O O
. O O

The O O
present O O
study O O
shows O O
that O O
the O O
inhibitory O O
effect O O
of O O
GM O O
on O O
the O O
TNFalpha B-protein B-protein
production O O
of O O
activated O B-cell_type
human B-cell_type I-cell_type
monocytes I-cell_type I-cell_type
is O O
mediated O O
by O O
the O O
suppression O O
of O O
NFkappaB B-protein B-protein
activation O O
, O O
while O O
the O O
mechanism O O
of O O
UTI O O
inhibiting O O
TNFalpha B-protein B-protein
production O O
of O O
human B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
may O O
be O O
due O O
to O O
the O O
inhibition O O
of O O
either O O
the O O
translation O O
or O O
secretion O O
of O O
TNFalpha B-protein B-protein
. O O

Homocysteine O O
stimulates O O
the O O
expression O O
of O O
monocyte B-protein B-protein
chemoattractant I-protein I-protein
protein-1 I-protein I-protein
in O O
endothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
leading O O
to O O
enhanced O O
monocyte O O
chemotaxis O O
. O O

Hyperhomocysteinemia O O
has O O
been O O
identified O O
as O O
an O O
independent O O
risk O O
factor O O
for O O
atherosclerosis O O
. O O

The O O
infiltration O O
of O O
monocytes B-cell_type B-cell_type
into O O
the O O
arterial O O
wall O O
is O O
one O O
of O O
the O O
key O O
events O O
during O O
atherogenesis O O
. O O

Monocyte B-protein B-protein
chemoattractant I-protein I-protein
protein-1 I-protein I-protein
( O O
MCP-1 B-protein B-protein
) O O
is O O
a O O
potent O O
chemokine B-protein B-protein
that O O
stimulates O O
the O O
migration O O
of O O
monocytes B-cell_type B-cell_type
into O O
the O O
intima O O
of O O
the O O
arterial O O
wall O O
. O O

The O O
mechanism O O
by O O
which O O
increased O O
monocyte O O
infiltration O O
occurs O O
in O O
atherosclerotic O O
lesions O O
in O O
patients O O
with O O
hyperhomocysteinemia O O
has O O
not O O
been O O
delineated O O
. O O

The O O
objective O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
the O O
effect O O
of O O
homocysteine O O
on O O
MCP-1 B-protein B-protein
production O O
in O O
endothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Cells O O
were O O
incubated O O
with O O
homocysteine O O
. O O

The O O
secretion O O
of O O
MCP-1 B-protein B-protein
protein I-protein I-protein
was O O
significantly O O
increased O O
( O O
195 O O
% O O
as O O
compared O O
to O O
the O O
control O O
) O O
in O O
cells O O
treated O O
with O O
pathological O O
concentrations O O
of O O
homocysteine O O
. O O

Such O O
effect O O
was O O
accompanied O O
by O O
an O O
increased O O
expression O O
of O O
MCP-1 B-RNA B-RNA
mRNA I-RNA I-RNA
( O O
176 O O
% O O
as O O
compared O O
to O O
the O O
control O O
) O O
in O O
endothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
which O O
resulted O O
in O O
enhanced O O
monocyte O O
chemotaxis O O
. O O

The O O
p38 B-protein B-protein
MAP I-protein I-protein
kinase I-protein I-protein
as O O
well O O
as O O
other O O
members O O
of O O
the O O
p38 O B-protein
MAP O I-protein
kinase O I-protein
pathway O O
, O O
including O O
MKK3 B-protein B-protein
, O O
MKK6 B-protein B-protein
, O O
ATF-2 B-protein B-protein
and O O
Elk-1 B-protein B-protein
, O O
were O O
activated O O
in O O
homocysteine-treated B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Homocysteine-induced O O
MCP-1 B-protein B-protein
expression O O
and O O
subsequent O O
monocyte O O
chemotaxis O O
were O O
blocked O O
by O O
a O O
p38 B-protein B-protein
MAP I-protein I-protein
kinase I-protein I-protein
inhibitor O O
( O O
SB203580 O O
) O O
suggesting O O
that O O
the O O
p38 B-protein B-protein
MAP I-protein I-protein
kinase I-protein I-protein
pathway O O
might O O
be O O
involved O O
in O O
homocysteine-induced O O
MCP-1 B-protein B-protein
expression O O
in O O
endothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

In O O
contrast O O
, O O
staurosporine O O
, O O
a O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
inhibitor O O
, O O
had O O
no O O
effect O O
on O O
homocysteine-induced O O
MCP-1 B-protein B-protein
expression O O
. O O

In O O
conclusion O O
, O O
our O O
results O O
indicate O O
that O O
homocysteine O O
stimulates O O
MCP-1 B-protein B-protein
expression O O
in O O
endothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
leading O O
to O O
enhanced O O
monocyte O O
chemotaxis O O
. O O

Inducible O O
resistance O O
to O O
Fas-mediated O O
apoptosis O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Apoptosis O O
produced O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
through O O
Fas B-protein B-protein
( O O
APO-1 B-protein B-protein
, O O
CD95 B-protein B-protein
) O O
triggering O O
is O O
regulated O O
by O O
signals O O
derived O O
from O O
other O O
surface O O
receptors O O
: O O
CD40 O B-protein
engagement O O
produces O O
upregulation O O
of O O
Fas B-protein B-protein
expression O O
and O O
marked O O
susceptibility O O
to O O
Fas B-protein B-protein
-induced O O
cell O O
death O O
, O O
whereas O O
antigen O O
receptor O O
engagement O O
, O O
or O O
IL-4R O B-protein
engagement O O
, O O
inhibits O O
Fas B-protein B-protein
killing O O
and O O
in O O
so O O
doing O O
induces O O
a O O
state O O
of O O
Fas B-protein B-protein
-resistance O O
, O O
even O O
in O O
otherwise O O
sensitive O O
, O O
CD40 B-protein B-protein
-stimulated O O
targets O O
. O O

Surface B-protein B-protein
immunoglobulin I-protein I-protein
and O O
IL-4R B-protein B-protein
utilize O O
at O O
least O O
partially O O
distinct O O
pathways O O
to O O
produce O O
Fas B-protein B-protein
-resistance O O
that O O
differentially O O
depend O O
on O O
PKC B-protein B-protein
and O O
STAT6 B-protein B-protein
, O O
respectively O O
. O O

Further O O
, O O
surface O O
immunoglobulin O B-protein
signaling O O
for O O
inducible O O
Fas B-protein B-protein
-resistance O O
bypasses O O
Btk B-protein B-protein
, O O
requires O O
NF-kappaB B-protein B-protein
, O O
and O O
entails O O
new O O
macromolecular O O
synthesis O O
. O O

Terminal O B-protein
effectors O I-protein
of O O
B B-cell_type B-cell_type
cell I-cell_type I-cell_type
Fas B-protein B-protein
-resistance O O
include O O
the O O
known O O
anti-apoptotic B-protein B-protein
gene I-protein I-protein
products I-protein I-protein
, O O
Bcl-xL B-protein B-protein
and O O
FLIP B-protein B-protein
, O O
and O O
a O O
novel O B-DNA
anti-apoptotic B-DNA I-DNA
gene I-DNA I-DNA
that O O
encodes O O
FAIM B-protein B-protein
( O O
Fas B-protein B-protein
Apoptosis I-protein I-protein
Inhibitory I-protein I-protein
Molecule I-protein I-protein
) O O
. O O

faim B-protein O
was O O
identified O O
by O O
differential O O
display O O
and O O
exists O O
in O O
two O O
alternatively O O
spliced O O
forms O O
; O O
faim-S B-protein B-protein
is O O
broadly O O
expressed O O
, O O
but O O
faim-L O B-protein
expression O O
is O O
tissue-specific O O
. O O

The O O
FAIM B-DNA B-DNA
sequence I-DNA I-DNA
is O O
highly O O
evolu- O O
tionarily O O
conserved O O
, O O
suggesting O O
an O O
important O O
role O O
for O O
this O O
molecule O O
throughout O O
phylogeny O O
. O O

Inducible O O
resistance O O
to O O
Fas B-protein B-protein
killing O O
is O O
hypothesized O O
to O O
protect O O
foreign O O
antigen-specific O B-cell_type
B B-cell_type I-cell_type
cells I-cell_type I-cell_type
during O O
potentially O O
hazardous O O
interactions O O
with O O
FasL-bearing B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
whereas O O
autoreactive B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
fail O O
to O O
become O O
Fas B-protein B-protein
-resistant O O
and O O
are O O
deleted O O
via O O
Fas B-protein B-protein
-dependent O O
cytotoxicity O O
. O O

Inadvertent O O
or O O
aberrant O O
acquisition O O
of O O
Fas B-protein B-protein
-resistance O O
may O O
permit O O
autoreactive B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
to O O
escape O O
Fas B-protein B-protein
deletion O O
, O O
and O O
malignant B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
to O O
impede O O
anti-tumor O O
immunity O O
. O O

Stromal B-protein B-protein
cell-derived I-protein I-protein
factor I-protein I-protein
1 I-protein I-protein
alpha I-protein I-protein
-induced O O
chemotaxis O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
is O O
mediated O O
by O O
nitric O O
oxide O O
signaling O O
pathways O O
. O O

Stromal B-protein B-protein
cell-derived I-protein I-protein
factor I-protein I-protein
1 I-protein I-protein
alpha I-protein I-protein
( O O
SDF1 B-protein B-protein
alpha I-protein I-protein
) O O
and O O
its O O
cognate O O
chemokine B-protein B-protein
receptor I-protein I-protein
CXCR4 I-protein B-protein
act O O
as O O
potent O O
chemoattractants O B-protein
and O O
regulate O O
trafficking O O
and O O
homing O O
of O O
hematopoietic B-cell_type B-cell_type
progenitor I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
lymphocytes B-cell_type B-cell_type
. O O

However O O
, O O
the O O
molecular O O
mechanisms O O
regulating O O
SDF1 B-protein B-protein
alpha I-protein I-protein
-driven O O
cell O O
migration O O
are O O
not O O
well O O
defined O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
explored O O
the O O
roles O O
of O O
the O O
second O O
messenger O O
NO O O
and O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
NF-kappa I-protein B-protein
B I-protein I-protein
in O O
SDF1 B-protein B-protein
alpha I-protein I-protein
-induced O O
T O O
cell O O
migration O O
. O O

SDF1 B-protein B-protein
alpha I-protein I-protein
treatment O O
of O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
increased O O
the O O
activity O O
of O O
NO B-protein B-protein
synthase I-protein I-protein
, O O
which O O
catalyzes O O
the O O
generation O O
of O O
NO O O
. O O

We O O
observed O O
that O O
pretreatment O O
of O O
Jurkat B-cell_line B-cell_line
cells I-cell_line I-cell_line
or O O
activated O O
PBLs B-cell_type B-cell_type
with O O
several O O
NO O O
donors O O
significantly O O
enhanced O O
the O O
SDF1 B-protein B-protein
alpha I-protein I-protein
-induced O O
migration O O
, O O
whereas O O
various O O
inhibitors O O
of O O
NO B-protein B-protein
synthase I-protein I-protein
markedly O O
abrogated O O
the O O
chemotactic O O
response O O
in O O
a O O
concentration-dependent O O
manner O O
. O O

Furthermore O O
, O O
we O O
observed O O
that O O
inhibitors O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
NF-kappa I-protein B-protein
B I-protein I-protein
, O O
which O O
is O O
linked O O
to O O
NO O O
signaling O O
pathways O O
, O O
also O O
significantly O O
blocked O O
the O O
SDF1 B-protein B-protein
alpha I-protein I-protein
-induced O O
chemotactic O O
response O O
. O O

However O O
, O O
these O O
compounds O O
did O O
not O O
have O O
a O O
significant O O
effect O O
on O O
SDF1 B-protein B-protein
alpha I-protein I-protein
-induced O O
mitogen-activated O B-protein
protein O I-protein
kinase O I-protein
activity O O
. O O

In O O
addition O O
, O O
the O O
MAP/Erk O B-protein
kinase O I-protein
kinase O I-protein
inhibitor O O
PD98059 O O
did O O
not O O
abrogate O O
SDF1 B-protein B-protein
alpha I-protein I-protein
-induced O O
chemotaxis O O
. O O

AKT B-protein B-protein
, O O
which O O
has O O
been O O
shown O O
to O O
mediate O O
NO O O
production O O
, O O
was O O
also O O
phosphorylated O O
upon O O
SDF1 B-protein B-protein
alpha I-protein I-protein
stimulation O O
. O O

These O O
studies O O
suggest O O
that O O
NO-related O O
signaling O O
pathways O O
may O O
mediate O O
SDF1 B-protein B-protein
alpha I-protein I-protein
-induced O O
chemotaxis O O
, O O
but O O
not O O
mitogen-activated B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
activation O O
. O O

The O O
lack O O
of O O
NF-kappa O B-protein
B O I-protein
transactivation O O
and O O
PKC O B-protein
epsilon O O
expression O O
in O O
CD4 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
CD8 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
correlates O O
with O O
negative O O
selection O O
. O O

Deletion O O
of O O
autoreactive B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
at O O
the O O
DP O O
stage O O
is O O
the O O
basis O O
for O O
tolerance O O
to O O
thymus-expressed B-protein B-protein
self I-protein I-protein
antigens I-protein I-protein
. O O

In O O
this O O
study O O
we O O
investigated O O
whether O O
distinct O O
signalling O O
pathways O O
are O O
induced O O
in O O
DP B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
as O O
compared O O
to O O
mature B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
upon O O
stimulation O O
with O O
antigen O O
. O O

Using O O
triple O O
transgenic O O
mice O O
expressing O O
a O O
TCR B-DNA B-DNA
transgene I-DNA I-DNA
, O O
dominant B-protein B-protein
negative I-protein I-protein
ras/Mek I-protein I-protein
proteins I-protein I-protein
and O O
a O O
reporter B-DNA B-DNA
gene I-DNA I-DNA
construct I-DNA I-DNA
with O O
AP-1 B-DNA B-protein
or I-DNA O
NF-kappa I-DNA B-DNA
B I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
, O O
we O O
showed O O
a O O
complete O O
lack O O
of O O
transcriptional O O
activity O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
but O O
not O O
AP-1 B-protein B-protein
in O O
DP B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
, O O
whereas O O
both O O
were O O
transcriptionally O O
active O O
in O O
mature B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
after O O
antigenic O O
stimulation O O
. O O

Lack O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
induction O O
correlated O O
with O O
increased O O
death O O
in O O
response O O
to O O
antigen B-protein O
. O O

AP-1 B-protein B-protein
induction O O
was O O
dependent O O
on O O
the O O
integrity O O
of O O
the O O
ras/Mek O B-protein
pathway O O
indicating O O
that O O
this O O
pathway O O
was O O
activated O O
in O O
the O O
DP B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
. O O

In O O
contrast O O
, O O
we O O
found O O
a O O
complete O O
lack O O
of O O
constitutive O O
expression O O
of O O
the O O
epsilon B-protein O
isoform I-protein O
of I-protein O
Protein I-protein B-protein
Kinase I-protein I-protein
C I-protein I-protein
( O O
PKC B-protein B-protein
) O O
in O O
DP B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
, O O
although O O
it O O
was O O
present O O
in O O
mature B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
and O O
peripheral B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Taken O O
together O O
the O O
results O O
suggest O O
that O O
the O O
lack O O
of O O
PKC B-protein B-protein
epsilon I-protein I-protein
in O O
DP B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
could O O
lead O O
to O O
the O O
absence O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
activity O O
after O O
antigenic O O
stimulation O O
contributing O O
to O O
negative O O
selection O O
. O O

Cell O O
Death O O
and O O
Differentiation O O
( O O
2000 O O
) O O
7 O O
, O O
1253 O O
- O O
1262 O O
. O O

CD2 O B-protein
stimulation O O
leads O O
to O O
the O O
delayed O O
and O O
prolonged O O
activation O O
of O O
STAT1 B-protein B-protein
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
but O O
not O O
NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

OBJECTIVE O O
: O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
can O O
be O O
activated O O
by O O
soluble O B-protein
factors O I-protein
such O O
as O O
cytokines B-protein B-protein
or O O
through O O
direct O O
cell-cell O O
interactions O O
. O O

Although O O
cytokine B-protein B-protein
receptors I-protein I-protein
are O O
known O O
to O O
signal O O
through O O
STAT B-protein B-protein
family I-protein I-protein
transcription I-protein I-protein
factors I-protein I-protein
, O O
the O O
mechanisms O O
by O O
which O O
other O O
cell-surface B-protein B-protein
molecules I-protein I-protein
, O O
such O O
as O O
CD2 B-protein B-protein
, O O
transduce O O
signals O O
is O O
unclear O O
. O O

The O O
goal O O
of O O
this O O
study O O
was O O
to O O
determine O O
whether O O
stimulation O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
through O O
CD2 B-protein B-protein
recapitulates O O
aspects O O
of O O
cytokine B-protein B-protein
-induced O O
T-cell O O
activation O O
by O O
use O O
of O O
STAT B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
treated O O
with O O
anti-CD2 B-protein B-protein
antibodies I-protein I-protein
or O O
cells O O
bearing O O
the O O
natural O O
CD2 B-protein B-protein
ligand I-protein I-protein
CD58 I-protein I-protein
, O O
after O O
which O O
signaling O O
through O O
STAT B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
was O O
assessed O O
. O O

RESULTS O O
: O O
Stimulation O O
of O O
CD2 B-protein B-protein
on O O
primary B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
leads O O
to O O
the O O
tyrosine O O
phosphorylation O O
, O O
nuclear O O
translocation O O
, O O
and O O
DNA O O
binding O O
of O O
STAT1 B-protein B-protein
. O O

In O O
contrast O O
to O O
stimulation O O
by O O
cytokines B-protein B-protein
, O O
the O O
activation O O
of O O
STAT1 B-protein B-protein
in O O
response O O
to O O
CD2 O B-protein
ligation O O
is O O
delayed O O
and O O
does O O
not O O
involve O O
Jak B-protein B-protein
kinases I-protein I-protein
. O O

Furthermore O O
, O O
while O O
STAT O B-protein
phosphorylation O O
induced O O
by O O
cytokines B-protein B-protein
is O O
generally O O
transient O O
, O O
STAT1 O B-protein
phosphorylation O O
following O O
CD2 O B-protein
stimulation O O
persists O O
for O O
a O O
period O O
of O O
days O O
. O O

Transcription O O
of O O
key O O
target O B-DNA
genes O I-DNA
such O O
as O O
IRF1 B-DNA B-protein
and O O
c-fos B-DNA B-DNA
proceeds O O
with O O
delayed O O
kinetics O O
following O O
CD2 O B-protein
stimulation O O
, O O
suggesting O O
that O O
this O O
unique O O
pattern O O
of O O
STAT O B-protein
activation O O
may O O
lead O O
to O O
a O O
distinct O O
cellular O O
response O O
following O O
CD2 O B-protein
ligation O O
. O O

This O O
pathway O O
appears O O
to O O
be O O
restricted O O
to O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
as O O
stimulation O O
of O O
CD2 B-protein B-protein
on O O
NK B-cell_type B-cell_type
cells I-cell_type I-cell_type
does O O
not O O
lead O O
to O O
STAT1 O B-protein
activation O O
. O O

CONCLUSION O O
: O O
Stimulation O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
through O O
cell-surface B-protein B-protein
molecules I-protein I-protein
such O O
as O O
CD2 B-protein B-protein
involves O O
activation O O
of O O
STAT B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
, O O
thus O O
recapitulating O O
elements O O
of O O
cytokine O B-protein
signaling O O
. O O

NFATc1 B-protein B-protein
and O O
NFATc2 B-protein B-protein
together O O
control O O
both O O
T O O
and O O
B O O
cell O O
activation O O
and O O
differentiation O O
. O O

NFAT B-protein B-protein
transcription I-protein O
factors I-protein O
play O O
critical O O
roles O O
in O O
gene O O
transcription O O
during O O
immune O O
responses O O
. O O

To O O
investigate O O
further O O
the O O
two O O
most O O
prominent O O
NFAT B-protein B-protein
family I-protein I-protein
members I-protein I-protein
, O O
NFATc1 B-protein B-protein
and O O
NFATc2 B-protein B-protein
, O O
we O O
generated O O
mice O O
bearing O O
lymphoid O O
systems O O
devoid O O
of O O
both O O
. O O

Doubly O O
deficient O B-cell_type
T B-cell_type I-cell_type
cells I-cell_type I-cell_type
displayed O B-cell_type
cell O I-cell_type
surface O I-protein
markers O I-protein
of O O
activation O O
yet O O
were O O
significantly O O
deficient O O
in O O
the O O
development O O
of O O
multiple O O
effector O O
functions O O
, O O
including O O
Th B-protein B-protein
cytokine I-protein I-protein
production O O
, O O
surface B-protein O
effector I-protein O
molecule I-protein O
expression O O
, O O
and O O
cytolytic O O
activity O O
. O O

Nevertheless O O
, O O
doubly B-cell_type O
deficient I-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
hyperactivated O O
, O O
as O O
evidenced O O
by O O
extremely O O
elevated O O
serum O B-protein
IgG1 B-protein I-protein
and O O
IgE B-protein B-protein
, O O
as O O
well O O
as O O
plasma B-cell_type O
cell I-cell_type O
expansion O O
and O O
infiltration O O
of O O
end O O
organs O O
. O O

Thus O O
, O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
NFATc1 B-protein B-protein
and O O
NFATc2 B-protein B-protein
are O O
dispensable O O
for O O
inflammatory O O
reactivity O O
but O O
are O O
required O O
for O O
effector O O
differentiation O O
, O O
while O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
NFATs B-protein B-protein
regulate O O
both O O
normal O O
homeostasis O O
and O O
differentiation O O
. O O

Epstein-barr O B-protein
virus O I-protein
immediate-early B-protein I-protein
protein I-protein I-protein
BZLF1 I-protein I-protein
is O O
SUMO-1 O B-protein
modified O O
and O O
disrupts O O
promyelocytic O O
leukemia O O
bodies O O
. O O

Although O O
the O O
immediate-early B-protein B-protein
proteins I-protein I-protein
of O O
both O O
herpes O O
simplex O O
virus O O
( O O
HSV O O
) O O
and O O
cytomegalovirus O O
( O O
CMV O O
) O O
are O O
known O O
to O O
modify O O
promyelocytic O O
leukemia O O
( O O
PML O O
) O O
( O O
ND10 O B-protein
) O O
bodies O O
in O O
the O O
nucleus O O
of O O
the O O
host O B-cell_type
cell O I-cell_type
, O O
it O O
has O O
been O O
unclear O O
whether O O
lytic O O
infection O O
with O O
gamma O O
herpesviruses O O
induces O O
a O O
similar O O
effect O O
. O O

The O O
PML B-protein B-protein
protein I-protein I-protein
is O O
induced O O
by O O
interferon B-protein B-protein
, O O
involved O O
in O O
major B-protein B-protein
histocompatibility I-protein I-protein
complex I-protein I-protein
class I-protein I-protein
I I-protein I-protein
presentation O O
, O O
and O O
necessary O O
for O O
certain O O
types O O
of O O
apoptosis O O
. O O

Therefore O O
, O O
it O O
is O O
likely O O
that O O
PML O O
bodies O O
function O O
in O O
an O O
antiviral O O
capacity O O
. O O

SUMO-1 O B-protein
modification O O
of O O
PML B-protein B-cell_type
is O O
known O O
to O O
be O O
required O O
for O O
the O O
formation O O
of O O
PML O B-cell_type
bodies O I-cell_type
. O O

To O O
examine O O
whether O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
lytic O O
replication O O
interferes O O
with O O
PML O B-cell_type
bodies O I-cell_type
, O O
we O O
expressed O O
the O O
EBV B-DNA B-DNA
immediate-early I-DNA I-DNA
genes I-DNA I-DNA
BZLF1 B-DNA B-DNA
( I-DNA O
Z I-DNA B-DNA
) I-DNA O
and O O
BRLF1 B-DNA B-DNA
( I-DNA O
R I-DNA O
) I-DNA O
in O O
EBV-positive B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
and O O
examined O O
PML B-protein O
localization O O
. O O

Both O O
Z O O
and O O
R O O
expression O O
resulted O O
in O O
PML B-protein B-cell_type
dispersion O O
in O O
EBV-positive B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Z O O
but O O
not O O
R O O
expression O O
is O O
sufficient O O
to O O
disrupt O O
PML O O
bodies O O
in O O
EBV-negative B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

We O O
show O O
that O O
dispersion O O
of O O
PML O O
bodies O O
by O O
Z B-DNA O
requires O O
a O O
portion O O
of O O
the O O
transcriptional B-DNA B-protein
activation I-DNA I-protein
domain I-DNA I-protein
of O O
Z B-DNA B-protein
but O O
not O O
the O O
DNA-binding O O
function O O
. O O

As O O
was O O
previously O O
reported O O
for O O
the O O
HSV-1 B-protein O
ICP0 I-protein B-protein
and I-protein O
CMV I-protein B-protein
IE1 I-protein I-protein
proteins I-protein I-protein
, O O
Z B-DNA B-protein
reduces O O
the O O
amount O O
of O O
SUMO-1-modified B-protein O
PML I-protein O
. O O

We O O
also O O
found O O
that O O
Z B-DNA O
itself O O
is O O
SUMO-1 O B-protein
modified O O
( O O
through O O
amino O B-protein
acid O I-protein
12 O I-protein
) O O
and O O
that O O
Z B-DNA O
competes O O
with O O
PML B-protein B-protein
for O O
limiting O O
amounts O O
of O O
SUMO-1 B-protein B-protein
. O O

These O O
results O O
suggest O O
that O O
disruption O O
of O O
PML O O
bodies O O
is O O
important O O
for O O
efficient O O
lytic O O
replication O O
of O O
EBV O O
. O O

Furthermore O O
, O O
Z B-DNA O
may O O
potentially O O
alter O O
the O O
function O O
of O O
a O O
variety O O
of O O
cellular O B-protein
proteins O I-protein
by O O
inhibiting O O
SUMO-1 O B-protein
modification O I-protein

Suppression O O
of O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
and O O
stimulation O O
of O O
inhibitor B-protein B-protein
kappaB I-protein I-protein
by O O
troglitazone O O
: O O
evidence O O
for O O
an O O
anti-inflammatory O O
effect O O
and O O
a O O
potential O O
antiatherosclerotic O O
effect O O
in O O
the O O
obese O O
. O O

To O O
elucidate O O
whether O O
troglitazone O O
exerts O O
an O O
antiinflammatory O O
effect O O
in O O
humans O O
, O O
in O O
vivo O O
, O O
we O O
investigated O O
the O O
suppression O O
of O O
nuclear B-protein B-protein
factor I-protein I-protein
kappaB I-protein I-protein
( O O
NFkappaB B-protein B-protein
) O O
in O O
mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
( I-cell_type O
MNC I-cell_type B-cell_type
) I-cell_type O
by O O
this O O
drug O O
. O O

We O O
measured O O
intranuclear B-protein B-protein
NFkappaB I-protein I-protein
, O O
total O O
cellular B-protein B-protein
NFkappaB I-protein I-protein
, O O
inhibitor B-protein B-protein
kappaB I-protein I-protein
( I-protein I-protein
IkappaB I-protein I-protein
) I-protein I-protein
alpha I-protein I-protein
, O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
generation O O
, O O
and O O
p47 B-protein B-protein
( I-protein I-protein
phox I-protein I-protein
) I-protein I-protein
subunit I-protein I-protein
( O O
a O O
key O O
component O O
protein O O
of O O
nicotinamide B-protein B-protein
adenine I-protein I-protein
dinucleotide I-protein I-protein
phosphate I-protein I-protein
oxidase I-protein I-protein
) O O
in O O
MNC B-cell_type B-cell_type
. O O

Plasma B-protein O
tumor I-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
( I-protein I-protein
TNF I-protein I-protein
) I-protein I-protein
-alpha I-protein I-protein
, O O
soluble B-protein B-protein
intercellular I-protein I-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
( O O
sICAM-1 B-protein B-protein
) O O
, O O
monocyte B-protein B-protein
chemoattractant I-protein I-protein
protein-1 I-protein I-protein
( I-protein O
MCP-1 I-protein B-protein
) I-protein O
, O O
plasminogen B-protein B-protein
activator I-protein I-protein
inhibitor I-protein I-protein
type I-protein I-protein
1 I-protein I-protein
( O O
PAI-1 B-protein B-protein
) O O
, O O
C-reactive B-protein B-protein
protein I-protein I-protein
( I-protein O
CRP I-protein B-protein
) I-protein O
, O O
and O O
interleukin B-protein B-protein
( I-protein I-protein
IL I-protein I-protein
) I-protein I-protein
-10 I-protein I-protein
( O I-protein
antiinflammatory B-protein I-protein
cytokine I-protein I-protein
) O O
concentrations O O
were O O
also O O
measured O O
as O O
mediators O O
of O O
inflammatory O O
activity O O
that O O
are O O
regulated O O
by O O
the O O
proinflammatory B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
NFkappaB I-protein B-protein
. O O

Seven O O
nondiabetic O O
obese O O
patients O O
were O O
given O O
400 O O
mg O O
troglitazone O O
daily O O
for O O
4 O O
weeks O O
. O O

Blood O O
samples O O
were O O
collected O O
before O O
and O O
at O O
weekly O O
intervals O O
thereafter O O
. O O

MNC B-cell_type B-cell_type
were O O
separated O O
; O O
and O O
the O O
levels O O
of O O
intranuclear B-protein B-protein
NFkappaB I-protein I-protein
, O O
total O O
cellular B-protein O
NFkappaB I-protein B-protein
, O O
IkappaBalpha B-protein B-protein
, O O
and O O
p47 B-protein B-protein
( I-protein I-protein
phox I-protein I-protein
) I-protein I-protein
subunit I-protein I-protein
and O O
ROS O O
generation O O
were O O
determined O O
. O O

Plasma O O
was O O
used O O
to O O
measure O O
insulin O O
glucose O O
, O O
TNFalpha B-protein B-protein
, O O
sICAM B-protein B-protein
, O O
MCP-1 B-protein B-protein
, O O
PAI-1 B-protein B-protein
, O O
CRP B-protein B-protein
, O O
and O O
IL-10 B-protein B-protein
. O O

Plasma O O
insulin O O
concentrations O O
fell O O
significantly O O
at O O
week O O
1 O O
, O O
from O O
31.2 O O
+/- O O
29.1 O O
to O O
14.2 O O
+/- O O
11.4 O O
mU/L O O
( O O
P O O
< O O
0.01 O O
) O O
and O O
remained O O
low O O
throughout O O
4 O O
weeks O O
. O O

Plasma O O
glucose O O
concentrations O O
did O O
not O O
alter O O
significantly O O
. O O

There O O
was O O
a O O
fall O O
in O O
intranuclear B-protein B-protein
NFkappaB I-protein I-protein
, O O
total O O
cellular B-protein O
NFkappaB I-protein B-protein
, O O
and O O
p47 B-protein B-protein
( I-protein I-protein
phox I-protein I-protein
) I-protein I-protein
subunit I-protein I-protein
, O O
with O O
an O O
increase O O
in O O
cellular O O
IkappaBalpha B-protein B-protein
at O O
week O O
2 O O
, O O
which O O
persisted O O
until O O
week O O
4 O O
. O O

There O O
was O O
a O O
parallel O O
fall O O
in O O
ROS O O
generation O O
by O O
MNC B-cell_type B-cell_type
at O O
week O O
1 O O
; O O
this O O
progressed O O
and O O
persisted O O
until O O
week O O
4 O O
( O O
P O O
< O O
0.001 O O
) O O
. O O

Plasma O O
TNF-alpha B-protein B-protein
, O O
sICAM-1 B-protein B-protein
, O O
MCP-1 B-protein B-protein
, O O
and O O
PAI-1 B-protein B-protein
concentrations O O
fell O O
significantly O O
at O O
week O O
4 O O
. O O

Plasma O O
IL-10 B-protein B-protein
concentration O O
increased O O
significantly O O
, O O
whereas O O
plasma B-protein O
CRP I-protein B-protein
concentrations O O
decreased O O
. O O

We O O
conclude O O
that O O
troglitazone O O
has O O
an O O
antiinflammatory O O
action O O
that O O
may O O
contribute O O
to O O
its O O
putative O O
antiatherosclerotic O O
effects O O
. O O

Tyrosine O O
phosphorylation-dependent O O
activation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
. O O

Requirement O O
for O O
p56 B-protein B-protein
LCK I-protein I-protein
and I-protein I-protein
ZAP-70 I-protein I-protein
protein I-protein I-protein
tyrosine I-protein I-protein
kinases I-protein I-protein
. O O

Phosphorylation O O
of O O
the O O
N-terminal B-protein B-protein
domain I-protein I-protein
of O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
inhibitory I-protein I-protein
subunits I-protein I-protein
induces O O
activation O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
NF-kappa I-protein B-protein
B I-protein I-protein
. O O

Although O O
serine O O
phosphorylation O O
has O O
been O O
shown O O
to O O
induce O O
ubiquitination O O
and O O
subsequent O O
proteasome-mediated O O
degradation O O
of O O
I B-protein B-protein
kappa I-protein I-protein
B-alpha I-protein I-protein
, O O
little O O
is O O
known O O
about O O
the O O
mechanisms O O
that O O
lead O O
to O O
release O O
of O O
active O O
NF-kappa B-protein B-protein
B I-protein I-protein
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
as O O
a O O
consequence O O
of O O
tyrosine O O
phosphorylation O O
of O O
I B-protein B-protein
kappa I-protein I-protein
B-alpha I-protein I-protein
[ O O
Imbert O O
, O O
V. O O
, O O
Rupec O O
, O O
R.A. O O
, O O
Livolsi O O
, O O
A. O O
, O O
Pahl O O
, O O
H.L. O O
, O O
Traenckner O O
, O O
B.M. O O
, O O
Mueller-Dieckmann O O
, O O
C. O O
, O O
Farahifar O O
, O O
D. O O
, O O
Rossi O O
, O O
B. O O
, O O
Auberger O O
, O O
P. O O
, O O
Baeuerle O O
, O O
P. O O
& O O
Peyron O O
, O O
J.F. O O
( O O
1996 O O
) O O
Cell O O
86 O O
, O O
787 O O
-- O O
798 O O
] O O
. O O

The O O
involvement O O
of O O
the O O
tyrosine B-protein B-protein
kinases I-protein I-protein
p56 B-protein B-protein
( I-protein I-protein
lck I-protein I-protein
) I-protein I-protein
and O O
ZAP-70 B-protein B-protein
in O O
this O O
reaction O O
is O O
demonstrated O O
here O O
using O O
specific O O
pharmacological O O
inhibitors O O
and O O
Jurkat B-cell_line B-cell_line
mutants I-cell_line I-cell_line
unable O O
to O O
express O O
these O O
kinases B-protein B-protein
. O O

Although O O
the O O
inhibitors O O
prevented O O
both O O
pervanadate-induced O O
phosphorylation O O
of O O
I B-protein B-protein
kappa I-protein I-protein
B-alpha I-protein I-protein
on O O
Tyr42 O O
and O O
NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
, O O
we O O
observed O O
that O O
, O O
in O O
p56 B-cell_line B-protein
( I-cell_line I-protein
lck I-cell_line I-protein
) I-cell_line I-protein
-deficient I-cell_line I-protein
Jurkat I-cell_line I-protein
mutants I-cell_line I-protein
, O O
NF-kappa B-protein B-protein
B I-protein I-protein
could O O
still O O
associate O O
with O O
I B-protein B-protein
kappa I-protein I-protein
B-alpha I-protein I-protein
despite O O
phosphorylation O O
on O O
Tyr42 O O
. O O

Furthermore O O
, O O
the O O
SH2 B-protein B-protein
domain I-protein I-protein
of O O
p56 B-protein B-protein
( I-protein I-protein
lck I-protein I-protein
) I-protein I-protein
appeared O O
to O O
be O O
required O O
for O O
pervanadate-induced O O
NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
but O O
not O O
for O O
Tyr42 O O
phosphorylation O O
. O O

These O O
results O O
show O O
that O O
p56 B-protein B-protein
( I-protein I-protein
lck I-protein I-protein
) I-protein I-protein
and O O
ZAP-70 B-protein B-protein
are O O
key O O
components O O
of O O
the O O
signaling O O
pathway O O
that O O
leads O O
to O O
phosphotyrosine-dependent O O
NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
confirm O O
that O O
tyrosine B-protein B-protein
kinases I-protein I-protein
must O O
control O O
at O O
least O O
two O O
different O O
steps O O
to O O
induce O O
activation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
. O O

Finally O O
, O O
we O O
show O O
that O O
H O B-protein
( O I-protein
2 O I-protein
) O I-protein
O O I-protein
( O I-protein
2 O I-protein
) O I-protein
, O O
which O O
stimulates O O
p56 B-protein B-protein
( I-protein I-protein
lck I-protein I-protein
) I-protein I-protein
and O O
ZAP-70 B-protein B-protein
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
is O O
an O O
activator O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
through O O
tyrosine O O
phosphorylation O O
of O O
I B-protein B-protein
kappa I-protein I-protein
B-alpha I-protein I-protein
. O O

Specific O O
missense O O
mutations O O
in O O
NEMO B-DNA B-protein
result O O
in O O
hyper-IgM O O
syndrome O O
with O O
hypohydrotic O O
ectodermal O O
dysplasia O O
. O O

The O O
gene O O
that O O
encodes O O
nuclear B-DNA B-protein
factor I-DNA I-protein
kappaB I-DNA I-protein
( I-DNA O
NF-kappaB I-DNA B-protein
) I-DNA O
essential I-DNA O
modulator I-DNA O
( O O
or O O
NEMO B-DNA B-protein
, O O
also O O
known O O
as O O
IKKgamma B-DNA B-protein
) O O
is O O
required O O
for O O
activation O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
NF-kappaB I-protein B-protein
. O O

We O O
describe O O
mutations O O
in O O
the O O
putative B-protein B-protein
zinc-finger I-protein I-protein
domain I-protein I-protein
of O O
NEMO B-protein B-protein
that O O
result O O
in O O
an O O
X-linked O O
primary O O
immunodeficiency O O
characterized O O
by O O
hyper-IgM O O
syndrome O O
and O O
hypohydrotic O O
ectodermal O O
dysplasia O O
( O O
XHM-ED O O
) O O
. O O

These O O
mutations O O
prevent O O
CD40 B-protein B-protein
ligand I-protein I-protein
( O O
CD40L B-protein B-protein
) O O
-mediated O O
degradation O O
of O O
inhibitor O O
of O O
NF-kappaB B-protein B-protein
alpha I-protein I-protein
( O O
IkappaB-alpha B-protein B-protein
) O O
and O O
account O O
for O O
the O O
following O O
observations O O
: O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
XHM-ED O O
patients O O
are O O
unable O O
to O O
undergo O O
immunoglobulin O B-protein
class-switch O B-cell_type
recombination O I-cell_type
and O I-cell_type
antigen-presenting B-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
APCs B-cell_type B-cell_type
) O O
are O O
unable O O
to O O
synthesize O O
the O O
NF-kappaB-regulated B-protein B-protein
cytokines I-protein I-protein
interleukin B-protein B-protein
12 I-protein I-protein
( O O
IL-12 B-protein B-protein
) O O
or O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
alpha I-protein I-protein
( O O
TNF-alpha B-protein B-protein
) O O
when O O
stimulated O O
with O O
CD40L B-protein B-protein
. O O

Nevertheless O O
, O O
innate O O
immunity O O
is O O
preserved O O
in O O
XHM-ED O O
patients O O
because O O
APCs B-cell_type B-cell_type
retain O O
the O O
capacity O O
to O O
respond O O
to O O
stimulation O O
by O O
lipopolysaccharide O O
or O O
Staphylococcus B-protein O
aureus I-protein O
Cowan I-protein O
's I-protein O
antigen I-protein O
( O O
SAC B-protein O
) O O
. O O

Overall O O
, O O
the O O
phenotype O O
observed O O
in O O
XHM-ED O O
patients O O
shows O O
that O O
the O O
putative B-protein B-protein
zinc-finger I-protein I-protein
domain I-protein I-protein
of O O
NEMO B-protein B-protein
has O O
a O O
regulatory O O
function O O
and O O
demonstrates O O
the O O
definite O O
requirement O O
of O O
CD40 B-protein B-protein
-mediated O O
NF-kappaB O B-protein
activation O O
for O O
B B-cell_type B-cell_type
cell I-cell_type I-cell_type
immunoglobulin O B-protein
class-switching O O
. O O

Granulocytic O O
differentiation O O
of O O
human B-cell_type B-cell_line
NB4 I-cell_type I-cell_line
promyelocytic I-cell_type I-cell_line
leukemia I-cell_type I-cell_line
cells I-cell_type I-cell_line
induced O O
by O O
all-trans O O
retinoic O O
acid O O
metabolites O O
. O O

The O O
metabolism O O
of O O
all-trans O O
retinoic O O
acid O O
( O O
ATRA O O
) O O
has O O
been O O
reported O O
to O O
be O O
partly O O
responsible O O
for O O
the O O
in O O
vivo O O
resistance O O
to O O
ATRA O O
seen O O
in O O
the O O
treatment O O
of O O
human O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
. O O

However O O
, O O
ATRA O O
metabolism O O
appears O O
to O O
be O O
involved O O
in O O
the O O
growth O O
inhibition O O
of O O
several O O
cancer B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
in O O
vitro O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
the O O
in O O
vitro O O
activity O O
of O O
the O O
principal O O
metabolites O O
of O O
ATRA O O
[ O O
4-hydroxy-retinoic O O
acid O O
( O O
4-OH-RA O O
) O O
, O O
18-hydroxy-retinoic O O
acid O O
( O O
18-OH-RA O O
) O O
, O O
4-oxo-retinoic O O
acid O O
( O O
4-oxo-RA O O
) O O
, O O
and O O
5 O O
, O O
6-epoxy-retinoic O O
acid O O
( O O
5 O O
, O O
6-epoxy-RA O O
) O O
] O O
in O O
NB4 B-cell_line B-cell_line
, I-cell_line O
a I-cell_line O
human I-cell_line B-cell_line
promyelocytic I-cell_line I-cell_line
leukemia I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
that O O
exhibits O O
the O O
APL O O
diagnostic O O
t O O
( O O
15 O O
; O O
17 O O
) O O
chromosomal O O
translocation O O
and O O
expresses O O
the O O
PML-RAR B-protein B-protein
alpha I-protein I-protein
fusion I-protein I-protein
protein I-protein I-protein
. O O

We O O
established O O
that O O
the O O
four O O
ATRA O O
metabolites O O
were O O
indeed O O
formed O O
by O O
the O O
NB4 B-cell_line B-cell_line
cells I-cell_line I-cell_line
in O O
vitro O O
. O O

NB4 O B-cell_line
cell O I-cell_line
growth O I-cell_line
was O O
inhibited O O
( O O
69-78 O O
% O O
at O O
120 O O
h O O
) O O
and O O
cell O O
cycle O O
progression O O
in O O
the O O
G1 O O
phase O O
( O O
82-85 O O
% O O
at O O
120 O O
h O O
) O O
was O O
blocked O O
by O O
ATRA O O
and O O
all O O
of O O
the O O
metabolites O O
at O O
1 O O
microM O O
concentration O O
. O O

ATRA O O
and O O
its O O
metabolites O O
could O O
induce O O
NB4 B-cell_line B-cell_line
cells I-cell_line I-cell_line
differentiation O O
with O O
similar O O
activity O O
, O O
as O O
evaluated O O
by O O
cell O O
morphology O O
, O O
by O O
the O O
nitroblue O O
tetrazolium O O
reduction O O
test O O
( O O
82-88 O O
% O O
at O O
120 O O
h O O
) O O
or O O
by O O
the O O
expression O O
of O O
the O O
maturation B-protein O
specific I-protein O
cell I-protein O
surface I-protein O
marker I-protein O
CD11c I-protein B-protein
. O O

In O O
addition O O
, O O
nuclear O O
body O O
reorganization O O
to O O
macropunctated O O
structures O O
, O O
as O O
well O O
as O O
the O O
degradation O O
of O O
PML-RAR B-protein B-protein
alpha I-protein I-protein
, O O
was O O
found O O
to O O
be O O
similar O O
for O O
ATRA O O
and O O
all O O
of O O
its O O
metabolites O O
. O O

Comparison O O
of O O
the O O
relative O O
potency O O
of O O
the O O
retinoids O O
using O O
the O O
nitroblue O O
tetrazolium O O
reduction O O
test O O
showed O O
effective O O
concentrations O O
required O O
to O O
differentiate O O
50 O O
% O O
of O O
cells O O
in O O
72 O O
h O O
as O O
follows O O
: O O
ATRA O O
, O O
15.8 O O
+/- O O
1.7 O O
nM O O
; O O
4-oxo-RA O O
, O O
38.3 O O
+/- O O
1.3 O O
nM O O
; O O
18-OH-RA O O
, O O
55.5 O O
+/- O O
1.8 O O
nM O O
; O O
4-OH-RA O O
, O O
79.8 O O
+/- O O
1.8 O O
nM O O
; O O
and O O
5 O O
, O O
6-epoxy-RA O O
, O O
99.5 O O
+/- O O
1.5 O O
nM O O
. O O

The O O
ATRA O O
metabolites O O
were O O
found O O
to O O
exert O O
their O O
differentiation O O
effects O O
via O O
the O O
RAR B-protein B-protein
alpha I-protein I-protein
nuclear I-protein I-protein
receptors I-protein I-protein
, O O
because O O
the O O
RAR O O
alpha-specific O O
antagonist O O
BMS614 O B-protein
blocked O O
metabolite-induced O O
CD11c O B-protein
expression O O
in O O
NB4 B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

These O O
data O O
demonstrate O O
that O O
the O O
principal O O
ATRA O O
Phase O O
1 O O
metabolites O O
can O O
elicit O O
leukemia B-cell_type O
cell I-cell_type O
growth O O
inhibition O O
and O O
differentiation O O
in O O
vitro O O
through O O
the O O
RAR O B-protein
alpha O I-protein
signaling O O
pathway O O
, O O
and O O
they O O
suggest O O
that O O
these O O
metabolites O O
may O O
play O O
a O O
role O O
in O O
ATRA O O
antileukemic O O
activity O O
in O O
vivo O O
. O O

Expression O O
of O O
oestrogen B-protein B-protein
and I-protein I-protein
progesterone I-protein I-protein
receptors I-protein I-protein
by O O
mast B-cell_type B-cell_type
cells I-cell_type I-cell_type
alone O O
, O O
but O O
not O O
lymphocytes B-cell_type B-cell_type
, O O
macrophages B-cell_type B-cell_type
or O O
other O O
immune B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
human O O
upper O O
airways O O
. O O

BACKGROUND O O
: O O
Nasal O O
polyposis O O
often O O
coexists O O
with O O
asthma O O
in O O
airway O O
inflammatory O O
conditions O O
characterised O O
by O O
the O O
infiltration O O
of O O
a O O
range O O
of O O
immune B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

A O O
potentially O O
important O O
role O O
for O O
ovarian O O
hormones O O
has O O
been O O
implicated O O
in O O
airway O O
inflammation O O
but O O
the O O
cellular O O
target O O
for O O
such O O
action O O
is O O
not O O
known O O
. O O

METHODS O O
: O O
Expression O O
of O O
oestrogen B-protein B-protein
receptors I-protein I-protein
( O O
ER B-protein B-protein
) O O
and O O
progesterone B-protein B-protein
receptors I-protein I-protein
( O O
PR B-protein B-protein
) O O
was O O
examined O O
using O O
immunohistochemistry O O
in O O
formalin O O
fixed O O
nasal O O
polyp O O
tissues O O
from O O
47 O O
subjects O O
. O O

The O O
cells O O
positive O O
for O O
ER B-protein B-protein
or O O
PR B-protein B-protein
were O O
confirmed O O
by O O
spatial O O
location O O
, O O
dual O O
immunolabelling O O
, O O
and O O
histochemical O O
staining O O
. O O

RESULTS O O
: O O
Consistent O O
with O O
the O O
known O O
features O O
of O O
nasal O O
polyps O O
, O O
CD4+ B-cell_type B-cell_type
( I-cell_type I-cell_type
T I-cell_type I-cell_type
helper/inducer I-cell_type I-cell_type
) I-cell_type O
, O O
CD8+ B-cell_type B-cell_type
( I-cell_type I-cell_type
cytotoxic/suppressor I-cell_type I-cell_type
) I-cell_type I-cell_type
, O I-cell_type
CD68+ B-cell_type I-cell_type
( O I-cell_type
macrophages B-cell_type I-cell_type
) O O
, O O
mast B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
eosinophils B-cell_type B-cell_type
and O O
neutrophils B-cell_type B-cell_type
were O O
all O O
clearly O O
detected O O
by O O
their O O
relevant O O
monoclonal B-protein B-protein
antibodies I-protein I-protein
or O O
appropriate O O
histochemical O O
staining O O
, O O
but O O
only O O
mast B-cell_type B-cell_type
cells I-cell_type I-cell_type
tested O O
positive O O
for O O
ER B-protein B-protein
/PR O B-protein
labelling O O
with O O
their O O
polyclonal B-protein O
and I-protein O
monoclonal I-protein B-protein
antibodies I-protein I-protein
. O O

The O O
frequencies O O
for O O
expression O O
were O O
61.7 O O
% O O
for O O
ER B-cell_type B-protein
positive I-cell_type O
and O O
59.6 O O
% O O
for O O
PR B-cell_type B-protein
positive I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
expression O O
of O O
ER B-protein B-protein
/ O O
PR B-protein B-protein
was O O
independent O O
of O O
patient O O
sex O O
and O O
age O O
but O O
was O O
highly O O
correlated O O
with O O
the O O
numbers O O
of O O
mast B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
r O O
= O O
0.973 O O
, O O
p O O
< O O
0.001 O O
for O O
ER B-protein B-protein
; O O
r O O
= O O
0.955 O O
, O O
p O O
< O O
0.001 O O
for O O
PR B-protein B-protein
) O O
. O O

Fewer O O
than O O
5 O O
% O O
of O O
mast B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
found O O
to O O
be O O
negative O O
for O O
ER B-protein B-protein
/ O O
PR B-protein B-protein
expression O O
. O O

CONCLUSIONS O O
: O O
Mast B-cell_type B-cell_type
cells I-cell_type I-cell_type
alone O O
, O O
but O O
not O O
lymphocytes B-cell_type B-cell_type
, O O
macrophages B-cell_type B-cell_type
, O O
or O O
other O O
immune B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
express O O
ER B-protein B-protein
/ O O
PR B-protein B-protein
in O O
human O O
upper O O
airways O O
. O O

Numerous O O
ER/PR B-cell_type B-cell_type
positive I-cell_type I-cell_type
mast I-cell_type I-cell_type
cells I-cell_type I-cell_type
exist O O
in O O
nasal O O
polyps O O
, O O
indicating O O
that O O
this O O
may O O
be O O
a O O
major O O
route O O
for O O
the O O
involvement O O
of O O
sex O O
hormones O O
in O O
airway O O
inflammation O O
when O O
exposed O O
to O O
the O O
higher O O
and O O
varying O O
concentration O O
of O O
oestrogen O O
and O O
progesterone O O
characteristic O O
of O O
females O O
. O O

NF O B-protein
kappa O I-protein
b O I-protein
signaling O O
in O O
posthypoxic B-cell_type B-cell_type
endothelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
: O O
relevance O O
to O O
E-selectin O B-protein
expression O O
and O O
neutrophil O B-cell_type
adhesion O O
. O O

Our O O
previous O O
studies O O
have O O
implicated O O
the O O
nuclear O B-protein
transcription O I-protein
factor O I-protein
kappa O I-protein
B O I-protein
( O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
) O O
in O O
the O O
regulation O O
of O O
adhesion B-protein B-protein
molecule I-protein I-protein
expression O O
in O O
endothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
exposed O O
to O O
anoxia-reoxygenation O O
( O O
A/R O O
) O O
or O O
a O O
redox O O
imbalance O O
. O O

The O O
objectives O O
of O O
this O O
study O O
were O O
( O O
1 O O
) O O
to O O
define O O
the O O
kinetics O O
of O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
activation O O
by O O
examining O O
I O B-protein
kappa O I-protein
B O I-protein
alpha O I-protein
degradation O O
and O O
the O O
nuclear O O
translocation O O
of O O
p65 B-protein B-protein
in O O
response O O
to O O
A/R O O
or O O
redox O O
imbalance O O
( O O
induced O O
by O O
treatment O O
of O O
cells O O
with O O
diamide O O
and O O
buthionine O O
sulfoximine O O
) O O
and O O
( O O
2 O O
) O O
to O O
determine O O
whether O O
the O O
signal O O
for O O
I O B-protein
kappa O I-protein
B O I-protein
alpha O I-protein
degradation O O
, O O
nuclear O O
translocation O O
of O O
p65 B-protein B-protein
, O O
and O O
E-selectin B-protein B-protein
-mediated O O
neutrophil O O
adhesion O O
is O O
related O O
to O O
the O O
activity O O
of O O
protein B-protein B-protein
tyrosine I-protein I-protein
kinase I-protein I-protein
( O O
PTK B-protein B-protein
) O O
, O O
protein B-protein B-protein
tyrosine I-protein I-protein
phosphatase I-protein I-protein
( O O
PTPase B-protein B-protein
) O O
and/or O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
( O O
PKC B-protein B-protein
) O O
. O O

The O O
results O O
demonstrate O O
that O O
both O O
A/R O O
and O O
redox O O
imbalance O O
led O O
to O O
I O B-protein
kappa O I-protein
B O I-protein
alpha O I-protein
degradation O O
within O O
30 O O
min O O
and O O
the O O
concomitant O O
appearance O O
of O O
p65 B-protein B-protein
in O O
the O O
nucleus O O
, O O
consistent O O
with O O
rapid O O
cytosolic O O
activation O O
of O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
and O O
subsequent O O
nuclear O O
translocation O O
of O O
the O O
activated B-protein O
p65 I-protein B-protein
subunit I-protein I-protein
. O O

Inhibition O O
of O O
PKC B-protein B-protein
blocked O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
degradation O O
and O O
p65 B-protein B-protein
translocation O O
in O O
A/R-challenged O O
, O O
but O O
not O O
redox-altered O O
, O O
endothelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

However O O
, O O
both O O
A/R- O O
and O O
redox-induced O O
NF O B-protein
kappa O I-protein
B O I-protein
activation O O
was O O
blocked O O
by O O
inhibition O O
of O O
PTK B-protein B-protein
. O O

Similarly O O
, O O
A/R-induced O O
E-selectin O B-protein
expression O O
and O O
neutrophil-endothelial O O
cell O O
adhesion O O
were O O
blocked O O
by O O
inhibition O O
of O O
PKC B-protein B-protein
or O O
PTK B-protein B-protein
, O O
while O O
only O O
PTK B-protein B-protein
inhibited O O
the O O
redox-induced O O
adhesion O O
response O O
. O O

Pretreatment O O
of O O
cells O O
with O O
N-acetyl O O
cysteine O O
effectively O O
blocked O O
A/R- O O
or O O
redox-induced O O
I O B-protein
kappa O I-protein
B O I-protein
degradation O O
and O O
significantly O O
attenuated O O
the O O
respective O O
neutrophil O B-cell_type
adhesion O O
responses O O
. O O

Collectively O O
, O O
these O O
findings O O
indicate O O
that O O
A/R-induced O O
E-selectin O B-protein
expression O O
and O O
neutrophil-endothelial O O
cell O O
adhesion O O
are O O
mediated O O
by O O
both O O
PKC B-protein B-protein
and O O
PTK B-protein B-protein
, O O
which O O
signal O O
rapid O O
activation O O
of O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
. O O

This O O
A/R-induced O O
NF B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
signaling O O
response O O
appears O O
to O O
be O O
mediated O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
intracellular O O
redox O O
imbalance O O
. O O

Copyright O O
2001 O O
S. O O
Karger O O
AG O O
, O O
Basel O O

Induction O O
of O O
apoptosis O O
in O O
human B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
by O O
the O O
herbicide O O
2 O O
, O O
4-dichlorophenoxyacetic O O
acid O O
. O O

Dimethylammonium O O
salt O O
of O O
2 O O
, O O
4-dichlorophenoxyacetic O O
acid O O
( O O
DMA-2 O O
, O O
4-D O O
) O O
is O O
a O O
widely O O
used O O
herbicide O O
that O O
is O O
considered O O
moderately O O
toxic O O
. O O

In O O
the O O
present O O
study O O
we O O
found O O
that O O
DMA-2 O B-protein
, O O
4-D O O
is O O
able O O
to O O
cause O O
apoptosis O O
in O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
of O O
healthy O O
individuals O O
and O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Apoptosis O O
induced O O
by O O
DMA-2 O O
, O O
4-D O O
was O O
dose O O
and O O
time O O
dependent O O
, O O
independent O O
of O O
Fas B-protein B-protein
, O O
TNF B-protein B-protein
receptor I-protein I-protein
1 I-protein I-protein
or O O
the O O
aromatic B-protein B-protein
hydrocarbon I-protein I-protein
receptor I-protein I-protein
, O O
and O O
involved O O
disruption O O
of O O
the O O
mitochondrial O O
transmembrane O O
potential O O
and O O
activation O O
of O O
caspase-9 B-protein B-protein
. O O

ZVAD-FMK O O
, O O
a O O
broad-spectrum O O
inhibitor O O
of O O
caspases B-protein B-protein
, O O
blocked O O
DMA-2 O B-protein
, O O
4-D-induced O O
apoptosis O O
completely O O
. O O

While O O
an O O
inhibitor O O
of O O
caspase-9 B-protein B-protein
, O O
as O O
well O O
as O O
caspase-9 B-protein B-protein
and O O
caspase-3 O O
inhibitors O O
in O O
combination O O
, O O
strongly O O
blocked O O
DMA-2 O B-protein
, O O
4-D-induced O O
apoptosis O O
, O O
an O O
inhibitor O O
of O O
caspase-3 B-protein B-protein
had O O
a O O
moderate O O
inhibitory O O
effect O O
. O O

Unlike O O
Fas B-protein B-protein
-mediated O O
apoptosis O O
, O O
the O O
initiator B-protein O
caspase I-protein B-protein
, O O
caspase-8 B-protein B-protein
, O O
was O O
not O O
involved O O
in O O
DMA-2 O O
, O O
4-D-induced O O
apoptosis O O
. O O

Transfection O O
of O O
Jurkat B-cell_line B-cell_line
cells I-cell_line I-cell_line
with O O
Bcl-2 B-protein B-protein
prevented O O
DMA-2 O B-protein
, O O
4-D-induced O O
disruption O O
of O O
the O O
mitochondrial O B-protein
transmembrane O I-protein
potential O O
and O O
led O O
to O O
a O O
complete O O
blockage O O
of O O
apoptosis O O
. O O

Our O O
data O O
indicate O O
that O O
DMA-2 O B-protein
, O O
4-D O O
kills O O
human B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
by O O
initiating O O
apoptosis O O
via O O
a O O
direct O O
effect O O
on O O
mitochondria O O
. O O

The O O
activation O O
of O O
caspases B-protein B-protein
occurs O O
downstream O O
of O O
mitochondrial O O
damage O O
, O O
and O O
the O O
dysfunction O O
of O O
mitochondria O O
appears O O
to O O
be O O
sufficient O O
for O O
triggering O O
all O O
downstream O O
events O O
leading O O
to O O
apoptosis O O
. O O

Inhibition O O
of O O
Th1 O O
differentiation O O
by O O
IL-6 B-protein B-protein
is O O
mediated O O
by O O
SOCS1 B-protein B-protein
. O O

Interleukin B-protein B-protein
6 I-protein I-protein
( O O
IL-6 B-protein B-protein
) O O
is O O
a O O
cytokine B-protein B-protein
produced O O
by O O
immune B-cell_type B-cell_type
and I-cell_type I-cell_type
nonimmune I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
exhibits O O
functional O O
pleiotropy O O
and O O
redundancy O O
. O O

IL-6 B-protein B-protein
plays O O
an O O
important O O
role O O
in O O
the O O
differentiation O O
of O O
several O O
cell O O
types O O
. O O

Here O O
, O O
we O O
describe O O
a O O
novel O O
function O O
of O O
IL-6 B-protein B-protein
: O O
the O O
negative O O
regulation O O
of O O
CD4 B-protein B-protein
+ O O
Th1 O O
cell O O
differentiation O O
. O O

While O O
IL-6 B-protein B-protein
-directed O O
CD4 B-protein B-protein
+ O O
Th2 O O
differentiation O O
is O O
mediated O O
by O O
IL-4 B-protein B-protein
, O O
inhibition O O
of O O
Th1 O O
differentiation O O
by O O
IL-6 B-protein B-protein
is O O
independent O O
of O O
IL-4 B-protein B-protein
. O O

IL-6 B-protein B-protein
upregulates O O
suppressor B-protein O
of I-protein O
cytokine I-protein B-protein
signaling I-protein I-protein
1 I-protein I-protein
( O O
SOCS1 B-protein B-protein
) O O
expression O O
in O O
activated B-cell_type O
CD4+ I-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
thereby O O
interfering O O
with O O
signal B-protein B-protein
transducer I-protein I-protein
and I-protein I-protein
activator I-protein I-protein
of I-protein I-protein
transcription I-protein I-protein
1 I-protein I-protein
( O O
STAT1 B-protein B-protein
) O O
phosphorylation O O
induced O O
by O O
interferon B-protein B-protein
gamma I-protein I-protein
( O O
IFNgamma B-protein B-protein
) O O
. O O

Inhibition O O
of O O
IFNgamma B-protein B-protein
receptor-mediated O O
signals O O
by O O
IL-6 B-protein B-protein
prevents O O
autoregulation O O
of O O
IFNgamma B-DNA B-DNA
gene I-DNA I-DNA
expression O O
by O O
IFNgamma B-protein B-protein
during O O
CD4+ B-cell_type B-cell_type
T I-cell_type I-cell_type
cell I-cell_type I-cell_type
activation O O
, O O
thereby O O
preventing O O
Th1 O O
differentiation O O
. O O

Thus O O
, O O
IL-6 B-protein B-protein
promotes O O
CD4 B-protein B-protein
+ O O
Th2 O O
differentiation O O
and O O
inhibits O O
Th1 O O
differentiation O O
by O O
two O O
independent O O
molecular O O
mechanisms O O
. O O

Interaction O O
between O O
CCAAT/enhancer B-protein B-protein
binding I-protein I-protein
protein I-protein I-protein
and O O
cyclic B-protein B-protein
AMP I-protein I-protein
response I-protein I-protein
element I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
1 I-protein I-protein
regulates O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
transcription O O
in O O
cells O O
of O O
the O O
monocyte/macrophage B-cell_type B-cell_type
lineage I-cell_type I-cell_type
. O O

Recent O O
observations O O
have O O
shown O O
two O O
CCAAT/enhancer B-DNA B-protein
binding I-DNA I-protein
protein I-DNA I-protein
( I-DNA I-DNA
C/EBP I-DNA I-DNA
) I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
to O O
be O O
critically O O
important O O
for O O
efficient O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
replication O O
within O O
cells O O
of O O
the O O
monocyte/macrophage B-cell_type B-cell_type
lineage I-cell_type I-cell_type
, O O
a O O
cell O O
type O O
likely O O
involved O O
in O O
transport O O
of O O
the O O
virus O O
to O O
the O O
brain O O
. O O

Additionally O O
, O O
sequence O O
variation O O
at O O
C/EBP B-DNA B-DNA
site I-DNA I-DNA
I I-DNA I-DNA
, O O
which O O
lies O O
immediately O O
upstream O O
of O O
the O O
distal B-DNA B-DNA
nuclear I-DNA I-DNA
factor I-DNA I-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
site I-DNA I-DNA
and O O
immediately O O
downstream O O
of O O
a O O
binding O B-DNA
site O I-DNA
for O O
activating B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
( O O
ATF B-protein B-protein
) O O
/ O O
cyclic B-protein B-protein
AMP I-protein I-protein
response I-protein I-protein
element I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
( O O
CREB B-protein B-protein
) O O
, O O
has O O
been O O
shown O O
to O O
affect O O
HIV-1 B-DNA B-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
activity O O
. O O

Given O O
that O O
C/EBP B-protein B-protein
proteins I-protein I-protein
have O O
been O O
shown O O
to O O
interact O O
with O O
many O O
other O O
transcription B-protein B-protein
factors I-protein I-protein
including O O
members O O
of O O
the O O
ATF/CREB B-protein B-protein
family I-protein I-protein
, O O
we O O
proceeded O O
to O O
determine O O
whether O O
an O O
adjacent O O
ATF/CREB B-DNA B-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
could O O
affect O O
C/EBP B-protein B-protein
protein I-protein I-protein
binding O O
to O O
C/EBP B-DNA B-DNA
site I-DNA I-DNA
I I-DNA I-DNA
. O O

Electrophoretic O O
mobility O O
shift O O
analyses O O
indicated O O
that O O
selected O O
ATF/CREB B-DNA B-DNA
site I-DNA I-DNA
variants I-DNA I-DNA
assisted O O
in O O
the O O
recruitment O O
of O O
C/EBP B-protein B-protein
proteins I-protein I-protein
to O O
an O O
adjacent O O
, O O
naturally O O
occurring O O
, O O
low-affinity O O
C/EBP B-DNA B-DNA
site I-DNA I-DNA
. O O

This O O
biophysical O O
interaction O O
appears O O
to O O
occur O O
via O O
at O O
least O O
two O O
mechanisms O O
. O O

First O O
, O O
low O O
amounts O O
of O O
CREB-1 B-protein B-protein
and O O
C/EBP B-protein B-protein
appear O O
to O O
heterodimerize O B-protein
and O O
bind O O
to O O
a O O
site O O
consisting O O
of O O
a O O
half O B-DNA
site O I-DNA
from O O
both O O
the O O
ATF/CREB B-DNA B-DNA
and I-DNA I-DNA
C/EBP I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
. O O

In O O
addition O O
, O O
CREB-1 B-protein B-protein
homodimers I-protein I-protein
bind O O
to O O
the O O
ATF/CREB B-DNA B-DNA
site I-DNA I-DNA
and O O
recruit O O
C/EBP B-protein B-protein
dimers I-protein I-protein
to O O
their O O
cognate O B-DNA
weak B-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
. O O

This O O
interaction O O
is O O
reciprocal O O
, O O
since O O
C/EBP B-protein B-DNA
dimer I-protein I-DNA
binding O O
to O O
a O O
strong O O
C/EBP B-DNA B-DNA
site I-DNA I-DNA
leads O O
to O O
enhanced O O
CREB-1 B-protein B-protein
recruitment O O
to O O
ATF/CREB B-DNA B-DNA
sites I-DNA I-DNA
that O O
are O O
weakly O O
bound O O
by O O
CREB B-protein B-protein
. O O

Sequence O O
variation O O
at O O
both O O
C/EBP B-DNA B-DNA
and I-DNA I-DNA
ATF/CREB I-DNA I-DNA
sites I-DNA I-DNA
affects O O
the O O
molecular O O
interactions O O
involved O O
in O O
mediating O O
both O O
of O O
these O O
mechanisms O O
. O O

Most O O
importantly O O
, O O
sequence O O
variation O O
at O O
the O O
ATF/CREB B-DNA B-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
affected O O
basal O O
LTR B-DNA B-DNA
activity O O
as O O
well O O
as O O
LTR B-DNA B-DNA
function O O
following O O
interleukin-6 B-protein B-protein
stimulation O O
, O O
a O O
treatment O O
that O O
leads O O
to O O
increases O O
in O O
C/EBP O B-protein
activation O O
. O O

Thus O O
, O O
HIV-1 B-DNA B-DNA
LTR I-DNA I-DNA
ATF/CREB B-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
sequence O I-DNA
variation O O
may O O
modulate O O
cellular O O
signaling O O
at O O
the O O
viral B-DNA B-DNA
promoter I-DNA I-DNA
through O O
the O O
C/EBP O B-DNA
pathway O I-DNA

Selective O O
inhibition O O
of O O
interleukin-4 O B-DNA
gene O I-DNA
expression O O
in O O
human B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
aspirin O O
. O O

Previous O O
studies O O
indicated O O
that O O
aspirin O O
( O O
acetylsalicylic O O
acid O O
[ O O
ASA O O
] O O
) O O
can O O
have O O
profound O O
immunomodulatory O O
effects O O
by O O
regulating O O
cytokine O B-DNA
gene O I-DNA
expression O O
in O O
several O O
types O O
of O O
cells O O
. O O

This O O
study O O
is O O
the O O
first O O
in O O
which O O
concentrations O O
of O O
ASA O O
in O O
the O O
therapeutic O O
range O O
were O O
found O O
to O O
significantly O O
reduce O O
interleukin B-protein B-protein
( I-protein I-protein
IL I-protein I-protein
) I-protein I-protein
-4 I-protein I-protein
secretion O O
and O O
RNA O O
expression O O
in O O
freshly B-cell_type O
isolated I-cell_type O
and I-cell_type O
mitogen-primed I-cell_type B-cell_line
human I-cell_type I-cell_line
CD4+ I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

In O O
contrast O O
, O O
ASA O O
did O O
not O O
affect O O
IL-13 B-protein B-protein
, O O
interferon-gamma B-protein B-protein
, O O
and O O
IL-2 B-protein B-protein
expression O O
. O O

ASA O O
inhibited O O
IL-4 B-protein B-protein
, O O
but O O
not O O
IL-2 B-protein B-protein
, O O
promoter-driven O O
chloramphenicol O B-protein
acetyltransferase O I-protein
expression O O
in O O
transiently O B-cell_line
transfected O I-cell_line
Jurkat B-cell_line I-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

The O O
structurally O O
unrelated O O
nonsteroidal O O
anti-inflammatory O O
drugs O O
indomethacin O O
and O O
flurbiprofen O O
did O O
not O O
affect O O
cytokine O B-DNA
gene O I-DNA
expression O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
whereas O O
the O O
weak O O
cyclo-oxygenase O O
inhibitor O O
salicylic O O
acid O O
was O O
at O O
least O O
as O O
effective O O
as O O
ASA O O
in O O
inhibiting O O
IL-4 B-protein B-protein
expression O O
and O O
promoter O O
activity O O
. O O

The O O
inhibitory O O
effect O O
of O O
ASA O O
on O O
IL-4 O B-protein
transcription O O
was O O
not O O
mediated O O
by O O
decreased O O
nuclear O O
expression O O
of O O
the O O
known O O
salicylate B-protein B-protein
target I-protein I-protein
nuclear I-protein I-protein
factor I-protein I-protein
( I-protein I-protein
NF I-protein I-protein
) I-protein I-protein
-kappaB I-protein I-protein
and O O
was O O
accompanied O O
by O O
reduced O O
binding O O
of O O
an O O
inducible O O
factor O O
to O O
an O O
IL-4 B-DNA B-DNA
promoter I-DNA I-DNA
region I-DNA I-DNA
upstream O O
of O O
, O O
but O O
not O O
overlapping O O
, O O
the O O
NF B-DNA B-DNA
of I-DNA I-DNA
activated I-DNA I-DNA
T I-DNA I-DNA
cells- I-DNA I-DNA
and I-DNA I-DNA
NF-kappaB-binding I-DNA I-DNA
P1 I-DNA I-DNA
element I-DNA I-DNA
. O O

It O O
is O O
concluded O O
that O O
anti-inflammatory O O
salicylates O O
, O O
by O O
means O O
of O O
a O O
previously O O
unrecognized O O
mechanism O O
of O O
action O O
, O O
can O O
influence O O
the O O
nature O O
of O O
adaptive O O
immune O O
responses O O
by O O
selectively O O
inhibiting O O
the O O
expression O O
of O O
IL-4 B-protein B-protein
, O O
a O O
critical O O
effector O O
of O O
these O O
responses O O
, O O
in O O
CD4+ B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Molecular O O
and O O
cellular O O
mediators O O
of O O
interleukin-1 B-protein B-protein
-dependent O O
acute O O
inflammatory O O
arthritis O O
. O O

OBJECTIVE O O
: O O
To O O
examine O O
the O O
molecular O O
and O O
cellular O O
mechanisms O O
in O O
a O O
model O O
of O O
acute O O
inflammatory O O
monarticular O O
arthritis O O
induced O O
by O O
methylated B-protein B-protein
bovine I-protein I-protein
serum I-protein I-protein
albumin I-protein I-protein
( O O
mBSA B-protein O
) O O
and O O
interleukin-1 B-protein B-protein
( O O
IL-1 B-protein B-protein
) O O
. O O

METHODS O O
: O O
Mice O O
were O O
injected O O
intraarticularly O O
with O O
mBSA B-protein O
on O O
day O O
0 O O
and O O
subcutaneously O O
with O O
recombinant B-protein B-protein
human I-protein I-protein
IL-1beta I-protein I-protein
on O O
days O O
0-2 O O
. O O

At O O
day O O
7 O O
, O O
knee O O
joints O O
were O O
removed O O
and O O
assessed O O
histologically O O
. O O

Flow O O
cytometry O O
and O O
RNase O B-protein
protection O O
were O O
used O O
to O O
analyze O O
IL-1 B-protein B-protein
-dependent O O
events O O
. O O

RESULTS O O
: O O
C57BL/6 O O
( O O
B6 O O
) O O
, O O
129/Sv O O
, O O
and O O
( O O
B6 O O
x O O
129/ O O
Sv O O
) O O
F1 O O
hybrid O O
mice O O
, O O
all O O
H-2b O O
strains O O
, O O
were O O
susceptible O O
to O O
mBSA B-protein O
/IL-1-induced O O
arthritis O O
, O O
whereas O O
C3H/HeJ O O
( O O
H-2k O O
) O O
mice O O
were O O
not O O
. O O

B6 O O
mice O O
lacking O O
T B-cell_type B-cell_type
and I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
RAG1-/- O O
) O O
or O O
major B-protein B-protein
histocompatibility I-protein I-protein
complex I-protein I-protein
( I-protein I-protein
MHC I-protein I-protein
) I-protein I-protein
class I-protein I-protein
II I-protein I-protein
antigens I-protein I-protein
( O O
MHCII-/- O B-protein
) O O
, O O
and O O
B6 O O
mice O O
treated O O
with O O
a O O
CD4+ B-protein B-protein
T I-protein I-protein
cell-depleting I-protein I-protein
monoclonal I-protein I-protein
antibody I-protein I-protein
, O O
were O O
resistant O O
to O O
disease O O
. O O

In O O
contrast O O
, O O
B O O
cell-deficient O O
( O O
muMT/ O O
muMT O O
) O O
mice O O
developed O O
arthritis O O
at O O
an O O
incidence O O
and O O
severity O O
similar O O
to O O
that O O
of O O
controls O O
. O O

RelB-deficient O O
( O O
RelB-/- O O
) O O
bone O O
marrow O O
chimeric O O
mice O O
had O O
arthritis O O
that O O
was O O
significantly O O
reduced O O
in O O
incidence O O
and O O
severity O O
. O O

In O O
B6 O O
mice O O
, O O
flow O O
cytometry O O
demonstrated O O
an O O
IL-1-dependent B-cell_type O
leukocyte I-cell_type O
infiltration O O
into O O
the O O
synovial O O
compartment O O
and O O
RNase O B-protein
protection O O
assays O O
revealed O O
induction O O
of O O
messenger B-RNA B-RNA
RNA I-RNA I-RNA
( O O
mRNA B-RNA B-RNA
) O O
for O O
the O O
chemokines B-protein B-protein
monocyte B-protein I-protein
chemoattractant I-protein I-protein
protein I-protein I-protein
1 I-protein I-protein
, O O
macrophage B-protein B-protein
inhibitory I-protein I-protein
protein I-protein I-protein
2 I-protein I-protein
( O O
MIP-2 B-protein B-protein
) O O
, O O
RANTES B-protein B-protein
, O O
MIP-1alpha B-protein B-protein
, O O
and O O
MIP-1beta B-protein B-protein
, O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

CONCLUSION O O
: O O
Arthritis O O
induced O O
by O O
mBSA B-protein O
/ O O
IL-1 B-protein B-protein
is O O
strain O O
specific O O
and O O
dependent O O
on O O
CD4+ B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
at O O
least O O
partially O O
on O O
RelB B-protein B-protein
, O O
but O O
not O O
on O O
B B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
or O O
antibody B-protein O
. O O

IL-1 B-protein B-protein
contributes O O
to O O
leukocyte O O
recruitment O O
to O O
the O O
synovium O O
and O O
directly O O
induces O O
chemokine O B-RNA
mRNA O I-RNA
production O O
by O O
synovial B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

This O O
model O O
of O O
acute O O
monarticular O O
arthritis O O
is O O
particularly O O
suitable O O
for O O
further O O
investigations O O
into O O
cell-mediated O O
immunity O O
in O O
arthritis O O
and O O
the O O
role O O
of O O
IL-1 B-protein B-protein
. O O

Positive O O
and O O
negative O O
regulation O O
of O O
granulopoiesis O O
by O O
endogenous B-protein O
RARalpha I-protein B-protein
. O O

Acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
is O O
always O O
associated O O
with O O
chromosomal O O
translocations O O
that O O
disrupt O O
the O O
retinoic B-DNA B-DNA
acid I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
( I-DNA I-DNA
RARalpha I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
. O O

Whether O O
these O O
translocations O O
relate O O
to O O
a O O
role O O
for O O
endogenous B-protein O
RARalpha I-protein B-protein
in O O
normal O O
granulopoiesis O O
remains O O
uncertain O O
because O O
most O O
studies O O
addressing O O
this O O
question O O
have O O
used O O
non-physiological O O
overexpression O O
systems O O
. O O

Granulocyte O O
differentiation O O
in O O
cells O O
derived O O
from O O
RARalpha-deficient O O
( O O
RARalpha O B-protein
( O O
-/- O O
) O O
) O O
mice O O
was O O
studied O O
and O O
evaluated O O
in O O
the O O
context O O
of O O
agonist-bound B-protein B-protein
and I-protein I-protein
ligand-free I-protein I-protein
RARalpha I-protein I-protein
. O O

Our O O
results O O
demonstrate O O
that O O
RARalpha B-protein B-protein
is O O
dispensable O O
for O O
granulopoiesis O O
, O O
as O O
RARalpha O B-protein
( O O
-/- O O
) O O
mice O O
have O O
a O O
normal B-cell_type B-cell_type
granulocyte I-cell_type I-cell_type
population I-cell_type I-cell_type
despite O O
an O O
impaired O O
ability O O
to O O
respond O O
to O O
retinoids O O
. O O

However O O
, O O
although O O
it O O
is O O
not O O
absolutely O O
required O O
, O O
RARalpha B-protein B-protein
can O O
bidirectionally O O
modulate O O
granulopoiesis O O
. O O

RARalpha B-protein B-protein
stimulates O O
differentiation O O
in O O
response O O
to O O
exogenous O O
retinoic O O
acid O O
. O O

Furthermore O O
, O O
endogenous O O
retinoids O O
control O O
granulopoiesis O O
in O O
vivo O O
, O O
as O O
either O O
vitamin O O
A-deficient O O
mice O O
or O O
animals O O
treated O O
with O O
an O O
RAR O O
antagonist O O
accumulate O O
more O O
immature B-cell_type B-cell_type
granulocytes I-cell_type I-cell_type
in O O
their O O
bone O O
marrow O O
. O O

Conversely O O
, O O
RARalpha B-protein B-protein
acts O O
to O O
limit O O
differentiation O O
in O O
the O O
absence O O
of O O
ligand B-protein O
because O O
granulocyte B-cell_type B-cell_type
precursors I-cell_type I-cell_type
from O O
RARalpha O B-protein
( O O
-/- O O
) O O
mice O O
differentiate O O
earlier O O
in O O
culture O O
. O O

Thus O O
, O O
the O O
block O O
in O O
granulopoiesis O O
exerted O O
by O O
RARalpha B-protein B-protein
fusion B-protein I-protein
proteins I-protein I-protein
expressed O O
in O O
APL B-cell_type B-cell_type
cells I-cell_type I-cell_type
may O O
correspond O O
to O O
an O O
amplification O O
of O O
a O O
normal O O
function O O
of O O
unliganded B-protein O
RARalpha I-protein B-protein
. O O

Expression O O
and O O
function O O
of O O
a O O
stem B-DNA B-DNA
cell I-DNA I-DNA
promoter I-DNA I-DNA
for O O
the O O
murine B-DNA B-DNA
CBFalpha2 I-DNA I-DNA
gene I-DNA I-DNA
: O O
distinct O O
roles O O
and O O
regulation O O
in O O
natural B-cell_type O
killer I-cell_type O
and I-cell_type O
T I-cell_type O
cell I-cell_type O
development O O
. O O

The O O
Runt B-protein B-protein
family I-protein I-protein
transcription I-protein I-protein
factor I-protein I-protein
CBFalpha2 B-protein B-protein
( O O
AML1 B-protein B-protein
, O O
PEBP2alphaB B-protein B-protein
, O O
or O O
Runx1 B-protein B-protein
) O O
is O O
required O O
by O O
hematopoietic B-cell_type B-cell_type
stem I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
expressed O O
at O O
high O O
levels O O
in O O
T-lineage B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

In O O
human B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
CBFalpha2 B-protein B-protein
is O O
usually O O
transcribed O O
from O O
a O O
different B-DNA O
promoter I-DNA B-DNA
( O O
distal B-DNA B-DNA
promoter I-DNA I-DNA
) O O
than O O
in O O
myeloid B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
proximal B-DNA O
promoter I-DNA O
) O O
, O O
but O O
the O O
developmental O O
and O O
functional O O
significance O O
of O O
this O O
promoter O O
switch O O
has O O
not O O
been O O
known O O
. O O

Here O O
, O O
we O O
report O O
that O O
both O O
coding B-DNA O
and I-DNA O
noncoding I-DNA O
sequences I-DNA O
of O O
the O O
distal B-DNA B-DNA
5 I-DNA I-DNA
' I-DNA I-DNA
end I-DNA I-DNA
are O O
highly O O
conserved O O
between O O
the O O
human B-DNA O
and I-DNA O
the I-DNA O
murine I-DNA B-DNA
genes I-DNA I-DNA
, O O
and O O
the O O
distal B-DNA B-DNA
promoter I-DNA I-DNA
is O O
responsible O O
for O O
the O O
overwhelming O O
majority O O
of O O
CBFalpha2 O B-protein
expression O O
in O O
murine O B-cell_type
hematopoietic B-cell_type I-cell_type
stem I-cell_type I-cell_type
cells I-cell_type I-cell_type
as O O
well O O
as O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Distal O B-DNA
promoter O I-DNA
activity O O
is O O
maintained O O
throughout O O
T O O
cell O O
development O O
and O O
at O O
lower O O
levels O O
in O O
B O O
cell O O
development O O
, O O
but O O
downregulated O O
in O O
natural O O
killer O O
cell O O
development O O
. O O

The O O
distal B-DNA B-protein
N-terminal I-DNA I-protein
isoform I-DNA I-protein
binds O O
to O O
functionally O O
important O O
regulatory B-DNA B-DNA
sites I-DNA I-DNA
from O O
known O O
target B-DNA B-DNA
genes I-DNA I-DNA
with O O
two- O O
to O O
threefold O O
higher O O
affinity O O
than O O
the O O
proximal B-DNA B-protein
N-terminal I-DNA I-protein
isoform I-DNA I-protein
. O O

Neither O O
full-length B-DNA O
isoform I-DNA O
alters O O
growth O O
of O O
a O O
myeloid B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
under O O
nondifferentiating O O
conditions O O
, O O
but O O
the O O
proximal B-DNA O
isoform I-DNA O
selectively O O
delays O O
mitotic O O
arrest O O
of O O
the O O
cell O B-cell_line
line O I-cell_line
under O O
differentiating O O
conditions O O
, O O
resulting O O
in O O
the O O
generation O O
of O O
greater O O
numbers O O
of O O
neutrophils B-cell_type B-cell_type
. O O

Constitutive O O
PI3-K O B-protein
activity O O
is O O
essential O O
for O O
proliferation O O
, O O
but O O
not O O
survival O O
, O O
of O O
Theileria B-cell_type B-cell_type
parva-transformed I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Theileria O O
is O O
an O O
intracellular O O
parasite O O
that O O
causes O O
lymphoproliferative O O
disorders O O
in O O
cattle O O
, O O
and O O
infection O O
of O O
leucocytes B-cell_type B-cell_type
induces O O
a O O
transformed O O
phenotype O O
similar O O
to O O
tumour B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
but O O
the O O
mechanisms O O
by O O
which O O
the O O
parasite O O
induces O O
this O O
phenotype O O
are O O
not O O
understood O O
. O O

Here O O
, O O
we O O
show O O
that O O
infected B-cell_type B-cell_type
B I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
display O O
constitutive O O
phosphoinositide O B-protein
3-kinase O I-protein
( O O
PI3-K O B-protein
) O O
activity O O
, O O
which O O
appears O O
to O O
be O O
necessary O O
for O O
proliferation O O
, O O
but O O
not O O
survival O O
. O O

Importantly O O
, O O
we O O
demonstrate O O
that O O
one O O
mechanism O O
by O O
which O O
PI3-K B-protein B-protein
mediates O O
the O O
proliferation O O
of O O
infected B-cell_type B-cell_type
B I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
is O O
through O O
the O O
induction O O
of O O
a O O
granulocyte-monocyte B-protein B-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
( O O
GM-CSF B-protein B-protein
) O O
-dependent O O
autocrine O O
loop O O
. O O

PI3-K B-protein B-protein
induction O O
of O O
GM-CSF B-protein B-protein
appears O O
to O O
be O O
at O O
the O O
transcriptional O O
level O O
and O O
, O O
consistently O O
, O O
we O O
demonstrate O O
that O O
PI3-K B-protein B-protein
is O O
also O O
involved O O
in O O
the O O
constitutive O O
induction O O
of O O
AP-1 B-protein B-protein
and O O
NF-kappaB B-protein B-protein
, O O
which O O
characterizes O O
Theileria-infected O B-cell_type
leucocytes B-cell_type I-cell_type
. O O

Taken O O
together O O
, O O
our O O
results O O
highlight O O
a O O
novel O O
strategy O O
exploited O O
by O O
the O O
intracellular O O
parasite O O
Theileria O O
to O O
induce O O
continued O O
proliferation O O
of O O
its O O
host B-cell_type B-cell_type
leucocyte I-cell_type I-cell_type
. O O

Lymphokine B-protein O
dependence O O
of O O
STAT3 O B-protein
activation O O
produced O O
by O O
surface O B-protein
immunoglobulin O I-protein
cross-linking O O
and O O
by O O
phorbol O O
ester O O
plus O O
calcium O O
ionophore O O
treatment O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Stimulation O O
of O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
by O O
surface B-protein B-protein
immunoglobulin I-protein I-protein
( O O
sIg B-protein B-protein
) O O
triggering O O
, O O
or O O
through O O
the O O
mitogenic O O
combination O O
of O O
phorbol O O
ester O O
and O O
calcium O O
ionophore O O
, O O
is O O
accompanied O O
by O O
activation O O
of O O
STAT B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
. O O

The O O
mechanism O O
responsible O O
for O O
the O O
delayed O O
nuclear O O
accumulation O O
of O O
phosphorylated B-protein O
STAT3 I-protein B-protein
was O O
examined O O
in O O
detail O O
, O O
focusing O O
on O O
the O O
role O O
of O O
B B-protein B-protein
cell-derived I-protein I-protein
lymphokines I-protein I-protein
. O O

sIg B-protein B-protein
-induced O O
activation O O
of O O
STAT3 B-protein B-protein
was O O
partially O O
inhibited O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
obtained O O
from O O
IL-6- O O
or O O
IL-10-deficient O O
mice O O
, O O
and O O
was O O
partially O O
blocked O O
by O O
neutralizing B-protein B-protein
antibodies I-protein I-protein
directed O O
against O O
either O O
of O O
these O O
lymphokines B-protein B-protein
. O O

sIg B-protein B-protein
-induced O O
STAT3 O B-protein
activation O O
was O O
completely O O
inhibited O O
by O O
combining O O
IL-6- B-protein O
and I-protein O
IL-10-specific I-protein B-protein
neutralizing I-protein I-protein
antibodies I-protein I-protein
, O O
or O O
by O O
adding O O
individual O O
neutralizing B-protein B-protein
antibodies I-protein I-protein
to O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
obtained O O
from O O
lymphokine-deficient O O
animals O O
. O O

In O O
contrast O O
, O O
IL-10 B-protein B-protein
alone O O
appeared O O
to O O
account O O
for O O
STAT3 O B-protein
activation O O
resulting O O
from O O
B O O
cell O O
stimulation O O
with O O
phorbol O O
ester O O
and O O
calcium O O
ionophore O O
. O O

In O O
keeping O O
with O O
these O O
results O O
, O O
soluble O O
IL-6 B-protein B-protein
and O O
IL-10 B-protein B-protein
were O O
found O O
in O O
supernatant O O
fluid O O
obtained O O
from O O
stimulated B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

This O O
work O O
indicates O O
that O O
a O O
lymphokine O B-protein
pathway O O
is O O
responsible O O
for O O
STAT3 O B-protein
activation O O
that O O
occurs O O
late O O
after O O
B O O
cell O O
stimulation O O
, O O
and O O
points O O
out O O
differences O O
in O O
B O O
cell O O
activation O O
that O O
result O O
from O O
stimulation O O
through O O
the O O
antigen B-protein B-protein
receptor I-protein I-protein
and O O
through O O
pharmacological O O
mimicry O O
of O O
signaling B-protein B-protein
mediators I-protein I-protein
. O O

Transcription B-protein B-protein
factor I-protein I-protein
AP-4 I-protein B-protein
is O O
a O O
ligand B-protein O
for O O
immunoglobulin-kappa B-DNA B-DNA
promoter I-DNA I-DNA
E-box I-DNA I-DNA
elements I-DNA I-DNA
. O O

Immunoglobulin B-DNA B-DNA
( I-DNA I-DNA
Ig I-DNA I-DNA
) I-DNA I-DNA
-kappa I-DNA I-DNA
promoters I-DNA I-DNA
from O O
humans O O
and O O
mice O O
share O O
conserved B-DNA B-DNA
sequences I-DNA I-DNA
. O O

The O O
octamer B-DNA B-DNA
element I-DNA I-DNA
is O O
common O O
to O O
all O O
Ig B-DNA B-DNA
promoters I-DNA I-DNA
and O O
pivotal O O
for O O
their O O
function O O
. O O

However O O
, O O
other O O
conserved B-DNA B-DNA
sequence I-DNA I-DNA
motifs I-DNA I-DNA
, O O
that O O
differ O O
between O O
Ig B-DNA B-DNA
variable I-DNA I-DNA
gene I-DNA I-DNA
families I-DNA I-DNA
, O O
are O O
required O O
for O O
normal O O
promoter O O
function O O
. O O

These O O
conserved O B-DNA
motifs O I-DNA
do O O
not O O
stimulate O O
transcription O O
in O O
the O O
absence O O
of O O
an O O
octamer B-DNA B-DNA
. O O

One O O
example O O
is O O
an O O
E-box B-DNA B-protein
of O O
the O O
E47/E12 B-DNA B-DNA
type I-DNA I-DNA
( I-DNA O
5'-CAGCTG-3 I-DNA O
' I-DNA O
) I-DNA O
, O O
which O O
is O O
found O O
in O O
all O O
promoters O B-DNA
of O O
the O O
human B-DNA B-DNA
and I-DNA I-DNA
murine I-DNA I-DNA
Ig-kappa I-DNA I-DNA
gene I-DNA I-DNA
subgroups/families I-DNA I-DNA
, O O
with O O
the O O
exception O O
of O O
subgroups O O
II O O
and O O
VI O O
and O O
their O O
related O O
murine B-DNA O
families I-DNA O
. O O

In O O
the O O
present O O
study O O
we O O
show O O
that O O
the O O
ubiquitously O B-protein
expressed O I-protein
transcription B-protein I-protein
factor I-protein I-protein
AP-4 I-protein B-protein
, O O
and O O
not O O
E47 B-protein B-protein
, O O
interacts O O
specifically O O
with O O
the O O
kappa B-DNA B-DNA
promoter I-DNA I-DNA
E-boxes I-DNA I-DNA
when O O
tested O O
in O O
electrophoretic O O
mobility-shift O O
assays O O
using O O
nuclear O O
extracts O O
derived O O
from O O
human B-cell_line B-cell_line
and I-cell_line I-cell_line
murine I-cell_line I-cell_line
B-cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

Furthermore O O
, O O
AP-4 B-protein B-protein
, O O
unlike O O
E47 B-protein B-protein
, O O
did O O
not O O
act O O
as O O
a O O
transactivator B-protein B-protein
, O O
which O O
is O O
in O O
agreement O O
with O O
previous O O
studies O O
on O O
intact O O
kappa B-DNA B-DNA
promoters I-DNA I-DNA
, O O
showing O O
that O O
transcription O O
is O O
absent O O
when O O
the O O
octamer B-DNA B-DNA
element I-DNA I-DNA
has O O
been O O
mutated O O
. O O

Based O O
on O O
these O O
data O O
, O O
and O O
the O O
conservation O O
of O O
the O O
5'-CAGCTG-3 B-DNA B-DNA
' I-DNA I-DNA
motif I-DNA I-DNA
among O O
human B-DNA B-DNA
and I-DNA I-DNA
murine I-DNA I-DNA
kappa I-DNA I-DNA
promoters I-DNA I-DNA
, O O
we O O
propose O O
that O O
AP-4 B-protein B-protein
is O O
the O O
major B-protein O
ligand I-protein O
for O O
Ig-kappa B-DNA B-DNA
promoter I-DNA I-DNA
E-boxes I-DNA I-DNA
. O O

A O O
16-mer O O
peptide O O
( O O
RQIKIWFQNRRMKWKK O O
) O O
from O O
antennapedia O O
preferentially O O
targets O O
the O O
Class O O
I O O
pathway O O
. O O

Translocation O O
of O O
antigenic O O
peptides O O
into O O
the O O
cytosol O O
of O O
antigen B-cell_type B-cell_type
presenting I-cell_type I-cell_type
cells I-cell_type I-cell_type
facilitates O O
proteosomal O O
processing O O
and O O
loading O O
into O O
Class B-protein O
I I-protein B-protein
molecules I-protein I-protein
for O O
MHC O B-protein
presentation O O
on O O
the O O
cell O O
surface O O
. O O

The O O
DNA B-protein B-protein
binding I-protein I-protein
domain I-protein I-protein
of O O
the O O
Drosophila B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
( O O
Antennapedia B-protein B-protein
) O O
, O O
a O O
60 B-protein B-protein
amino I-protein I-protein
acid I-protein I-protein
protein I-protein I-protein
, O O
is O O
rapidly O O
taken O O
up O O
by O O
cells O O
and O O
has O O
been O O
fused O O
to O O
selected O O
antigens B-protein O
to O O
enhance O O
their O O
immunogenicity O O
. O O

We O O
now O O
demonstrate O O
that O O
a O O
16 O O
amino O O
acid O O
peptide O O
from O O
antennapedia O O
can O O
facilitate O O
the O O
cytoplasmic O O
uptake O O
of O O
CTL O O
epitope O O
9-mer O O
peptides O O
. O O

Synthetic O O
peptides O O
were O O
made O O
containing O O
the O O
16-mer O O
antennapedia O O
peptide O O
linked O O
in O O
tandem O O
to O O
the O O
ovalbumin O O
SIINFEKL O O
CTL O O
peptide O O
. O O

The O O
peptide O O
complex O O
was O O
shown O O
to O O
rapidly O O
internalise O O
into O O
APCs B-cell_type B-cell_type
by O O
confocal O O
microscopy O O
. O O

This O O
peptide O O
induced O O
CTL B-cell_type B-cell_type
in O O
C57BL/6 O O
mice O O
and O O
protected O O
them O O
against O O
growth O O
of O O
an O O
ovalbumin B-cell_line B-cell_line
expressing I-cell_line I-cell_line
tumour I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
( O O
E.G7-OVA B-cell_line O
) O O
. O O

The O O
ability O O
of O O
the O O
hybrid O O
peptide O O
to O O
be O O
processed O O
and O O
presented O O
by O O
APCs B-cell_type B-cell_type
was O O
similar O O
, O O
whether O O
the O O
SIINFEKL O B-DNA
sequence O I-DNA
was O O
appended O O
at O O
the O O
C-terminus B-protein B-protein
or O O
N-terminus B-protein O
of O O
the O O
Antennapedia O O
peptide O O
. O O

The O O
production O O
of O O
synthetic O O
peptides O O
containing O O
other O O
CTL O B-protein
peptide O I-protein
epitopes O I-protein
may O O
be O O
useful O O
for O O
priming O B-cell_type
CTLs B-cell_type I-cell_type
in O O
vitro O O
and O O
in O O
vivo O O

Bone B-cell_type B-cell_type
marrow I-cell_type I-cell_type
cells I-cell_type I-cell_type
promote O O
TH2 O B-cell_type
polarization O O
and O O
inhibit O O
virus-specific O O
CTL O O
generation O O
. O O

This O O
laboratory O O
recently O O
reported O O
that O O
human B-cell_type B-cell_type
bone I-cell_type I-cell_type
marrow I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
BMC B-cell_type B-cell_type
) O O
inhibit O O
the O O
generation O O
of O O
virus-specific B-cell_type B-cell_type
CTL I-cell_type I-cell_type
in O O
culture O O
. O O

The O O
culture O O
supernatants O O
contained O O
increased O O
levels O O
of O O
prostaglandin B-protein O
E I-protein O
( I-protein O
2 I-protein O
) I-protein O
( I-protein O
PGE I-protein O
( I-protein O
2 I-protein O
) I-protein O
) I-protein O
( O O
shown O O
to O O
favor O O
TH2 O O
cell O O
development O O
) O O
and O O
also O O
inhibited O O
EBV-CTL O O
effector O O
cell O O
development O O
. O O

In O O
this O O
study O O
, O O
we O O
obtained O O
PBL B-cell_type B-cell_type
from O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
IgG B-protein B-protein
antibody I-protein I-protein
positive O O
kidney O O
transplant O O
recipients O O
( O O
R O O
) O O
and O O
their O O
living-related O O
donors O O
( O O
LRD O O
) O O
one O O
year O O
after O O
renal O O
transplantation O O
. O O

EBV-specific B-cell_type B-cell_line
CTL I-cell_type I-cell_line
were O O
then O O
generated O O
in O O
vitro O O
by O O
stimulating O B-cell_type
PBL B-cell_type I-cell_type
with O O
autologous O B-cell_line
EBV-transformed B-cell_type I-cell_line
B I-cell_type I-cell_line
cells I-cell_type I-cell_line
( O O
EBV-B B-cell_type B-cell_line
) O O
in O O
the O O
presence O O
or O O
absence O O
of O O
autologous B-cell_type O
BMC I-cell_type O
. O O

The O O
addition O O
of O O
BMC B-cell_type O
to O O
the O O
EBV-CTL B-cell_type O
generation I-cell_type O
cultures I-cell_type O
increased O O
the O O
intracellular O O
expression O O
in O O
CD3+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
of O O
IL-4 B-protein B-protein
, I-protein I-protein
-5 I-protein I-protein
, I-protein I-protein
-6 I-protein I-protein
, I-protein I-protein
-10 I-protein I-protein
, I-protein I-protein
and I-protein I-protein
-13 I-protein I-protein
. O O

These O O
CD3+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
also O O
expressed O O
increased O O
levels O O
of O O
the O O
TH2 B-protein B-protein
associated I-protein I-protein
receptor I-protein I-protein
CCR3 I-protein B-protein
. O O

Inhibition O O
was O O
even O O
observed O O
by O O
preparing O O
EBV-CTL B-cell_type O
generating I-cell_type O
cultures I-cell_type O
in O O
trans-wells O O
that O O
separated O O
the O O
autologous B-cell_type O
BMC I-cell_type O
from O O
the O O
PBL B-cell_type B-cell_type
+ O O
EBV-B B-cell_type B-cell_line
. O O

It O O
was O O
then O O
observed O O
that O O
CD3+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
obtained O O
after O O
7 O O
days O O
of O O
culture O O
in O O
the O O
presence O O
of O O
autologous B-cell_type O
BMC I-cell_type O
could O O
be O O
used O O
as O O
inhibitors O O
of O O
EBV-CTL O O
generation O O
. O O

Protein B-protein B-protein
Kinase I-protein I-protein
A I-protein I-protein
( O O
PKA B-protein B-protein
) O O
, O O
a O O
cAMP B-protein B-protein
kinase I-protein I-protein
that O O
is O O
involved O O
in O O
the O O
upregulation O O
of O O
TH2 B-protein B-protein
cytokine I-protein I-protein
activity O O
, O O
was O O
increased O O
in O O
EBV-CTL B-cell_type B-cell_line
cultures I-cell_type I-cell_line
by O O
the O O
presence O O
of O O
BMC B-cell_type B-cell_type
. O O

Additionally O O
, O O
IL-4-mediated O O
signal O O
transduction O O
and O O
activation O O
of O O
transcription O O
( O O
STAT-6 B-protein B-protein
) O O
phosphorylation O O
was O O
slightly O O
increased O O
. O O

These O O
results O O
show O O
that O O
the O O
BMC B-cell_type O
inhibition O O
is O O
mediated O O
by O O
soluble B-protein B-protein
factors I-protein I-protein
( O O
cytokines B-protein B-protein
) O O
and O O
that O O
cell-cell O O
contact O O
in O O
this O O
autologous O O
system O O
is O O
not O O
required O O
, O O
so O O
that O O
BMC B-cell_type O
( O O
at O O
least O O
partially O O
, O O
via O O
cytokine O B-protein
production O O
) O O
promote O O
TH2 O O
polarization O O
in O O
culture O O
. O O

Moreover O O
, O O
TH2 B-cell_type B-cell_type
cells I-cell_type I-cell_type
induced O O
by O O
culturing O O
with O O
autologous B-cell_type O
BMC I-cell_type O
directly O O
inhibit O O
EBV-CTL O O
generation O O
, O O
and O O
TH2 B-protein B-protein
associated O O
PKA B-protein B-protein
, O O
CCR3 B-protein B-protein
, O O
and O O
STAT-6 B-protein B-protein
phosphorylation O O
are O O
enhanced O O
by O O
BMC B-cell_type O
. O O

Reduction O O
in O O
DNA O O
binding O O
activity O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
Pax-5a B-protein B-protein
in O O
B B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
of O O
aged O O
mice O O
. O O

Aging O O
has O O
been O O
associated O O
with O O
intrinsic O O
changes O O
of O O
the O O
humoral O O
immune O O
response O O
, O O
which O O
may O O
lead O O
to O O
an O O
increased O O
occurrence O O
of O O
autoimmune O O
disorders O O
and O O
pathogenic O O
susceptibility O O
. O O

The O O
transcription B-protein B-protein
factor I-protein I-protein
Pax-5 B-protein B-protein
is O O
a O O
key O O
regulator O O
of O O
B O O
cell O O
development O O
. O O

Pax-5a/B B-protein B-protein
cell-specific I-protein I-protein
activator I-protein I-protein
protein I-protein I-protein
and O O
an O O
alternatively B-protein O
spliced I-protein O
isoform I-protein O
, I-protein O
Pax-5d I-protein B-protein
, O O
may O O
have O O
opposing O O
functions O O
in O O
transcriptional O O
regulation O O
due O O
to O O
the O O
lack O O
of O O
a O O
transactivation B-protein B-protein
domain I-protein I-protein
in O O
Pax-5d B-protein O
. O O

To O O
study O O
B B-cell_type B-cell_type
cell I-cell_type I-cell_type
-specific O O
changes O O
that O O
occur O O
during O O
the O O
aging O O
process O O
, O O
we O O
investigated O O
expression O O
patterns O O
of O O
Pax-5a B-protein B-protein
and I-protein O
5d I-protein O
in O O
mature B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
of O O
young O O
and O O
aged O O
mice O O
. O O

RNase O B-protein
protection O O
assays O O
showed O O
a O O
similar O O
transcriptional O O
pattern O O
for O O
both O O
age O O
groups O O
that O O
indicates O O
that O O
aging O O
has O O
no O O
affect O O
on O O
transcription O O
initiation O O
or O O
alternative O O
splicing O O
for O O
either O O
isoform B-protein O
. O O

In O O
contrast O O
, O O
a O O
significant O O
reduction O O
in O O
the O O
DNA O O
binding O O
activity O O
of O O
Pax-5a B-protein B-protein
but O O
not O O
Pax-5d B-protein B-protein
protein O I-protein
was O O
observed O O
in O O
aged B-cell_type O
B I-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
vitro O O
, O O
while O O
Western O O
blot O O
analyses O O
showed O O
that O O
similar O O
levels O O
of O O
Pax-5a B-protein B-protein
and I-protein I-protein
5d I-protein I-protein
proteins O I-protein
were O O
present O O
in O O
both O O
age O O
groups O O
. O O

The O O
observed O O
decrease O O
in O O
Pax-5a B-protein B-protein
binding O O
activity O O
correlated O O
with O O
changes O O
in O O
expression O O
of O O
two O O
Pax-5 B-DNA B-DNA
target I-DNA I-DNA
genes I-DNA I-DNA
in O O
aged B-cell_type O
B I-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Expression O O
of O O
the O O
Ig B-protein B-protein
J I-protein I-protein
chain I-protein I-protein
and O O
the O O
secreted O O
form O O
of O O
Ig B-protein B-protein
mu I-protein I-protein
, O O
which O O
are O O
both O O
known O O
to O O
be O O
suppressed O O
by O O
Pax-5a B-protein B-protein
in O O
mature B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
were O O
increased O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
of O O
aged O O
mice O O
. O O

Together O O
, O O
our O O
studies O O
suggest O O
that O O
changes O O
associated O O
with O O
the O O
aging O O
phenotype O O
cause O O
posttranslational O O
modification O O
( O O
s O O
) O O
of O O
Pax-5a B-protein B-protein
but O O
not O O
Pax-5d B-protein B-protein
, O O
which O O
may O O
lead O O
to O O
an O O
abnormal O O
B O O
cell O O
phenotype O O
in O O
aged O O
mice O O
, O O
associated O O
with O O
elevated O O
levels O O
of O O
J B-protein B-protein
chain I-protein I-protein
, O O
and O O
secretion O O
of O O
IgM B-protein B-protein

NF-kappa B-protein B-protein
B/Rel I-protein I-protein
participation O O
in O O
the O O
lymphokine-dependent O O
proliferation O O
of O O
T B-cell_type B-cell_type
lymphoid I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Proliferative O O
responses O O
of O O
lymphoid B-cell_type B-cell_type
cells I-cell_type I-cell_type
to O O
IL-2 B-protein B-protein
and O O
IL-4 B-protein B-protein
depend O O
on O O
activation O O
of O O
the O O
cells O O
, O O
but O O
the O O
mechanism O O
( O O
s O O
) O O
by O O
which O O
activation O O
enhances O O
cellular O O
competence O O
to O O
respond O O
to O O
cytokines B-protein B-protein
is O O
not O O
fully O O
understood O O
. O O

The O O
NF-kappaB/Rel B-protein B-protein
family I-protein I-protein
represents O O
one O O
signal O O
transduction O O
pathway O O
induced O O
during O O
such O O
activation O O
. O O

We O O
show O O
in O O
this O O
study O O
that O O
inhibition O O
of O O
NF-kappaB B-protein B-protein
through O O
the O O
expression O O
of O O
an O O
IkappaBalpha B-protein B-protein
( O O
inhibitory B-protein B-protein
protein I-protein I-protein
that O O
dissociates O O
from O O
NF-kappaB B-protein B-protein
) O O
mutant O O
refractory O O
to O O
signal-induced O O
degradation O O
( O O
IkappaBalpha B-protein B-protein
( I-protein O
DeltaN I-protein B-protein
) I-protein O
) O O
interfered O O
with O O
the O O
acquisition O O
of O O
competence O O
to O O
proliferate O O
in O O
response O O
to O O
IL-4 B-protein B-protein
as O O
well O O
as O O
IL-2 B-protein B-protein
. O O

Thymocytes B-cell_type B-cell_type
and O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
IkappaBalpha B-protein B-protein
( I-protein I-protein
DeltaN I-protein I-protein
) I-protein O
transgenic O O
mice O O
expressed O O
normal O O
levels O O
of O O
IL-2R B-protein B-protein
subunits I-protein I-protein
. O O

However O O
, O O
transgenic B-cell_type B-cell_type
cells I-cell_type I-cell_type
exhibited O O
a O O
dramatic O O
defect O O
in O O
Stat5A O O
activation O O
treatment O O
with O O
IL-2 B-protein B-protein
, O O
and O O
a O O
similar O O
defect O O
was O O
observed O O
for O O
IL-4 B-protein B-protein
-induced O O
Stat5 B-protein B-protein
. O O

In O O
contrast O O
, O O
T B-cell_type B-cell_type
lymphoid I-cell_type I-cell_type
cells I-cell_type I-cell_type
with O O
inhibition O O
of O O
NF-kappaB B-protein B-protein
showed O O
normal O O
insulin O B-protein
receptor O I-protein
substrate-2 O B-protein
phosphorylation O O
and O O
only O O
a O O
modest O O
decrease O O
in O O
Stat6 O B-protein
activation O O
and O O
insulin O B-protein
receptor O I-protein
substrate-1 O I-protein
phosphorylation O O
after O O
IL-4 O B-protein
stimulation O O
. O O

These O O
results O O
indicate O O
that O O
the O O
NF-kappaB/Rel/IkappaBalpha O B-protein
system O O
can O O
regulate O O
cytokine B-protein B-protein
receptor I-protein I-protein
capacitation O O
through O O
effects O O
on O O
the O O
induction O O
of O O
downstream O O
signaling O O
by O O
the O O
Stat B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
family I-protein I-protein
. O O

BMS-189453 O O
, O O
a O O
novel O O
retinoid O B-protein
receptor O I-protein
antagonist O O
, O O
is O O
a O O
potent O O
testicular O O
toxin O O
. O O

BMS-189453 O O
is O O
a O O
synthetic O O
retinoid O O
that O O
acts O O
as O O
an O O
antagonist O O
at O O
retinoic B-protein B-protein
acid I-protein I-protein
receptors I-protein I-protein
alpha I-protein I-protein
, I-protein I-protein
beta I-protein I-protein
, I-protein I-protein
and I-protein I-protein
gamma I-protein I-protein
. O O

In O O
Sprague O O
Dawley O O
rats O O
at O O
daily O O
oral O O
doses O O
of O O
15 O O
, O O
60 O O
, O O
or O O
240 O O
mg/kg O O
for O O
1 O O
month O O
, O O
BMS-189453 O O
produced O O
increases O O
in O O
leukocyte B-cell_type O
counts O O
, O O
alkaline B-protein B-protein
phosphatase I-protein I-protein
and O O
alanine B-protein O
aminotransferase I-protein O
levels O O
, O O
and O O
marked O O
testicular O O
degeneration O O
and O O
atrophy O O
at O O
all O O
doses O O
. O O

Significant O O
overt O O
signs O O
of O O
toxicity O O
and O O
deaths O O
occurred O O
at O O
240 O O
mg/kg O O
, O O
whereas O O
body-weight O O
and O O
food-consumption O O
decreases O O
occurred O O
at O O
60 O O
and O O
240 O O
mg/kg O O
. O O

When O O
BMS-189453 O O
was O O
administered O O
to O O
male O O
rats O O
at O O
daily O O
doses O O
ranging O O
from O O
12.5 O O
to O O
100 O O
mg/kg O O
for O O
1 O O
week O O
, O O
only O O
minimal O O
testicular O O
changes O O
occurred O O
at O O
all O O
doses O O
, O O
shortly O O
after O O
the O O
dosing O O
period O O
. O O

However O O
, O O
after O O
a O O
1-month O O
drug-free O O
observation O O
period O O
, O O
marked O O
testicular O O
atrophy O O
was O O
evident O O
at O O
all O O
doses O O
. O O

BMS-189453 O O
was O O
then O O
administered O O
at O O
doses O O
of O O
2 O O
, O O
10 O O
, O O
or O O
50 O O
mg/kg O O
to O O
male O O
rats O O
for O O
1 O O
, O O
3 O O
, O O
or O O
7 O O
consecutive O O
days O O
. O O

Dose- O O
and O O
duration-dependent O O
testicular O O
toxicity O O
that O O
occurred O O
after O O
a O O
1-month O O
observation O O
period O O
did O O
not O O
recover O O
, O O
and O O
, O O
in O O
some O O
cases O O
, O O
was O O
more O O
severe O O
4 O O
months O O
after O O
the O O
last O O
dose O O
. O O

In O O
rabbits O O
administered O O
BMS-189453 O O
at O O
oral O O
doses O O
of O O
2 O O
, O O
10 O O
, O O
or O O
50 O O
mg/kg O O
for O O
1 O O
week O O
, O O
testicular O O
degeneration O O
and O O
atrophy O O
were O O
evident O O
in O O
the O O
high-dose O O
group O O
at O O
1 O O
month O O
following O O
treatment O O
. O O

These O O
studies O O
indicate O O
that O O
retinoid O O
antagonists O O
can O O
selectively O O
produce O O
progressive O O
and O O
prolonged O O
testicular O O
toxicity O O
after O O
single O O
or O O
repeated O O
oral O O
doses O O
that O O
are O O
otherwise O O
well O O
tolerated O O
. O O

Sequential O O
involvement O O
of O O
NFAT B-protein B-protein
and O O
Egr B-protein B-protein
transcription B-protein I-protein
factors I-protein I-protein
in O O
FasL O B-protein
regulation O O
. O O

The O O
critical O O
function O O
of O O
NFAT B-protein B-protein
proteins I-protein I-protein
in O O
maintaining O O
lymphoid O O
homeostasis O O
was O O
revealed O O
in O O
mice O O
lacking O O
both O O
NFATp B-protein B-protein
and O O
NFAT4 B-protein B-protein
( O I-protein
DKO O I-protein
) O O
. O O

DKO O O
mice O O
exhibit O O
increased O O
lymphoproliferation O O
, O O
decreased O O
activation-induced O O
cell O O
death O O
, O O
and O O
impaired O O
induction O O
of O O
FasL B-protein B-protein
. O O

The O O
transcription B-protein B-protein
factors I-protein I-protein
Egr2 B-protein B-protein
and O O
Egr3 B-protein B-protein
are O O
potent O O
activators O O
of O O
FasL O B-protein
expression O O
. O O

Here O O
we O O
find O O
that O O
Egr2 B-DNA B-protein
and O O
Egr3 B-DNA B-protein
are O O
NFAT B-DNA B-DNA
target I-DNA I-DNA
genes I-DNA I-DNA
. O O

Activation O O
of O O
FasL B-protein B-protein
occurs O O
via O O
the O O
NFAT B-protein B-protein
-dependent O O
induction O O
of O O
Egr3 B-DNA B-protein
, O O
as O O
demonstrated O O
by O O
the O O
ability O O
of O O
exogenously O O
provided O O
NFATp B-protein B-protein
to O O
restore O O
Egr B-protein B-protein
-dependent O O
FasL O B-protein
promoter O O
activity O O
in O O
DKO B-cell_type B-cell_type
lymph I-cell_type I-cell_type
node I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Further O O
, O O
Egr3 B-DNA B-protein
expression O O
is O O
enriched O O
in O O
Th1 B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
suggesting O O
a O O
molecular O O
basis O O
for O O
the O O
known O O
preferential O O
expression O O
of O O
FasL B-protein B-protein
in O O
the O O
Th1 O B-cell_type
versus O I-cell_type
Th2 O I-cell_type
subset O I-cell_type
. O O

Mechanisms O O
and O O
clinical O O
relevance O O
of O O
nongenomic O O
glucocorticoid O O
actions O O
. O O

Glucocorticoids O O
have O O
profound O O
anti-inflammatory O O
and O O
immunosuppressive O O
actions O O
when O O
used O O
therapeutically O O
. O O

The O O
therapeutic O O
dose O O
is O O
quite O O
variable O O
and O O
depends O O
on O O
the O O
disease O O
, O O
but O O
ranges O O
from O O
very O O
low O O
to O O
extremely O O
high O O
. O O

The O O
rationale O O
for O O
the O O
use O O
of O O
various O O
dosage O O
regimens O O
for O O
specific O O
clinical O O
indications O O
is O O
the O O
existence O O
of O O
three O O
distinct O O
, O O
therapeutically O O
relevant O O
effects O O
: O O
genomic O O
, O O
specific O O
nongenomic O O
and O O
unspecific O O
nongenomic O O
. O O

Genomic O O
effects O O
are O O
mediated O O
by O O
cytosolic B-protein B-protein
receptors I-protein I-protein
that O O
alter O O
expression O O
of O O
specific O B-DNA
genes O I-DNA
. O O

Specific O O
nongenomic O O
effects O O
occur O O
within O O
a O O
few O O
minutes O O
and O O
are O O
mediated O O
by O O
steroid-selective B-protein B-protein
membrane I-protein I-protein
receptors I-protein I-protein
. O O

Unspecific O O
nongenomic O O
effects O O
occur O O
within O O
seconds O O
, O O
but O O
only O O
at O O
high O O
glucocorticoid O O
dosages O O
, O O
and O O
seem O O
to O O
result O O
from O O
direct O O
interactions O O
with O O
biological O O
membranes O O
. O O

For O O
unspecific O O
nongenomic O O
effects O O
, O O
methylprednisolone O O
and O O
other O O
glucocorticoids O O
have O O
been O O
shown O O
to O O
inhibit O O
cation O O
cycling O O
across O O
the O O
plasma O O
membrane O O
, O O
but O O
to O O
have O O
little O O
effect O O
on O O
protein O O
synthesis O O
. O O

Thus O O
, O O
glucocorticoids O O
could O O
diminish O O
or O O
prevent O O
the O O
acute O O
immune O O
response O O
by O O
interfering O O
with O O
processes O O
such O O
as O O
the O O
rise O O
in O O
intracellular O O
Ca2+ O O
concentration O O
. O O

It O O
is O O
proposed O O
that O O
the O O
additional O O
therapeutic O O
benefit O O
of O O
higher O O
doses O O
is O O
obtained O O
via O O
these O O
nongenomic O O
effects O O
. O O

High O O
glucose-induced O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
( O O
ICAM-1 B-protein B-protein
) O O
expression O O
through O O
an O O
osmotic O O
effect O O
in O O
rat B-cell_type B-cell_type
mesangial I-cell_type I-cell_type
cells I-cell_type I-cell_type
is O O
PKC-NF-kappa O B-protein
B-dependent O O
. O O

AIMS/HYPOTHESIS O O
: O O
Infiltration O O
of O O
mononuclear B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
glomerular O O
enlargement O O
accompanied O O
by O O
glomerular B-cell_type O
cell I-cell_type O
proliferation O O
are O O
very O O
early O O
characteristics O O
of O O
the O O
pathophysiology O O
of O O
diabetes O O
. O O

To O O
clarify O O
the O O
mechanism O O
of O O
early O O
diabetic O O
nephropathy O O
, O O
we O O
measured O O
[ O O
3H O O
] O O
-thymidine O O
incorporation O O
and O O
cell O O
numbers O O
to O O
show O O
the O O
influence O O
of O O
a O O
high O O
ambient O O
glucose O O
concentration O O
and O O
the O O
osmotic O O
effect O O
on O O
rat B-cell_type O
mesangial I-cell_type O
cell I-cell_type O
proliferation O O
. O O

We O O
also O O
measured O O
the O O
effect O O
of O O
high O O
glucose O O
on O O
the O O
expression O O
of O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
and O O
vascular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
by O O
flow O O
cytometry O O
and O O
semiquantitative O O
RT-PCR O O
in O O
mesangial B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
the O O
adhesion O O
of O O
leukocytes B-cell_type B-cell_type
to O O
mesangial B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

METHODS/RESULTS O O
: O O
Cells O O
exposed O O
to O O
high O O
D-glucose O O
( O O
30 O O
mmol/l O O
) O O
caused O O
an O O
increase O O
in O O
[ O O
3H O O
] O O
-thymidine O O
incorporation O O
and O O
cell O O
numbers O O
at O O
24 O O
and O O
48 O O
h O O
and O O
normalized O O
at O O
72 O O
h O O
( O O
p O O
< O O
0.05 O O
) O O
, O O
whereas O O
these O O
changes O O
were O O
not O O
found O O
in O O
high O O
mannitol O O
( O O
30 O O
mmol/l O O
) O O
, O O
IL-1 B-protein B-protein
beta I-protein I-protein
, O O
or O O
TNF B-protein B-protein
alpha I-protein I-cell_line
-stimulated O I-cell_line
mesangial B-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

Cells O O
exposed O O
to O O
high-glucose O O
( O O
15 O O
, O O
30 O O
, O O
or O O
60 O O
mmol/l O O
) O O
or O O
osmotic O O
agents O O
( O O
L-glucose O O
, O O
raffinose O O
and O O
mannitol O O
) O O
showed O O
that O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
expression O O
began O O
to O O
increase O O
after O O
24 O O
h O O
, O O
reached O O
its O O
maximum O O
at O O
24 O O
and O O
48 O O
h O O
and O O
gradually O O
decreased O O
afterwards O O
. O O

The O O
stimulatory O O
effects O O
of O O
high O O
glucose O O
and O O
high O O
mannitol O O
on O O
mRNA O O
expression O O
were O O
observed O O
as O O
early O O
as O O
6 O O
h O O
and O O
reached O O
its O O
maximum O O
at O O
12 O O
h O O
. O O

Up-regulation O O
of O O
ICAM-1 B-protein B-protein
protein O I-protein
and O O
mRNA O B-RNA
was O O
also O O
found O O
in O O
IL-1-beta B-protein B-protein
and O O
TNF-alpha B-protein B-protein
-stimulated O O
mesangial B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Neither O O
vascular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
protein O I-protein
nor O O
mRNA O O
expression O O
was O O
, O O
however O O
, O O
affected O O
by O O
high O O
glucose O O
and O O
high O O
mannitol O O
. O O

Notably O O
, O O
the O O
protein O B-protein
kinase O I-protein
C O I-protein
inhibitors O O
calphostin O O
C O O
and O O
staurosporine O O
reduced O O
high O O
glucose- O O
or O O
high O O
mannitol-induced O O
intercellular B-RNA O
adhesion I-RNA O
molecule-1 I-RNA O
mRNA O O
expression O O
and O O
high O O
glucose-induced O O
proliferation O O
. O O

Furthermore O O
, O O
the O O
NF-kappa O B-protein
B O I-protein
inhibitor O O
N-tosyl-L-phenylalanine O O
chloromethyl O O
ketone O O
reduced O O
high O O
glucose- O O
or O O
high O O
mannitol-induced O O
intercellular B-RNA O
adhesion I-RNA O
molecule-1 I-RNA O
mRNA O O
expression O O
and O O
high O O
glucose-induced O O
proliferation O O
. O O

Results O O
showed O O
that O O
high O O
glucose O O
( O O
15 O O
, O O
30 O O
mmol/l O O
) O O
or O O
high O O
concentrations O O
of O O
osmotic O O
agents O O
remarkably O O
increased O O
the O O
number O O
of O O
adherent O B-cell_type
leukocytes B-cell_type I-cell_type
to O O
mesangial B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
p O O
< O O
0.01 O O
) O O
compared O O
with O O
control B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
5 O O
mmol/l O O
D-glucose O O
) O O
. O O

Functional O O
blocking O O
of O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
on O O
mesangial B-cell_type B-cell_type
cells I-cell_type I-cell_type
with O O
rat B-protein B-protein
intercellular I-protein I-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
monoclonal I-protein I-protein
antibody I-protein I-protein
, O O
calphostin O O
C O O
, O O
staurosporine O O
, O O
or O O
N-tosyl-L-phenylalanine O O
chloromethyl O O
ketone O O
significantly O O
inhibited O O
high O O
glucose- O O
or O O
high O O
mannitol-induced O O
increase O O
in O O
leukocyte O O
adhesion O O
( O O
p O O
< O O
< O O
0.05 O O
) O O
. O O

CONCLUSION/INTERPRETATION O O
: O O
These O O
results O O
suggest O O
that O O
high O O
glucose O O
can O O
upregulate O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
protein O I-protein
and O O
mRNA O O
expression O O
but O O
not O O
vascular O B-protein
adhesion O I-protein
molecule-1 O I-protein
expression O O
in O O
mesangial B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
promote O O
leukocyte O O
adhesion O O
through O O
up-regulation O O
of O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
through O O
osmotic O O
effect O O
, O O
possibly O O
depending O O
on O O
the O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
nuclear B-protein B-protein
factor-kappa I-protein I-protein
B I-protein I-protein
( O O
PKC B-protein B-protein
- O O
NF-kappa B-protein B-protein
B I-protein I-protein
) O O
pathway O O
. O O

High O O
glucose O O
itself O O
can O O
also O O
promote O O
mesangial O O
cell O O
proliferation O O
through O O
the O O
PKC-NF-kappa O B-protein
B O I-protein
pathways O O
. O O

We O O
conclude O O
that O O
hyperglycaemia O O
in O O
itself O O
seems O O
to O O
be O O
an O O
important O O
factor O O
in O O
the O O
development O O
of O O
early O O
diabetic O O
nephropathy O O
. O O

Combined O O
corticosteroid/ O B-protein
granulocyte B-protein I-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
( O O
G-CSF B-protein B-protein
) O O
therapy O O
in O O
the O O
treatment O O
of O O
severe O O
congenital O O
neutropenia O O
unresponsive O O
to O O
G-CSF B-protein B-protein
: O O
Activated O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
synergize O O
with O O
G-CSF B-protein B-protein
signals O O
. O O

More O O
than O O
90 O O
% O O
of O O
patients O O
with O O
severe O O
congenital O O
neutropenia O O
( O O
SCN O O
) O O
respond O O
to O O
granulocyte B-protein B-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
( O O
G-CSF B-protein B-protein
) O O
therapy O O
. O O

The O O
basis O O
for O O
the O O
refractory O O
state O O
in O O
the O O
remaining O O
patients O O
is O O
unknown O O
. O O

To O O
address O O
this O O
issue O O
, O O
we O O
studied O O
a O O
child O O
with O O
SCN O O
who O O
was O O
totally O O
unresponsive O O
to O O
G-CSF B-protein B-protein
and O O
had O O
a O O
novel O O
point O O
mutation O O
in O O
the O O
extracellular B-protein B-protein
domain I-protein I-protein
of O O
the O O
G-CSF B-protein B-protein
receptor I-protein I-protein
( O O
GCSF-R B-protein B-protein
) O O
. O O

Marrow O O
stromal O O
support O O
of O O
granulopoiesis O O
was O O
evaluated O O
by O O
plating O B-cell_type
CD34 B-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
on O O
preformed O O
stromal O O
layers O O
. O O

Nonadherent B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
harvested O O
and O O
assayed O O
in O O
clonogenic O O
assays O O
for O O
granulocytic O O
colony O O
production O O
. O O

The O O
in O O
vitro O O
effect O O
of O O
G-CSF B-protein B-protein
and O O
corticosteroids O O
on O O
granulopoiesis O O
was O O
evaluated O O
in O O
clonogenic O O
assays O O
of O O
marrow B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
by O O
proliferation O O
studies O O
of O O
the O O
murine B-cell_line B-cell_line
myeloid I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
32D I-cell_line I-cell_line
expressing O O
the O O
patient O O
's O O
mutated B-protein O
G-CSFR I-protein B-protein
, O O
and O O
by O O
measuring O O
STAT5 O B-protein
activation O O
in O O
nuclear O O
extracts O O
from O O
stimulated B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Patient O O
's O O
stroma O O
supported O O
granulopoiesis O O
derived O O
from O O
control O B-cell_type
marrow B-cell_type I-cell_type
CD34 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
a O O
normal O O
manner O O
. O O

Normal O O
stroma O O
, O O
however O O
, O O
failed O O
to O O
induce O O
granulopoiesis O O
from O O
patient O B-cell_type
's O I-cell_type
CD34 B-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Clonogenic O O
assays O O
of O O
the O O
patient O O
's O O
marrow B-cell_type B-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
incorporating O O
either O O
G-CSF B-protein B-protein
or O O
hydrocortisone O O
produced O O
little O O
neutrophil O O
growth O O
. O O

In O O
contrast O O
, O O
inclusion O O
of O O
both O O
G-CSF B-protein B-protein
and O O
hydrocortisone O O
in O O
the O O
cytokine B-protein B-protein
`` I-protein O
cocktail I-protein O
'' I-protein O
markedly O O
increased O O
the O O
neutrophil O O
numbers O O
. O O

Proliferation O O
of O O
32D B-cell_line B-cell_line
cells I-cell_line I-cell_line
expressing O O
the O O
mutated B-protein O
receptor I-protein O
and O O
STAT5 O B-protein
activation O O
were O O
improved O O
by O O
a O O
combination O O
of O O
G-CSF B-protein B-protein
and O O
dexamethasone O O
. O O

When O O
small O O
daily O O
doses O O
of O O
oral O O
prednisone O O
were O O
then O O
administered O O
to O O
the O O
patient O O
with O O
conventional O O
doses O O
of O O
subcutaneous B-protein O
G-CSF I-protein B-protein
, O O
the O O
patient O O
responded O O
with O O
increased O O
neutrophil O O
numbers O O
and O O
with O O
a O O
complete O O
reversal O O
of O O
the O O
infectious O O
problems O O
. O O

These O O
data O O
provide O O
insight O O
into O O
SCN O O
unresponsive O O
to O O
standard O O
G-CSF B-protein B-protein
treatment O O
and O O
to O O
the O O
potential O O
corrective O O
action O O
of O O
combined O O
treatment O O
with O O
G-CSF B-protein B-protein
and O O
corticosteroids O O
through O O
synergistic O O
activation O O
of O O
STAT5 B-protein B-protein
. O O

Human B-cell_type B-cell_line
renal I-cell_type I-cell_line
mesangial I-cell_type I-cell_line
cells I-cell_type I-cell_line
are O O
a O O
target O O
for O O
the O O
anti-inflammatory O O
action O O
of O O
9-cis O O
retinoic O O
acid O O
. O O

Mesangial B-cell_type B-cell_type
cells I-cell_type I-cell_type
play O O
an O O
active O O
role O O
in O O
the O O
inflammatory O O
response O O
to O O
glomerular O O
injury O O
. O O

We O O
have O O
studied O O
in O O
cultured B-cell_line B-cell_line
human I-cell_line I-cell_line
mesangial I-cell_line I-cell_line
cells I-cell_line I-cell_line
( O O
CHMC B-cell_line B-cell_type
) O O
several O O
effects O O
of O O
9-cis O O
retinoic O O
acid O O
( O O
9-cRA O O
) O O
, O O
an O O
activator O O
of O O
both O O
retinoic B-protein B-protein
acid I-protein I-protein
receptors I-protein I-protein
( O O
RARs B-protein B-protein
) O O
and O O
retinoid B-protein B-protein
X I-protein I-protein
receptors I-protein I-protein
( O O
RXRs B-protein B-protein
) O O
. O O

9-cRA O O
inhibited O O
foetal O O
calf O O
serum-induced O O
CHMC B-cell_line O
proliferation O O
. O O

It O O
also O O
prevented O O
CHMC B-cell_line O
death O O
induced O O
by O O
the O O
inflammatory O B-protein
mediator O I-protein
H O I-protein
( O I-protein
2 O I-protein
) O I-protein
O O I-protein
( O I-protein
2 O I-protein
) O I-protein
. O O

This O O
preventive O O
effect O O
was O O
not O O
due O O
to O O
any O O
increase O O
in O O
H O B-protein
( O I-protein
2 O I-protein
) O I-protein
O O I-protein
( O O
2 O O
) O O
catabolism O O
and O O
it O O
persisted O O
even O O
when O O
both O O
catalase O B-protein
and O O
glutathione O O
synthesis O O
were O O
inhibited O O
. O O

Finally O O
, O O
9-cRA O O
diminished O O
monocyte O O
adhesion O O
to O O
FCS-stimulated B-cell_line B-cell_line
CHMC I-cell_line I-cell_line
. O O

Interestingly O O
, O O
the O O
retinoid O O
also O O
inhibited O O
in O O
FCS-stimulated B-cell_type B-cell_line
cells I-cell_type I-cell_line
the O O
protein O O
expression O O
of O O
two O O
mesangial B-protein B-protein
adhesion I-protein I-protein
molecules I-protein I-protein
, O O
fibronectin B-protein B-protein
and O O
osteopontin B-protein B-protein
, O O
but O O
it O O
did O O
not O O
modify O O
the O O
protein O O
expression O O
of O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
and O O
vascular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
. O O

All O O
major O O
RARs B-protein B-protein
and I-protein O
RXRs I-protein B-protein
isotypes I-protein I-protein
were O O
expressed O O
in O O
CHMC B-cell_line O
regardless O O
of O O
the O O
presence O O
or O O
absence O O
of O O
9-cRA O O
. O O

Transcripts O O
to O O
RAR-alpha B-RNA B-protein
, O O
RAR-beta B-RNA B-protein
and O O
RXR-alpha B-RNA B-protein
increased O O
after O O
incubation O O
with O O
9-cRA O O
whereas O O
RXR-gamma B-RNA B-protein
was O O
inhibited O O
, O O
suggesting O O
a O O
major O O
role O O
for O O
RARs B-protein B-protein
and O O
RXRs B-protein B-protein
in O O
9-cRA-anti-inflammatory O O
effects O O
. O O

9-cRA O O
was O O
toxic O O
only O O
at O O
50 O O
microM O O
( O O
a O O
concentration O O
50 O O
- O O
5000 O O
times O O
higher O O
than O O
required O O
for O O
the O O
effects O O
above O O
) O O
. O O

Cell O O
death O O
occurred O O
by O O
apoptosis O O
, O O
whose O O
onset O O
was O O
associated O O
with O O
a O O
pronounced O O
increase O O
in O O
catalase O B-protein
activity O O
and O O
reduced O O
glutathione O O
content O O
, O O
being O O
more O O
effectively O O
induced O O
by O O
all-trans O O
retinoic O O
acid O O
. O O

Modulation O O
of O O
the O O
oxidant/antioxidant O O
balance O O
failed O O
to O O
inhibit O O
apoptosis O O
. O O

We O O
conclude O O
that O O
mesangial B-cell_type B-cell_type
cells I-cell_type I-cell_type
might O O
be O O
a O O
target O O
for O O
the O O
treatment O O
of O O
inflammatory O O
glomerulopathies O O
with O O
9-cRA O O
. O O

Expression O O
of O O
mammalian B-DNA B-DNA
defensin I-DNA I-DNA
genes I-DNA I-DNA
. O O

Antimicrobial O O
peptides O O
are O O
a O O
prevalent O O
mechanism O O
of O O
host O O
defense O O
found O O
throughout O O
nature O O
. O O

In O O
mammals O O
, O O
defensins B-protein B-protein
are O O
among O O
the O O
most O O
abundant O O
of O O
these O O
broad-spectrum O O
antibiotics O O
, O O
and O O
are O O
expressed O O
in O O
epithelial B-cell_type B-cell_type
and I-cell_type I-cell_type
hematopoietic I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
defensin O O
peptides O O
are O O
especially O O
abundant O O
in O O
neutrophils B-cell_type B-cell_type
; O O
however O O
, O O
gene O O
expression O O
is O O
limited O O
to O O
the O O
promyelocyte O O
stage O O
. O O

In O O
epithelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
defensin B-DNA B-DNA
genes I-DNA I-DNA
are O O
found O O
as O O
both O O
constitutively O O
expressed O O
and O O
inducible O O
. O O

Induction O O
has O O
been O O
observed O O
in O O
vitro O O
by O O
stimulation O O
with O O
bacterial O O
lipopolysaccharide O O
as O O
well O O
as O O
inflammatory O B-protein
mediators O I-protein
. O O

In O O
vivo O O
, O O
up-regulation O O
of O O
several O O
defensin B-DNA B-DNA
genes I-DNA I-DNA
occurs O O
in O O
both O O
infectious O O
and O O
inflammatory O O
states O O
. O O

Gene O O
regulation O O
occurs O O
via O O
signal O O
transduction O O
pathways O O
common O O
to O O
other O O
innate O O
immune O O
responses O O
, O O
utilizing O O
transcription B-protein B-protein
factors I-protein I-protein
such O O
as O O
nuclear B-protein B-protein
factor I-protein I-protein
( I-protein I-protein
NF I-protein I-protein
) I-protein I-protein
-kappaB I-protein I-protein
and O O
NF B-protein B-protein
interleukin-6 I-protein I-protein
. O O

Together O O
, O O
the O O
data O O
suggest O O
a O O
broad-based O O
innate O O
host O O
defense O O
whereby O O
potent O O
antimicrobial O O
peptides O O
are O O
present O O
to O O
prevent O O
initial O O
colonization O O
by O O
pathogenic O O
microorganisms O O
. O O

In O O
addition O O
, O O
the O O
recognition O O
of O O
bacteria O O
coupled O O
with O O
a O O
nascent O O
inflammatory O O
response O O
can O O
bolster O O
this O O
defense O O
by O O
a O O
coordinated O O
up-regulation O O
of O O
the O O
peptides O O
. O O

Multiple O O
signals O O
required O O
for O O
cyclic B-protein B-protein
AMP-responsive I-protein I-protein
element I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
( O O
CREB B-protein B-protein
) O O
binding O O
protein O O
interaction O O
induced O O
by O O
CD3/CD28 O B-protein
costimulation O O
. O O

The O O
optimal O O
activation O O
of O O
cAMP-responsive B-protein B-protein
element I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
( O O
CREB B-protein B-protein
) O O
, O O
similar O O
to O O
the O O
full O O
activation O O
of O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
, O O
requires O O
the O O
stimulation O O
of O O
both O O
CD3 B-protein B-protein
and O O
CD28 B-protein B-protein
. O O

Using O O
a O O
reporter O O
system O O
to O O
detect O O
interaction O O
of O O
CREB B-protein B-protein
and O O
CREB-binding B-protein B-protein
protein I-protein I-protein
( O O
CBP B-protein B-protein
) O O
, O O
in O O
this O O
study O O
we O O
found O O
that O O
CREB B-protein B-protein
binds O O
to O O
CBP B-protein B-protein
only O O
by O O
engagement O O
of O O
both O O
CD3 B-protein B-protein
and O O
CD28 B-protein B-protein
. O O

CD3/CD28 B-protein B-protein
-promoted O B-RNA
CREB B-protein B-protein
- O O
CBP B-protein B-protein
interaction O O
was O O
dependent O O
on O O
p38 B-protein B-protein
mitogen-activated I-protein I-protein
protein I-protein I-protein
kinase I-protein I-protein
( O O
MAPK B-protein B-protein
) O O
and O O
calcium/calmodulin-dependent B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
( I-protein O
CaMK I-protein B-protein
) I-protein I-protein
IV I-protein I-protein
in O O
addition O O
to O O
the O O
previously O O
identified O O
extracellular O O
signal-regulated O O
kinase O O
pathway O O
. O O

Extracellular B-protein B-protein
signal-regulated I-protein I-protein
kinase I-protein I-protein
, I-protein O
CaMKIV I-protein B-protein
, O O
and O O
p38 B-protein B-protein
MAPK I-protein I-protein
were O O
also O O
the O O
kinases O O
involved O O
in O O
CREB B-protein O
Ser O O
( O O
133 O O
) O O
phosphorylation O O
induced O O
by O O
CD3/CD28 B-protein B-protein
. O O

A O O
reconstitution O O
experiment O O
illustrated O O
that O O
optimum O O
CREB B-protein B-protein
- O O
CBP B-protein B-protein
interaction O O
and O O
CREB B-protein B-protein
trans-activation O O
were O O
attained O O
when O O
these O O
three O O
kinase O O
pathways O O
were O O
simultaneously O O
activated O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Our O O
results O O
demonstrate O O
that O O
coordinated O O
activation O O
of O O
different O O
kinases B-protein B-protein
leads O O
to O O
full O O
activation O O
of O O
CREB B-protein B-protein
. O O

Notably O O
, O O
CD28 O B-protein
ligation O O
activated O O
p38 B-protein B-protein
MAPK I-protein I-protein
and O O
CaMKIV B-protein B-protein
, O O
the O O
kinases B-protein O
stimulated O O
by O O
CD3 O B-protein
engagement O O
, O O
suggesting O O
that O O
CD28 B-protein B-protein
acts O O
by O O
increasing O O
the O O
activation O O
extent O O
of O O
p38 B-protein B-protein
MAPK I-protein I-protein
and O O
CaMKIV B-protein B-protein
. O O

These O O
results O O
support O O
the O O
model O O
of O O
a O O
minimum O O
activation O O
threshold O O
for O O
CREB B-protein B-protein
- O O
CBP B-protein B-protein
interaction O O
that O O
can O O
be O O
reached O O
only O O
when O O
both O O
CD3 B-protein B-protein
and O O
CD28 B-protein B-protein
are O O
stimulated O O
. O O

The O O
murine B-DNA B-DNA
IL-2 I-DNA I-DNA
promoter I-DNA I-DNA
contains O O
distal B-DNA B-DNA
regulatory I-DNA I-DNA
elements I-DNA I-DNA
responsive O O
to O O
the O O
Ah B-protein B-protein
receptor I-protein I-protein
, O O
a O O
member O O
of O O
the O O
evolutionarily O O
conserved O O
bHLH-PAS B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
family I-protein I-protein
. O O

Signaling O O
through O O
the O O
TCR B-protein B-protein
and O O
costimulatory O O
signals O O
primarily O O
control O O
transcription O O
of O O
the O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
in O O
naive B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
minimal B-DNA B-DNA
promoter I-DNA I-DNA
necessary O O
for O O
this O O
expression O O
lies O O
proximal O O
, O O
between O O
-300 O O
and O O
the O O
transcription B-DNA B-DNA
start I-DNA I-DNA
site I-DNA I-DNA
. O O

We O O
had O O
previously O O
shown O O
that O O
activation O O
of O O
the O O
arylhydrocarbon B-protein B-protein
receptor I-protein I-protein
( O O
AHR B-protein B-protein
) O O
, O O
a O O
member O O
of O O
the O O
bHLH-PAS B-protein B-protein
family I-protein I-protein
of I-protein O
transcription I-protein B-protein
factors I-protein I-protein
, O O
leads O O
to O O
increased O O
mRNA O O
expression O O
of O O
IL-2 B-RNA B-protein
in O O
murine B-cell_type B-cell_type
fetal I-cell_type I-cell_type
thymocytes I-cell_type I-cell_type
. O O

The O O
AHR B-protein B-protein
is O O
abundant O O
in O O
the O O
thymus O O
and O O
may O O
play O O
a O O
role O O
for O O
the O O
development O O
of O O
the O O
immune O O
system O O
. O O

Moreover O O
, O O
its O O
overactivation O O
by O O
chemicals O O
such O O
as O O
dioxins O O
leads O O
to O O
immunosuppression O O
and O O
thymic O O
involution O O
. O O

Binding O B-protein
motifs O I-protein
for O O
the O O
liganded B-protein B-protein
AHR I-protein I-protein
can O O
be O O
identified O O
in O O
the O O
distal B-DNA B-DNA
region I-DNA I-DNA
-1300 I-DNA I-DNA
to I-DNA I-DNA
-800 I-DNA I-DNA
of O O
the O O
mouse B-DNA B-DNA
IL-2 I-DNA I-DNA
promoter I-DNA I-DNA
. O O

We O O
show O O
here O O
that O O
these O O
DNA B-DNA B-DNA
motifs I-DNA I-DNA
, O O
the O O
so-called O O
dioxin B-DNA B-DNA
response I-DNA I-DNA
elements I-DNA I-DNA
, O O
after O O
binding O O
to O O
the O O
liganded B-protein B-protein
AHR I-protein I-protein
are O O
sufficient O O
to O O
transactivate O O
luciferase O B-protein
expression O O
in O O
a O O
reporter O B-DNA
gene O I-DNA
system O I-DNA
. O O

The O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
can O O
be O O
induced O O
by O O
the O O
AHR B-protein B-protein
also O O
in O O
thymocytes B-cell_type B-cell_type
in O O
vivo O O
after O O
injection O O
of O O
2 O O
, O O
3 O O
, O O
7 O O
, O O
8-tetrachlorodibenzo-p-dioxin O O
, O O
a O O
potent O O
ligand O O
of O O
the O O
AHR B-protein B-protein
. O O

The O O
AHR B-protein B-protein
mediates O O
the O O
IL-2 O B-protein
induction O O
as O O
shown O O
with O O
AHR B-protein B-protein
-deficient O O
mice O O
. O O

However O O
, O O
in O O
spleen B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
vitro O O
costimulation O O
via O O
the O O
TCR B-protein B-protein
is O O
necessary O O
for O O
optimal O O
IL-2 B-DNA B-protein
gene I-DNA O
induction O O
. O O

Thus O O
, O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
region I-DNA I-DNA
contains O O
novel O O
distal B-DNA B-DNA
regulatory I-DNA I-DNA
elements I-DNA I-DNA
that O O
can O O
be O O
addressed O O
by O O
the O O
AHR B-protein B-protein
to O O
induce O O
IL-2 B-DNA B-protein
and O O
can O O
cooperate O O
with O O
the O O
proximal B-DNA B-DNA
promoter I-DNA I-DNA

Visualization O O
of O O
Syk-antigen B-protein B-protein
receptor I-protein I-protein
interactions O O
using O O
green B-protein B-protein
fluorescent I-protein I-protein
protein I-protein I-protein
: O O
differential O O
roles O O
for O O
Syk B-protein B-protein
and O O
Lyn B-protein B-protein
in O O
the O O
regulation O O
of O O
receptor O O
capping O O
and O O
internalization O O
. O O

The O O
cross-linking O O
of O O
the O O
B B-protein B-protein
cell I-protein I-protein
Ag I-protein I-protein
receptor I-protein I-protein
( O O
BCR B-protein B-protein
) O O
is O O
coupled O O
to O O
the O O
stimulation O O
of O O
multiple O O
intracellular O O
signal O O
transduction O O
cascades O O
via O O
receptor-associated O O
, O O
protein B-protein B-protein
tyrosine I-protein I-protein
kinases I-protein I-protein
of O O
both O O
the O O
Src B-protein B-protein
and I-protein I-protein
Syk I-protein I-protein
families I-protein I-protein
. O O

To O O
monitor O O
changes O O
in O O
the O O
subcellular O O
distribution O O
of O O
Syk B-protein B-protein
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
responding O O
to O O
BCR B-protein B-protein
cross-linking O O
, O O
we O O
expressed O O
in O O
Syk B-protein B-protein
-deficient O I-cell_line
DT40 B-cell_line I-cell_line
B I-cell_line I-cell_line
cells I-cell_line I-cell_line
a O O
fusion B-protein O
protein I-protein O
consisting O O
of O O
Syk B-protein B-protein
coupled O O
to O O
green B-protein B-protein
fluorescent I-protein I-protein
protein I-protein I-protein
. O O

Treatment O O
of O O
these O O
cells O O
with O O
anti-IgM B-protein B-protein
Abs I-protein I-protein
leads O O
to O O
the O O
recruitment O O
of O O
the O O
kinase B-protein B-protein
from O O
cytoplasmic O O
and O O
nuclear O O
compartments O O
to O O
the O O
site O O
of O O
the O O
cross-linked B-protein O
receptor I-protein O
at O O
the O O
plasma O O
membrane O O
. O O

The O O
Syk-receptor B-protein B-protein
complexes I-protein I-protein
aggregate O O
into O O
membrane O O
patches O O
that O O
redistribute O O
to O O
form O O
a O O
cap O O
at O O
one O O
pole O O
of O O
the O O
cell O O
. O O

Syk B-protein B-protein
is O O
not O O
demonstrably O O
associated O O
with O O
the O O
internalized B-protein B-protein
receptor I-protein I-protein
. O O

Catalytically O O
active O O
Syk B-protein B-protein
promotes O O
and O O
stabilizes O O
the O O
formation O O
of O O
tightly B-protein O
capped I-protein O
BCR I-protein B-protein
complexes I-protein I-protein
at O O
the O O
plasma O O
membrane O O
. O O

Lyn B-protein B-protein
is O O
not O O
required O O
for O O
the O O
recruitment O O
of O O
Syk B-protein B-protein
to O O
the O O
cross-linked B-protein B-protein
receptor I-protein I-protein
, O O
but O O
is O O
required O O
for O O
the O O
internalization O O
of O O
the O O
clustered O O
BCR B-protein B-protein
complexes I-protein I-protein
. O O

In O O
the O O
absence O O
of O O
Lyn B-protein B-protein
, O O
receptor-Syk B-protein B-protein
complexes I-protein I-protein
at O O
the O O
plasma O O
membrane O O
are O O
long O O
lived O O
, O O
and O O
the O O
receptor-mediated O O
activation O O
of O O
the O O
NF-AT B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
is O O
enhanced O O
. O O

Thus O O
, O O
Lyn B-protein B-protein
appears O O
to O O
function O O
to O O
negatively O O
regulate O O
aspects O O
of O O
BCR B-protein B-protein
-dependent O O
signaling O O
by O O
stimulating O O
receptor O O
internalization O O
and O O
down-regulation O O
. O O

Renal O O
interstitial O O
fibrosis O O
is O O
reduced O O
in O O
angiotensin B-protein B-protein
II I-protein I-protein
type I-protein I-protein
1a I-protein I-protein
receptor I-protein I-protein
-deficient O O
mice O O
. O O

Unilateral O O
ureteral O O
obstruction O O
( O O
UUO O O
) O O
results O O
in O O
tubulointerstitial O O
fibrosis O O
of O O
the O O
affected O O
kidney O O
by O O
stimulating O O
the O O
renin-angiotensin O O
system O O
. O O

This O O
study O O
established O O
a O O
UUO O O
model O O
in O O
angiotensin B-protein B-protein
type I-protein I-protein
1a I-protein I-protein
receptor I-protein I-protein
( O O
AT1a B-protein B-protein
) O O
deficient O O
( O O
mutant O O
) O O
mice O O
to O O
elucidate O O
the O O
role O O
of O O
angiotensin B-protein B-protein
II I-protein I-protein
through O O
AT1a B-protein B-protein
on O O
the O O
fibrosis O O
of O O
the O O
obstructed O O
kidney O O
( O O
OBK O O
) O O
. O O

The O O
relative O O
volume O O
of O O
the O O
tubulointerstitium O O
was O O
measured O O
by O O
an O O
image O O
analyzer O O
; O O
deposition O O
of O O
collagen B-protein B-protein
types I-protein I-protein
III I-protein I-protein
and I-protein O
IV I-protein O
and O O
monocyte B-cell_type O
/ O O
macrophage B-cell_type O
infiltration O O
were O O
histologically O O
examined O O
using O O
specific B-protein O
antibodies I-protein B-protein
. O O

Also O O
determined O O
were O O
the O O
mRNA O O
levels O O
of O O
transforming B-protein B-protein
growth I-protein I-protein
factor-beta I-protein I-protein
by O O
Northern O O
blot O O
analysis O O
. O O

Nuclear B-protein B-protein
factor-kappaB I-protein I-protein
activity O O
was O O
assessed O O
by O O
gel O O
shift O O
assay O O
. O O

UUO O O
in O O
wild O O
mice O O
resulted O O
in O O
a O O
marked O O
expansion O O
of O O
relative O O
volume O O
of O O
the O O
tubulointerstitium O O
, O O
together O O
with O O
increased O O
deposition O O
of O O
collagen B-protein B-protein
types I-protein I-protein
III I-protein I-protein
and I-protein O
IV I-protein O
and O O
number O O
of O O
infiltrated O B-cell_type
monocytes B-cell_type I-cell_type
/ O O
macrophages B-cell_type B-cell_type
in O O
the O O
interstitium O O
, O O
relative O O
to O O
sham-operated O O
mice O O
. O O

In O O
comparison O O
, O O
these O O
changes O O
were O O
significantly O O
lower O O
in O O
mutant O O
mice O O
with O O
UUO O O
. O O

The O O
mRNA O B-RNA
level O O
of O O
transforming B-protein B-protein
growth I-protein I-protein
factor-beta I-protein I-protein
was O O
significantly O O
higher O O
in O O
the O O
OBK O O
of O O
wild O O
mice O O
with O O
UUO O O
compared O O
with O O
sham-operated O O
mice O O
. O O

In O O
contrast O O
, O O
the O O
increase O O
in O O
mRNA O O
level O O
in O O
the O O
OBK O O
of O O
mutant O O
mice O O
was O O
significantly O O
less O O
than O O
in O O
wild O O
mice O O
. O O

Finally O O
, O O
UUO O O
resulted O O
in O O
activation O O
of O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
in O O
wild O O
mice O O
but O O
was O O
inhibited O O
in O O
the O O
OBK O O
of O O
mutant O O
mice O O
. O O

The O O
results O O
provide O O
direct O O
evidence O O
that O O
angiotensin B-protein B-protein
II I-protein I-protein
acting O O
via O O
the O O
AT1a B-protein B-protein
plays O O
a O O
pivotal O O
role O O
in O O
the O O
development O O
of O O
tubulointerstitial O O
fibrosis O O
in O O
UUO O O
. O O

HLA-DQ B-protein B-protein
tetramers I-protein I-protein
identify O I-protein
epitope-specific B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
peripheral O O
blood O O
of O O
herpes O O
simplex O O
virus O O
type O O
2-infected O O
individuals O O
: O O
direct O O
detection O O
of O O
immunodominant B-cell_type B-cell_type
antigen-responsive I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Ag-specific B-cell_type B-cell_line
CD4+ I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
are O O
present O O
in O O
peripheral O O
blood O O
in O O
low O O
frequency O O
, O O
where O O
they O O
undergo O O
recruitment O O
and O O
expansion O O
during O O
immune O O
responses O O
and O O
in O O
the O O
pathogenesis O O
of O O
numerous O O
autoimmune O O
diseases O O
. O O

MHC B-protein B-protein
tetramers I-protein I-protein
, O O
which O O
constitute O O
a O O
labeled B-protein O
MHC-peptide I-protein O
ligand I-protein O
suitable O O
for O O
binding O O
to O O
the O O
Ag-specific B-protein B-protein
receptor I-protein I-protein
on O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
provide O O
a O O
novel O O
approach O O
for O O
the O O
detection O O
and O O
characterization O O
of O O
such O O
rare B-cell_type O
cells I-cell_type O
. O O

In O O
this O O
study O O
, O O
we O O
utilized O O
this O O
technology O O
to O O
identify O O
HLA B-protein B-cell_type
DQ I-protein I-cell_type
-restricted O I-cell_type
Ag-specific B-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
the O O
peripheral O O
blood O O
of O O
human O O
subjects O O
and O O
to O O
identify O O
immunodominant O B-protein
epitopes O I-protein
associated O O
with O O
viral O O
infection O O
. O O

Peptides O O
representing O O
potential O O
epitope B-protein B-protein
regions I-protein I-protein
of O O
the O O
VP16 B-protein B-protein
protein I-protein I-protein
from O O
HSV-2 O O
were O O
loaded O O
onto O O
recombinant B-protein B-protein
DQ0602 I-protein I-protein
molecules I-protein I-protein
to O O
generate O O
a O O
panel O O
of O O
Ag-specific B-protein O
DQ0602 I-protein O
tetramers I-protein O
. O O

VP16 B-protein B-protein
Ag I-protein I-protein
-specific O O
DQ-restricted B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
identified O O
and O O
expanded O O
from O O
the O O
peripheral O O
blood O O
of O O
HSV-2-infected O O
individuals O O
, O O
representing O O
two O O
predominant O O
epitope O O
specificities O O
. O O

Although O O
the O O
VP16 O B-protein
369-380 O I-protein
peptide O O
has O O
a O O
lower O O
binding O O
affinity O O
for O O
DQ0602 B-protein B-protein
molecules I-protein I-protein
than O O
the O O
VP16 O O
33-52 O O
peptide O O
, O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
that O O
recognized O O
the O O
VP16 O B-protein
369-380 O O
peptide O O
occurred O O
at O O
a O O
much O O
higher O O
frequency O O
than O O
those O O
that O O
were O O
specific O O
for O O
the O O
VP16 O O
33-52 O O
peptide O O
. O O

Down-regulation O O
of O O
BOB.1/OBF.1 B-protein B-protein
and O O
Oct2 B-protein B-protein
in O O
classical O O
Hodgkin O O
disease O O
but O O
not O O
in O O
lymphocyte O B-cell_type
predominant O O
Hodgkin O O
disease O O
correlates O O
with O O
immunoglobulin O B-protein
transcription O O
. O O

In O O
contrast O O
to O O
the O O
tumor B-cell_type B-cell_type
cells I-cell_type I-cell_type
( O O
L B-cell_type B-cell_type
& I-cell_type I-cell_type
H I-cell_type I-cell_type
cells I-cell_type I-cell_type
) O O
of O O
lymphocyte O O
predominant O O
Hodgkin O O
disease O O
( O O
LPHD O O
) O O
, O O
Hodgkin B-cell_type B-cell_line
and I-cell_type I-cell_line
Reed-Sternberg I-cell_type I-cell_line
( I-cell_type I-cell_line
HRS I-cell_type I-cell_line
) I-cell_type I-cell_line
cells I-cell_type I-cell_line
of O O
classical O O
Hodgkin O O
disease O O
( O O
cHD O O
) O O
are O O
unable O O
to O O
transcribe O O
immunoglobulin B-protein B-protein
, O O
despite O O
the O O
presence O O
of O O
rearranged B-DNA B-DNA
immunoglobulin I-DNA I-DNA
genes I-DNA I-DNA
. O O

Although O O
initial O O
studies O O
have O O
suggested O O
crippling O O
immunoglobulin O B-DNA
gene O I-DNA
mutations O O
to O O
be O O
the O O
cause O O
of O O
absent O O
immunoglobulin O B-protein
expression O O
in O O
cHD O O
, O O
recent O O
work O O
of O O
our O O
group O O
has O O
demonstrated O O
an O O
impaired O O
activation O O
of O O
the O O
immunoglobulin B-DNA B-DNA
promoter I-DNA I-DNA
as O O
a O O
superior O O
mechanism O O
. O O

As O O
immunoglobulin O B-protein
transcription O O
is O O
mainly O O
regulated O O
by O O
the O O
B-cell B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
Oct2 B-protein B-protein
and O O
BOB.1/OBF.1 B-protein B-protein
, O O
we O O
analyzed O O
35 O O
cases O O
of O O
LPHD O O
, O O
32 O O
cases O O
of O O
cHD O B-cell_line
, O I-cell_line
and O I-cell_line
2 O I-cell_line
Hodgkin B-cell_line I-cell_line
disease I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
for O O
the O O
expression O O
of O O
these O O
transcription B-protein B-protein
factors I-protein I-protein
and O O
also O O
in O O
parallel O O
for O O
immunoglobulin O B-protein
expression O O
. O O

Our O O
results O O
demonstrate O O
an O O
absence O O
of O O
Oct2 B-protein B-protein
and/or O O
BOB.1/OBF.1 B-protein B-protein
in O O
cHD O O
and O O
a O O
striking O O
overexpression O O
of O O
Oct2 B-protein B-protein
in O O
LPHD O O
. O O

Immunoglobulin O B-protein
expression O O
was O O
lacking O O
in O O
cHD O O
but O O
present O O
in O O
LPHD O O
. O O

Furthermore O O
, O O
the O O
reintroduction O O
of O O
BOB.1/OBF.1 B-protein B-protein
and O O
Oct2 B-protein B-protein
into O O
cultured O B-cell_line
HRS B-cell_type I-cell_line
cells I-cell_type I-cell_line
restored O O
the O O
activity O O
of O O
cotransduced O O
immunoglobulin B-DNA B-DNA
promoter I-DNA I-DNA
constructs I-DNA I-DNA
. O O

Our O O
findings O O
dismiss O O
the O O
concept O O
that O O
the O O
different O O
immunoglobulin O B-protein
expression O O
in O O
cHD O O
and O O
LPHD O O
is O O
due O O
to O O
disrupting O O
mutations O O
of O O
immunoglobulin B-DNA B-DNA
V I-DNA I-DNA
genes I-DNA I-DNA
in O O
cHD O O
but O O
is O O
most O O
likely O O
due O O
to O O
a O O
down-regulation O O
of O O
Oct2 B-protein B-protein
and/or O O
BOB.1/OBF.1 B-protein B-protein
. O O

This O O
study O O
further O O
revealed O O
Oct2 B-protein B-protein
as O O
a O O
new O O
and O O
valuable O O
marker O O
for O O
the O O
identification O O
of O O
L B-cell_type B-cell_type
& I-cell_type I-cell_type
H I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
their O O
distinction O O
from O O
HRS B-cell_type B-cell_line
cells I-cell_type I-cell_line
. O O

The O O
impairment O O
of O O
immunoglobulin O B-protein
transcription O O
with O O
a O O
down-regulated O O
synthesis O O
of O O
Oct2 B-protein B-protein
and O O
BOB.1/OBF.1 B-protein B-protein
is O O
the O O
first O O
established O O
general O O
recurrent O O
defect O O
found O O
in O O
HRS B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Constitutive O O
expression O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
is O O
a O O
characteristic O O
feature O O
of O O
mycosis O O
fungoides O O
: O O
implications O O
for O O
apoptosis O O
resistance O O
and O O
pathogenesis O O
. O O

The O O
NF-kappa B-protein B-protein
B I-protein I-protein
family I-protein I-protein
of I-protein O
transcription I-protein B-protein
factors I-protein I-protein
is O O
an O O
important O O
regulator O O
of O O
genes O O
expressed O O
during O O
inflammatory O O
responses O O
, O O
immunoglobulin O B-protein
( O I-protein
Ig O I-protein
) O O
class O O
switching O O
, O O
cellular O O
differentiation O O
, O O
and O O
apoptosis O O
. O O

Recently O O
, O O
members O O
of O O
the O O
NF-kappaB B-protein B-protein
family I-protein I-protein
, O O
including O O
p65 B-protein B-protein
( I-protein O
Rel I-protein B-protein
A I-protein I-protein
) I-protein O
, O O
have O O
been O O
implicated O O
in O O
promoting O O
survival O O
of O O
various O O
hematopoeitic O O
neoplasms O O
, O O
including O O
T O O
cell O O
malignancies O O
such O O
as O O
adult O O
T O O
cell O O
leukemia-lymphoma O O
. O O

We O O
investigated O O
the O O
expression O O
of O O
active B-protein O
NF-kappa I-protein B-protein
B I-protein I-protein
p65 I-protein I-protein
( I-protein O
Rel I-protein B-protein
A I-protein I-protein
) I-protein O
in O O
cases O O
of O O
mycosis O O
fungoides O O
( O O
MF O O
) O O
and O O
the O O
effect O O
of O O
chemical O O
inhibitors O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
on O O
apoptosis O O
in O O
cutaneous B-cell_line B-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
lymphoma I-cell_line I-cell_line
( I-cell_line I-cell_line
CTCL I-cell_line I-cell_line
) I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

Paraffin-embedded O O
tissues O O
from O O
23 O O
cutaneous O O
lesions O O
and O O
a O O
single O O
lymph O O
node O O
biopsy O O
from O O
patients O O
diagnosed O O
with O O
MF O O
were O O
evaluated O O
for O O
p65 O B-protein
( O O
Rel O B-protein
A O I-protein
) O O
expression O O
by O O
using O O
a O O
monoclonal B-protein B-protein
mouse I-protein I-protein
antibody I-protein I-protein
that O O
detects O O
the O O
activated O O
form O O
of O O
p65 B-protein B-protein
( I-protein O
Rel I-protein B-protein
A I-protein I-protein
) I-protein O
. O O

Apoptosis O O
after O O
treatment O O
with O O
the O O
NF-kappa O B-protein
B O I-protein
inhibitors O O
gliotoxin O O
, O O
MG132 O O
, O O
BAY O O
11-7082 O O
, O O
and O O
BAY O O
11-7085 O O
was O O
quantitatively O O
measured O O
in O O
the O O
CTCL B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
HuT-78 I-cell_line B-cell_line
and I-cell_line O
HH I-cell_line O
by O O
propidium O O
iodide O O
( O O
PI O O
) O O
/cell O O
cycle O O
analysis O O
for O O
detection O O
of O O
a O O
hypodiploid O O
( O O
sub-G O O
( O O
0 O O
) O O
) O O
population O O
and O O
by O O
determination O O
of O O
increased O O
Annexin O O
V/7-amino-actinomycin O O
D O O
( O O
7-AAD O O
) O O
expression O O
. O O

Nuclear O O
extracts O O
from O O
CTCL B-cell_type B-cell_type
cells I-cell_type I-cell_type
before O O
and O O
after O O
chemical O O
inhibition O O
were O O
analyzed O O
for O O
NF-kappa O B-protein
B O I-protein
nuclear O O
DNA-binding O O
activity O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
( O O
EMSA O O
) O O
with O O
quantitative O O
densitometry O O
. O O

Nuclear O O
expression O O
of O O
p65 B-protein B-protein
( I-protein O
Rel I-protein B-protein
A I-protein I-protein
) I-protein O
before O O
and O O
after O O
treatment O O
with O O
the O O
various O O
inhibitory O O
compounds O O
was O O
measured O O
by O O
immunofluorescence O O
staining O O
in O O
each O O
CTCL B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

Neoplastic B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
from O O
22 O O
of O O
24 O O
cases O O
of O O
MF O O
showed O O
strong O O
nuclear O O
and O O
cytoplasmic O O
expression O O
of O O
active B-protein O
p65 I-protein B-protein
( I-protein O
Rel I-protein B-protein
A I-protein I-protein
) I-protein O
. O O

Compared O O
with O O
untreated O B-cell_type
control B-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
a O O
marked O O
increase O O
in O O
apoptosis O O
, O O
a O O
significant O O
decrease O O
in O O
NF-kappa O B-protein
B O I-protein
DNA-binding O O
activity O O
, O O
and O O
a O O
marked O O
decrease O O
in O O
nuclear O O
p65 O B-protein
( O O
Rel O B-protein
A O I-protein
) O O
expression O O
were O O
seen O O
in O O
cells O O
from O O
both O O
CTCL B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
after O O
chemical O O
NF-kappa O B-protein
B O I-protein
inhibition O O
. O O

These O O
data O O
show O O
that O O
the O O
active O O
form O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
p65 I-protein I-protein
( I-protein O
Rel I-protein B-protein
A I-protein I-protein
) I-protein O
is O O
commonly O O
expressed O O
in O O
neoplastic B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
in O O
patients O O
with O O
MF O O
. O O

In O O
CTCL B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
the O O
significant O O
decrease O O
in O O
nuclear O O
NF-kappa O B-protein
B O I-protein
expression O O
and O O
the O O
marked O O
increase O O
in O O
spontaneous O O
apoptosis O O
caused O O
by O O
chemical O O
NF-kappa O B-protein
B O I-protein
inhibition O O
suggest O O
a O O
critical O O
role O O
for O O
NF-kappa B-protein B-protein
B I-protein I-protein
in O O
the O O
pathogenesis O O
and O O
tumor O O
cell O O
maintenance O O
of O O
CTCLs O O
. O O

HUM O O
PATHOL O O
31 O O
: O O
1482-1490 O O
. O O

Human O B-protein
T-cell O I-protein
leukemia O I-protein
virus O I-protein
type O I-protein
1 O I-protein
tax B-protein I-protein
protein I-protein I-protein
activates O O
transcription O O
through O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
by O O
inducing O O
DNA O O
binding O O
activity O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Human O B-protein
T-cell O I-protein
leukemia O I-protein
virus O I-protein
type O I-protein
1 O I-protein
( O I-protein
HTLV-1 O I-protein
) O I-protein
Tax B-protein I-protein
protein I-protein I-protein
induces O O
the O O
expression O O
of O O
various O O
family O O
members O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
AP-1 I-protein B-protein
, O O
such O O
as O O
c-Jun B-protein B-protein
, O O
JunD B-protein B-protein
, O O
c-Fos B-protein B-protein
, O O
and O O
Fra-1 B-protein B-protein
, O O
at O O
the O O
level O O
of O O
RNA O O
expression O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

We O O
examined O O
the O O
activity O O
of O O
Tax B-protein B-protein
in O O
transcription O O
through O O
AP-1-binding B-DNA B-DNA
sites I-DNA I-DNA
( O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
) O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Transient O O
transfection O O
studies O O
showed O O
that O O
Tax B-protein B-protein
activated O O
the O O
expression O O
of O O
a O O
luciferase B-DNA B-DNA
gene I-DNA I-DNA
regulated O O
by O O
two O O
copies O O
of O O
an O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
in O O
the O O
human B-cell_line B-cell_line
Jurkat I-cell_line I-cell_line
T-cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

Tax B-protein B-protein
activates O O
the O O
expression O O
of O O
viral B-DNA B-DNA
and I-DNA I-DNA
cellular I-DNA I-DNA
genes I-DNA I-DNA
through O O
two O O
different O O
enhancers O B-DNA
: O O
a O O
cAMP-responsive B-DNA B-DNA
( I-DNA I-DNA
CRE I-DNA I-DNA
) I-DNA I-DNA
-like I-DNA I-DNA
element I-DNA I-DNA
and O O
a O O
kappaB B-DNA B-DNA
element I-DNA I-DNA
. O O

Two O O
Tax B-protein B-protein
mutants I-protein I-protein
differentially O O
activated O O
expression O O
of O O
these O O
two O O
elements O O
. O O

Tax703 B-protein B-protein
preferentially O O
activated O O
the O O
kappaB B-DNA B-DNA
element I-DNA I-DNA
but O O
not O O
the O O
CRE-like O B-DNA
one O O
, O O
whereas O O
TaxM22 B-protein B-protein
showed O O
the O O
reverse O O
. O O

In O O
addition O O
, O O
Tax703 B-protein B-protein
and O O
Tax B-protein B-protein
, O O
but O O
not O O
TaxM22 B-protein B-protein
, O O
converted O O
cell O O
growth O O
of O O
a O O
mouse B-cell_line B-cell_line
T-cell I-cell_line I-cell_line
line I-cell_line I-cell_line
from O O
being O O
interleukin O B-protein
( O I-protein
IL O I-protein
) O O
-2-dependent O O
to O O
being O O
IL-2-independent O O
. O O

Unlike O O
the O O
wild-type B-protein B-protein
Tax I-protein I-protein
, O O
Tax703 B-protein B-protein
and O O
TaxM22 B-protein B-protein
only O O
weakly O O
activated O O
the O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
in O O
the O O
T-cell B-cell_line B-cell_line
line I-cell_line I-cell_line
. O O

Thus O O
, O O
Tax B-protein B-protein
seems O O
to O O
activate O O
the O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
via O O
mechanisms O O
distinct O O
from O O
those O O
of O O
kappaB B-DNA B-DNA
or I-DNA I-DNA
CRE-like I-DNA I-DNA
elements I-DNA I-DNA
, O O
and O O
the O O
activation O O
of O O
the O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
is O O
dispensable O O
for O O
IL-2-independent O O
growth O O
of O O
CTLL-2 O B-cell_line
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
showed O O
that O O
Tax B-protein B-protein
induced O O
strong O O
binding O O
activity O O
to O O
an O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
in O O
CTLL-2 O B-cell_line
, O O
whereas O O
Tax703 B-protein B-protein
did O O
not O O
, O O
indicating O O
that O O
the O O
induction O O
of O O
binding O O
activity O O
to O O
the O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
is O O
essential O O
for O O
the O O
transcriptional O O
activation O O
by O O
Tax B-protein B-protein
. O O

The O O
binding B-protein O
complex I-protein O
induced O O
by O O
Tax B-protein B-protein
in O O
CTLL-2 O B-cell_line
contained O O
JunD B-protein B-protein
and O O
Fra-2 B-protein B-protein
. O O

Other O O
AP-1 B-protein B-protein
proteins I-protein I-protein
were O O
undetectable O O
. O O

Activation O O
of O O
transcription O O
through O O
the O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
in O O
Jurkat B-cell_line B-cell_line
cells I-cell_line I-cell_line
by O O
JunD B-protein B-protein
and/or O O
Fra-2 B-protein B-protein
was O O
weak O O
. O O

c-Jun B-protein B-protein
, O O
JunB B-protein B-protein
, O O
and O O
c-Fos B-protein B-protein
activation O O
was O O
greater O O
, O O
although O O
the O O
level O O
was O O
still O O
less O O
than O O
that O O
with O O
Tax B-protein B-protein
. O O

Thus O O
, O O
the O O
induction O O
of O O
AP-1 B-RNA B-RNA
mRNA I-RNA I-RNA
by O O
Tax B-protein B-protein
may O O
not O O
be O O
sufficient O O
for O O
a O O
complete O O
activation O O
of O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
by O O
Tax B-protein B-protein
. O O

Our O O
results O O
suggest O O
that O O
Tax B-protein B-protein
activates O O
the O O
transcription O O
of O O
cellular B-DNA B-DNA
genes I-DNA I-DNA
with O O
AP-1 B-DNA B-DNA
sites I-DNA I-DNA
by O O
inducing O O
the O O
DNA-binding O O
activity O O
of O O
AP-1 B-protein B-protein
proteins I-protein I-protein
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
a O O
mechanism O O
distinct O O
from O O
those O O
of O O
CRE-like B-DNA B-DNA
and I-DNA I-DNA
kappaB I-DNA I-DNA
elements I-DNA I-DNA
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

Strict O O
control O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
replication O O
by O O
a O O
genetic O O
switch O O
: O O
Tet O O
for O O
Tat O B-protein
. O O

Live-attenuated O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
variants O O
have O O
shown O O
great O O
promise O O
as O O
AIDS O O
vaccines O O
, O O
but O O
continued O O
replication O O
can O O
lead O O
to O O
the O O
selection O O
of O O
faster-replicating O O
variants O O
that O O
are O O
pathogenic O O
. O O

We O O
therefore O O
designed O O
HIV-1 B-DNA B-DNA
genomes I-DNA I-DNA
that O O
replicate O O
exclusively O O
upon O O
addition O O
of O O
the O O
nontoxic O O
effector O O
doxycycline O O
( O O
dox O O
) O O
. O O

This O O
was O O
achieved O O
by O O
replacement O O
of O O
the O O
viral O O
TAR-Tat O O
system O O
for O O
transcriptional O O
activation O O
by O O
the O O
Escherichia O O
coli-derived O O
Tet O O
system O O
for O O
inducible O O
gene O O
expression O O
. O O

These O O
designer O O
`` O O
HIV-rtTA O O
'' O O
viruses O O
replicate O O
in O O
a O O
strictly O O
dox-dependent O O
manner O O
both O O
in O O
a O O
T-cell B-cell_line B-cell_line
line I-cell_line I-cell_line
and O O
in O O
primary B-cell_type B-cell_type
blood I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
and O O
the O O
rate O O
of O O
replication O O
can O O
be O O
fine-tuned O O
by O O
simple O O
variation O O
of O O
the O O
dox O O
concentration O O
. O O

These O O
HIV-rtTA O O
viruses O O
provide O O
a O O
tool O O
to O O
perform O O
genetics O O
, O O
e.g. O O
, O O
selection O O
and O O
optimization O O
experiments O O
, O O
with O O
the O O
E. O O
coli-derived O O
Tet O O
reagents O O
in O O
a O O
eukaryotic O O
background O O
. O O

Furthermore O O
, O O
such O O
viruses O O
may O O
represent O O
improved O O
vaccine O O
candidates O O
because O O
their O O
replication O O
can O O
be O O
turned O O
on O O
and O O
off O O
at O O
will O O
. O O

Synovial O O
fluid O O
induced O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
DNA O O
binding O O
in O O
a O O
monocytic B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

OBJECTIVE O O
: O O
To O O
determine O O
the O O
effects O O
of O O
synovial O O
fluids O O
( O O
SF O O
) O O
on O O
DNA O O
binding O O
activity O O
of O O
transcription B-protein B-protein
factor I-protein I-protein
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
( O O
NF-kappaB B-protein B-protein
) O O
in O O
the O O
Mono B-cell_line B-cell_line
Mac I-cell_line I-cell_line
6 I-cell_line I-cell_line
monocytic/macrophage I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
as O O
a O O
model O O
for O O
the O O
interaction O O
between O O
SF O B-protein
and O O
synovial B-cell_type B-cell_type
tissue I-cell_type I-cell_type
macrophages I-cell_type I-cell_type
in O O
arthritis O O
. O O

METHODS O O
: O O
Mono B-cell_line B-cell_line
Mac I-cell_line I-cell_line
6 I-cell_line I-cell_line
cells I-cell_line I-cell_line
were O O
incubated O O
with O O
SF O B-protein
from O O
the O O
knee O O
joints O O
of O O
human O O
subjects O O
with O O
rheumatoid O O
arthritis O O
( O O
RA O O
) O O
, O O
undifferentiated O O
seronegative O O
oligoarthritis O O
, O O
and O O
osteoarthritis O O
( O O
OA O O
) O O
. O O

Nuclear O O
extracts O O
prepared O O
from O O
the O O
Mono B-cell_line B-cell_line
Mac I-cell_line I-cell_line
6 I-cell_line I-cell_line
cells I-cell_line I-cell_line
and O O
RA O O
synovial O O
tissue O O
were O O
analyzed O O
by O O
electrophoretic O O
mobility O O
shift O O
analysis O O
( O O
EMSA O O
) O O
for O O
NF-kappaB B-protein B-protein
DNA I-protein I-protein
binding I-protein I-protein
proteins I-protein I-protein
. O O

RESULTS O O
: O O
Induction O O
of O O
NF-kappaB B-protein B-protein
DNA O O
binding O O
by O O
the O O
p65 B-protein B-protein
( I-protein I-protein
RelA I-protein I-protein
) I-protein I-protein
/p50 I-protein I-protein
heterodimer I-protein I-protein
was O O
observed O O
in O O
response O O
to O O
incubation O O
of O O
Mono B-cell_line B-cell_line
Mac I-cell_line I-cell_line
6 I-cell_line I-cell_line
cells I-cell_line I-cell_line
with O O
SF O O
( O O
20 O O
% O O
in O O
culture O O
medium O O
) O O
from O O
5 O O
of O O
8 O O
subjects O O
with O O
RA O O
, O O
4 O O
of O O
5 O O
with O O
OA O O
, O O
and O O
none O O
of O O
3 O O
with O O
undifferentiated O O
seronegative O O
oligoarthritis O O
. O O

Incubation O O
of O O
SF O B-protein
with O O
neutralizing B-protein B-protein
antibodies I-protein I-protein
against O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor-alpha I-protein I-protein
( I-protein O
TNF-alpha I-protein B-protein
) I-protein O
, O O
but O O
not O O
antibodies B-protein O
against O O
interleukin B-protein B-protein
6 I-protein I-protein
( I-protein O
IL-6 I-protein B-protein
) I-protein O
, O O
significantly O O
reduced O O
the O O
induction O O
of O O
p65/p50 O B-protein
binding O O
activity O O
in O O
SF O O
from O O
subjects O O
with O O
RA O O
and O O
OA O O
. O O

Unexpectedly O O
, O O
a O O
slowly O O
migrating O O
SF O O
inducible O O
NF-kappaB B-protein B-protein
-binding O O
complex O O
was O O
observed O O
in O O
EMSA O O
of O O
Mono B-cell_line B-cell_line
Mac I-cell_line I-cell_line
6 I-cell_line I-cell_line
cells I-cell_line I-cell_line
after O O
incubation O O
with O O
SF O O
from O O
5 O O
of O O
8 O O
RA O O
and O O
2 O O
of O O
5 O O
OA O O
subjects O O
. O O

The O O
induction O O
of O O
this O O
complex O O
by O O
SF O B-protein
was O O
not O O
affected O O
by O O
neutralization O O
of O O
TNF-alpha B-protein B-protein
or O O
IL-6 B-protein B-protein
in O O
SF O O
, O O
and O O
the O O
complex O O
was O O
not O O
inducible O O
by O O
TNF-alpha B-protein B-protein
, O O
IL-1beta O B-protein
, O O
TNF-alpha B-protein B-protein
/ O O
IL-1beta B-protein B-protein
, O O
IL-6 B-protein B-protein
, O O
platelet B-protein B-protein
derived I-protein I-protein
growth I-protein I-protein
factor I-protein I-protein
, O O
lipopolysaccharide O O
, O O
or O O
tetradecanoyl O O
phorbol O O
acetate O O
. O O

The O O
slowly O O
migrating B-protein O
complex I-protein O
could O O
not O O
be O O
supershifted O O
with O O
antibodies B-protein O
against O O
NF-kappaB B-protein B-protein
, O O
Jun B-protein B-protein
, O O
or O O
the O O
transcriptional O B-protein
coactivators O I-protein
p300 B-protein B-protein
or O O
CBP B-protein B-protein
. O O

A O O
NF-kappaB-binding B-protein B-protein
complex I-protein I-protein
with O O
similar O O
slow O O
mobility O O
was O O
observed O O
in O O
nuclear O O
extracts O O
prepared O O
from O O
fresh O O
human O O
RA O O
synovial O O
tissue O O
. O O

CONCLUSION O O
: O O
Biological O O
activity O O
of O O
TNF-alpha B-protein B-protein
in O O
SF O O
from O O
RA O O
and O O
OA O O
subjects O O
is O O
capable O O
of O O
inducing O O
p65/p50 B-protein B-protein
NF-kappaB I-protein B-protein
DNA O O
binding O O
activity O O
in O O
macrophages B-cell_type B-cell_type
. O O

A O O
property O O
of O O
SF O B-protein
that O O
is O O
independent O O
of O O
TNF-alpha B-protein B-protein
and O O
other O O
cytokines B-protein B-protein
is O O
responsible O O
for O O
the O O
induction O O
of O O
a O O
novel O O
slowly O O
migrating O O
NF-kappaB-binding B-protein B-protein
complex I-protein I-protein
. O O

Soluble O O
mediators O O
in O O
SF O O
of O O
subjects O O
with O O
RA O O
and O O
OA O O
can O O
therefore O O
modulate O O
binding O O
of O O
nuclear B-protein B-protein
proteins I-protein I-protein
to O O
the O O
NF-kappaB B-protein B-DNA
binding I-protein I-DNA
site I-protein I-DNA
in O O
macrophages B-cell_type B-cell_type
and O O
may O O
play O O
a O O
role O O
in O O
inflammatory O O
gene O O
expression O O
in O O
arthritis O O
. O O

Peroxisome B-protein B-protein
proliferator I-protein I-protein
activator I-protein I-protein
receptor-gamma I-protein I-protein
agonists O O
and O O
15-deoxy-Delta O O
( O O
12 O O
, O O
14 O O
) O O
( O O
12 O O
, O O
14 O O
) O O
-PGJ O O
( O O
2 O O
) O O
induce O O
apoptosis O O
in O O
normal O O
and O O
malignant O B-cell_type
B-lineage B-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
research O O
described O O
herein O O
evaluates O O
the O O
expression O O
and O O
functional O O
significance O O
of O O
peroxisome B-protein B-protein
proliferator I-protein I-protein
activator I-protein I-protein
receptor-gamma I-protein I-protein
( I-protein O
PPAR-gamma I-protein B-protein
) I-protein O
on O O
B-lineage B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Normal B-cell_type B-cell_type
mouse I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
a O O
variety O O
of O O
B B-cell_type B-cell_type
lymphoma I-cell_type I-cell_type
cells I-cell_type I-cell_type
reflective O O
of O O
stages O O
of O O
B O O
cell O O
differentiation O O
( O O
e.g. O O
, O O
70Z/3 O B-cell_line
, O O
CH31 O B-cell_line
, O O
WEHI-231 O O
, O O
CH12 O B-cell_line
, O O
and O O
J558 O O
) O O
express O O
PPAR-gamma B-RNA B-RNA
mRNA I-RNA I-RNA
and O O
, O O
by O O
Western O O
blot O O
analysis O O
, O O
the O O
67-kDa B-protein B-protein
PPAR-gamma I-protein I-protein
protein I-protein I-protein
. O O

15-Deoxy-Delta O O
( O O
12 O O
, O O
14 O O
) O O
-PGJ O O
( O O
2 O O
) O O
( O O
15d-PGJ O O
( O O
2 O O
) O O
) O O
, O O
a O O
PPAR-gamma O B-protein
agonist O O
, O O
has O O
a O O
dose-dependent O O
antiproliferative O O
and O O
cytotoxic O O
effect O O
on O O
normal B-cell_type O
and I-cell_type O
malignant I-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
as O O
shown O O
by O O
[ O O
( O O
3 O O
) O O
H O O
] O O
thymidine O O
and O O
3- O O
[ O O
4 O O
, O O
5-dimethylthiazol-2-yl O O
] O O
-2 O O
, O O
5-diphenyltetrazolium O O
bromide O O
assays O O
. O O

Only O O
PPAR-gamma O O
agonists O O
( O O
thiazolidinediones O O
) O O
, O O
and O O
not O O
PPAR-alpha O B-protein
agonists O O
, O O
mimicked O O
the O O
effect O O
of O O
15d-PGJ O O
( O O
2 O O
) O O
on O O
B-lineage B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
indicating O O
that O O
the O O
mechanism O O
by O O
which O O
15d-PGJ O O
( O O
2 O O
) O O
negatively O O
affects O O
B-lineage B-cell_type B-cell_type
cells I-cell_type I-cell_type
involves O O
in O O
part O O
PPAR-gamma B-protein B-protein
. O O

The O O
mechanism O O
by O O
which O O
PPAR-gamma O B-protein
agonists O O
induce O O
cytotoxicity O O
is O O
via O O
apoptosis O O
, O O
as O O
shown O O
by O O
annexin O O
V O O
staining O O
and O O
as O O
confirmed O O
by O O
DNA O O
fragmentation O O
detected O O
using O O
the O O
TUNEL O O
assay O O
. O O

Interestingly O O
, O O
addition O O
of O O
PGF O B-protein
( O I-protein
2alpha O I-protein
) O I-protein
, O O
which O O
was O O
not O O
known O O
to O O
affect O O
lymphocytes B-cell_type B-cell_type
, O O
dramatically O O
attenuated O O
the O O
deleterious O O
effects O O
of O O
PPAR-gamma O B-protein
agonists O O
on O O
B B-cell_type O
lymphomas I-cell_type O
. O O

Surprisingly O O
, O O
15d-PGJ O O
( O O
2 O O
) O O
induced O O
a O O
massive O O
increase O O
in O O
nuclear O B-protein
mitogen-activated O I-protein
protein O I-protein
kinase O I-protein
activation O O
, O O
and O O
pretreatment O O
with O O
PGF O O
( O O
2alpha O O
) O O
blunted O O
the O O
mitogen-activated O B-protein
protein O I-protein
kinase O I-protein
activation O O
. O O

This O O
is O O
the O O
first O O
study O O
evaluating O O
PPAR-gamma O B-protein
expression O O
and O O
its O O
significance O O
on O O
B B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

PPAR-gamma O B-protein
agonists O O
may O O
serve O O
as O O
a O O
counterbalance O O
to O O
the O O
stimulating O O
effects O O
of O O
other O O
PGs O O
, O O
namely O O
PGE O O
( O O
2 O O
) O O
, O O
which O O
promotes O O
B O O
cell O O
differentiation O O
. O O

Finally O O
, O O
the O O
use O O
of O O
PGs O O
, O O
such O O
as O O
15d-PGJ O O
( O O
2 O O
) O O
, O O
and O O
synthetic O O
PPAR-gamma O B-protein
agonists O O
to O O
induce O O
apoptosis O O
in O O
B-lineage B-cell_type B-cell_type
cells I-cell_type I-cell_type
may O O
lead O O
to O O
the O O
development O O
of O O
novel O O
therapies O O
for O O
fatal B-cell_type O
B I-cell_type B-cell_type
lymphomas I-cell_type I-cell_type

Inhibition O O
of O O
STAT3 O B-protein
signaling O O
leads O O
to O O
apoptosis O O
of O O
leukemic B-cell_type B-cell_type
large I-cell_type I-cell_type
granular I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
decreased O O
Mcl-1 O B-protein
expression O O
. O O

Large O B-cell_type
granular O I-cell_type
lymphocyte O I-cell_type
( O O
LGL O O
) O O
leukemia O O
is O O
characterized O O
by O O
the O O
expansion O O
of O O
antigen-activated B-cell_type B-cell_type
cytotoxic I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

These O O
leukemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
are O O
resistant O O
to O O
Fas-mediated O O
apoptosis O O
despite O O
expressing O O
high O O
levels O O
of O O
Fas B-protein B-protein
. O O

We O O
found O O
that O O
leukemic B-cell_type B-cell_type
LGL I-cell_type I-cell_type
from O O
19 O O
patients O O
displayed O O
high O O
levels O O
of O O
activated B-protein O
STAT3 I-protein B-protein
. O O

Treatment O O
of O O
leukemic B-cell_type B-cell_type
LGL I-cell_type I-cell_type
with O O
the O O
JAK-selective O O
tyrosine O O
kinase O O
inhibitor O O
AG-490 O O
induced O O
apoptosis O O
with O O
a O O
corresponding O O
decrease O O
in O O
STAT B-protein B-protein
-DNA O O
binding O O
activity O O
. O O

Moreover O O
, O O
using O O
an O O
antisense O O
oligonucleotide O O
approach O O
to O O
diminish O O
STAT3 O B-protein
expression O O
, O O
we O O
found O O
that O O
Fas O B-protein
sensitivity O O
was O O
restored O O
in O O
leukemic B-cell_type B-cell_type
LGL I-cell_type I-cell_type
. O O

AG-490-induced O O
apoptosis O O
in O O
leukemic B-cell_type B-cell_type
LGL I-cell_type I-cell_type
was O O
independent O O
of O O
Bcl-xL O B-protein
or O O
Bcl-2 O B-protein
expression O O
. O O

However O O
, O O
we O O
found O O
that O O
the O O
Bcl-2-family B-protein B-protein
protein I-protein I-protein
Mcl-1 I-protein B-protein
was O O
significantly O O
reduced O O
by O O
AG-490 O O
treatment O O
. O O

Activated B-protein O
STAT3 I-protein B-protein
was O O
shown O O
to O O
bind O O
an O O
SIE-related B-DNA B-DNA
element I-DNA I-DNA
in O O
the O O
murine B-DNA O
mcl-1 I-DNA B-DNA
promoter I-DNA I-DNA
. O O

Using O O
a O O
luciferase O B-DNA
reporter O I-DNA
assay O O
, O O
we O O
demonstrated O O
that O O
v-src O B-DNA
overexpression O O
in O O
NIH3T3 O B-protein
induced O O
STAT3 B-protein B-protein
-dependent O O
transcriptional O O
activity O O
from O O
the O O
mcl-1 B-DNA B-DNA
promoter I-DNA I-DNA
and O O
increased O O
endogenous O O
Mcl-1 O B-protein
protein O O
levels O O
. O O

We O O
conclude O O
that O O
STAT3 B-protein B-protein
activation O O
contributed O O
to O O
accumulation O O
of O O
the O O
leukemic B-cell_type B-cell_line
LGL I-cell_type I-cell_line
clones I-cell_type I-cell_line
. O O

These O O
findings O O
suggest O O
that O O
investigation O O
should O O
focus O O
on O O
novel O O
strategies O O
targeting O O
STAT3 B-protein B-protein
in O O
the O O
treatment O O
of O O
LGL O O
leukemia O O
. O O

Decreased O O
immediate O O
inflammatory B-DNA B-DNA
gene I-DNA I-DNA
induction O O
in O O
activating B-protein O
transcription I-protein B-protein
factor-2 I-protein I-protein
mutant O I-protein
mice O O
. O O

Transcription B-protein B-protein
factor I-protein I-protein
activating I-protein I-protein
transcription I-protein I-protein
factor I-protein I-protein
( I-protein I-protein
ATF I-protein I-protein
) I-protein I-protein
-2 I-protein I-protein
is O O
activated O O
by O O
inflammatory O O
signals O O
transduced O O
by O O
the O O
JNK O B-protein
and O O
p38 O B-protein
MAP O I-protein
kinase O I-protein
pathways O O
. O O

To O O
better O O
define O O
the O O
role O O
of O O
ATF-2 B-protein B-protein
in O O
inflammation O O
, O O
adult O O
mice O O
expressing O O
small O O
amounts O O
of O O
a O O
mutant B-protein B-protein
ATF-2 I-protein I-protein
protein I-protein I-protein
were O O
challenged O O
with O O
lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
anti-CD3 B-protein B-protein
antibody I-protein I-protein
or O O
virus O O
. O O

Within O O
3 O O
h O O
of O O
challenge O O
by O O
LPS O O
, O O
ATF-2 O B-protein
mutant O I-protein
mice O O
had O O
decreased O O
induction O O
of O O
the O O
adhesion B-protein B-protein
molecules I-protein I-protein
E-selectin B-protein B-protein
, O O
P-selectin B-protein B-protein
and O O
VCAM-1 B-protein B-protein
as O O
well O O
as O O
the O O
cytokines B-protein B-protein
tumor B-protein I-protein
necrosis I-protein I-protein
factor-alpha I-protein I-protein
, O O
IL-1beta B-protein B-protein
and O O
IL-6 B-protein B-protein
compared O O
with O O
control O O
mice O O
. O O

Stimulation O O
of O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
by O O
anti-CD3 B-protein B-protein
antibody I-protein I-protein
also O O
showed O O
less O O
induction O O
of O O
IL-1 B-protein B-protein
and O O
IL-6 B-protein B-protein
in O O
ATF-2 O B-protein
mutant O O
tissues O O
. O O

ATF-2 B-cell_type B-protein
mutant I-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
treated O O
with O O
anti-CD3 B-protein B-protein
antibody I-protein I-protein
in O O
vitro O O
demonstrated O O
reduced O O
induction O O
of O O
c-Jun B-protein B-protein
, O O
JunB B-protein B-protein
, O O
JunD B-protein B-protein
and O O
Fra-2 B-protein B-protein
. O O

However O O
, O O
similar O O
to O O
what O O
was O O
observed O O
after O O
p38 O B-protein
kinase O I-protein
inhibition O O
in O O
normal O O
mice O O
, O O
relative O O
ATF-2 O B-protein
deficiency O O
did O O
not O O
prevent O O
the O O
development O O
of O O
a O O
mononuclear B-cell_type O
cell I-cell_type O
infiltrate O O
in O O
the O O
week O O
following O O
an O O
inflammatory O O
stimulus O O
. O O

ATF-2 O B-protein
mutant O O
mice O O
proved O O
more O O
susceptible O O
to O O
death O O
than O O
control O O
mice O O
from O O
LPS O O
plus O O
D-galactosamine O O
injection O O
or O O
Coxsackievirus O O
B3 O O
infection O O
and O O
had O O
a O O
higher O O
incidence O O
of O O
mononuclear O O
pulmonary O O
infiltrates O O
after O O
exposure O O
to O O
Herpes O O
simplex O O
virus-1 O O
. O O

ATF-2 B-protein B-protein
is O O
essential O O
for O O
maximal O O
immediate O O
induction O O
of O O
adhesion B-protein B-protein
molecules I-protein I-protein
and O O
cytokine B-DNA B-DNA
genes I-DNA I-DNA
, O O
but O O
at O O
later O O
time O O
points O O
may O O
even O O
protect O O
against O O
overactive O O
immune O O
responses O O
. O O

LIGHT B-protein B-protein
, O O
a O O
TNF-like B-protein B-protein
molecule I-protein I-protein
, O O
costimulates O B-cell_type
T O I-cell_type
cell O I-cell_type
proliferation O O
and O O
is O O
required O O
for O O
dendritic B-cell_type O
cell I-cell_type O
-mediated O O
allogeneic O O
T O O
cell O O
response O O
. O O

LIGHT B-protein B-protein
is O O
a O O
recently O O
identified O O
member O O
of O O
the O O
TNF B-protein B-protein
superfamily I-protein I-protein
and O O
its O O
receptors O O
, O O
herpesvirus B-protein O
entry I-protein O
mediator I-protein O
and O O
lymphotoxin B-protein B-protein
beta I-protein I-protein
receptor I-protein I-protein
, O O
are O O
found O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
stromal B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

In O O
this O O
study O O
, O O
we O O
demonstrate O O
that O O
LIGHT B-protein B-protein
is O O
selectively O O
expressed O O
on O O
immature B-cell_type B-cell_type
dendritic I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
DCs B-cell_type B-cell_type
) O O
generated O O
from O O
human B-cell_type B-cell_type
PBMCs I-cell_type I-cell_type
. O O

In O O
contrast O O
, O O
LIGHT B-protein B-protein
is O O
not O O
detectable O O
in O O
DCs B-cell_type B-cell_type
either O O
freshly O O
isolated O O
from O O
PBMCs B-cell_type B-cell_type
or O O
rendered O O
mature O O
in O O
vitro O O
by O O
LPS O O
treatment O O
. O O

Blockade O O
of O O
LIGHT B-protein B-protein
by O O
its O O
soluble B-protein O
receptors I-protein O
, O O
lymphotoxin B-protein B-protein
beta I-protein I-protein
receptor-Ig I-protein I-protein
or O O
HVEM-Ig B-protein O
, O O
inhibits O O
the O O
induction O O
of O O
DC B-cell_type B-cell_type
-mediated O O
primary O O
allogeneic O O
T O O
cell O O
response O O
. O O

Furthermore O O
, O O
engagement O O
of O O
LIGHT B-protein B-protein
costimulates O I-cell_type
human O I-cell_type
T O I-cell_type
cell O I-cell_type
proliferation O O
, O O
amplifies O O
the O O
NF-kappaB O B-protein
signaling O O
pathway O O
, O O
and O O
preferentially O O
induces O O
the O O
production O O
of O O
IFN-gamma B-protein B-protein
, O O
but O O
not O O
IL-4 B-protein B-protein
, O O
in O O
the O O
presence O O
of O O
an O O
antigenic O O
signal O O
. O O

Our O O
results O O
suggest O O
that O O
LIGHT B-protein B-protein
is O O
a O O
costimulatory B-protein B-protein
molecule I-protein I-protein
involved O O
in O O
DC B-cell_type B-cell_type
-mediated O O
cellular O O
immune O O
responses O O
. O O

Suppression O O
of O O
HIV O O
type O O
1 O O
replication O O
by O O
a O O
dominant-negative B-protein B-protein
Ets-1 I-protein I-protein
mutant I-protein I-protein
. O O

Activity O O
of O O
the O O
distal B-DNA B-DNA
region I-DNA I-DNA
of O O
the O O
human O B-DNA
immunodeficiency O I-DNA
virus O I-DNA
( O I-DNA
HIV-1 O I-DNA
) O I-DNA
long B-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
, O O
which O O
contains O O
binding B-DNA B-DNA
sites I-DNA I-DNA
for O O
the O O
Ets-1 B-protein B-protein
and I-protein O
USF-1 I-protein B-protein
proteins I-protein I-protein
, O O
is O O
integral O O
for O O
HIV-1 O O
replication O O
. O O

The O O
Ets-1 B-protein B-protein
and I-protein O
USF-1 I-protein B-protein
proteins I-protein I-protein
play O O
a O O
critical O O
role O O
in O O
the O O
activity O O
of O O
the O O
HIV-1 B-DNA B-DNA
LTR I-DNA I-DNA
distal I-DNA I-DNA
enhancer I-DNA I-DNA
region I-DNA I-DNA
, O O
as O O
indicated O O
by O O
the O O
potent O O
dominant O O
negative O O
effect O O
of O O
a O O
mutant B-DNA O
Ets-1 I-DNA B-protein
lacking I-DNA O
trans-activation I-DNA B-protein
domains I-DNA I-protein
on O O
the O O
transcriptional O O
activity O O
of O O
the O O
LTR B-DNA B-DNA
. O O

To O O
determine O O
the O O
biological O O
relevance O O
of O O
the O O
Ets-1 B-protein B-protein
and I-protein I-protein
USF-1 I-protein I-protein
proteins I-protein I-protein
in O O
HIV-1 O O
replication O O
, O O
we O O
examined O O
the O O
effect O O
of O O
expression O O
of O O
the O O
dominant-negative O B-protein
mutant O I-protein
of O O
Ets-1 B-DNA B-protein
( O O
dnEts-1 B-DNA B-protein
) O O
on O O
HIV-1 O O
infection O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

We O O
demonstrated O O
that O O
expression O O
of O O
dnEts B-DNA O
markedly O O
suppressed O O
HIV-1 O O
infection O O
of O O
a O O
T B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

This O O
finding O O
indicates O O
that O O
formation O O
of O O
a O O
transcriptionaly B-protein O
active I-protein O
USF-1/Ets-1 I-protein B-protein
complex I-protein I-protein
is O O
important O O
in O O
the O O
productive O O
infection O O
of O O
cells O O
by O O
HIV-1 O O
, O O
and O O
suggests O O
that O O
inhibition O O
of O O
the O O
interaction O O
between O O
USF-1 B-protein B-protein
and O O
Ets-1 B-protein B-protein
with O O
the O O
HIV-1 B-DNA B-DNA
LTR I-DNA I-DNA
may O O
provide O O
a O O
new O O
target O O
for O O
anti-HIV-1 O O
gene O O
therapy O O
. O O

Human B-cell_type B-cell_type
eosinophils I-cell_type I-cell_type
constitutively O O
express O O
nuclear B-protein B-protein
factor I-protein I-protein
of I-protein I-protein
activated I-protein I-protein
T I-protein I-protein
cells I-protein I-protein
p I-protein I-protein
and I-protein I-protein
c I-protein I-protein
. O O

BACKGROUND O O
: O O
Eosinophils B-cell_type B-cell_type
are O O
now O O
known O O
to O O
produce O O
a O O
variety O O
of O O
proinflammatory B-protein B-protein
cytokines I-protein I-protein
, O O
although O O
the O O
molecular O B-protein
factors O I-protein
that O O
regulate O O
their O O
production O O
are O O
poorly O O
understood O O
. O O

The O O
expression O O
of O O
almost O O
all O O
of O O
the O O
cytokines B-protein B-protein
produced O O
by O O
eosinophils B-cell_type B-cell_type
, O O
including O O
the O O
proallergic B-protein B-protein
cytokine I-protein I-protein
IL-4 I-protein B-protein
, O O
is O O
now O O
known O O
to O O
be O O
regulated O O
at O O
the O O
level O O
of O O
transcription O O
by O O
members O O
of O O
the O O
nuclear B-protein B-protein
factor I-protein I-protein
of I-protein I-protein
activated I-protein I-protein
T I-protein I-protein
cells I-protein I-protein
( O I-protein
NFAT B-protein I-protein
) O I-protein
family O I-protein
of O O
transcription O B-protein
factors O I-protein
. O O

OBJECTIVE O O
: O O
We O O
sought O O
to O O
characterize O O
the O O
expression O O
of O O
different O O
NFAT B-protein B-protein
proteins I-protein I-protein
in O O
resting B-cell_type B-cell_type
and I-cell_type I-cell_type
activated I-cell_type I-cell_type
eosinophils I-cell_type I-cell_type
. O O

METHODS O O
: O O
Nuclear O O
and O O
whole O O
cell O O
extracts O O
were O O
obtained O O
from O O
both O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
eosinophils I-cell_type I-cell_type
and O O
those O O
obtained O O
from O O
bronchoalveolar O O
lavage O O
fluid O O
of O O
asthmatic O O
subjects O O
after O O
endobronchial O O
allergen O O
challenge O O
. O O

NFAT B-protein B-protein
expression O O
was O O
determined O O
by O O
using O O
immunoprecipitation O O
and O O
Western O O
blot O O
analysis O O
, O O
DNA-binding O O
assays O O
, O O
and O O
RT-PCR O O
analysis O O
of O O
eosinophil B-RNA B-RNA
mRNA I-RNA I-RNA
. O O

RESULTS O O
: O O
Both O O
peripheral B-cell_type O
blood I-cell_type O
and I-cell_type O
bronchoalveolar I-cell_type B-cell_type
lavage I-cell_type I-cell_type
fluid I-cell_type I-cell_type
eosinophils I-cell_type I-cell_type
expressed O O
NFATp B-protein B-protein
and I-protein O
NFATc I-protein B-protein
protein I-protein I-protein
. O O

Unlike O O
activated B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
which O O
express O O
multiple O O
NFATc O B-protein
isoforms O I-protein
, O O
eosinophils B-cell_type B-cell_type
preferentially O O
express O O
the O O
approximately O O
85-kd O B-protein
isoform O I-protein
. O O

In O O
addition O O
, O O
eosinophils B-cell_type B-cell_type
were O O
found O O
to O O
constitutively O O
express O O
NFATc B-RNA B-RNA
mRNA I-RNA I-RNA
. O O

A O O
brief O O
incubation O O
with O O
the O O
T B-protein B-protein
( I-protein I-protein
H I-protein I-protein
) I-protein I-protein
2 I-protein I-protein
cytokines I-protein I-protein
IL-4 B-protein B-protein
and O O
IL-5 B-protein B-protein
was O O
sufficient O O
to O O
induce O O
the O O
nuclear O O
translocation O O
of O O
NFATc B-protein B-protein
. O O

Eosinophil O O
nuclear O O
extracts O O
contain O O
multiple O B-protein
factors O I-protein
that O O
can O O
specifically O O
recognize O O
the O O
IL-4 B-DNA B-DNA
promoter I-DNA I-DNA
P1 I-DNA I-DNA
NFAT I-DNA I-DNA
site I-DNA I-DNA
in O O
DNA-binding O O
assays O O
, O O
including O O
NFATp B-protein B-protein
. O O

CONCLUSION O O
: O O
NFATp B-protein B-protein
and O O
NFATc B-protein B-protein
can O O
regulate O O
the O O
expression O O
of O O
cytokines B-protein B-protein
and O O
other O O
genes O O
in O O
eosinophils B-cell_type B-cell_type
but O O
appear O O
to O O
be O O
regulated O O
by O O
a O O
novel O O
signal O O
transduction O O
mechanism O O
in O O
these O O
cells O O
. O O

BLyS B-protein B-protein
BINDS O O
TO O O
B B-cell_type O
CELLS I-cell_type O
WITH O O
HIGH O O
AFFINITY O O
AND O O
INDUCES O O
ACTIVATION O O
OF O O
THE O O
TRANSCRIPTION B-protein O
FACTORS I-protein O
NF-kappaB B-protein B-protein
AND O O
ELF-1 B-protein B-protein
. O O

B B-protein B-cell_type
lymphocyte I-protein I-cell_type
stimulator I-protein I-cell_type
( O O
BLyS B-protein B-protein
) O O
is O O
a O O
novel O O
member O O
of O O
the O O
TNF B-protein B-protein
family I-protein I-protein
of I-protein O
proteins I-protein O
expressed O O
by O O
myeloid B-cell_type B-cell_type
cells I-cell_type I-cell_type
as O O
membrane-bound O B-protein
and O I-protein
soluble O I-protein
forms O I-protein
. O O

BLyS B-protein B-protein
was O O
shown O O
to O O
act O O
specifically O O
on O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
inducing O O
proliferation O O
and O O
immunoglobulin O B-protein
production O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

The O O
present O O
study O O
was O O
undertaken O O
to O O
characterize O O
binding O O
of O O
radiolabeled B-protein O
BLyS I-protein B-protein
to O O
its O O
cognate B-protein O
receptor I-protein O
on O O
human B-cell_type B-cell_type
B I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
examine O O
intracellular O O
events O O
initiated O O
by O O
BLyS B-protein B-protein
binding O O
. O O

Similar O O
to O O
other O O
TNF B-protein B-protein
family I-protein I-protein
members I-protein I-protein
, O O
BLyS B-protein B-protein
is O O
present O O
in O O
solution O O
as O O
a O O
homotrimer B-protein O
as O O
determined O O
by O O
gel O O
filtration O O
chromatography O O
and O O
light O O
scattering O O
analysis O O
. O O

BLyS B-protein B-protein
binding O O
to O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
is O O
specific O O
as O O
other O O
TNF B-protein B-protein
family I-protein I-protein
members I-protein I-protein
tested O O
did O O
not O O
compete O O
for O O
( O O
125 O O
) O O
I- O O
BLyS B-protein B-protein
binding O O
. O O

Analysis O O
of O O
equilibrium O O
binding O O
of O O
( B-protein O
125 I-protein O
) I-protein O
I-labeled I-protein O
BLyS I-protein B-protein
to O O
purified O O
human B-cell_type B-cell_type
tonsillar I-cell_type I-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
demonstrated O O
saturable O O
binding O O
. O O

Scatchard O O
analysis O O
of O O
the O O
binding O O
data O O
revealed O O
a O O
single O O
class O O
of O O
high-affinity O O
binding O O
on O O
human B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
with O O
approximately O O
2600 O B-DNA
binding O I-DNA
sites O I-DNA
per O O
cell O O
and O O
an O O
apparent O O
dissociation O O
constant O O
( O O
K O O
( O O
D O O
) O O
) O O
of O O
about O O
0.1 O O
nM O O
. O O

In O O
addition O O
we O O
report O O
that O O
BLyS B-protein B-protein
binding O O
to O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
results O O
in O O
the O O
activation O O
of O O
NF-kappaB B-protein B-protein
and O O
the O O
Ets B-protein B-protein
family I-protein I-protein
transcription I-protein I-protein
factor I-protein I-protein
, O O
ELF-1 B-protein B-protein
, O O
and O O
in O O
the O O
induction O O
of O O
mRNA O B-RNA
for O O
Polo-like B-protein B-protein
kinase I-protein I-protein
( O O
PLK B-protein B-protein
) O O
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

Design O O
and O O
use O O
of O O
an O O
inducibly O O
activated O O
human O B-protein
immunodeficiency O I-protein
virus O I-protein
type O I-protein
1 O I-protein
Nef B-protein I-protein
to O O
study O O
immune O O
modulation O O
. O O

The O O
Nef B-protein B-protein
protein I-protein I-protein
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
has O O
been O O
shown O O
to O O
enhance O O
the O O
infectivity O O
of O O
virus O O
particles O O
, O O
downmodulate O B-protein
cell B-protein I-protein
surface I-protein I-protein
proteins I-protein I-protein
, O O
and O O
associate O O
with O O
many O O
intracellular B-protein B-protein
proteins I-protein I-protein
that O O
are O O
thought O O
to O O
facilitate O O
HIV O O
infection O O
. O O

One O O
of O O
the O O
challenges O O
in O O
defining O O
the O O
molecular O O
events O O
regulated O O
by O O
Nef B-protein B-protein
has O O
been O O
obtaining O O
good O O
expression O O
of O O
Nef B-protein B-protein
protein I-protein I-protein
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

This O O
has O O
been O O
attributed O O
to O O
effects O O
of O O
Nef B-protein B-protein
on O O
cell O O
proliferation O O
and O O
apoptosis O O
. O O

We O O
have O O
designed O O
a O O
Nef B-protein B-protein
protein I-protein I-protein
that O O
is O O
readily O O
expressed O O
in O O
T-cell B-cell_line B-cell_line
lines I-cell_line I-cell_line
and O O
whose O O
function O O
is O O
inducibly O O
activated O O
. O O

It O O
is O O
composed O O
of O O
a O O
fusion O O
between O O
full-length B-protein B-protein
Nef I-protein I-protein
and O O
the O O
estrogen B-protein B-protein
receptor I-protein I-protein
hormone-binding I-protein I-protein
domain I-protein I-protein
( O O
Nef-ER B-protein B-protein
) O O
. O O

The O O
Nef-ER B-protein B-protein
is O O
kept O O
in O O
an O O
inactive O O
state O O
due O O
to O O
steric O O
hindrance O O
, O O
and O O
addition O O
of O O
the O O
membrane-permeable O O
drug O O
4-hydroxytamoxifen O O
( O O
4-HT O O
) O O
, O O
which O O
binds O O
to O O
the O O
ER B-protein B-protein
domain I-protein I-protein
, O O
leads O O
to O O
inducible O O
activation O O
of O O
Nef-ER B-protein O
within O O
cells O O
. O O

We O O
demonstrate O O
that O O
Nef-ER B-protein B-protein
inducibly O O
associates O O
with O O
the O O
62-kDa B-protein B-protein
Ser/Thr I-protein I-protein
kinase I-protein I-protein
and O O
is O O
localized O O
to O O
specific O O
membrane O O
microdomains O O
( O O
lipid O O
rafts O O
) O O
only O O
after O O
activation O O
. O O

Using O O
this O O
inducible O B-protein
Nef B-protein I-protein
, O O
we O O
also O O
compared O O
the O O
specific O O
requirements O O
for O O
CD4 B-protein B-protein
and O O
HLA-A2 B-protein B-protein
downmodulation O O
in O O
a O O
SupT1 B-cell_line B-cell_line
T-cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

Half-maximal O O
downmodulation O O
of O O
cell B-protein B-protein
surface I-protein I-protein
CD4 I-protein I-protein
required O O
very O O
little O O
active O O
Nef-ER B-protein B-protein
and O O
occurred O O
as O O
early O O
as O O
4 O O
h O O
after O O
addition O O
of O O
4-HT O O
. O O

In O O
contrast O O
, O O
50 O O
% O O
downmodulation O O
of O O
HLA-A2 B-protein B-protein
by O O
Nef B-protein B-protein
required O O
16 O O
to O O
24 O O
h O O
and O O
about O O
50- O O
to O O
100-fold-greater O O
concentrations O O
of O O
4-HT O O
. O O

These O O
data O O
suggest O O
that O O
HLA-A2 B-protein B-protein
downmodulation O O
may O O
require O O
certain O O
threshold O O
levels O O
of O O
active O O
Nef B-protein B-protein
. O O

The O O
differential O O
timing O O
of O O
CD4 B-protein B-protein
and O O
HLA-A2 B-protein B-protein
downmodulation O O
may O O
have O O
implications O O
for O O
HIV O O
pathogenesis O O
and O O
immune O O
evasion O O
. O O

Regulation O O
of O O
chemokine O B-RNA
mRNA O I-RNA
expression O O
in O O
a O O
rat O O
model O O
of O O
vanadium-induced O O
pulmonary O O
inflammation O O
. O O

Environmental O O
and O O
occupational O O
exposure O O
to O O
vanadium O O
dusts O O
results O O
in O O
toxic O O
effects O O
mainly O O
confined O O
to O O
the O O
respiratory O O
system O O
. O O

Using O O
a O O
rat O O
model O O
of O O
acute O O
lung O O
inflammation O O
induced O O
by O O
intratracheal O O
instillation O O
of O O
sodium O O
metavanadate O O
( O O
NaVO3 O O
) O O
at O O
the O O
dose O O
of O O
200 O O
microg O O
V/kg O O
, O O
we O O
investigated O O
the O O
relationship O O
between O O
the O O
cytologic O O
characterization O O
of O O
pulmonary O O
inflammation O O
and O O
the O O
expression O O
of O O
chemokine B-RNA B-RNA
mRNA I-RNA I-RNA
. O O

Significant O O
polymorphonuclear B-cell_type B-cell_type
leukocyte I-cell_type I-cell_type
( O O
PMN B-cell_type B-cell_type
) O O
influx O O
( O O
P O O
< O O
0.01 O O
) O O
into O O
the O O
lung O O
was O O
noted O O
4 O O
h O O
after O O
NaVO3 O O
instillation O O
, O O
whereas O O
alveolar B-cell_type B-cell_type
macrophages I-cell_type I-cell_type
( O O
AMs B-cell_type B-cell_type
) O O
in O O
bronchoalveolar B-cell_type B-cell_type
lavage I-cell_type I-cell_type
( I-cell_type I-cell_type
BAL I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
appeared O O
to O O
decrease O O
significantly O O
. O O

In O O
contrast O O
, O O
neither O O
PMNs B-cell_type B-cell_type
nor O O
AMs B-cell_type B-cell_type
changed O O
substantially O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
. O O

By O O
Northern O O
analysis O O
, O O
macrophage B-RNA B-RNA
inflammatory I-RNA I-RNA
protein I-RNA I-RNA
( I-RNA I-RNA
MIP I-RNA I-RNA
) I-RNA I-RNA
-2 I-RNA I-RNA
mRNA I-RNA I-RNA
in O O
BAL B-cell_type B-cell_type
cells I-cell_type I-cell_type
increased O O
markedly O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
and O O
reduced O O
a O O
little O O
bit O O
at O O
4 O O
h O O
, O O
whereas O O
MIP-1alpha B-RNA B-RNA
mRNA I-RNA I-RNA
in O O
BAL B-cell_type B-cell_type
cells I-cell_type I-cell_type
was O O
expressed O O
relatively O O
high O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
, O O
although O O
a O O
basal O O
expression O O
was O O
detected O O
in O O
control O O
group O O
, O O
and O O
returned O O
rapidly O O
nearly O O
to O O
control O O
level O O
at O O
4 O O
h O O
. O O

Since O O
MIP-2 B-protein B-protein
is O O
a O O
potent O O
PMN B-cell_type B-protein
chemoattractant O I-protein
and O O
MIP-1alpha B-protein B-protein
is O O
a O O
potent O O
macrophage/monocyte O B-protein
chemoattractant O I-protein
has O O
been O O
well O O
known O O
. O O

The O O
facts O O
that O O
PMN B-cell_type O
influx O O
was O O
preceded O O
by O O
increased O O
MIP-2 O B-RNA
mRNA O I-RNA
expression O O
, O O
suggesting O O
that O O
MIP-2 B-protein B-protein
is O O
involved O O
in O O
the O O
development O O
of O O
NaVO3-induced O O
pulmonary O O
inflammation O O
, O O
whereas O O
increased O O
MIP-1alpha B-RNA B-RNA
mRNA I-RNA I-RNA
expression O O
was O O
followed O O
by O O
decreased O O
AMs B-cell_type B-cell_type
in O O
BAL B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
suggesting O O
AMs B-cell_type B-cell_type
might O O
be O O
activated O O
by O O
MIP-1alpha B-protein B-protein
, O O
adherent O O
to O O
the O O
lining O O
surface O O
of O O
the O O
airways O O
and O O
then O O
resistant O O
to O O
be O O
washed O O
out O O
. O O

To O O
delineate O O
the O O
mechanisms O O
of O O
transcriptional O O
activation O O
, O O
we O O
recently O O
cloned O O
the O O
5'-flanking B-DNA B-DNA
region I-DNA I-DNA
of O O
the O O
MIP-2 B-DNA B-DNA
gene I-DNA I-DNA
. O O

The O O
promotor B-DNA B-DNA
region I-DNA I-DNA
contains O O
consensus B-DNA B-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
for O O
transcription B-protein B-protein
factor I-protein I-protein
nuclear I-protein I-protein
factor I-protein I-protein
kappaB I-protein I-protein
( O O
NF-kappaB B-protein B-protein
) O O
and O O
activator B-protein B-protein
protein-1 I-protein I-protein
( O O
AP-1 B-protein B-protein
) O O
. O O

Using O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
increased O O
nuclear O B-protein
NF-kappaB B-protein I-protein
, O O
not O O
AP-1 B-protein B-protein
, O O
binding O O
activity O O
was O O
detected O O
1 O O
h O O
after O O
NaVO3 O O
instillation O O
, O O
which O O
correlated O O
with O O
the O O
induction O O
of O O
MIP-2 B-RNA B-RNA
mRNA I-RNA I-RNA
. O O

p65 B-protein B-protein
( I-protein O
Rel I-protein B-protein
A I-protein I-protein
) I-protein O
and O O
p50 B-protein B-protein
protein I-protein I-protein
appears O O
to O O
be O O
involved O O
in O O
MIP-2 O B-protein
NF-kappaB B-protein B-protein
binding O O
. O O

Taken O O
together O O
, O O
our O O
studies O O
suggest O O
that O O
MIP-2 B-protein B-protein
is O O
an O O
important O O
mediator O O
of O O
NaVO3-induced O O
pulmonary O O
inflammation O O
in O O
the O O
rat O O
model O O
. O O

In O O
addition O O
, O O
elevated O O
MIP-2 B-RNA B-RNA
mRNA I-RNA I-RNA
levels O O
are O O
accompanied O O
by O O
increased O O
NF-kappaB B-protein B-protein
binding O O
activity O O
in O O
BAL B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
suggesting O O
possible O O
MIP-2 B-protein B-protein
transcriptional O O
regulation O O
through O O
NF-kappaB B-protein B-protein
. O O

Activation O O
of O O
signal O O
transduction O O
and O O
apoptosis O O
in O O
healthy B-cell_type B-cell_type
lymphomonocytes I-cell_type I-cell_type
exposed O O
to O O
bystander O B-cell_type
HIV-1-infected B-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Persistent O O
activation O O
of O O
the O O
immune O O
system O O
is O O
one O O
of O O
the O O
hallmarks O O
of O O
HIV-1 O O
infection O O
. O O

In O O
this O O
study O O
we O O
analysed O O
the O O
induction O O
of O O
factors O O
involved O O
in O O
cytokine O B-protein
signal O O
transduction O O
, O O
such O O
as O O
STAT B-protein B-protein
1 I-protein I-protein
proteins I-protein I-protein
and O O
IRF-1 B-RNA B-RNA
mRNA I-RNA I-RNA
, O O
in O O
normal B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
PBMC B-cell_type B-cell_type
) O O
exposed O O
to O O
HIV-infected B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
and O O
the O O
induction O O
of O O
apoptosis O O
. O O

Western O O
blot O O
analyses O O
and O O
reverse O O
transcriptase-polymerase O O
chain O O
reaction O O
results O O
indicate O O
that O O
both O O
cells O O
infected O O
with O O
a O O
X4 O B-cell_type
strain O I-cell_type
and O I-cell_type
cells O I-cell_type
infected O O
with O O
a O O
R5 O O
strain O O
are O O
able O O
to O O
increase O O
intracellular O O
levels O O
of O O
STAT B-protein B-protein
1alpha I-protein I-protein
and I-protein I-protein
beta I-protein I-protein
proteins O I-protein
as O O
well O O
as O O
IRF-1 B-RNA B-RNA
mRNA I-RNA I-RNA
. O O

This O O
effect O O
was O O
prevented O O
by O O
neutralizing O B-protein
antibodies O I-protein
against O I-protein
interferon-alpha B-protein B-protein
( O O
IFN-alpha B-protein B-protein
) O O
. O O

HIV-1-infected B-cell_type B-cell_line
cells I-cell_type I-cell_line
dose-dependently O O
induced O O
apoptotic O O
commitment O O
in O O
normal B-cell_type O
PBMC I-cell_type B-cell_type
, O O
as O O
revealed O O
by O O
DNA O O
fragmentation O O
analysis O O
, O O
but O O
this O O
was O O
not O O
accompanied O O
by O O
an O O
increase O O
of O O
caspase-3 O B-protein
activity O O
, O O
even O O
if O O
a O O
slight O O
up-regulation O O
of O O
IL-1beta-converting B-RNA B-RNA
enzyme I-RNA I-RNA
mRNA I-RNA I-RNA
was O O
detected O O
. O O

Apoptosis O O
induction O O
could O O
be O O
abrogated O O
mainly O O
by O O
antibodies B-protein B-protein
against O O
tumour B-protein B-protein
necrosis I-protein I-protein
factor-alpha I-protein I-protein
( O O
TNF-alpha B-protein B-protein
) O O
and O O
, O O
to O O
a O O
lesser O O
extent O O
, O O
by O O
antibodies B-protein B-protein
against O O
IFN-gamma B-protein B-protein
. O O

All O O
these O O
findings O O
suggest O O
that O O
uninfected B-cell_type O
PBMC I-cell_type B-cell_type
can O O
undergo O O
activation O O
of O O
signal O O
transduction O O
and O O
apoptosis O O
after O O
exposure O O
to O O
bystander O B-cell_type
HIV-infected B-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
subsequent O O
to O O
the O O
induction O O
of O O
cytokines B-protein B-protein
such O O
as O O
IFNs B-protein B-protein
and O O
TNF-alpha B-protein B-protein
. O O

The O O
physical O O
association O O
of O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
theta I-protein I-protein
with O O
a O O
lipid O O
raft-associated O O
inhibitor O O
of O O
kappa B-protein B-protein
B I-protein I-protein
factor I-protein I-protein
kinase I-protein I-protein
( I-protein I-protein
IKK I-protein I-protein
) I-protein I-protein
complex I-protein I-protein
plays O O
a O O
role O O
in O O
the O O
activation O O
of O O
the O O
NF-kappa O B-protein
B O I-protein
cascade O O
by O O
TCR B-protein B-protein
and O O
CD28 B-protein B-protein
. O O

We O O
investigated O O
the O O
role O O
of O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
theta I-protein I-protein
( O O
PKCtheta B-protein B-protein
) O O
in O O
the O O
activation O O
of O O
the O O
NF-kappaB B-protein B-protein
cascade O O
in O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
CD4 I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Among O O
six O O
or O O
so O O
PKC B-protein B-protein
isoforms I-protein I-protein
expressed O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
only O O
PKCtheta B-protein B-protein
participates O O
in O O
the O O
assembly O O
of O O
the O O
supramolecular O O
activation O O
clusters O O
at O O
the O O
contact O O
site O O
of O O
the O O
TCR B-protein B-protein
with O O
Ag B-protein B-protein
. O O

Signaling O O
via O O
both O O
the O O
TCR B-protein B-protein
and O O
CD28 B-protein B-protein
is O O
required O O
for O O
optimal O O
activation O O
of O O
the O O
multisubunit B-protein B-protein
IkappaB I-protein I-protein
kinase I-protein I-protein
( I-protein I-protein
IKK I-protein I-protein
) I-protein I-protein
complex I-protein I-protein
in O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
; O O
this O O
activation O O
could O O
be O O
inhibited O O
by O O
a O O
Ca O O
( O O
2+ O O
) O O
-independent O O
PKC O B-protein
isoform O I-protein
inhibitor O O
, O O
rottlerin O O
. O O

Moreover O O
, O O
endogenous O O
PKCtheta B-protein B-protein
physically O O
associates O O
with O O
activated O O
IKK B-protein B-protein
complexes I-protein I-protein
in O O
CD3/CD28-costimulated B-cell_type B-cell_line
primary I-cell_type I-cell_line
CD4 I-cell_type I-cell_line
( I-cell_type I-cell_line
+ I-cell_type I-cell_line
) I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

The O O
same O O
set O O
of O O
stimuli O O
also O O
induced O O
relocation O O
of O O
endogenous O O
PKCtheta B-protein B-protein
and O O
IKKs B-protein B-protein
to O O
a O O
GM1 O O
ganglioside-enriched O O
, O O
detergent-insoluble O O
membrane O O
compartment O O
in O O
primary B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

IKKs B-protein B-protein
recruited O O
to O O
these O O
lipid O O
rafts O O
were O O
capable O O
of O O
phosphorylating O O
a O O
recombinant O O
IkappaBalpha O B-protein
sustrate O O
. O O

Confocal O O
microscopy O O
further O O
demonstrated O O
that O O
exogenously O O
expressed O O
PKCtheta B-protein B-protein
and O O
IKKss B-protein B-protein
colocalize O O
in O O
the O O
membrane O O
of O O
CD3/CD28-costimulated B-cell_line B-cell_line
Jurkat I-cell_line I-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Constitutively O O
active O O
but O O
not O O
kinase-inactive B-protein B-protein
PKCtheta I-protein I-protein
activated O I-protein
IKKbeta B-protein B-protein
in O O
Jurkat B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Expression O O
of O O
dominant-active B-protein B-protein
PKCtheta I-protein I-protein
also O O
had O O
stimulatory O O
effects O O
on O O
the O O
CD28 B-DNA B-DNA
response I-DNA I-DNA
element I-DNA I-DNA
of O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Taken O O
together O O
, O O
these O O
data O O
show O O
that O O
the O O
activation O O
of O O
PKCtheta B-protein B-protein
by O O
the O O
TCR B-protein B-protein
and O O
CD28 B-protein B-protein
plays O O
an O O
important O O
role O O
in O O
the O O
assembly O O
and O O
activation O O
of O O
IKK B-protein B-protein
complexes I-protein I-protein
in O O
the O O
T O B-cell_type
cell O I-cell_type
membrane O I-cell_type

T-cell B-cell_type O
-mediated O O
regulation O O
of O O
osteoclastogenesis O O
by O O
signalling O O
cross-talk O O
between O O
RANKL B-protein B-protein
and O O
IFN-gamma B-protein B-protein
. O O

Bone O O
resorption O O
is O O
regulated O O
by O O
the O O
immune O O
system O O
, O O
where O O
T-cell B-cell_type O
expression O O
of O O
RANKL B-protein B-protein
( O O
receptor B-protein O
activator I-protein O
of I-protein O
nuclear I-protein B-protein
factor I-protein I-protein
( I-protein I-protein
NF I-protein I-protein
) I-protein I-protein
-kappaB I-protein I-protein
ligand I-protein I-protein
) O O
, O O
a O O
member O O
of O O
the O O
tumour-necrosis B-protein B-protein
factor I-protein I-protein
family I-protein I-protein
that O O
is O O
essential O O
for O O
osteoclastogenesis O O
, O O
may O O
contribute O O
to O O
pathological O O
conditions O O
, O O
such O O
as O O
autoimmune O O
arthritis O O
. O O

However O O
, O O
whether O O
activated B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
maintain O O
bone O O
homeostasis O O
by O O
counterbalancing O O
the O O
action O O
of O O
RANKL B-protein B-protein
remains O O
unknown O O
. O O

Here O O
we O O
show O O
that O O
T-cell B-cell_type O
production O O
of O O
interferon B-protein B-protein
( I-protein I-protein
IFN I-protein I-protein
) I-protein I-protein
-gamma I-protein I-protein
strongly O O
suppresses O O
osteoclastogenesis O O
by O O
interfering O O
with O O
the O O
RANKL B-protein B-protein
-RANK O B-protein
signalling O O
pathway O O
. O O

IFN-gamma B-protein B-protein
induces O O
rapid O O
degradation O O
of O O
the O O
RANK B-protein B-protein
adapter I-protein I-protein
protein I-protein I-protein
, O O
TRAF6 B-protein B-protein
( O O
tumour B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
receptor-associated I-protein I-protein
factor I-protein I-protein
6 I-protein I-protein
) O O
, O O
which O O
results O O
in O O
strong O O
inhibition O O
of O O
the O O
RANKL B-protein B-protein
-induced O O
activation O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
NF-kappaB B-protein B-protein
and O O
JNK B-protein B-protein
. O O

This O O
inhibition O O
of O O
osteoclastogenesis O B-protein
is O O
rescued O O
by O O
overexpressing O O
TRAF6 B-protein B-protein
in O O
precursor B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
which O O
indicates O O
that O O
TRAF6 B-protein B-protein
is O O
the O O
target O O
critical O O
for O O
the O O
IFN-gamma B-protein B-protein
action O O
. O O

Furthermore O O
, O O
we O O
provide O O
evidence O O
that O O
the O O
accelerated O O
degradation O O
of O O
TRAF6 B-protein B-protein
requires O O
both O O
its O O
ubiquitination O O
, O O
which O O
is O O
initiated O O
by O O
RANKL B-protein B-protein
, O O
and O O
IFN-gamma B-protein B-protein
-induced O O
activation O O
of O O
the O O
ubiquitin-proteasome O O
system O O
. O O

Our O O
study O O
shows O O
that O O
there O O
is O O
cross-talk O O
between O O
the O O
tumour B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
and O O
IFN B-protein B-protein
families I-protein I-protein
of O O
cytokines B-protein B-protein
, O O
through O O
which O O
IFN-gamma B-protein B-protein
provides O O
a O O
negative O O
link O O
between O O
T-cell B-cell_type O
activation O O
and O O
bone O O
resorption O O
. O O

Our O O
results O O
may O O
offer O O
a O O
therapeutic O O
approach O O
to O O
treat O O
the O O
inflammation-induced O O
tissue O O
breakdown O O
. O O

Stromal-derived B-protein B-protein
factor I-protein I-protein
1 I-protein I-protein
and O O
thrombopoietin B-protein B-protein
regulate O O
distinct O O
aspects O O
of O O
human O O
megakaryopoiesis O O
. O O

The O O
role O O
of O O
the O O
chemokine B-protein B-protein
binding O I-protein
stromal-derived B-protein I-protein
factor I-protein I-protein
1 I-protein I-protein
( O O
SDF-1 B-protein B-protein
) O O
in O O
normal O O
human O O
megakaryopoiesis O O
at O O
the O O
cellular O O
and O O
molecular O O
levels O O
and O O
its O O
comparison O O
with O O
that O O
of O O
thrombopoietin B-protein B-protein
( O O
TPO B-protein B-protein
) O O
have O O
not O O
been O O
determined O O
. O O

In O O
this O O
study O O
it O O
was O O
found O O
that O O
SDF-1 B-protein B-protein
, O O
unlike O O
TPO B-protein B-protein
, O O
does O O
not O O
stimulate O O
alpha O B-protein
( O I-protein
IIb O I-protein
) O I-protein
beta O I-protein
( O I-protein
3 O I-protein
) O O
( O O
+ O O
) O O
cell O O
proliferation O O
or O O
differentiation O O
or O O
have O O
an O O
antiapoptotic O O
effect O O
. O O

However O O
, O O
it O O
does O O
induce O O
chemotaxis O O
, O O
trans-Matrigel O O
migration O O
, O O
and O O
secretion O O
of O O
matrix O B-protein
metalloproteinase B-protein I-protein
9 I-protein I-protein
( O O
MMP-9 B-protein B-protein
) O O
and O O
vascular B-protein B-protein
endothelial I-protein I-protein
growth I-protein I-protein
factor I-protein I-protein
( O O
VEGF B-protein B-protein
) O O
by O O
these O O
cells O O
, O O
and O O
both O O
SDF-1 B-protein B-protein
and O O
TPO B-protein B-protein
increase O O
the O O
adhesion O O
of O O
alpha B-cell_type B-protein
( I-cell_type I-protein
IIb I-cell_type I-protein
) I-cell_type I-protein
beta I-cell_type I-protein
( I-cell_type I-protein
3 I-cell_type I-protein
) I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
to O O
fibrinogen B-protein B-protein
and O O
vitronectin B-protein B-protein
. O O

Investigating O O
the O O
intracellular O O
signaling O O
pathways O O
induced O O
by O O
SDF-1 B-protein B-protein
and O O
TPO B-protein B-protein
revealed O O
some O O
overlapping O O
patterns O O
of O O
protein O O
phosphorylation/activation O O
( O O
mitogen-activated B-protein B-protein
protein I-protein I-protein
kinase I-protein I-protein
[ I-protein O
MAPK I-protein B-protein
] I-protein O
p42/44 I-protein B-protein
, O O
MAPK B-protein B-protein
p38 I-protein I-protein
, O O
and O O
AKT B-protein B-protein
[ I-protein O
protein I-protein B-protein
kinase I-protein I-protein
B I-protein I-protein
] I-protein O
) O O
and O O
some O O
that O O
were O O
distinct O O
for O O
TPO B-protein B-protein
( O O
eg O O
, O O
JAK-STAT B-protein B-protein
) O O
and O O
for O O
SDF-1 B-protein B-protein
( O O
eg O O
, O O
NF-kappa B-protein B-protein
B I-protein I-protein
) O O
. O O

It O O
was O O
also O O
found O O
that O O
though O O
inhibition O O
of O O
phosphatidyl-inositol B-protein B-protein
3-kinase I-protein I-protein
( O O
PI-3K B-protein B-protein
) O O
by O O
LY294002 O O
in O O
alpha B-cell_type B-protein
( I-cell_type I-protein
IIb I-cell_type I-protein
) I-cell_type I-protein
beta I-cell_type I-protein
( I-cell_type I-protein
3 I-cell_type I-protein
) I-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
induced O O
apoptosis O O
and O O
inhibited O O
chemotaxis O O
adhesion O O
and O O
the O O
secretion O O
of O O
MMP-9 B-protein B-protein
and O O
VEGF B-protein B-protein
, O O
the O O
inhibition O O
of O O
MAPK B-protein B-protein
p42/44 I-protein I-protein
( O O
by O O
the O O
MEK O B-protein
inhibitor O O
U0126 O O
) O O
had O O
no O O
effect O O
on O O
the O O
survival O O
, O O
proliferation O O
, O O
and O O
migration O O
of O O
these O O
cells O O
. O O

Hence O O
, O O
it O O
is O O
suggested O O
that O O
the O O
proliferative O O
effect O O
of O O
TPO B-protein B-protein
is O O
more O O
related O O
to O O
activation O O
of O O
the O O
JAK-STAT O B-protein
pathway O O
( O O
unique O O
to O O
TPO B-protein B-protein
) O O
, O O
and O O
the O O
PI-3K-AKT O B-protein
axis O O
is O O
differentially O O
involved O O
in O O
TPO- O O
and O O
SDF-1-dependent O O
signaling O O
. O O

Accordingly O O
, O O
PI-3K B-protein B-protein
is O O
involved O O
in O O
TPO B-protein B-protein
-mediated O O
inhibition O O
of O O
apoptosis O O
, O O
TPO- O O
and O O
SDF-1-regulated O O
adhesion O O
to O O
fibrinogen B-protein B-protein
and O O
vitronectin B-protein B-protein
, O O
and O O
SDF-1 B-protein B-protein
-mediated O O
migration O O
. O O

This O O
study O O
expands O O
the O O
understanding O O
of O O
the O O
role O O
of O O
SDF-1 B-protein B-protein
and O O
TPO B-protein B-protein
in O O
normal O O
human O O
megakaryopoiesis O O
and O O
indicates O O
the O O
molecular O O
basis O O
of O O
the O O
observed O O
differences O O
in O O
cellular O O
responses O O
. O O

( O O
Blood. O O
2000 O O
; O O
96 O O
: O O
4142-4151 O O
) O O

Adhesion O O
of O O
immature B-cell_type B-cell_type
and I-cell_type I-cell_type
mature I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
induces O O
in O O
human B-cell_type B-cell_type
thymic I-cell_type I-cell_type
epithelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
TEC B-cell_type B-cell_type
) O O
activation O O
of O O
IL-6 B-protein B-protein
gene I-protein I-protein
trascription I-protein I-protein
factors I-protein I-protein
( O O
NF-kappaB B-protein B-protein
and O O
NF-IL6 B-protein B-protein
) O O
and O O
IL-6 O B-protein
gene O O
expression O O
: O O
role O O
of O O
alpha3beta1 B-protein B-protein
and I-protein O
alpha6beta4 I-protein B-protein
integrins I-protein I-protein
. O O

T B-cell_type B-cell_type
cell I-cell_type I-cell_type
precursors I-cell_type I-cell_type
homed O O
to O O
thymus O O
develop O O
in O O
close O O
contact O O
with O O
stromal B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Among O O
them O O
, O O
thymic B-cell_type B-cell_type
epithelial I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
TEC B-cell_type B-cell_type
) O O
are O O
known O O
to O O
exert O O
dominant O O
roles O O
in O O
their O O
survival O O
and O O
functional O O
shaping O O
. O O

Key O O
molecules O O
mediating O O
TEC B-cell_type B-cell_type
/ O O
thymocytes B-cell_type B-cell_type
interactions O O
include O O
cytokines B-protein B-protein
and O O
growth B-protein B-protein
factors I-protein I-protein
secreted O O
by O O
the O O
two O O
cell O O
types O O
and O O
adhesion B-protein B-protein
receptors I-protein I-protein
mediating O O
cell O O
contact O O
. O O

Signaling O O
events O O
triggered O O
in O O
thymocytes B-cell_type B-cell_type
by O O
adhesion O O
to O O
epithelial B-cell_type B-cell_type
cells I-cell_type I-cell_type
have O O
been O O
extensively O O
investigated O O
, O O
whereas O O
little O O
is O O
known O O
on O O
the O O
opposite O O
phenomenon O O
. O O

We O O
have O O
previously O O
investigated O O
this O O
issue O O
in O O
a O O
co-culture O O
system O O
composed O O
of O O
TEC B-cell_type B-cell_line
cultures I-cell_type I-cell_line
derived O O
from O O
human O O
normal O O
thymus O O
and O O
heterologous B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
. O O

We O O
demonstrated O O
that O O
thymocytes B-cell_type B-cell_type
adhere O O
to O O
TEC B-cell_type B-protein
involving O O
beta1 B-protein B-protein
and I-protein I-protein
beta4 I-protein I-protein
integrins I-protein I-protein
and O O
induce O O
the O O
clustering O O
of O O
alpha3beta1 B-protein B-protein
and I-protein O
alpha6beta4 I-protein B-protein
heterodimers I-protein I-protein
at O O
the O O
TEC O B-cell_type
surface O O
. O O

In O O
addition O O
thymocyte O O
adhesion O O
was O O
followed O O
by O O
activation O O
of O O
NF-kappaB B-protein B-protein
and O O
NF-IL6 B-protein B-DNA
gene B-protein I-DNA
transcription I-protein B-protein
factors I-protein I-protein
and O O
enhanced O O
IL-6 O B-protein
production O O
. O O

The O O
two O O
latter O O
phenomena O O
were O O
reproduced O O
by O O
the O O
cross-linking O O
of O O
the O O
alpha3 B-protein B-protein
, O O
alpha6 B-protein B-protein
, O I-protein
beta1 B-protein I-protein
and I-protein I-protein
beta4 I-protein I-protein
integrins I-protein I-protein
, O O
thus O O
implying O O
that O O
the O O
alpha3beta1 B-protein B-protein
and I-protein O
alpha6beta4 I-protein B-protein
heterodimers I-protein I-protein
can O O
signal O O
during O O
thymocyte O O
adhesion O O
. O O

We O O
have O O
extended O O
our O O
previous O O
work O O
investigating O O
in O O
the O O
same O O
experimental O O
setting O O
the O O
inducing O O
activity O O
of O O
non O O
stimulated O O
or O O
activated O B-cell_type
policlonal B-cell_type I-cell_type
or I-cell_type I-cell_type
clonal I-cell_type I-cell_type
mature I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
as O O
representative O O
of O O
the O O
more O O
mature B-cell_type B-cell_type
thymocyte I-cell_type I-cell_type
subset I-cell_type I-cell_type
. O O

We O O
found O O
that O O
adhesion O O
of O O
unstimulated B-cell_type B-cell_type
T I-cell_type I-cell_type
cell I-cell_type I-cell_type
i O O
) O O
involved O O
beta1 O B-protein
, O O
but O O
not O O
beta4 O B-protein
integrin O I-protein
functions O O
at O O
the O O
surface O O
ii O O
) O O
induced O O
the O O
clustering O O
of O O
alpha3beta1 B-protein B-protein
, O O
but O O
not O O
alpha2beta1 B-protein B-protein
heterodimers I-protein I-protein
at O O
the O O
TEC O B-cell_line
surface O I-cell_line
and O O
iii O O
) O O
up-regulated O O
the O O
nuclear O O
binding O O
activity O O
of O O
NF-kappaB B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
and O O
the O O
IL-6 O B-protein
secretion O O
. O O

We O O
propose O O
that O O
alpha3beta1 B-protein B-protein
and I-protein O
alpha6beta4 I-protein B-protein
heterodimers I-protein I-protein
are O O
induced O O
to O O
cluster O O
at O O
the O O
TEC O B-cell_type
surface O O
recognizing O O
yet O O
unknown O O
cellular B-protein O
ligands I-protein O
differentially O O
expressed O O
during O O
T O O
cell O O
development O O
. O O

Identification O O
and O O
characterization O O
of O O
SKAT-2 B-DNA B-protein
, O O
a O O
novel O B-DNA
Th2-specific B-DNA I-DNA
zinc I-DNA I-DNA
finger I-DNA I-DNA
gene I-DNA I-DNA
. O O

We O O
have O O
identified O O
a O O
novel O O
Kruppel-type B-DNA B-DNA
zinc I-DNA I-DNA
finger I-DNA I-DNA
( I-DNA I-DNA
ZF I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
, O O
SKAT-2 B-DNA B-protein
, O O
which O O
is O O
selectively O O
expressed O O
by O O
murine B-cell_type B-cell_type
Th2 I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

The O O
protein O O
encoded O O
by O O
this O O
gene O O
has O O
14 O B-DNA
C2H2-type O I-DNA
ZF O I-DNA
tandemly O I-DNA
arrayed O O
at O O
its O O
C B-DNA B-protein
terminus I-DNA I-protein
and O O
N-terminal B-DNA B-protein
SCAN B-DNA I-protein
box I-DNA B-protein
and O O
KRAB B-DNA B-protein
domains I-DNA I-protein
. O O

SKAT-2 B-DNA B-protein
is O O
tissue O O
restricted O O
in O O
expression O O
at O O
the O O
RNA O O
level O O
, O O
detectable O O
only O O
in O O
brain O O
and O O
at O O
low O O
levels O O
in O O
kidney O O
and O O
spleen O O
and O O
few O O
hematopoietic B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

By O O
in O O
situ O O
hybridization O O
, O O
SKAT-2 B-DNA B-protein
expression O O
was O O
found O O
to O O
peak O O
in O O
antigen-stimulated O B-cell_type
CD4 B-cell_type I-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
after O O
2-3 O O
days O O
of O O
culture O O
under O O
Th2 O O
but O O
not O O
Th1 O O
biasing O O
conditions O O
. O O

This O O
pattern O O
of O O
expression O O
closely O O
mirrored O O
that O O
of O O
GATA-3 B-protein B-protein
in O O
the O O
same O O
cells O O
. O O

In O O
transient O O
transfection O O
experiments O O
in O O
phorbol O B-cell_line
12-myristate O I-cell_line
13-acetate/ionomycin-stimulated O I-cell_line
EL4 B-cell_line I-cell_line
cells I-cell_line I-cell_line
, O O
SKAT-2 B-DNA B-protein
was O O
found O O
to O O
up-regulate O O
the O O
activity O O
of O O
the O O
IL-4 B-DNA B-protein
but I-DNA O
not I-DNA O
the I-DNA O
IL-5 I-DNA B-DNA
promoter I-DNA I-DNA
, O O
contrasting O O
with O O
the O O
ability O O
of O O
GATA-3 B-protein B-protein
to O O
activate O O
both O O
promoters B-DNA B-DNA
. O O

This O O
result O O
was O O
confirmed O O
using O O
clones O O
of O O
EL4 B-cell_line B-cell_line
cells I-cell_line I-cell_line
stably O O
expressing O O
an O O
inducible O O
form O O
of O O
SKAT-2 B-DNA B-protein
, O O
thus O O
SKAT-2 B-DNA B-protein
is O O
a O O
novel O B-DNA
Th2-specific B-DNA I-DNA
gene I-DNA I-DNA
that O O
may O O
play O O
a O O
role O O
in O O
selective O O
regulation O O
of O O
cytokine B-DNA B-DNA
genes I-DNA I-DNA
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

hsp70 B-protein B-protein
interacting I-protein I-protein
protein I-protein I-protein
Hip I-protein I-protein
does O O
not O O
affect O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
folding O O
by O O
the O O
hsp90-based O O
chaperone O O
machinery O O
except O O
to O O
oppose O O
the O O
effect O O
of O O
BAG-1 B-protein B-protein
. O O

Reticulocyte O O
lysate O O
contains O O
a O O
chaperone O B-protein
system O I-protein
that O O
assembles O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
( I-protein I-protein
GR I-protein I-protein
) I-protein I-protein
.hsp90 I-protein I-protein
heterocomplexes I-protein I-protein
. O O

Using O O
purified B-protein B-protein
proteins I-protein I-protein
, O O
we O O
have O O
prepared O O
a O O
five-protein O B-protein
heterocomplex O I-protein
assembly O O
system O O
consisting O O
of O O
two O O
proteins O O
essential O O
for O O
heterocomplex O O
assembly- O O
hsp90 B-protein B-protein
and O O
hsp70 B-protein B-protein
-and O O
three O O
proteins O O
that O O
act O O
as O O
co-chaperones O O
to O O
enhance O O
assembly- O B-protein
Hop B-protein I-protein
, O O
hsp40 B-protein B-protein
, O O
p23 B-protein B-protein
[ O O
Morishima O O
, O O
Y. O O
, O O
Kanelakis O O
, O O
K. O O
C. O O
, O O
Silverstein O O
, O O
A. O O
M. O O
, O O
Dittmar O O
, O O
K. O O
D. O O
, O O
Estrada O O
, O O
L. O O
, O O
and O O
Pratt O O
, O O
W. O O
B. O O
( O O
2000 O O
) O O
J. O O
Biol. O O
Chem. O O
275 O O
, O O
6894-6900 O O
] O O
. O O

The O O
hsp70 B-protein B-protein
co-chaperone I-protein I-protein
Hip I-protein B-protein
has O O
been O O
recovered O O
in O O
receptor.hsp90 B-protein B-protein
heterocomplexes I-protein I-protein
at O O
an O O
intermediate O O
stage O O
of O O
assembly O O
in O O
reticulocyte O O
lysate O O
, O O
and O O
Hip B-protein B-protein
is O O
also O O
thought O O
to O O
be O O
an O O
intrinsic O O
component O O
of O O
the O O
assembly O O
machinery O O
. O O

Here O O
we O O
show O O
that O O
immunodepletion O O
of O O
Hip B-protein O
from O O
reticulocyte O O
lysate O O
or O O
addition O O
of O O
high O O
levels O O
of O O
Hip B-protein O
to O O
the O O
purified O O
five-protein O O
system O O
does O O
not O O
affect O O
GR.hsp90 O B-protein
heterocomplex O I-protein
assembly O O
or O O
the O O
activation O O
of O O
steroid O O
binding O O
activity O O
that O O
occurs O O
with O O
assembly O O
. O O

Despite O O
the O O
fact O O
that O O
Hip B-protein O
does O O
not O O
affect O O
assembly O O
, O O
it O O
is O O
recovered O O
in O O
GR.hsp90 B-protein B-protein
heterocomplexes I-protein I-protein
assembled O O
by O O
both O O
systems O O
. O O

In O O
the O O
five-protein O O
system O O
, O O
Hip B-protein O
prevents O O
inhibition O O
of O O
assembly O O
by O O
the O O
hsp70 B-protein B-protein
co-chaperone I-protein I-protein
BAG-1 I-protein B-protein
, O O
and O O
cotransfection O O
of O O
Hip B-protein O
with O O
BAG-1 B-protein B-protein
opposes O O
BAG-1 B-protein B-protein
reduction O O
of O O
steroid O O
binding O O
activity O O
in O O
COS B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

We O O
conclude O O
that O O
Hip B-protein O
is O O
not O O
a O O
component O O
of O O
the O O
assembly O O
machinery O O
but O O
that O O
it O O
could O O
play O O
a O O
regulatory O O
role O O
in O O
opposition O O
to O O
BAG-1 B-protein B-protein
. O O

Cutting O O
edge O O
: O O
STAT6-deficient O O
mice O O
have O O
enhanced O O
tumor O O
immunity O O
to O O
primary O O
and O O
metastatic O O
mammary O O
carcinoma O O
. O O

STAT4 B-protein B-protein
and O O
STAT6 B-protein B-protein
are O O
essential O O
for O O
the O O
development O O
of O O
CD4 O B-cell_type
( O I-cell_type
+ O I-cell_type
) O I-cell_type
Th1 O I-cell_type
and O O
Th2 O O
development O O
, O O
respectively O O
. O O

Tumor O O
immunologists O O
have O O
hypothesized O O
that O O
Th1 B-cell_type B-cell_type
cells I-cell_type I-cell_type
are O O
critical O O
in O O
tumor O O
immunity O O
because O O
they O O
facilitate O O
differentiation O O
of O O
CD8 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
which O O
are O O
potent O O
anti-tumor B-cell_type O
effectors I-cell_type O
. O O

We O O
have O O
used O O
STAT4 O B-protein
( O O
-/- O O
) O O
and O O
STAT6 O B-protein
( O O
-/- O O
) O O
mice O O
to O O
test O O
this O O
hypothesis O O
. O O

BALB/c O O
and O O
knockout O O
mice O O
were O O
challenged O O
in O O
the O O
mammary O O
gland O O
with O O
the O O
highly O O
malignant O O
and O O
spontaneously O O
metastatic O O
BALB/c-derived O O
4T1 O O
mammary O O
carcinoma O O
. O O

Primary O O
tumor O O
growth O O
and O O
metastatic O O
disease O O
are O O
reduced O O
in O O
STAT6 O B-protein
( O O
-/- O O
) O O
mice O O
relative O O
to O O
BALB/c O O
and O O
STAT4 O B-protein
( O O
-/- O O
) O O
mice O O
. O O

Ab O O
depletions O O
demonstrate O O
that O O
the O O
effect O O
is O O
mediated O O
by O O
CD8 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
and O O
immunized O O
STAT6 O B-protein
( O O
-/- O O
) O O
mice O O
have O O
higher O O
levels O O
of O O
4T1-specific B-cell_type B-cell_type
CTL I-cell_type I-cell_type
than O O
BALB/c O O
or O O
STAT4 O B-protein
( O O
-/- O O
) O O
mice O O
. O O

Surprisingly O O
, O O
Th1 B-cell_type B-cell_type
or I-cell_type I-cell_type
Th2 I-cell_type I-cell_type
cells I-cell_type I-cell_type
are O O
not O O
involved O O
, O O
because O O
CD4 O B-protein
depletion O O
does O O
not O O
diminish O O
the O O
anti-tumor O O
effect O O
. O O

Therefore O O
, O O
deletion O O
of O O
the O O
STAT6 B-DNA B-DNA
gene I-DNA I-DNA
facilitates O O
development O O
of O O
potent O O
anti-tumor O O
immunity O O
via O O
a O O
CD4 O B-protein
( O O
+ O O
) O O
-independent O O
pathway O O
. O O

Activation O O
of O O
oncogenic B-protein B-protein
transcription I-protein I-protein
factor I-protein I-protein
AP-1 I-protein I-protein
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
infected O O
with O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
. O O

Human O O
T O B-cell_type
cell O I-cell_type
leukemia O I-protein
virus O I-protein
type O I-protein
1 O I-protein
( O I-protein
HTLV-1 O I-protein
) O I-protein
Tax B-protein I-protein
protein I-protein I-protein
transforms O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
vitro O O
. O O

We O O
previously O O
showed O O
that O O
Tax B-protein B-protein
induces O O
the O O
expression O O
of O O
various O O
family O O
members O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
AP-1 I-protein B-protein
such O O
as O O
c-Jun B-protein B-protein
, O O
JunD B-protein B-protein
, O O
c-Fos B-protein B-protein
, O O
and O O
Fra-1 B-protein B-protein
at O O
the O O
mRNA O O
level O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

In O O
this O O
study O O
, O O
we O O
have O O
examined O O
the O O
ability O O
of O O
Tax B-protein B-protein
to O O
activate O O
transcription O O
through O O
the O O
AP-1-binding B-DNA B-DNA
site I-DNA I-DNA
( O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
) O O
. O O

A O O
transient O O
transfection O O
study O O
showed O O
that O O
Tax B-protein B-protein
can O O
activate O O
transcription O O
through O O
the O O
AP-1-binding B-DNA B-DNA
site I-DNA I-DNA
in O O
a O O
human B-cell_line B-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
, O O
whereas O O
any O O
combination O O
of O O
AP-1 B-protein B-protein
proteins I-protein I-protein
did O O
so O O
much O O
less O O
than O O
Tax B-protein B-protein
, O O
indicating O O
that O O
the O O
activation O O
of O O
the O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
by O O
Tax B-protein B-protein
may O O
require O O
a O O
mechanism O O
other O O
than O O
the O O
induction O O
of O O
AP-1 B-RNA B-RNA
mRNA I-RNA I-RNA
. O O

Fresh B-cell_type O
peripheral I-cell_type O
blood I-cell_type B-cell_type
leukemia I-cell_type I-cell_type
cells I-cell_type I-cell_type
of O O
all O O
surveyed O O
ATL O O
patients O O
displayed O O
constitutive O O
AP-1 O B-protein
DNA-binding O O
activity O O
, O O
whereas O O
no O O
normal O O
individuals O O
did O O
. O O

However O O
, O O
the O O
HTLV-1 B-DNA B-DNA
genes I-DNA I-DNA
, O O
including O O
tax B-DNA B-DNA
, O O
are O O
not O O
significantly O O
expressed O O
in O O
fresh O O
leukemia B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
ATL O O
patients O O
. O O

Our O O
present O O
results O O
suggest O O
that O O
activation O O
of O O
AP-1 B-protein B-protein
occurs O O
through O O
Tax-dependent O O
and O O
-independent O O
mechanisms O O
in O O
HTLV-1-infected O B-cell_type
T B-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
which O O
may O O
play O O
some O O
roles O O
in O O
dysregulated O O
phenotypes O O
of O O
HTLV-1-infected B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-pentachlorobiphenyl O O
induces O O
apoptosis O O
in O O
human B-cell_type B-cell_type
monocytic I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Polychlorinatedbiphenyls O O
( O O
PCBs O O
) O O
are O O
a O O
group O O
of O O
persistent O O
and O O
widely O O
dispersed O O
environmental O O
pollutants O O
, O O
some O O
of O O
which O O
may O O
be O O
immunotoxic O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
investigated O O
the O O
effect O O
of O O
PCBs O O
on O O
immune O O
system O O
by O O
assessing O O
apoptotic O O
cell O O
death O O
in O O
human B-cell_line B-cell_line
monocytic I-cell_line I-cell_line
U937 I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Among O O
the O O
various O O
congeners O O
tested O O
, O O
2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-pentachlorobiphenyl O O
( O O
PeCB O O
) O O
, O O
a O O
highly O O
ortho-substituted O O
congener O O
, O O
specifically O O
induced O O
DNA O O
fragmentation O O
, O O
a O O
hallmark O O
of O O
apoptosis O O
, O O
while O O
the O O
other O O
examined O O
di- O O
, O O
tri- O O
, O O
tetra- O O
, O O
and O O
pentachlorobiphenyls O O
did O O
not O O
. O O

To O O
further O O
study O O
the O O
2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-PeCB-induced O O
cell O O
death O O
, O O
various O O
features O O
of O O
apoptosis O O
were O O
examined O O
. O O

2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-PeCB O O
caused O O
a O O
decrease O O
in O O
cell O O
viability O O
and O O
induced O O
cellular O O
morphologic O O
features O O
characteristic O O
of O O
apoptosis O O
such O O
as O O
chromatin O O
aggregation O O
and O O
apoptotic O O
bodies O O
. O O

In O O
addition O O
, O O
caspase-3 B-protein B-protein
, O O
an O O
executioner O O
of O O
apoptosis O O
, O O
was O O
activated O O
and O O
its O O
substrate O O
, O O
poly B-protein B-protein
( I-protein I-protein
ADP-ribose I-protein I-protein
) I-protein I-protein
polymerase I-protein I-protein
( O O
PARP B-protein B-protein
) O O
, O O
was O O
cleaved O O
during O O
2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-PeCB-induced O O
apoptosis O O
. O O

In O O
contrast O O
, O O
3 O O
, O B-DNA
3 O I-DNA
' O I-DNA
, O I-DNA
4 O I-DNA
, O I-DNA
4 O I-DNA
' O I-DNA
, O O
5-PeCB O O
, O O
a O O
congener O O
of O O
coplanar O O
structure O O
, O O
as O O
well O O
as O O
2 O O
, O O
3 O O
, O O
7 O O
, O O
8-TCDD O O
did O O
not O O
induce O O
apoptosis O O
in O O
these O O
human B-cell_type B-cell_type
monocytic I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
although O O
they O O
potently O O
induced O O
CYP B-protein B-protein
1A1 I-protein I-protein
in O O
human B-cell_line B-cell_line
hepatoma I-cell_line I-cell_line
Hep I-cell_line I-cell_line
G2 I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Taken O O
together O O
, O O
the O O
data O O
indicate O O
that O O
2 O O
, O O
2 O O
' O O
, O O
4 O O
, O O
6 O O
, O O
6'-PeCB O B-protein
induces O O
apoptosis O O
in O O
human B-cell_type B-cell_type
monocytic I-cell_type I-cell_type
cells I-cell_type I-cell_type
through O O
a O O
mechanism O O
that O O
is O O
independent O O
of O O
the O O
arylhydrocarbon B-protein B-protein
receptor I-protein I-protein
. O O

This O O
suggests O O
a O O
possibly O O
separate O O
mechanism O O
by O O
which O O
PCBs O O
cause O O
immunosuppression O O
. O O

Effects O O
of O O
deregulated O O
Raf O B-protein
activation O O
on O O
integrin B-protein B-protein
, O O
cytokine-receptor O B-protein
expression O O
and O O
the O O
induction O O
of O O
apoptosis O O
in O O
hematopoietic B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
effects O O
of O O
deregulated O O
Raf O B-protein
activation O O
on O O
the O O
growth O O
and O O
differentiation O O
of O O
hematopoietic B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
investigated O O
. O O

The O O
cytokine-dependent B-cell_line B-cell_line
murine I-cell_line I-cell_line
myeloid I-cell_line I-cell_line
FDC-P1 I-cell_line I-cell_line
and O O
human B-cell_line B-cell_line
erythroleukemic I-cell_line I-cell_line
TF-1 I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
were O O
transformed O O
to O O
grow O O
in O O
response O O
to O O
deregulated O O
Raf O B-protein
expression O O
in O O
the O O
absence O O
of O O
exogenous B-protein B-protein
cytokines I-protein I-protein
. O O

The O O
conditionally O O
active O O
Raf B-protein B-protein
proteins I-protein I-protein
were O O
regulated O O
by O O
beta-estradiol O O
as O O
cDNAs B-DNA B-DNA
containing O O
the O O
Raf B-protein B-protein
catalytic I-protein I-protein
, O O
but O O
lacking O O
negative-regulatory B-protein B-protein
domains I-protein I-protein
, O O
were O O
ligated O O
to O O
the O O
hormone B-protein B-protein
binding I-protein I-protein
domain I-protein I-protein
of O O
the O O
estrogen B-protein B-protein
receptor I-protein I-protein
( O O
deltaRaf B-protein B-protein
: I-protein I-protein
ER I-protein I-protein
) O O
. O O

Continuous O O
deltaRaf B-protein O
expression O O
prevented O O
apoptosis O O
in O O
the O O
absence O O
of O O
exogenous B-protein B-protein
cytokines I-protein I-protein
and O O
altered O O
the O O
morphology O O
of O O
the O O
FD/deltaRaf B-cell_type B-cell_line
: I-cell_type I-cell_line
ER I-cell_type I-cell_line
cells I-cell_type I-cell_line
as O O
they O O
grew O O
in O O
large O O
aggregated O O
masses O O
( O O
> O O
100 O O
cells O O
) O O
whereas O O
the O O
parental B-cell_line B-cell_line
cytokine-dependent I-cell_line I-cell_line
FDC-P1 I-cell_line I-cell_line
cells I-cell_line I-cell_line
grew O O
in O O
smaller O O
grape-like O O
clusters O O
( O O
< O O
10 O O
cells O O
) O O
. O O

FD/deltaRaf-1 B-cell_line O
: I-cell_line O
ER I-cell_line B-cell_type
cells I-cell_line I-cell_type
growing O O
in O O
response O O
to O O
Raf O B-protein
activation O O
displayed O O
decreased O O
levels O O
of O O
the O O
Mac-2 B-protein B-protein
and I-protein O
Mac-3 I-protein B-protein
molecules I-protein I-protein
on O O
their O O
cell B-cell_type O
surface I-cell_type O
. O O

In O O
contrast O O
, O O
when O O
these O O
cells O O
were O O
cultured O O
in O O
IL-3 B-protein B-protein
, O O
higher O O
levels O O
of O O
these O O
adhesion B-protein B-protein
molecules I-protein I-protein
were O O
detected O O
. O O

Expression O O
of O O
activated O O
Raf B-protein B-protein
oncoproteins I-protein I-protein
also O O
abrogated O O
cytokine O B-protein
dependency O O
and O O
prevented O O
apoptosis O O
of O O
TF-1 B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

Moreover O O
, O O
the O O
differentiation O O
status O O
of O O
these O O
Raf-responsive B-cell_type B-cell_type
cells I-cell_type I-cell_type
was O O
more O O
immature O O
upon O O
Raf O B-protein
activation O O
as O O
culture O O
with O O
the O O
differentiation-inducing O O
agent O O
phorbol O O
12 O O
myristate O O
13-acetate O O
( O O
PMA O O
) O O
and O O
beta-estradiol O O
resulted O O
in O O
decreased O O
levels O O
of O O
the O O
CD11b B-protein B-protein
and I-protein I-protein
CD18 I-protein I-protein
integrin I-protein I-protein
molecules I-protein I-protein
on O O
the O O
cell B-cell_type O
surface I-cell_type O
. O O

In O O
contrast O O
when O O
the O O
Raf-responsive B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
induced O O
to O O
differentiate O O
with O O
PMA O O
and O O
GM-CSF B-protein B-protein
, O O
in O O
the O O
absence O O
of O O
deltaRaf B-protein O
: I-protein O
ER I-protein B-protein
activation O O
, O O
increased O O
levels O O
of O O
the O O
CD11b B-protein B-protein
and I-protein O
CD18 I-protein B-protein
molecules I-protein I-protein
were O O
detected O O
. O O

Retinoic O O
acid O O
( O O
RA O O
) O O
inhibited O O
3H-thymidine O O
incorporation O O
in O O
response O O
to O O
GM-CSF B-protein B-protein
. O O

Interestingly O O
, O O
Raf O B-protein
activation O O
counterbalanced O O
the O O
inhibition O O
of O O
DNA O O
synthesis O O
caused O O
by O O
RA O O
but O O
not O O
PMA O O
. O O

Thus O O
deregulated O O
Raf O B-protein
expression O O
can O O
alter O O
cytokine O B-protein
dependency O O
, O O
integrin O B-protein
expression O O
and O O
the O O
stage O O
of O O
differentiation O O
. O O

These O O
Raf-responsive B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
will O O
be O O
useful O O
in O O
elucidating O O
the O O
roles O O
of O O
the O O
MAP O B-protein
kinase O I-protein
cascade O O
on O O
hematopoietic B-cell_type O
cell I-cell_type O
differentiation O O
and O O
malignant O B-cell_type
transformation O I-cell_type

Cyclic O O
AMP O O
activates O O
p38 B-protein B-protein
mitogen-activated I-protein I-protein
protein I-protein I-protein
kinase I-protein I-protein
in O O
Th2 B-cell_type B-cell_line
cells I-cell_type I-cell_line
: O O
phosphorylation O O
of O O
GATA-3 B-protein B-protein
and O O
stimulation O O
of O O
Th2 B-cell_type B-DNA
cytokine O I-DNA
gene O I-DNA
expression O O
. O O

cAMP O O
is O O
an O O
important O O
second O O
messenger O O
with O O
immunomodulatory O O
properties O O
. O O

Elevation O O
of O O
intracellular O O
cAMP O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
induced O O
by O O
agents O O
such O O
as O O
IL-1alpha B-protein B-protein
or O O
PGs B-protein O
, O O
inhibits O O
T O O
cell O O
activation O O
. O O

In O O
effector O B-cell_type
T B-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
an O O
increase O O
in O O
the O O
level O O
of O O
intracellular O O
cAMP O O
inhibits O O
cytokine B-protein B-protein
production O O
in O O
Th1 B-cell_type B-cell_type
cells I-cell_type I-cell_type
but O O
stimulates O O
cytokine B-protein B-protein
production O O
in O O
Th2 B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Here O O
we O O
report O O
that O O
cAMP-induced O O
effects O O
in O O
Th2 B-cell_type B-cell_type
cells I-cell_type I-cell_type
occur O O
independently O O
of O O
the O O
protein B-protein B-protein
kinase I-protein I-protein
A I-protein I-protein
pathway O O
, O O
which O O
is O O
the O O
major O O
mediator O O
of O O
cAMP-induced O O
signaling O O
events O O
in O O
most O O
cell O O
types O O
. O O

Instead O O
, O O
cAMP O O
stimulates O O
activation O O
of O O
p38 B-protein B-protein
mitogen-activated I-protein I-protein
protein I-protein I-protein
kinase I-protein I-protein
in O O
Th2 B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

This O O
appears O O
to O O
be O O
a O O
Th2 B-cell_type O
-selective O O
event O O
because O O
cAMP O O
barely O O
increased O O
p38 B-protein B-protein
phosphorylation O O
in O O
Th1 B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

We O O
show O O
that O O
in O O
Th2 B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
cAMP O O
promotes O O
the O O
production O O
of O O
both O O
IL-5 B-protein B-protein
and O O
IL-13 B-protein B-protein
, O O
which O O
play O O
distinct O O
but O O
critical O O
roles O O
in O O
asthma O O
pathogenesis O O
. O O

Our O O
data O O
also O O
show O O
that O O
cAMP O O
causes O O
increased O O
phosphorylation O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
GATA-3 I-protein B-protein
, O O
which O O
we O O
have O O
shown O O
is O O
a O O
critical O O
regulator O O
of O O
Th2 B-cell_type B-DNA
cytokine O I-DNA
gene O I-DNA
expression O O
and O O
, O O
in O O
turn O O
, O O
of O O
airway O O
inflammation O O
in O O
mice O O
. O O

Thus O O
, O O
Th2 B-cell_type B-protein
-specific O O
GATA-3 B-protein B-protein
expression O O
and O O
p38 B-protein B-protein
mitogen-activated I-protein I-protein
protein I-protein I-protein
kinase I-protein I-protein
activation O O
together O O
provide O O
a O O
molecular O O
basis O O
for O O
the O O
differential O O
effects O O
of O O
cAMP O O
in O O
the O O
two O O
T B-cell_type B-cell_type
helper I-cell_type I-cell_type
cell I-cell_type I-cell_type
subsets I-cell_type I-cell_type
. O O

Characterization O O
of O O
IL-4 B-protein B-protein
and O O
IL-13 B-protein B-protein
signals O O
dependent O O
on O O
the O O
human B-protein O
IL-13 I-protein B-protein
receptor I-protein I-protein
alpha I-protein I-protein
chain I-protein I-protein
1 I-protein I-protein
: O O
redundancy O O
of O O
requirement O O
of O O
tyrosine O O
residue O O
for O O
STAT3 O B-protein
activation O O
. O O

IL-4 B-protein B-protein
and O O
IL-13 B-protein B-protein
are O O
pleiotropic B-protein B-protein
cytokines I-protein I-protein
whose O O
biological O O
activities O O
overlap O O
with O O
each O O
other O O
. O O

IL-13 B-protein B-protein
receptor I-protein I-protein
alpha I-protein I-protein
chain I-protein I-protein
1 I-protein I-protein
( O O
IL-13R B-protein B-protein
alpha I-protein I-protein
1 I-protein I-protein
) O O
is O O
necessary O O
for O O
binding O O
to O O
IL-13 B-protein B-protein
, O O
and O O
the O O
heterodimer O O
composed O O
of O O
IL-13R B-protein B-protein
alpha I-protein I-protein
1 I-protein I-protein
and O O
IL-4R B-protein B-protein
alpha I-protein I-protein
chain I-protein I-protein
transduces O O
IL-13 B-protein B-protein
and O O
IL-4 B-protein B-protein
signals O O
; O O
however O O
, O O
the O O
functional O O
mapping O O
of O O
the O O
intracellular B-protein B-protein
domain I-protein I-protein
of O O
IL-13R B-protein B-protein
alpha I-protein I-protein
1 I-protein I-protein
is O O
not O O
fully O O
understood O O
. O O

In O O
this O O
study O O
, O O
we O O
constructed O O
wild O O
and O O
mutated O O
types O O
of O O
human B-protein O
IL-13R I-protein B-protein
alpha I-protein I-protein
1 I-protein I-protein
, O O
and O O
analyzed O O
IL-4 B-protein B-protein
and O O
IL-13 B-protein B-protein
signals O O
using O O
an O O
IL-13R B-protein B-protein
alpha I-protein I-cell_line
1 I-protein I-cell_line
-transfected O I-cell_line
human B-cell_line I-cell_line
B I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

Expression O O
of O O
IL-13R B-protein B-protein
alpha I-protein I-protein
1 I-protein I-protein
evoked O O
STAT3 B-protein B-protein
activation O O
by O O
IL-4 B-protein B-protein
and O O
IL-13 B-protein B-protein
, O O
and O O
in O O
stimulated O B-cell_line
human B-cell_type I-cell_line
B I-cell_type I-cell_line
cells I-cell_type I-cell_line
, O O
on O O
which O O
IL-13R B-protein B-protein
alpha I-protein I-protein
1 I-protein I-protein
was O O
highly O O
expressed O O
, O O
IL-4 B-protein B-protein
and O O
IL-13 B-protein B-protein
induced O O
STAT3 B-protein B-protein
activation O O
. O O

Replacement O O
of O O
the O O
two O O
tyrosine O O
residues O O
completely O O
abolished O O
STAT3 B-protein B-protein
activation O O
, O O
although O O
replacing O O
either O O
tyrosine O O
residue O O
alone O O
retained O O
it O O
. O O

Furthermore O O
, O O
we O O
found O O
that O O
the O O
Box1 B-protein B-DNA
region I-protein I-DNA
and O O
the O O
C-terminal B-protein B-protein
tail I-protein I-protein
of O O
IL-13R B-protein B-protein
alpha I-protein I-protein
1 I-protein I-protein
were O O
critical O O
for O O
binding O O
to O O
Tyk2 B-protein B-protein
, O O
and O O
activation O O
of O O
Jak1 B-protein B-protein
, O O
Tyk2 B-protein B-protein
, O O
the O O
insulin B-protein B-protein
receptor I-protein I-protein
substrate-1 I-protein I-protein
and O O
STAT6 B-protein B-protein
respectively O O
. O O

These O O
results O O
suggest O O
that O O
STAT3 B-protein B-protein
activation O O
is O O
involved O O
with O O
IL-4 B-protein B-protein
and O O
IL-13 B-protein B-protein
signals O O
in O O
human B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
along O O
with O O
the O O
activation O O
of O O
STAT6 B-protein B-protein
, O O
and O O
that O O
there O O
is O O
a O O
unique O O
sequence O O
in O O
IL-13R B-protein B-protein
alpha I-protein I-protein
1 I-protein I-protein
to O O
activate O O
STAT3 B-protein B-protein
. O O

Functional O O
uncoupling O O
of O O
the O O
Janus O B-protein
kinase O I-protein
3-Stat5 O B-protein
pathway O O
in O O
malignant O O
growth O O
of O O
human O B-cell_line
T O I-cell_line
cell O I-cell_line
leukemia O I-cell_line
virus O I-cell_line
type O I-cell_line
1-transformed O I-cell_line
human B-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

Human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
( O O
HTLV-1 O O
) O O
transforms O O
cytokine B-protein B-protein
-dependent O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
and O O
causes O O
adult O O
T O O
cell O O
leukemia O O
. O O

Janus B-protein B-protein
tyrosine I-protein I-protein
kinase I-protein I-protein
( I-protein I-protein
Jak I-protein I-protein
) I-protein I-protein
3 I-protein I-protein
and O O
transcription B-protein B-protein
factors I-protein I-protein
Stat5a B-protein B-protein
and O O
Stat5b B-protein B-protein
are O O
essential O O
for O O
the O O
proliferation O O
of O O
normal B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
are O O
constitutively O O
hyperactivated O O
in O O
both O O
HTLV-1-transformed B-cell_line B-cell_line
human I-cell_line I-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
and O O
lymphocytes B-cell_type B-cell_type
isolated O O
from O O
HTLV-1-infected O O
patients O O
; O O
therefore O O
, O O
a O O
critical O O
role O O
for O O
the O O
Jak3-Stat5 O B-protein
pathway O O
in O O
the O O
progression O O
of O O
this O O
disease O O
has O O
been O O
postulated O O
. O O

We O O
recently O O
reported O O
that O O
tyrphostin O O
AG-490 O O
selectively O O
blocked O O
IL-2 O B-protein
activation O O
of O O
Jak3/Stat5 B-protein B-protein
and O O
growth O O
of O O
murine B-cell_line B-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

Here O O
we O O
demonstrate O O
that O O
disruption O O
of O O
Jak3/Stat5a/b O B-protein
signaling O O
with O O
AG-490 O O
( O O
50 O O
& O O
mgr O O
; O O
M O O
) O O
blocked O O
the O O
proliferation O O
of O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
, O O
but O O
paradoxically O O
failed O O
to O O
inhibit O O
the O O
proliferation O O
of O O
HTLV-1-transformed B-cell_line B-cell_line
human I-cell_line I-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
HuT-102 B-cell_line B-cell_line
and O O
MT-2 B-cell_line B-cell_line
. O O

Structural O O
homologues O O
of O O
AG-490 O O
also O O
inhibited O O
the O O
proliferation O O
of O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
but O O
not O O
HTLV-1-infected B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Disruption O O
of O O
constitutive O O
Jak3/Stat5 O B-protein
activation O O
by O O
AG-490 O O
was O O
demonstrated O O
by O O
inhibition O O
of O O
1 O O
) O O
tyrosine O O
phosphorylation O O
of O O
Jak3 B-protein B-protein
, O O
Stat5a B-protein B-protein
( O O
Tyr O O
( O O
694 O O
) O O
) O O
, O O
and O O
Stat5b B-protein B-protein
( O O
Tyr O O
( O O
699 O O
) O O
) O O
; O O
2 O O
) O O
serine O O
phosphorylation O O
of O O
Stat5a B-protein B-protein
( O O
Ser O O
( O O
726 O O
) O O
) O O
as O O
determined O O
by O O
a O O
novel O O
phosphospecific B-protein B-protein
Ab I-protein I-protein
; O I-protein
and O I-protein
3 O I-protein
) O I-protein
Stat5a/b O B-protein
DNA O O
binding O O
to O O
the O O
Stat5-responsive B-DNA B-DNA
beta-casein I-DNA I-DNA
promoter I-DNA I-DNA
. O O

In O O
contrast O O
, O O
AG-490 O O
had O O
no O O
effect O O
on O O
DNA O O
binding O O
by O O
p50/p65 B-protein B-protein
components I-protein O
of O O
NF-kappaB B-protein B-protein
, O O
a O O
transcription B-protein B-protein
factor I-protein I-protein
activated O O
by O O
the O O
HTLV-1-encoded B-protein B-protein
phosphoprotein I-protein I-protein
, I-protein O
Tax I-protein B-protein
. O O

Collectively O O
, O O
these O O
data O O
suggest O O
that O O
the O O
Jak3-Stat5 O B-protein
pathway O O
in O O
HTLV-1-transformed B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
has O O
become O O
functionally O O
redundant O O
for O O
proliferation O O
. O O

Reversal O O
of O O
this O O
functional O O
uncoupling O O
may O O
be O O
required O O
before O O
Jak3/Stat5 O O
inhibitors O O
will O O
be O O
useful O O
in O O
the O O
treatment O O
of O O
this O O
malignancy O O
. O O

The O O
Epstein-Barr B-DNA O
virus I-DNA O
promoter I-DNA O
initiating O O
B-cell O O
transformation O O
is O O
activated O O
by O O
RFX B-protein B-protein
proteins I-protein I-protein
and O O
the O O
B-cell-specific B-protein B-protein
activator I-protein I-protein
protein I-protein I-protein
BSAP/Pax5 I-protein B-protein
. O O

Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
-induced O O
B-cell B-cell_type O
growth O O
transformation O O
, O O
a O O
central O O
feature O O
of O O
the O O
virus O O
' O O
strategy O O
for O O
colonizing O O
the O O
human O O
B-cell O O
system O O
, O O
requires O O
full O O
virus O O
latent O O
gene O O
expression O O
and O O
is O O
initiated O O
by O O
transcription O O
from O O
the O O
viral B-DNA B-DNA
promoter I-DNA I-DNA
Wp I-DNA B-DNA
. O O

Interestingly O O
, O O
when O O
EBV O O
accesses O O
other O O
cell O O
types O O
, O O
this O O
growth-transforming O O
program O O
is O O
not O O
activated O O
. O O

The O O
present O O
work O O
focuses O O
on O O
a O O
region O O
of O O
Wp B-DNA B-DNA
which O O
in O O
reporter O O
assays O O
confers O O
B-cell B-cell_type B-protein
-specific O O
activity O O
. O O

Bandshift O O
studies O O
indicate O O
that O O
this O O
region O O
contains O O
three O O
factor O B-DNA
binding O I-DNA
sites O I-DNA
, O O
termed O B-DNA
sites B-DNA I-DNA
B I-DNA I-DNA
, I-DNA O
C I-DNA B-DNA
, I-DNA O
and I-DNA O
D I-DNA O
, O O
in O O
addition O O
to O O
a O O
previously O O
characterized O O
CREB B-DNA B-DNA
site I-DNA I-DNA
. O O

Here O O
we O O
show O O
that O O
site B-DNA B-protein
C I-DNA I-protein
binds O O
members O O
of O O
the O O
ubiquitously O O
expressed O O
RFX B-protein B-protein
family I-protein I-protein
of I-protein O
proteins I-protein O
, O O
notably O O
RFX1 B-protein B-protein
, O O
RFX3 B-protein B-protein
, O O
and O O
the O O
associated O O
factor O B-protein
MIBP1 B-protein B-protein
, O O
whereas O O
sites B-DNA B-DNA
B I-DNA I-DNA
and I-DNA I-DNA
D I-DNA I-DNA
both O O
bind O O
the O O
B-cell-specific B-protein B-protein
activator I-protein I-protein
protein I-protein I-protein
BSAP/Pax5 I-protein B-protein
. O O

In O O
reporter O O
assays O O
with O O
mutant B-DNA B-DNA
Wp I-DNA I-DNA
constructs I-DNA I-DNA
, O O
the O O
loss O O
of O O
factor O O
binding O O
to O O
any O O
one O O
of O O
these O O
sites O O
severely O O
impaired O O
promoter O O
activity O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
while O O
the O O
wild-type B-DNA B-DNA
promoter I-DNA I-DNA
could O O
be O O
activated O O
in O O
non-B B-cell_type B-cell_type
cells I-cell_type I-cell_type
by O O
ectopic O O
BSAP O B-protein
expression O O
. O O

We O O
suggest O O
that O O
Wp B-DNA B-DNA
regulation O O
by O O
BSAP B-protein B-protein
helps O O
to O O
ensure O O
the O O
B-cell B-cell_type O
specificity O O
of O O
EBV O O
's O O
growth-transforming O O
function O O
. O O

Activation O O
of O O
the O O
Lck B-protein B-protein
tyrosine I-protein I-protein
protein I-protein I-protein
kinase I-protein I-protein
by O O
the O O
Herpesvirus O B-protein
saimiri O I-protein
tip B-protein I-protein
protein I-protein I-protein
involves O O
two O O
binding O O
interactions O O
. O O

The O O
Tip B-protein B-protein
protein I-protein I-protein
of O O
Herpesvirus O O
saimiri O O
strain O O
484C O O
binds O O
to O O
and O O
activates O O
the O O
Lck B-protein B-protein
tyrosine I-protein I-protein
protein I-protein I-protein
kinase I-protein I-protein
. O O

Two O O
sequences O O
in O O
the O O
Tip B-protein B-protein
protein I-protein I-protein
were O O
previously O O
shown O O
to O O
be O O
involved O O
in O O
binding O O
to O O
Lck B-protein B-protein
. O O

A O O
proline-rich B-protein B-protein
region I-protein I-protein
, O O
residues O B-protein
132-141 O I-protein
, O O
binds O O
to O O
the O O
SH3 B-protein B-protein
domain I-protein I-protein
of O O
the O O
Lck B-protein B-protein
protein I-protein I-protein
. O O

We O O
show O O
here O O
that O O
the O O
other O O
Lck-binding B-protein B-protein
domain I-protein I-protein
, O O
residues O B-protein
104-113 O I-protein
, O O
binds O O
to O O
the O O
carboxyl-terminal B-protein B-protein
half I-protein I-protein
of O O
Lck B-protein B-protein
and O O
that O O
this O O
binding O O
does O O
not O O
require O O
the O O
Lck B-protein B-protein
SH3 I-protein I-protein
domain I-protein I-protein
. O O

Mutated O O
Tip B-protein O
containing O O
only O O
one O O
functional O O
Lck-binding B-protein B-protein
domain I-protein I-protein
can O O
bind O O
stably O O
to O O
Lck B-protein B-protein
, O O
although O O
not O O
as O O
strongly O O
as O O
wild-type B-protein O
Tip I-protein O
. O O

Interaction O O
of O O
Tip B-protein B-protein
with O O
Lck B-protein B-protein
through O O
either O O
Lck-binding B-protein B-protein
domain I-protein I-protein
increases O O
the O O
activity O O
of O O
Lck B-protein B-protein
in O O
vivo O O
. O O

Simultaneous O O
binding O O
of O O
both O O
domains O O
is O O
required O O
for O O
maximal O O
activation O O
of O O
Lck B-protein B-protein
. O O

The O O
transient O O
expression O O
of O O
Tip B-protein B-protein
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
was O O
found O O
to O O
stimulate O O
both O O
Stat3 B-protein B-protein
-dependent O O
and O O
NF-AT B-protein B-protein
-dependent O O
transcription O O
. O O

Mutant O O
forms O O
of O O
Tip B-protein B-protein
lacking O O
one O O
or O O
the O O
other O O
of O O
the O O
two O O
Lck-binding B-protein B-protein
domains I-protein I-protein
retained O O
the O O
ability O O
to O O
stimulate O O
Stat3 B-protein B-protein
-dependent O O
transcription O O
. O O

Tip B-protein B-protein
lacking O O
the O O
proline-rich O B-protein
Lck-binding B-protein I-protein
domain I-protein I-protein
exhibited O O
almost O O
wild-type O O
activity O O
in O O
this O O
assay O O
. O O

In O O
contrast O O
, O O
ablation O O
of O O
either O O
Lck-binding B-protein B-protein
domain I-protein I-protein
abolished O O
the O O
ability O O
of O O
Tip B-protein B-protein
to O O
stimulate O O
NF-AT B-protein B-protein
-dependent O O
transcription O O
. O O

Full O O
biological O O
activity O O
of O O
Tip B-protein B-protein
, O O
therefore O O
, O O
appears O O
to O O
require O O
both O O
Lck-binding B-protein B-protein
domains I-protein I-protein
. O O

Accumulation O O
of O O
RXR B-protein B-protein
alpha I-protein I-protein
during O O
activation O O
of O O
cycling O B-cell_type
human B-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
: O O
modulation O O
of O O
RXRE O B-DNA
transactivation O O
function O O
by O O
mitogen-activated O B-protein
protein O I-protein
kinase O I-protein
pathways O O
. O O

We O O
have O O
previously O O
reported O O
that O O
the O O
activation O O
of O O
resting O B-cell_type
human B-cell_type I-cell_type
immature I-cell_type I-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
T I-cell_type I-cell_type
( I-cell_type I-cell_type
PBT I-cell_type I-cell_type
) I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
is O O
associated O O
with O O
the O O
loss O O
of O O
retinoid B-protein B-protein
X I-protein I-protein
receptor I-protein I-protein
alpha I-protein I-protein
( O O
RXRalpha B-protein B-protein
) O O
expression O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
have O O
demonstrated O O
that O O
, O O
unlike O O
resting O B-cell_type
cells O I-cell_type
, O O
activation O O
of O O
cycling B-cell_type B-cell_type
human I-cell_type I-cell_type
mature I-cell_type I-cell_type
PBT I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
, O O
and O O
T B-cell_line B-cell_line
lymphocyte I-cell_line I-cell_line
leukemia I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
is O O
accompanied O O
by O O
the O O
accumulation O O
of O O
RXRalpha B-protein B-RNA
mRNA O I-RNA
and O O
protein O O
. O O

Interestingly O O
, O O
cyclosporin O O
A O O
further O O
augmented O O
RXRalpha B-protein B-protein
expression O O
, O O
indicating O O
the O O
involvement O O
of O O
calcineurin O B-protein
pathways O O
in O O
the O O
process O O
. O O

9-cis O O
retinoic O O
acid O O
inhibited O O
the O O
accumulation O O
, O O
suggesting O O
that O O
retinoids O O
can O O
regulate O O
the O O
synthesis O O
of O O
their O O
own O O
receptors O O
during O O
T O O
cell O O
activation O O
. O O

Transfection O O
analysis O O
in O O
Jurkat B-cell_line B-cell_line
cells I-cell_line I-cell_line
, O O
using O O
RXRE-dependent O O
reporter O O
assays O O
, O O
showed O O
that O O
RXRalpha B-protein B-protein
accumulated O O
during O O
T O O
cell O O
activation O O
was O O
transcriptionally O O
inactive O O
. O O

To O O
investigate O O
the O O
mechanism O O
of O O
such O O
inhibition O O
, O O
the O O
role O O
of O O
two O O
mitogen-activated O B-protein
protein O I-protein
kinase O I-protein
pathways O O
, O O
c-Jun B-protein B-protein
N-terminal I-protein I-protein
kinase I-protein I-protein
( O O
JNK B-protein B-protein
) O O
and O O
extracellular B-protein B-protein
signal-regulated I-protein I-protein
kinase I-protein I-protein
( O O
ERK B-protein B-protein
) O O
, O O
in O O
modulating O O
RXRE-dependent O O
transcription O O
, O O
was O O
explored O O
. O O

The O O
expression O O
of O O
constitutively O O
active O O
MAP/ERK B-protein B-protein
kinase I-protein I-protein
kinase I-protein I-protein
1 I-protein I-protein
( O O
MEKK1 B-protein B-protein
) O O
inhibited O O
RXRE-dependent O O
transcription O O
, O O
whereas O O
dominant B-protein O
negative I-protein O
MEKK1 I-protein B-protein
increased O O
the O O
transcription O O
, O O
indicating O O
the O O
involvement O O
of O O
JNK B-protein B-protein
signaling O O
pathways O O
in O O
the O O
process O O
. O O

In O O
contrast O O
, O O
expression O O
of O O
constitutively B-protein O
active I-protein O
MEK1 I-protein B-protein
, O O
which O O
activates O O
ERK B-protein B-protein
pathway O O
, O O
enhanced O O
RXRE-dependent O O
activation O O
. O O

When O O
both O O
were O O
activated O O
simultaneously O O
, O O
JNK B-protein B-protein
pathway O O
was O O
dominant O O
over O O
ERK B-protein B-protein
pathway O O
and O O
resulted O O
in O O
inhibition O O
of O O
RXRE-mediated O O
transcription O O
. O O

These O O
data O O
demonstrate O O
a O O
dual O O
regulatory O O
control O O
of O O
RXRalpha B-protein B-protein
expression O O
during O O
the O O
activation O O
of O O
resting B-cell_type B-cell_type
and I-cell_type I-cell_type
cycling I-cell_type I-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
indicate O O
a O O
dynamic O O
balance O O
between O O
JNK O B-protein
and O O
ERK O B-protein
pathways O O
in O O
modulating O O
RXRE-mediated O O
transactivation O O
. O O

The O O
proteasome B-protein B-protein
regulates O O
receptor-mediated O O
endocytosis O O
of O O
interleukin-2 B-protein B-protein
. O O

Recent O O
studies O O
have O O
increasingly O O
implicated O O
the O O
proteasome B-protein B-protein
in O O
the O O
regulation O O
of O O
cell B-protein B-protein
surface I-protein I-protein
receptors I-protein I-protein
. O O

In O O
the O O
present O O
study O O
, O O
we O O
investigated O O
the O O
role O O
of O O
the O O
proteasome B-protein B-protein
for O O
ligand-dependent O O
endocytosis O O
and O O
degradation O O
of O O
the O O
interleukin-2 B-protein B-protein
( I-protein I-protein
IL-2 I-protein I-protein
) I-protein I-protein
-interleukin-2 I-protein I-protein
receptor I-protein I-protein
( I-protein I-protein
IL-2R I-protein I-protein
) I-protein I-protein
complex I-protein I-protein
. O O

Proteasome O O
inhibitors O O
impaired O O
internalization O O
of O O
IL-2.IL-2R B-protein B-protein
and O O
prevented O O
the O O
lysosomal O O
degradation O O
of O O
this O O
cytokine B-protein B-protein
. O O

Based O O
on O O
time-course O O
studies O O
, O O
proteasome B-protein B-protein
activity O O
is O O
primarily O O
required O O
after O O
initial O O
endocytosis O O
of O O
the O O
IL-2.IL-2R B-protein B-protein
. O O

Proteasome O O
function O O
was O O
also O O
necessary O O
for O O
the O O
lysosomal O O
degradation O O
of O O
IL-2 B-protein B-protein
internalized O O
by O O
IL-2R B-protein B-protein
that O O
were O O
comprised O O
of O O
cytoplasmic B-protein B-protein
tailless I-protein I-protein
beta- B-protein I-protein
or I-protein I-protein
gamma I-protein I-protein
c-subunits I-protein I-protein
, O O
suggesting O O
that O O
the O O
target O B-protein
protein O I-protein
for O O
the O O
proteasome B-protein B-protein
is O O
independent O O
of O O
either O O
the O O
cytoplasmic B-protein B-protein
tail I-protein I-protein
of O O
the O O
IL-2R B-protein B-protein
beta- B-protein I-protein
or I-protein I-protein
gamma I-protein I-protein
c-subunits I-protein I-protein
and O O
their O O
associated O O
signaling O O
components O O
. O O

Therefore O O
, O O
a O O
functional O O
proteasome B-protein B-protein
is O O
required O O
for O O
optimal O O
endocytosis O O
of O O
the O O
IL-2R/ligand B-protein B-protein
complex I-protein I-protein
and O O
is O O
essential O O
for O O
the O O
subsequent O O
lysosomal O O
degradation O O
of O O
IL-2 B-protein B-protein
, O O
possibly O O
by O O
regulating O O
trafficking O O
to O O
the O O
lysosome O O
. O O

Functional O O
characterization O O
of O O
the O O
two O O
alternative O B-DNA
promoters O I-DNA
of O O
human B-DNA B-DNA
p45 I-DNA I-DNA
NF-E2 I-DNA I-DNA
gene I-DNA I-DNA
. O O

OBJECTIVE O O
: O O
The O O
transcription B-protein B-protein
factor I-protein I-protein
NF-E2 I-protein B-protein
, O O
a O O
heterodimeric B-protein B-protein
protein I-protein I-protein
complex I-protein I-protein
composed O O
of O O
p45 B-protein B-protein
and O I-protein
small O I-protein
Maf B-protein I-protein
family I-protein I-protein
proteins I-protein I-protein
, O O
is O O
considered O O
crucial O O
for O O
the O O
proper O O
differentiation O O
of O O
erythrocytes B-cell_type B-cell_type
and O O
megakaryocytes B-cell_type B-cell_type
in O O
vivo O O
. O O

We O O
report O O
the O O
results O O
of O O
studies O O
aimed O O
at O O
understanding O O
the O O
regulatory O O
mechanisms O O
controlling O O
p45 B-DNA B-protein
gene I-DNA O
expression O O
in O O
erythroid B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Human B-RNA B-RNA
p45 I-RNA I-RNA
mRNAs I-RNA I-RNA
have O O
two O O
alternative O O
isoforms O O
, O O
aNF-E2 B-RNA B-protein
and O O
fNF-E2 B-RNA B-protein
, O O
and O O
these O O
isoforms O O
are O O
transcribed O O
from O O
the O O
alternative B-DNA B-DNA
promoters I-DNA I-DNA
. O O

We O O
investigated O O
lineage-specific O O
expression O O
of O O
both O O
isomers O O
in O O
human O B-cell_type
erythroid B-cell_type I-cell_type
and I-cell_type I-cell_type
megakaryocytic I-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
reverse O B-protein
transcriptase O I-protein
polymerase O I-protein
chain O I-protein
reaction O O
or O O
Northern O O
blot O O
analysis O O
. O O

For O O
functional O O
characterization O O
of O O
both O O
promoters O B-DNA
, O O
plasmids O B-DNA
in O O
which O O
reporter B-DNA B-DNA
genes I-DNA I-DNA
were O O
placed O O
under O O
the O O
control O O
of O O
a O O
series O O
of O O
truncated O O
or O O
mutated O B-DNA
promoter B-DNA I-DNA
fragments I-DNA I-DNA
were O O
transfected O O
to O O
human B-cell_line B-cell_line
hematopoietic I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

RESULTS O O
: O O
When O O
CD34 B-cell_type B-cell_type
( I-cell_type I-cell_type
+ I-cell_type I-cell_type
) I-cell_type I-cell_type
cells I-cell_type I-cell_type
isolated O O
from O O
human O O
cord O O
blood O O
were O O
induced O O
to O O
unilineage O O
erythroid O O
or O O
megakaryocytic O O
differentiation O O
in O O
liquid O O
suspension O O
culture O O
, O O
both O O
transcripts O O
, O O
although O O
barely O O
detected O O
at O O
day O O
0 O O
, O O
were O O
induced O O
in O O
both O O
erythroid O B-cell_line
and O I-cell_line
megakaryocytic O I-cell_line
cultures O I-cell_line
. O O

fNF-E2 B-RNA B-RNA
mRNA I-RNA I-RNA
was O O
found O O
to O O
be O O
more O O
abundant O O
in O O
erythroid B-cell_type B-cell_type
cells I-cell_type I-cell_type
than O O
megakaryocytic B-cell_type B-cell_type
cells I-cell_type I-cell_type
at O O
day O O
7 O O
of O O
culture O O
. O O

Although O O
both O O
isomers O O
were O O
expressed O O
in O O
human B-cell_line B-cell_line
erythroid-megakaryocytic I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
megakaryocytic O O
maturation O O
with O O
loss O O
of O O
erythroid O O
phenotype O O
induced O O
by O O
phorbol O O
12-myristate O O
13-acetate O O
( O O
PMA O O
) O O
resulted O O
in O O
exclusive O O
downregulation O O
of O O
fNF-E2 B-RNA B-protein
, O O
suggesting O O
that O O
fNF-E2 B-DNA B-DNA
promoter I-DNA I-DNA
is O O
more O O
erythroid O O
specific O O
. O O

Functional O O
analysis O O
of O O
fNF-E2 B-DNA B-DNA
promoter I-DNA I-DNA
showed O O
that O O
the O O
promoter O B-DNA
is O O
active O O
only O O
in O O
erythroid-megakaryocytic B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
that O O
the O O
double B-DNA B-DNA
GATA I-DNA I-DNA
sit I-DNA I-DNA
e O I-DNA
in O O
the O O
proximal O B-DNA
region O I-DNA
is O O
necessary O O
for O O
its O O
efficient O O
activity O O
. O O

CONCLUSION O O
: O O
These O O
results O O
suggest O O
that O O
GATA B-protein B-protein
proteins I-protein I-protein
, O O
which O O
govern O O
the O O
differentiation O O
of O O
erythroid B-cell_type B-cell_type
lineage I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
are O O
required O O
for O O
full O O
promoter O O
activity O O
of O O
the O O
p45 B-DNA B-DNA
gene I-DNA I-DNA
. O O

Transcriptional O O
activation O O
of O O
heme B-DNA B-protein
oxygenase-1 I-DNA I-protein
and O O
its O O
functional O O
significance O O
in O O
acetaminophen-induced O O
hepatitis O O
and O O
hepatocellular O O
injury O O
in O O
the O O
rat O O
. O O

BACKGROUND/AIM O O
: O O
Glutathione O O
depletion O O
contributes O O
to O O
acetaminophen O O
hepatotoxicity O O
and O O
is O O
known O O
to O O
induce O O
the O O
oxidative O O
stress O B-protein
reactant O I-protein
heme B-protein I-protein
oxygenase-1 I-protein I-protein
. O O

The O O
metabolites O O
of O O
the O O
heme O B-protein
oxygenase O I-protein
pathway O O
, O O
biliverdin O O
, O O
carbon O O
monoxide O O
, O O
and O O
iron O O
may O O
modulate O O
acetaminophen O O
toxicity O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
assess O O
cell-type O O
specific O O
expression O O
of O O
heme B-DNA B-protein
oxygenase-1 I-DNA I-protein
and O O
its O O
impact O O
on O O
liver O O
injury O O
and O O
microcirculatory O O
disturbances O O
in O O
a O O
model O O
of O O
acetaminophen-induced O O
hepatitis O O
. O O

METHODS O O
: O O
Gene O O
expression O O
of O O
heme B-DNA B-protein
oxygenase-1 I-DNA I-protein
was O O
studied O O
by O O
Northern- O O
and O O
Western O O
analysis O O
as O O
well O O
as O O
immunohistochemistry O O
. O O

The O O
time O O
course O O
of O O
heme B-protein B-protein
oxygenase-1 I-protein I-protein
and I-protein I-protein
-2 I-protein I-protein
, O I-protein
cytokine-induced B-protein I-protein
neutrophil I-protein I-protein
chemoattractant-1 I-protein I-protein
, O O
and O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
was O O
studied O O
by O O
Northern O O
analysis O O
. O O

DNA-binding O O
activity O O
of O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
was O O
determined O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

Sinusoidal O O
perfusion O O
and O O
leukocyte-endothelial O O
interactions O O
were O O
assessed O O
by O O
intravital O O
microscopy O O
. O O

RESULTS O O
: O O
Acetaminophen O O
caused O O
a O O
moderate O O
sinusoidal O O
perfusion O O
failure O O
( O O
-15 O O
% O O
) O O
and O O
infiltration O O
of O O
neutrophils B-cell_type B-cell_type
along O O
with O O
activation O O
of O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
and O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
and O O
cytokine-induced B-protein B-RNA
neutrophil I-protein I-RNA
chemoattractant-1 I-protein I-RNA
mRNAs O I-RNA
. O O

Induction O O
of O O
heme B-protein B-protein
oxygenase-1 I-protein B-RNA
mRNA O I-RNA
and O O
protein O O
( O O
approximately O O
30-fold O O
) O O
in O O
hepatocytes B-cell_type B-cell_type
and O O
non-parenchymal B-cell_type B-cell_type
cells I-cell_type I-cell_type
paralleled O O
the O O
inflammatory O O
response O O
. O O

Blockade O O
of O O
heme O B-protein
oxygenase O I-protein
activity O O
with O O
tin-protoporphyrin-IX O O
abrogated O O
acetaminophen-induced O O
hepatic B-cell_type O
neutrophil I-cell_type O
accumulation O O
and O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
activation O O
, O O
but O O
failed O O
to O O
affect O O
sinusoidal O O
perfusion O O
and O O
liver O O
injury O O
. O O

CONCLUSIONS O O
: O O
The O O
inflammatory O O
response O O
associated O O
with O O
acetaminophen O O
hepatotoxicity O O
is O O
modulated O O
by O O
the O O
parallel O O
induction O O
of O O
the O O
heme B-DNA B-DNA
oxygenase-1 I-DNA I-DNA
gene I-DNA I-DNA
. O O

However O O
, O O
heme B-DNA B-protein
oxygenase-1 I-DNA I-protein
has O O
no O O
permissive O O
effect O O
on O O
sinusoidal O O
perfusion O O
and O O
does O O
not O O
affect O O
liver O O
injury O O
in O O
this O O
model O O
. O O

These O O
data O O
argue O O
against O O
a O O
central O O
role O O
of O O
nuclear B-protein B-protein
factor-kappaB I-protein I-protein
activation O O
and O O
neutrophil O O
infiltration O O
as O O
perpetuating O O
factors O O
of O O
liver O O
injury O O
in O O
acetaminophen O O
toxicity O O
. O O

Tumor B-protein B-protein
necrosis I-protein I-protein
factor-alpha I-protein I-protein
-induced O O
proliferation O O
requires O O
synthesis O O
of O O
granulocyte-macrophage B-protein B-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
. O O

OBJECTIVE O O
: O O
Tumor B-protein B-protein
necrosis I-protein I-protein
factor- I-protein I-protein
alpha I-protein I-protein
( O O
TNF-alpha B-protein B-protein
) O O
induces O O
a O O
variety O O
of O O
cellular O O
responses O O
, O O
some O O
of O O
them O O
being O O
at O O
least O O
seemingly O O
contradictory O O
. O O

Thus O O
, O O
we O O
set O O
out O O
to O O
find O O
differences O O
in O O
the O O
modes O O
of O O
proliferative O O
and O O
apoptotic O O
responses O O
to O O
TNF- B-protein B-protein
alpha I-protein I-protein
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
We O O
screened O O
a O O
panel O O
of O O
acute B-cell_line B-cell_line
myeloid I-cell_line I-cell_line
leukemia-derived I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
for O O
TNF- B-protein O
alpha I-protein O
-responsiveness O O
. O O

In O O
two O O
lines O O
( O O
OCI-AML-1 B-cell_line B-cell_line
, O O
OCI-AML-11 B-cell_line B-cell_line
) O O
, O O
TNF- B-protein B-protein
alpha I-protein I-protein
acted O O
as O O
an O O
apoptotic O O
agent O O
; O O
in O O
others O O
( O O
HU-3 B-cell_line O
, O O
M-07e B-cell_line O
, O O
TF-1 B-cell_line B-cell_line
) O O
, O O
it O O
had O O
the O O
opposite O O
effect O O
, O O
preventing O O
apoptosis O O
and O O
inducing O O
proliferation O O
. O O

Direct O O
and O O
indirect O O
signaling O O
mechanisms O O
, O O
including O O
NF-kappaB B-protein B-protein
activation O O
and O O
cytokine O B-protein
synthesis O O
, O O
were O O
analyzed O O
. O O

RESULTS O O
: O O
All O O
cell O O
lines O O
tested O O
expressed O O
TNF- B-protein B-protein
alpha I-protein I-protein
receptors I-protein I-protein
I I-protein I-protein
and I-protein I-protein
II I-protein I-protein
and O O
responded O O
to O O
TNF- B-protein B-protein
alpha I-protein I-protein
by O O
upregulation O O
of O O
intercellular B-protein B-protein
adhesion I-protein I-protein
molecule-1 I-protein I-protein
. O O

In O O
contrast O O
to O O
granulocyte-macrophage B-protein B-protein
colony-stimulating I-protein I-protein
factor I-protein I-protein
( O O
GM-CSF B-protein B-protein
) O O
, O O
TNF- B-protein B-protein
alpha I-protein I-protein
did O O
not O O
activate O O
the O O
MAP B-protein B-protein
kinase I-protein I-protein
and O O
p70S6 O B-protein
kinase O I-protein
pathways O O
. O O

Nevertheless O O
, O O
inhibitors O O
of O O
these O O
pathways O O
clearly O O
reduced O O
the O O
TNF-alpha B-protein B-protein
-induced O O
cell O O
growth O O
, O O
indicating O O
that O O
TNF- B-cell_type B-cell_type
alpha-proliferative I-cell_type I-cell_type
cells I-cell_type I-cell_type
produced O O
a O O
growth O B-protein
factor O I-protein
that O O
induced O O
proliferation O O
upon O O
stimulation O O
of O O
the O O
above O O
pathways O O
. O O

Anti-GM-CSF B-protein B-protein
antibodies I-protein I-protein
inhibited O O
the O O
TNF-alpha B-protein B-protein
-induced O O
growth O O
, O O
suggesting O O
the O O
presence O O
of O O
an O O
autocrine O O
loop O O
for O O
cell O O
proliferation O O
mediated O O
by O O
GM-CSF B-protein B-protein
. O O

Supporting O O
this O O
notion O O
, O O
TNF-alpha B-protein B-protein
-induced O O
upregulation O O
of O O
GM-CSF B-RNA B-RNA
mRNA I-RNA I-RNA
levels O O
and O O
protein O O
secretion O O
in O O
the O O
TNF-alpha B-protein B-protein
-proliferative O O
, O O
but O O
not O O
in O O
the O O
TNF-alpha-apoptotic B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
. O O

CONCLUSION O O
: O O
These O O
data O O
identify O O
GM-CSF B-protein B-protein
synthesis O O
as O O
an O O
early O O
and O O
essential O O
step O O
in O O
TNF- O O
alpha-induced O O
proliferation O O
. O O

We O O
show O O
for O O
the O O
first O O
time O O
that O O
TNF-alpha-treated B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
producing O O
no O O
or O O
only O O
minimal O O
amounts O O
of O O
GM-CSF B-protein B-protein
demonstrate O O
an O O
apoptotic O O
phenotype O O
, O O
while O O
cell O B-cell_line
lines O I-cell_line
with O O
high O O
GM-CSF B-protein B-protein
expression O O
rates O O
can O O
escape O O
from O O
growth O O
arrest O O
or O O
even O O
apoptosis O O
. O O

In O O
this O O
context O O
, O O
we O O
discuss O O
arguments O O
pointing O O
at O O
NF-kappaB B-protein B-protein
as O O
regulator O O
of O O
GM-CSF B-protein B-protein
synthesis O O
and O O
thus O O
indirectly O O
as O O
regulator O O
for O O
the O O
escape O O
of O O
TNF-alpha B-protein B-protein
-induced O O
apoptosis O O

Glucocorticoid B-protein B-protein
receptor I-protein I-protein
content O O
of O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
: O O
evidence O O
for O O
heterogeneity O O
. O O

Glucocorticoid B-protein B-protein
receptors I-protein I-protein
were O O
measured O O
in O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
that O O
were O O
isolated O O
from O O
peripheral O O
blood O O
by O O
either O O
nylon O O
wool O O
filtration O O
or O O
E-rosette O O
sedimentation O O
. O O

T B-cell_type B-cell_type
cells I-cell_type I-cell_type
isolated O O
by O O
nylon O O
wool O O
filtration O O
specifically O O
bind O O
6.7 O O
+/- O O
0.2 O O
fmol O O
of O O
dexamethasone O B-cell_type
per O I-cell_type
million O I-cell_type
cells O I-cell_type
( O O
equivalent O O
to O O
4000 O O
+/- O O
200 O O
receptors O O
per O O
cell O O
) O O
, O O
whereas O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
isolated O O
by O O
E-rosette O O
sedimentation O O
bind O O
12.0 O O
+/- O O
0.7 O O
fmol O O
of O O
dexamethasone O B-cell_type
per O I-cell_type
million O I-cell_type
cells O I-cell_type
( O O
equivalent O O
to O O
7200 O O
+/- O O
400 O O
receptors O O
per O O
cell O O
) O O
. O O

This O O
difference O O
in O O
the O O
amount O O
of O O
dexamethasone O O
bound O O
by O O
the O O
two O O
T O O
cell O O
preparations O O
was O O
significant O O
( O O
p O O
less O O
than O O
.001 O O
) O O
and O O
was O O
present O O
immediately O O
after O O
cell O O
isolation O O
. O O

The O O
binding O O
affinities O O
of O O
the O O
different O O
T B-cell_line O
cell I-cell_line O
preparations I-cell_line O
for O O
dexamethasone O O
were O O
similar O O
. O O

T O B-cell_type
cells O I-cell_type
that O O
are O O
isolated O O
by O O
a O O
combination O O
of O O
nylon O O
wool O O
filtration O O
followed O O
by O O
E-rosette O O
sedimentation O O
bind O O
the O O
same O O
amount O O
of O O
dexamethasone O O
as O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
isolated O O
by O O
nylon O O
wool O O
filtration O O
alone O O
. O O

T B-cell_type B-cell_type
cells I-cell_type I-cell_type
isolated O O
by O O
a O O
combination O O
of O O
E-rosette O O
sedimentation O O
following O O
by O O
nylon O O
wool O O
filtration O O
bind O O
less O O
dexamethasone O O
than O O
do O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
isolated O O
by O O
E-rosette O O
sedimentation O O
alone O O
. O O

These O O
findings O O
suggest O O
that O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
are O O
heterogeneous O O
with O O
respect O O
to O O
their O O
quantity O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
. O O

Isolation O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
by O O
E-rosette O B-cell_type
sedimentation O O
enriches O O
for O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
that O O
have O O
a O O
greater O O
number O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
, O O
and O O
isolation O O
of O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
by O O
nylon O O
wool O O
filtration O O
enriches O O
for O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
that O O
have O O
a O O
lesser O O
number O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
. O O

Glucocorticoid B-protein B-protein
receptors I-protein I-protein
and O O
glucocorticoid O O
sensitivity O O
of O O
human B-cell_type B-cell_type
leukemic I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

We O O
have O O
established O O
optimal O O
conditions O O
for O O
the O O
measurement O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
( O O
GR B-protein B-protein
) O O
in O O
human B-cell_type B-cell_type
white I-cell_type I-cell_type
cells I-cell_type I-cell_type
using O O
a O O
whole-cell O O
binding O O
assay O O
with O O
[ O O
3H O O
] O O
dexamethasone O O
as O O
the O O
ligand O O
, O O
and O O
the O O
subsequent O O
determination O O
of O O
the O O
GR B-protein B-protein
content O O
in O O
normal B-cell_type B-cell_type
human I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
in O O
leukemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
of O O
patients O O
with O O
various O O
forms O O
of O O
acute O O
and O O
chronic O O
leukemia O O
. O O

A O O
number O O
of O O
leukemia B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
in O O
continuous O O
culture O O
were O O
also O O
subjected O O
to O O
the O O
GR B-protein B-protein
assay O O
, O O
and O O
the O O
results O O
were O O
correlated O O
with O O
the O O
sensitivity O O
of O O
these O O
cell B-cell_line B-cell_line
lines I-cell_line I-cell_line
to O O
glucocorticoid O O
steroids O O
in O O
vitro O O
. O O

The O O
GR B-protein B-protein
content O O
of O O
normal B-cell_type B-cell_type
human I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
amounted O O
to O O
4 O O
, O O
850 O O
+/- O O
1 O O
, O O
340 O O
( O O
mean O O
+/- O O
SD O O
) O O
receptors/cell O O
. O O

The O O
mean O O
equilibrium O O
dissociation O O
constant O O
( O O
KD O O
) O O
of O O
the O O
interaction O O
of O O
[ O O
3H O O
] O O
dexamethasone O O
with O O
the O O
GR B-protein B-protein
was O O
1.2 O O
x O O
10 O O
( O O
-8 O O
) O O
M O O
. O O

Steroidal O O
compounds O O
with O O
a O O
known O O
glucocorticoid O O
potency O O
effectively O O
competed O O
for O O
the O O
binding O O
, O O
whereas O O
steroids O O
devoid O O
of O O
glucocorticoid O O
activity O O
( O O
e.g. O O
estradiol-17 O O
beta O O
and O O
testosterone O O
) O O
were O O
ineffective O O
. O O

The O O
GR B-protein B-protein
content O O
of O O
the O O
blast B-cell_type B-cell_type
cells I-cell_type I-cell_type
obtained O O
from O O
eight O O
patients O O
suffering O O
from O O
acute O O
leukemia O O
and O O
four O O
patients O O
with O O
a O O
blast O O
crisis O O
of O O
chronic O O
myelocytic O O
leukemia O O
was O O
found O O
to O O
be O O
highly O O
variable O O
( O O
3 O O
, O O
230-29 O O
, O O
900 O O
receptors/cell O O
) O O
, O O
while O O
the O O
lymphocytes B-cell_type B-cell_type
of O O
six O O
patients O O
with O O
chronic O O
lymphatic O O
leukemia O O
contained O O
a O O
rather O O
stable O O
GR B-protein B-protein
content O O
( O O
2 O O
, O O
930-5 O O
, O O
120 O O
receptors/cell O O
) O O
, O O
which O O
was O O
comparable O O
with O O
that O O
of O O
normal B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

GR B-protein B-protein
was O O
identified O O
in O O
all O O
the O O
12 O B-cell_line
malignant B-cell_line I-cell_line
continuous I-cell_line I-cell_line
white I-cell_line I-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
studied O O
. O O

Large O B-cell_type
cells O I-cell_type
contained O O
more O O
GR B-protein B-protein
than O O
the O O
smaller O O
ones O O
. O O

There O O
was O O
no O O
apparent O O
correlation O O
between O O
the O O
GR B-protein B-protein
concentration O O
and O O
the O O
sensitivity O O
of O O
the O O
cells O O
in O O
vitro O O
to O O
glucocorticoids O O
as O O
judged O O
by O O
[ O O
3H O O
] O O
thymidine O O
incorporation O O
studies O O
. O O

Distribution O O
of O O
the O O
surface O B-protein
markers O I-protein
in O O
the O O
leukemic B-cell_line B-cell_line
cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
did O O
not O O
relate O O
to O O
the O O
GR B-protein B-protein
concentration O O
. O O

We O O
conclude O O
that O O
the O O
presence O O
of O O
GR B-protein B-protein
is O O
probably O O
a O O
universal O O
feature O O
of O O
the O O
leukemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
and O O
, O O
from O O
a O O
clinical O O
standpoint O O
, O O
probably O O
does O O
not O O
alone O O
imply O O
steroid O O
responsiveness O O
. O O

Evidence O O
for O O
a O O
steroid B-protein B-protein
receptor I-protein I-protein
in O O
rheumatoid B-cell_type B-cell_type
synovial I-cell_type I-cell_type
tissue I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

One O O
mechanism O O
by O O
which O O
glucocorticoids O O
could O O
exert O O
their O O
anti-inflammatory O O
action O O
is O O
via O O
rapidly O O
saturable O O
, O O
stereo-specific B-protein O
cytoplasmic I-protein B-protein
protein I-protein I-protein
receptors I-protein I-protein
. O O

This O O
report O O
is O O
of O O
an O O
investigation O O
into O O
such O O
a O O
possibility O O
in O O
synovial B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Synovium O O
, O O
obtained O O
from O O
knee O O
joints O O
of O O
rheumatoid O O
patients O O
undergoing O O
surgery O O
, O O
was O O
incubated O O
with O O
clostridiopeptidase B-protein O
A I-protein O
and O O
trypsin-EDTA B-protein O
to O O
obtain O O
cell O O
suspensions O O
. O O

These O O
, O O
together O O
with O O
cells O O
obtained O O
from O O
synovial O O
fluid O O
aspirated O O
from O O
patients O O
with O O
rheumatoid O O
arthritis O O
, O O
were O O
identified O O
by O O
electron O O
microscopy O O
. O O

Duplicate O O
samples O O
of O O
these O O
cell O O
suspensions O O
were O O
incubated O O
with O O
increasing O O
concentrations O O
of O O
H3Dexamethasone O O
( O O
1 O O
x O O
10 O O
( O O
-10 O O
) O O
M-1 O O
x O O
10 O O
( O O
-9 O O
) O O
M O O
) O O
for O O
30 O O
minutes O O
at O O
37 O O
degrees O O
C O O
. O O

Analysis O O
of O O
the O O
proportion O O
of O O
steroid O O
bound O O
to O O
whole B-cell_type O
cells I-cell_type O
showed O O
evidence O O
for O O
specific O O
, O O
rapidly O O
saturable O O
, O O
receptors O O
in O O
the O O
cells O O
obtained O O
from O O
synovial O O
tissue O O
, O O
but O O
this O O
was O O
not O O
found O O
in O O
synovial B-cell_type B-cell_type
fluid I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Electron O O
micrographs O O
showed O O
that O O
cells O O
obtained O O
from O O
synovial O O
tissue O O
consisted O O
of O O
synovial B-cell_type B-cell_line
fibroblast I-cell_type I-cell_line
- O I-cell_line
and O I-cell_line
macrophage-types B-cell_type I-cell_line
, O I-cell_line
lymphocytes B-cell_type I-cell_line
, O O
monocytes B-cell_type B-cell_type
and O O
macrophages B-cell_type B-cell_type
. O O

Polymorphonuclear B-cell_type B-cell_type
leucocytes I-cell_type I-cell_type
appeared O O
to O O
be O O
absent O O
. O O

However O O
, O O
in O O
synovial B-cell_type B-cell_type
fluid I-cell_type I-cell_type
cell I-cell_type I-cell_type
type I-cell_type I-cell_type
polymorphonuclear I-cell_type I-cell_type
leucocytes I-cell_type I-cell_type
were O O
the O O
predominant O O
cell O O
type O O
. O O

We O O
concluded O O
from O O
this O O
, O O
that O O
one O O
or O O
more O O
of O O
the O O
cell O O
types O O
present O O
in O O
synovial O O
tissue O O
contain O O
a O O
specific B-protein O
steroid I-protein B-protein
receptor I-protein I-protein
, O O
but O O
that O O
this O O
is O O
lacking O O
in O O
synovial B-cell_type B-cell_type
fluid I-cell_type I-cell_type
polymorphonuclear I-cell_type I-cell_type
leucocytes I-cell_type I-cell_type
. O O

Clinical O O
implications O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
human O O
leukemia O O
. O O

Glucorticoid B-protein B-protein
receptors I-protein I-protein
were O O
studied O O
in O O
various O O
populations O O
of O O
normal O B-cell_type
human B-cell_type I-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
and O O
leukemic B-cell_type B-cell_type
lymphoblasts I-cell_type I-cell_type
. O O

Normal B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
contain O O
low O O
levels O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
( O O
approximately O O
2 O O
, O O
500 O O
sites/cell O O
) O O
which O O
are O O
identical O O
in O O
T- O B-cell_type
and O O
non-T-fractions O O
. O O

Phytohemagglutinin B-protein B-protein
treatment O O
increases O O
levels O O
about O O
3-fold O O
. O O

Leukemic B-cell_type B-cell_type
lymphoblasts I-cell_type I-cell_type
contain O O
larger O O
numbers O O
of O O
receptor O B-protein
sites O I-protein
. O O

Presence O O
of O O
receptor O O
is O O
correlated O O
with O O
in O O
vitro O O
sensitivitiy O O
to O O
glucocorticoids O O
and O O
in O O
vivo O O
response O O
to O O
therapy O O
. O O

Quantity O O
of O O
receptor O O
is O O
also O O
correlated O O
with O O
complete O O
remission O O
duration O O
independently O O
of O O
leukemic B-cell_type O
cell I-cell_type O
type I-cell_type O
( O O
T O O
or O O
null O O
) O O
, O O
initial O O
WBC B-cell_type B-cell_type
, O O
or O O
age O O
of O O
patient O O
. O O

Quantitative O O
determination O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
levels O O
in O O
acute O O
lymphoblastic O O
leukemia O O
may O O
be O O
of O O
value O O
both O O
as O O
an O O
independent O O
prognostic O O
variable O O
and O O
in O O
suggesting O O
which O O
patients O O
should O O
receive O O
glucocorticoid O O
therapy O O
. O O

Functional O O
and O O
physical O O
interaction O O
of O O
protein-tyrosine B-protein B-protein
kinases I-protein I-protein
Fyn I-protein B-protein
and I-protein O
Csk I-protein B-protein
in O O
the O O
T-cell O O
signaling O O
system O O
. O O

The O O
Src-like B-protein B-protein
protein-tyrosine I-protein I-protein
kinase I-protein I-protein
Fyn B-protein I-protein
is O O
associated O O
with O O
T-cell B-protein B-protein
antigen I-protein I-protein
receptor I-protein I-protein
. O O

Transient O O
expression O O
of O O
actively O B-protein
mutated O I-protein
Fyn B-protein I-protein
, O O
having O O
Phe-528 O B-protein
instead O O
of O O
Tyr-528 O O
or O O
Thr-338 O O
instead O O
of O O
Ile-338 O O
, O O
in O O
Jurkat B-cell_type B-cell_line
T-cells I-cell_type I-cell_line
stimulated B-DNA O
the I-DNA O
serum I-DNA B-DNA
response I-DNA I-DNA
element I-DNA I-DNA
( O O
SRE B-DNA B-DNA
) O O
, O O
12-O-tetradecanoyl-phorbol-13-acetate B-DNA B-DNA
response I-DNA I-DNA
element I-DNA I-DNA
, O O
cyclic B-DNA B-DNA
AMP I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
, O O
and O O
c-fos B-DNA B-DNA
promoter I-DNA I-DNA
. O O

The O O
stimulation O O
of O O
SRE B-DNA B-DNA
was O O
particularly O O
prominent O O
not O O
only O O
with O O
active O O
Fyn B-protein B-protein
but O O
also O O
with O O
normal B-protein O
( I-protein O
wild-type I-protein B-protein
) I-protein I-protein
Fyn I-protein I-protein
. O O

SRE B-DNA B-protein
was O O
also O O
stimulated O O
by O O
both O O
normal B-protein O
and I-protein O
active I-protein O
Lck I-protein B-protein
. O O

Furthermore O O
, O O
normal B-protein O
and I-protein O
active I-protein O
Fyn I-protein B-protein
stimulated O O
transcription O O
from O O
the O O
IL-2 B-DNA B-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
when O O
transfected O B-cell_line
cells O I-cell_line
were O O
stimulated O O
by O O
concanavalin B-protein O
A I-protein O
plus O O
12-O-tetradecanoylphorbol-13-acetate O O
. O O

Under O O
the O O
same O O
conditions O O
, O O
Lck B-protein B-protein
did O O
not O O
stimulate O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
unless O O
it O O
was O O
activated O O
by O O
mutation O O
. O O

Interestingly O O
, O O
a O O
mutant B-protein B-protein
Fyn I-protein I-protein
, O O
which O O
has O O
deletions O O
within O O
the O O
SH2 B-protein B-DNA
region I-protein I-DNA
and O O
so O O
is O O
able O O
to O O
transform O O
chicken B-cell_type B-cell_type
embryo I-cell_type I-cell_type
fibroblasts I-cell_type I-cell_type
, O O
did O O
not O O
stimulate O O
either O O
the O O
c-fos B-DNA B-DNA
or I-DNA I-DNA
IL-2 I-DNA I-DNA
promoter I-DNA I-DNA
, O O
suggesting O O
the O O
importance O O
of O O
this O O
region O O
in O O
T-cell B-cell_type O
signaling O O
. O O

Csk B-protein B-protein
, O O
which O O
phosphorylates O O
tyrosine O O
residues O O
in O O
the O O
negative O B-DNA
regulatory O I-DNA
sites O I-DNA
of O O
Src B-protein B-protein
family I-protein I-protein
kinases I-protein I-protein
, O O
down-regulated O O
Fyn- O O
and O O
Lck-mediated O O
stimulation O O
of O O
the O O
serum B-DNA B-DNA
response I-DNA I-DNA
element I-DNA I-DNA
and O O
Fyn-mediated O O
enhancement O O
of O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
activity O O
. O O

These O O
data O O
suggest O O
that O O
Fyn B-protein B-protein
and O O
Lck B-protein B-protein
, O O
whose O O
activities O O
are O O
regulated O O
by O O
Csk B-protein B-protein
, O O
are O O
involved O O
in O O
different O O
phases O O
of O O
T-cell B-cell_type O
activation O O
. O O

A O O
novel O O
NF-kappa B-protein B-protein
B I-protein I-protein
complex I-protein I-protein
containing O O
p65 B-protein B-protein
homodimers I-protein I-protein
: O O
implications O O
for O O
transcriptional O O
control O O
at O O
the O O
level O O
of O O
subunit O O
dimerization O O
. O O

The O O
predominant O O
inducible O O
form O O
of O O
the O O
NF-kappa B-protein B-protein
B I-protein I-protein
transcription I-protein I-protein
factor I-protein I-protein
is O O
a O O
heteromeric B-protein B-protein
complex I-protein I-protein
containing O O
two O O
Rel-related B-protein B-protein
DNA-binding I-protein I-protein
subunits I-protein I-protein
, O O
termed B-protein O
p65 I-protein B-protein
and O O
p50 B-protein B-protein
. O O

Prior O O
transfection O O
studies O O
have O O
shown O O
that O O
when O O
these O O
p65 B-protein B-protein
and I-protein I-protein
p50 I-protein I-protein
subunits I-protein I-protein
are O O
expressed O O
independently O O
as O O
stable B-protein O
homodimers I-protein B-protein
, O O
p65 B-protein B-protein
stimulates O O
kappa O O
B-directed O O
transcription O O
, O O
whereas O O
p50 B-protein B-protein
functions O O
as O O
a O O
kappa O O
B-specific O O
repressor O O
. O O

While O O
authentic O O
p50 B-protein B-protein
homodimers I-protein I-protein
( O O
previously O O
termed O O
KBF1 B-protein B-protein
) O O
have O O
been O O
detected O O
in O O
nuclear O O
extracts O O
from O O
nontransfected O B-cell_line
cells O I-cell_line
, O O
experimental O O
evidence O O
supporting O O
the O O
existence O O
of O O
p65 B-protein B-protein
homodimers I-protein I-protein
in O O
vivo O O
was O O
lacking O O
. O O

We O O
now O O
provide O O
direct O O
biochemical O O
evidence O O
for O O
the O O
presence O O
of O O
an O O
endogenous O O
pool O O
of O O
inducible O O
p65 B-protein B-protein
homodimers I-protein I-protein
in O O
intact O B-cell_type
human B-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

As O O
with O O
the O O
prototypical O O
NF-kappa B-protein B-protein
B I-protein I-protein
p50-p65 I-protein I-protein
heterodimer I-protein I-protein
, O O
this O O
novel O O
p65 B-protein B-protein
homodimeric I-protein I-protein
form I-protein I-protein
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
is O O
functionally O O
sequestered O O
in O O
the O O
cytoplasm O O
but O O
rapidly O O
appears O O
in O O
the O O
nuclear O O
compartment O O
following O O
cellular O O
stimulation O O
. O O

Site-directed O O
mutagenesis O O
studies O O
indicate O O
that O O
the O O
homodimerization O O
function O O
of O O
p65 B-protein B-protein
is O O
dependent O O
upon O O
the O O
presence O O
of O O
cysteine O O
216 O O
and O O
a O O
conserved O O
recognition O O
motif O O
for O O
protein B-protein B-protein
kinase I-protein I-protein
A I-protein I-protein
( O I-protein
RRPS B-protein I-protein
; O I-protein
amino O I-protein
acids O I-protein
273 O I-protein
to O I-protein
276 O I-protein
) O O
, O O
both O O
of O O
which O O
reside O O
within O O
a O O
91-amino-acid O B-DNA
segment O I-DNA
of O O
the O O
Rel B-protein B-protein
homology I-protein I-protein
domain I-protein I-protein
that O O
mediates O O
self-association O O
. O O

In O O
contrast O O
, O O
mutations O O
at O O
these O O
two O O
sites O O
do O O
not O O
affect O O
heterodimerization O O
of O O
p65 B-protein B-protein
with O O
p50 B-protein B-protein
or O O
its O O
functional O O
interaction O O
with O O
I O B-protein
kappa O I-protein
B O I-protein
alpha O I-protein
. O O

These O O
later O O
findings O O
indicate O O
that O O
neither O O
homo- O O
nor O O
heterodimer O O
formation O O
is O O
an O O
absolute O O
prerequisite O O
for O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
recognition O O
of O O
p65 B-protein B-protein
. O O

Taken O O
together O O
with O O
prior O O
in O O
vivo O O
transcription O O
studies O O
, O O
these O O
results O O
suggest O O
that O O
the O O
biological O O
activities O O
of O O
p65 B-protein B-protein
and I-protein O
p50 I-protein B-protein
homodimers I-protein I-protein
are O O
independently O O
regulated O O
, O O
thereby O O
providing O O
an O O
integrated O O
and O O
flexible O O
control O O
mechanism O O
for O O
the O O
rapid O O
activation O O
and O O
repression O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
/ O O
Rel B-protein B-protein
-directed O O
gene O O
expression O O
. O O

Carrier O O
determination O O
for O O
X-linked O O
agammaglobulinemia O O
using O O
X O O
inactivation O O
analysis O O
of O O
purified B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

We O O
report O O
the O O
development O O
of O O
a O O
relatively O O
quick O O
and O O
simple O O
method O O
for O O
the O O
assessment O O
of O O
X O O
inactivation O O
status O O
for O O
carrier O O
determination O O
in O O
families O O
affected O O
by O O
X-linked O O
agammaglobulinemia O O
( O O
XLA O O
) O O
. O O

This O O
method O O
utilises O O
an O O
immunomagnetic O O
separation O O
technique O O
for O O
B B-cell_type O
cell I-cell_type O
purification O O
and O O
a O O
polymerase O O
chain O O
reaction O O
( O O
PCR O O
) O O
based O O
assay O O
for O O
the O O
determination O O
of O O
methylation O O
status O O
at O O
the O O
androgen B-DNA B-DNA
receptor I-DNA I-DNA
( I-DNA I-DNA
AR I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
locus I-DNA I-DNA
to O O
assess O O
whether O O
X O O
inactivation O O
is O O
random O O
or O O
non-random O O
at O O
this O O
locus O O
. O O

We O O
report O O
the O O
results O O
we O O
have O O
obtained O O
using O O
this O O
assay O O
to O O
investigate O O
females O O
known O O
to O O
be O O
carriers O O
of O O
various O O
X-linked O O
immunodeficiency O O
disorders O O
. O O

In O O
addition O O
, O O
we O O
investigated O O
four O O
females O O
from O O
different O O
families O O
affected O O
by O O
XLA O O
, O O
two O O
of O O
whom O O
were O O
of O O
unknown O O
carrier O O
status O O
, O O
and O O
we O O
discuss O O
the O O
results O O
obtained O O
with O O
this O O
and O O
other O O
X-inactivation O O
assays O O
. O O

A O O
similar O O
assay O O
has O O
recently O O
been O O
described O O
by O O
Allen O O
et O O
al. O O
( O O
1992 O O
) O O
and O O
applied O O
to O O
members O O
of O O
one O O
family O O
affected O O
by O O
XLA O O
. O O

Effects O O
of O O
IL-4 B-protein B-protein
and O O
Fc B-protein B-protein
gamma I-protein I-protein
receptor I-protein I-protein
II I-protein I-protein
engagement O O
on O O
Egr-1 B-protein B-protein
expression O O
during O O
stimulation O O
of O O
B B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
by O O
membrane O O
immunoglobulin O B-protein
crosslinking O O
. O O

Egr-1 B-DNA B-protein
is O O
an O O
immediate B-DNA B-DNA
early I-DNA I-DNA
gene I-DNA I-DNA
that O O
is O O
rapidly O O
upregulated O O
in O O
response O O
to O O
mitogenic O O
signals O O
induced O O
by O O
antigen O B-protein
receptor O I-protein
crosslinking O O
on O O
murine B-cell_type B-cell_type
B I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

It O O
has O O
been O O
shown O O
that O O
levels O O
of O O
Egr-1 B-DNA B-protein
expression O O
are O O
closely O O
correlated O O
with O O
B B-cell_type O
cell I-cell_type O
proliferation O O
in O O
several O O
models O O
of O O
B O O
cell O O
activation O O
and O O
tolerance O O
. O O

We O O
compared O O
the O O
expression O O
of O O
Egr-1 B-DNA B-protein
during O O
B O O
cell O O
stimulation O O
with O O
Fab'2 B-protein B-protein
and O O
IgG B-protein B-protein
anti-immunoglobulin I-protein I-protein
( O O
anti-Ig B-protein B-protein
) O O
, O O
since O O
it O O
is O O
known O O
that O O
Fab'2 B-protein B-protein
anti-Ig I-protein I-protein
is O O
mitogenic O O
while O O
IgG B-protein B-protein
anti-Ig I-protein I-protein
is O O
not O O
, O O
owing O O
to O O
a O O
dominant O O
inhibitory O O
effect O O
of O O
crosslinking O O
the O O
B B-protein B-cell_type
cell I-protein I-cell_type
Fc I-protein B-protein
gamma I-protein I-protein
RII I-protein I-protein
to O O
membrane B-protein B-protein
Ig I-protein I-protein
. O O

While O O
mitogenic O O
doses O O
of O O
Fab'2 B-protein B-protein
anti-Ig I-protein I-protein
induce O O
large O O
and O O
rapid O O
increases O O
in O O
Egr-1 O B-protein
expression O O
, O O
IgG B-protein B-protein
anti-Ig I-protein I-protein
results O O
in O O
smaller O O
increases O O
in O O
Egr-1 B-RNA B-RNA
mRNA I-RNA I-RNA
, O O
comparable O O
to O O
that O O
seen O O
with O O
submitogenic O O
concentrations O O
of O O
Fab'2 B-protein B-protein
anti-Ig I-protein I-protein
. O O

However O O
, O O
the O O
correlation O O
between O O
Egr-1 O B-protein
expression O O
and O O
B O O
cell O O
proliferation O O
breaks O O
down O O
when O O
IL-4 B-protein B-protein
is O O
added O O
as O O
a O O
co-mitogen O O
to O O
induce O O
B O O
cell O O
proliferation O O
with O O
IgG B-protein B-protein
anti-Ig I-protein I-protein
or O O
submitogenic O O
concentrations O O
of O O
Fab'2 B-protein B-protein
anti-Ig I-protein I-protein
. O O

No O O
corresponding O O
increases O O
in O O
Egr-1 B-RNA O
mRNA I-RNA O
levels O O
are O O
observed O O
when O O
IL-4 B-protein B-protein
is O O
added O O
. O O

Therefore O O
, O O
IL-4 B-protein B-protein
overcomes O O
Fc O B-protein
receptor-mediated O O
inhibition O O
of O O
B B-cell_type O
cell I-cell_type O
proliferation O O
without O O
affecting O O
inhibition O O
of O O
Egr-1 B-RNA B-RNA
mRNA I-RNA I-RNA
induction O O
, O O
as O O
demonstrated O O
earlier O O
for O O
c-myc B-RNA B-RNA
mRNA I-RNA I-RNA
in O O
this O O
system O O
. O O

Identification O O
of O O
a O O
novel O B-DNA
cyclosporin-sensitive B-DNA I-DNA
element I-DNA I-DNA
in O O
the O O
human B-DNA B-DNA
tumor I-DNA I-DNA
necrosis I-DNA I-DNA
factor I-DNA I-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
alpha I-protein I-protein
( O O
TNF-alpha B-protein B-protein
) O O
, O O
a O O
cytokine B-protein B-protein
with O O
pleiotropic O O
biological O O
effects O O
, O O
is O O
produced O O
by O O
a O O
variety O O
of O O
cell O O
types O O
in O O
response O O
to O O
induction O O
by O O
diverse O O
stimuli O O
. O O

In O O
this O O
paper O O
, O O
TNF-alpha B-RNA B-RNA
mRNA I-RNA I-RNA
is O O
shown O O
to O O
be O O
highly O O
induced O O
in O O
a O O
murine B-cell_line B-cell_line
T I-cell_line I-cell_line
cell I-cell_line I-cell_line
clone I-cell_line I-cell_line
by O O
stimulation O O
with O O
T B-protein B-protein
cell I-protein I-protein
receptor I-protein I-protein
( O O
TCR B-protein B-protein
) O O
ligands O O
or O O
by O O
calcium O O
ionophores O O
alone O O
. O O

Induction O O
is O O
rapid O O
, O O
does O O
not O O
require O O
de O O
novo O O
protein O O
synthesis O O
, O O
and O O
is O O
completely O O
blocked O O
by O O
the O O
immunosuppressant O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
. O O

We O O
have O O
identified O O
a O O
human B-DNA B-DNA
TNF-alpha I-DNA I-DNA
promoter I-DNA I-DNA
element I-DNA I-DNA
, O O
kappa B-DNA B-DNA
3 I-DNA I-DNA
, O O
which O O
plays O O
a O O
key O O
role O O
in O O
the O O
calcium-mediated O O
inducibility O O
and O O
CsA O O
sensitivity O O
of O O
the O O
gene O O
. O O

In O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
an O O
oligonucleotide O O
containing O O
kappa B-DNA B-DNA
3 I-DNA I-DNA
forms O O
two O O
DNA O B-protein
protein O I-protein
complexes O I-protein
with O O
proteins O O
that O O
are O O
present O O
in O O
extracts O O
from O O
unstimulated B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

These O O
complexes O O
appear O O
in O O
nuclear O O
extracts O O
only O O
after O O
T O O
cell O O
stimulation O O
. O O

Induction O O
of O O
the O O
inducible O O
nuclear B-protein B-protein
complexes I-protein I-protein
is O O
rapid O O
, O O
independent O O
of O O
protein O O
synthesis O O
, O O
and O O
blocked O O
by O O
CsA O O
, O O
and O O
thus O O
, O O
exactly O O
parallels O O
the O O
induction O O
of O O
TNF-alpha B-RNA B-RNA
mRNA I-RNA I-RNA
by O O
TCR O B-protein
ligands O O
or O O
by O O
calcium O O
ionophore O O
. O O

Our O O
studies O O
indicate O O
that O O
the O O
kappa B-protein B-protein
3 I-protein I-protein
binding I-protein I-protein
factor I-protein I-protein
resembles O O
the O O
preexisting O O
component O O
of O O
nuclear B-protein B-protein
factor I-protein I-protein
of O I-protein
activated B-cell_type I-protein
T I-cell_type I-protein
cells I-cell_type I-protein
. O O

Thus O O
, O O
the O O
TNF-alpha B-DNA B-DNA
gene I-DNA I-DNA
is O O
an O O
immediate O B-DNA
early O I-DNA
gene O I-DNA
in O O
activated O B-cell_type
T B-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
provides O O
a O O
new O O
model O O
system O O
in O O
which O O
to O O
study O O
CsA-sensitive B-DNA B-DNA
gene I-DNA I-DNA
induction O O
in O O
activated B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Differences O O
in O O
expression O O
of O O
transcription B-protein B-protein
factor I-protein I-protein
AP-1 I-protein I-protein
in O O
human B-cell_line B-cell_line
promyelocytic I-cell_line I-cell_line
HL-60 I-cell_line I-cell_line
cells I-cell_line I-cell_line
during O O
differentiation O O
towards O O
macrophages B-cell_type B-cell_type
versus O O
granulocytes B-cell_type B-cell_type
. O O

Commitment O O
of O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
to O O
macrophage O O
or O O
granulocytic O O
differentiation O O
was O O
achieved O O
by O O
incubation O O
with O O
4 O O
beta-phorbol O O
12-myristate O O
13-acetate O O
( O O
PMA O O
) O O
for O O
30-60 O O
min O O
or O O
with O O
dimethyl O O
sulphoxide O O
( O O
DMSO O O
) O O
for O O
24 O O
h O O
respectively O O
. O O

The O O
commitment O O
stage O O
towards O O
PMA-induced O O
macrophage O O
differentiation O O
was O O
associated O O
with O O
increases O O
in O O
jun O B-DNA
B O I-DNA
and O O
c-fos O O
mRNA O O
levels O O
, O O
as O O
well O O
as O O
with O O
an O O
increase O O
in O O
the O O
binding O O
activity O O
of O O
transcription B-protein B-protein
factor I-protein I-protein
AP-1 I-protein B-protein
. O O

Nevertheless O O
, O O
gel O O
retardation O O
analysis O O
indicated O O
that O O
the O O
AP-1 B-protein B-protein
activity O O
detected O O
in O O
untreated O B-cell_type
cells O I-cell_type
was O O
drastically O O
reduced O O
during O O
the O O
commitment O O
stage O O
of O O
DMSO-induced O O
HL-60 O O
differentiation O O
towards O O
granulocytes B-cell_type B-cell_type
. O O

When O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
were O O
treated O O
with O O
sodium O O
butyrate O O
, O O
which O O
induced O O
monocytic O O
differentiation O O
, O O
a O O
remarkable O O
increase O O
in O O
AP-1 O B-protein
binding O O
activity O O
was O O
detected O O
. O O

Treatment O O
of O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
with O O
1 O O
alpha O O
, O O
25-dihydroxyvitamin O O
D3 O O
, O O
another O O
monocytic O O
differentiation O O
agent O O
, O O
induced O O
a O O
weak O O
, O O
but O O
appreciable O O
, O O
increase O O
in O O
AP-1 B-protein B-protein
activity O O
. O O

Furthermore O O
, O O
addition O O
of O O
sodium O O
butyrate O O
or O O
1 O O
alpha O O
, O O
25-dihydroxyvitamin O O
D3 O O
to O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
induced O O
the O O
expression O O
of O O
c-fos B-DNA B-DNA
, I-DNA O
c-jun I-DNA B-DNA
, I-DNA O
jun I-DNA B-DNA
B I-DNA I-DNA
and I-DNA O
jun I-DNA B-DNA
D I-DNA I-DNA
proto-oncogenes I-DNA I-DNA
. O O

In O O
contrast O O
, O O
when O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
were O O
treated O O
with O O
retinoic O O
acid O O
, O O
a O O
granulocytic O O
differentiation O O
inducer O O
, O O
no O O
enhanced O O
AP-1 O B-protein
binding O O
activity O O
was O O
observed O O
, O O
and O O
only O O
a O O
weak O O
increase O O
in O O
jun B-RNA B-RNA
D I-RNA I-RNA
mRNA I-RNA I-RNA
level O O
was O O
detected O O
. O O

These O O
data O O
indicate O O
that O O
formation O O
of O O
AP-1 B-protein B-protein
is O O
not O O
required O O
for O O
the O O
induction O O
of O O
HL-60 B-cell_line O
differentiation O O
towards O O
granulocytes B-cell_type B-cell_type
, O O
whereas O O
induction O O
of O O
monocytic O O
differentiation O O
is O O
correlated O O
with O O
an O O
increase O O
in O O
AP-1 B-protein B-protein
activity O O
. O O

The O O
differential O O
expression O O
of O O
AP-1 B-protein B-protein
activity O O
may O O
be O O
critical O O
in O O
the O O
differentiation O O
of O O
HL-60 B-cell_line B-cell_line
cells I-cell_line I-cell_line
towards O O
monocytic B-cell_type B-cell_type
or I-cell_type I-cell_type
granulocytic I-cell_type I-cell_type
lineages I-cell_type I-cell_type

Glucocorticoid B-protein B-protein
receptors I-protein I-protein
and O O
sensitivity O O
in O O
leukemias O O
. O O

In O O
an O O
attempt O O
to O O
investigate O O
the O O
utility O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
determination O O
to O O
predict O O
clinical O O
responsiveness O O
in O O
human O O
leukemias O O
we O O
have O O
studied O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
the O O
leukemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
from O O
46 O O
patients O O
and O O
in O O
the O O
lymphocytes B-cell_type B-cell_type
from O O
18 O O
normal O O
donors O O
. O O

In O O
the O O
normal B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
there O O
were O O
3 O O
, O O
875 O O
( O O
Median O O
) O O
specific O O
binding O B-DNA
sites O I-DNA
per O O
cell O O
. O O

The O O
blasts B-cell_type B-cell_type
from O O
17 O O
patients O O
with O O
ANLL O O
had O O
on O O
average O O
higher O O
levels O O
of O O
binding B-protein B-DNA
sites I-protein I-DNA
per O B-cell_type
cell O I-cell_type
( O O
Median O O
= O O
7 O O
, O O
250 O O
, O O
range O O
: O O
0 O O
to O O
15 O O
, O O
295 O O
) O O
than O O
the O O
other O O
leukemias O O
. O O

Of O O
the O O
15 O O
patients O O
with O O
CLL O O
, O O
six O O
had O O
received O O
glucocorticoid O O
treatment O O
for O O
3 O O
to O O
5 O O
years O O
. O O

Their O O
lymphocytes B-cell_type B-cell_type
had O O
lower O O
number O O
of O O
receptors O O
( O O
Median O O
= O O
2 O O
, O O
000 O O
) O O
than O O
the O O
other O O
cases O O
which O O
were O O
newly O O
diagnosed O O
( O O
Median O O
= O O
4 O O
, O O
500 O O
) O O
. O O

Four O O
patients O O
had O O
ALL/AUL O O
, O O
three O O
patients O O
had O O
blast O O
crisis O O
as O O
terminal O O
phase O O
of O O
CML O O
, O O
and O O
seven O O
had O O
leukemic O O
Non-Hodgkin O O
lymphomas O O
( O O
Median O O
= O O
3 O O
, O O
500 O O
sites/cell O O
) O O
. O O

In O O
24 O O
patients O O
we O O
have O O
also O O
studied O O
the O O
in O O
vitro O O
sensitivity O O
of O O
the O O
leukemic B-cell_type B-cell_type
cells I-cell_type I-cell_type
to O O
dexamethasone O O
. O O

There O O
was O O
no O O
marked O O
correlation O O
between O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
levels O O
and O O
in O O
vitro O O
sensitivity O O
. O O

An O O
attempt O O
to O O
correlate O O
receptor O O
levels O O
with O O
clinical O O
responsiveness O O
demonstrated O O
that O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
determination O O
might O O
be O O
of O O
value O O
in O O
patients O O
with O O
lymphoid O O
malignancies O O
but O O
probably O O
not O O
in O O
patients O O
with O O
other O O
leukemias O O
. O O

'Activation-labile B-protein B-protein
' I-protein I-protein
glucocorticoid-receptor I-protein I-protein
complexes I-protein I-protein
of O O
a O O
steroid-resistant O O
variant O O
of O O
CEM-C7 B-cell_line B-cell_line
human I-cell_line I-cell_line
lymphoid I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

For O O
cytoplasmic B-protein B-protein
glucocorticoid-receptor I-protein I-protein
complexes I-protein I-protein
to O O
enter O O
and O O
accumulate O O
in O O
the O O
nucleus O O
a O O
temperature-dependent O O
event O O
, O O
'activation O O
' O O
is O O
required O O
. O O

Activation O O
can O O
be O O
achieved O O
in O O
vitro O O
by O O
increased O O
ionic O O
strength O O
, O O
dilution O O
or O O
gel O O
filtration O O
and O O
is O O
manifested O O
by O O
an O O
increased O O
affinity O O
of O O
steroid-receptor B-protein B-protein
complex I-protein I-protein
for O O
DNA B-DNA O
and O O
an O O
altered O O
elution O O
profile O O
from O O
ion-exchange O O
resins O O
. O O

Munck O O
and O O
Foley O O
have O O
shown O O
that O O
activated B-protein B-protein
complexes I-protein I-protein
isolated O O
from O O
thymocytes O B-cell_type
elute O O
from O O
DEAE-cellulose O O
in O O
a O O
manner O O
identical O O
to O O
complexes O O
activated O O
in O O
vitro O O
. O O

We O O
report O O
here O O
that O O
DEAE-cellulose O O
chromatography O O
of O O
steroid-receptor B-protein B-protein
complexes I-protein I-protein
from O O
CEM-C7 B-cell_line B-cell_line
, O O
a O O
cloned B-cell_line B-cell_line
human I-cell_line I-cell_line
leukaemic I-cell_line I-cell_line
T-cell I-cell_line I-cell_line
line I-cell_line I-cell_line
sensitive O O
to O O
the O O
cytolytic O O
action O O
of O O
glucocorticoids O O
, O O
and O O
its O O
steroid-resistant B-cell_line B-cell_line
subclone I-cell_line I-cell_line
4R4 I-cell_line I-cell_line
demonstrated O O
that O O
steroid B-protein B-protein
receptors I-protein I-protein
of O O
clone B-cell_line B-cell_line
4R4 I-cell_line I-cell_line
can O O
not O O
form O O
stable O O
activated O O
complexes O O
. O O

This O O
defines O O
a O O
new O O
defect O O
in O O
receptor O O
action O O
, O O
activation O O
lability O O
( O O
r+act1 O O
) O O
, O O
which O O
is O O
unlike O O
either O O
the O O
r- B-cell_line O
, I-cell_line O
r+nt- I-cell_line O
, I-cell_line O
or I-cell_line O
r+nti I-cell_line O
phenotypes I-cell_line O
previously O O
described O O
for O O
mouse B-cell_line B-cell_line
lymphoid I-cell_line I-cell_line
variants I-cell_line I-cell_line
. O O

Granulocytes B-cell_type O
in O O
the O O
endometrium O O
of O O
post-partum O O
women O O
. O O

Endometrial O O
samples O O
of O O
women O O
at O O
various O O
stages O O
of O O
gonadal O O
activity O O
after O O
parturition O O
were O O
examined O O
for O O
the O O
presence O O
and O O
numbers O O
of O O
endometrial B-cell_type B-cell_type
granulocytes I-cell_type I-cell_type
. O O

Although O O
samples O O
at O O
all O O
the O O
stages O O
contained O O
significant O O
numbers O O
of O O
the O O
granulocytes B-cell_type B-cell_type
( O O
i.e. O O
greater O O
than O O
7/high-power O O
field O O
) O O
, O O
the O O
100 O O
% O O
values O O
for O O
late-proliferative O O
and O O
adaptation O O
hyperplasia O O
were O O
significantly O O
higher O O
than O O
the O O
values O O
for O O
the O O
resting O O
( O O
81.8 O O
% O O
) O O
, O O
early O O
( O O
82.4 O O
% O O
) O O
and O O
mid- O O
( O O
87.9 O O
% O O
) O O
proliferative O O
and O O
secretory O O
( O O
83.3 O O
% O O
) O O
phases O O
. O O

We O O
suggest O O
that O O
this O O
correlates O O
with O O
the O O
suggestion O O
that O O
the O O
granulocytes B-cell_type B-cell_type
constitute O O
a O O
receptor O O
system O O
for O O
oestrogens O O
. O O

Interaction O O
of O O
glucocorticoids O O
with O O
macrophages B-cell_type B-cell_type
. O O

Identification O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
monocytes B-cell_type B-cell_type
and O O
macrophages B-cell_type B-cell_type
. O O

Glucocorticoid O O
binding O O
was O O
measured O O
in O O
resident O O
and O O
thioglycollate-elicited B-cell_type B-cell_type
mouse I-cell_type I-cell_type
peritoneal I-cell_type I-cell_type
macrophages I-cell_type I-cell_type
, O O
rabbit B-cell_type B-cell_type
alveolar I-cell_type I-cell_type
macrophages I-cell_type I-cell_type
, O O
and O O
human B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
. O O

Two O O
assays O O
of O O
binding O O
were O O
used O O
-- O O
an O O
assay O O
with O O
intact B-cell_type B-cell_type
cells I-cell_type I-cell_type
in O O
suspension O O
or O O
monolayers O O
, O O
and O O
an O O
assay O O
of O O
cytosol O O
and O O
nuclear O O
forms O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
. O O

The O O
mononuclear B-cell_type B-cell_type
phagocytes I-cell_type I-cell_type
contained O O
approximately O O
equal O O
to O O
4 O O
-- O O
10 O O
X O O
10 O O
( O O
3 O O
) O O
high B-protein O
affinity I-protein B-DNA
receptor I-protein I-DNA
sites I-protein I-DNA
per O O
cell O O
, O O
with O O
dissociation O O
constants O O
of O O
approximately O O
equal O O
to O O
2 O O
-- O O
8 O O
nM O O
dexamethasone O O
. O O

The O O
binding O O
to O O
the O O
saturable B-protein B-DNA
sites I-protein I-DNA
was O O
specific O O
for O O
steroids O O
with O O
glucocorticoid O O
or O O
antiglucocorticoid O O
activity O O
. O O

Cortisol O O
, O O
corticosterone O O
, O O
and O O
progesterone O O
competed O O
with O O
dexamethasone O O
for O O
binding O O
, O O
whereas O O
estradiol O O
, O O
dihydrotestosterone O O
, O O
and O O
11-epicortisol O O
competed O O
very O O
little O O
. O O

Binding O O
of O O
dexamethasone O O
to O O
cytosol O O
and O O
nuclear O O
forms O O
of O O
the O O
receptor B-protein B-protein
complex I-protein I-protein
and O O
temperature-sensitive O O
translocation O O
of O O
cytosol O O
forms O O
to O O
nuclear O O
forms O O
were O O
shown O O
. O O

At O O
37 O O
degrees O O
C O O
the O O
predominant O O
form O O
of O O
the O O
hormone-receptor B-protein B-protein
complex I-protein I-protein
was O O
nuclear O O
. O O

These O O
results O O
demonstrate O O
that O O
corticosteroids O O
interact O O
with O O
macrophages B-cell_type B-cell_type
at O O
physiological O O
concentrations O O
. O O

Nitric O O
oxide O O
signaling O O
: O O
a O O
possible O O
role O O
for O O
G B-protein B-protein
proteins I-protein I-protein
. O O

We O O
have O O
previously O O
reported O O
various O O
inductive O O
effects O O
of O O
nitric O O
oxide O O
on O O
human B-cell_type B-cell_type
PBMC I-cell_type I-cell_type
. O O

We O O
describe O O
a O O
novel O O
and O O
potentially O O
important O O
mechanism O O
of O O
nitric O O
oxide O O
signaling-through O O
direct O O
activation O O
of O O
guanine B-protein B-protein
nucleotide-binding I-protein I-protein
proteins I-protein I-protein
( O O
G B-protein B-protein
proteins I-protein I-protein
) O O
. O O

We O O
have O O
found O O
that O O
nitric O O
oxide O O
treatment O O
of O O
membranes O O
isolated O O
from O O
fresh B-cell_type O
human I-cell_type B-cell_type
PBMC I-cell_type I-cell_type
enhances O O
the O O
ability O O
of O O
these O O
membranes O O
to O O
hydrolyze O O
[ O O
gamma-32P O O
] O O
GTP O O
and O O
bind O O
[ O O
gamma-35S O O
] O O
GTP O O
. O O

In O O
addition O O
, O O
treatment O O
of O O
whole O O
cells O O
with O O
nitric O O
oxide O O
yielded O O
membranes O O
with O O
enhanced O O
GTPase O B-protein
activity O O
. O O

Furthermore O O
, O O
the O O
GTPase O B-protein
activity O O
of O O
pure O O
, O O
recombinant O B-protein
Gs B-protein I-protein
alpha I-protein I-protein
, O O
Gi B-protein B-protein
alpha I-protein I-protein
1 I-protein I-protein
, O O
and O O
p21ras B-protein B-protein
was O O
greatly O O
enhanced O O
by O O
nitric O O
oxide O O
. O O

In O O
support O O
of O O
the O O
existence O O
of O O
this O O
pathway O O
in O O
whole O O
cells O O
, O O
we O O
found O O
that O O
the O O
G O O
protein O O
inhibitor O O
, O O
GDP-beta-S O O
, O O
blocked O O
NF-kappa B-protein B-protein
B I-protein I-protein
translocation O O
induced O O
by O O
nitric O O
oxide O O
or O O
LPS O O
in O O
permeabilized B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

In O O
addition O O
, O O
nitric O O
oxide O O
greatly O O
reduced O O
the O O
pertussis O O
toxin-mediated O O
ADP-ribosylation O O
of O O
45- B-protein B-protein
and I-protein I-protein
41-kDa I-protein I-protein
proteins I-protein I-protein
in O O
membranes O O
of O O
these O O
cells O O
. O O

Because O O
G B-protein B-protein
proteins I-protein I-protein
play O O
a O O
central O O
role O O
in O O
many O O
diverse O O
signaling O O
systems O O
, O O
activation O O
by O O
an O O
endogenous O O
and O O
inducible O O
oxidant O O
may O O
represent O O
a O O
novel O O
signaling O O
pathway O O
. O O

The O O
granulocyte-macrophage B-DNA B-DNA
colony-stimulating I-DNA I-DNA
factor I-DNA I-DNA
promoter I-DNA I-DNA
cis-acting I-DNA B-DNA
element I-DNA I-DNA
CLE0 B-DNA B-DNA
mediates O O
induction O O
signals O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
is O O
recognized O O
by O O
factors O O
related O O
to O O
AP1 B-protein B-protein
and O O
NFAT B-protein B-protein
. O O

Expression O O
of O O
the O O
granulocyte-macrophage B-DNA B-DNA
colony-stimulating I-DNA I-DNA
factor I-DNA I-DNA
( I-DNA I-DNA
GM-CSF I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
in O O
T O B-cell_type
cells O I-cell_type
is O O
activated O O
by O O
the O O
combination O O
of O O
phorbol O O
ester O O
( O O
phorbol O O
myristate O O
acetate O O
) O O
and O O
calcium O O
ionophore O O
( O O
A23187 O O
) O O
, O O
which O O
mimic O O
antigen O O
stimulation O O
through O O
the O O
T-cell B-protein B-protein
receptor I-protein I-protein
. O O

We O O
have O O
previously O O
shown O O
that O O
a O O
fragment O O
containing O O
bp B-DNA B-DNA
-95 I-DNA I-DNA
to I-DNA I-DNA
+27 I-DNA I-DNA
of O O
the O O
mouse B-DNA B-DNA
GM-CSF I-DNA I-DNA
promoter I-DNA I-DNA
can O O
confer O O
inducibility O O
to O O
reporter B-DNA B-DNA
genes I-DNA I-DNA
in O O
the O O
human B-cell_line B-cell_line
Jurkat I-cell_line I-cell_line
T-cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

Here O O
we O O
use O O
an O O
in O O
vitro O O
transcription O O
system O O
to O O
demonstrate O O
that O O
a O O
cis-acting B-DNA B-DNA
element I-DNA I-DNA
( O O
positions B-DNA B-DNA
-54 I-DNA I-DNA
to I-DNA I-DNA
-40 I-DNA I-DNA
) O O
, O O
referred O O
to O O
as O O
CLE0 B-DNA B-DNA
, O O
is O O
a O O
target O O
for O O
the O O
induction O O
signals O O
. O O

We O O
observed O O
induction O O
with O O
templates O O
containing O O
intact O O
CLE0 B-DNA B-DNA
but O O
not O O
with O O
templates O O
with O O
deleted B-DNA O
or I-DNA O
mutated I-DNA B-DNA
CLE0 I-DNA I-DNA
. O O

We O O
also O O
observed O O
that O O
two O O
distinct O O
signals O O
were O O
required O O
for O O
the O O
stimulation O O
through O O
CLE0 B-DNA B-DNA
, O O
since O O
only O O
extracts O O
from O O
cells O O
treated O O
with O O
both O O
phorbol O O
myristate O O
acetate O O
and O O
A23187 O O
supported O O
optimal O O
induction O O
. O O

Stimulation O O
probably O O
was O O
mediated O O
by O O
CLE0-binding B-protein B-protein
proteins I-protein I-protein
because O O
depletion O O
of O O
these O O
proteins O O
specifically O O
reduced O O
GM-CSF B-protein B-protein
transcription O O
. O O

One O O
of O O
the O O
binding B-protein B-protein
factors I-protein I-protein
possessed O O
biochemical O O
and O O
immunological O O
features O O
identical O O
to O O
those O O
of O O
the O O
transcription B-protein B-protein
factor I-protein I-protein
AP1 I-protein B-protein
. O O

Another O O
factor O O
resembled O O
the O O
T-cell-specific B-protein B-protein
factor I-protein I-protein
NFAT I-protein B-protein
. O O

The O O
characteristics O O
of O O
these O O
two O O
factors O O
are O O
consistent O O
with O O
their O O
involvement O O
in O O
GM-CSF O B-protein
induction O O
. O O

The O O
presence O O
of O O
CLE0-like B-DNA B-DNA
elements I-DNA I-DNA
in O O
the O O
promoters B-DNA B-DNA
of O O
interleukin-3 B-DNA B-protein
( I-DNA O
IL-3 I-DNA B-protein
) I-DNA O
, I-DNA O
IL-4 I-DNA B-protein
, I-DNA O
IL-5 I-DNA B-protein
, I-DNA O
GM-CSF I-DNA B-protein
, I-DNA O
and I-DNA O
NFAT I-DNA B-DNA
sites I-DNA I-DNA
in O O
the O O
IL-2 B-DNA B-DNA
promoter I-DNA I-DNA
suggests O O
that O O
the O O
factors O O
we O O
detected O O
, O O
or O O
related O O
factors O O
that O O
recognize O O
these O O
sites O O
, O O
may O O
account O O
for O O
the O O
coordinate O O
induction O O
of O O
these O O
genes O O
during O O
T-cell B-cell_type O
activation O O
. O O

Identification O O
and O O
characterization O O
of O O
an O O
Alu-containing B-DNA O
, I-DNA O
T-cell-specific I-DNA B-DNA
enhancer I-DNA I-DNA
located O O
in O O
the O O
last O O
intron B-DNA B-DNA
of O O
the O O
human B-DNA B-DNA
CD8 I-DNA I-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
. O O

Expression O O
of O O
the O O
human B-DNA B-DNA
CD8 I-DNA I-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
is O O
restricted O O
to O O
cells O O
of O O
the O O
lymphoid B-cell_type B-cell_type
lineage I-cell_type I-cell_type
and O O
developmentally O O
regulated O O
during O O
thymopoiesis O O
. O O

As O O
an O O
initial O O
step O O
towards O O
understanding O O
the O O
molecular O O
basis O O
for O O
tissue-specific O O
expression O O
of O O
this O O
gene O O
, O O
we O O
surveyed O O
the O O
surrounding O O
chromatin O B-DNA
structure O I-DNA
for O O
potential O O
cis-acting B-DNA B-DNA
regulatory I-DNA I-DNA
regions I-DNA I-DNA
by O O
DNase B-protein B-protein
I I-protein I-protein
hypersensitivity O O
mapping O O
and O O
found O O
four O O
hypersensitive O B-DNA
sites O I-DNA
, O O
three O O
of O O
which O O
were O O
T O O
cell O O
restricted O O
. O O

By O O
using O O
a O O
reporter-based O O
expression O O
approach O O
, O O
a O O
T-cell-specific B-DNA B-DNA
enhancer I-DNA I-DNA
was O O
identified O O
by O O
its O O
close O O
association O O
with O O
a O O
prominent O O
T-cell-restricted B-DNA B-DNA
hypersensitive I-DNA I-DNA
sites I-DNA I-DNA
in O O
the O O
last O O
intron O B-DNA
of O O
the O O
CD8 B-DNA B-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
. O O

Deletion O O
studies O O
demonstrated O O
that O O
the O O
minimal O B-DNA
enhancer O I-DNA
is O O
adjacent O O
to O O
a O O
negative O B-DNA
regulatory O I-DNA
element O I-DNA
. O O

DNA O O
sequence O O
analysis O O
of O O
the O O
minimal B-DNA B-DNA
enhancer I-DNA I-DNA
revealed O O
a O O
striking O O
cluster O O
of O O
consensus B-DNA B-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
for O O
Ets-1 B-protein B-protein
, I-protein O
TCF-1 I-protein B-protein
, I-protein O
CRE I-protein B-DNA
, I-protein O
GATA-3 I-protein B-protein
, I-protein O
LyF-1 I-protein B-protein
, I-protein O
and I-protein O
bHLH I-protein B-protein
proteins I-protein I-protein
which O O
were O O
verified O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
. O O

In O O
addition O O
, O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
end I-DNA I-DNA
of O O
the O O
enhancer B-DNA B-DNA
was O O
composed O O
of O O
an O O
Alu O B-DNA
repeat O I-DNA
which O O
contained O O
the O O
GATA-3 B-DNA B-DNA
, I-DNA I-DNA
bHLH I-DNA I-DNA
, I-DNA I-DNA
and I-DNA I-DNA
LyF-1 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
. O O

Site-directed O O
mutation O O
of O O
the O O
Ets-1 B-DNA B-DNA
and I-DNA I-DNA
GATA-3 I-DNA I-DNA
sites I-DNA I-DNA
dramatically O O
reduced O O
enhancer O O
activity O O
. O O

The O O
functional O O
importance O O
of O O
the O O
other O O
binding O B-DNA
sites O I-DNA
only O O
became O O
apparent O O
when O O
combinations O O
of O O
mutations O O
were O O
analyzed O O
. O O

Taken O O
together O O
, O O
these O O
results O O
suggest O O
that O O
the O O
human B-DNA B-DNA
CD8 I-DNA I-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
is O O
regulated O O
by O O
the O O
interaction O O
of O O
multiple O O
T-cell B-protein B-protein
nuclear I-protein I-protein
proteins I-protein I-protein
with O O
a O O
transcriptional O B-DNA
enhancer O I-DNA
located O O
in O O
the O O
last O B-DNA
intron B-DNA I-DNA
of O O
the O O
gene O O
. O O

Comparison O O
of O O
the O O
CD8 B-DNA B-DNA
alpha I-DNA I-DNA
enhancer I-DNA I-DNA
with O O
other O O
recently O O
identified O O
T-cell-specific B-DNA B-DNA
regulatory I-DNA I-DNA
elements I-DNA I-DNA
suggests O O
that O O
a O O
common O O
set O O
of O O
transcription B-protein B-protein
factors I-protein I-protein
regulates O O
several O O
T-cell B-DNA B-DNA
genes I-DNA I-DNA
. O O

Molecular O O
regulation O O
of O O
the O O
human B-DNA B-DNA
IL-3 I-DNA I-DNA
gene I-DNA I-DNA
: O O
inducible O O
T O O
cell-restricted O O
expression O O
requires O O
intact O O
AP-1 B-DNA B-protein
and I-DNA O
Elf-1 I-DNA B-DNA
nuclear I-DNA I-DNA
protein I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
. O O

Interleukin B-protein B-protein
3 I-protein I-protein
( O O
IL-3 B-protein B-protein
) O O
is O O
a O O
hematopoietic B-protein B-cell_type
stem-cell I-protein I-cell_type
growth I-protein B-protein
and I-protein I-protein
differentiation I-protein I-protein
factor I-protein I-protein
that O O
is O O
expressed O O
solely O O
in O O
activated O B-cell_type
T B-cell_type I-cell_type
and I-cell_type I-cell_type
NK I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Studies O O
to O O
date O O
have O O
identified O B-DNA
elements O I-DNA
5 O B-DNA
' O O
to O O
the O O
IL-3 B-DNA B-DNA
coding I-DNA I-DNA
sequences I-DNA I-DNA
that O O
regulate O O
its O O
transcription O O
, O O
but O O
the O O
sequences O O
that O O
confer O O
T O O
cell-specific O O
expression O O
remain O O
to O O
be O O
clearly O O
defined O O
. O O

We O O
have O O
now O O
identified O O
DNA B-DNA B-DNA
sequences I-DNA I-DNA
that O O
are O O
required O O
for O O
T O B-DNA
cell-restricted O I-DNA
IL-3 B-DNA I-DNA
gene I-DNA I-DNA
transcription O O
. O O

A O O
series O O
of O O
transient O O
transfections O O
performed O O
with O O
human B-DNA B-DNA
IL-3-chloramphenicol I-DNA I-DNA
acetyltransferase I-DNA I-DNA
( I-DNA I-DNA
CAT I-DNA I-DNA
) I-DNA I-DNA
reporter I-DNA I-DNA
plasmids I-DNA I-DNA
in O O
T B-cell_type B-cell_type
and I-cell_type I-cell_type
non-T I-cell_type I-cell_type
cells I-cell_type I-cell_type
revealed O O
that O O
a O O
plasmid B-DNA B-DNA
containing O O
319 O O
bp O O
of O O
5 B-DNA B-DNA
' I-DNA I-DNA
flanking I-DNA I-DNA
sequences I-DNA I-DNA
was O O
active O O
exclusively O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Deletion O O
analysis O O
revealed O O
that O O
T B-cell_type O
cell I-cell_type O
specificity O O
was O O
conferred O O
by O O
a O O
49-bp B-DNA B-DNA
fragment I-DNA I-DNA
( O O
bp B-DNA B-DNA
-319 I-DNA I-DNA
to I-DNA I-DNA
-270 I-DNA I-DNA
) O O
that O O
included O O
a O O
potential B-DNA B-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
for O O
AP-1 B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
6 O I-protein
bp O O
upstream O O
of O O
a O O
binding B-DNA B-DNA
site I-DNA I-DNA
for I-DNA O
Elf-1 I-DNA B-protein
, O O
a O O
member O O
of O O
the O O
Ets B-protein B-protein
family I-protein I-protein
of O O
transcription B-protein B-protein
factors I-protein I-protein
. O O

DNaseI B-protein O
footprint O O
and O O
electrophoretic O O
mobility O O
shift O O
assay O O
analyses O O
performed O O
with O O
MLA-144 B-cell_line O
T I-cell_line O
cell I-cell_line O
nuclear O O
extracts O O
demonstrated O O
that O O
this O O
49-bp B-DNA B-DNA
region I-DNA I-DNA
contains O O
a O O
nuclear B-DNA B-DNA
protein I-DNA I-DNA
binding I-DNA I-DNA
region I-DNA I-DNA
that O O
includes O O
consensus B-DNA B-DNA
AP-1 I-DNA I-DNA
and I-DNA I-DNA
Elf-1 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
. O O

In O O
addition O O
, O O
extracts O O
prepared O O
from O O
purified B-cell_type B-cell_line
human I-cell_type I-cell_line
T I-cell_type I-cell_line
cells I-cell_type I-cell_line
contained O O
proteins O O
that O O
bound O O
to O O
synthetic O O
oligonucleotides O O
corresponding O O
to O O
the O O
AP-1 B-DNA B-DNA
and I-DNA I-DNA
Elf-1 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
. O O

In O O
vitro-transcribed O O
and O O
-translated O O
Elf-1 B-protein B-protein
protein I-protein I-protein
bound O O
specifically O O
to O O
the O O
Elf-1 B-DNA B-DNA
site I-DNA I-DNA
, O O
and O O
Elf-1 O B-protein
antisera O I-protein
competed O O
and O O
super O O
shifted O O
nuclear O B-protein
protein O I-protein
complexes O I-protein
present O O
in O O
MLA-144 B-cell_line O
nuclear O O
extracts O O
. O O

Moreover O O
, O O
addition O O
of O O
anti-Jun O B-protein
family O I-protein
antiserum O I-protein
in O O
electrophoretic O O
mobility O O
shift O O
assay O O
reactions O O
completely O O
blocked O O
formation O O
of O O
the O O
AP-1-related B-protein B-protein
complexes I-protein I-protein
. O O

Transient O O
transfection O O
studies O O
in O O
MLA-144 B-cell_line B-cell_line
T I-cell_line I-cell_line
cells I-cell_line I-cell_line
revealed O O
that O O
constructs O O
containing O O
mutations O O
in O O
the O O
AP-1 B-DNA B-DNA
site I-DNA I-DNA
almost O O
completely O O
abolished O O
CAT O B-protein
activity O O
while O O
mutation O O
of O O
the O O
Elf-1 B-DNA B-DNA
site I-DNA I-DNA
or O O
the O O
NF-IL-3 B-DNA B-DNA
site I-DNA I-DNA
, O O
a O O
previously O O
described O O
nuclear B-DNA B-DNA
protein I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
( O O
bp. B-DNA B-DNA
-155 I-DNA I-DNA
to I-DNA I-DNA
-148 I-DNA I-DNA
) O O
in O O
the O O
IL-3 B-DNA B-DNA
promoter I-DNA I-DNA
, O O
reduced O O
CAT O B-protein
activity O O
to O O
< O O
25 O O
% O O
of O O
the O O
activity O O
given O O
by O O
wild-type O B-DNA
constructs O I-DNA
. O O

We O O
conclude O O
that O O
expression O O
of O O
the O O
human B-DNA B-DNA
IL-3 I-DNA I-DNA
gene I-DNA I-DNA
requires O O
the O O
AP-1 B-DNA B-DNA
and I-DNA I-DNA
Elf-1 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
; O O
however O O
, O O
unlike O O
other O O
previously O O
characterized O O
cytokine B-DNA B-DNA
genes I-DNA I-DNA
such O O
as O O
IL-2 B-protein B-protein
, O O
the O O
AP-1 B-protein B-protein
and I-protein O
Elf-1 I-protein B-protein
factors I-protein I-protein
can O O
bind O O
independently O O
in O O
the O O
IL-3 B-DNA B-DNA
gene I-DNA I-DNA
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

Combination O O
IL-2 B-protein B-protein
and O O
IL-4 B-protein B-protein
reduces O O
glucocorticoid O O
receptor-binding O O
affinity O O
and O O
T B-cell_type O
cell I-cell_type O
response O O
to O O
glucocorticoids O O
. O O

The O O
mechanisms O O
contributing O O
to O O
persistent O O
T B-cell_type O
cell I-cell_type O
activation O O
and O O
poor O O
response O O
to O O
glucocorticoids O O
in O O
chronic O O
inflammatory O O
illnesses O O
such O O
as O O
steroid O O
resistant O O
( O O
SR O O
) O O
asthma O O
are O O
poorly O O
defined O O
. O O

We O O
examined O O
the O O
possibility O O
that O O
certain O O
cytokines O B-protein
, O O
specifically O O
IL-2 B-protein B-protein
and O O
IL-4 B-protein B-protein
, O O
could O O
affect O O
T O O
cell O O
response O O
to O O
glucocorticoids O O
. O O

A O O
[ O O
3H O O
] O O
dexamethasone O O
radioligand-binding O O
assay O O
was O O
used O O
to O O
measure O O
the O O
number O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
( O O
GR B-protein B-protein
) O O
and O O
dissociation O O
constant O O
( O O
Kd O O
) O O
in O O
PBMC B-cell_type B-cell_type
from O O
normal O O
donors O O
and O O
patients O O
with O O
SR O O
asthma O O
, O O
cultured O O
in O O
the O O
absence O O
and O O
presence O O
of O O
these O O
cytokines B-protein B-protein
. O O

PBMC O B-cell_type
from O O
normal O O
donors O O
incubated O O
for O O
48 O O
h O O
in O O
the O O
presence O O
of O O
combination O O
IL-2 B-protein B-protein
+ O O
IL-4 B-protein B-protein
had O O
nuclear O O
GR O B-protein
with O O
significantly O O
reduced O O
binding O O
affinity O O
( O O
GR O B-protein
Kd O O
= O O
36.1 O O
+/- O O
1.63 O O
nM O O
, O O
mean O O
+/- O O
SEM O O
; O O
p O O
= O O
0.0001 O O
) O O
as O O
compared O O
with O O
PBMC B-cell_type B-cell_type
incubated O O
with O O
medium O O
alone O O
( O O
GR O O
Kd O O
= O O
6.74 O O
+/- O O
0.46 O O
nM O O
) O O
. O O

The O O
cytosolic O O
GR O B-protein
Kd O O
remained O O
unchanged O O
. O O

However O O
, O O
when O O
PBMC B-cell_type B-cell_type
were O O
incubated O O
with O O
IL-2 B-protein B-protein
alone O O
or O O
IL-4 B-protein B-protein
alone O O
, O O
no O O
change O O
in O O
GR-binding O O
affinity O O
was O O
observed O O
. O O

Furthermore O O
, O O
when O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
and O O
non-T B-cell_type B-cell_type
cells I-cell_type I-cell_type
were O O
individually O O
stimulated O O
with O O
combination O O
IL-2 O B-protein
+ O O
IL-4 O B-protein
, O O
a O O
significant O O
reduction O O
in O O
GR-binding O O
affinity O O
was O O
observed O O
only O O
in O O
the O O
T B-cell_type O
cell I-cell_type O
population I-cell_type O
( O O
p O O
= O O
0.0001 O O
) O O
. O O

The O O
IL-2 O B-protein
+ O O
IL-4-induced O O
alteration O O
in O O
PBMC O B-cell_type
GR O B-protein
Kd O O
was O O
associated O O
with O O
an O O
increase O O
in O O
GR O B-protein
number O O
( O O
8348 O O
+/- O O
964 O O
vs O O
1710 O O
+/- O O
228 O O
sites/cell O O
; O O
p O O
= O O
0.0003 O O
) O O
. O O

More O O
importantly O O
, O O
the O O
alteration O O
in O O
PBMC O B-cell_type
GR-binding O O
affinity O O
with O O
IL-2 B-protein B-protein
+ O O
IL-4 B-protein B-protein
was O O
associated O O
with O O
a O O
functional O O
change O O
in O O
T O O
cell O O
response O O
to O O
methylprednisolone O O
MPN O O
, O O
i.e. O O
, O O
a O O
reduced O O
inhibitory O O
effect O O
of O O
MPN O O
on O O
PMA/ionomycin-induced O O
T B-cell_type O
cell I-cell_type O
proliferation O O
. O O

These O O
effects O O
of O O
IL-2 B-protein B-protein
+ O O
IL-4 B-protein B-protein
on O O
PBMC B-cell_type B-cell_type
GR B-protein B-protein
affinity O O
and O O
response O O
to O O
MPN O O
were O O
blocked O O
by O O
co-incubation O O
with O O
IFN-gamma B-protein B-protein
. O O

Freshly O O
isolated O O
PBMC B-cell_type B-cell_type
from O O
four O O
patients O O
with O O
SR O O
asthma O O
had O O
a O O
significantly O O
reduced O O
GR-binding O O
affinity O O
( O O
Kd O O
= O O
40.0 O O
+/- O O
2.68 O O
nM O O
; O O
p O O
= O O
0.0001 O O
) O O
when O O
compared O O
with O O
seven O O
normal O O
subjects O O
( O O
7.15 O O
+/- O O
0.41 O O
nM O O
) O O
. O O

The O O
altered O O
PBMC O B-cell_type
GR O B-protein
binding O O
from O O
patients O O
with O O
SR O O
asthma O O
reversed O O
to O O
normal O O
when O O
incubated O O
with O O
medium O O
alone O O
, O O
but O O
was O O
sustained O O
with O O
IL-2 B-protein B-protein
+ O O
IL-4 B-protein B-protein
. O O

These O O
observations O O
suggest O O
that O O
with O O
persistent O O
inflammation O O
certain O O
cytokines B-protein B-protein
may O O
contribute O O
to O O
an O O
impaired O O
response O O
to O O
glucocorticoids O O
. O O

Furthermore O O
, O O
the O O
effects O O
of O O
IL-2 B-protein B-protein
and O O
IL-4 B-protein B-protein
were O O
blocked O O
by O O
IFN-gamma B-protein B-protein
. O O

Characterization O O
of O O
the O O
human B-DNA B-DNA
CD4 I-DNA I-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
: O O
transcription O O
from O O
the O O
CD4 B-DNA B-DNA
gene I-DNA I-DNA
core I-DNA I-DNA
promoter I-DNA I-DNA
is O O
tissue-specific O O
and O O
is O O
activated O O
by O O
Ets B-protein B-protein
proteins I-protein I-protein
. O O

We O O
analyzed O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
transcription I-DNA I-DNA
control I-DNA I-DNA
sequences I-DNA I-DNA
of O O
the O O
human B-DNA B-DNA
CD4 I-DNA I-DNA
gene I-DNA I-DNA
. O O

We O O
located O O
the O O
transcription B-DNA B-DNA
initiation I-DNA I-DNA
site I-DNA I-DNA
and O O
showed O O
that O O
the O O
CD4 B-DNA B-DNA
core I-DNA I-DNA
promoter I-DNA I-DNA
( O O
positions B-DNA B-DNA
-40 I-DNA I-DNA
to I-DNA I-DNA
+16 I-DNA I-DNA
) O O
lacks O O
a O O
classical O B-DNA
`` O I-DNA
TATA O I-DNA
'' O I-DNA
or O I-DNA
initiator B-DNA I-DNA
positioning I-DNA I-DNA
consensus I-DNA I-DNA
sequence I-DNA I-DNA
but O O
directs O O
precise O O
and O O
efficient O O
transcription O O
when O O
coupled O O
to O O
the O O
ubiquitously O B-DNA
active O I-DNA
simian B-DNA I-DNA
virus I-DNA I-DNA
40 I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

The O O
transcriptional O O
activity O O
of O O
the O O
CD4 B-DNA B-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
correlated O O
with O O
CD4 O B-protein
expression O O
in O O
various O O
cell O O
types O O
. O O

Interestingly O O
, O O
the O O
CD4 B-DNA B-DNA
core I-DNA I-DNA
promoter I-DNA I-DNA
also O O
displayed O O
a O O
tissue-specific O O
transcriptional O O
activity O O
. O O

Within O O
this O O
fragment O O
, O O
three O O
nucleic O B-DNA
acid O I-DNA
sequences O I-DNA
are O O
completely O O
conserved O O
in O O
the O O
murine B-DNA B-DNA
CD4 I-DNA I-DNA
gene I-DNA I-DNA
. O O

One O O
of O O
these O O
sequences O O
contains O O
a O O
perfect B-DNA B-DNA
ETS I-DNA I-DNA
consensus I-DNA I-DNA
sequence I-DNA I-DNA
. O O

Another O O
ETS B-DNA B-DNA
consensus I-DNA I-DNA
sequence I-DNA I-DNA
is O O
located O O
1060 O O
nt O O
upstream O O
. O O

Electrophoretic-mobility-shift O O
assays O O
showed O O
that O O
the O O
core O B-DNA
promoter O I-DNA
ETS O I-DNA
motif O I-DNA
binds O O
an O O
Ets-related B-protein B-protein
protein I-protein I-protein
specifically O O
expressed O O
at O O
high O O
levels O O
in O O
CD4+ B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Moreover O O
, O O
in O O
CD4- B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
overexpression O O
of O O
Ets-1 B-protein B-protein
or O O
Ets-2 B-protein B-protein
efficiently O O
and O O
specifically O O
activated O O
transcription O O
from O O
the O O
CD4 B-DNA B-DNA
promoter I-DNA I-DNA
and O O
core B-DNA B-DNA
promoter I-DNA I-DNA
. O O

These O O
data O O
indicate O O
that O O
Ets B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
play O O
a O O
central O O
role O O
in O O
controlling O O
CD4 O B-DNA
gene O I-DNA
expression O O
, O O
by O O
binding O O
to O O
both O O
a O O
classical B-DNA O
remote I-DNA O
site I-DNA O
and O O
an O O
unusual O B-DNA
proximal B-DNA I-DNA
activator I-DNA I-DNA
sequence I-DNA I-DNA

Glucocorticoid O B-protein
receptor O I-protein
activation O O
and O O
inactivation O O
in O O
c O B-cell_type
ultured B-cell_line I-cell_type
human I-cell_line I-cell_type
lymphocytes I-cell_line I-cell_type
. O O

Although O O
glucocorticoids O O
are O O
not O O
cytolytic O O
for O O
and O O
do O O
not O O
inhibit O O
the O O
growth O O
of O O
the O O
IM-9 B-cell_line B-cell_line
line I-cell_line I-cell_line
of O O
cultured B-cell_line B-cell_line
human I-cell_line I-cell_line
lymphoblasts I-cell_line I-cell_line
, O O
these O O
cells O O
have O O
a O O
high O O
steroid-binding O O
capacity O O
. O O

We O O
have O O
used O O
IM-9 B-cell_type B-cell_line
cells I-cell_type I-cell_line
in O O
order O O
to O O
examine O O
whether O O
unoccupied B-protein O
glucocorticoid I-protein B-protein
receptors I-protein I-protein
are O O
inactivated O O
and O O
activated O O
in O O
intact B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

when O O
IM-9 B-cell_type B-cell_line
cells I-cell_type I-cell_line
are O O
incubated O O
in O O
glucose-free O O
medium O O
in O O
a O O
nitrogen O O
atmosphere O O
, O O
both O O
their O O
ability O O
to O O
bind O O
triamcinolone O O
acetonide O O
and O O
their O O
ATP O O
levels O O
decline O O
and O O
, O O
when O O
glucose O O
and O O
oxygen O O
are O O
reintroduced O O
, O O
ATP O O
levels O O
and O O
receptor O O
activity O O
return O O
. O O

The O O
specific O O
glucocorticoid-binding O O
activity O O
of O O
cytosol O O
prepared O O
from O O
cells O O
exposed O O
to O O
various O O
degrees O O
of O O
energy O O
limitation O O
is O O
directly O O
correlated O O
with O O
the O O
ATP O O
content O O
. O O

Receptor O O
activation O O
in O O
intact B-cell_type B-cell_type
cells I-cell_type I-cell_type
is O O
rapid O O
and O O
independent O O
of O O
protein O O
synthesis O O
. O O

Cytosol O O
prepared O O
from O O
inactivated O B-cell_type
cells O I-cell_type
can O O
not O O
be O O
activated O O
by O O
addition O O
of O O
ATP O O
. O O

The O O
inactivation O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
that O O
occurs O O
when O O
cytosol O O
from O O
normal O B-cell_type
IM-9 B-cell_line I-cell_type
cells I-cell_line I-cell_type
is O O
incubated O O
at O O
25 O O
degrees O O
C O O
is O O
inhibited O O
by O O
molybdate O O
, O O
vanadate O O
, O O
fluoride O O
, O O
ATP O O
, O O
and O O
several O O
other O O
nucleotides O O
. O O

The O O
experiments O O
with O O
intact B-cell_type B-cell_type
human I-cell_type I-cell_type
lymphoblasts I-cell_type I-cell_type
suggest O O
that O O
assays O O
of O O
specific O O
glucocorticoid-binding O O
capacity O O
do O O
not O O
necessarily O O
reflect O O
the O O
cellular O O
content O O
of O O
receptor B-protein B-protein
protein I-protein I-protein
. O O

Glucocorticoids O O
and O O
lymphocytes B-cell_type B-cell_type
. O O

II O O
. O O

Cell O O
cycle-dependent O O
changes O O
in O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
content O O
. O O

To O O
study O O
variations O O
in O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
levels O O
during O O
the O O
cell O O
cycle O O
, O O
we O O
have O O
separated O O
mitogen-stimulated B-cell_line B-cell_type
human I-cell_line I-cell_type
peripheral I-cell_line I-cell_type
lymphocytes I-cell_line I-cell_type
and O O
rat B-cell_type B-cell_type
lymph I-cell_type I-cell_type
node I-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
unit O O
gravity O O
sedimentation O O
and O O
measured O O
glucocorticoid O O
binding O O
in O O
the O O
resultant O O
fractions O O
. O O

By O O
morphologic O O
criteria O O
and O O
thymidine O O
incorporation O O
, O O
the O O
fractions O O
were O O
separated O O
into O O
populations O O
of O O
G0 B-cell_type O
and I-cell_type O
G1 I-cell_type O
phase I-cell_type O
and I-cell_type O
S I-cell_type B-cell_line
and I-cell_type I-cell_line
post-S I-cell_type I-cell_line
phase I-cell_type I-cell_line
cells I-cell_type I-cell_line
. O O

A O O
2- O O
to O O
3-fold O O
increase O O
in O O
glucocorticoid O B-protein
receptor O I-protein
sites O I-protein
per O O
cell O O
, O O
for O O
cells O O
in O O
the O O
S O O
and O O
post-S O O
phase O O
over O O
those O O
in O O
G0 O O
and O O
G1 O O
, O O
was O O
observed O O
with O O
both O O
nonstimulated B-cell_type O
rat I-cell_type O
lymph I-cell_type O
node I-cell_type O
cell I-cell_type O
suspensions I-cell_type O
and O O
concanavalin B-cell_line B-cell_line
A-stimulated I-cell_line I-cell_line
human I-cell_line I-cell_line
peripheral I-cell_line I-cell_line
lymphocytes I-cell_line I-cell_line
. O O

These O O
observations O O
together O O
with O O
those O O
from O O
other O O
studies O O
indicate O O
that O O
formation O O
of O O
new O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
near O O
the O O
S O O
phase O O
may O O
be O O
a O O
general O O
phenomenon O O
in O O
proliferating B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

We O O
propose O O
that O O
this O O
increase O O
in O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
during O O
the O O
cell O O
cycle O O
may O O
explain O O
the O O
increase O O
in O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
mitogen-stimulated B-cell_type B-cell_line
lymphocytes I-cell_type I-cell_line
. O O

The O O
leukocyte B-cell_type O
migration O O
inhibition O O
response O O
to O O
certain O O
breast B-protein O
cancer-related I-protein O
antigens I-protein O
( O O
MCF-7 B-protein O
and O O
MuMTV B-protein O
) O O
: O O
their O O
potential O O
as O O
discriminants O O
. O O

Certain O O
oncogenic O O
viruses O O
have O O
been O O
implicated O O
in O O
human O O
breast O O
cancer O O
, O O
including O O
the O O
murine O O
mammary O O
tumor O O
virus O O
( O O
MuMTV O O
) O O
and O O
the O O
Mason-Pfizer O O
monkey O O
virus O O
( O O
MPMV O O
) O O
. O O

We O O
have O O
used O O
the O O
leukocyte O O
migration O O
inhibition O O
( O O
LMI O O
) O O
response O O
to O O
assay O O
the O O
response O O
to O O
several O O
potential O O
breast O O
cancer-related O B-protein
antigens O I-protein
, O O
including O O
MuMTV B-protein O
, O O
MPMV B-protein O
, O O
and O O
a O O
breast B-cell_line B-cell_line
cancer I-cell_line I-cell_line
cultured I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
, O O
MCF-7 B-cell_line B-cell_line
, O O
in O O
96 O O
breast O O
cancer O O
patients O O
, O O
in O O
32 O O
women O O
with O O
benign O O
breast O O
disease O O
, O O
and O O
in O O
67 O O
normal O O
women O O
. O O

The O O
lowest O O
tenth O O
percentile O O
of O O
control O O
( O O
LMI O O
) O O
responses O O
was O O
used O O
as O O
the O O
cutoff O O
point O O
to O O
designate O O
responders O O
. O O

Breast O O
cancer O O
patients O O
showed O O
significant O O
responses O O
to O O
MuMTV B-protein O
( O O
49 O O
% O O
and O O
to O O
MCF-7 O B-cell_line
( O O
50 O O
% O O
) O O
, O O
but O O
not O O
to O O
MPMV B-protein O
( O O
29 O O
% O O
) O O
. O O

In O O
a O O
paired-antigen O O
study O O
using O O
MuMTV B-protein O
and O O
MCF-7 B-protein O
, O O
75 O O
% O O
of O O
the O O
breast O O
cancer O O
patients O O
responded O O
, O O
versus O O
18 O O
% O O
of O O
the O O
normal O O
women O O
( O O
P O O
less O O
than O O
0.0050 O O
) O O
. O O

The O O
potential O O
for O O
this O O
assay O O
to O O
distinguish O O
`` O O
normal O O
'' O O
from O O
`` O O
breast O O
cancer O O
'' O O
was O O
analyzed O O
using O O
a O O
migration O O
index O O
derived O O
from O O
discriminant O O
analysis O O
. O O

The O O
ability O O
of O O
the O O
assay O O
to O O
discriminate O O
`` O O
normal O O
'' O O
from O O
`` O O
cancer O O
'' O O
was O O
significant O O
( O O
P O O
less O O
than O O
0.001 O O
) O O
and O O
showed O O
a O O
sensitivity O O
of O O
detecting O O
`` O O
cancer O O
'' O O
of O O
75 O O
% O O
. O O

The O O
overall O O
responses O O
to O O
MuMTV B-protein O
and O O
MCF-7 B-protein O
were O O
analyzed O O
with O O
reference O O
to O O
certain O O
prognostic O O
factors O O
, O O
but O O
showed O O
no O O
relation O O
to O O
age O O
, O O
menstrual O O
status O O
, O O
estrogen O O
receptor O O
status O O
, O O
or O O
stage O O
of O O
disease O O
. O O

The O O
above O O
reactions O O
suggest O O
that O O
a O O
large O O
proportion O O
of O O
breast O O
cancer O O
patients O O
exhibit O O
presensitization O O
to O O
antigenfs O O
found O O
in O O
MuMTV B-protein O
and O O
MCF-7 B-protein B-cell_line
, O O
which O O
may O O
be O O
cross-reactive O O
with O O
antigens O O
in O O
the O O
primary O O
cancer O O
. O O

These O O
responses O O
appear O O
to O O
be O O
independent O O
of O O
major O O
prognostic O O
variables O O
. O O

Further O O
refinement O O
of O O
this O O
assay O O
may O O
yield O O
one O O
which O O
is O O
more O O
highly O O
discriminating O O
for O O
breast O O
cancer O O
. O O

Chronic O O
lymphatic O O
leukaemia O O
: O O
cellular O O
effects O O
of O O
glucocorticoids O O
in O O
vitro O O
. O O

Glucocorticoid B-protein B-protein
receptor I-protein I-protein
levels O O
and O O
steroid O O
induced O O
inhibition O O
of O O
nucleic O O
acid O O
precursors O O
have O O
been O O
examined O O
in O O
lymphocytes B-cell_type B-cell_type
from O O
27 O O
patients O O
at O O
different O O
stages O O
of O O
chronic O O
lymphatic O O
leukaemia O O
. O O

No O O
correlation O O
can O O
be O O
found O O
between O O
the O O
level O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
and O O
the O O
stage O O
of O O
the O O
disease O O
. O O

On O O
the O O
other O O
hand O O
, O O
a O O
significant O O
difference O O
( O O
P O O
less O O
than O O
0.02 O O
) O O
was O O
found O O
between O O
stage O O
O O O
and O O
stage O O
III/IV O O
patients O O
, O O
in O O
terms O O
of O O
the O O
in O O
vitro O O
effect O O
of O O
dexamethasone O O
on O O
[ O O
3H O O
] O O
uridine O O
incorporation O O
. O O

Pyrrolidine O O
dithiocarbamate O O
inhibits O O
NF-kappa B-protein B-protein
B I-protein I-protein
mobilization O O
and O O
TNF O B-protein
production O O
in O O
human B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
. O O

The O O
human B-DNA B-DNA
TNF I-DNA I-DNA
promoter I-DNA I-DNA
contains O O
four O O
potential O O
nuclear B-DNA B-protein
factor-kappa I-DNA I-protein
B I-DNA I-protein
( I-DNA O
NF-kappa I-DNA B-DNA
B I-DNA I-DNA
) I-DNA I-DNA
-binding I-DNA I-DNA
sites I-DNA I-DNA
, O O
with O O
the O O
strongest O O
binding O O
seen O O
for O O
the O O
-605 O B-DNA
motif O I-DNA
. O O

Nuclear O O
extracts O O
from O O
unstimulated B-cell_line B-cell_type
cells I-cell_line I-cell_type
of O O
the O O
human B-cell_line B-cell_line
monocytic I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
, O O
Mono B-cell_line B-cell_line
Mac I-cell_line I-cell_line
6 I-cell_line I-cell_line
, O O
contain O O
one O O
specific B-protein O
binding I-protein O
protein I-protein O
( O O
complex B-protein B-protein
II I-protein I-protein
) O O
, O O
consistent O O
with O O
a O O
constitutive B-protein O
p50 I-protein B-protein
homodimer I-protein I-protein
. O O

Stimulation O O
of O O
Mono B-cell_line B-cell_line
Mac I-cell_line I-cell_line
6 I-cell_line I-cell_line
cells I-cell_line I-cell_line
with O O
LPS O O
will O O
increase O O
complex B-protein B-protein
II I-protein I-protein
and O O
will O O
strongly O O
induce O O
a O O
second O O
specific O O
complex O O
( O O
complex B-protein B-protein
I I-protein I-protein
) O O
, O O
which O O
represents O O
the O O
p50/65 B-protein B-protein
heterodimer I-protein I-protein
. O O

Treatment O O
of O O
Mono B-cell_type B-cell_line
Mac I-cell_type I-cell_line
6 I-cell_type I-cell_line
cells I-cell_type I-cell_line
with O O
pyrrolidine-dithiocarbamate O O
( O O
PDTC O O
) O O
at O O
300 O O
microM O O
will O O
block O O
the O O
LPS-induced B-protein B-protein
complex I-protein I-protein
I I-protein I-protein
almost O O
completely O O
and O O
will O O
reduce O O
complex B-protein B-protein
II I-protein I-protein
to O O
the O O
constitutive O O
level O O
. O O

Binding O O
activity O O
of O O
other O O
nuclear B-protein B-protein
factors I-protein I-protein
that O O
recognize O O
the O O
SP-1 O B-DNA
and O I-DNA
c/EBP O I-DNA
motifs O I-DNA
of O O
the O O
human B-DNA B-DNA
TNF I-DNA I-DNA
promoter I-DNA I-DNA
is O O
not O O
affected O O
by O O
such O O
treatment O O
. O O

Northern O O
blot O O
analysis O O
demonstrates O O
that O O
PDTC O O
treatment O O
will O O
strongly O O
reduce O O
LPS-induced B-protein B-RNA
TNF I-protein I-RNA
transcripts I-protein I-RNA
. O O

Secreted O O
TNF B-protein B-protein
protein I-protein I-protein
as O O
detected O O
in O O
the O O
Wehi O O
164S/ActD O O
bioassay O O
and O O
in O O
a O O
sandwich O O
immunoassay O O
was O O
similarly O O
reduced O O
by O O
PDTC O O
. O O

Kinetic O O
analyses O O
show O O
that O O
after O O
LPS O O
stimulation O O
, O O
NF-kappa B-protein B-protein
B I-protein I-protein
will O O
peak O O
at O O
1 O O
h O O
, O O
TNF O B-RNA
transcript O I-RNA
prevalence O O
at O O
2 O O
h O O
, O O
and O O
TNF B-protein B-protein
protein I-protein I-protein
at O O
4 O O
h O O
. O O

PDTC O O
did O O
not O O
shift O O
this O O
response O O
to O O
LPS O O
to O O
a O O
later O O
time O O
, O O
but O O
suppressed O O
NF-kappa O B-protein
B O I-protein
mobilization O O
, O O
TNF B-protein B-RNA
transcripts I-protein I-RNA
, O O
and O O
TNF B-protein B-protein
protein I-protein I-protein
over O O
the O O
entire O O
8-h O O
observation O O
period O O
. O O

Analysis O O
of O O
freshly O O
isolated O O
, O O
LPS-stimulated B-cell_type B-cell_type
blood I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
showed O O
a O O
similar O O
blockade O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
. O O

Furthermore O O
, O O
in O O
these O O
primary O B-cell_type
cells O I-cell_type
, O O
induction O O
of O O
TNF B-protein B-RNA
transcripts I-protein I-RNA
, O O
as O O
determined O O
by O O
Northern O O
blot O O
analysis O O
and O O
by O O
quantitative O O
polymerase O O
chain O O
reaction O O
, O O
was O O
prevented O O
by O O
PDTC O O
as O O
was O O
TNF B-protein B-protein
protein I-protein O
production O O
. O O

These O O
data O O
show O O
that O O
dithiocarbamates O O
can O O
profoundly O O
affect O O
cytokine O B-protein
expression O O
and O O
suggest O O
that O O
NF-kappa B-protein B-protein
B I-protein I-protein
is O O
involved O O
in O O
LPS-induced O O
TNF O B-protein
gene O O
expression O O
in O O
human B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
. O O

Comparing O O
regions O O
of O O
the O O
Epstein-Barr B-protein B-protein
virus I-protein I-protein
ZEBRA I-protein I-protein
protein I-protein I-protein
which O O
function O O
as O O
transcriptional B-DNA B-DNA
activating I-DNA I-DNA
sequences I-DNA I-DNA
in O O
Saccharomyces O O
cerevisiae O O
and O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
ZEBRA B-protein B-protein
protein I-protein I-protein
activates O O
expression O O
of O O
Epstein-Barr O B-DNA
virus O I-DNA
early-lytic-cycle B-DNA I-DNA
genes I-DNA I-DNA
in O O
human B-cell_type B-cell_type
B I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Here O O
it O O
is O O
shown O O
that O O
ZEBRA B-protein B-protein
also O O
behaves O O
as O O
a O O
sequence-specific B-protein B-protein
transcriptional I-protein I-protein
activator I-protein I-protein
in O O
Saccharomyces O O
cerevisiae O O
. O O

Deletional O O
mutagenesis O O
defined O O
three O O
regions O O
of O O
ZEBRA B-protein B-protein
that O O
participate O O
in O O
activation O O
in O O
S. O O
cerevisiae O O
. O O

These O O
regions O O
are O O
designated O O
YI B-protein B-protein
( O O
amino B-protein B-protein
acids I-protein I-protein
[ I-protein O
aa I-protein O
] I-protein O
1 I-protein O
to I-protein O
25 I-protein O
) O O
, O O
YII B-protein O
( O O
aa B-protein O
51 I-protein O
to I-protein O
102 I-protein O
) O O
, O O
and O O
YIII B-protein B-protein
( O O
aa B-protein O
228 I-protein O
to I-protein O
245 I-protein O
) O O
. O O

Two O O
of O O
the O O
three O O
regions O O
of O O
the O O
native O O
ZEBRA B-protein B-protein
protein I-protein I-protein
act O O
together O O
to O O
mediate O O
activation O O
when O O
assayed O O
on O O
ZEBRA B-protein B-DNA
binding I-protein I-DNA
sites I-protein I-DNA
. O O

However O O
, O O
when O O
fused O O
to O O
the O O
DNA B-protein B-protein
binding I-protein I-protein
domain I-protein I-protein
of O O
GAL B-protein B-protein
4 O I-protein
and O O
assayed O O
on O O
GAL4 B-protein B-DNA
binding I-protein I-DNA
sites I-protein I-DNA
, O O
regions B-protein B-DNA
YII I-protein I-DNA
and I-protein O
YIII I-protein B-protein
were O O
each O O
sufficient O O
to O O
confer O O
activation O O
in O O
S. O O
cerevisiae O O
. O O

Regions O O
of O O
ZEBRA B-protein B-protein
which O O
affected O O
activation O O
in O O
S. O O
cerevisiae O O
were O O
also O O
required O O
in O O
human B-cell_type B-cell_type
B I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

The O O
amino-terminal B-protein B-protein
region I-protein I-protein
of O O
ZEBRA B-protein B-protein
( O O
aa B-protein B-protein
1 I-protein I-protein
to I-protein I-protein
98 I-protein I-protein
) O O
was O O
required O O
for O O
activation O O
both O O
in O O
S. O O
cerevisiae O O
and O O
in O O
human B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
; O O
deletion O O
of O O
the O O
carboxy-terminal B-protein B-protein
18 I-protein I-protein
aa I-protein I-protein
also O O
significantly O O
reduced O O
activation O O
in O O
both O O
cell O O
types O O
. O O

Thus O O
, O O
the O O
behavior O O
of O O
ZEBRA B-protein B-protein
in O O
human B-cell_type B-cell_type
B I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
S. O O
cerevisiae O O
suggests O O
that O O
the O O
protein O O
contains O O
universal B-protein B-DNA
activation I-protein I-DNA
motifs I-protein I-DNA
that O O
interact O O
with O O
conserved O O
components O O
of O O
the O O
transcription O O
machinery O O
. O O

However O O
, O O
certain O O
deletion B-protein O
mutants I-protein O
of O O
ZEBRA B-protein B-protein
containing O O
mutations O O
in O O
the O O
N-terminal B-protein B-protein
region I-protein I-protein
exhibited O O
discordant O O
behaviors O O
in O O
S. O O
cerevisiae O O
and O O
in O O
B O B-cell_type
cells O I-cell_type
. O O

For O O
example O O
, O O
deletion O O
of O O
ZEBRA B-protein B-protein
aa I-protein I-protein
26 I-protein I-protein
to I-protein O
51 I-protein O
impaired O O
activation O O
to O O
a O O
great O O
extent O O
in O O
B B-cell_type B-cell_type
cells I-cell_type I-cell_type
but O O
had O O
little O O
or O O
no O O
effect O O
in O O
S. O O
cerevisiae O O
. O O

The O O
discordant O O
mutants O O
may O O
reflect O O
interactions O O
with O O
a O O
variable B-protein B-protein
domain I-protein I-protein
of O O
a O O
conserved O O
component O O
or O O
unique O O
interactions O O
with O O
specialized O O
components O O
of O O
the O O
basal O O
transcription O O
apparatus O O
in O O
different O O
cells O O
. O O

Functional O O
interaction O O
of O O
the O O
v-Rel B-protein B-protein
and I-protein I-protein
c-Rel I-protein I-protein
oncoproteins I-protein I-protein
with O O
the O O
TATA-binding B-protein B-protein
protein I-protein I-protein
and O O
association O O
with O O
transcription B-protein B-protein
factor I-protein I-protein
IIB I-protein I-protein
. O O

Rel B-protein B-protein
family I-protein I-protein
proteins I-protein I-protein
regulate O O
the O O
expression O O
of O O
genes O O
linked O O
to O O
kappa O B-DNA
B-binding O I-DNA
motifs O I-DNA
. O O

Little O O
is O O
known O O
, O O
however O O
, O O
of O O
the O O
mechanism O O
by O O
which O O
they O O
enhance O O
transcription O O
. O O

We O O
have O O
investigated O O
the O O
ability O O
of O O
the O O
v-Rel B-protein B-protein
and I-protein I-protein
c-Rel I-protein I-protein
oncoproteins I-protein I-protein
to O O
interact O O
with O O
components O O
of O O
the O O
basal O O
transcription O O
machinery O O
. O O

Here O O
we O O
report O O
that O O
both O O
the O O
acidic O B-protein
transcription O I-protein
activation O I-protein
domain O I-protein
mapping O O
to O O
the O O
unique O O
C B-protein B-protein
terminus I-protein I-protein
of O O
chicken B-protein O
c-Rel I-protein B-protein
and O O
the O O
F9 B-protein B-DNA
cell-specific I-protein I-DNA
activation I-protein I-DNA
region I-protein I-DNA
common O O
to O O
both O O
v-Rel B-protein B-protein
and O O
c-Rel B-protein B-protein
interact O O
with O O
the O O
TATA-binding B-protein B-protein
protein I-protein I-protein
( O O
TBP B-protein B-protein
) O O
and O O
transcription B-protein B-protein
factor I-protein I-protein
IIB I-protein I-protein
( O O
TFIIB B-protein B-protein
) O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

We O O
also O O
demonstrate O O
that O O
TPB B-protein O
interaction O O
with O O
Rel B-protein B-protein
activation I-protein I-protein
regions I-protein I-protein
leads O O
to O O
synergistic O O
activation O O
of O O
transcription O O
of O O
a O O
kappa B-DNA B-DNA
B-linked I-DNA I-DNA
reporter I-DNA I-DNA
gene I-DNA I-DNA
. O O

Combined O O
with O O
the O O
observation O O
that O O
the O O
mouse B-protein O
c-Rel I-protein B-protein
and I-protein O
human I-protein B-protein
RelA I-protein I-protein
proteins I-protein I-protein
also O O
interact O O
with O O
TBP B-protein B-protein
and O O
TFIIB B-protein B-protein
in O O
vitro O O
, O O
these O O
results O O
suggest O O
that O O
association O O
with O O
basal B-protein B-protein
transcription I-protein I-protein
factors I-protein I-protein
is O O
important O O
for O O
the O O
transcriptional O O
activities O O
of O O
Rel B-protein B-protein
family I-protein I-protein
proteins I-protein I-protein
. O O

p21ras B-protein B-protein
and O O
calcineurin O B-protein
synergize O O
to O O
regulate O O
the O O
nuclear B-protein B-protein
factor I-protein I-protein
of O I-protein
activated O I-protein
T B-cell_type I-protein
cells I-cell_type I-protein
. O O

In O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
, O O
triggering O O
of O O
the O O
T B-protein B-protein
cell I-protein I-protein
receptor I-protein I-protein
( O O
TCR B-protein B-protein
) O O
induces O O
several O O
signaling O O
cascades O O
which O O
ultimately O O
synergize O O
to O O
induce O O
the O O
activity O O
of O O
the O O
nuclear B-protein B-protein
factor I-protein I-protein
of O I-protein
activated O I-protein
T B-cell_type I-protein
cells I-cell_type I-protein
( O O
NFAT B-cell_line B-protein
) O O
, O O
a O O
DNA B-protein B-protein
binding I-protein I-protein
complex I-protein I-protein
critical O O
to O O
the O O
inducibility O O
and O O
T O O
cell O O
specificity O O
of O O
the O O
T B-protein B-protein
cell I-protein I-protein
growth I-protein I-protein
factor I-protein I-protein
interleukin B-protein B-protein
2 I-protein I-protein
. O O

One O O
immediate O O
consequence O O
of O O
T O O
cell O O
activation O O
via O O
the O O
TCR B-protein B-protein
is O O
an O O
increase O O
in O O
cytosolic O O
calcium O O
. O O

Calcium O O
signals O O
are O O
important O O
for O O
NFAT B-cell_line B-protein
induction O O
, O O
and O O
recent O O
studies O O
have O O
identified O O
calcineurin B-protein B-protein
, O O
a O O
calcium-calmodulin B-protein B-protein
dependent I-protein I-protein
serine-threonine I-protein I-protein
phosphatase I-protein I-protein
, O O
as O O
a O O
prominent O O
component O O
of O O
the O O
calcium O O
signaling O O
pathway O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

A O O
second O O
important O O
molecule O O
in O O
TCR O B-protein
signal O O
transduction O O
is O O
the O O
guanine B-protein B-protein
nucleotide I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
, O O
p21ras B-protein B-protein
, O O
which O O
is O O
coupled O O
to O O
the O O
TCR B-protein B-protein
by O O
a O O
protein B-protein B-protein
tyrosine I-protein I-protein
kinase I-protein I-protein
dependent O O
mechanism O O
. O O

The O O
experiments O O
presented O O
here O O
show O O
that O O
expression O O
by O O
transfection O O
of O O
mutationally O O
activated O O
calcineurin B-protein B-protein
or O O
activated O O
p21ras B-protein B-protein
alone O O
is O O
insufficient O O
for O O
NFAT B-cell_type B-protein
transactivation O O
. O O

However O O
, O O
coexpression O O
of O O
the O O
activated O O
calcineurin O B-protein
with O O
activated O O
p21ras O B-protein
could O O
mimic O O
TCR O B-protein
signals O O
in O O
NFAT B-cell_type B-protein
induction O O
. O O

These O O
data O O
identify O O
calcineurin B-protein B-protein
and O O
p21ras B-protein B-protein
as O O
cooperative O O
partners O O
in O O
T B-cell_type O
cell I-cell_type O
activation O O
. O O

Expression O O
of O O
the O O
chicken B-protein B-protein
GATA I-protein I-protein
factor I-protein I-protein
family I-protein I-protein
during O O
early O O
erythroid O O
development O O
and O O
differentiation O O
. O O

The O O
DNA O B-DNA
motif O I-DNA
WGATAR O B-protein
has O O
been O O
identified O O
within O O
transcriptional B-DNA B-DNA
regulatory I-DNA I-DNA
domains I-DNA I-DNA
of O O
globin B-DNA B-protein
and O O
other O O
erythroid-specific B-DNA B-DNA
genes I-DNA I-DNA
and O O
the O O
activator B-protein B-protein
proteins I-protein I-protein
that O O
bind O O
to O O
this O O
regulatory B-DNA B-DNA
element I-DNA I-DNA
, O O
the O O
GATA B-protein B-protein
factors I-protein I-protein
, O O
belong O O
to O O
a O O
multi-gene B-protein O
family I-protein O
that O O
is O O
expressed O O
in O O
chicken B-cell_type B-cell_type
erythroid I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Here O O
we O O
show O O
that O O
, O O
as O O
in O O
chickens O O
, O O
multiple O O
members O O
of O O
the O O
GATA B-protein B-protein
factor I-protein I-protein
family I-protein I-protein
are O O
expressed O O
in O O
human B-cell_type B-cell_type
and I-cell_type I-cell_type
murine I-cell_type I-cell_type
erythroid I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

During O O
the O O
early O O
stages O O
of O O
chicken O O
embryogenesis O O
( O O
well O O
before O O
blood O O
island O O
formation O O
) O O
, O O
each O O
of O O
the O O
GATA B-protein B-protein
family I-protein I-protein
members I-protein I-protein
is O O
transcribed O O
with O O
a O O
unique O O
temporal O O
and O O
spatial O O
pattern O O
. O O

In O O
the O O
primitive B-cell_type B-cell_type
erythroid I-cell_type I-cell_type
lineage I-cell_type I-cell_type
, O O
transcription O O
of O O
the O O
embryonic B-DNA B-DNA
epsilon-globin I-DNA I-DNA
gene I-DNA I-DNA
parallels O O
GATA-1 O B-protein
expression O O
while O O
the O O
switch O O
to O O
beta-globin O B-protein
transcription O O
in O O
definitive B-cell_type B-cell_type
erythroid I-cell_type I-cell_type
cells I-cell_type I-cell_type
is O O
directly O O
preceded O O
by O O
a O O
pronounced O O
increase O O
in O O
GATA-3 B-protein B-protein
accumulation O O
. O O

The O O
timing O O
and O O
pattern O O
of O O
expression O O
of O O
these O O
different O O
mRNAs B-RNA B-RNA
during O O
avian O O
erythroid O O
development O O
and O O
differentiation O O
suggests O O
that O O
temporally O O
regulated O O
changes O O
in O O
GATA B-protein B-protein
factor I-protein I-protein
expression O O
are O O
required O O
for O O
vertebrate O O
hematopoiesis O O
. O O

Molecular O O
regulation O O
of O O
human B-protein B-protein
interleukin I-protein I-protein
2 I-protein I-protein
and O I-protein
T-cell B-cell_type I-protein
function O O
by O O
interleukin B-protein B-protein
4 I-protein I-protein
. O O

Distinct O O
functional O B-cell_type
T-cell B-cell_type I-cell_type
subsets I-cell_type I-cell_type
, O O
differing O O
in O O
the O O
patterns O O
of O O
lymphokines B-protein B-protein
produced O O
, O O
regulate O O
cell-mediated O O
and O O
humoral O O
immune O O
responses O O
. O O

The O O
two O O
major O O
types O O
and O O
their O O
principal O O
products O O
, O O
interleukin B-protein B-protein
4 I-protein I-protein
and O O
interferon B-protein B-protein
gamma I-protein I-protein
( O O
IL-4 B-protein B-protein
and O O
IFN-gamma B-protein B-protein
) O O
, O O
are O O
reciprocally O O
negatively O O
interactive O O
. O O

To O O
analyze O O
the O O
molecular O O
mechanism O O
of O O
IL-4-mediated O O
suppression O O
of O O
cell-mediated O O
immunity O O
we O O
studied O O
its O O
effects O O
on O O
expression O O
of O O
interleukin B-protein B-protein
2 I-protein I-protein
( O O
IL-2 B-protein B-protein
) O O
and O O
IFN-gamma B-protein B-protein
. O O

IL-4 B-protein B-protein
pretreatment O O
of O O
Jurkat B-cell_type B-cell_line
cells I-cell_type I-cell_line
prior O O
to O O
stimulation O O
resulted O O
in O O
a O O
decrease O O
in O O
transcription O O
of O O
the O O
IL2 B-DNA B-DNA
gene I-DNA I-DNA
. O O

IL-4 B-protein B-protein
suppressed O O
IL-2 O B-protein
and O O
IFN-gamma O O
mRNA O O
levels O O
in O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
and O O
addition O O
of O O
anti-CD28 B-protein B-protein
antibodies I-protein I-protein
relieved O O
this O O
suppression O O
. O O

Using O O
enhancer-reporter B-DNA B-DNA
constructs I-DNA I-DNA
, O O
IL-4 B-protein B-protein
specifically O O
down-regulated O O
the O O
NFIL-2B B-DNA B-DNA
element I-DNA I-DNA
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
using O O
a O O
DNA O B-DNA
oligomer O I-DNA
containing O O
the O O
NFIL-2B B-DNA B-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
indicated O O
that O O
IL-4 B-protein B-protein
inhibited O O
the O O
NFIL-2B B-protein B-protein
complex I-protein I-protein
and O O
that O O
the O O
NFIL-2B B-protein B-protein
DNA I-protein I-protein
binding I-protein I-protein
factor I-protein I-protein
is O O
distinct O O
from O O
AP- B-protein O
1 O O
. O O

These O O
results O O
suggest O O
that O O
IL-4 B-protein B-protein
may O O
regulate O O
development O O
and O O
function O O
of O O
T-cell B-cell_type B-cell_type
subsets I-cell_type I-cell_type
involved O O
in O O
cell-mediated O O
immunity O O
in O O
part O O
by O O
inhibiting B-protein B-protein
factors I-protein I-protein
required O O
for O O
transcription O O
of O O
the O O
IL2 B-DNA B-DNA
gene I-DNA I-DNA

Immunochemical O O
differences O O
between O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
from O O
corticoid-sensitive B-cell_type B-cell_line
and I-cell_type I-cell_line
-resistant I-cell_type I-cell_line
malignant I-cell_type I-cell_line
lymphocytes I-cell_type I-cell_line
. O O

We O O
have O O
explored O O
the O O
possibility O O
of O O
using O O
antibodies B-protein B-protein
against O O
purified O O
rat O B-protein
liver O I-protein
glucocorticoid B-protein I-protein
receptors I-protein I-protein
to O O
study O O
the O O
immunochemical O O
properties O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
from O O
murine B-cell_type O
and I-cell_type O
human I-cell_type B-cell_type
malignant I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

For O O
this O O
purpose O O
, O O
purified B-protein B-protein
immune I-protein I-protein
immunoglobulin I-protein I-protein
G I-protein I-protein
was O O
covalently O O
linked O O
to O O
Sepharose B-protein O
CL-4B I-protein O
. O O

We O O
then O O
examined O O
the O O
ability O O
of O O
the O O
affinity O O
gel O O
to O O
recognize O O
cytosolic B-protein O
[ I-protein O
3H I-protein O
] I-protein O
triamcinolone I-protein B-protein
acetonide-receptor I-protein I-protein
complexes I-protein I-protein
from O O
the O O
corticoid-sensitive B-cell_line O
( I-cell_line O
CS I-cell_line O
) I-cell_line O
and I-cell_line O
-resistant I-cell_line O
strains I-cell_line O
of I-cell_line O
mouse I-cell_line O
lymphoma I-cell_line O
P1798 I-cell_line O
, O O
from O O
CS B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
of O O
patients O O
with O O
chronic O O
lymphatic O O
leukemia O O
, O O
and O O
from O O
a O O
CS B-cell_line B-cell_line
clone I-cell_line I-cell_line
of O O
human B-cell_type B-cell_type
leukemic I-cell_type I-cell_type
lymphoblasts I-cell_type I-cell_type
in O O
tissue O O
culture O O
( O O
CH6 B-cell_line O
) O O
. O O

Mouse O O
thymus O O
was O O
used O O
as O O
a O O
source O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
from O O
normal B-cell_type B-cell_type
CS I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Whereas O O
the O O
immunoaffinity O O
column O O
retained O O
70 O O
to O O
84 O O
% O O
of O O
the O O
58- O O
to O O
62-A O O
( O O
Stokes O O
radius O O
) O O
[ B-protein O
3H I-protein O
] I-protein O
triamcinolone I-protein O
acetonide-receptor I-protein B-protein
complexes I-protein I-protein
characteristic O O
of O O
the O O
CS B-cell_line B-cell_line
mouse I-cell_line I-cell_line
and I-cell_line O
human I-cell_line B-cell_type
lymphocytes I-cell_line I-cell_type
, O O
it O O
failed O O
to O O
recognize O O
the O O
27- O O
to O O
28-A O O
( O O
Stokes O O
radius O O
) O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
present O O
in O O
corticoid-resistant O B-cell_line
mouse B-cell_line I-cell_line
lymphoma I-cell_line I-cell_line
P1798 I-cell_line I-cell_line
cells I-cell_line I-cell_line
. O O

Therefore O O
, O O
under O O
appropriate O O
experimental O O
conditions O O
, O O
it O O
was O O
possible O O
to O O
demonstrate O O
cross-reactivity O O
between O O
the O O
antiserum O O
against O O
rat B-protein B-protein
liver I-protein I-protein
glucocorticoid I-protein I-protein
receptor I-protein I-protein
and O O
the O O
58- O O
to O O
62-A O O
( O O
Stokes O O
radius O O
) O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
from O O
species O O
as O O
diverse O O
as O O
mouse O O
and O O
humans O O
. O O

Heterogeneity O O
of O O
the O O
in O O
vitro O O
responses O O
to O O
glucocorticoids O O
in O O
acute O O
leukemia O O
. O O

In O O
leukocyte B-cell_type B-cell_type
population I-cell_type I-cell_type
freshly O O
isolated O O
from O O
the O O
blood O O
of O O
26 O O
patients O O
with O O
acute O O
leukemia O O
, O O
we O O
have O O
measured O O
several O O
parameters O O
including O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
, O O
nucleoside O O
incorporation O O
, O O
percentage O O
of O O
cells O O
in O O
S O O
phase O O
, O O
and O O
steroid-induced O O
cell O O
lysis O O
. O O

In O O
addition O O
, O O
in O O
some O O
cases O O
, O O
the O O
short-term O O
response O O
to O O
steroid O O
therapy O O
was O O
determined O O
. O O

Although O O
, O O
in O O
all O O
the O O
patients O O
studied O O
, O O
leukocytes B-cell_type B-cell_type
were O O
found O O
to O O
contain O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
, O O
we O O
failed O O
to O O
demonstrate O O
any O O
correlation O O
between O O
the O O
level O O
of O O
binding O B-DNA
sites O I-DNA
and O O
the O O
in O O
vitro O O
or O O
in O O
vivo O O
response O O
to O O
glucocorticoids O O
. O O

This O O
absence O O
of O O
correlation O O
could O O
be O O
in O O
part O O
explained O O
by O O
the O O
marked O O
heterogeneity O O
of O O
the O O
steroid O O
response O O
demonstrated O O
in O O
leukocyte O B-cell_type
subpopulations O I-cell_type
. O O

It O O
appears O O
, O O
however O O
, O O
that O O
the O O
degree O O
of O O
steroid O O
action O O
in O O
vitro O O
as O O
well O O
as O O
the O O
extent O O
of O O
spontaneous O O
and O O
dexamethasone-induced O O
cell O O
death O O
may O O
be O O
related O O
to O O
the O O
number O O
of O O
cells O O
in O O
the O O
S O O
phase O O
of O O
the O O
cell O O
cycle O O
. O O

Glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
cytosol O O
and O O
nuclear O O
extract O O
of O O
human B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
. O O

Cortisol O O
binding O O
by O O
cytosol O O
and O O
0.4 O O
M O O
KCl O O
extract O O
of O O
the O O
nuclear O O
fraction O O
of O O
human B-cell_type B-cell_type
leukocytes I-cell_type I-cell_type
were O O
studied O O
by O O
gel O O
chromatography O O
and O O
ion O O
exchange O O
filtration O O
on O O
DEAE O O
cellulose O O
. O O

The O O
cytoplasmic B-protein B-protein
cortisol I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
has O O
a O O
molecular O O
weight O O
95 O B-protein
000 O I-protein
and O O
the O O
soluble B-protein B-protein
nuclear I-protein I-protein
binding I-protein I-protein
protein I-protein I-protein
50 O I-protein
000 O I-protein
. O O

The O O
absence O O
of O O
the O O
uptake O O
of O O
radioactive O O
cortisol O O
by O O
isolated O O
nuclei O O
and O O
the O O
apparent O O
requirement O O
of O O
the O O
cytosol O O
for O O
glucocorticoid O O
specific O O
binding O O
in O O
nuclear O B-DNA
receptor O I-DNA
sites O I-DNA
was O O
observed O O
. O O

The O O
association O O
constant O O
characterising O O
the O O
binding O O
of O O
cortisol O O
to O O
cytosol O O
was O O
KA O O
= O O
3.5 O O
. O O
10 O O
( O O
9 O O
) O O
l/mol O O
. O O

Corticosteroid-induced O O
lymphopenia O O
, O O
immunosuppression O O
, O O
and O O
body O O
defense O O
. O O

The O O
apparent O O
paradox O O
of O O
heightened O O
adrenal O O
corticosteroid O O
levels O O
associated O O
with O O
reduction O O
in O O
the O O
competence O O
of O O
the O O
body O O
's O O
defensive O O
apparatus O O
to O O
cope O O
with O O
exposure O O
to O O
new O O
microbial B-protein B-protein
antigens I-protein I-protein
is O O
considered O O
. O O

The O O
question O O
is O O
asked O O
how O O
this O O
lowered O O
defensive O O
capability O O
, O O
which O O
occurs O O
in O O
the O O
face O O
of O O
a O O
threat O O
to O O
body O O
integrity O O
, O O
is O O
consistent O O
with O O
Cannon O O
's O O
principals O O
of O O
the O O
`` O O
wisdom O O
of O O
the O O
body. O O
'' O O

The O O
suggestion O O
is O O
offered O O
that O O
the O O
immunologic O O
response O O
to O O
self-antigens B-protein B-protein
exposed O O
by O O
disease O O
or O O
trauma O O
may O O
be O O
suppressed O O
by O O
corticosteroid O O
to O O
offset O O
the O O
likelihood O O
of O O
autoimmune O O
attack O O
. O O

Protein B-protein B-protein
tyrosine I-protein I-protein
kinase I-protein I-protein
activation O O
is O O
required O O
for O O
lipopolysaccharide O O
induction O O
of O O
cytokines B-protein B-protein
in O O
human B-cell_type B-cell_type
blood I-cell_type I-cell_type
monocytes I-cell_type I-cell_type
. O O

Bacterial O O
LPS O O
induce O O
production O O
of O O
cytokines B-protein B-protein
such O O
as O O
IL-1 B-protein B-protein
, O O
IL-6 B-protein B-protein
, O O
and O O
TNF B-protein B-protein
in O O
mononuclear B-cell_type B-cell_type
phagocytes I-cell_type I-cell_type
, O O
and O O
this O O
represents O O
a O O
central O O
component O O
in O O
the O O
pathogenesis O O
of O O
septic O O
shock O O
syndrome O O
. O O

However O O
, O O
the O O
mechanisms O O
by O O
which O O
LPS O O
activates O O
these O O
cells O O
to O O
express O O
cytokines B-protein B-protein
are O O
not O O
completely O O
characterized O O
. O O

The O O
present O O
study O O
addressed O O
the O O
role O O
of O O
different O O
protein B-protein B-protein
kinases I-protein I-protein
in O O
the O O
LPS O O
induction O O
of O O
cytokines B-protein B-protein
. O O

It O O
is O O
shown O O
that O O
LPS O O
induced O O
a O O
12- O O
to O O
16-fold O O
increase O O
in O O
IL-1 O B-protein
beta O I-protein
, O O
IL-6 O B-protein
, O O
and O O
TNF-alpha O B-protein
mRNA O O
levels O O
, O O
and O O
this O O
was O O
completely O O
or O O
more O O
than O O
80 O O
% O O
blocked O O
by O O
the O O
protein O B-protein
tyrosine O I-protein
kinase O I-protein
specific O O
inhibitors O O
herbimycin O O
A O O
and O O
genistein O O
at O O
the O O
concentrations O O
of O O
1.7 O O
and O O
37 O O
microM O O
, O O
respectively O O
. O O

Protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
inhibition O O
by O O
staurosporine O O
reduced O O
LPS O O
induction O O
of O O
TNF-alpha B-protein B-protein
, O O
whereas O O
it O O
had O O
no O O
effects O O
on O O
IL-6 B-protein B-protein
and O O
IL-1 O B-protein
beta O I-protein
. O O

Inhibition O O
of O O
protein B-protein B-protein
kinase I-protein I-protein
A I-protein I-protein
by O O
H89 O O
reduced O O
IL-6 B-RNA B-protein
mRNA I-RNA O
levels O O
but O O
did O O
not O O
detectably O O
change O O
IL-1 O B-protein
beta O I-protein
or O O
TNF-alpha O O
mRNA O O
levels O O
. O O

In O O
contrast O O
, O O
LPS O O
did O O
not O O
increase O O
leukemia B-RNA B-RNA
inhibitory I-RNA I-RNA
factor I-RNA I-RNA
mRNA I-RNA I-RNA
, O O
which O O
was O O
constitutively O O
expressed O O
and O O
not O O
significantly O O
reduced O O
by O O
these O O
inhibitors O O
. O O

In O O
addition O O
to O O
cytokine B-RNA B-RNA
mRNA I-RNA I-RNA
levels O O
, O O
LPS-induced O O
IL-6 O B-protein
protein O I-protein
synthesis O O
and O O
IL-6 O B-protein
bioactivity O O
were O O
also O O
reduced O O
to O O
baseline O O
levels O O
by O O
the O O
PTK O B-protein
inhibitors O O
herbimycin O O
A O O
and O O
genistein O O
. O O

Both O O
PTK O B-protein
inhibitors O O
also O O
reduced O O
the O O
LPS O O
activation O O
of O O
nuclear B-protein B-protein
factor-kappa I-protein I-protein
B I-protein I-protein
( O O
NF-kappa B-protein B-protein
B I-protein I-protein
) O O
, O O
which O O
is O O
a O O
transcription B-protein B-protein
factor I-protein I-protein
involved O O
in O O
the O O
expression O O
of O O
cytokine B-RNA B-DNA
genes I-RNA I-DNA
such O O
as O O
IL-6 B-DNA B-protein
and O O
TNF-alpha B-DNA B-protein
. O O

The O O
activation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
was O O
also O O
reduced O O
by O O
H89 O O
, O O
whereas O O
staurosporine O O
had O O
no O O
effect O O
on O O
this O O
response O O
. O O

In O O
summary O O
, O O
these O O
findings O O
suggest O O
that O O
protein B-protein B-protein
kinase I-protein I-protein
C I-protein I-protein
and O O
protein B-protein B-protein
kinase I-protein I-protein
A I-protein I-protein
appear O O
to O O
have O O
selective O O
effects O O
in O O
the O O
LPS O O
induction O O
of O O
cytokines B-protein B-protein
, O O
whereas O O
PTK B-protein B-protein
is O O
required O O
for O O
LPS O O
induction O O
of O O
a O O
broad O O
spectrum O O
of O O
cytokines B-protein B-protein
and O O
NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
in O O
monocytes B-cell_type B-cell_type
. O O

In O O
vivo O O
control O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
activation O O
by O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
. O O

The O O
transcription B-protein B-protein
factor I-protein I-protein
NF-kappa B-protein I-protein
B I-protein I-protein
is O O
stored O O
in O O
the O O
cytoplasm O O
in O O
complexes O O
with O O
the O O
inhibitor B-protein B-protein
protein I-protein I-protein
I I-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
. O O

It O O
has O O
been O O
shown O O
in O O
vitro O O
that O O
dissociation O O
of O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
from O O
these O O
complexes O O
results O O
in O O
active B-protein O
NF-kappa I-protein B-protein
B I-protein I-protein
. O O

In O O
this O O
report O O
we O O
show O O
that O O
lipopolysaccharide O O
( O O
LPS O O
) O O
-induced O O
activation O O
of O O
B B-cell_type B-cell_type
or I-cell_type I-cell_type
pre-B I-cell_type I-cell_type
cells I-cell_type I-cell_type
results O O
in O O
loss O O
of O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
from O O
NF-kappa B-protein B-protein
B I-protein I-protein
complexes I-protein I-protein
in O O
vivo O O
. O O

Many O O
liberated O O
NF-kappa B-protein B-protein
B I-protein I-protein
dimers I-protein I-protein
reached O O
the O O
nucleus O O
, O O
where O O
increased O O
c-rel B-protein B-protein
, O O
p65 O B-protein
and O O
p50 O B-protein
were O O
detected O O
by O O
immunoblotting O O
and O O
by O O
DNA O O
binding O O
assays O O
. O O

Some O O
liberated B-protein B-protein
dimers I-protein I-protein
were O O
retained O O
in O O
the O O
cytoplasm O O
, O O
however O O
, O O
through O O
binding O O
to O O
newly O O
synthesized O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
, O O
a O O
finding O O
which O O
strongly O O
suggests O O
( O O
i O O
) O O
that O O
the O O
LPS-induced O O
signal O O
causes O O
dissociation O O
of O O
complexes O O
rather O O
than O O
preventing O O
their O O
association O O
and O O
( O O
ii O O
) O O
that O O
dissociation O O
results O O
from O O
modification O O
of O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
and O O
not O O
of O O
c-rel B-protein B-protein
or O O
p65 B-protein B-protein
. O O

No O O
effect O O
of O O
LPS O O
treatment O O
was O O
detected O O
on O O
p105 B-protein B-protein
or O O
p100 B-protein B-protein
, O O
which O O
also O O
retain O O
rel B-protein B-protein
family I-protein I-protein
members I-protein I-protein
in O O
the O O
cytoplasm O O
. O O

Quite O O
unexpectedly O O
, O O
we O O
also O O
found O O
that O O
in O O
unstimulated B-cell_type B-cell_type
cells I-cell_type I-cell_type
there O O
is O O
a O O
constant O O
ongoing O O
process O O
of O O
degradation O O
and O O
replacement O O
of O O
complexed B-protein O
I I-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
. O O

We O O
propose O O
that O O
this O O
turnover O O
results O O
in O O
the O O
low O O
level O O
of O O
active B-protein O
NF-kappa I-protein B-protein
B I-protein I-protein
presumably O O
necessary O O
even O O
in O O
the O O
unstimulated O B-cell_type
cell O I-cell_type
, O O
and O O
that O O
the O O
high O O
rate O O
of O O
synthesis O O
of O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
provides O O
the O O
ability O O
to O O
turn O O
off O O
NF-kappa B-protein B-protein
B I-protein I-protein
activity O O
rapidly O O
as O O
soon O O
as O O
the O O
activating O O
signal O O
ceases O O
. O O

Identification O O
of O O
a O O
killer B-DNA B-DNA
cell-specific I-DNA I-DNA
regulatory I-DNA I-DNA
element I-DNA I-DNA
of O O
the O O
mouse B-DNA B-DNA
perforin I-DNA I-DNA
gene I-DNA I-DNA
: O O
an O O
Ets-binding O B-DNA
site-homologous O I-DNA
motif O I-DNA
that O O
interacts O O
with O O
Ets-related B-protein B-protein
proteins I-protein I-protein
. O O

The O O
gene O O
encoding O O
the O O
cytolytic B-protein B-protein
protein I-protein I-protein
perforin B-protein I-protein
is O O
selectively O O
expressed O O
by O O
activated B-cell_type B-cell_type
killer I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

To O O
understand O O
the O O
mechanisms O O
underlying O O
the O O
cell-type-specific O O
expression O O
of O O
this O O
gene O O
, O O
we O O
have O O
characterized O O
the O O
regulatory O O
functions O O
and O O
the O O
DNA-protein O O
interactions O O
of O O
the O O
5'-flanking B-DNA B-DNA
region I-DNA I-DNA
of O O
the O O
mouse B-DNA B-DNA
perforin I-DNA I-DNA
gene I-DNA I-DNA
( O O
Pfp B-DNA O
) O O
. O O

A O O
region O O
extending O O
from O O
residues B-DNA B-protein
+62 I-DNA I-protein
through I-DNA O
-141 I-DNA O
, O O
which O O
possesses O O
the O O
essential O O
promoter O O
activity O O
, O O
and O O
regions O O
further O O
upstream O O
, O O
which O O
are O O
able O O
to O O
either O O
enhance O O
or O O
suppress O O
gene O O
expression O O
, O O
were O O
identified O O
. O O

The O O
region O O
between O O
residues B-DNA B-protein
-411 I-DNA I-protein
and I-DNA O
-566 I-DNA O
was O O
chosen O O
for O O
further O O
characterization O O
, O O
since O O
it O O
contains O O
an O O
enhancer-like O O
activity O O
. O O

We O O
have O O
identified O O
a O O
32-mer O O
sequence O O
( O O
residues B-DNA B-DNA
-491 I-DNA I-DNA
to I-DNA I-DNA
-522 I-DNA I-DNA
) O O
which O O
appeared O O
to O O
be O O
capable O O
of O O
enhancing O O
gene O O
expression O O
in O O
a O O
killer O O
cell-specific O O
manner O O
. O O

Within O O
this O O
segment O O
, O O
a O O
9-mer O B-DNA
motif O I-DNA
( O O
5'-ACAGGAAGT-3 O O
' O O
, O O
residues B-DNA B-DNA
-505 I-DNA I-DNA
to I-DNA I-DNA
-497 I-DNA I-DNA
; O O
designated O O
NF-P O B-DNA
motif O I-DNA
) O O
, O O
which O O
is O O
highly O O
homologous O O
to O O
the O O
Ets B-DNA B-DNA
proto-oncoprotein-binding I-DNA I-DNA
site I-DNA I-DNA
, O O
was O O
found O O
to O O
interact O O
with O O
two O O
proteins O O
, O O
NF-P1 B-protein B-protein
and O O
NF-P2 B-protein B-protein
. O O

NF-P2 B-protein B-protein
appears O O
to O O
be O O
induced O O
by O O
reagents O O
known O O
to O O
up-regulate O O
the O O
perforin O B-protein
message O O
level O O
and O O
is O O
present O O
exclusively O O
in O O
killer B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Electrophoretic O O
mobility O O
shift O O
assay O O
and O O
UV O O
cross-linking O O
experiments O O
revealed O O
that O O
NF-P1 B-protein B-protein
and O O
NF-P2 B-protein B-protein
may O O
possess O O
common O O
DNA-binding B-protein B-protein
subunits I-protein I-protein
. O O

However O O
, O O
the O O
larger O O
native O O
molecular O O
mass O O
of O O
NF-P1 B-protein B-protein
suggests O O
that O O
NF-P1 B-protein B-protein
contains O O
an O O
additional O O
non-DNA-binding B-protein B-protein
subunit I-protein I-protein
( O O
s O O
) O O
. O O

In O O
view O O
of O O
the O O
homology O O
between O O
the O O
NF-P B-protein B-DNA
motif I-protein I-DNA
and O O
other O O
Ets B-protein B-DNA
proto-oncoprotein-binding I-protein I-DNA
sites I-protein I-DNA
, O O
it O O
is O O
postulated O O
that O O
NF-P1 B-protein B-protein
and O O
NF-P2 B-protein B-protein
belong O O
to O O
the O O
Ets B-protein B-protein
protein I-protein I-protein
family I-protein I-protein
. O O

Results O O
obtained O O
from O O
the O O
binding O O
competition O O
assay O O
, O O
nevertheless O O
, O O
suggest O O
that O O
NF-P1 B-protein B-protein
and O O
NF-P2 B-protein B-protein
are O O
related O O
to O O
but O O
distinct O O
from O O
Ets B-protein B-protein
proteins I-protein I-protein
, O O
e.g. O O
, O O
Ets-1 B-protein B-protein
, O O
Ets-2 B-protein B-protein
, O O
and O O
NF-AT/Elf-1 B-protein B-protein
, O O
known O O
to O O
be O O
expressed O O
in O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
role O O
of O O
NF-kappa B-DNA B-protein
B1 I-DNA I-protein
( I-DNA O
p50/p105 I-DNA B-protein
) I-DNA O
gene I-DNA O
expression O O
in O O
activation O O
of O O
human B-cell_type B-cell_type
blood I-cell_type I-cell_type
T-lymphocytes I-cell_type I-cell_type
via O O
CD2 B-protein B-protein
and I-protein O
CD28 I-protein B-protein
adhesion I-protein B-protein
molecules I-protein I-protein
. O O

Stimulation O O
of O O
primary B-cell_type B-cell_type
human I-cell_type I-cell_type
T-lymphocytes I-cell_type I-cell_type
via O O
CD2 B-protein B-protein
and I-protein O
CD28 I-protein B-protein
adhesion I-protein B-protein
molecules I-protein I-protein
induces O O
a O O
long-lasting O O
proliferation O O
( O O
> O O
3 O O
weeks O O
) O O
. O O

This O O
potent O O
activation O O
does O O
not O O
require O O
accessory O B-cell_type
cells O I-cell_type
, O O
such O O
as O O
monocytes B-cell_type B-cell_type
, O O
but O O
depends O O
on O O
persistent O O
interleukin B-protein B-protein
2 I-protein I-protein
( O O
IL-2 B-protein B-protein
) O O
secretion O O
and O O
receptivity O O
, O O
which O O
is O O
associated O O
with O O
high O O
and O O
prolonged O O
expression O O
of O O
the O O
inducible O O
CD25/IL-2 B-DNA B-protein
receptor I-DNA I-protein
alpha I-DNA I-protein
( I-DNA O
IL-2R I-DNA B-DNA
alpha I-DNA I-DNA
) I-DNA I-DNA
chain I-DNA I-DNA
gene I-DNA I-DNA
. O O

The O O
transcription B-protein B-protein
factor I-protein I-protein
NF-kappa I-protein B-protein
B I-protein I-protein
participates O O
in O O
the O O
regulation O O
of O O
both O O
IL-2 B-DNA B-DNA
and I-DNA I-DNA
IL-2R I-DNA I-DNA
alpha I-DNA I-DNA
genes I-DNA I-DNA
, O O
as O O
well O O
as O O
multiple B-DNA B-DNA
cellular I-DNA I-DNA
genes I-DNA I-DNA
involved O O
in O O
T-cell O O
proliferation O O
. O O

To O O
evaluate O O
the O O
role O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
in O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
T-lymphocytes I-cell_type I-cell_type
, O O
we O O
previously O O
analyzed O O
the O O
activation O O
of O O
NF-kappa B-protein B-protein
B-related I-protein I-protein
complexes I-protein I-protein
in O O
response O O
to O O
CD2+CD28 O B-protein
costimulation O O
. O O

We O O
demonstrated O O
a O O
long-term O O
induction O O
of O O
p50/p65 B-protein B-protein
heterodimer I-protein I-protein
, O O
a O O
putative B-protein O
p65/c-Rel I-protein B-protein
heterodimer I-protein I-protein
, O O
and O O
a O O
constitutive O O
nuclear O O
expression O O
of O O
KBF1/p50 B-protein B-protein
homodimers I-protein I-protein
. I-protein O

As O O
the O O
role O O
of O O
p50 B-protein B-protein
remains O O
unclear O O
, O O
we O O
focused O O
our O O
present O O
study O O
on O O
NF-kappa B-protein B-protein
B1 I-protein I-protein
( O O
p50/p105 B-protein B-protein
) O O
gene O O
regulation O O
. O O

Using O O
electrophoretic O O
mobility O O
shift O O
assays O O
and O O
Western O O
and O O
Northern O O
blot O O
analyses O O
, O O
we O O
studied O O
NF-kappa B-DNA B-DNA
B1 I-DNA I-DNA
gene I-DNA I-DNA
expression O O
during O O
T-cell O O
stimulation O O
via O O
CD2+CD28 B-protein B-protein
. O O

We O O
observed O O
a O O
transient O O
4- O O
to O O
5-fold O O
increase O O
of O O
NF-kappa O B-DNA
B1 O I-DNA
gene O I-DNA
expression O O
at O O
both O O
the O O
mRNA O O
and O O
protein O O
levels O O
, O O
lasting O O
for O O
at O O
least O O
24 O O
h O O
. O O

p50 O B-protein
DNA-binding O O
activity O O
apparently O O
stays O O
highly O O
controlled O O
when O O
p105 O B-protein
expression O O
is O O
enhanced O O
by O O
a O O
physiological O O
stimulus O O
of O O
peripheral B-cell_type B-cell_type
blood I-cell_type I-cell_type
T-cells I-cell_type I-cell_type
. O O

Partial O O
inhibition O O
of O O
p50 O B-protein
and O O
p105 O B-protein
expression O O
by O O
NF-kappa B-protein B-protein
B1 I-protein I-protein
antisense O O
oligonucleotides O O
significantly O O
reduced O O
T-cell O O
proliferation O O
and O O
CD25/IL-2R B-protein O
alpha I-protein O
cell O O
surface O O
expression O O
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Vitamin B-protein B-protein
D I-protein I-protein
receptor I-protein I-protein
quantitation O O
in O O
human B-cell_type B-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
in O O
health O O
and O O
disease O O
. O O

Vitamin B-protein B-protein
D I-protein I-protein
receptor I-protein I-protein
( O O
VDR O B-protein
) O O
concentration O O
was O O
quantitated O O
in O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
mononuclear I-cell_type I-cell_type
cells I-cell_type I-cell_type
( O O
PBMC B-cell_type B-cell_type
) O O
from O O
patients O O
with O O
absorptive O O
hypercalciuria O O
( O O
AH O O
) O O
and O O
patients O O
with O O
high O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
due O O
to O O
acquired O O
or O O
transient O O
disease O O
states O O
and O O
the O O
results O O
compared O O
to O O
those O O
in O O
normal O O
subjects O O
. O O

VDR O B-protein
concentration O O
in O O
resting B-cell_type B-cell_type
cells I-cell_type I-cell_type
was O O
not O O
different O O
between O O
the O O
three O O
groups O O
and O O
represented O O
constitutive O O
receptor O O
expression O O
of O O
monocytes B-cell_type B-cell_type
. O O

Following O O
activation O O
with O O
phytohemagglutinin B-protein B-protein
, O O
patients B-cell_type O
with O O
hypercalcitriolemia O O
demonstrated O O
significantly O O
greater O O
VDR O B-protein
concentrations O O
. O O

Patients O O
with O O
AH O O
demonstrated O O
a O O
normal O O
value O O
for O O
the O O
group O O
, O O
but O O
6 O O
patients O O
had O O
significantly O O
greater O O
concentrations O O
of O O
VDR B-protein B-protein
despite O O
normal O O
plasma O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
in O O
four O O
of O O
the O O
patients O O
. O O

Proliferation O O
, O O
as O O
assessed O O
from O O
[ O O
3H O O
] O O
thymidine O O
incorporation O O
was O O
inversely O O
correlated O O
with O O
serum O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
and O O
was O O
significant O O
( O O
R O O
= O O
-0.299 O O
, O O
p O O
= O O
0.048 O O
) O O
. O O

Taken O O
together O O
, O O
the O O
results O O
suggest O O
that O O
PBMC B-cell_type B-cell_type
provide O O
a O O
useful O O
system O O
for O O
studying O O
VDR B-protein B-protein
status O O
in O O
transient O O
or O O
acquired O O
states O O
of O O
hypercalcitriolemia O O
. O O

Furthermore O O
, O O
the O O
studies O O
in O O
patients O O
with O O
absorptive O O
hypercalciuria O O
disclosed O O
it O O
to O O
be O O
a O O
heterogeneous O O
disorder O O
, O O
characterized O O
by O O
both O O
vitamin O O
D-dependent O O
and O O
D-independent O O
forms O O
of O O
receptor O O
up-regulation O O
. O O

Reactive O O
oxygen O O
intermediates O O
activate O O
NF-kappa B-protein B-protein
B I-protein I-protein
in O O
a O O
tyrosine O O
kinase-dependent O O
mechanism O O
and O O
in O O
combination O O
with O O
vanadate O O
activate O O
the O O
p56lck B-protein B-protein
and I-protein I-protein
p59fyn I-protein I-protein
tyrosine I-protein I-protein
kinases I-protein I-protein
in O O
human B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

We O O
have O O
previously O O
observed O O
that O O
ionizing O O
radiation O O
induces O O
tyrosine O O
phosphorylation O O
in O O
human B-cell_type B-cell_type
B-lymphocyte I-cell_type I-cell_type
precursors I-cell_type I-cell_type
by O O
stimulation O O
of O O
unidentified O O
tyrosine B-protein B-protein
kinases I-protein I-protein
and O O
this O O
phosphorylation O O
is O O
substantially O O
augmented O O
by O O
vanadate O O
. O O

Ionizing O O
radiation O O
generates O O
reactive O O
oxygen O O
intermediates O O
( O O
ROI O O
) O O
. O O

Because O O
H2O2 O O
is O O
a O O
potent O O
ROI O O
generator O O
that O O
readily O O
crosses O O
the O O
plasma O O
membrane O O
, O O
we O O
used O O
H2O2 O O
to O O
examine O O
the O O
effects O O
of O O
ROI O O
on O O
signal O O
transduction O O
. O O

We O O
now O O
provide O O
evidence O O
that O O
the O O
tyrosine O B-protein
kinase O I-protein
inhibitor O O
herbimycin O O
A O O
and O O
the O O
free O O
radical O O
scavenger O O
N-acetyl-cysteine O O
inhibit O O
both O O
radiation-induced O O
and O O
H2O2-induced O O
activation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
, O O
indicating O O
that O O
activation O O
triggered O O
by O O
ROI O O
is O O
dependent O O
on O O
tyrosine O B-protein
kinase O I-protein
activity O O
. O O

H2O2 O O
was O O
found O O
to O O
stimulate O O
Ins-1 B-protein B-protein
, I-protein O
4 I-protein O
, I-protein O
5-P3 I-protein O
production O O
in O O
a O O
tyrosine O O
kinase-dependent O O
manner O O
and O O
to O O
induce O O
calcium O O
signals O O
that O O
were O O
greatly O O
augmented O O
by O O
vanadate O O
. O O

The O O
synergistic O O
induction O O
of O O
tyrosine O O
phosphorylation O O
by O O
H2O2 O O
plus O O
vanadate O O
included O O
physiologically O O
relevant O O
proteins O O
such O O
as O O
PLC B-protein B-protein
gamma I-protein I-protein
1 I-protein I-protein
. O O

Although O O
treatment O O
of O O
cells O O
with O O
H2O2 O O
alone O O
did O O
not O O
affect O O
the O O
activity O O
of O O
src B-protein B-protein
family I-protein I-protein
kinases I-protein I-protein
, O O
treatment O O
with O O
H2O2 O O
plus O O
vanadate O O
led O O
to O O
activation O O
of O O
the O O
p56lck B-protein B-protein
and I-protein O
p59fyn I-protein B-protein
tyrosine I-protein I-protein
kinases I-protein I-protein
. O O

The O O
combined O O
inhibition O O
of O O
phosphatases B-protein B-protein
and O O
activation O O
of O O
kinases B-protein B-protein
provides O O
a O O
potent O O
mechanism O O
for O O
the O O
synergistic O O
effects O O
of O O
H2O2 O O
plus O O
vanadate O O
. O O

Induction O O
of O O
tyrosine O O
phosphorylation O O
by O O
ROI O O
may O O
thus O O
lead O O
to O O
many O O
of O O
the O O
pleiotropic O O
effects O O
of O O
ROI O O
in O O
lymphoid B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
including O O
downstream O O
activation O O
of O O
PLC B-protein B-protein
gamma I-protein I-protein
1 I-protein I-protein
and O O
NF-kappa B-protein B-protein
B I-protein I-protein

Influence O O
of O O
sex B-protein B-protein
hormone I-protein I-protein
binding I-protein I-protein
globulin I-protein I-protein
and O O
serum B-protein B-protein
albumin I-protein I-protein
on O O
the O O
conversion O O
of O O
androstenedione O O
to O O
testosterone O O
by O O
human B-cell_type B-cell_type
erythrocytes I-cell_type I-cell_type
. O O

The O O
influence O O
of O O
human B-protein B-protein
serum I-protein I-protein
albumin I-protein I-protein
and O O
sex B-protein B-protein
hormone I-protein I-protein
binding I-protein I-protein
globulin I-protein I-protein
( O O
SHBG B-protein B-protein
) O O
on O O
the O O
enzymic O O
conversion O O
of O O
androstenedione O O
to O O
testosterone O O
in O O
human B-cell_type B-cell_type
erythrocytes I-cell_type I-cell_type
was O O
investigated O O
in O O
vitro O O
. O O

Total O O
plasma O O
and O O
albumin B-protein B-protein
delayed O O
the O O
conversion O O
rate O O
of O O
androstenedione O O
, O O
while O O
SHBG B-protein B-protein
increased O O
it O O
markedly O O
. O O

The O O
effect O O
of O O
SHBG B-protein B-protein
was O O
largely O O
abolished O O
by O O
heating O O
to O O
60 O O
degrees O O
C O O
for O O
1 O O
h O O
and O O
by O O
saturating O O
its O O
binding O B-DNA
sites O I-DNA
by O O
DHT O O
. O O

The O O
effect O O
of O O
both O O
proteins O O
was O O
found O O
to O O
be O O
related O O
to O O
their O O
concentration O O
. O O

It O O
appears O O
that O O
the O O
binding O B-DNA
sites O I-DNA
of O O
albumin B-protein B-protein
provide O O
a O O
mechanism O O
for O O
retarding O O
androstenedione O O
uptake O O
by O O
the O O
erythrocytes B-cell_type B-cell_type
and O O
that O O
the O O
high O O
binding O O
affinity O O
of O O
SHBG B-protein B-protein
for O O
testosterone O O
facilitates O O
the O O
diffusion O O
of O O
this O O
steroid O O
out O O
of O O
the O O
cell O O
and O O
thus O O
, O O
displaces O O
the O O
chemical O O
equilibrium O O
within O O
the O O
cell O O
. O O

Glucocorticoids O O
and O O
lymphocytes B-cell_type B-cell_type
. O O

I O O
. O O

Increased O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
levels O O
in O O
antigen-stimulated B-cell_line B-cell_type
lymphocytes I-cell_line I-cell_type
. O O

Recently O O
a O O
2- O O
to O O
3-fold O O
increase O O
in O O
the O O
number O O
of O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
has O O
been O O
noted O O
after O O
in O O
vitro O O
mitogen O B-protein
stimulation O O
. O O

Here O O
, O O
we O O
extend O O
these O O
observations O O
to O O
in O O
vivo O O
immunization O O
. O O

After O O
unilateral O O
immunization O O
of O O
adrenalectomized O O
male O O
rats O O
, O O
a O O
50 O O
% O O
increase O O
in O O
glucocorticoid O B-protein
receptor O I-protein
sites O I-protein
per O O
cell O O
, O O
determined O O
by O O
binding O O
of O O
dexamethasone O O
, O O
was O O
observed O O
in O O
cell O O
suspensions O O
of O O
homolateral O O
lymph O O
nodes O O
over O O
those O O
from O O
the O O
contralateral O O
nonimmunized O O
side O O
of O O
the O O
same O O
animal O O
. O O

The O O
association O O
constant O O
for O O
dexamethasone O O
was O O
similar O O
in O O
both O O
groups O O
, O O
as O O
was O O
the O O
stereospecificity O O
for O O
various O O
steroids O O
, O O
the O O
time O O
course O O
of O O
cytoplasmic O O
and O O
nuclear O O
association O O
, O O
and O O
cytoplasmic-to-nuclear O O
translocation O O
. O O

Despite O O
a O O
50 O O
% O O
increase O O
in O O
the O O
number O O
of O O
glucocorticoid O B-protein
receptor O I-protein
sites O I-protein
per O O
cell O O
, O O
the O O
cells O O
from O O
the O O
homolateral O O
and O O
controlateral O O
lymph O O
nodes O O
were O O
equally O O
sensitive O O
to O O
the O O
inhibitory O O
effects O O
of O O
dexamethasone O O
, O O
as O O
determined O O
by O O
measurements O O
of O O
the O O
incorporation O O
of O O
radiolabeled O O
precursors O O
of O O
protein O O
, O O
RNA O B-RNA
, O O
and O O
DNA O O
, O O
or O O
measurements O O
of O O
in O O
vitro O O
cell O O
survival O O
. O O

Glucocorticoid O B-protein
receptors O I-protein
and O O
actions O O
in O O
rat B-cell_type B-cell_type
thymocytes I-cell_type I-cell_type
and O O
immunologically O B-cell_type
stimulated O I-cell_type
human B-cell_type I-cell_type
peripheral I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

After O O
reviewing O O
briefly O O
our O O
earlier O O
studies O O
on O O
glucocorticoid O B-protein
receptors O I-protein
and O O
mechanisms O O
in O O
thymus B-cell_type B-cell_type
cells I-cell_type I-cell_type
, O O
we O O
have O O
outlined O O
results O O
from O O
the O O
following O O
two O O
areas O O
of O O
current O O
interest O O
in O O
our O O
laboratories O O
: O O
the O O
`` O O
life-cycle O O
'' O O
of O O
glucocorticoid O B-protein
receptors O I-protein
and O O
complexes O O
in O O
thymus B-cell_type O
cells I-cell_type O
, O O
and O O
the O O
levels O O
of O O
glucocorticoid O B-protein
receptors O I-protein
and O O
sensitivity O O
in O O
immunologically B-cell_type B-cell_type
stimulated I-cell_type I-cell_type
human I-cell_type I-cell_type
peripheral I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Several O O
of O O
our O O
results O O
on O O
energetics O O
and O O
kinetics O O
of O O
hormone O O
binding O O
to O O
glucocorticoid B-protein B-protein
receptors I-protein I-protein
in O O
rat B-cell_type B-cell_type
thymus I-cell_type I-cell_type
cells I-cell_type I-cell_type
seem O O
to O O
require O O
extension O O
of O O
the O O
simplest O O
model O O
of O O
hormone-receptor O O
transformations O O
in O O
intact B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

ATP-depletion O O
experiments O O
suggest O O
the O O
existence O O
of O O
a O O
nonbinding O O
form O O
of O O
the O O
receptor O O
; O O
`` O O
chase O O
'' O O
experiments O O
suggest O O
reaction O O
of O O
hormone O O
directly O O
with O O
nuclear-bound O B-protein
receptor O I-protein
; O O
experiments O O
on O O
depletion O O
and O O
replenishment O O
of O O
cytoplasmic B-protein B-protein
receptor I-protein I-protein
using O O
cortisol O O
and O O
dexamethasone O O
suggest O O
the O O
existence O O
of O O
at O O
least O O
two O O
subpopulations O O
of O O
nuclear-bound B-protein B-protein
hormone-receptor I-protein I-protein
complex I-protein I-protein
. O O

We O O
have O O
found O O
that O O
mitogen O B-protein
or O O
immunologic O O
stimulation O O
of O O
human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
in O O
culture O O
leads O O
within O O
24 O O
h O O
or O O
so O O
to O O
a O O
striking O O
increase O O
in O O
the O O
number O O
of O O
glucocorticoid B-protein B-protein
receptor I-protein I-protein
sites O I-protein
per O O
cell O O
. O O

We O O
believe O O
this O O
increase O O
may O O
be O O
due O O
to O O
partial O O
synchronization O O
of O O
the O O
cell O O
population O O
in O O
a O O
phase O O
of O O
the O O
cell O O
cycle O O
in O O
which O O
receptor O O
content O O
is O O
high O O
. O O

Contrary O O
to O O
the O O
widely O O
held O O
view O O
that O O
mitogen-stimulated B-cell_type B-cell_type
cells I-cell_type I-cell_type
become O O
insensitive O O
to O O
glucocorticoids O O
, O O
our O O
experiments O O
show O O
that O O
with O O
respect O O
to O O
inhibition O O
of O O
thymidine O O
and O O
uridine O O
incorporation O O
and O O
glucose O O
uptake O O
, O O
the O O
cells O O
are O O
highly O O
sensitive O O
to O O
dexamethasone O O
at O O
24 O O
, O O
48 O O
, O O
and O O
72 O O
h O O
after O O
stimulation O O
with O O
concanavalin B-protein O
A I-protein O
. O O

Nuclear O O
glucocorticoid O O
binding O O
in O O
chronic B-cell_type B-cell_type
lymphatic I-cell_type I-cell_type
leukemia I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

A O O
reliable O O
procedure O O
is O O
described O O
for O O
isolating O O
3H-triamcinolone B-protein B-protein
acetonide I-protein I-protein
( I-protein I-protein
3H-TA I-protein I-protein
) I-protein I-protein
receptor I-protein I-protein
complexes I-protein I-protein
from O O
purified O O
chronic O O
lymphatic B-cell_type O
leukemia I-cell_type O
( I-cell_type O
CLL I-cell_type O
) I-cell_type O
lymphocyte I-cell_type O
nuclei O O
, O O
based O O
on O O
the O O
use O O
of O O
carbobenzoxy-L-phenylalanine O O
( O O
CBZ-L-phe O O
) O O
to O O
prevent O O
breakdown O O
of O O
hormone-receptor B-protein B-protein
complexes I-protein I-protein
during O O
extraction O O
of O O
nuclei O O
with O O
0.6M O O
KCl O O
. O O

Using O O
this O O
method O O
, O O
specific O O
nuclear O O
glucocorticoid O O
binding O O
was O O
demonstrated O O
in O O
14/14 O O
patients O O
with O O
untreated O O
CLL O O
. O O

No O O
correlation O O
was O O
found O O
between O O
levels O O
of O O
nuclear-associated O O
3H-TA O O
and O O
peripheral O O
white O O
blood O O
cell O O
count O O
or O O
rosetting O O
ability O O
of O O
circulating B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Multiple O O
closely-linked O B-DNA
NFAT/octamer B-DNA I-DNA
and O I-DNA
HMG B-DNA I-DNA
I I-DNA I-DNA
( I-DNA I-DNA
Y I-DNA I-DNA
) I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
are O O
part O O
of O O
the O O
interleukin-4 O B-DNA
promoter O I-DNA
. O O

We O O
show O O
here O O
that O O
the O O
immediate B-DNA B-DNA
upstream I-DNA I-DNA
region I-DNA I-DNA
( O O
from O O
position O B-DNA
-12 O I-DNA
to O I-DNA
-270 O I-DNA
) O O
of O O
the O O
murine B-DNA B-DNA
interleukin I-DNA I-DNA
4 I-DNA I-DNA
( I-DNA I-DNA
Il-4 I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
harbors O I-DNA
a O O
strong O O
cell-type O O
specific O O
transcriptional B-DNA B-DNA
enhancer I-DNA I-DNA
. O O

In O O
T B-cell_type B-cell_type
lymphoma I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
the O O
activity O O
of O O
the O O
Il-4 B-DNA B-DNA
promoter/enhancer I-DNA I-DNA
is O O
stimulated O O
by O O
phorbol O O
esters O O
, O O
Ca++ O O
ionophores O O
and O O
agonists O O
of O O
protein B-protein B-protein
kinase I-protein I-protein
A I-protein I-protein
and O O
inhibited O O
by O O
low O O
doses O O
of O O
the O O
immunosuppressant O O
cyclosporin O O
A O O
. O O

The O O
Il-4 B-DNA B-DNA
promoter/enhancer I-DNA I-DNA
is O O
transcriptionally O O
inactive O O
in O O
B B-cell_type B-cell_type
lymphoma I-cell_type I-cell_type
cells I-cell_type I-cell_type
and O O
HeLa B-cell_type B-cell_line
cells I-cell_type I-cell_line
. O O

DNase O B-protein
I O O
footprint O O
protection O O
experiments O O
revealed O O
six O O
sites O O
of O O
the O O
Il-4 B-DNA B-DNA
promoter/enhancer I-DNA I-DNA
to O O
be O O
bound O O
by O O
nuclear B-protein B-protein
proteins I-protein I-protein
from O O
lymphoid B-cell_type B-cell_type
and I-cell_type I-cell_type
myeloid I-cell_type I-cell_type
cells I-cell_type I-cell_type
. O O

Among O O
them O O
are O O
four O O
purine O B-DNA
boxes O I-DNA
which O O
have O O
been O O
described O O
to O O
be O O
important O B-DNA
sequence O I-DNA
motifs O I-DNA
of O O
the O O
Il-2 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

They O O
contain O O
the O O
motif O B-DNA
GGAAA O I-DNA
and O O
are O O
recognized O O
by O O
the O O
inducible B-protein O
and I-protein O
cyclosporin I-protein B-protein
A-sensitive I-protein I-protein
transcription I-protein I-protein
factor I-protein I-protein
NFAT-1 I-protein B-protein
. O O

Three O O
of O O
the O O
Il-4 B-DNA B-DNA
NFAT-1 I-DNA I-DNA
sites I-DNA I-DNA
are O O
closely O O
linked O O
to O O
weak O O
binding O B-DNA
sites O I-DNA
of O O
Octamer B-protein B-protein
factors I-protein I-protein
. O O

Several O O
purine O B-DNA
boxes O I-DNA
and O O
an O O
AT-rich B-DNA B-DNA
protein-binding I-DNA I-DNA
site I-DNA I-DNA
of O O
the O O
Il-4 O B-DNA
promoter O I-DNA
are O O
also O O
recognized O O
by O O
the O O
high B-protein B-protein
mobility I-protein I-protein
group I-protein I-protein
protein I-protein I-protein
HMG B-protein I-protein
I I-protein I-protein
( I-protein I-protein
Y I-protein I-protein
) O I-protein
. O O

Whereas O O
the O O
binding O O
of O O
NFAT-1 B-protein B-protein
and O O
Octamer B-protein B-protein
factors I-protein I-protein
enhance O O
the O O
activity O O
of O O
the O O
Il-4 B-DNA B-DNA
promoter I-DNA I-DNA
, O O
the O O
binding O O
of O O
HMG O B-protein
I O I-protein
( O I-protein
Y O I-protein
) O I-protein
suppresses O O
its O O
activity O O
and O O
, O O
therefore O O
, O O
appears O O
to O O
be O O
involved O O
in O O
the O O
suppression O O
of O O
Il-4 B-protein B-protein
transcription O O
in O O
resting B-cell_type B-cell_type
T I-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
. O O

Reversibility O O
of O O
the O O
differentiated O O
state O O
in O O
somatic B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

Analysis O O
of O O
de O O
novo O O
gene O O
activation O O
in O O
multinucleated B-cell_type B-cell_line
heterokaryons I-cell_type I-cell_line
has O O
shown O O
that O O
the O O
differentiated O O
state O O
, O O
although O O
stable O O
, O O
is O O
not O O
irreversible O O
, O O
and O O
can O O
be O O
reprogrammed O O
in O O
the O O
presence O O
of O O
appropriate O O
combinations O O
of O O
trans-acting B-protein B-protein
regulatory I-protein I-protein
molecules I-protein I-protein
. O O

These O O
properties O O
have O O
been O O
exploited O O
to O O
design O O
strategies O O
for O O
identifying O O
novel O O
regulators O O
of O O
cellular O O
differentiation O O
. O O

Phosphatidylcholine O O
hydrolysis O O
activates O O
NF-kappa B-protein B-protein
B I-protein I-protein
and O O
increases O O
human O O
immunodeficiency O O
virus O O
replication O O
in O O
human B-cell_type B-cell_type
monocytes I-cell_type I-cell_type
and O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
. O O

We O O
have O O
tested O O
whether O O
breakdown O O
of O O
phosphatidylcholine O O
( O O
PC O O
) O O
initiated O O
by O O
exogenous O O
addition O O
of O O
a O O
PC-specific B-protein B-protein
phospholipase I-protein I-protein
C I-protein I-protein
( O O
PC-PLC B-protein O
) O O
from O O
Bacillus O O
cereus O O
or O O
by O O
endogenous O O
overexpression O O
of O O
PC-PLC B-protein B-protein
induces O O
functional O O
activation O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
and O O
increases O O
human B-DNA O
immunodeficiency I-DNA O
virus I-DNA O
( I-DNA O
HIV I-DNA O
) I-DNA O
enhancer I-DNA O
activity O O
. O O

PC-PLC-activated O O
hydrolysis O O
of O O
PC O O
was O O
found O O
to O O
induce O O
bona O O
fide O O
p50/p65 B-protein B-protein
NF-kappa I-protein I-protein
B I-protein I-protein
binding O O
activity O O
in O O
three O O
different O O
cell B-cell_line B-cell_line
lines I-cell_line I-cell_line
of O O
human O O
or O O
murine O O
origin O O
. O O

No O O
significant O O
changes O O
in O O
the O O
turnover O O
of O O
other O O
cellular O O
phospholipids O O
were O O
detected O O
in O O
PC-PLC-treated B-cell_line B-cell_line
cells I-cell_line I-cell_line
. O O

Induction O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
by O O
PC-PLC B-protein O
did O O
not O O
depend O O
on O O
de O O
novo O O
synthesis O O
of O O
proteins O O
or O O
autocrine O O
secretion O O
of O O
either O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
or O O
interleukin B-protein B-protein
1 I-protein I-protein
. O O

In O O
human B-cell_line B-cell_line
monocytic I-cell_line I-cell_line
and I-cell_line I-cell_line
lymphoblastoid I-cell_line I-cell_line
T-cell I-cell_line I-cell_line
lines I-cell_line I-cell_line
, O O
induction O O
of O O
NF-kappa B-protein B-protein
B I-protein I-protein
by O O
PC-PLC B-protein B-protein
resulted O O
in O O
clear O O
induction O O
of O O
luciferase B-protein B-DNA
expression O I-DNA
vectors O I-DNA
placed O O
under O O
the O O
control O O
of O O
synthetic B-DNA O
kappa I-DNA B-DNA
B I-DNA I-DNA
enhancers I-DNA I-DNA
or O O
wild O O
type O O
, O O
but O O
not O O
kappa O B-DNA
B-mutated O I-DNA
, O I-DNA
HIV B-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
constructs I-DNA I-DNA
. O O

HIV O O
replication O O
was O O
increased O O
by O O
PC-PLC B-protein B-protein
in O O
chronically O B-cell_type
infected O I-cell_type
monocytes B-cell_type I-cell_type
and O O
T O B-cell_type
lymphocytes B-cell_type I-cell_type
. O O

NF-kappa O B-protein
B O I-protein
activation O O
promoted O O
by O O
addition O O
of O O
exogenous B-protein O
PC-PLC I-protein B-protein
correlated O O
with O O
an O O
intense O O
production O O
of O O
diacylglycerol O O
. O O

However O O
, O O
addition O O
of O O
a O O
phosphatidylinositol-specific B-protein O
PLC I-protein O
from O O
B.cereus O O
also O O
induced O O
diacylglycerol O O
but O O
did O O
not O O
activate O O
kappa B-protein B-DNA
B I-protein I-DNA
enhancer-directed I-protein I-DNA
vectors I-protein I-DNA
. O O

PC-PLC-induced O O
NF-kappa O B-protein
B O I-protein
activation O O
could O O
not O O
be O O
blocked O O
by O O
a O O
specific O O
inhibitor O O
of O O
phorbol B-protein B-protein
ester-inducible I-protein I-protein
protein I-protein I-protein
kinases I-protein I-protein
C I-protein I-protein
. O O

These O O
results O O
indicate O O
that O O
a O O
cellular O O
transduction O O
pathway O O
, O O
dependent O O
on O O
specific O O
PC O O
breakdown O O
, O O
is O O
functional O O
in O O
T B-cell_type B-cell_type
lymphocytes I-cell_type I-cell_type
and O O
monocytes B-cell_type B-cell_type
and O O
may O O
be O O
used O O
by O O
various O O
transmembrane O B-protein
receptors O I-protein
to O O
activate O O
HIV O O
transcription O O
through O O
NF-kappa O B-protein
B-dependent O O
induction O O
of O O
the O O
HIV B-DNA B-DNA
enhancer I-DNA I-DNA
. O O

Novel O O
mechanism O O
for O O
inhibition O O
of O O
human B-cell_type B-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
by O O
glucocorticoids O O
. O O

Glucocorticoids O O
inhibit O O
signal O O
transduction O O
through O O
IL-2 B-protein B-protein
receptor I-protein I-protein
. O O

Interaction O O
of O O
IL-2 B-protein B-protein
with O O
its O O
high B-protein B-protein
affinity I-protein I-protein
membrane I-protein I-protein
receptor I-protein I-protein
complex I-protein I-protein
( O O
IL-2R B-protein B-protein
) O O
present O O
on O O
activated O B-cell_type
T B-cell_type I-cell_type
lymphocytes I-cell_type I-cell_type
induces O O
cell O O
proliferation O O
and O O
mediates O O
effector O O
functions O O
. O O

Glucocorticoids O O
inhibit O O
IL-2 B-protein B-protein
production O O
by O O
inhibiting O O
TCR-mediated O O
signal O O
transduction O O
. O O

We O O
asked O O
whether O O
they O O
also O O
inhibit O O
the O O
action O O
of O O
IL-2 B-protein B-protein
by O O
inhibiting O O
signal O O
transduction O O
through O O
IL-2R B-protein B-protein
. O O

Human B-cell_type B-cell_type
peripheral I-cell_type I-cell_type
blood I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
stimulated O O
with O O
PMA O O
for O O
48 O O
h O O
( O O
PMA B-cell_line B-cell_type
blasts I-cell_line I-cell_type
) O O
, O O
were O O
incubated O O
with O O
IL-2 B-protein B-protein
in O O
the O O
presence O O
of O O
incremental O O
dosages O O
of O O
dexamethasone O O
( O O
Dex O O
; O O
10 O O
( O O
-5 O O
) O O
-10 O O
( O O
-9 O O
) O O
M O O
) O O
. O O

Dex O O
inhibited O O
the O O
IL-2-dependent O O
proliferation O O
of O O
PMA B-cell_line B-cell_type
blasts I-cell_line I-cell_type
in O O
a O O
dose-dependent O O
fashion O O
( O O
IC50 O O
, O O
5 O O
x O O
10 O O
( O O
-8 O O
) O O
M O O
) O O
. O O

Cell O O
surface O O
expression O O
of O O
IL-2R B-protein B-protein
alpha- I-protein I-protein
and I-protein O
beta-chains I-protein B-protein
as O O
determined O O
by O O
immunofluorescence O O
analysis O O
was O O
not O O
affected O O
by O O
Dex O O
. O O

In O O
addition O O
, O O
Scatchard O O
plot O O
analysis O O
of O O
125I-labeled B-protein B-protein
IL-2 I-protein I-protein
showed O O
that O O
Dex O O
did O O
not O O
affect O O
the O O
binding O O
of O O
IL-2 B-protein B-protein
, O O
thus O O
suggesting O O
that O O
inhibition O O
is O O
due O O
to O O
a O O
postreceptor O O
effect O O
. O O

Inhibition O O
of O O
T O O
cell O O
proliferation O O
by O O
Dex O O
was O O
associated O O
with O O
decreased O O
IL-2-dependent O O
tyrosine O O
phosphorylation O O
of O O
several O O
intracellular B-protein B-protein
proteins I-protein I-protein
and O O
decreased O O
phosphorylation O O
of O O
the O O
retinoblastoma B-protein B-protein
gene I-protein I-protein
product I-protein I-protein
Rb I-protein B-protein
, O O
a O O
protein O O
essential O O
for O O
controlling O O
the O O
progression O O
of O O
cells O O
through O O
the O O
cell O O
cycle O O
. O O

IL-2-dependent O O
IL-2R O B-protein
alpha O I-protein
expression O O
in O O
PMA B-cell_line B-cell_type
blasts I-cell_line I-cell_type
and O O
NF-kB B-protein B-protein
induction O O
in O O
resting B-cell_type B-cell_type
human I-cell_type I-cell_type
T I-cell_type I-cell_type
cells I-cell_type I-cell_type
were O O
also O O
inhibited O O
by O O
Dex O O
. O O

These O O
results O O
demonstrate O O
that O O
glucocorticoids O O
inhibit O O
preactivated B-cell_line B-cell_type
T I-cell_line I-cell_type
cells I-cell_line I-cell_type
by O O
down-regulating O O
signal O O
transduction O O
through O O
IL-2R B-protein B-protein
. O O

Chronic O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
infection O O
stimulates O O
distinct O O
NF-kappa O B-protein
B/rel O I-protein
DNA O O
binding O O
activities O O
in O O
myelomonoblastic B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

The O O
relationship O O
between O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV-1 O O
) O O
infection O O
and O O
the O O
induction O O
of O O
NF-kappa O B-protein
B O I-protein
binding O O
activity O O
was O O
examined O O
in O O
a O O
myeloid B-cell_line O
cell I-cell_line O
model I-cell_line O
of O O
HIV-1 O O
infection O O
derived O O
from O O
the O O
PLB-985 B-cell_line B-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

Chronic O O
infection O O
of O O
PLB-985 B-cell_line B-cell_line
cells I-cell_line I-cell_line
led O O
to O O
increased O O
monocyte-specific O O
surface O O
marker O O
expression O O
, O O
increased O O
c-fms O B-DNA
gene O I-DNA
transcription O O
, O O
and O O
morphological O O
alterations O O
consistent O O
with O O
differentiation O O
along O O
the O O
monocytic O O
pathway O O
. O O

PLB-IIIB B-cell_line B-cell_line
cells I-cell_line I-cell_line
displayed O O
a O O
constitutive O O
NF-kappa O B-protein
B-like O I-protein
binding O O
activity O O
that O O
was O O
distinct O O
from O O
that O O
induced O O
by O O
tumor B-protein B-protein
necrosis I-protein I-protein
factor I-protein I-protein
alpha I-protein I-protein
or O O
phorbol O O
12-myristate O O
13-acetate O O
treatment O O
of O O
the O O
parental B-cell_line B-cell_line
PLB-985 I-cell_line I-cell_line
cell I-cell_line I-cell_line
line I-cell_line I-cell_line
. O O

This O O
unique O O
DNA O O
binding O O
activity O O
consisted O O
of O O
proteins O O
of O O
70 B-protein O
, I-protein O
90 I-protein O
, I-protein O
and I-protein O
100 I-protein O
kDa I-protein O
with O O
a O O
high O O
degree O O
of O O
binding O O
specificity O O
for O O
the O O
NF-kappa B-protein B-DNA
B I-protein I-DNA
site I-protein I-DNA
within O O
the O O
PRDII B-protein B-protein
domain I-protein I-protein
of O O
beta B-protein B-protein
interferon I-protein I-protein
. O O

In O O
this O O
report O O
, O O
we O O
characterize O O
the O O
nature O O
of O O
these O O
proteins O O
and O O
demonstrate O O
that O O
binding O O
of O O
these O O
proteins O O
is O O
also O O
induced O O
following O O
Sendai O O
paramyxovirus O O
infection O O
. O O

The O O
70-kDa B-protein O
protein I-protein O
corresponds O O
to O O
the O O
NF-kappa B-protein B-protein
B I-protein I-protein
RelA I-protein I-protein
( I-protein I-protein
p65 I-protein I-protein
) I-protein I-protein
subunit I-protein I-protein
, O O
which O O
is O O
activated O O
in O O
response O O
to O O
an O O
acute O O
paramyxovirus O O
infection O O
or O O
a O O
chronic O O
HIV-1 O O
infection O O
. O O

Virus O O
infection O O
does O O
not O O
appear O O
to O O
alter O O
the O O
amount O O
of O O
RelA B-protein B-protein
( O O
p65 B-protein B-protein
) O O
or O O
NFKB1 B-protein B-protein
( O O
p50 B-protein B-protein
) O O
but O O
rather O O
affects O O
the O O
capacity O O
of O O
I B-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha I-protein I-protein
to O O
sequester O O
RelA B-protein B-protein
( I-protein O
p65 I-protein B-protein
) I-protein O
, O O
therefore O O
leading O O
to O O
constitutive O O
levels O O
of O O
RelA O B-protein
DNA O O
binding O O
activity O O
and O O
to O O
increased O O
levels O O
of O O
NF-kappa O B-protein
B-dependent O O
gene O O
activity O O
. O O

The O O
virally O O
induced O O
90- B-protein O
to I-protein O
100-kDa I-protein B-protein
proteins I-protein I-protein
have O O
a O O
distinct O O
binding O O
specificity O O
for O O
the O O
PRDII B-DNA B-DNA
domain I-DNA I-DNA
and O O
an O O
AT-rich B-DNA B-DNA
sequence I-DNA I-DNA
but O O
do O O
not O O
cross-react O O
with O O
NF-kappa O B-protein
B O I-protein
subunit-specific O I-protein
antisera O I-protein
directed O O
against O O
NFKB1 B-protein B-protein
( O O
p105 B-protein B-protein
or O O
p50 B-protein B-protein
) O O
, O O
NFKB2 B-protein B-protein
( O O
p100 B-protein B-protein
or O O
p52 B-protein B-protein
) O O
, O O
RelA B-protein B-protein
( O O
p65 B-protein B-protein
) O O
, O O
or O O
c-rel B-protein B-protein
. O O

DNA O O
binding O O
of O O
the O O
90- B-protein B-protein
to I-protein I-protein
100-kDa I-protein I-protein
proteins I-protein I-protein
was O O
not O O
inhibited O O
by O O
recombinant B-protein O
I I-protein B-protein
kappa I-protein I-protein
B I-protein I-protein
alpha/MAD-3 I-protein I-protein
and O O
was O O
resistant O O
to O O
tryptic O O
digestion O O
, O O
suggesting O O
that O O
these O O
proteins O O
may O O
not O O
be O O
NF-kappa B-protein B-protein
B I-protein I-protein
related I-protein O
. O O

Transient O O
cotransfection O O
experiments O O
demonstrated O O
that O O
RelA O B-protein
and O O
NFKB1 O B-protein
expression O O
maximally O O
stimulated O O
HIV-1 B-DNA B-DNA
LTR- I-DNA I-DNA
and I-DNA I-DNA
NF-kappa I-DNA I-DNA
B-dependent I-DNA I-DNA
reporter I-DNA I-DNA
genes I-DNA I-DNA
; O O
differences O O
in O O
NF-kappa O B-protein
B-like O I-protein
binding O O
activity O O
were O O
also O O
reflected O O
in O O
higher O O
constitutive O O
levels O O
of O O
NF-kappa O B-DNA
B-regulated O I-DNA
gene O I-DNA
expression O O
in O O
HIV-1-infected B-cell_line B-cell_type
myeloid I-cell_line I-cell_type
cells I-cell_line I-cell_type
. O O

Presence O O
of O O
estrogen-binding O B-DNA
sites O I-DNA
on O O
macrophage-like B-cell_type B-cell_type
synoviocytes I-cell_type I-cell_type
and O O
CD8+ B-cell_line B-cell_type
, I-cell_line I-cell_type
CD29+ I-cell_line I-cell_type
, I-cell_line I-cell_type
CD45RO+ I-cell_line I-cell_type
T I-cell_line I-cell_type
lymphocytes I-cell_line I-cell_type
in O O
normal O O
and O O
rheumatoid O O
synovium O O
. O O

OBJECTIVE O O
. O O

To O O
study O O
the O O
presence O O
of O O
estrogen-binding O B-protein
sites O I-protein
( O O
EBS O B-DNA
) O O
in O O
the O O
synovial O O
tissues O O
of O O
male O O
and O O
female O O
patients O O
with O O
rheumatoid O O
arthritis O O
( O O
RA O O
) O O
and O O
in O O
age- O O
and O O
sex-matched O O
healthy O O
controls O O
. O O

METHODS O O
. O O

Both O O
type O O
1 O O
( O O
high O O
affinity O O
, O O
low O O
binding O O
capacity O O
) O O
and O O
type O O
2 O O
( O O
reduced O O
affinity O O
, O O
higher O O
binding O O
capacity O O
) O O
EBS O B-protein
were O O
investigated O O
in O O
both O O
soluble O O
and O O
nuclear O O
fractions O O
of O O
homogenized O O
synovial O O
tissue O O
samples O O
by O O
a O O
dextran-coated O O
charcoal O O
method O O
. O O

To O O
determine O O
what O O
type O O
of O O
synovial B-cell_type O
cell I-cell_type O
was O O
positive O O
for O O
EBS O B-protein
, O O
cryosections O O
of O O
synovial O O
tissues O O
were O O
immunostained O O
with O O
a O O
specific O O
monoclonal B-protein B-protein
anti-estrogen I-protein I-protein
receptor I-protein I-protein
antibody I-protein I-protein
( O O
anti-ER B-protein B-protein
MAb I-protein I-protein
) O O
using O O
both O O
immunofluorescence O O
and O O
immunoperoxidase O O
techniques O O
. O O

Double O O
immunostaining O O
with O O
the O O
anti-ER B-protein B-protein
MAb I-protein I-protein
and O O
with O O
specific B-protein O
MAb I-protein O
to O O
detect O O
different O O
macrophage B-protein B-protein
antigens I-protein I-protein
( O O
Ber-MAC3 B-protein O
, O O
MAC387 B-protein B-protein
, O O
CD68 B-protein B-protein
) O I-cell_type
and O I-cell_type
CD8+ B-cell_line I-cell_type
T I-cell_line I-cell_type
cell I-cell_line I-cell_type
subsets I-cell_line I-cell_type
( O O
CD29+ B-cell_line O
, O O
CD45RO+ B-cell_line B-cell_type
and O O
CD29- B-cell_line O
, O O
CD45RO- B-cell_line O
) O O
was O O
performed O O
. O O

RESULTS O O
. O O

Higher O O
affinity O O
EBS O B-protein
were O O
found O O
mostly O O
in O O
nuclear O O
cell O O
fractions O O
of O O
either O O
RA O O
or O O
control O O
synovial O O
tissues O O
( O O
28 O O
of O O
the O O
33 O O
) O O
. O O

These O O
EBS O B-DNA
were O O
present O O
to O O
a O O
lesser O O
extent O O
in O O
soluble O O
cell O O
fractions O O
( O O
11 O O
of O O
the O O
33 O O
) O O
. O O

Immunostaining O O
showed O O
the O O
estrogen B-cell_type B-cell_type
receptor-positive I-cell_type I-cell_type
cells I-cell_type I-cell_type
to O O
be O O
the O O
macrophage-like B-cell_type B-cell_type
synoviocytes I-cell_type I-cell_type
and O O
the O O
CD8+ B-cell_line B-cell_type
, O I-cell_type
CD29+ B-cell_line I-cell_type
T I-cell_line I-cell_type
cells I-cell_line I-cell_type
both O O
in O O
RA O O
and O O
in O O
control O O
synovial O O
tissues O O
. O O

Higher O O
nuclear O O
content O O
of O O
EBS O B-protein
was O O
consistent O O
with O O
more O O
intense O O
nuclear O O
staining O O
of O O
synoviocytes B-cell_type B-cell_type
and O O
T B-cell_type B-cell_type
cells I-cell_type I-cell_type
. O O

CONCLUSION O O
. O O

It O O
is O O
conceivable O O
that O O
the O O
immunomodulatory O O
activity O O
exerted O O
by O O
estrogens O O
is O O
at O O
least O O
partly O O
mediated O O
through O O
their O O
interaction O O
with O O
EBS O B-protein
that O O
are O O
present O O
on O O
macrophage-like B-cell_type B-cell_type
synoviocytes I-cell_type I-cell_type
, O O
functioning O O
as O O
antigen-processing B-cell_type B-cell_type
and I-cell_type I-cell_type
antigen-presenting I-cell_type I-cell_type
cells I-cell_type I-cell_type
, O O
and O O
on O O
antigen-experienced B-cell_line B-cell_type
( I-cell_line I-cell_type
memory I-cell_line I-cell_type
) I-cell_line I-cell_type
CD8+ I-cell_line I-cell_type
T I-cell_line I-cell_type
lymphocytes I-cell_line I-cell_type
( O O
CD29+ B-cell_line B-cell_type
, O O
CD45RO+ B-cell_line B-protein
